Anti-viral compounds to treat hcv infection.
Abstract
Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.

Term
No projected expiry on record.
- Priority
- Filed
- Granted
- Today
16 claims: 3 independent, 13 dependent
- 1CLAIMS REIVINDICACIONES 1, - A compound of Formula I, or a pharmaceutically acceptable salt thereof, 1,- Un compuesto de la Fórmula I, o una sal farmacéuticamente aceptable del mismo, 1-3 1-3 I I Y-A-L,—X—L2—Β—Z I YAL, —X — L2—Β — ZI IMPIé IMPIé INSTITUTO MEXICANO DELAI'ROntU'.and industrial in which:INSTITUTO MEXICANO DELAI'ROntU'.y industrial en la cual: 10 X is in which the nitrogen atom of the ring is directly linked to -L3-D, and in which X is optionally substituted with one or more RTO;10 X es en el cual el átomo de nitrógeno del anillo está 15 directamente ligado a -L3-D, y en el cual X está opcionalmente sustituido con uno o más RA;Li, L2 and L3 they are link;Li, L2 y L3 son enlace;A and B are each independently and each independently is optionally substituted with one or more RTO;A y B son cada uno de manera independiente y cada uno de manera independiente está opcionalmente sustituido con uno o más RA;D es carbociclo de C3-Ci2 o heterociclo de 3 a 12 miembros, y está opcionalmente sustituido con uno o más RA;D is carbocycle of C3-Ci2 or 3- to 12-membered heterocycle, and is optionally substituted with one or more RTO;Y es -G-CCRtR^NÍR-O-T-Rd, Y is -G-CCRtR ^ NÍR-OT-Rd, -G-C(R3R4)C(R6R7)-T-Rd, -GC (R3R4) C (R6R7) -T-Rd, 800 800 IMPI IMPI N (Rb) C (O) C (R1R2) N (R5) -TRd, or N (RB) C (O) C (R3R4) C (ReS '^ ®g N(Rb)C(O)C(R1R2)N(R5)-T-Rd, o N(RB)C(O)C(R3R4)C(ReS'^®g Z es -G-C(R8Rg)N(R12)-T-Rq, -G-C(RiqRii)C(R-i3Ri4)-T-Rp N(Rb)C(O)C(R8R9)N(R12)-T-Rd, o NÍRbJCÍOJCíRwR-.OCíR^RmJ-T-Rd;Z is -GC (R8Rg) N (R12) -T-Rq, -GC (RiqRii) C (Ri3Ri4) -T-Rp N (Rb) C (O) C (R8R9) N (R12) -TRd, or NÍRbJCÍOJCíRwR-.OCíR ^ RmJ-T-Rd;Ri es Rc, y R2 y Rs, tomados junto con los átomos a los cuales éstos están unidos, forman un heterociclo de 3 a 12 miembros el cual está opclonalmente sustituido con uno o más RA;Ri is Rc, and R2 and Rs, taken together with the atoms to which they are attached, form a 3- to 12-membered heterocycle which is optionally substituted with one or more RTO;R3 and R6 are each independently Rc, and R4 and R7, taken together with the atoms to which they are attached, form a 3- to 12-membered carbocyclyl or heterocycle which is optionally substituted with one or more RTO;R3 y R6 son cada uno de manera independiente Rc, y R4 y R7, tomados junto con los átomos a los cuales éstos están unidos, forman un carbociclilo o heterociclo de 3 a 12 miembros el cual está opclonalmente sustituido con uno o más RA;R8 es Rc, y Rg y Ri2, tomados junto con los átomos a los cuales éstos están unidos, forman un heterociclo de 3 a 12 miembros el cual está opcionalmente sustituido con uno o más RA;R8 is Rc, and Rg and Ri2, taken together with the atoms to which they are attached, form a 3- to 12-membered heterocycle which is optionally substituted with one or more RTO;Rio and R13 are each independently Rc, and Rn and R14, taken together with the atoms to which they are attached, form a 3- to 12-membered carbocyclyl or heterocycle which is optionally substituted with one or more RTO;Río y R13 son cada uno de manera Independiente Rc, y Rn y R14, tomados junto con los átomos a los cuales éstos están unidos, forman un carbociclilo o heterociclo de 3 a 12 miembros el cual está opcionalmente sustituido con uno o más RA;G es cada uno de manera independiente carbociclo de C5C6 o heterociclo de 5 a 6 miembros, y cada uno está de manera independiente opcionalmente sustituido con uno o más RA;G is each independently carbocycle of C5C6 or 5- to 6-membered heterocycle, each independently optionally substituted with one or more RTO;T is selected each independently each time it appears from link, -Ls-, -Ls-MLs'-, or -Ls-M-Ls'-M'l_s-, in which M and M' are each independently selected each time they appear from the link, -O-, -S-, N ( Rb) -, -C (O) -, -S (O)2-, -S (O) -, -OS (O) -, - OS (O)2-, -S (O)2O-, -S (O) O- T se selecciona cada uno de manera independiente cada vez que aparece a partir de enlace, -Ls-, -Ls-M-Ls'-, o -Ls-M-Ls'-M'l_s-, en los cuales M y M’ se seleccionan cada uno de manera independiente cada vez que aparecen a partir d enlace, -O-, -S-, N(Rb)-, -C(O)-, -S(O)2-, -S(O)-, -OS(O)-, - OS(O)2-, -S(O)2O-, -S(O)O- 801 801 Etfssasa ^ Etfssasa^ -C (O) O-, -OC (O) -, -OC (O) O-, -Ο (Ο) Ν (ΠΒ) τ ^ | «ΤΒΙ) ®Ηά) ^^^ -C(O)O-, -OC(O)-, -OC(O)O-, -Ο(Ο)Ν(ΠΒ)τ^|«ΤΒΙ)®Ηά)^^^ D € .LA 1-ROrH'OAO 'C ^ e ^ & jsbr INPUSTJJAL D€ .LA 1-ROrH'OAO 'C^e^&jsbr INPUSTJJAL N (Rb) C (O) O-, -OC (O) N (Rb) -, -N (Rb) S (O) -, -N (Rb)SW)2-, - S (O) N (Rb)-, N(Rb)C(O)O-, -OC(O)N(Rb)-, -N(Rb)S(O)-, -N(Rb)S(O)2-, - S(O)N(Rb)-, -S(O)2N(Rb)-, -C(O)N(Rb)C(O)-, -N(Rb)C(O)N(Rb’)-, - N(Rb)SO2N(Rb'), -N(Rb)S(O)N(Rb')-, carbociclo de C3-Ci2 o heterociclo de 3 a 12 miembros, y en los cuales dicho carbociclo de C3-C12 y heterociclo d 3 a 12 miembros está cada uno de manera independiente opcionalmente sustituido cada vez que aparecen con uno o más Ra;-SW)2N (Rb) -, -C (O) N (Rb) C (O) -, -N (Rb) C (O) N (Rb') -, - N (Rb)SW2N (Rb'), -N (Rb) S (O) N (Rb') -, carbocycle of C3-Ci2 or 3-12 membered heterocycle, and in which said carbocycle of C3-C12 and 3- to 12-membered d heterocycle is each independently optionally substituted each occurrence with one or more Rto;Rd each is independently selected each time it appears from hydrogen or RTO Rd se selecciona cada uno de manera independiente cada vez que aparece a partir de hidrógeno o RA¡ Ra se selecciona de manera independiente cada vez que aparece a partir de halógeno, nitro, oxo, fosfonoxi, fosfono, tioxo, ciano, o -Ls-Re;Rto is independently selected each occurrence from halogen, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano, or -Ls-Rand;Rb and Rb 'are each independently selected each time they appear from hydrogen;or Ci-C alkyl6, C alkenyl2-C6 or C alkynyl2-C6, each of which is independently optionally substituted whenever they occur with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano or 3- to 6-membered carbocycle or heterocycle;or 3- to 6-membered carbocycle or heterocycle;in which each 3-6 membered carbocycle or heterocycle in RB or RBindependently it is optionally substituted whenever they appear with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci- alkyl C6, C alkenyl2-C6, Rb y Rb' se seleccionan cada uno de man ra independiente cada vez que aparecen a partir de hidrógeno;o alquilo de Ci-C6, alquenilo de C2-C6 o alquinilo de C2-C6, cada uno de los cuales de manera independiente está opcionalmente sustituido cada vez que aparecen con uno o más sustituyentes que se seleccionan a partir de halógeno, hidroxi, mercapto, amino, carboxi, nitro, oxo, fosfonoxi, fosfono, tioxo, formilo, ciano o carbociclo o heterociclo de 3 a 6 miembros;o carbociclo o heterociclo de 3 a 6 miembros;en los cuales cada carbociclo o heterociclo de 3 a 6 miembros en RB o RB' de manera independiente está opcionalmente sustituido cada vez que aparecen con uno o más sustituyentes que se seleccionan a partir de halógeno, hidroxi, mercapto, amino, carboxi, nitro, oxo, fosfonoxi, fosfono, tioxo, formilo, ciano, alquilo de Ci-C6, alquenilo de C2-C6, 802 802 IMPIOS IMPIOS INSTITUTO MEXICANO . · _ DE LA PROPIEDAD vVM»-Z¿íL·. MEXICAN INSTITUTE. · _ PROPERTY vVM »-Z¿íL ·. C alkynyl2-C6, Cj-Cg halogenoalkyl, halogenoalqWfítt © σϊ * - = · _ ^ alquinilo de C2-C6, halogenoalquilo de Cj-Cg, halogenoalqWfítt© σϊ*--=·_^ C2-C6 o halogenoalquinllo de C2-C6;............ C2-C6 or halogenoalkyl C2-C6;............ Rc each occurrence is independently selected from hydrogen, halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, or cyano;or Cj-Cg alkyl, C alkenyl2-C6 or C alkynyl2-C6, each of which independently is optionally substituted each occurrence with one or more substituents selected from halogen, hydroxl, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano or carbocycle or heterocycle of Rc se selecciona de manera independiente cada vez qu aparece a partir de hidrógeno, halógeno, hldroxi, mercapto, amino, carboxi, nitro, oxo, fosfonoxi, fosfono, tioxo, formilo o ciano;o alquilo de Cj-Cg, alquenilo de C2-C6 o alquinilo de C2-C6, cada uno de los cuales de manera independiente está opcionalmente sustituido cada vez que aparecen con uno o más sustituyentes que se seleccionan a partir de halógeno, hidroxl, mercapto, amino, carboxi, nitro, oxo, fosfonoxi, fosfono, tioxo, formilo, ciano o carbociclo o heterociclo de 3 6 members;or 3- to 6-membered carbocycle or heterocycle;in which each 3- to 6-membered carbocycle or heterocycle in Rc independently is optionally substituted each time they appear with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, alkyl of CU-Cg , C alkenyl2-C6, C alkynyl2-C6, Cj-Cg haloalkyl, C haloalkenyl2-Cg or C haloalkynyl2-C6;3 a 6 miembros;o carbociclo o heterociclo de 3 a 6 miembros;en los cuales cada carbociclo o heterociclo de 3 a 6 miembros en Rc de manera independiente está opcionalmente sustituido cada vez que aparecen con uno o más sustituyentes que se seleccionan a partir d halógeno, hidroxi, mercapto, amino, carboxi, nitro, oxo, fosfonoxi, fosfono, tioxo, formilo, ciano, alquilo de CU-Cg, alquenilo de C2-C6, alquinilo de C2-C6, halogenoalquilo de Cj-Cg, halogenoalquenilo de C2-Cg o halogenoalquinilo de C2-C6;Rand is selected independently each time it appears from -ORs, -MRs, -C (O) RS, - OC (O) RS, -C (O) ORS, N (RsRs'), -S (O) Rs, -SO2Rs, -C (O) N (RsRs'), - N (RS) C (O) RS'. N (Rs) C (O) N (Rs'Rs) - -N (Rs)SW2Rs', -SO2N (RsRS '), N (Rs) SO2N (Rs'Rs), -N (Rs) S (O) N (Rs'Rs), -OS (O) -Rs, -BEAR)2-Rs, S (O)2ORs, -S (O) ORs, -OC (O) ORs, N (Rs) C (O) ORs', -OC (O) N (RsRs'). N (Rs) S (O) -Rs', -S (O) N (RsRs') or -C (O) N (Rs) C (O) -Rs';or C alkylv Re se selecciona de manera independiente cada vez que aparece a partir de -O-Rs, -S-Rs, -C(O)RS, - OC(O)RS, -C(O)ORS, N(RsRs'), -S(O)Rs, -SO2Rs, -C(O)N(RsRs'), - N(RS)C(O)RS'. N(Rs)C(O)N(Rs'Rs)- -N(Rs)SO2Rs', -SO2N(RsRS'), N(Rs)SO2N(Rs'Rs), -N(Rs)S(O)N(Rs'Rs), -OS(O)-Rs, -OS(O)2-Rs, S(O)2ORs, -S(O)ORs, -OC(O)ORs, N(Rs)C(O)ORs', -OC(O)N(RsRs’). N(Rs)S(O)-Rs', -S(O)N(RsRs’) o -C(O)N(Rs)C(O)-Rs';o alquilo de Cv 803 803 C6, C alkenyl2-C6 or C alkynyl2-C6, each independently way is optionally substituted each time C6, alquenilo de C2-C6 o alquinilo de C2-C6, cada uno manera independiente está opcionalmente sustituido cada vez que ....... un ... m .ti-ítt i— rjrt - τη · πτ.ι ~ τ · ιΓ ~~ '~ τ ~ ιτ.ΐΓ ~ τ ~ - · * ^ ~ ·· appears with one or more substituents that are selected from halogen, hydroxy, mercapto, amino, carboxy, nit ro, oxo, phosphonoxy, .......un... m .t-i-ítt i— rjrt—τη·πτ.ι~τ·ιΓ~~'~τ~ιτ.ΐΓ~τ~-·*^~·· aparece con uno o más sustituyentes que se seleccionan a partir de halógeno, hidroxi, mercapto, amino, carboxi, nitro, oxo, fosfonoxi, 5 phosphono, thioxo, formyl, or cyano;or C carbocycle3-C6 or 3- to 6-membered heterocycle, each of which independently is optionally substituted each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, 5 fosfono, tioxo, formilo o ciano;o carbociclo de C3-C6 o heterociclo de 3 a 6 miembros, cada uno de los cuales de manera independiente está opcionalmente sustituido cada vez que aparece con uno o más sustituyentes que se seleccionan a partir de halógeno, hidroxi, mercapto, amino, carboxi, nitro, oxo, fosfonoxi, fosfono, tioxo, 10 formyl, cyano, (/ -C-alkyl, C-alkenyl2-C6, C alkynyl2C6, C ^ Cg haloalkyl, C haloalkenyl2-C6 or halogenoalkynyl of C2-C6;10 formilo, ciano, alquilo de (/-Cs, alquenilo de C2-C6, alquinilo de C2C6, halogenoalquilo de C^Cg, halogenoalquenilo de C2-C6 o halogenoalquinilo de C2-C6;Rl is independently selected each occurrence from halogen, nitro, oxo, phosphonoxy, phosphono, thioxo, Rl se selecciona de manera independiente cada vez que aparece a partir de halógeno, nitro, oxo, fosfonoxi, fosfono, tioxo, 15 ciano, -O-Rs, -S-Rs, -C(O)RS, -OC(O)RS, - C(O)ORS, -N(RSRS'), S(O)Rs, -SO2Rs, -C(O)N(RsRs') o -N(RS)C(O)RS’;o carbociclo de C3C6 o heterociclo de 3 a 6 miembros, cada uno de los cuales de manera independiente está opcionalmente sustituido cada vez que aparece con uno o más sustituyentes que se seleccionan a partir de fifteen cyano, -ORs, -MRs, -C (O) RS, -OC (O) RS, - C (O) ORS, -N (RSRS'), S (O) Rs, -SO2Rs, -C (O) N (RsRs') or -N (RS) C (O) RS';or C carbocycle3C6 or 3- to 6-membered heterocycle, each of which independently is optionally substituted each occurrence with one or more substituents selected from 20 halógeno, hidroxi, mercapto, amino, carboxi, nitro, oxo, fosfonoxi, fosfono, tioxo, formilo, ciano, alquilo de C^Cg, alquenilo de C2-C6, alquinilo de C2-C6, halogenoalquilo de C--C6, halogenoalquenilo de C2-C6 o halogenoalquinilo de C2-C6;twenty halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, C ^ Cg alkyl, C alkenyl2-C6, C alkynyl2-C6, C-C haloalkyl6, C halogenoalkenyl2-C6 or halogenoalkynyl of C2-C6;Ls, Ls' and Ls each one is selected d way Ls, Ls' y Ls se seleccionan cada uno d manera 25 independent each time they appear from link;or alkylene 25 independiente cada vez que aparecen a partir de enlace;o alquileno 804 aemsie «.txicANí? · by CiC6l C alkenylene2-C6 or C alkynylene2-C6, calíepwí®- 'déi which independently are npriinnnliTt-g-nto or substitution. every time it appears with one or more RL;and 804 aemsie «.txicANí?· de C-i-C6l alquenileno de C2-C6 o alquinileno de C2-C6, calíepwí®-’ déi los cuales de manera independiente está npriinnnliTt-g-nto oustituidn. cada vez que aparece con uno o más RL;y Rs, Rs' and Rs are each independently selected each time they appear from hydrogen;C alkyl, - C6, C alkenyl2-C6 or C alkynyl2-C6, each of which independently is optionally substituted each time it appears with one or more substituents that are selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano or carbocycle or heterocycle Rs, Rs' y Rs se seleccionan cada uno de manera independiente cada vez que aparecen a partir de hidrógeno;alquilo de C.,-C6, alquenilo de C2-C6 o alquinilo de C2-C6, cada uno de los cuales de manera independiente está opcionalmente sustituido cada vez que aparece con uno o más sustituyentes que se seleccionan a partir de halógeno, hidroxi, mercapto, amino, carboxi, nitro, oxo, fosfonoxi, fosfono, tioxo, formilo, ciano o carbociclo o heterociclo de 3 6 members;or 3- to 6-membered carbocycle or heterocycle;in which each 3- to 6-membered carbocycle or heterocycle in Rs, Rs' or Rs'independently is optionally substituted each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci- Ce, C alkenyl2-C6, C alkynyl2-C6, Ci-C haloalkyl6, C halogenoalkenyl2-C6 or halogenoalkynyl of C2-C6, wherein each of said heterocycles is independently a saturated ring system, a partially saturated ring system, or a fully unsaturated ring system, in which at least one ring atom in said ring system is a heteroatom. 3 a 6 miembros;o carbociclo o heterociclo de 3 a 6 miembros;en los cuales cada carbociclo o heterociclo de 3 a 6 miembros en Rs, Rs' o Rs' de manera independiente está opcionalmente sustituido cada vez que aparecen con uno o más sustituyentes que se seleccionan a partir de halógeno, hidroxi, mercapto, amino, carboxi, nitro, oxo, fosfonoxi, fosfono, tioxo, formilo, ciano, alquilo de Ci-Ce, alquenilo de C2-C6, alquinilo de C2-C6, halogenoalquilo de Ci-C6, halogenoalquenilo de C2-C6 o halogenoalquinilo de C2-C6, en donde cada uno de dichos heterociclos es de man ra independiente un sistema de anillo saturado, un sistema de anillo parcialmente saturado, o un sistema de anillo completamente insaturado, en los cuales por lo menos un átomo de anillo en dicho sistema de anillo es un heteroátomo.
- 10- El compuesto o sal de conformidad con la 10.- The compound or salt in accordance with
Independent claims3
6,414 paragraphs in 890 sections, as filed
(54) Title: ANTI-VIRAL COMPOUNDS.
(54) Title: ANTI-VIRAL COMPOUNDS TO TREAT HCV INFECTION.
(57) Summary
Compounds effective to inhibit the replication of the Hepatitis C Virus (HCV) are described. This invention also relates to methods of making said compounds, to compositions comprising said compounds, and to methods of using said compounds to treat HCV infection.
(57) Abstract
Compounds effective in inhibiting replication of Hepatitis C virus (HCV) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.
Institut
Μ xicano of the Property
Industrial
PATENT TITLE NO. 339989 is
Owner (s): ABBVIE BAHAMAS LTD.
Address: Sasson House Shirley Street & Victoria Av. New Providersce, Nassau, BAHAMAS
D nomination: ANTI-VIRAL COMPOUNDS.
Classification: lnt.CI.8: A61K31 / 14; A61K31 / 4178: A61K31 / 4184; A61K31 / 4196; A61K31 / 425;
A61K31 / 4439; C07D403 / 14; C07D417 / 14
Inventor (s): DAVID A, DEGOEY; WARREN Μ. ΚΑΤΙ; CHARLES W. HUTCHINS; PAMELA L.
DONNER; ALLAN C. KRUEGER; CHRISTOPHER E. MOTTER; LISSA T. NELSON; SACHIN V. PATEL; MARK A. MATULENKO; RYAN G. KEDDY; TAMMIE K. JINKERSON; Yl GAO; DOUGLAS K. HUTCHINSON; CHARLES A. FLENTGE: ROLF WAGNER; CLARENCE J. MARING; MICHAEL D. TUFANO; DAVID / \ tífclfcbfcNNtK: iODü W. KUGKVVAY, UmCHUN LlU JOHN K PRATT;
'KATHY SARRIS KEVN R WOLLFR SEB1 β H WAGAW JEAN C CALIFANO;
WENKE Ll, DANIEL D CAS<sup>D</sup>I MARY E. BELLIZZI; J OHHT RANDOLPH
REQUEST
<td>MX / a / 2015 / 002¿8</td><td colspan="2">International filing dateiMlí ί June 10, 2010 Divisional Patent Number: 330658 , PRIORITY</td>
<td>Country:</td><td>8 Date:</td><td>Number:</td>
<td>US</td><td>June 11, 2009</td><td> 61/186,291</td>
<td>US</td><td>September 16, 2009</td><td> 61/242,836</td>
<td>US</td><td>September 18, 2009</td><td> 61/243,596</td>
Validity: Twenty years
Winding: June 10, 2030?
item based on articles 1 *. 2 * fraction V. 6th fraction III, and 59 of the Propledall Industrial Law. ilo 23 of I »Industrial Property Law the present patent has a validity of twenty years, non-extendable, and the presentation of the tetsmaconai and datsiá application subject to> payment of the fee to maintain Agents the title lo Ifjce based on or arranged ' by tes srtfcufes 6 ° fractions III and 7 ° bis 2 of the Law of the
Official of the Federation (0.0 F.) 2Q06 / 1991, amended to 02/08/1994. 25/10 / 1996.26 / 12/1997. 05/17/1999,
01/2006, 06/05 / 2009.06 / 01/2010, 18/06/2010 28/06/2010, 27/01 '2012 and 09/04 / 2íF2); artlcufóst<sup>s</sup>, 3rd section V subsection a), 4th and 12th sections I and III of the Regulations of the Mexican Institute of Industrial Property (DOF 12/14/1999, amended on 07/01/2002, 07/15/2004, 28 / 07/2004 and 7/09/2007); Articles 1, 3, 4, 5, section V, subsection a), 16 sections I and III and 30 of the Organic Statute of the Mexican Institute of Industrial Property (DOF) 12/27/1999, amended on 10/10/2002, 07/29/2004, 08/04/2004 and 09/13/2007); 1, 3 and 5 paragraph a) of the Agreement that delegates powers to the Deputy Directors General, Coordinator, Divisional Directors, Holders of Regional Offices, Divisional Deputy Directors, Departmental Coordinators and other subordinates of the Mexican Institute of Industrial Property. (DOF 12/15/1999, amended on 02/04/2000, 07/29/2004, 08/04/2004 and 09/13/2007).
Issue Date: June 21, 2016
<img file="MX339989B_D0001.tif" />
/ ΖΟ 'S / ZL?
ANTI-VIRAL COMPOUNDS
IMPI
MEXICAN INSTITUTE OF PECFÍEDAD
INDUSTRIAL
<img file="MX339989B_D0002.tif" />
This application claims the benefit of and incorporates for reference the full content the Provisional Application US Series No. 61 / 186,291, filed on June 11, 2009, Provisional Application US Series No. 61 / 242,836, filed on September 16 2009, and US Provisional Application Serial No. 61 / 243,596, filed on September 18, 2009.
FIELD OF THE INVENTION
The present invention relates to compounds effective to inhibit Hepatitis C Virus (HCV) replication. The present invention also relates to compositions comprising such compounds and to methods of using these compounds to treat HCV infection.
BACKGROUND OF THE INVENTION
HCV is an RNA virus that belongs to the genus
Hepacivirus in the family Flaviviridae. The enveloped HCV virion contains a positive strand RNA genome that codes for all known virus-specific proteins in a single, uninterrupted, open reading frame. The open reading frame comprises approximately 9500 nucleotides and c © 9g ^ S ^ o<sup>X</sup>f | S ^ Í8a
<img file="MX339989B_D0003.tif" />
INDUSTRIAL individual large polyprotein of approximately 3000 amino acids. The polyprotein comprises a core protein, E1 and E2 envelope proteins, a membrane-bound p7 protein, and the nonstructural proteins NS2, NS3, NS4A, NS4B, NS5A, and NS5B.
HCV infection is associated with progressive liver disease, including cirrhosis and hepatocellular carcinoma. Chronic hepatitis C can be treated with PEG-interferon alfa in combination with ribavirin. Substantial limitations to efficacy and tolerability remain because many users suffer from side effects, and viral clearance from the body is often inadequate. Therefore, there is a need for new drugs to treat HCV infection.
BRIEF DESCRIPTION OF THE INVENTION
The present invention presents compounds of formulas I, l<sub>TO</sub>, Ib, l<sub>c</sub> and Id, and pharmaceutically acceptable salts thereof. These compounds and salts can inhibit HCV replication and are therefore useful for treating HCV infection.
The present invention also features compositions comprising the compounds or salts of the present invention. The compositions may also include additional therapeutic agents, such as HCV helicase inhibitors, HCV polymerase inhibitors, HCV protease inhibitors, HCV NS5A inhibitors, CD81 inhibitors, inhibitorjsj ^ [
INSTITUTO MEXICANO internal ribosome entry site inhibitors<sup>D £</sup>flíK®rS ^ LpiSi5 ^ K). The present invention also presents methods for using the compounds or salts of the present invention to inhibit HCV replication. The methods comprise contacting cells infected with the HCV virus with a compound or salt of the present invention, thereby inhibiting the replication of the HCV virus in the cells.
Furthermore, the present invention presents methods for using the compounds or salts of the present invention, or compositions comprising them, to treat HCV infection. The methods comprise administering a compound or salt of the present invention, or a pharmaceutical composition comprising them, to a patient in need thereof, thereby reducing the blood or tissue level of HCV virus in the patient.
The present invention also presents the use of the compounds or salts of the present invention for the manufacture of medicaments for the treatment of HCV infection.
Likewise, the present invention presents processes for the preparation of the compounds or salts of the invention.
Other features, objectives, and advantages of the present invention are apparent from the following detailed description. However, it is to be understood that the detailed description, although preferred embodiments of the invention are indicated, are provided by way of illustration only, not limitation.
<img file="MX339989B_D0004.tif" />
Modifications within the scope of the invention will become apparent to those skilled in the art from the detailed description.
DETAILED DESCRIPTION OF THE INVENTION
The present invention features compounds having formula I, and pharmaceutically acceptable salts thereof,
YAL<sub>1</sub>-XL<sub>2</sub>-BZ in which:
X is carbocycle of C<sub>3</sub>-C<sub>12</sub> or 3- to 12-membered heterocycle, and is optionally substituted with one or more R<sub>TO</sub>;
L! and L<sub>2</sub> each are independently selected from link; or C ^ Ce alkylene, C alkenylene<sub>2</sub>-C<sub>6</sub> or C alkynylene<sub>2</sub>-C<sub>6</sub>, each of which, independently, is optionally substituted each time it appears with one or more R<sub>L</sub>;
L<sub>3</sub> is link or -L<sub>s</sub>-KL<sub>s</sub>'-, in which K is selected from bond, -O-, -S-, -N (R<sub>B</sub>) -, -C (O) -, -S (O)<sub>2</sub>-, -S (O) -, -OS (O) -OS (O)<sub>2</sub>-, -S (O)<sub>2</sub>O-, -S (O) O-, -C (O) O-, -OC (O) -, -OC (O) O-,
-C (O) N (R<sub>b</sub>) -, -N (R<sub>b</sub>) C (O) -, -N (R<sub>b</sub>) C (O) O-, -OC (O) N (R<sub>b</sub>) -, -N (R<sub>b</sub>)SW)-,
-N (R<sub>b</sub>)SW)<sub>2</sub>-S (O) N (R<sub>b</sub>) -, -S (O)<sub>2</sub>N (R<sub>b</sub>)-,
-C (O) N (Rb) C (O) -, jam.
<img file="MX339989B_D0005.tif" />
-N (R<sub>b</sub>) C (O) N (R<sub>b</sub>') -, -N (R<sub>b</sub>)SW<sub>2</sub>N (R<sub>b</sub>') -, or -N (R<sub>b</sub>)THEY ARE
A and B are each independently C3-C12 carbocicToT or 3- to 12-membered heterocycle, and are each independently optionally substituted with one or more R<sub>TO</sub>;
D is C3-G12 carbocycle or 3- to 12-membered heterocycle, and is optionally substituted with one or more R<sub>TO</sub>; or D is hydrogen or R<sub>TO</sub>;
Y is selected from -T'-C (RiR2) N (R<sub>5</sub>) -TR<sub>d</sub>, -T'-C (R<sub>3</sub>R4) C (R<sub>6</sub>R<sub>7</sub>) -TR<sub>d</sub>, -L<sub>k</sub>-TR<sub>d</sub>, or -L<sub>K</sub>-AND;
R-ι and R<sub>2</sub> are each independently R<sub>c</sub>, and R5 is R<sub>b</sub>; or R1 is R<sub>c</sub>, and R2 and R5. Taken together with the atoms to which they are attached, they form a 3- to 12-membered heterocycle which is optionally substituted with one or more R<sub>TO</sub>;
R3, R4, Re. And R7 are each independently Rc, 'or R<sub>3</sub> and R<sub>6</sub> are each independently R<sub>c</sub>, and R<sub>4</sub> and R<sub>7</sub>Taken together with the atoms to which they are attached, they form a 3- to 12-membered carbocycle or heterocycle which is optionally substituted with one or more R<sub>TO</sub>;
Z is selected from -T'-C (R<sub>8</sub>R9) N (R<sub>12</sub>) -TR<sub>D</sub>, -T'-C (R<sub>10</sub>Rii) C (R<sub>13</sub>Ri4) -TR<sub>D</sub>, -I_k-T-Rd, or -L<sub>k</sub>-AND;
R<sub>8</sub> and R<sub>9</sub> are each independently R<sub>c</sub>, and R12 is Rb; or Re is Rc, and Re and Rí2, taken together with the atoms to which they are attached, form a 3- to 12-membered heterocycle which is optionally substituted with one or more R<sub>TO</sub>;
R10, R11, R13, and R14 are each independently R<sub>c</sub>; or R<sub>w</sub> and R13 are each manJ ^ JJd ^ fe ^
OF THE PROPERTY
INDUSTRIAL
Rc. and R11 and Ri4, taken together with the atoms to which they are attached, form a 3- to 12-membered carbocycle or heterocycle which is optionally substituted with one or more R<sub>TO</sub>;
T and T 'are each independently selected each time they appear from link, -L<sub>s</sub>-, -L<sub>s</sub>-ML<sub>s</sub>'-, or -Ls-M-Ls'-M'-Ls-, in which M and M' are each independently selected each time they appear from link, -O-,
-S-, -N (R<sub>b</sub>) - -C (O) -, -S (O)<sub>2</sub>-, -S (O) -, -OS (O) -, - OS (O)<sub>2</sub>-, -S (O)<sub>2</sub>O-, -S (O) O-, -C (O) O-, -OC (O) -, -OC (O) O-, -C (O) N (R<sub>b</sub>) -, -N (R<sub>b</sub>) C (O) -, -N (Rb) C (O) O-, -OC (O) N (Rb) -, -N (Rb) S (O) -, -N (R<sub>b</sub>)SW)<sub>2</sub>-, -S (O) N (R<sub>b</sub>) -, -S (O)<sub>2</sub>N (R<sub>b</sub>) -, -C (O) N (Rb) C (O) -, -N (Rb) C (O) N (R<sub>b</sub>') -, -N (Rb) SO<sub>2</sub>N (R<sub>b</sub>') -. -N (R<sub>b</sub>) S (O) N (R<sub>b</sub>') -, carbocycle of C<sub>3</sub>-C<sub>12</sub> or 3- to 12-membered heterocycle, and in which said C carbocycle<sub>3</sub>-Ci<sub>2</sub> and 3- to 12-membered heterocycle are each independently optionally substituted each time they appear with one or more R<sub>TO</sub>;
L<sub>K</sub> is selected independently each time it appears from link, -L<sub>S</sub>-N (R<sub>B</sub>)CABBAGE<sub>S</sub>'- or -L<sub>s</sub>-C (O) N (R<sub>B</sub>) -Ls'-; or CiC alkylene<sub>6</sub>, alken filled with C<sub>2</sub>-C<sub>6</sub> or alkyne filled with C<sub>2</sub>-C<sub>6</sub>, each of which, independently, is optionally substituted each time it appears with one or more R<sub>L</sub>; or carbocycle of C<sub>3</sub>-C<sub>12</sub> or 3- to 12-membered heterocycle, each of which, independently, is optionally substituted each time it occurs with one or more R<sub>TO</sub>;
E is independently selected each time
<img file="MX339989B_D0006.tif" />
appears from carbocycle of C<sub>3</sub>-C<sub>12</sub> or hetero% i ('<sup>, w</sup>’ '^ ** <sup>r</sup> MEXICAN INSTITUTE
OWNED members, and independently is optionally replaced!
every time it appears with one or more R<sub>TO</sub>;
R<sub>d</sub> each is independently selected each time it appears from hydrogen or R<sub>TO</sub>;
R<sub>to</sub> is independently selected each occurrence from halogen, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano, or -L<sub>s</sub>-Re <in which two R<sub>TO</sub> Adjacent, taken together with the atoms to which they are attached and any atoms between the atoms to which they are attached, may optionally form carbocycle or heterocycle;
R<sub>B</sub> and R<sub>b</sub>'each are independently selected each time they appear from hydrogen; or Ci-Ce alkyl, C alkenyl<sub>2</sub>-C<sub>6</sub> or C alkynyl<sub>2</sub>-C<sub>s</sub>, each of which, independently, is optionally substituted each time it appears with one or more substituents that are selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl 6-membered, cyano or carbocycle or heterocycle; or 3- to 6-membered carbocycle or heterocycle; in which each 3-6 membered carbocycle or heterocycle in R<sub>B</sub> or R<sub>B</sub>'independently is optionally substituted each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, alkyl of Ο- ι-Οβ, C alkenyl<sub>2</sub>-C<sub>6</sub>, C alkynyl<sub>2</sub>-C<sub>6</sub>, halogenoalkyl of Οτ-Οβ, halogenoalkenyl of
IPllJWIIZr.yj-t .-. V - ··.
IMPI
<img file="MX339989B_D0007.tif" />
C<sub>2</sub>-C<sub>6</sub> or halogenoalkynyl of C<sub>2</sub>-C<sub>6</sub>; <sub>Ikl</sub>„<sub>1T</sub>, „* ° ° z □ i INSTITUTO MEXICANO
OF THE PROPERTY
INDUSTRIAL _
Re is independently selected for each occurrence from hydrogen, halogen, hydroxy, mercapto, arrimó, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, or cyano; or Cj-Ce alkyl, C alkenyl<sub>2</sub>-C<sub>6</sub> or C alkynyl<sub>2</sub>-C<sub>6</sub>, each of which, independently, is optionally substituted each time it appears with one or more substituents that are selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl 6-membered, cyano or carbocycle or heterocycle; or 3- to 6-membered carbocycle or heterocycle; in which each 3-6 membered carbocycle or heterocycle in R<sub>c</sub> independently it is optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, C- alkyl | -C<sub>6</sub>, C alkenyl<sub>2</sub>-C<sub>6</sub>, C alkynyl<sub>2</sub>-C<sub>6</sub>, Ci-Ce haloalkyl, C haloalkenyl<sub>2</sub>-C<sub>6</sub> or halogenoalkynyl of C<sub>2</sub>-C<sub>6</sub>;
Re is independently selected each time it appears from -OR<sub>s</sub>, -MR<sub>s</sub>, -C (O) R<sub>S</sub>, -OC (O) R<sub>S</sub>, -C (O) OR<sub>S</sub>, -N (RsRs'), -S (O) R<sub>s</sub>, -SO<sub>2</sub>R<sub>s</sub>, -C (O) N (R<sub>s</sub>R<sub>s</sub>'), -N (R<sub>s</sub>) C (O) R<sub>s</sub>', -N (Rs) C (O) N (R<sub>s</sub>'R<sub>s</sub>”), -N (Rs) SO<sub>2</sub>R<sub>s</sub>', -SO<sub>2</sub>N (R<sub>s</sub>Rs'),
-N (Rs) SO<sub>2</sub>N (R<sub>s</sub>'R<sub>s</sub>”), - N (R<sub>s</sub>) S (O) N (Rs'R<sub>s</sub>”), -OS (O) -R<sub>s</sub>, -BEAR)<sub>2</sub>-R<sub>s</sub>,
-SW)<sub>2</sub>OR<sub>s</sub>, -S (O) OR<sub>s</sub>, -OC (O) OR<sub>S</sub>, -N (R<sub>S</sub>) C (O) OR<sub>S</sub>', -OC (O) N (R<sub>s</sub>Rs'),
-N (R<sub>s</sub>) S (O) -R<sub>s</sub>', -S (O) N (R<sub>s</sub>R<sub>s</sub>') or -C (O) N (R<sub>S</sub>) C (O) -R<sub>S</sub>'; or rent from
Ci-C<sub>6l</sub> C alkenyl<sub>2</sub>-C<sub>6</sub> or C alkynyl<sub>2</sub>-C<sub>6</sub>, each of which, independently, is optionally
<img file="MX339989B_D0008.tif" />
once it appears with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, or cyano; or C carbocycle<sub>3</sub>-C<sub>6</sub> or 3- to 6-membered heterocycle, each of which, independently, is optionally substituted each time it appears with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-Ce alkyl, C alkenyl<sub>2</sub>-C<sub>6</sub>, C alkynyl<sub>2</sub>-C<sub>6</sub>, CiC haloalkyl<sub>6</sub>, C halogenoalkenyl<sub>2</sub>-C<sub>6</sub> or halogenoalkynyl of C<sub>2</sub>-C<sub>6</sub>;
R<sub>L</sub> is independently selected each time it appears from halogen, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano, -OR<sub>s</sub>, -MR<sub>s</sub>, -C (O) R<sub>S</sub>, -OC (O) R<sub>S</sub>, -C (O) OR<sub>S</sub>, -N (R<sub>S</sub>R<sub>S</sub>'). -S (O) R<sub>s</sub>, -SO<sub>2</sub>R<sub>s</sub>, -C (O) N (R<sub>s</sub>R<sub>s</sub>') or -N (R<sub>S</sub>) C (O) R<sub>S</sub>'; or C carbocycle<sub>3</sub>-C<sub>6</sub> 3-6 membered heterocycle, each of which independently is optionally substituted each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy , phosphono, thioxo, formyl, cyano, Ci-C alkyl<sub>6</sub>, C alkenyl<sub>2</sub>-C<sub>6</sub>, C alkynyl<sub>2</sub>-C<sub>6</sub>, Ci-C haloalkyl<sub>6</sub>, C halogenoalkenyl<sub>2</sub>-C<sub>6</sub> or halogenoalkynyl of C<sub>2</sub>-C<sub>6</sub>; in which two R<sub>L</sub> Adjacent, taken together with the atoms to which they are attached and any atoms between the atoms to which they are attached, may optionally form carbocycle or heterocycle;
Ls,
L<sub>s</sub>'and L<sub>s</sub>”Are selected each
<img file="MX339989B_D0009.tif" />
OF INDUSTRIAL PROPERTY
<img file="MX339989B_D0010.tif" />
independent each time they appear from link; or CiC alkylene<sub>6</sub>, C alkenylene<sub>2</sub>-C<sub>6</sub> or C alkynylene<sub>2</sub>-C<sub>6</sub>, each of which, independently, is optionally substituted each time it appears with one or more R<sub>L</sub>; and
Rs, Rs' and Rs "are each independently selected each time they appear from hydrogen; Ci-C alkyl<sub>6</sub>, C alkenyl<sub>2</sub>-C<sub>6</sub> or C alkynyl<sub>2</sub>-C<sub>6</sub>, each of which, independently, is optionally substituted each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl , cyano or carbocycle or 6-membered heterocycle; or 3- to 6-membered carbocycle or heterocycle; in which each 3- to 6-membered carbocycle or heterocycle in Rs, Rs 'or Rs' is independently optionally substituted each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy , nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Οτ-θβ alkyl, C alkenyl<sub>2</sub>-C<sub>6</sub>, C alkynyl<sub>2</sub>-C<sub>6</sub>, Cj-Cs haloalkyl, C haloalkenyl<sub>2</sub>-C6 or C haloalkynyl<sub>2</sub>-C<sub>6</sub>.
A and B are preferably independently selected from carbocycle of C<sub>5</sub>-C<sub>6</sub> (e.g. phenyl), 5-6 membered heterocycle (e.g. pyridinyl or thiazolyl), or 8-12 membered bicycles such as
IMPI
<img file="MX339989B_D0011.tif" />
<img file="MX339989B_D0012.tif" />
in which Z<sub>1</sub> is independently selected each time it appears from O, S, NH, or CH<sub>2</sub>, Z<sub>2</sub> is independently selected each time it appears from N or CH, Z<sub>3</sub> is independently selected each time it appears from N or CH, Z<sub>4</sub> is independently selected each time it appears from O, S, NH, or CH<sub>2</sub>, and W- ,, W<sub>2</sub>, W<sub>3</sub>, W<sub>4</sub>, W<sub>5</sub> and W<sub>6</sub> are each independently selected each time they appear from CH or N. A and B are each independently optionally substituted with one or more R<sub>TO</sub>.
More preferably, A is selected from carbocycle of C<sub>5</sub>-C<sub>6</sub>, 5- to 6-membered heterocycle,
<img file="MX339989B_D0013.tif" />
<img file="MX339989B_D0014.tif" />
W<sub>6</sub> y is optionally substituted with one or more R<sub>TO</sub>; B is selected from carbocycle of C<sub>5</sub>-C<sub>6</sub>, 5- to 6-membered heterocycle,
<img file="MX339989B_D0015.tif" />
y is optionally substituted with one or more R<sub>TO</sub>; in which Zi, Z<sub>2</sub>, Z<sub>3</sub>, Z<sub>4</sub>, W<sub>1f</sub> W<sub>2</sub>, W<sub>3</sub>, W<sub>4</sub>, W<sub>5</sub>, W<sub>6</sub> they are as defined above. Preferably Z<sub>3</sub> is N and Z<sub>4</sub> is NH. For example, A se
<img file="MX339989B_D0016.tif" />
you can select from;
IMPIOS
INSTITUTO MEXICANO DE LA PROPERTY INDUSTRIAL pyridinyl (for example, j
X.
tiazolllo (for example,
<img file="MX339989B_D0017.tif" />
§) and is optionally substituted with one or more R<sub>TO</sub>; and B can be selected from;
phenyl (for example,
<img file="MX339989B_D0018.tif" />
), thiazolyl (e.g. pyridinyl (e.g.
<img file="MX339989B_D0019.tif" />
(for example
<img file="MX339989B_D0020.tif" />
trjKMA-.A.-yy -.-. Tt-fk »- ·
<img file="MX339989B_D0021.tif" />
and is optionally substituted with one or more
OF THE Rather preferred INDUSTRIAL PROPERTY, both A and B are phenyl (for example, both A and B are $
<img file="MX339989B_D0022.tif" />
). Also quite preferably,
A is
A is
<img file="MX339989B_D0023.tif" />
Λ
X
N;
A is
A is
A is and B is | ά; or
<img file="MX339989B_D0024.tif" />
; or in which each of A and B independently is optionally substituted with one or more R<sub>TO</sub>.
D is preferably selected from carbocycle of C<sub>5</sub>-C<sub>6</sub>, 5 to 6 membered heterocycle, or 6 to 12 membered skeletons, and is optionally substituted with one or more R<sub>TO</sub>. D can also be preferably selected from Ci-C alkyl<sub>6</sub>, C alkenyl<sub>2</sub>-C<sub>6</sub> or C alkynyl<sub>2</sub>-C<sub>6</sub>, and is optionally substituted with one or more substituents that are selected from R<sub>l</sub>. More preferably, D is carbocycle of C<sub>5</sub>-C<sub>6</sub> (eg phenyl), 5- to 6-membered heterocycle (eg, pyridinyl, pyrimidinyl, thiazolyl), or 6 to 12-member bicycles indan i lo, 4,5,6,7-tetrahydrobenzo [d] thiazolyl, benzo [d] thiazolyl,
<img file="MX339989B_D0025.tif" />
INDUSTRIAL PROPERTY indazolyl, benzo [d] [1,3] dioxol-5-yl), and is substituted with one or more Rm, in which R<sub>M</sub> is halogen, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano, or -L<sub>S</sub>-R<sub>AND</sub>. Also preferably, D is phenyl, and is optionally substituted with one or more R<sub>to</sub>. More preferably, D is phenyl, and is substituted with one or more R<sub>M</sub>, in which R<sub>m</sub> it is as defined above. Quite preferably,
D is
<img file="MX339989B_D0026.tif" />
<img file="MX339989B_D0027.tif" />
or in which R<sub>m</sub> is as defined above, and each R<sub>N</sub> is independently selected from R<sub>D</sub> and is preferably hydrogen. One or more of R<sub>N</sub> preferably it can also be halogen such as F.
D is also preferably pyridinyl, pyrimidinyl, or thiazolyl, optionally substituted with one or more R<sub>TO</sub>. More preferably D is pyridinyl, pyrimidinyl, or thiazolyl, and is substituted with one or more R<sub>M</sub>. Rather preferably, D is
<img file="MX339989B_D0028.tif" />
ιΛΛΛ /
<img file="MX339989B_D0029.tif" />
N λλλ /
<img file="MX339989B_D0030.tif" />
A / W '• M rle ^ í 3rd di
MEXICAN INSTITUTE OF PROPERTY
<img file="MX339989B_D0031.tif" />
in which R<sub>M</sub> is as defined above selects me independently from R<sub>D</sub> and of<sup>D</sup>pTeYererícTá is hydrogen. One or more of R<sub>N</sub> preferably it may be halogen such as F. D is also preferably indanyl, 4,5,6,7-tetrahydrobenzo [d] thiazolyl, benzo [d] thiazolyl, or indazolyl, and is optionally substituted with one or more Ra-De more preferably D is indanyl, 4,5,6,7-tetrahydrobenzo [d] thiazolyl, benzo [d] thiazolyl, indazolyl, or benzo [d] [1,3] dioxol-5-yl, and is substituted with one or more R<sub>m</sub>. Rather preferably, D is
<img file="MX339989B_D0032.tif" />
y is optionally substituted with one or more R<sub>M</sub>.
Preferably R<sub>M</sub> is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or ϋ, -Οβ alkyl, C alkenyl<sub>2</sub>-C<sub>6</sub> or C alkynyl<sub>2</sub>-C<sub>6</sub>, each of which, independently, is optionally substituted each time it appears with one or more substituents that are selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or carbocycle of C<sub>3</sub>-C<sub>6</sub> or 3- to 6-membered heterocycle, each of which, independently, is optionally substituted at each occurrence with one or more substituents selected from halogen,
..4
'.Ί • 1 hydroxy, mercapto, amino, carboxy, nitro, oxo, XoiVfcdxi
<img file="MX339989B_D0033.tif" />
I thioxo, formyl, cyano, Ch-Cg alkyl, ΟΣ-ύΓβΤ alkenyl ^ ίΙυίηΐΤ ^ ΤΓβ C<sub>2</sub>-C<sub>6</sub>, Ci-Cg haloalkyl, haloalkenyl <sup>1</sup> of Cr<sub>2</sub>-b<sub>6</sub>'0' * "C halogenoalkenyl<sub>2</sub>-C<sub>6</sub>. More preferably, R<sub>M</sub> is halogen, hydroxy, mercapto, amino, carboxy; or Ci-C alkyl<sub>6</sub>, C alkenyl<sub>2</sub>-C<sub>6</sub> or C alkynyl<sub>2</sub>-C<sub>6</sub>, each of which, independently, is optionally substituted each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, or carboxy. Rather preferably, R<sub>M</sub> is C - \ - C alkyl<sub>6</sub> which is optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, or carboxy.
Also preferably, R<sub>M</sub> is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, or cyano; or R<sub>M</sub> is -L<sub>S</sub>-R<sub>AND</sub>, in which L<sub>s</sub> is a bond or alkylene of
Ο, -Ce, and R<sub>and</sub> is -N (R<sub>S</sub>R<sub>S</sub>'), -OR<sub>s</sub>, -C (O) R<sub>S</sub>, -C (O) OR<sub>S</sub>, -C (O) N (R<sub>S</sub>R<sub>S</sub>’).
-N (R<sub>S</sub>) C (O) R<sub>S</sub>', -N (R<sub>S</sub>) C (O) OR<sub>S</sub>', -N (R<sub>s</sub>)SW<sub>2</sub>R<sub>s</sub>', -SO<sub>2</sub>R<sub>s</sub>, -MR<sub>s</sub>, or -P (0) (0Rs) 2, in which R<sub>s</sub> and Rs' can be selected, for example, each independently each occurrence from (1) hydrogen or (2) Ci-C alkyl<sub>6</sub> optionally substituted each occurrence with one or more halogen, hydroxy, -O-C-C alkyl<sub>6</sub> or 3-6 membered heterocycle; or R<sub>M</sub> is C ^ Cg alkyl, C alkenyl<sub>2</sub>-C<sub>6</sub> or C alkynyl<sub>2</sub>-C<sub>6</sub>, each of which, independently, is optionally substituted each occurrence with one or more substituents selected from
<img file="MX339989B_D0034.tif" />
halogen, hydroxy, mercapto, amino, carboxy, niisojuto, io ^ an6o
INDUSTRIAL phosphono, thioxo, formyl or cyano; or R<sub>M</sub> is carbocycle of C<sub>3</sub>-C<sub>6</sub> or 3- to 6-membered heterocycle, each of which, independently, is optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, alkyl of Ο,-alquβ, alkenyl of C<sub>2</sub>-C<sub>6</sub>, C alkynyl<sub>2</sub>-C<sub>6</sub>, halogenoalkullo of CpCe, halogenoalquenllo of C<sub>2</sub>-C<sub>6</sub>, C halogenoalkynyl<sub>2</sub>-C<sub>6</sub>, -C (O) OR<sub>S</sub>, or - N (R<sub>S</sub>R<sub>S</sub>'). More preferably, R<sub>M</sub> is halogen (e.g. fluoro, chloro, bromine, iodo), hydroxy, mercapto, amino, carboxy, or C ^ -Ce alkyl (e.g. methyl, isopropyl, tert-butyl), C-alkenyl<sub>2</sub>-C<sub>6</sub> or C alkynyl<sub>2</sub>-C<sub>6</sub>, each of which, independently, is optionally substituted each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, cyano, or carboxy. For example R<sub>M</sub> is CF<sub>3</sub>, -C (CF<sub>3</sub>)<sub>2</sub>OH, -C (CH<sub>3</sub>)<sub>2</sub>-CN, -C (CH<sub>3</sub>)<sub>2</sub>-CH<sub>2</sub>OH, or -C (CH<sub>3</sub>)<sub>2</sub>-CH<sub>2</sub>NH<sub>2</sub>. Also preferably R<sub>M</sub> is -L<sub>S</sub>-R<sub>AND</sub> in which L<sub>s</sub> is a link and R<sub>AND</sub> is -N (RsRs), -O-Rs, -N (R<sub>S</sub>) C (O) OR<sub>S</sub>', -N (R<sub>s</sub>)SW<sub>2</sub>R<sub>s</sub>', -SO<sub>2</sub>R<sub>s</sub>, or -SR<sub>s</sub>. For example in cases where L<sub>s</sub> is a link, R<sub>AND</sub> is -N (alkyl (C<sub>1</sub>-C<sub>6</sub>))<sub>2 </sub>(for example, -NMe<sub>2</sub>); -N (alkylene (Ci-C<sub>6</sub>) -O- (alkyl (CiC<sub>6</sub>))<sub>2</sub> (for example -N (CH<sub>2</sub>CH<sub>2</sub>OMe)<sub>2</sub>); -NíalquIKC ^ CejjíalquileníC ^ Cej-Oalquil (C<sub>1</sub>-C<sub>6</sub>)) (for example -N (CH<sub>3</sub>) (CH<sub>2</sub>CH<sub>2</sub>OMe)); -O-C., -C alkyl<sub>6</sub> (eg -Ο-Me, -O-Et, -O-isopropyl, -O-tert-butyl, -O-nhexyl); -O-halogenoalkyl of C<sub>r</sub>C<sub>6</sub> (for example, -OCF<sub>3</sub>, -OCH<sub>2</sub>CF<sub>3</sub>);
-O-alkylene (Ci-C<sub>6</sub>) -piperidine (for example, -OC fa mbu <INDUSTRIAL PROPERTY RI
<img file="MX339989B_D0035.tif" />
<img file="MX339989B_D0036.tif" />
-N (alkyl (CiC<sub>6</sub>)) C (O) O-C- | -C alkyl<sub>6</sub> (for example, -N (CH<sub>3</sub>) C (O) OCH<sub>2</sub>CH (CH<sub>3</sub>) 2), -NíalquIKCi-Ce ^ SOa-C-alkyl<sub>r</sub>C<sub>6</sub> (for example, -N (CH<sub>3</sub>)SW<sub>2</sub>CH<sub>3</sub>); -SW<sub>2</sub>-C alkyl<sub>r</sub>C<sub>6</sub> (for example, -SO<sub>2</sub>I); -SW<sub>2</sub>-halogenoalkyl of C<sub>r</sub>C<sub>6</sub> (for example, -SO<sub>2</sub>CF<sub>3</sub>); or -S-halogenoalkyl of C ^ -Ce (for example, SCF<sub>3</sub>). Also preferably R<sub>M</sub> is -Lg-R<sub>AND</sub> in which L<sub>s</sub> is C- | -C alkylene<sub>6</sub> (for example, -CH<sub>2</sub>-, -C (CH<sub>3</sub>)<sub>2</sub>-, -C (CH<sub>3</sub>)<sub>2</sub>-CH<sub>2</sub>-) and R<sub>AND</sub> is -OR<sub>s</sub>, -C (O) OR<sub>S</sub>, -N (R<sub>S</sub>) C (O) OR<sub>S</sub>', or -P (O) (OR<sub>s</sub>)<sub>2</sub>. For example R<sub>M</sub> is -alkylene-Cb-Ce) OR<sub>s</sub> (for example, -C (CH<sub>3</sub>)<sub>2</sub>-CH<sub>2</sub>-OMe); -alkylene (C<sub>1</sub>-C<sub>6</sub>) -C (O) OR<sub>s </sub>(for example, -C (CH<sub>3</sub>)<sub>2</sub>-C (O) OMe); -alqu¡len (Ci-C<sub>6</sub>) -N (R<sub>s</sub>) C (O) OR<sub>s</sub>'(for example, -C (CH<sub>3</sub>)<sub>2</sub>-CH<sub>2</sub>-NHC (O) OCH<sub>3</sub>); or -alkylene (Ci-C<sub>6</sub>) P (O) (OR<sub>s</sub>)<sub>2</sub> (for example, -CH<sub>2</sub>-P (O) (OEt)<sub>2</sub>). Also more preferably R<sub>M</sub> is carbocycle of C<sub>3</sub>-C<sub>6</sub> or 3- to 6-membered heterocycle, each of which, independently, is optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C alkyl<sub>6</sub>, C alkenyl<sub>2</sub>-C<sub>6</sub>, C alkynyl<sub>2</sub>-C<sub>6</sub>, C ^ -C halogenoalkyl, C halogenalkenyl<sub>2</sub>-C<sub>6</sub>, halogenoalkynyl O<sub>2</sub>-C<sub>6</sub>, -C (O) OR<sub>S</sub>, or -N (R<sub>S</sub>R<sub>S</sub>'). For example R<sub>M</sub> is cycloalkyl (eg cyclopropyl, 2,2-dichloro-l-methycloprop1-yl, cyclohexyl), phenyl, heterocyclyl (eg morpholin-4-yl,
1,1-dioxydothiomorpholin-4-yl, 4-methylpiperazin-1-yl, 4-methoxycarbonylpiperazin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, 4-methyl-piperidin-1-yl, 3,5-dimethylpiperidin-1-yl, 4,4-difl
INSTITUTO MEXICANO tetrahydropyran-4-yl, pyridinyl, pyridin-3-yl, 6- (dimetifS
<img file="MX339989B_D0037.tif" />
ilo). Rather preferably, R<sub>M</sub> is alkyl of ei ο ·· οΐ is optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino or carboxy (e.g. tert-butyl, CF<sub>3</sub>).
X is preferably carbocycle of C<sub>5</sub>-C<sub>6</sub>, 5- to 6-membered heterocycle, or 6 to 12-membered bicycles, and is optionally substituted with one or more R<sub>TO</sub>. X can also be carbocycle of C<sub>5</sub>-C<sub>6</sub> or 5- to 6-membered heterocycle which is optionally substituted with one or more R<sub>TO</sub>, in which two R<sub>TO</sub> Adjacent in X, taken together with the ring atoms to which they are attached, optionally form a 5- to 6-membered carbocycle or heterocycle. Also preferably, X is
Λ / W
<img file="MX339989B_D0038.tif" />
in which X<sub>3</sub> is C (H) or preferably N and is directly appended to -L<sub>3</sub>-D; X<sub>4</sub> is C alkylene<sub>2</sub>-C<sub>4</sub>, C alkenylene<sub>2</sub>-C<sub>4</sub> or C alkynylene<sub>2</sub>-C<sub>4</sub>each of which optionally contains one or two heteroathogens selected from O, S, or N; and X is optionally substituted with one or more R<sub>TO</sub>, and two R<sub>TO</sub> Adjacent at X, taken together with the ring atoms to which they are attached, can optionally form a carbocycle or heterocycle of
<img file="MX339989B_D0039.tif" />
in which X<sub>3</sub> is C and is directly attached to -L<sub>3</sub>-D, X<sub>4</sub> is C alkylene<sub>2</sub>-C<sub>4</sub>, C alkenylene<sub>2</sub>-C<sub>4</sub> or C alkynylene<sub>2</sub>-C<sub>4</sub> each of which optionally contains one or two heteroatoms selected from O, S, or N, and X is optionally substituted with one or more R<sub>TO</sub>, and two R<sub>TO</sub> Adjacent at X, taken together with the ring atoms to which they are attached, optionally form a 5- to 6-membered carbocycle or heterocycle.
For example, X can be
<img file="MX339989B_D0040.tif" />
in which Xi is independently selected each time it appears from cte CH<sub>2</sub>, O, S or NH, X<sub>2</sub> is independently selected each time it appears from CH or N, X<sub>3</sub> is N and is directly attached to -L<sub>3</sub>-D, and X<sub>3</sub>'is C and is directly attached to -L<sub>3</sub>-D; and X is optionally substituted with one or more R<sub>TO</sub>, and two
<img file="MX339989B_D0041.tif" />
R<sub>to</sub> adjacent in X, taken together with the at \
INSTITUTO MEXICANO / 2 DE LA PROPERTY C which these are united, optionally form a<sup>IN</sup>% 5-6 membered heterocycle cyWocn. For another example / 'X eswjuv »ww% / vw / γ<sup>Χ</sup>3γ ^ / γ<sup>Χ3</sup>γ \ <sup>Xl</sup>Xf<sup>Xl</sup> t, <sup>Χ</sup>'-χΥ εΛΛΖΧΖ * wuv
<img file="MX339989B_D0042.tif" />
dWV »
<img file="MX339989B_D0043.tif" />
* ΛΛΛΓ / γ<sup>Χ3</sup>γ>
* 1 ιΛΛΛΓ
<img file="MX339989B_D0044.tif" />
<img file="MX339989B_D0045.tif" />
<sup>Χ</sup>2 <5 · χ ·<sup>Χ</sup>one χ<sub>2</sub> ι »ΛΛΖν * ^ γ<sup>Χ3</sup>γ ^ / γ<sup>χ</sup>γΑ <sup>Χ</sup>2^ <sup>Χ</sup>1 ^ Χ<sup>Χ</sup>1 <sup>λ</sup>2 , <sup>Χ</sup>one tZVW * ιΛ / ΙΛΛ
<img file="MX339989B_D0046.tif" />
<sup>Χ</sup>1χ - ^ ·<sup>Χ</sup>2 <sup>Χ</sup>2<%. /<sup>Χ</sup>1 <sup>χ</sup>two ο χ<sub>2</sub> in which Χι is selected independently each time it appears from CH<sub>2</sub>, O, S or NH, X<sub>2</sub> is independently selected each time it appears from CH or N, X<sub>3</sub> is N and is directly attached to -L<sub>3</sub>-D, and X<sub>3</sub>'is C and is directly attached to -L<sub>3</sub>-D; and in which X is optionally substituted with one or more R<sub>to</sub>, and two R<sub>TO</sub> Adjacent in X, taken together with the ring atoms to which they are attached, optionally form a 5- to 6-membered carbocycle or heterocycle.
Rather preferably, X is
<img file="MX339989B_D0047.tif" />
«ZVVVP
<img file="MX339989B_D0048.tif" />
IMPIOS ^ ΙΜΐΪΓθΓθ3ΕΧΙ (ΐΑΝηΟ '/>% Μ £ ^> <.
in which X<sub>3</sub> is C (H) or N and is directly ufWiearoaEM <L8ioD \
OF THE INDUSTRIAL PROPERTY is C and is directly attached to -L<sub>3</sub>-D, and in which X is optionally substituted with one or more R<sub>TO</sub>, and two R<sub>TO</sub> Adjacent at X, taken together with the ring atoms to which they are attached, optionally form a 5- to 6-membered carbocycle or heterocycle. More preferably, X<sub>3</sub> is N.
Non-limiting examples of X include:
<img file="MX339989B_D0049.tif" />
<img file="MX339989B_D0050.tif" />
in which indicates the covalent bond to -L<sub>3</sub>-D. Each X can be optionally substituted with one or more R<sub>TO</sub>, and two R<sub>TO </sub>Adjacent at X, taken together with the ring atoms to which they are attached, optionally form a 5- to 6-membered carbocycle or heterocycle.
Non-limiting examples of preferred X include the following pyrrolidine rings, each of which is
IMPI
MEXICAN INSTITUTE OF INDUSTRIAL FROFIEDAD
<img file="MX339989B_D0051.tif" />
optionally substituted with one or more R<sub>TO</sub>:
<img file="MX339989B_D0052.tif" />
TV
Ty 7 ϊη positions 2 and 5
As shown, the relative stereochemistry of the pyrrolidine ring above can be either cis or trans. The stereochemistry of the R substituents<sub>TO</sub> Optional at positions 3 or 4 of pyrrolidine can vary relative to any substituent at any other position on the pyrrolidine ring. Depending on the particular substituents attached to the pyrrolidine, the stereochemistry at any carbon can be (R) or (S).
Non-limiting examples of preferred X also include the following pyrrole, triazole, or thiomorpholine rings, each of which is optionally substituted with one or more R<sub>TO</sub>:
<img file="MX339989B_D0053.tif" />
oo
As shown, the relative stereochemistry at positions 3 and 5 of the thiomorphollna ring can be either cis or trans
<img file="MX339989B_D0054.tif" />
For the particular substituents attached to thiomorpholine, the stereochemistry at any carbon can be (R) or (S).
L<sub>1</sub> and l_2 are preferably independently C, -C bond or alkylene<sub>6</sub>, L<sub>3</sub> preferably it is selected from bond, C ^ Ce alkylene or -C (O) -, and L · ,, L<sub>2</sub>, and L<sub>3</sub> are each independently optionally substituted with one or more R<sub>L</sub>. More preferably, Ln, L<sub>2</sub> and L<sub>3</sub> are each independently C- | -C bond or alkylene<sub>6</sub> (for example, -CH<sub>2</sub>- or -CH<sub>2</sub>CH<sub>2</sub>-), and are each independently optionally substituted with one or more R<sub>L</sub>. Rather preferably l_t, L<sub>2</sub> and l_<sub>3</sub> they are link.
And preferably it is selected from -LsC (RtR<sub>2</sub>) N (R<sub>5</sub>) -TR<sub>D</sub>, -L<sub>s</sub>-C (R<sub>3</sub>R<sub>4</sub>) C (R<sub>6</sub>R<sub>7</sub>) -TR<sub>d</sub>, -GC (R<sub>1</sub>R<sub>2</sub>) N (R<sub>5</sub>) -TR<sub>d</sub>, -GC (R<sub>3</sub>R<sub>4</sub>) C (R<sub>6</sub>R<sub>7</sub>) -TR<sub>d</sub>, -N (R<sub>b</sub>) C (O) C (R<sub>1</sub>R<sub>2</sub>) N (R<sub>5</sub>) -TR<sub>d</sub>,
-N (R<sub>b</sub>) C (O) C (R<sub>3</sub>R<sub>4</sub>) C (R<sub>6</sub>R<sub>7</sub>) -T-Rd, -C (O) N (R<sub>b</sub>) C (RiR<sub>2</sub>) N (R5) -TR<sub>d</sub>,
-C (O) N (R<sub>b</sub>) C (R<sub>3</sub>R<sub>4</sub>) C (R<sub>6</sub>R<sub>7</sub>) -TR<sub>d</sub>, -N (R<sub>b</sub>) C (O) -Ls-E, or -C (O) N (R<sub>b</sub>) -I_sE. G is carbocycle of C<sub>5</sub>-C<sub>6</sub> or 5-6 membered heterocycle, such as
<img file="MX339989B_D0055.tif" />
y is optionally substituted with one or more R<sub>TO</sub> (for example, one or more chlorine or bromine). E is preferably a 7 to 12-membered bike (such as
<img file="MX339989B_D0056.tif" />
.0
ΙΜΡΙΓ
MEXICAN INSTITUTE OF INDUSTRIAL FROFIEDAD
<img file="MX339989B_D0057.tif" />
in which U is independently selected each time it appears from - (CH<sub>2</sub>) - or - (NH) -; V and Z<sub>2</sub>or are each independently selected from alkylene to alkenylene C<sub>2</sub>-C<sub>4</sub> or C alkynylene<sub>2</sub>-C<sub>4</sub>, in which at least one carbon atom can be, independently, optionally replaced with O, S or N), and is optionally substituted with one or more R<sub>TO</sub>. More preferably, R-ι is Re, and R<sub>2</sub> and R5, taken together with the atoms to which they are attached, form a 5- to 6-membered heterocycle or 6 to 12-membered bicyclo (for example,
H.
which is optionally substituted with one or more R<sub>TO</sub> (such as, but not limited to, hydroxy, halogen (eg, fluoro), C-alkyl<sub>r</sub>C<sub>6</sub> (eg, methyl), or C alkenyl<sub>2</sub>-C<sub>6</sub> (for example, aillo)); and R<sub>3</sub> and Re are each independently Re, and R4 and R7, taken together with the atoms to which they are attached, form a 5- to 6-membered carbocycle / heterocycle (e.g.
<img file="MX339989B_D0058.tif" />
<img file="MX339989B_D0059.tif" />
which is optionally substituted with one or more R<sub>TO</sub> (such as, but not limited to, hydroxy, halogen (eg, fluoro), Ci-Ce alkyl (eg, methyl), or C alkenyl<sub>2</sub>-C<sub>6</sub> (eg allyl)).
And it can also be selected from -MC (R<sub>1</sub>R<sub>2</sub>) N (R<sub>5</sub>)-CABBAGE<sub>and</sub>'-M'-R<sub>d</sub>, -MC (R<sub>1</sub>R<sub>2</sub>) N (R<sub>5</sub>) -L<sub>and</sub>'-M'-RD,
-Ls-CíR-.R ^ NÍRsJ-CÍOj-LY'-M'-RD, -Ls-CfR, R<sub>2</sub>) N (R<sub>5</sub>) -L<sub>AND</sub>'-M'-R<sub>D</sub>,
-MC (R<sub>3</sub>R<sub>4</sub>) C (R<sub>6</sub>R7) -C (O) -Ly'-M'-R<sub>d</sub>,
-MC (R3R4) C (R<sub>6</sub>R<sub>7</sub>) -Ly'-M'-R<sub>d</sub>,
-L<sub>s</sub>-C (R3R4) C (R<sub>6</sub>R<sub>7</sub>) -C (O) -Ly'-M'-R<sub>d</sub>, or -L<sub>s</sub>-C (R<sub>3</sub>R4) C (R<sub>6</sub>R<sub>7</sub>) -Ly'-M'-R<sub>d</sub>, in which M is preferably bond, -C (O) N (R<sub>b</sub>) - or -N (R<sub>b</sub>) C (O) -, M 'is preferably bond, -C (O) N (R<sub>b</sub>) -, -N (R<sub>b</sub>) C (O) -, -N (R<sub>b</sub>) C (O) O-, N (R<sub>b</sub>) C (O) N (R<sub>b</sub>') -, -N (R<sub>b</sub>) S (O) - or -N (R<sub>b</sub>)SW)<sub>2</sub>-, and L<sub>AND</sub>'preferably is C alkylene<sub>r</sub>C<sub>6</sub> which is optionally substituted with one or more R<sub>l</sub>. L<sub>and</sub>', for example, is a C ^ -Ce alkylene such as, but not limited to,
Ax
<img file="MX339989B_D0060.tif" />
<img file="MX339989B_D0061.tif" />
and the R<sub>l</sub> optional is a substitute such as, but not limited to
<img file="MX339989B_D0062.tif" />
phenyl, -SMe, or methoxy. Any stereochemical Jj? J? Í
MEXICAh INSTITUTE OF THE PKOPJED?
within group L<sub>AND</sub>'can be either (R) or (S)?<sup>Dl</sup>£ yé?<sup>TO,</sup>my most favorite, Ri is R<sub>c</sub>, and R2 and R5, taken together with the atoms to which they are attached, form a 5- to 6-membered heterocycle or 6 to 12-membered bicycles (for example,
<img file="MX339989B_D0063.tif" />
<img file="MX339989B_D0064.tif" />
which is optionally substituted with one or more R<sub>TO</sub> (eg, one or more hydroxy); and R<sub>3</sub> and R<sub>6</sub> are each independently Rc, and R4 and R7, taken together with the atoms to which they are attached, form a 5- to 6-membered carbocycle / heterocycle or a 6 to 12-membered bicycle (eg,
<img file="MX339989B_D0065.tif" />
<img file="MX339989B_D0066.tif" />
which is optionally substituted with one or more R<sub>TO</sub>.
Also preferably, Y is selected from
-N (R<sub>b</sub>) CO-C (Ri R2) N (R5) -C (O) -I_y'-N (Rb) C (O) OR<sub>d</sub>, -N (R<sub>b</sub>) COGÍRiR ^) N1R ^ -C (0) -L<sub>and</sub>'-NIR<sub>b</sub>) C (0) -Rd, -N (Rb) CO-C (R<sub>1</sub>R2) N (R<sub>5</sub>)-CABBAGE<sub>and</sub>'-N (Rb) S (O)<sub>2</sub>-Rd, -N (R<sub>b</sub>) CO-C (R<sub>1</sub>R<sub>2</sub>) N (R<sub>5</sub>)-CABBAGE<sub>and</sub><sup>,</sup>-N (R<sub>b</sub>R<sub>b</sub>') -R<sub>d</sub>, -N (R<sub>b</sub>) CO-C (R<sub>1</sub>R<sub>2</sub>) N (R<sub>5</sub>)-CABBAGE<sub>and</sub>'-OR<sub>d</sub>, -N (R<sub>b</sub>) CO · ^! R<sub>2</sub>) N (R<sub>5</sub>)CABBAGE<sub>and</sub>'-R<sub>d</sub>, -N (R<sub>b</sub>) CO-C (R<sub>1</sub>R<sub>2</sub>) N (R<sub>5</sub>) -R<sub>d</sub>, -Ls-CÍR.RzjNÍRsj-CCOj-LY29
<img file="MX339989B_D0067.tif" />
OF THE INDUSTRIAL PROPERTY
N (R<sub>b</sub>) C (O) OR<sub>d</sub>, -L<sub>s</sub>-C (R<sub>1</sub>R<sub>2</sub>) N (R<sub>5</sub>)-CABBAGE<sub>s</sub>-C (R<sub>1</sub>R<sub>2</sub>) N (R<sub>5</sub>) -C (O) -Ly'-N (Rb) S (O)<sub>2</sub>-R<sub>d</sub>, -Ls-C (R<sub>1</sub>R<sub>2</sub>) N (R<sub>5</sub>) -C (O) -Ly'N (R<sub>b</sub>Rb ') - Rd, -Ls-CÍRtRzJNÍRsJ-CCOJ-Ly'-O-Rd, -Ls-C (RiR<sub>2</sub>) N (R<sub>5</sub>)CABBAGE<sub>and</sub>'-R<sub>d</sub>, -Ls-C (R., R<sub>2</sub>) N (R<sub>5</sub>) -R<sub>d></sub> -N (R<sub>b</sub>) CO-C (R<sub>3</sub>R<sub>4</sub>) C (R<sub>6</sub>R<sub>7</sub>) -C (O) Ly'-N (R<sub>b</sub>) C (O) OR<sub>d></sub> -N (R<sub>b</sub>) CO-C (R<sub>3</sub>R<sub>4</sub>) C (R<sub>6</sub>R<sub>7</sub>)-CABBAGE<sub>and</sub>'-N (R<sub>b</sub>) C (O) Rd, -N (Rb) CO-C (R<sub>3</sub>R<sub>4</sub>) C (R<sub>6</sub>R<sub>7</sub>) -C (O) -Ly'-N (Rb) S (O) 2-Rd, -N (R<sub>b</sub>) COC (R<sub>3</sub>R<sub>4</sub>) C (R<sub>6</sub>R<sub>7</sub>) -C (O) -Ly'-N (R<sub>b</sub>R<sub>b</sub>') -R<sub>d</sub>, -N (R<sub>b</sub>) CO-C (R<sub>3</sub>R<sub>4</sub>) C (R<sub>6</sub>R<sub>7</sub>)CABBAGE<sub>and</sub>'-OR<sub>d</sub>, -N (R<sub>b</sub>) CO-C (R<sub>3</sub>R<sub>4</sub>) C (R<sub>6</sub>R<sub>7</sub>)-CABBAGE<sub>and</sub>'-R<sub>d</sub>, -N (R<sub>b</sub>) COC (R<sub>3</sub>R<sub>4</sub>) C (R<sub>6</sub>R<sub>7</sub>) -R<sub>d</sub>, -L<sub>s</sub>-C (R<sub>3</sub>R<sub>4</sub>) C (R<sub>6</sub>R<sub>7</sub>)-CABBAGE<sub>and</sub>'-N (Rb) C (O) O-Rd,
-L<sub>s</sub>-C (R<sub>3</sub>R<sub>4</sub>) C (R<sub>6</sub>R<sub>7</sub>) -C (O) -Ly'-N (R<sub>b</sub>) C (O) -R<sub>d</sub>, -Ls-C (R<sub>3</sub>R<sub>4</sub>) C (R<sub>6</sub>R<sub>7</sub>) C (0) -Ly'-N (R<sub>b</sub>)SW)<sub>2</sub>-R<sub>d</sub>, -L<sub>s</sub>-C (R<sub>3</sub>R<sub>4</sub>) C (R<sub>6</sub>R<sub>7</sub>) -C (O) -Ly'-N (R<sub>b</sub>R<sub>b</sub><sup>,</sup>) -R<sub>d</sub>, L<sub>s</sub>-C (R<sub>3</sub>R<sub>4</sub>) C (R<sub>6</sub>R<sub>7</sub>) -C (O) -Ly'-O-Rd, -L<sub>s</sub>-C (R<sub>3</sub>R<sub>4</sub>) C (R<sub>6</sub>R<sub>7</sub>) -C (O) -Ly'-R<sub>d</sub>, or -L<sub>s</sub>-C (R<sub>3</sub>R<sub>4</sub>) C (R<sub>6</sub>R<sub>7</sub>) -Rd. ®n which L<sub>AND</sub>'preferably is alkylene of CL-Cq which is optionally substituted with one or more R<sub>l</sub>. Ri can be R<sub>c</sub>, and R2 and Rs, taken together with the atoms to which they are attached, may form a 5- to 6-membered heterocycle or 6 to 12-membered bicycles (for example,
<img file="MX339989B_D0068.tif" />
<img file="MX339989B_D0069.tif" />
which is optionally substituted with one or more R<sub>TO</sub>; and R3 and R6 can each be independently R<sub>c</sub>, and R4 and R<sub>7</sub>, taken together with the atoms to which they are attached, can form a 5- to 6-membered carbocycle / heterocycle or 6 to 12-membered skeleton (for example,
<img file="MX339989B_D0070.tif" />
MEXICAN INSTITUTE OF PROPERTY
INDUSTRIAL
<img file="MX339989B_D0071.tif" />
<img file="MX339989B_D0072.tif" />
which is optionally substituted with one or more R<sub>TO</sub>.
Quite preferably, Y is selected from
-N (Rb) CO-C (R<sub>1</sub>R<sub>2</sub>) N (R<sub>5</sub>)-CABBAGE<sub>and</sub>-N (Rb) C (O) -L<sub>s</sub>-R<sub>and</sub> or -C (R<sub>1</sub>R<sub>2</sub>) N (R<sub>5</sub>)CABBAGE<sub>and</sub>-N (R<sub>b</sub>) C (O) -Ls-Re, or Y is -GC (R<sub>1</sub>R<sub>2</sub>) N (R<sub>5</sub>)-CABBAGE<sub>AND</sub>N (R<sub>b</sub>)CABBAGE<sub>s</sub>-R<sub>and</sub>, in which L<sub>AND</sub> is C, -C alkylene<sub>6 </sub>optionally substituted with one or more R<sub>L</sub>, and Rb is each independently R<sub>B</sub>. Rb and Rí are each preferably hydrogen or C- | -C alkyl<sub>s</sub>, and R<sub>2</sub> and R<sub>5</sub>, taken together with the atoms to which they are attached, preferably form a 5- to 6-membered heterocycle or a 6 to 12-membered fork (for example, which is optionally substituted with one or more R<sub>TO</sub> (such as, but not limited to, hydroxl, halogen (eg, fluoro), Ci-Ce alkyl (eg, methyl), or C-alkenyl<sub>2</sub>-C<sub>6</sub> (for example, aillo)). Preferably L<sub>AND</sub> is C ^ Ce alkylene substituted with one or more R<sub>L </sub>such as a carbocycle of C<sub>3</sub>-C<sub>6</sub> 3-6 membered heterocycle which is optionally substituted with one or more substituents
<img file="MX339989B_D0073.tif" />
tKIcfi, ... OF INDUSTRIAL PROPERTY
<img file="MX339989B_D0074.tif" />
selected from halogen, hydroxy, mercapto, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-CesT alkyl, C alkenyl<sub>2</sub>-C<sub>6</sub>, C alkynyl<sub>2</sub>-C<sub>6</sub>, halogenoalkyl of Ο -, - Οβ, halogenoalkenyl of C<sub>2</sub>- C<sub>6</sub> or halogenoalkynyl of C<sub>2</sub>-C<sub>and</sub>. Quite preferably, L<sub>AND</sub> is a CiC alkylene<sub>6</sub> such as, but not limited to,
Z Λ A z \
A A.
<img file="MX339989B_D0075.tif" />
<img file="MX339989B_D0076.tif" />
<img file="MX339989B_D0077.tif" />
(the stereochemistry at a carbon within group L<sub>AND</sub> can be either (R) or (S)), L<sub>AND</sub> is optionally substituted with one or more R<sub>L</sub> (e.g. one or more phenyl or methoxy), G preferably is
H
<img file="MX339989B_D0078.tif" />
R<sub>b</sub> is hydrogen; -C (R<sub>1</sub>R<sub>2</sub>) N (R<sub>5</sub>)- it is
<img file="MX339989B_D0079.tif" />
λλλγ
Ls is a link; and R<sub>AND</sub> it is methoxy.
Non-limiting examples of preferred Y include:
<img file="MX339989B_D0080.tif" />
<img file="MX339989B_D0081.tif" />
<img file="MX339989B_D0082.tif" />
in which T and R<sub>D</sub> are as defined in the present invention. T, for example, can be -L<sub>s</sub>-ML<sub>s</sub>'-M'-L<sub>s</sub>- in which L<sub>s</sub> is a link; M is C (O); L<sub>s</sub>'is Ci-C alkylene<sub>6</sub> such as, but not limited to,
A A. Λ X
<img file="MX339989B_D0083.tif" />
<img file="MX339989B_D0084.tif" />
<img file="MX339989B_D0085.tif" />
in which Ls' is optionally substituted with one or more R<sub>L</sub>; R | _ is a substituent such as, but not limited to, phenyl or methoxy; M 'is -NHC (O) - or -NMeC (O) -; and L<sub>s</sub> is a link. Any stereochemistry on a carbon within group L<sub>s</sub>'can be either (R) or (S). R<sub>D</sub>, for example it is methoxy. TR<sub>D</sub> includes, but is not limited to:
ww
<img file="MX339989B_D0086.tif" />
TR<sub>d</sub> it can also include certain stereochemistry; therefore TR<sub>D</sub> includes, but is not limited to ^^ *
<img file="MX339989B_D0087.tif" />
MEXICAN INSTITUTE OF PROPERTY
<img file="MX339989B_D0088.tif" />
<img file="MX339989B_D0089.tif" />
<img file="MX339989B_D0090.tif" />
Z preferably is selected to -id <
MEXICAN INSTITUTE OF TROPIEDAD
C (R<sub>8</sub>R<sub>9</sub>) N (R<sub>12</sub>) -TR<sub>D</sub>, -Ls-C (R<sub>10</sub>Rii) C (R<sub>13</sub>Ri4) -TR<sub>D)</sub> -GC (PHYTO ^ (R ^ 2 tr<sub>d</sub>, -gc (r<sub>10</sub>Rii) C (r<sub>13</sub>Ri4) -tr<sub>d</sub>, -N (R<sub>B</sub>) C (0) cTO<sub>9</sub>) N (k<sub>12</sub>jik<sub>d</sub>;
-N (R<sub>b</sub>) C (O) C (R<sub>10</sub>R<sub>11</sub>) C (R<sub>13</sub>R<sub>1</sub>4) -TR<sub>d</sub>, -C (O) N (R<sub>b</sub>) C (R<sub>8</sub>R<sub>9</sub>) N (R<sub>12</sub>) -TR<sub>d</sub>,
-C (0) N (R<sub>b</sub>) C (RioRh) C (R<sub>13</sub>R<sub>14</sub>) -TR<sub>d</sub>, -N (R<sub>b</sub>) C (O) -Ls-E, or -C (O) N (R<sub>b</sub>) L<sub>s</sub>-AND. G is carbocycle of C<sub>5</sub>-C<sub>6</sub> or 5-6 membered heterocycle, such as
<img file="MX339989B_D0091.tif" />
HN-n
<img file="MX339989B_D0092.tif" />
y is optionally substituted with one or more R<sub>to</sub> (for example, one or more chlorine or bromine).
E is preferably an 8 to 12 membered bike (such as
<img file="MX339989B_D0093.tif" />
in which U is independently selected each time it appears from - (CH<sub>2</sub>) - or - (NH) -; and V and Z<sub>20</sub> are each independently selected from Ct-C alkylene<sub>4</sub>, C aiquenitene<sub>2</sub>-C<sub>4</sub> or C2-C4 alkynylene, in which at least one carbon atom, independently, is optionally replaced with O, S or N), and is optionally substituted with one or more R<sub>TO</sub>. More preferably, R<sub>8</sub> is R<sub>c</sub>, and
Rg and R12> taken together with what is attached, form a heterocycle of members (for example,
<img file="MX339989B_D0094.tif" />
<img file="MX339989B_D0095.tif" />
which is optionally substituted with one or more R<sub>TO</sub> (such as, but not limited to, hydroxy, halogen (eg, fluoro), Ci-C alkyl<sub>6</sub> (eg, methyl), or C alkenyl<sub>2</sub>-C<sub>6</sub> (eg allyl)); and Rio and R13 are each independently R<sub>c</sub>, and Rn and Rn, taken together with the atoms to which they are attached, form a 5- to 6-membered carbocycle / heterocycle or 6-membered bicyclo (for example,
<img file="MX339989B_D0096.tif" />
<img file="MX339989B_D0097.tif" />
which is optionally substituted with one or more R<sub>TO</sub> (such as, but stn tñmtafse to hydroxy, halogen (eg, fluoro), Ci-C alkyl<sub>6</sub> (eg, methyl), or C alkenyl<sub>2</sub>-C<sub>6</sub> (eg allyl)).
Z can also be selected from
-MC (R<sub>8</sub>R<sub>9</sub>) N (R<sub>12</sub>)-CABBAGE<sub>AND</sub>'-M'-R<sub>D</sub>,
-MC (R<sub>8</sub>R<sub>9</sub>) N (R<sub>12</sub>) -L<sub>and</sub>'-M'-R<sub>d</sub>
<img file="MX339989B_D0098.tif" />
<img file="MX339989B_D0099.tif" />
L<sub>and</sub>'-M'-R<sub>d</sub>, in which M is preferably bond, -C (O) N (R<sub>B</sub>) - or -N (R<sub>B</sub>) C (O) -, M 'is preferably bond, -C (O) N (R<sub>B</sub>) -, -N (R<sub>B</sub>) C (O) -, -N (R<sub>B</sub>) C (O) O-, N (R<sub>b</sub>) C (O) N (R<sub>b</sub>') -, -N (Rb) S (O) - or -N (R<sub>b</sub>)SW)<sub>2</sub>-, and L<sub>AND</sub>'preferably is C-C alkylene<sub>6</sub> which is optionally substituted with one or more R<sub>L</sub>. L<sub>AND</sub>', for example, is a C ^ Ce alkylene such as, but not limited to, and R<sub>l</sub> Optional is a substituent such as, but not limited to, phenyl, -SMe, or methoxy. Any stereochemistry on a carbon within group L<sub>AND</sub>'can be either (R) or (S). More preferably, R<sub>8</sub> is R<sub>c</sub>, and Rg and R12, taken together with the atoms to which they are attached, form a 5- to 6-membered heterocycle or 6 to 12-membered bicyclo (for example, which is optionally substituted with one or more R<sub>TO</sub> (eg, one or more hydroxy); and R10 and R13 are each so
ΙΜΡΙ independent Re, and Rn and R14, taken together with itersirá
TO INDUSTRIAL PROPIEPAÍ
<img file="MX339989B_D0100.tif" />
which these are attached form a 5-6 membered carbocycle / heterocycle or 6-12 membered bicycle (eg
<img file="MX339989B_D0101.tif" />
) which is optionally substituted with one or more R<sub>TO</sub>.
Also preferably, Z is selected from
-N (R<sub>b</sub>) CO-C (R<sub>8</sub>R<sub>9</sub>) N (R<sub>12</sub>) -C (O) -Ly'-N (R<sub>b</sub>) C (O) OR<sub>d</sub>, -N (R<sub>b</sub>) COC (R<sub>8</sub>R<sub>9</sub>) N (R<sub>12</sub>)-CABBAGE<sub>and</sub>'-N (Rb) C (O) -R<sub>d</sub>, -N (R<sub>b</sub>) CO-C (R<sub>8</sub>R<sub>9</sub>) N (R<sub>12</sub>)CABBAGE<sub>and</sub>'-N (R<sub>b</sub>)SW)<sub>2</sub>-R<sub>d</sub>, -N (R<sub>b</sub>) CO-C (R<sub>8</sub>R<sub>9</sub>) N (R<sub>12</sub>) -C (O) -Ly'-N (R<sub>b</sub>Rb ') Rd, -N (R<sub>b</sub>) CO-C (R<sub>8</sub>R<sub>9</sub>) N (R<sub>12</sub>) -C (O) -Ly'-OR<sub>d</sub>, -N (R<sub>b</sub>) COC (R<sub>8</sub>R<sub>9</sub>) N (R<sub>12</sub>)-CABBAGE<sub>and</sub>'-R<sub>d</sub>, -N (Rb) CO-C (R<sub>8</sub>R<sub>9</sub>) N (R<sub>12</sub>) -R<sub>d</sub>, -l_sC (R<sub>8</sub>R<sub>9</sub>) N (Ri2) -C (O) -L<sub>and</sub>'-N (Rb) C (O) OR<sub>d</sub>, -L<sub>s</sub>-C (R<sub>8</sub>R<sub>9</sub>) N (R<sub>12</sub>)-CABBAGE<sub>and</sub>'N (R<sub>b</sub>) C (O) -R<sub>d</sub>, -L<sub>s</sub>-C (R<sub>8</sub>R<sub>9</sub>) N (R<sub>12</sub>)-CABBAGE<sub>and</sub>'-N (R<sub>b</sub>)SW)<sub>2</sub>-R<sub>d</sub>, -LsC (R<sub>8</sub>R<sub>9</sub>) N (R<sub>12</sub>) -C (O) -Ly'-N (R<sub>b</sub>Rb ') - Rd, -L<sub>s</sub>-C (R<sub>8</sub>R<sub>9</sub>) N (R<sub>12</sub>)-CABBAGE<sub>and</sub>'-OR<sub>d</sub>, -Ls-C (R<sub>8</sub>R<sub>9</sub>) N (R<sub>12</sub>)-CABBAGE<sub>and</sub>'-R<sub>d</sub>, -L<sub>s</sub>-C (R<sub>8</sub>R<sub>9</sub>) N (R<sub>12</sub>) -Rd, -N (R<sub>b</sub>) COOK ^ RujCíR ^ R ^ J-CÍOj-LY'-NÍRBjCÍOjO-RD, -N (R<sub>B</sub>) COC (R<sub>10</sub>R<sub>1</sub>i) C (R<sub>13</sub>R<sub>1</sub>4) -C (O) -Ly'-N (Rb) C (O) -R<sub>d</sub>, -N (Rb) COC (R<sub>10</sub>Rii) C (Ri3Ri4) -C (O) -Ly'-N (R<sub>b</sub>)SW)<sub>2</sub>-R<sub>d</sub>, -N (R<sub>b</sub>) CO-G {RT<sub>OR</sub>R-<sub>t</sub>-<sub>l</sub>> C (R<sub>19</sub>R<sub>14</sub>) -C4O) -L<sub>and</sub>'-N (R<sub>B</sub>RB ') - Rj). -N (R<sub>B</sub>) COC (R<sub>10</sub>R<sub>11</sub>) C (R<sub>13</sub>Ri4) -C (O) -L<sub>AND</sub><sup>,</sup>-OR<sub>D</sub>, -N (Rb) CO-C (R<sub>10</sub>Rii) C (R<sub>13</sub>R<sub>14</sub>) C (O) -Ly'-R<sub>d</sub>, -N (R<sub>b</sub>) CO-C (R<sub>10</sub>R<sub>11</sub>) C (R<sub>13</sub>R<sub>14</sub>) -R<sub>d</sub>, -LsC (R<sub>10</sub>Rii) C (R<sub>13</sub>Ri4) -C (O) -Ly'-N (Rb) C (O) OR<sub>Gave</sub> -L<sub>s</sub>-C (R<sub>10</sub>R<sub>11</sub>) C (R<sub>13</sub>Ri4) 38
-- --.
C (O) -Ly'-N (R<sub>b</sub>) C (O) -R<sub>d</sub>,
-Ls-C (R<sub>10</sub>Ri -i) C (Ri<sub>3</sub>Ri <sub>4</sub>) -C (
<img file="MX339989B_D0102.tif" />
OF THE INDUSTRIAL l'RPMEUAD
<img file="MX339989B_D0103.tif" />
-Ls
R<sub>d</sub>, -Ls-C (R<sub>1</sub>oR<sub>11</sub>) C (R<sub>13</sub>Ri<sub>4</sub>) -C (0) -L<sub>and</sub>'-N (RbRb') - Rd.
C (R<sub>10</sub>Ri i) C (R<sub>13</sub>R<sub>14</sub>) -C (O) -Ly'-0-R<sub>d</sub>,
-L<sub>s</sub>-C (R<sub>10</sub>Rii) C (R<sub>13</sub>R<sub>14</sub>)-CABBAGE<sub>and</sub>'R<sub>d</sub>, or -L<sub>s</sub>-C (R<sub>10</sub>R<sub>1</sub> i) C (Ri<sub>3</sub>R<sub>14</sub>) -R<sub>d</sub>, in which L<sub>AND</sub>'preferably is Ci-C alkylene<sub>6</sub> which is optionally substituted with one or more R<sub>l</sub>. Re can be R<sub>C)</sub> and Rg and Ri<sub>2</sub>, taken together with the atoms to which they are attached, can form a 5- to 6-membered heterocycle or 6 to 12-membered bicyclo (for example,
<img file="MX339989B_D0104.tif" />
<img file="MX339989B_D0105.tif" />
which is optionally substituted with one or more R<sub>TO</sub>; and R<sub>10</sub> and R<sub>13 </sub>they can each be independently R<sub>c</sub>, and Ru and Ri<sub>4</sub>, taken together with the atoms to which they are attached, can form a 5- to 6-membered carbocycle / heterocycle or 6 to 12-membered bicyclo (for example,
<img file="MX339989B_D0106.tif" />
<img file="MX339989B_D0107.tif" />
"I which is optionally substituted with one or more R<sub>TO</sub>
Quite preferably, Z is selected from
-N (R<sub>b</sub>) CO-C (R<sub>8</sub>R<sub>9</sub>) N (R<sub>12</sub>) -C (O) -Ly-N (R<sub>b</sub>) C (O) -Ls-Re or
-C (R<sub>8</sub>R<sub>9</sub>) N (Ri<sub>2</sub>)-CABBAGE<sub>and</sub>-N (R<sub>b</sub>) C (O) -Ls-Re, or Z is -GC (R<sub>8</sub>R<sub>9</sub>) N (R<sub>12</sub>)39
ΙΜΡΪ
C (O) -Ly-N (R<sub>b</sub>)CABBAGE<sub>s</sub>-R<sub>and</sub>, in which L<sub>AND</sub> is alqffiW & SJf & fc
INDUSTRIAL optionally substituted with one or more R<sub>L</sub>, and Rb is each independently R<sub>b</sub>. R<sub>b</sub> and Re are each preferably hydrogen or C-¡-C alkyl<sub>6</sub>, and Rg and R12, taken together with the atoms to which they are attached, preferably form a 5- to 6-membered heterocycle or 6 to 12-membered pitchfork (for example,
<img file="MX339989B_D0108.tif" />
<img file="MX339989B_D0109.tif" />
which is optionally substituted with one or more R<sub>TO</sub> (such as, but not limited to, hydroxy, halogen (eg, fluoro), C., -C alkyl<sub>6</sub> (eg, methyl), or C alkenyl<sub>2</sub>-C<sub>6</sub> (eg allyl)). Preferably L<sub>AND</sub> is C ^ -Ce alkylene substituted with one or more R<sub>L </sub>such as a carbocycle of C<sub>3</sub>-C<sub>6</sub> 3- to 6-membered heterocycle which is optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci- alkyl C<sub>6</sub>, C alkenyl<sub>2</sub>-C<sub>6</sub>, C alkynyl<sub>2</sub>-C<sub>6</sub>, Cé-Ce halogenoalkyl, C halogenoalkenyl<sub>2</sub>-C<sub>6</sub> or halogenoalkyl C<sub>2</sub>-C<sub>6</sub>. Quite preferably, L<sub>AND</sub> is an alkylene of C<sub>t</sub>-C «such as, but not limited to,
XX
<img file="MX339989B_D0110.tif" />
<img file="MX339989B_D0111.tif" />
(the stereochemistry at a carbon within group L<sub>AND</sub> can be any of (R) or (S)); L<sub>AND</sub> is optionally substituted with one or more R<sub>l</sub> (eg, one or more phenyl or methoxy); G is preferably
H
<img file="MX339989B_D0112.tif" />
R<sub>B</sub> is hydrogen; -C (R<sub>8</sub>R<sub>9</sub>) N (R<sub>12</sub>)- it is
<img file="MX339989B_D0113.tif" />
I t / VW
L<sub>s</sub> is a link; and R<sub>AND</sub> it is methoxy.
Non-limiting examples of preferred Z include:
<img file="MX339989B_D0114.tif" />
<img file="MX339989B_D0115.tif" />
<img file="MX339989B_D0116.tif" />
J 3 i
<img file="MX339989B_D0117.tif" />
<img file="MX339989B_D0118.tif" />
<img file="MX339989B_D0119.tif" />
Τ-
<img file="MX339989B_D0120.tif" />
βη which T and R<sub>D</sub> they are as defined in the present application. T, for example, can be -L<sub>s</sub>-M-Ls'-M'-L<sub>s</sub>- in which L<sub>s</sub> is a link; M is C (O); Ls' is alkylene of (Ζ-Οβ such as, but not limited to,
A / V
<img file="MX339989B_D0121.tif" />
X Λ
Λ X.
<img file="MX339989B_D0122.tif" />
in which Ls' is optionally substituted with one or more R<sub>L</sub>; the R<sub>l</sub> optional is a substituent such as, but not limited to, phenyl or methoxy; M 'is -NHC (O) - or -NMeC (O) -; and L<sub>s</sub> is a link. Any stereochemistry on a carbon within group L<sub>s</sub>'can be either (R) or (S). R<sub>D</sub>, for example it is methoxy. TR<sub>D</sub> includes, but is not limited to:
Λ / W
<img file="MX339989B_D0123.tif" />
TR<sub>d</sub> It can also include certain stereochemical configurations; therefore TR<sub>D</sub> includes, but is not limited to:
<img file="MX339989B_D0124.tif" />
IMPI
MEXICAN INSTITUTE OF THE PRCPIEDAÍXrtAZ
<img file="MX339989B_D0125.tif" />
Non-limiting examples of
Preferred Zs also include:
<img file="MX339989B_D0126.tif" />
<img file="MX339989B_D0127.tif" />
IMPI
MEXICAN INSTITUTE OF INDUSTRIAL PROPERTY
<img file="MX339989B_D0128.tif" />
<img file="MX339989B_D0129.tif" />
vQ
V<sup>NH</sup> JH <sup>1</sup> OR.
AhY
Ό independent each time it appears you can select from -C (O) -L<sub>S</sub>'-, -C (O) OL<sub>s</sub>'-, -C (O) -L<sub>s</sub>'-N (R<sub>b</sub>) C (O) -Ls-, -C (O) -L<sub>s</sub>'-N (R<sub>b</sub>) C (O) OL<sub>s</sub>-,
-N (R<sub>b</sub>)CABBAGE<sub>s</sub>'-N (R<sub>b</sub>) C (O) -Ls-, -N (R<sub>b</sub>) C (O) -Ls<sup>,</sup>-N (R<sub>b</sub>) C (O) O-Ls-, or
-N (R<sub>b</sub>)CABBAGE<sub>s</sub>'-N (R<sub>b</sub>) -L<sub>s</sub>-. Preferably, T is independently selected each time it appears from -C (O) -L<sub>S</sub>'-M'Ls- or -N (R<sub>b</sub>) C (O) -I_s'-M'— L<sub>s</sub>-. More preferably, T is independently selected each time it occurs from -C (O) -L<sub>s</sub>'-N (R<sub>b</sub>)CABBAGE<sub>s</sub>- or -C (O) -L<sub>S</sub>'-N (R<sub>B</sub>) C (O) OL<sub>S</sub>-.
T can also be, for example, -Ls-M-Ls'-M'-Ls- in which L<sub>s</sub> is a link; M is C (O); L<sub>s</sub>'is Ct-C alkylene<sub>6</sub> (for example,), in which L<sub>s</sub>'is optionally substituted with
R<sub>T</sub>; the R<sub>T</sub> Optional is a substituent which is selected from alkyl Ci-Ce), -alkenyl (C<sub>2</sub>-C<sub>6</sub>), -alkyl (Ci-C<sub>6</sub>) -OH, -Ci-C alkylCt-Cgj-Oalkyl<sub>6</sub>, 3- to 6-membered heterocycle (eg, tetrahydrofuranyl), or C carbocyclyl<sub>3</sub>-C<sub>6</sub> (eg phenyl, cyclohexyl); M 'is -NHC (O) -, -N (Et) C (O) - or -N (Me) C (O) -; and L<sub>s</sub> is a link. R<sub>d</sub> preferably it is hydrogen, -Ct-Cs alkyl (for example, methyl), -O-Ct-Ce alkyl (for example, methoxy, tert-butoxy), methoxymethyl, or -N (alkyl (C<sub>1</sub>-C<sub>6</sub>))<sub>2</sub> (for example, -NMe<sub>2</sub>).
TR<sub>d</sub> can be, without limitation, 'ZVUV | / VVV' ° γ<sup>Ν</sup>Υ ^ Ο / ° γ<sup>Ν</sup>γΧ<sub>0</sub>
Ύ
or.
IMPI
1NSWUTO MEXICANO <sub>or</sub> PROPERTY π I INDUSTRIAL
<img file="MX339989B_D0130.tif" />
χΟγΝ
<img file="MX339989B_D0131.tif" />
-V
<img file="MX339989B_D0132.tif" />
Ό
<img file="MX339989B_D0133.tif" />
O ζ ° γΚ
<img file="MX339989B_D0134.tif" />
H, ° γ<sup>Ν</sup>
<img file="MX339989B_D0135.tif" />
<img file="MX339989B_D0136.tif" />
in which the stereochemistry at a carbon within the TR group<sub>D </sub>it can be either (R) or (S).
T can also be, without limitation, -L<sub>s</sub>-ML<sub>s</sub>'- in which Ls is a bond; M is C (O); L<sub>s</sub>'is C- | -C alkylene<sub>6</sub> (for example,> in which L<sub>s</sub>'is optionally substituted with R<sub>T</sub>; the R<sub>T </sub>Optional is a substituent selected from -alkyl (CiC<sub>6</sub>), -alkyl (CiC<sub>6</sub>) -OH, -Ci-C alkyl-rCej-O-alkyl<sub>6</sub>, or a carbocyclyl of C<sub>3</sub>-C<sub>6</sub> (eg phenyl, cyclohexyl). R<sub>D</sub>, for example is -OH; -OC (O) Me; -NH (alkyl (Ci-C<sub>6</sub>)) (for example, -NHMe,
<img file="MX339989B_D0137.tif" />
-NHEt); -N (alkyl (C<sub>1</sub>-C<sub>6</sub>)) 2 (for example, -N lleM PeL
INSTITUTO MEXICANO DE LA PROPERTY 3- to 10-membered heterocyclyl (eg imidazolidinyl, hexahydropyrimidinyl, morphoHrrttü, - ~ pipei¡diirftuj optionally substituted with one or more halogen, oxo; C3-C10 carbocycle (eg cyclopentyl) optionally substituted with -OH; -Ci-C alkyl<sub>6</sub> (eg isopropyl, 3-pentyl) optionally substituted with -OH; or NHR<sub>T</sub> wherein Rt is a 3 to 6 membered heterocyclyl (eg, thiazolyl, pyrimidinyl). TR<sub>D</sub> includes, but is not limited to:
<img file="MX339989B_D0138.tif" />
in which the stereochemistry at a carbon within the TR group<sub>D</sub>
IMPI
<img file="MX339989B_D0139.tif" />
it can be either (R) or (S).
MEXICAN INSTITUTE
For each compound in the Formula you can independently select each see that appears at. from a link; -L<sub>s</sub>'-N (R<sub>B</sub>) C (O) -Ls-; -L<sub>S</sub>'-C (O) N (R<sub>B</sub>) -L<sub>S</sub>-; or Ci-Ce alkylene, C alkenylene<sub>2</sub>-C<sub>6</sub>, C alkylene<sub>2</sub>-C<sub>6</sub>, C carbocycle<sub>3</sub>-C<sub>10</sub> or 3- to 10-membered heterocycle, each of which, independently, is optionally substituted at each occurrence with one or more substituents selected from halogen, R<sub>T</sub>, - OR<sub>s</sub>, -MR<sub>s</sub>, -N (R<sub>s</sub>Rs'), -OC (O) R<sub>S</sub>, -C (O) ORs, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano, in which L<sub>s</sub> and L<sub>s</sub>'are as defined above.
For formula I as well as for formulas l<sub>TO</sub>, Ib. Ic and Id described later, including each and all the modalities described under them, R<sub>TO</sub> preferably it is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or C / -C6 alkyl, C alkenyl<sub>2</sub>-C<sub>6</sub> or C alkynyl<sub>2</sub>-C<sub>6</sub>, each of which, independently, is optionally substituted each time it appears with one or more substituents that are selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or carbocycle of
C<sub>3</sub>-C<sub>6</sub> or 3- to 6-membered heterocycle, each of which, independently, is optionally substituted each time it occurs with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, CpCg alkyl, C alkenyl<sub>2</sub>-C<sub>6</sub>,
<img file="MX339989B_D0140.tif" />
C alkynyl<sub>2</sub>-C<sub>6</sub>, C ^ Ce halogenoalkyl, halocJejfeífdLlqBjejl.i
MEXICAN INSTITUTE OF PROPERTY
C<sub>2</sub>-C<sub>6</sub> or halogenoalkynyl of C<sub>2</sub>-C<sub>6</sub>; or -L<sub>TO</sub>-OR<sub>S</sub>, -L<sub>TO</sub>-MR<sub>s</sub>,
-L<sub>to</sub>-OC (O) R<sub>s</sub>, -L<sub>to</sub>-C (O) OR<sub>s</sub>, -L<sub>to</sub>-N (R<sub>s</sub>R<sub>s</sub>'), - L <sub>to</sub>- SfOTR sT'-LX-S'O <sub>2</sub>- * s, -L<sub>to</sub>-C (O) N (R<sub>s</sub>R<sub>s</sub>'), -L<sub>to</sub>-N (R<sub>s</sub>) C (O) R<sub>s</sub>', -L<sub>to</sub>-N (R<sub>s</sub>) C (O) N (R<sub>s</sub>'R<sub>s</sub>), -L<sub>to</sub>-N (R<sub>s</sub>)SW<sub>2</sub>R<sub>s</sub>', -L<sub>to</sub>-SW<sub>2</sub>N (R<sub>s</sub>Rs'). -L<sub>to</sub>-N (R<sub>s</sub>)SW<sub>2</sub>N (R<sub>s</sub>'R<sub>s</sub>), -L<sub>to</sub>-N (Rs) S (O) N (R<sub>s</sub>'Rs), -L<sub>to</sub>-OS (O) -Rs, -L<sub>to</sub>-BEAR)<sub>2</sub>-R<sub>s</sub>, -L<sub>to</sub>-SW)<sub>2</sub>OR<sub>s</sub>, -L<sub>to</sub>-S (O) OR<sub>s</sub>, -L<sub>to</sub>-OC (O) OR<sub>s</sub>, -L<sub>to</sub>-N (R<sub>s</sub>) C (O) OR<sub>s</sub>', -L<sub>to</sub>-OC (O) N (R<sub>s</sub>Rs'),
-L<sub>to</sub>-N (Rs) S (O) -R<sub>s</sub>', -La-S (O) N (R<sub>s</sub>Rs') or -L<sub>to</sub>-C (O) N (R<sub>s</sub>) C (O) -R<sub>s</sub>', in which L<sub>to</sub> is bond, Ci-C alkylene<sub>6</sub>, C alkenylene<sub>2</sub>-C<sub>6</sub> or C alkynylene<sub>2</sub>-C<sub>6</sub>.
More preferably, R<sub>TO</sub> is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or C ^ Ce alkyl, C alkenyl<sub>2</sub>-C<sub>6</sub> or C alkynyl<sub>2</sub>-C<sub>6</sub>, each of which, independently, is optionally substituted each time it appears with one or more substituents that are selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or carbocycle of C<sub>3</sub>-C<sub>6</sub> or 3-6 membered heterocycle, each of which, independently, is optionally substituted each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thoxo<sub>+</sub> formyl, cyano, CrCe alkyl, C alkenyl<sub>2</sub>-C<sub>5</sub>, C alkynyl<sub>2</sub>-C<sub>6</sub>, CiC haloalkyl<sub>6</sub>, halogenoalkenyl of C<sub>2</sub>-C<sub>6</sub> or halogenoalkynyl of C<sub>2</sub>-C<sub>6</sub>.
Rather preferably, R<sub>TO</sub> is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphon ^ 'j ^^ u & ía
- INDUSTRIAL
IMPIfSI sraiwas & ils
INDUSTRIAL or C- | -C alkyl<sub>6</sub>, C alkenyl<sub>2</sub>-C<sub>6</sub> or C alkynyl<sub>2</sub>-C<sub>6</sub>, each of which independently is optionally substituted each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, or cyano .
L<sub>s</sub>, Ls' and Ls are preferably each independently selected each time it appears from link; or Cj-Cs alkylene, C alkenylene<sub>2</sub>-C<sub>6</sub> or C alkynylene<sub>2</sub>-C<sub>6</sub>.
A and B can be the same or different. Similarly, Lj and L<sub>2</sub>, or Y and Z, or YA- and ZB-, or -AL ·, - and -BL<sub>2</sub>-, They can be the same or different. In some cases, YA-Lt is identical to ZBL<sub>2</sub>-, In some other cases, YAL · - is different from ZBL<sub>2</sub>-.
In one embodiment, A and B are each independently 5- or 6-membered carbocycle or heterocycle (eg, phenyl such as | \ 7-f) and are each independently optionally substituted with one or more R<sub>TO</sub>- X is 5- or 6-membered carbocycle or heterocycle or 6 to 12-membered bicyclo (for example,
<img file="MX339989B_D0141.tif" />
in which X<sub>3</sub> is N and is directly attached to -L<sub>3</sub>-D) and is optionally substituted with one or more R<sub>to</sub>. Specific examples of X were previously described in the present application. D is
IMPI carbocycle of C<sub>5</sub>-C<sub>6</sub> or heterocycle of 5 to 6 members<sup>T</sup>'^ p ^ | ^^ n
<img file="MX339989B_D0142.tif" />
phenyl), and is optionally substituted with one or more R<sub>TO</sub>. Preferably, D is
<img file="MX339989B_D0143.tif" />
in which R<sub>M</sub> and R<sub>N</sub> they are as defined above. L<sub>1</sub> and L<sub>2 </sub>are each independently C-bond or alkylene, -C<sub>6</sub>, and I_<sub>3</sub> is bond, Ci-C alkylene<sub>6</sub> or -C (O) -, and Li, L<sub>2</sub>, and L<sub>3</sub> are each independently optionally substituted with one or more R<sub>l</sub>. Preferably L<sub>1(</sub> L<sub>2</sub>, and L<sub>3</sub> they are link. And it is
-N (R<sub>B</sub>) C (O) C (R<sub>1</sub>R<sub>2</sub>) N (R<sub>5</sub>) -TR<sub>D</sub>, or -N (R<sub>b</sub>) C (O) C (R<sub>3</sub>R<sub>4</sub>) C (R<sub>6</sub>R<sub>7</sub>) -TR<sub>d</sub>, And it is
-N (R<sub>b</sub>) C (O) C (R<sub>8</sub>R<sub>9</sub>) N (R<sub>12</sub>) -TR<sub>d</sub>,
-N (R<sub>b</sub>) C (O) C (Ri<sub>0</sub>Rii) C (R<sub>13</sub>R<sub>14</sub>) -TR<sub>d</sub>. R! is R<sub>c</sub>, and R<sub>2</sub> and Rs, taken together with the atoms to which they are attached, form a 5- to 6-membered heterocyclic ring (for example,)
which is optionally substituted with one or more R<sub>TO</sub>; R<sub>3</sub> and R<sub>6</sub> are each independently Rc * and R<sub>4</sub> and R<sub>7</sub>, taken together with the atoms to which they are attached, form a 5- to 6-membered carbocyclic or heterocyclic ring (for example,
<img file="MX339989B_D0144.tif" />
IMPIi
MEXICAN INSTITUTE OF INDUSTRIAL PROPERTY
<img file="MX339989B_D0145.tif" />
which is optionally substituted with one or more R<sub>TO</sub>. Re is R<sub>c</sub>, and Rg and R<sub>12</sub>, taken together with the atoms to which they are attached, form a 5- to 6-membered heterocyclic ring (for example,)
which is optionally substituted with one or more R<sub>TO</sub>; and R<sub>10</sub> and R13 are each independently R<sub>c</sub>, and Rn and Ri<sub>4</sub>, taken together with the atoms to which they are attached, form a 5- to 6-membered carbocyclic or heterocyclic ring (for example,)
which is optionally substituted with one or more R<sub>to</sub>. T is preferably independently selected each time it appears from -C (O) -Ly'-N (R<sub>b</sub>)CABBAGE<sub>s</sub>- or -C (O) -L<sub>and</sub>'-N (R<sub>b</sub>) C (O) OL<sub>s</sub>-. L<sub>AND</sub>'is each independently L<sub>s</sub>'and, preferably, each is independently C ^ Ce alkylene (e.g., -CH<sub>2</sub>-) and optionally substituted with one or more substituents selected from R<sub>l</sub>. T can also be selected, without limitation, from -C (O) -L<sub>AND</sub>'-L<sub>S</sub>-, -C (O) -L<sub>AND</sub>'-OL<sub>S</sub>51
IMPI. -CABBAGE<sub>and</sub>'-N (Rb) -L<sub>s</sub>-, or -C (O) -Ly'-N (R<sub>b</sub>)SW)<sub>2</sub>-Ls-. 'PffK'SfretK<sup>0</sup>
INDtíiTM In cases, at least one of Y and Z is, or both Y and Z are of
<img file="MX339989B_D0146.tif" />
independent manner, in which the non-limiting examples of R<sub>D</sub> include (1) -O-C- | -C alkyl<sub>6</sub>, -O-alkenyl of C<sub>2</sub>-C<sub>6</sub>, -O-alkynyl of C<sub>2</sub>-C<sub>6</sub>, C ^ Ce alkyl, C alkenyl<sub>2</sub>-C<sub>6</sub> or C alkynyl<sub>2</sub>-C<sub>6</sub>, each of which, independently, is optionally substituted each time it appears with one or more substituents that are selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl , cyano, carbocycle of C<sub>3</sub>-C<sub>s</sub> or 3-6 membered heterocycle; or (2) to carbocycle of C<sub>3</sub>-C<sub>6</sub> or 3- to 6-membered heterocycle each of which, independently, is optionally substituted each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy , phosphono, thioxo, formyl, cyano, Cb-Ce alkyl. C alkenyl<sub>2</sub>-C<sub>6</sub>, C alkynyl<sub>2</sub>-C<sub>6</sub>, Ci-Ce haloalkyl, C haloalkenyl<sub>2</sub>-C<sub>6</sub> or halogenoalkynyl of C<sub>2</sub>-C<sub>6</sub>; and the non-limiting examples of L<sub>AND</sub>'include Ct-C alkylene<sub>6</sub> optionally substituted with halogen, hydroxy, mercapto, amino, carboxy, phosphonoxy, -O-Ci-C-alkyl<sub>6</sub>, -Oalkenyl of C<sub>2</sub>-C<sub>6</sub>, -O-alkynyl of C<sub>2</sub>-C<sub>6</sub>, or 3- to 6-membered carbocycle or heterocycle, said 3- to 6-membered carbocycle or heterocycle is optionally substituted with one or more substitutes
<img file="MX339989B_D0147.tif" />
selected from halogen, hydroxy, mercapto, amiri'5<sup>></sup>)<sup>js</sup>^ á<sup>l</sup>rbo5rr7 nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, alkyla d and CpCe, C alkenyl<sub>2</sub>-C<sub>5</sub>, C alkynyl<sub>2</sub>-C<sub>6</sub>, C ^ -C halogenoalkyl, C halogenalkenyl<sub>2</sub>-C<sub>6</sub> or halogenoalkynyl of C<sub>2</sub>-C<sub>6</sub>.
In another modality,
A is or
, and is optionally substituted with one or more R<sub>TO</sub>;
B is
<img file="MX339989B_D0148.tif" />
, and is optionally substituted with one or more R<sub>TO</sub>. Z-, is independently selected each time it appears from O, S, NH, or CH<sub>2</sub>; and Z<sub>2 </sub>is independently selected each time it appears from N or CH. X is a 5- or 6-membered carbocycle or heterocycle or 6 to 12-membered bicyclo (e.g. uAZb in which X<sub>3</sub> is N and is directly attached to -L<sub>3</sub>-D) and is optionally substituted with one or more R<sub>TO</sub>. Specific examples of X are described earlier in the present application. D is »ΑΛ · Λ · Λ-ώβίι-Μ, ^;
C carbocycle<sub>5</sub>-C<sub>6</sub> or heterocycle of 5 to 6 m¡embrd ^<sup>T</sup>®>^<sup>AND</sup>o '^ jn
IMPI
IKSTITUTA h E) acÑe®n
INDUSTRIAL
<img file="MX339989B_D0149.tif" />
phenyl), and is optionally substituted with one or more R<sub>TO</sub>. Preferably, D is
<img file="MX339989B_D0150.tif" />
in which R<sub>M</sub> and Rn are as defined above. L-ι and L<sub>2 </sub>are each independently C- | -C bond or alkylene<sub>6</sub>, and L<sub>3</sub> is bond, C- | -C alkylene<sub>6</sub> or -C (O) -, and L<sub>1t</sub> L<sub>2</sub>, and L<sub>3</sub> are each independently optionally substituted with one or more R<sub>L</sub>. Preferably L- ,, L<sub>2</sub>, and L<sub>3</sub> they are link. And it is
<img file="MX339989B_D0151.tif" />
<img file="MX339989B_D0152.tif" />
and R<sub>5</sub>, taken together with the atoms to which they are attached, form a 5- to 6-membered heterocyclic ring (for example,)
which is optionally substituted with one or more R<sub>TO</sub>; R<sub>3</sub> and R<sub>6</sub> each is independently Rc, and R4 and R7, taken together with the atoms to which they are attached, form a 5- to 6-membered carbocyclic or heterocyclic ring (eg)
IMPI '
<img file="MX339989B_D0153.tif" />
MEXICAN INSTITUTE OF IA PROPERTY
INDUSTRIAL
<img file="MX339989B_D0154.tif" />
which is optionally substituted with one or more R<sub>TO</sub>. R<sub>8</sub> is R<sub>c</sub>, and Rs and R12, taken together with the atoms to which they are attached, form a 5- to 6-membered heterocyclic ring (eg)
which is optionally substituted with one or more R<sub>TO</sub>; and R<sub>10</sub> and R13 are each independently R<sub>c</sub>, and Rn and Rn, taken together with the atoms to which they are attached, form a 5- to 6-membered carbocyclic or heterocyclic ring (for example,)
which is optionally substituted with one or more R<sub>TO</sub>. T is preferably independently selected each time it appears from -C (O) -Ly'-N (R<sub>b</sub>)CABBAGE<sub>s</sub>- or -C (O) -L<sub>and</sub>'-N (R<sub>b</sub>) C (O) OL<sub>s</sub>-. L<sub>AND</sub>'is each independently L<sub>s</sub>'and preferably is independently Ci-C alkylene<sub>6</sub> (for example, -CH<sub>2</sub>-) and optionally substituted with one or more substituents selected from R<sub>L</sub>. T can also be selected, without limitation, from -C (O) -L<sub>AND</sub>'-L<sub>S</sub>-, -C (O) -L<sub>AND</sub>'-O — L<sub>s</sub>-, -C (O) -L<sub>AND</sub>’55
.. «Μ»: ·.%> - · »Α — 5 --—
N (R<sub>b</sub>) -L<sub>s</sub>-, or -C (O) -L<sub>and</sub>'-N (Rb) S (O)<sub>2</sub>-L<sub>s</sub>-.
minus one of Y and Z is, or both Y independent,
<img file="MX339989B_D0155.tif" />
as Z are so
<img file="MX339989B_D0156.tif" />
in which the non-limiting examples of R<sub>D</sub> include (1) -O-Cj-Cealkyl, -O-Cj-alkenyl<sub>2</sub>-C<sub>6</sub>, -O-alkynyl of C<sub>2</sub>-C<sub>6</sub>, C-rCe alkyl, C alkenyl<sub>2</sub>-C<sub>6</sub> or C alkynyl<sub>2</sub>-C<sub>6</sub>, each of which, independently, is optionally substituted each time it appears with one or more substituents that are selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl , cyano, carbocycle of C<sub>3</sub>-C<sub>6</sub> or 3-6 membered heterocycle; or (2) carbocycle of C<sub>3</sub>-C<sub>6</sub> or 3- to 6-membered heterocycle each of which, independently, is optionally substituted each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy , phosphono, thioxo, formyl, cyano, Ci-C alkyl<sub>6</sub>, Cj-Ce alkenyl, C alkynyl<sub>2</sub>-C<sub>6</sub>, Cj-Ce haloalkyl, C haloalkenyl<sub>2</sub>-C<sub>6</sub> or halogenoalkynyl of C<sub>2</sub>-C<sub>6</sub>; and the non-limiting examples of L<sub>AND</sub>'include C.-C alkylene, optionally substituted with halogen, hydroxy, mercapto, amino, carboxy, phosphonoxy, -O-alkyl of CA-Ce, -O-alkenyl of C<sub>2</sub>-C<sub>6</sub>, -O-alkynyl of C<sub>2</sub>-C<sub>6</sub>, or carbocycle or heterocycle of 3 to 6 members, said carbocycle or heterocycle of 3 to
IMPIOS iNsnTOroMEX'Ojw?
Members are optionally substituted with one ixoSfiuffiát substituents which are selected from haphegen, —txidxoxu mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, C alkyl<sub>r</sub>C<sub>6</sub>, C alkenyl<sub>2</sub>-C<sub>6</sub>, C alkynyl<sub>2</sub>-Cg, halogenoalkyl of Ci-C<sub>6</sub>, C halogenoalkenyl<sub>2</sub>-C<sub>6</sub> or halogenoalkynyl of C<sub>2</sub>-C<sub>6</sub>.
In yet another embodiment, A and B are each independently 5- or 6-membered carbocycle or heterocycle (eg, A and B are each independently phenyl, such as | \), and are each independently optionally substituted with one or more R<sub>TO</sub>. X is 5- or 6-membered carbocycle or heterocycle or 6 to 12-membered bicycle (eg, ovo c /
<img file="MX339989B_D0157.tif" />
<img file="MX339989B_D0158.tif" />
in which X<sub>3</sub> is N and is directly attached to -L<sub>3</sub>-D) and is optionally substituted with one or more R<sub>TO</sub>. Specific examples of X are described earlier in the present application. D can be, for example, carbocycle of C<sub>5</sub>-C<sub>6</sub> or 5- to 6-membered heterocycle (eg, phenyl), and is optionally substituted with one or more
R<sub>TO</sub>. Preferably, D is
Rn.
Rm
Rm
Rn
Rn
Rn in which R<sub>M</sub> and Rn are as defined beforeWí ^ l $ & | $ ^ NgL
INDUSTRIAL
IMPI
WS «£ i
INDUSTRIAL are each independently bond or alkylene of Οτ-Οβ, and
<img file="MX339989B_D0159.tif" />
L<sub>3</sub> is bond, C ^ Ce alkylene or -C (O) -, and L<sub>1;</sub> L<sub>2</sub>, and L<sub>3</sub> are each independently optionally substituted with one or more R<sub>L</sub>. Preferably L- ,, L<sub>2</sub>, and L<sub>3</sub> they are link. Y is -GC (R<sub>1</sub>R<sub>2</sub>) N (R<sub>5</sub>) -TR<sub>D</sub> or -GC (R<sub>3</sub>R<sub>4</sub>) C (R<sub>6</sub>R<sub>7</sub>) -TR<sub>d</sub>, and Z is -GC (RgRg) N (R1<sub>2</sub>) -TR<sub>d</sub> or -GC (RioRii) C (Ri<sub>3</sub>Ri4) -TR<sub>d</sub>. G is independently carbocycle from C<sub>5</sub>-C<sub>6</sub> or 5-6 membered heterocycle, such as
H
<img file="MX339989B_D0160.tif" />
H
<img file="MX339989B_D0161.tif" />
and independently is optionally substituted with one or more R<sub>to</sub>. Ri is R<sub>c</sub>, and R2 and Re, taken together with the atoms to which they are attached, form a 5- to 6-membered heterocyclic ring (for example,
<img file="MX339989B_D0162.tif" />
which is optionally substituted with one or more R<sub>TO</sub>; R<sub>3</sub> and R<sub>6</sub> are each independently R<sub>c</sub>, and R<sub>4</sub> and R<sub>7</sub>, taken together with the atoms to which they are attached, form a 5- to 6-membered carbocyclic or heterocyclic ring (for example,
IMPI '
<img file="MX339989B_D0163.tif" />
INSTITUTO MEXICANO DELAFROPIEDaD
INDUSTRIAL
<img file="MX339989B_D0164.tif" />
which is optionally substituted with one or more R<sub>TO</sub>. Rs is R<sub>c</sub>, and R<sub>g</sub> and R12, taken together with the atoms to which they are attached, form a 5- to 6-membered heterocyclic ring (for example,)
which is optionally substituted with one or more R<sub>TO</sub>; and R-, ο and R13 are each independently Rc, and Rn and Rn, taken together with the atoms to which they are attached, form a 5- to 6-membered carbocyclic or heterocyclic ring (for example,)
which is optionally substituted with one or more R<sub>TO</sub>. T is preferably independently selected each time it appears from -C (O) -L<sub>and</sub>'-N (Rb) C (O) -L<sub>s</sub>- or -C (O) -L<sub>AND</sub>'-N (R<sub>B</sub>) C (O) OL<sub>s</sub>-. L<sub>AND</sub>'is each independently L<sub>s</sub>'and, preferably, each is independently alkylene of (e.g. -CH<sub>2</sub>-) and optionally substituted with one or more substituents selected from R<sub>L</sub>. T can also be selected, without limitation, from -C (O) -L<sub>AND</sub>'-L<sub>S</sub>-, -C (O) -L<sub>AND</sub>'-OL<sub>S</sub>-
<img file="MX339989B_D0165.tif" />
IMPI • MEXICAN INSTITUTE
DE LA PROHEDAD, -C (O) -L<sub>and</sub>'-N (R<sub>b</sub>) -Ls-, or -C (O) -Ly'-N (R<sub>b</sub>)SW)<sub>2</sub>-Ls.-.
cases, at least one of Y and Z is, or both T UUlliu · Z iun 'dt # · independently,
<img file="MX339989B_D0166.tif" />
in which non-limiting examples of R<sub>D</sub> include (1) -O-Cj-Cealkyl, -O-Cj-alkenyl<sub>2</sub>-C<sub>6</sub>, -O-alkynyl of C<sub>2</sub>-C<sub>6</sub>, Οϊ-Οθ alkyl, C alkenyl<sub>2</sub>-C<sub>6</sub> or C alkynyl<sub>2</sub>-C<sub>6</sub>, each of which, independently, is optionally substituted each time it appears with one or more substituents that are selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl , cyano, carbocycle of C<sub>3</sub>-C<sub>6</sub> or 3-6 membered heterocycle; or (2) carbocycle of C<sub>3</sub>-C<sub>6</sub> or 3- to 6-membered heterocycle each of which, independently, is optionally substituted each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy , phosphono, thioxo, formyl, cyano, CiC alkyl<sub>6</sub>, C alkenyl<sub>2</sub>-C<sub>6</sub>, C alkynyl<sub>2</sub>-C<sub>6</sub>, haloalkyl of geno, -Ο<sub>Β</sub>, C halogenoalkenyl<sub>2</sub>-C<sub>6</sub> or halogenoalkynyl of C<sub>2</sub>-C<sub>6</sub>; and the non-limiting examples of L<sub>AND</sub>'include CiC alkylene<sub>6</sub> optionally substituted with halogen, hydroxy, mercapto, amino, carboxy, phosphonoxy, -O-C- | -C alkyl<sub>6</sub>, -O60
<img file="MX339989B_D0167.tif" />
C alkenyl<sub>2</sub>-C<sub>6</sub>, -O-alkynyl of C<sub>2</sub>-C<sub>6</sub>, or 3-6 membered carbocy, said 3-6 membered carbocycle or heterocycle is optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-Ce alkyl. C alkenyl<sub>2</sub>-C<sub>6</sub>, C alkynyl<sub>2</sub>-C<sub>6</sub>, CiC haloalkyl<sub>6</sub>, C halogenoalkenyl<sub>2</sub>-C<sub>6</sub> or halogenoalkynyl of C<sub>2</sub>-C<sub>6</sub>.
In still another embodiment, A and B are each independently 5- or 6-membered carbocycle or heterocycle (eg, A and B are each independently phenyl, such as |), and are each independently optionally substituted with one or more R<sub>TO</sub>. X is 5- or 6-membered carbocycle or heterocycle or 6 to 12-membered bicyclo (for example,
<img file="MX339989B_D0168.tif" />
<img file="MX339989B_D0169.tif" />
in which X<sub>3</sub> is N and is directly attached to -L<sub>3</sub>-D) and is optionally substituted with one or more R<sub>TO</sub>. Specific examples of X are described earlier in the present application. D can be, for example, carbocycle of C<sub>5</sub>-C<sub>6</sub> or 5- to 6-membered heterocycle (eg, feruk>), and is optionally substituted with one or more R<sub>to</sub>. Preferably, D is
<img file="MX339989B_D0170.tif" />
OR
IMPI
MEXICAN INSTITUTE OF PROPERTY
INDUSTRIAL
<img file="MX339989B_D0171.tif" />
in which R<sub>M</sub> and R<sub>N</sub> they are as defined above. Lt and L<sub>2 </sub>are each independently Ci-C bond or alkylene<sub>6</sub>, and L<sub>3</sub> is bond, C alkylene<sub>r</sub>C<sub>6</sub> or -C (O) -, and L-ι, L<sub>2</sub>, and L<sub>3</sub> are each independently optionally substituted with one or more R<sub>l</sub>. Preferably L<sub>b</sub> L<sub>2</sub>, and L<sub>3</sub> they are link. Y is -NíReOC ^ C ^ R ^ NÍRsJ-T-Rd or -N (R<sub>b</sub>) C (O) C (R<sub>3</sub>R<sub>4</sub>) C (R<sub>6</sub>R<sub>7</sub>) -TR<sub>d</sub>, and Z is -GC (R<sub>8</sub>Rg) N (R<sub>12</sub>) -TR<sub>D</sub> or -GC (R-ioRii) C (Ri3Ri4)<sup>_</sup>T-Rd¡ or Y is -G-CíRtRzJNíRsJ-T-Rd or -GC (R<sub>3</sub>R<sub>4</sub>) C (R<sub>6</sub>R<sub>7</sub>) -TR<sub>d</sub>, and Z is -N (R<sub>b</sub>) C (O) C (R<sub>8</sub>R<sub>9</sub>) N (R<sub>12</sub>) -TR<sub>d</sub> or -NÍRtOCíCDCíRtoRuJCíRTsRubT-RD. Ri is R<sub>c</sub>, and R<sub>2</sub> and Rs, taken together with the atoms to which they are attached, form a 5- to 6-membered heterocyclic ring (for example,)
which is optionally substituted with one or more R<sub>TO</sub>; R3 and Re are each independently R<sub>c</sub>, and R<sub>4</sub> and R<sub>7</sub>, taken together with the atoms to which they are attached, form a 5- to 6-membered carbocyclic or heterocyclic ring (for example,
<img file="MX339989B_D0172.tif" />
IMPI
MEXICAN INSTITUTE OF PROPERTY
INDUSTRIAL
<img file="MX339989B_D0173.tif" />
which is optionally substituted with one or more R<sub>TO</sub>. Re is Rc, and R<sub>g</sub> and R12, taken together with the atoms to which they are attached, form a 5- to 6-membered heterocyclic ring (for example,
<img file="MX339989B_D0174.tif" />
which is optionally substituted with one or more R<sub>TO</sub>; and R<sub>10</sub> and R13 are each independently Rc, and Rn and R14, taken together with the atoms to which they are attached, form a 5- to 6-membered carbocyclic or heterocyclic ring (for example,
<img file="MX339989B_D0175.tif" />
which is optionally substituted with one or more R<sub>TO</sub>. G is independently carbocycle from C<sub>5</sub>-C<sub>6</sub> or 5-6 membered heterocycle, such as
H
N „
and independently is optionally substituted with one or more R<sub>TO</sub>. T is preferably independently selected each time it appears from -C (O) - L<sub>AND</sub>'—N (fJ) ^<sup>1</sup>^) ^ L ^ <sup>m T</sup>Of the property
INDUSTRIAL
-C (O) -Ly'-N (R<sub>b</sub>) C (O) O-Ls- · L<sub>and</sub>* is each independently L<sub>s</sub>'and preferably each is independently alkylene from Οτ-Οβ (eg -CH<sub>2</sub>-) and optionally substituted with one or more substituents selected from R<sub>L</sub>. T can also be selected, without limitation, from -C (O) -L<sub>AND</sub>'-L<sub>S</sub>-, -C (O) L<sub>AND</sub>'-O-Ls-, -C (O) -L<sub>AND</sub>'-N (R<sub>B</sub>) -L<sub>S</sub>-, or -C (O) -L<sub>AND</sub>'-N (R<sub>B</sub>)SW)<sub>2</sub>-L<sub>s</sub>-. In some cases, Y is. H, O \ -<sup>N</sup>
<img file="MX339989B_D0176.tif" />
X, 'V <Ly n
-R<sub>b</sub> as described above, and Z is
<img file="MX339989B_D0177.tif" />
as described above
In some other cases, Y is
<img file="MX339989B_D0178.tif" />
as described above, and Z is
ΪΜΡΙ
V
Η
Ν ·
<img file="MX339989B_D0179.tif" />
<img file="MX339989B_D0180.tif" />
<sup>Λ3</sup>*·* "*· as described above.
In still another embodiment, A is carbocycle or heterocycle
<img file="MX339989B_D0181.tif" />
(for example,
<img file="MX339989B_D0182.tif" />
(for example,
<img file="MX339989B_D0183.tif" />
and B is 5- or 6-membered carbocycle or heterocycle (eg, phenyl such as). A and B are each so • e ^ paes
Independent IMPI optionally substituted with one fí '<sup>ST</sup>Iii '^ l<sup>AND</sup>or ^ A?
INDUSTRIAL selects independently each time it appears from O, S, NH or CH<sub>2</sub>; and Z<sub>2</sub> is independently selected each time it appears from N or CH.
X is carbocycle or 5- or 6-membered heterocycle or bicycle
<img file="MX339989B_D0184.tif" />
<img file="MX339989B_D0185.tif" />
in which X<sub>3</sub> is N and is directly attached to -L<sub>3</sub>-D) and is optionally substituted with one or more R<sub>TO</sub>. Specific examples of X are described earlier in the present application. D is carbocycle of C<sub>5</sub>-C<sub>6</sub>5- to 6-membered carbocycle or heterocycle (e.g. phenyl), and is
Preferably, D is
Rn<sub>x</sub> r / in which R<sub>M</sub> and R<sub>N</sub> they are as defined above. Li and L<sub>2 </sub>are each independently bond or Cj-C alkylene<sub>6</sub>, and L<sub>3</sub> is bond, Cj-Ce alkylene or -C (O) -, and Li, L<sub>2</sub>, and L<sub>3</sub> are each independently optionally substituted with one or more R<sub>l</sub>. Preferably L<sub>n</sub> L<sub>2</sub>, and L<sub>3</sub> they are link.
optionally substituted with one or more R<sub>TO</sub>.
Rl
<img file="MX339989B_D0186.tif" />
Rn
Rm
<img file="MX339989B_D0187.tif" />
<img file="MX339989B_D0188.tif" />
Rn
IB *.
<img file="MX339989B_D0189.tif" />
IMPI
When A is carbocycle or heterocycle of
INDUSTRIAL (e.g., phenyl such as |), Y is - N (R<sub>b</sub>) C (O) C (RiR<sub>2</sub>) N (R<sub>5</sub>) -TR<sub>d</sub>, -N (Rb) C (O) C (R<sub>3</sub>R4) C (R<sub>6</sub>R7) -TR<sub>d</sub>, -GC (R, R<sub>2</sub>) N (R<sub>5</sub>) -TR<sub>d</sub> or -GC (R<sub>3</sub>R<sub>4</sub>) C (R<sub>6</sub>R<sub>7</sub>) -TR<sub>D</sub>, and Z is -L<sub>S</sub>-C (R<sub>8</sub>R<sub>9</sub>) N (R<sub>12</sub>) -TR<sub>D</sub> or -I_s-C (RioRii) C (R |<sub>3</sub>R |<sub>4</sub>) -T-Rd.
When B is 5- or 6-membered carbocycle or heterocycle (eg, phenyl such as $ -), Y is -L<sub>S</sub>-C (R<sub>1</sub>R<sub>2</sub>) N (R<sub>5</sub>) -TR<sub>D</sub> or -I_s-C (R<sub>3</sub>R<sub>4</sub>) C (R<sub>6</sub>R<sub>7</sub>) -TR<sub>d</sub>, and Z is -N (R<sub>B</sub>) C (O) C (R<sub>8</sub>R<sub>9</sub>) N (R<sub>12</sub>) -TR<sub>D</sub>, -N (R<sub>B</sub>) C (O) C (R<sub>10</sub>R<sub>11</sub>) C (R<sub>13</sub>R<sub>14</sub>) -TR<sub>D</sub>, -GC (R<sub>8</sub>R<sub>9</sub>) N (R<sub>12</sub>) -TR<sub>d</sub> or
-GC (Ri<sub>0</sub>Rii) C (R<sub>13</sub>R<sub>14</sub>) -TR<sub>d</sub>. R, is R<sub>c</sub>, and R<sub>2</sub> and Rs, taken together with the atoms to which they are attached, form a 5- to 6-membered heterocyclic ring (for example,
<img file="MX339989B_D0190.tif" />
which is optionally substituted with one or more R<sub>TO</sub>; R3 and Re are each independently Rc, and R<sub>4</sub> and R7, taken together with the atoms to which they are attached, form a 5- to 6-membered carbocyclic or heterocyclic ring (for example,
<img file="MX339989B_D0191.tif" />
) which is optionally substituted with one or more R<sub>TO</sub>. R<sub>8</sub> is R<sub>c</sub>, and R<sub>9</sub> and R<sub>12</sub>, taken together with the atoms to which they are attached, form a 5- to 6-membered heterocyclic ring (for
<img file="MX339989B_D0192.tif" />
example,
IMPI
MEXICAN INSTITUTE OF INDUSTRIAL PROPERTY
<img file="MX339989B_D0193.tif" />
which is optionally substituted with one or more R<sub>TO</sub>; and Rio and Rn are each independently R<sub>c</sub>, and R-- and R<sub>14</sub>, taken together with the atoms to which they are attached, form a 5- to 6-membered carbocyclic or heterocyclic ring (for example,
<img file="MX339989B_D0194.tif" />
which is optionally substituted with one or more R<sub>TO</sub>. G is independently carbocycle from C<sub>5</sub>-C<sub>6</sub> or 5-6 membered heterocycle, such as
<img file="MX339989B_D0195.tif" />
and independently is optionally substituted with one or more R<sub>TO</sub>. T is preferably independently selected each time it appears from -C (O) -L<sub>and</sub>'-N (Rb) C (O) -L<sub>s</sub>- or -C (O) L<sub>and</sub>'-N (R<sub>b</sub>) C (O) OL<sub>s</sub>-. L<sub>AND</sub>'is each independently L<sub>s</sub>'and preferably each is independently alkylene from CiC<sub>6</sub> (for example, -CH<sub>2</sub>-) and optionally substituted with one or more substituents selected from R<sub>L</sub>. T can also be selected, without limitation, from -C (O) -L<sub>AND</sub>'-L<sub>S</sub>-, -C (O) -L<sub>AND</sub>'-OL<sub>S</sub>68
IMPIOS
INSTITUTO MEXICANO, -C (O) -Ly'-N (Rb) -Ls-, or -C (O) -Ly'-N (R<sub>b</sub>)SW)<sub>2</sub>-L<sub>s</sub>-. when A is 5- or 6-membered carbocycle or heterocycle (for example,
<img file="MX339989B_D0196.tif" />
phenyl such as j
<img file="MX339989B_D0197.tif" />
), And it is
<img file="MX339989B_D0198.tif" />
as described above, and Z is
<img file="MX339989B_D0199.tif" />
as described above. In some other cases when B is 5- or 6-membered carbocycle or heterocycle (e.g., phenyl such as), Y is
<img file="MX339989B_D0200.tif" />
as described above, and Z is
<img file="MX339989B_D0201.tif" />
<img file="MX339989B_D0202.tif" />
N <sup>L</sup>and Or as previously described.
saasec 3Scan <P
SAY INDUSTRIAL PROPERTY
<img file="MX339989B_D0203.tif" />
In another aspect, the present compounds of formula l<sub>TO</sub> and pharmaceutically acceptable salts thereof.
D
<img file="MX339989B_D0204.tif" />
in which:
R<sub>nb</sub> each is independently selected from R<sub>B</sub>;
R<sub>c</sub>'each is independently selected from R<sub>c</sub>;
R<sub>d</sub>'each is independently selected from R<sub>D</sub>;
R<sub>2</sub> and Rs, taken together with the atoms to which they are attached, form a 3- to 12-membered heterocycle which is optionally substituted with one or more R<sub>TO</sub>;
R<sub>g</sub> and R¡<sub>2</sub>, taken together with the atoms to which they are attached, form a 3- to 12-membered heterocycle which is optionally substituted with one or more R<sub>TO</sub>;
A, B, D, X, Li,
L<sub>2</sub>, L<sub>3i</sub> T, R<sub>to</sub>, R<sub>b</sub>, R<sub>c</sub>, and R<sub>D</sub> are as previously described in Formula I.
In this regard, A and B are preferably selected from
ΙΜΡΙί ~
MEXICAN INSTITUTE i
MEXICAN INSTITUTE OF INDUSTRIAL PROPERTY
<img file="MX339989B_D0205.tif" />
independently from carbocycle of C<sub>5</sub>-OR<sub>6</sub> or 5- to 6-membered heterocycle, and are each independently optionally substituted with one or more R<sub>TO</sub>. More preferably, at least one of A and B is phenyl (eg,
<img file="MX339989B_D0206.tif" />
Fy— | )' AND<sup>it is</sup>It is optionally substituted with one or more R<sub>TO</sub>. Quite preferably, both A and B are each in a manner), and are each independently phenyl (eg, | independently optionally substituted with one or more R<sub>TO</sub>.
D is preferably selected from carbocycle of
C<sub>5</sub>-C<sub>6</sub>, 5- to 6-membered heterocycle, or 8 to 12-membered bicycles, and is optionally substituted with one or more R<sub>TO</sub>. D can also be preferably selected from Ci-C alkyl<sub>6</sub>, C alkenyl<sub>2</sub>-C<sub>6</sub> or C alkynyl<sub>2</sub>-C<sub>6</sub>, and is optionally substituted with one or more R<sub>L</sub>. More preferably, D is carbocycle of C<sub>5</sub>-C<sub>6</sub>, 5-6 membered heterocycle, or 6-12 membered bicycles, and is substituted with one or more R<sub>M</sub>, in which R<sub>M</sub> is halogen, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano, or -L<sub>s</sub>-Re Also preferably, D is phenyl, and is optionally substituted with one or more R<sub>TO</sub>. More preferably, D is phenyl, and is substituted with one or more R<sub>M</sub>, in which R<sub>M</sub> it is as defined above. Quite preferably, D is
<img file="MX339989B_D0207.tif" />
<img file="MX339989B_D0208.tif" />
INDUSTRIAL
IMPÍ
D l. MEXICAN INSTITUTE. 'of the property
<img file="MX339989B_D0209.tif" />
in which R<sub>M</sub> is as defined above, and each R<sub>N</sub> is independently selected from R<sub>D</sub> and is preferably hydrogen. One or more of R<sub>N</sub> preferably it can also be halogen such as F.
D is also preferably pyridinyl, pyrimidinyl, or thiazolyl, optionally substituted with one or more R<sub>TO</sub>. More preferably D is pyridinyl, pirlmidinyl, or thiazolyl, and is substituted with one or more R<sub>M</sub>. Rather preferably, D is
<img file="MX339989B_D0210.tif" />
in which R<sub>M</sub> is as defined above, and each R<sub>N</sub> is independently selected from R<sub>D</sub> and is preferably hydrogen. One or more of R<sub>n</sub> preferably it may also be halogen such as F. D is also preferably indanyl, 4,5,6,7-tetrahydrobenzo [dltilazolyl, benzo [d] thiazolyl, or indazolyl, and is optionally substituted with one or more R<sub>to</sub>. More preferably D is indanyl, 4,5,6,7-tetrahydrobenzo [d] thiazolyl, benzo [d] thiazolyl, indazolyl, or benzo [d] [1,3] dioxol-5-yl, and is substituted with one or more
R<sub>M</sub>. Rather preferably, D is
<img file="MX339989B_D0211.tif" />
<img file="MX339989B_D0212.tif" />
y is optionally substituted with one or more R<sub>M</sub>.
Preferably R<sub>M</sub> is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxl, phosphono, tloxo, cyano; or Ci-C alkyl<sub>6</sub>, C alkenyl<sub>2</sub>-C<sub>6</sub> or C alkynyl<sub>2</sub>-C<sub>6</sub>, each of which, independently, is optionally substituted each time it appears with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, tloxo, formllo or cyano; or carbocyl of C<sub>3</sub>-C<sub>6</sub> or 3- to 6-membered heterocycle, each of which, independently, is optionally substituted each time it appears with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxyl, nitro, oxo, phosphonoxy, phosphono, tloxo, formyl, cyano, Ci-C alkyl<sub>6</sub>, C alkenyl<sub>2</sub>-C<sub>6</sub>, C alkynyl<sub>2</sub>-C<sub>6</sub>, CiC halogenoalkyl<sub>6</sub>, halogenoalkenyl of C<sub>2</sub>-C<sub>6</sub> or C halogenoalkylnyl<sub>2</sub>-C<sub>6</sub>. More preferably, R<sub>M</sub> is halogen, hydroxy, mercapto, amino, carboxy; or C alkyl<sub>r</sub>C<sub>6! </sub>C alkenyl<sub>2</sub>-C<sub>6</sub> or C alkynyl<sub>2</sub>-C<sub>6</sub>, each of which, independently, is optionally substituted each time it appears with one or more substituents selected from
IMPI halogen, hydroxy, mercapto, amino or carboxy. Of
INDUSTRIAL
<img file="MX339989B_D0213.tif" />
preferred, R<sub>M</sub> it is CJ-Cg alkyl which is optionally substituted with one or more substituents which are selected from halogen, hydroxy, mercapto, amino or carboxy.
Also preferably, R<sub>M</sub> is halogen, hydroxy mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, or cyano; or Rm is -L<sub>s</sub>-Re, in which L<sub>s</sub> is a bond or alkylene of
<img file="MX339989B_D0214.tif" />
-N (Rs) C (O) R<sub>s</sub>'-N (R<sub>S</sub>) C (O) OR<sub>S</sub>', -N (R<sub>s</sub>)SW<sub>2</sub>R<sub>s</sub>', -SO<sub>2</sub>R<sub>s</sub>, -MR<sub>s</sub>. or -P (O) (ORs)<sub>2</sub>, in which R<sub>s</sub> and Rs' For example may be independently selected each occurrence from (1) hydrogen or (2) alkyl of CrCe optionally substituted each occurrence with one or more halogen, hydroxy, -O-alkyl from DC<sub>6</sub> or 3-6 membered heterocycle; or R<sub>M</sub> is Ci-C alkyl<sub>6</sub>, C alkenyl<sub>2</sub>-C<sub>6</sub> or C alkynyl<sub>2</sub>-C<sub>6</sub>, each of which, independently, is optionally substituted each time it appears with one or more substituents that are selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or R<sub>M</sub> is carbocycle of C<sub>3</sub>-C<sub>6</sub> or 3- to 6-membered heterocycle, each of which, independently, is optionally substituted each time it appears with urre or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C alkyl<sub>6</sub>, C alkenyl<sub>2</sub>-C<sub>6</sub>, C alkynyl<sub>2</sub>-C<sub>6</sub>, haloalkyl of Ο ·, -Ο<sub>6</sub>, C halogenoalkenyl<sub>2</sub>-C<sub>6</sub>,
C halogenoalkynyl IMPI<sub>2</sub>-C<sub>6</sub>, -C (O) OR<sub>S</sub>, or -N (R<sub>s</sub>Rs') · D
INDUSTRIAL preferred, R<sub>M</sub> it is halogen (eg fluoro, chloro, bromo, iodo), hydroxy, mercapto, amino, carboxy, or C ^ Cs alkyl (eg methyl, isopropyl, tert-butyl), C alkenyl<sub>2</sub>-C<sub>6</sub> or alkynyl of O<sub>2</sub>-C<sub>6</sub>, each of which, independently, is optionally substituted each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, cyano, or carboxy. For example R<sub>M</sub> is CF<sub>3</sub>, -C (CF<sub>3</sub>)<sub>2</sub>OH, -C (CH<sub>3</sub>)<sub>2</sub>-CN, -C (CH<sub>3</sub>)<sub>2</sub>-CH<sub>2</sub>OH, or -C (CH<sub>3</sub>)<sub>2</sub>-CH<sub>2</sub>NH<sub>2</sub>. Also preferably R<sub>M</sub> is -L<sub>S</sub>-R<sub>AND</sub> in which L<sub>s</sub> is a link and R<sub>AND</sub> is N (R<sub>s</sub>Rs), -OR<sub>s</sub>, -N (Rs) C (O) OR<sub>s</sub>', -N (R<sub>s</sub>)SW<sub>2</sub>R<sub>s</sub>', -SO<sub>2</sub>R<sub>s</sub>, or -SR<sub>s</sub>. For example in cases where Ls is a bond, R<sub>AND</sub> is -N (alqull (Ci-C<sub>2</sub>))<sub>2 </sub>(for example, -NMe<sub>2</sub>); -N (alkylene (Ci-C<sub>6</sub>) -O-(Ci-C6) alkyl) 2 (for example -N (CH<sub>2</sub>CH<sub>2</sub>OMe)<sub>2</sub>); -NíalkylíC ^ CejJíalkileníC ^ Csj-OalkyíCi-Ce)) (for example - N (CH<sub>3</sub>) (CH<sub>2</sub>CH<sub>2</sub>OMe)); - O-alkyl of G<sub>and</sub>C<sub>6</sub> (eg -Ο-Me, -O-Et, -O-isopropyl, -O-tert-butyl, -O-nhexyl); -O-halogen alkyl of (e.g. -OCF<sub>3</sub>,
-OCH<sub>2</sub>CF<sub>3</sub>); -O-alkyleneiCi-Cej-piperidine (for example, -O-CH<sub>2</sub>CH<sub>2</sub>-1piperid yl o); -N (alkyl (C., - C<sub>s</sub>)) C (O) O-Ci-C alkyl<sub>6</sub> (for example, -N (CH<sub>3</sub>) C (O) O-CH<sub>2</sub>CH (CH<sub>3</sub>)<sub>2</sub>), -N (alkyl (C<sub>1</sub>-C<sub>6</sub>))SW<sub>2</sub>-C alkyl<sub>r</sub>C<sub>and </sub>(for example, -N (CH<sub>3</sub>)SW<sub>2</sub>CH<sub>3</sub>); -SW<sub>2</sub>-alkyl of C -, - C<sub>6</sub> (for example, -SG2Me>; -S0<sub>2</sub>-haloalkyl of CLt-Ce (for example, -SO<sub>2</sub>CF<sub>3</sub>); or -S-C ^ Ce halogenoalkyl (for example, SCF<sub>3</sub>). Also preferably R<sub>M</sub> is -L<sub>S</sub>-R<sub>AND</sub> in which L<sub>s</sub> is Ci-C alkylene<sub>6</sub> (for example, -CH<sub>2</sub>-, -C (CH<sub>3</sub>)<sub>2</sub>-, -C (CH<sub>3</sub>)<sub>2</sub>-CH<sub>2</sub>-) and R<sub>AND</sub> is -OR<sub>s</sub>, -C (O) OR<sub>S</sub>,
<img file="MX339989B_D0215.tif" />
IMPI
<img file="MX339989B_D0216.tif" />
-N (R<sub>S</sub>) C (O) OR<sub>S</sub>', or -P (O) (OR<sub>s</sub>) 2- For example R<sub>M</sub> is OR<sub>s</sub> (for example, -C (CH<sub>3</sub>)<sub>2</sub>-CH<sub>2</sub>-OI \ / le); -alqu¡len (C<sub>1</sub>-C<sub>6</sub>) -C (Q) QR<sub>s </sub>(for example, -C (CH<sub>3</sub>)<sub>2</sub>-C (O) OMe); -alkyleneC ^ ^ CeJ-NíRsJCÍOJORs' (for example, -C (CH<sub>3</sub>)<sub>2</sub>-CH<sub>2</sub>-NHC (O) OCH<sub>3</sub>); or -alkylene Cj-Ce) P (O) (ORs) 2 (for example, -CH<sub>2</sub>-P (O) (OEt)<sub>2</sub>). Also more preferably R<sub>M</sub> is carbocycle of C<sub>3</sub>-C<sub>6</sub> or 3- to 6-membered heterocycle, each of which, independently, is optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C alkyl<sub>6</sub>, C alkenyl<sub>2</sub>-C<sub>6</sub>, C alkynyl<sub>2</sub>-C<sub>6</sub>, Ci-CA haloalkyl, C haloalkenyl<sub>2</sub>-C<sub>6</sub>, C halogenoalkynyl<sub>2</sub>-C<sub>6</sub>, -C (O) OR<sub>S</sub>, or -N (R<sub>S</sub>R<sub>S</sub>'). For example R<sub>M </sub>is cycloalkyl (eg cyclopropyl, 2,2-dichloro-1-methylcyclopropyl-yl, cyclohexyl), phenyl, heterocyclyl (eg morpholin-4-yl,
1,1-dioxidot¡omorpholin-4-¡lo, 4-methylp¡peraz¡n-1-yl, 4-methoxycarbonylpiperazin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, 4-methylpiperidin-1 -yl, 3,5-dimethylpiperidin-1 -yl, 4,4-difluoropiperidin-1¡lo, tetrahydropyran-4-yl, pyridinyl, pyridin-3-ilo, 6 (dimethylamino ) pyridin-3-lo). Rather preferably, R<sub>M</sub> is Ci-C alkyl<sub>6</sub> which is optionally substituted with one or more substituents that are selected from halogen, hydroxy, mercapto, amino or carboxy (eg, tert-butyl, CF<sub>3</sub>).
X is preferably carbocycle of C<sub>5</sub>-C<sub>6</sub>, 5- to 6-membered heterocycle, or 6 to 12-membered bikes (for example,
<img file="MX339989B_D0217.tif" />
IMPI
INSTTTLTO WSCCiCMO Dt LA k'fcCntLLAD
INIX> S ~ AÍAL
<img file="MX339989B_D0218.tif" />
in which X<sub>3</sub> is N and is directly attached to -L<sub>3</sub>-D), and is optionally substituted with one or more R<sub>TO</sub>. Non-limiting examples of X are described earlier in the present application.
L! and L<sub>2</sub> preferably they are independently bond or alkylene of C - ^ - Ce, L<sub>3</sub> preferably selected from bond, ileno · ι-Ο alkylene<sub>6</sub> o -C (O) -, and L · ,, L<sub>2</sub>, and L<sub>3</sub> are each independently optionally substituted with one or more R<sub>l</sub>. More preferably, L<sub>n</sub> L<sub>2</sub> and L<sub>3</sub> are each independently bond or alkylene of C -, - C<sub>6</sub> (for example, -CH<sub>2</sub>- or -CH<sub>2</sub>CH<sub>2</sub>-), and are each independently optionally substituted with one or more R<sub>L</sub>. Rather preferably, L-ι, L<sub>2</sub> and L<sub>3</sub> they are link.
R<sub>2</sub> and R<sub>5</sub>, taken together with the atoms to which they are attached, preferably form a 5-membered heterocycle or 6 to 12-membered bicyclo (e.g.,), which is optionally substituted with one or more R<sub>TO</sub>.
Π
R<sub>9</sub> and R<sub>12</sub>, taken together with the atoms
<img file="MX339989B_D0219.tif" />
are attached, preferably form a 5- to 6-membered heterocycle or 6 to 12-membered bicycles (eg,), which is optionally substituted with one or more R<sub>TO</sub>.
-TR<sub>d</sub>', without limitation, can be selected independently each time it appears from -C (O) - L<sub>AND</sub>'- -C (O) OLy'-Rd', -C (O) -L<sub>and</sub><sup>,</sup>-N (Rb) C (O) -Ls<sup>,,</sup>-Rd ', -C (O) -Ly'-N (Rb) C (O) OL<sub>s</sub>-R<sub>d</sub>', -N (Rb) C (O) -L<sub>and</sub>'-N (Rb) C (O) -Ls<sup>,,</sup>-R<sub>d</sub>', -N (R<sub>b</sub>)CABBAGE<sub>and</sub>'—N (Rb) C (O) OL<sub>s</sub>R<sub>d</sub>', or -N (R<sub>b</sub>)CABBAGE<sub>and</sub>'—N (R<sub>b</sub>) -L<sub>s</sub>-R<sub>d</sub>', in which L<sub>AND</sub>'is each independently L<sub>s</sub>'and preferably each is independently C-alkylene, - C<sub>6</sub> (for example, -CH<sub>2</sub>-) and optionally substituted with one or more substituents selected from R<sub>L</sub>. Preferably -TR<sub>D</sub>'is independently selected each time it appears from -C (O) -L<sub>AND</sub>'-M'L<sub>s</sub>-Rd 'or -N (R<sub>b</sub>) C (O) - I_<sub>and</sub>—M'— Ls-R<sub>d</sub>'. Most preferably, -TR<sub>d</sub>'is independently selected each time it appears from -C (O) -Ly'-N (R<sub>b</sub>) C (O) -Ls-Rd 'or -C (O) -L<sub>and</sub>'-N (R<sub>b</sub>) C (O) OL<sub>s</sub>R<sub>d</sub>'- Preferably, -TR<sub>D</sub>'is independently selected each time it appears from -C (O) -L<sub>and</sub>'-N (R<sub>b</sub>) C (O) R<sub>d</sub>'o -C (O) - I_y' — N (R<sub>b</sub>) C (O) OR<sub>d</sub>', in which L<sub>AND</sub>'preferably each is independently C-C alkylene<sub>6</sub> (for example,
-CH<sub>2</sub>-) and optionally substituted with one or more selected from R<sub>L</sub>.
<img file="MX339989B_D0220.tif" />
Rnb and Rc 'are preferably hicliógeriu, and R<sub>D</sub>'Og preference is selected independently each time it appears from R<sub>AND</sub>. More preferably, R<sub>D</sub>'is independently selected each occurrence from C, -C alkyl<sub>6</sub>. C alkenyl<sub>2</sub>-C<sub>6</sub> or C alkynyl<sub>2</sub>-C<sub>6</sub>, each of which, independently, is optionally substituted each time it appears with one or more substituents that are selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl , cyano, carbocycle of C<sub>3</sub>-C<sub>6</sub> or 3-6 membered heterocycle; or carbocycle of C<sub>3</sub>-C<sub>6</sub> or 6-membered heterocycle, each of which, independently, is optionally substituted each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy , phosphono, thioxo, formyl, cyano, Ci-C alkyl<sub>6</sub>, C alkenyl<sub>2</sub>-C<sub>6</sub>, C alkynyl<sub>2</sub>-C<sub>6</sub>, C, -C halogenoalkyl<sub>6</sub>, C halogenoalkenyl<sub>2</sub>-C<sub>and</sub> or halogenoalkynyl of C<sub>2</sub>-C<sub>6</sub>.
Ra is preferably halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or Qi-Ce alkyl, C alkenyl<sub>2</sub>-C6 or C alkynyl<sub>2</sub>-C<sub>6</sub>, each of which, independently, is optionally substituted each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo,
IMPI
<img file="MX339989B_D0221.tif" />
INSTITUTE .V EXICANE phosphonoxy, phosphono, thioxo, formyl or cyano; or carbocicIcy ^ jg ^ ygjígC 3- to 6-membered heterocycle, each of which, independently, is optionally substituted each time it occurs with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy , nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ο · ι-Ο alkyl<sub>6</sub>, C alkenyl<sub>2</sub>-C<sub>6</sub>, C alkynyl<sub>2</sub>-C<sub>6</sub>, Ci-C haloalkyl<sub>6</sub>, C halogenoalkenyl<sub>2</sub>-C<sub>6</sub> or halogenoalkynyl of C<sub>2</sub>-C<sub>6</sub>; or -L<sub>TO</sub>-OR<sub>S</sub>, -L<sub>TO</sub>-MR<sub>s</sub>, -L<sub>TO</sub>-C (O) R<sub>S</sub>, -L<sub>to</sub>-OC (O) R<sub>s</sub>, -L<sub>to</sub>-C (O) OR<sub>s</sub>, -L<sub>to</sub>-N (R<sub>s</sub>R<sub>s</sub>'), -L<sub>to</sub>-S (O) R<sub>s</sub>, -L<sub>to</sub>-SW<sub>2</sub>R<sub>s</sub>,
-L<sub>to</sub>-C (O) N (R<sub>s</sub>Rs'), -L<sub>to</sub>-N (Rs) C (O) R<sub>s</sub>', -L<sub>to</sub>-N (R<sub>s</sub>) C (O) N (Rs'R<sub>s</sub>),
-L<sub>to</sub>-N (Rs) SO<sub>2</sub>R<sub>s</sub>', -L<sub>to</sub>-SW<sub>2</sub>N (R<sub>s</sub>R<sub>s</sub>'), -L<sub>to</sub>-N (R<sub>s</sub>)SW<sub>2</sub>N (R<sub>s</sub>'Rs),
-L<sub>to</sub>-N (Rs) S (O) N (R<sub>s</sub>'R<sub>s</sub>), -L<sub>to</sub>-OS (O) -R<sub>s</sub>, -L<sub>to</sub>-BEAR)<sub>2</sub>-R<sub>s</sub>, -L<sub>to</sub>-SW)<sub>2</sub>OR<sub>s</sub>, -L<sub>to</sub>-S (O) OR<sub>s</sub>, -L<sub>to</sub>-OC (O) ORs, -L<sub>to</sub>-N (Rs) C (O) OR<sub>s</sub>’,
-L<sub>to</sub>-OC (O) N (RsRs'), -L<sub>to</sub>-N (R<sub>s</sub>) S (O) -R<sub>s</sub>', -L<sub>to</sub>-S (O) N (R<sub>s</sub>R<sub>s</sub>') or -L<sub>to</sub>-C (O) N (R<sub>s</sub>) C (O) -Rs', in which L<sub>TO</sub> is bond, Ci-C alkylene<sub>6</sub>, C alkenylene<sub>2</sub>-C<sub>6</sub> or C alkynylene<sub>2</sub>-C<sub>6</sub>.
More preferably, R<sub>to</sub> is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or Ci-C alkyl<sub>6</sub>, C alkenyl<sub>2</sub>-C<sub>6</sub> or C alkynyl<sub>2</sub>-C<sub>6</sub>, each of which, independently, is optionally substituted each time it appears with one or more substituents that are selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or carbocycle of C<sub>3</sub>-C<sub>6</sub> or heterocycle of 3 to 6 members, each of which, independently, is optionally substituted each time it appears with one or more substituents that are selected halogen, hydroxy, mercapto, amino, carboxy , nitro, oxo, <sup>lf</sup>¥ oslonox¡, phosphono, thioxo, formyl, cyano, alqu alkyl, -Οβ alkyl floe C<sub>2</sub>-CZ
<img file="MX339989B_D0222.tif" />
C alkynyl<sub>2</sub>-C<sub>6</sub>, C ^ -C halogenoalkyl, C halogenoalkenyl<sub>2</sub>-C<sub>6</sub> or halogenoalkynyl of C<sub>2</sub>-C<sub>6</sub>.
Rather preferably, R<sub>TO</sub> is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or C ^ Ce alkyl, C alkenyl<sub>2</sub>-C<sub>6</sub> or C alkynyl<sub>2</sub>-C<sub>6</sub>, each of which, independently, is optionally substituted each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano.
Ls, L<sub>s</sub>'and L<sub>s</sub> preferably they are each independently selected each time they appear from link; or Ci-C alkylene<sub>6</sub>, C alkenylene<sub>2</sub>-C<sub>6</sub> or C alkynylene<sub>2</sub>-C<sub>6</sub>.
A and B can be the same or different. Similarly, L-ι and L<sub>2</sub> they may be the same or different.
In one embodiment of this aspect, A, B, and D are each independently phenyl, and are each independently optionally substituted with one or more R<sub>TO</sub>. Preferably, D is
<img file="MX339989B_D0223.tif" />
<img file="MX339989B_D0224.tif" />
<img file="MX339989B_D0225.tif" />
r
<img file="MX339989B_D0226.tif" />
in which R<sub>M</sub> and R<sub>N</sub> are as defined above ^ mtwMfcicA ·
OF INDUSTRIAL FROFIEDAD are each independently bond or Cj-Ce alkylene, and l_3 is bond, Cj-Ce alkylene or -C (O) -, and L<sub>1f</sub> L<sub>2</sub>, and L<sub>3</sub> are each independently optionally substituted with one or more R<sub>l</sub>. Preferably L<sub>2</sub>, and l_<sub>3</sub> they are link. -TR<sub>D</sub>'is independently selected each time it appears from -C (O) -L<sub>AND</sub>'N (R<sub>b</sub>)CABBAGE<sub>s</sub>-Rd 'O -C (O) -I_y'-N (R<sub>b</sub>) C (O) OL<sub>s</sub>-Rd ', in which L<sub>AND</sub>'is C ^ Ce alkylene (for example, -CH<sub>2</sub>-) and optionally substituted with one or more substituents selected from Rl, and Ls is preferably bond. -TR<sub>D</sub>'can also be selected, without limitation, from -C (O) -L<sub>and</sub>'-L<sub>s</sub>-Rd ', -C (O) -L<sub>and</sub>'-OL<sub>s</sub>-Rd ', -C (O) L<sub>and</sub>'-N (R<sub>b</sub>) -L<sub>s</sub><sup>,,</sup>-R<sub>d</sub>', or -C (O) -L<sub>and</sub>'-N (R<sub>b</sub>)SW)<sub>2</sub>-L<sub>s</sub>-R<sub>d</sub>’.
In yet another aspect, the present invention features compounds of formula l<sub>B</sub> and pharmaceutically acceptable salts thereof:
Rd'-T
Rs go<sub>2</sub>
N,
L-3
-A — LX — L<sub>2</sub>- BRc 'T — R<sub>d</sub>'
Rc
Rr
Ib in which:
Rc 'is each independently selected from R<sub>c</sub>;
R<sub>d</sub>'each is selected independently of
<img file="MX339989B_D0227.tif" />
R<sub>2</sub> and Rs. Taken together with the atoms to which they are attached, they form a 3- to 12-membered heterocycle which is optionally substituted with one or more R<sub>TO</sub>;
R<sub>g</sub> and R<sub>12</sub>, taken together with the atoms to which they are attached, form a 3- to 12-membered heterocycle which is optionally substituted with one or more R<sub>TO</sub>;
A, B, D, X, L-, l_<sub>2</sub>, l_3, T, R<sub>TO</sub>, R<sub>c</sub>, and Rd are as previously described in Formula I.
In this regard, A and B are preferably independently selected from 8 to 12-membered bikes such as
<img file="MX339989B_D0228.tif" />
in which Ζ<sub>ή</sub> is independently selected each time it appears from O, S, NH, or CH<sub>2</sub>, Z<sub>2</sub> is independently selected each time it appears from N or CH, Z<sub>3</sub> is independently selected each time it appears from N or CH, Z<sub>4</sub> is independently selected each time it appears from O, S, NH, or CH<sub>2</sub>, and W-ι, W<sub>2</sub>, W<sub>3</sub>, W<sub>4</sub>, W<sub>5</sub> and W<sub>6</sub> each is independently selected each time it appears from CH or N. A and B are each independently optionally substituted with one or more R<sub>TO</sub>.
More preferably, A is selected from
Wo // y is optionally substituted with one or more R<sub>TO</sub>; B is selected from
Toilet
INDUSTUAL
IMPI xWa Mexican institute
- DELAFRCntD.O
<img file="MX339989B_D0229.tif" />
w.
w<sub>fi</sub> w<sub>2</sub><sub>x</sub>Wi \ N
<img file="MX339989B_D0230.tif" />
* -3, W<sub>d</sub>
Toilet
-z<sub>2</sub> %
W<sub>6</sub> y is optionally substituted with one or more R<sub>TO</sub>, in which Z- ,, Z<sub>2</sub>, Z<sub>3</sub>, Z<sub>4</sub>, W<sub>b</sub> W<sub>2</sub>, W<sub>3</sub>, W<sub>4</sub>, W<sub>5</sub>, W<sub>6</sub> they are as defined above. Preferably Z<sub>3</sub> is N and Z<sub>4</sub> is NH. For example, A can be selected from
<img file="MX339989B_D0231.tif" />
(for example
<img file="MX339989B_D0232.tif" />
(for example
<img file="MX339989B_D0233.tif" />
), and is optionally substituted with one or more R<sub>TO</sub>; and B can be selected from
<img file="MX339989B_D0234.tif" />
IMPI
<img file="MX339989B_D0235.tif" />
optionally with one or more R<sub>TO</sub>.
MEXICAN INSTITUTE OF PROPERTY ÍNDL'STRJAl
<img file="MX339989B_D0236.tif" />
Also preferably, A is'!
example
<img file="MX339989B_D0237.tif" />
H), and B is
N.
<img file="MX339989B_D0238.tif" />
H (for example
<img file="MX339989B_D0239.tif" />
H i ·), in which A 'and B' are independently selected from carbocycle of C<sub>5</sub>-C<sub>6</sub> or 5- to 6-membered heterocycle, and A and B independently are optionally substituted with one or more R<sub>TO</sub>.
D is preferably selected from carbocycle of
C<sub>5</sub>-C<sub>6</sub>, 5- to 6-membered heterocycle, or 6 to 12-membered bicycles, and is optionally substituted with one or more R<sub>TO</sub>. D may also preferably be selected from C alkenyl alkyl<sub>2</sub>-C<sub>6</sub> or Ci-C alkynyl<sub>6</sub>, and is optionally substituted with one or more substituents that are selected from R<sub>L</sub>. More preferably, D is carbocycle of C<sub>s</sub>-C<sub>6</sub>, 5-6 membered heterocycle, or 6-12 membered bicycles, and is substituted with one or more R<sub>m</sub>, in which R<sub>M</sub> is halogen, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano, or -L<sub>S</sub>-R<sub>AND</sub>. Also preferably, D is phenyl, and is optionally substituted with one or more R<sub>TO</sub>. More preferably, D is phenyl, and is substituted with one or more R<sub>M</sub>, in which Rm is as previously defined. Quite preferably, D is
<img file="MX339989B_D0240.tif" />
IMPI
MEXICAN INSTITUTE OF EA PROPERTY INDUSTRIAL
<img file="MX339989B_D0241.tif" />
in which R<sub>M</sub> is as defined above, and each R<sub>N</sub> is independently selected from R<sub>D</sub> and is preferably hydrogen. One or more of R<sub>N</sub> preferably it can also be halogen such as F.
D is also preferably pyridinyl, pyrimidinyl, or thiazolyl, optionally substituted with one or more R<sub>TO</sub>. More preferably D is pyridinyl, pyrimidinyl, or thiazolyl, and is substituted with one or more R<sub>M</sub>. Rather preferably, D is
<img file="MX339989B_D0242.tif" />
<img file="MX339989B_D0243.tif" />
N
Ri
R, in which R<sub>M</sub> is as defined above, and each R<sub>N</sub> is independently selected from R<sub>D</sub> and is preferably hydrogen. One or more of R<sub>N</sub> preferably they may also be halogen such as F. D is also preferably indanyl, 4,5,6,7-tetrahydrobenzo [d] thiazolyl, benzo [d] thiazolyl, or indazolium, and is optionally substituted with one or more R<sub>TO</sub>. Most preferably D is indanyl, 4,5,6,7-tetrahydrobenzo [d] thiazolyl, benzo [d] thiazolyl, indazolium, or benzo [d] [1,3] dioxol-5-it, and is substituted with one or more
R<sub>M</sub>- Quite preferably, D is
<img file="MX339989B_D0244.tif" />
IMPI
MEXICAN INSTITUTE OF INDUSTRIAL PROPERTY
<img file="MX339989B_D0245.tif" />
y is optionally substituted with one or more R<sub>M</sub>.
Preferably R<sub>M</sub> is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or Ci-Ce alkyl, C alkenyl<sub>2</sub>-C<sub>6</sub> or C alkynyl<sub>2</sub>-C<sub>6</sub>, each of which, independently, is optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or carbocycle of C<sub>3</sub>-C<sub>6</sub> or 3- to 6-membered heterocycle, each of which, independently, is optionally substituted each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C alkyl<sub>6</sub>, C alkenyl<sub>2</sub>-C<sub>6</sub>, C alkynyl<sub>2</sub>-C<sub>6</sub>, C, -C halogenoalkyl<sub>6</sub>, C halogenoalkenyl<sub>2</sub>-C<sub>6</sub> or halogenoalkyl C<sub>2</sub>-C<sub>6</sub>. More preferably, R<sub>M</sub> is halogen, hydroxy, mercapto, amino, carboxy; or C ^ Ce alkyl, C alkenyl<sub>2</sub>-C<sub>6</sub> or C alkynyl<sub>2</sub>-C<sub>6</sub>, each of which, independently, is optionally substituted each time it appears with one or more substitutes that are selected from
IMPI 013¾. . ,,. „INSTITUTO MEXICANO halogen, hydroxy, mercapto, amino or carboxy. Most preferred, R<sub>M</sub> it is alkyl of Ο, -Οβ which is optionally substituted with one or more substituents which are selected from halogen, hydroxy, mercapto, amino or carboxy.
Also preferably, R<sub>M</sub> is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, or cyano; or R<sub>M</sub> is -L<sub>S</sub>-R<sub>AND</sub>, in which L<sub>s</sub> is a Ci-C bond or alkylene<sub>6</sub>, and R<sub>and</sub> is -N (R<sub>S</sub>R<sub>S</sub>'), -OR<sub>s</sub>, -C (O) R<sub>S</sub>, -C (O) OR<sub>S</sub>, -C (O) N (R<sub>S</sub>R<sub>S</sub>'), -N (R<sub>s</sub>) C (O) Rs', -N (R<sub>S</sub>) C (O) OR<sub>S</sub>', -N (R<sub>s</sub>)SW<sub>2</sub>R<sub>s</sub>', -SO<sub>2</sub>R<sub>s</sub>, -MR<sub>s</sub>, or -P (O) (OR<sub>s</sub>)<sub>2</sub>, in which R<sub>s</sub> and Rs' can be selected, for example, each independently, each occurrence from (1) hydrogen or (2) Ci-Ce alkyl optionally substituted each occurrence with one or more halogen, hydroxy, -Oalkyl of CrCg or 3-6 membered heterocycle; or R<sub>M</sub> is C alkenyl alkyl<sub>2</sub>-C<sub>6</sub> or C alkynyl<sub>2</sub>-C<sub>6</sub>, each of which, independently, is optionally substituted each time it appears with one or more substituents that are selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or R<sub>M</sub> is carbocycle of C<sub>3</sub>-C<sub>6 </sub>or 3- to 6-membered heterocycle, each of which, independently, is optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, C alkyl<sub>r</sub>C<sub>s</sub>, C alkenyl<sub>2</sub>-C<sub>6</sub>, C alkynyl<sub>2</sub>-C<sub>6</sub>, C-C haloalkyl<sub>6</sub>, halogenoalkenyl of C<sub>2</sub>-C<sub>6</sub>, iMPií «g> -%
MEXICAN INSTITUTE
PROPERTY OF C halogenoalkynyl<sub>2</sub>-C<sub>6</sub>, -C (O) OR<sub>S</sub>, or -N (R<sub>s</sub>Rs') · De m'arfe ^ preferred, R<sub>M</sub> is halogen (eg, fluoro, doto, bi'óhlü, yudu), · —— hydroxy, mercapto, amino, carboxy, or Ci-Cg alkyl (eg, methyl, isopropyl, tert-butyl), C alkenyl<sub>2</sub>-C<sub>6</sub> or C alkynyl<sub>2</sub>-C<sub>6</sub>, each of which, independently, is optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, cyano, or carboxy. For example R<sub>M</sub> is CF<sub>3</sub>, -C (CF<sub>3</sub>)<sub>2</sub>OH, -C (CH<sub>3</sub>)<sub>2</sub>-CN, -C (CH<sub>3</sub>)<sub>2</sub>-CH<sub>2</sub>OH, or -C (CH<sub>3</sub>)<sub>2</sub>-CH<sub>2</sub>NH<sub>2</sub>. Also preferably R<sub>M</sub> is -L<sub>S</sub>-R<sub>AND</sub> in which Ls is a bond and R<sub>AND</sub> is -N (RsRs'), -O-Rs, -N (Rs) C (O) OR<sub>s</sub>', -N (R<sub>s</sub>)SW<sub>2</sub>R<sub>s</sub>', -SO<sub>2</sub>R<sub>s</sub>, or -SR<sub>s</sub>. For example in cases where L<sub>s</sub> is a link, R<sub>AND</sub> is -N (alkyl (C<sub>1</sub>-C<sub>6</sub>))<sub>2 </sub>(for example, -NMe<sub>2</sub>); -N (alkylene (C<sub>1</sub>-C<sub>6</sub>) -O-alkyl (Ci-C<sub>6</sub>))<sub>2</sub> (for example -N (CH<sub>2</sub>CH<sub>2</sub>OMe)<sub>2</sub>); -N (alkyl (C<sub>1</sub>-C<sub>6</sub>)) (alkylene (C<sub>1</sub>-C<sub>6</sub>) -Oalky ^ C ^ Cg)) (for example -N (CH<sub>3</sub>) (CH<sub>2</sub>CH<sub>2</sub>OMe)); -O-alkyl of Ci-C<sub>6</sub> (eg -Ο-Me, -O-Et, -O-isopropyl, -O-tert-butyl, -On-hexyl); -O-halogenoalkyl of Ci-Cg (for example, -OCF<sub>3</sub>, -OCH<sub>2</sub>CF<sub>3</sub>); -O-alkyleneCi-Cgí-piperidine (for example, -O-CH<sub>2</sub>CH<sub>2</sub>-1piperidyl); -NíalquiKCi-Cg ^ CíOjO-alkyl de Ci-C<sub>6</sub> (for example, -N (CH<sub>3</sub>) C (O) O-CH<sub>2</sub>CH (CH<sub>3</sub>)<sub>2</sub>), -N (alkyl (C<sub>1</sub>-C<sub>6</sub>))SW<sub>2</sub>-0, -Cg alkyl (for example, -N (CH<sub>3</sub>)SW<sub>2</sub>CH<sub>3</sub>); -SW<sub>2</sub>-C ^ Cg alkyl (for example, -SO<sub>2</sub>I); -SW<sub>2</sub>-C ^ -Cg halogenoalkyl (e.g. -SO<sub>2</sub>CF<sub>3</sub>); or -S-C ^ -Ce haloalkyl (for example, SCF<sub>3</sub>). Also preferably R<sub>m</sub> is -L<sub>S</sub>-R<sub>AND</sub> in which L<sub>s</sub> is Ci-C alkylene<sub>6</sub> (for example, -CH<sub>2</sub>-, -C (CH<sub>3</sub>)<sub>2</sub>-, -C (CH<sub>3</sub>)<sub>2</sub>-CH<sub>2</sub>-) and R<sub>AND</sub> is -OR<sub>s</sub>, -C (O) OR<sub>S</sub>,
IMPIfé ^ V
Mexican institute
-N (R<sub>S</sub>) C (O) OR<sub>S</sub>', or -P (O) (OR<sub>S</sub>)<sub>2</sub>. For example R<sub>M</sub> it is
OR<sub>s</sub> (for example, -C (CH<sub>3</sub>)<sub>2</sub>-CH<sub>2</sub>-OMe); -alau¡leníC, -C<sub>g</sub>1-C (O) OR<sub>g</sub>_ (for example, -C (CH<sub>3</sub>)<sub>2</sub>-C (O) OMe); -alqu¡len (C<sub>1</sub>-C6) -N (R<sub>s</sub>) C (O) OR<sub>s</sub>'(for example, -C (CH<sub>3</sub>)<sub>2</sub>-CH<sub>2</sub>-NHC (O) OCH<sub>3</sub>); o -alkylene C ^ -Cg) P (O) (OR<sub>s</sub>)<sub>2</sub> (for example, -CH<sub>2</sub>-P (O) (OEt)<sub>2</sub>). Also more preferably R<sub>M</sub> is carbocycle of C<sub>3</sub>-C<sub>6</sub> or 3- to 6-membered heterocycle, each of which, independently, is optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C alkyl<sub>6</sub>, C alkenyl<sub>2</sub>-C<sub>6</sub>, C alkynyl<sub>2</sub>-C<sub>6</sub>, CY-Cg haloalkyl, C haloalkenyl<sub>2</sub>-C<sub>6</sub>, C halogenoalkynyl<sub>2</sub>-C<sub>6</sub>, -C (O) OR<sub>S</sub>, or -N (R<sub>S</sub>R<sub>S</sub>'). For example R<sub>M </sub>is cycloalkyl (e.g. cyclopropyl, 2,2-dichloro-1-methylcycloprop1-yl, cyclohexyl), phenyl, heterocyclyl (e.g. morpholin-4-yl,
1,1-dioxidot¡omorpholln-4-¡lo, 4-methylp¡perazin-1 -yl, 4-methoxycarbon¡lp¡peraz¡n-1-¡lo, pyrrolidin-1-yl, plperidin-1- yl, 4-methylpiperid i n-1 -yl, 3,5-dimethylpiperidin-1 -yl, 4,4-difluoropiperidin-1 lo, tetrahydropyran-4-yl, pyridinyl, pi rid i η-3-i lo, 6 (dimethylamine) pyridin-3-yl). Rather preferably, R<sub>M</sub> is C alkyl<sub>r</sub>C<sub>and</sub> which is optionally substituted with one or more substituents that are selected from halogen, hydroxy, mercapto, amino or carboxy (eg, tert-butyl, CF<sub>3</sub>).
X is preferably carbocycle of C<sub>5</sub>-C<sub>6</sub>, 5- to 6-membered heterocycle, or 6 to 12-membered bikes (for example, in which optionally application limiting.
<img file="MX339989B_D0246.tif" />
<img file="MX339989B_D0247.tif" />
IMPI
INSTITUTO MEXICANO CELA INDUSTRIAL PROPERTY
<img file="MX339989B_D0248.tif" />
substituted with one or more R<sub>TO</sub>. Examples non-X were previously described herein
Lj and L<sub>2</sub> preferably they are, independently, bond or alkylene of Cj-Cg, L<sub>3</sub> preferably selected from bond, Ci-Cg alkylene or -C (O) -, and L-ι, L<sub>2</sub>, and L<sub>3</sub> are each independently optionally substituted with one or more R<sub>l</sub>. More preferably, L<sub>1t</sub> L<sub>2</sub> and L<sub>3</sub> are each independently CiC bond or alkylene<sub>6</sub> (for example, -CH<sub>2</sub>- or -CH<sub>2</sub>CH<sub>2</sub>-), and are each independently optionally substituted with one or more R<sub>L</sub>. Rather preferably, L-ι, L<sub>2</sub> and
L<sub>3</sub> they are link.
R<sub>2</sub> and Rfii taken together with the atoms to which they are attached, preferably form a 5- to 6-membered heterocycle or 6 to 12-membered tricycle (for example,
<img file="MX339989B_D0249.tif" />
which is optionally substituted with one or more R<sub>TO</sub>. Rg and R12, taken together with the atoms to which they are attached, preferably form a 5- to 6-membered heterocycle or 6-membered bicyclo (for example,
<img file="MX339989B_D0250.tif" />
or
ΙΜΡΙ
INSTTTVTO MSWCANO DE LA PRCnCDAD fNDHSTWíAL
<img file="MX339989B_D0251.tif" />
which is optionally substituted with one or more R<sub>TO</sub>.
-T-Rd ', without limitation, can be selected independently each time it appears from -C (O) -L<sub>AND</sub>'-R<sub>D</sub>', -C (O) OL<sub>and</sub>'-R<sub>d</sub>', -C (O) -L<sub>and</sub>'-N (R<sub>b</sub>)CABBAGE<sub>s</sub>-R<sub>d</sub>', -C (O) -L<sub>and</sub>'-N (R<sub>b</sub>) C (O) OL<sub>s</sub>-R<sub>d</sub>', -N (R<sub>b</sub>)CABBAGE<sub>and</sub>'-N (Rb) C (O) -L<sub>s</sub>-R<sub>d</sub>', -N (R<sub>b</sub>)CABBAGE<sub>and</sub>’—
N (R<sub>b</sub>) C (O) OL<sub>s</sub>-Rd ', or -N (R<sub>b</sub>)CABBAGE<sub>and</sub>'—N (R<sub>b</sub>) -L<sub>s</sub>-Rd ', in which L<sub>AND</sub>'is each independently L<sub>s</sub>'and preferably each is independently CT-Cg alkylene (e.g., -CH<sub>2</sub>-) and optionally substituted with one or more substituents selected from R<sub>L</sub>. Preferably -TR<sub>D</sub>'is independently selected each time it appears from -C (O) -L<sub>AND</sub>'-M'L<sub>s</sub>-R<sub>d</sub>'or -N (R<sub>b</sub>)CABBAGE<sub>and</sub>'-M'-Ls-Rd' More preferably -TR<sub>D</sub>'is independently selected each time it appears from -C (O) -L<sub>and</sub>'-N (Rb) C (O) -L<sub>s</sub>-R<sub>d</sub>'or -C (O) -L<sub>and</sub>'-N (Rb) C (O) OL<sub>s</sub>-R<sub>d</sub>'. Rather preferably, -TR<sub>D</sub>'is independently selected each time it appears from -C (O) -L<sub>AND</sub>'-N (R<sub>B</sub>) C (O) R<sub>d</sub>'or -C (O) -L<sub>and</sub>'-N (R<sub>b</sub>) C (O) OR<sub>d</sub>', in which L<sub>AND</sub>'preferably each is independently C., -C alkylene<sub>6</sub> (for example, -CH<sub>2</sub>-) and optionally substituted with one or more substituents selected from R<sub>L</sub>.
Re 'is preferably hydrogen, and R<sub>D</sub>preferably
IMPI
MEXICAN INSTITUTE OF PROPERTY
<img file="MX339989B_D0252.tif" />
selects independently each time it appears ^ é ^ á<sup>1</sup> stop R<sub>and</sub>. More preferably, R<sub>D</sub>'seleculuiia de-mamau independent each time it appears from alkyl of Γ-Ce, alkenyl of C<sub>2</sub>-C<sub>6</sub> or C alkynyl<sub>2</sub>-C<sub>6</sub>, each of which, independently, is optionally substituted each time it appears with one or more substituents that are selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl , cyano, carbocycle of C<sub>3</sub>-C<sub>6</sub> or 3-membered heterocycle; or carbocycle of C<sub>3</sub>-C<sub>6</sub> or 3- to 6-membered heterocycle, each of which, independently, is optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Γ-Cs alkyl, C alkenyl<sub>2</sub>-C<sub>6</sub>, C alkynyl<sub>2</sub>-C<sub>6</sub>, C-C haloalkyl<sub>s</sub>, C halogenoalkenyl<sub>2</sub>-C<sub>6</sub> or halogenoalkynyl of C<sub>2</sub>-C<sub>6</sub>.
R<sub>to</sub> preferably it is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or Γ-Ce alkyl, C alkenyl<sub>2</sub>-C<sub>6</sub> or C alkynyl<sub>2</sub>-C<sub>6</sub>, each of which, independently, is optionally substituted each time it appears with one or more substituents that are selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or carbocycle of C<sub>3</sub>-C<sub>6</sub> or 3- to 6-membered heterocycle, each of which, independently, is optionally substituted each occurrence
IMPI with one or more substituents that are selected from
INDUSTRIAL hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-Cg alkyl, C alkenyl<sub>2</sub>-C<sub>6</sub>, C alkynyl<sub>2</sub>-C<sub>6</sub>, Ci-Ce haloalkyl, C haloalkenyl<sub>2</sub>-C<sub>6</sub> or halogenoalkynyl of C<sub>2</sub>-C<sub>6</sub>; or -L<sub>TO</sub>-OR<sub>S</sub>, -L<sub>to</sub>-MR<sub>s</sub>, -L<sub>to</sub>-C (O) R<sub>s</sub>, -L<sub>to</sub>-OC (O) R<sub>s</sub>, -L<sub>to</sub>-C (O) OR<sub>s</sub>, -L<sub>to</sub>-N (R<sub>s</sub>Rs'), -L<sub>to</sub>-S (O) R<sub>s</sub>, -L<sub>to</sub>-SW<sub>2</sub>R<sub>s</sub>, -L<sub>to</sub>-C (O) N (R<sub>s</sub>R<sub>s</sub>'), -L<sub>to</sub>-N (Rs) C (O) R<sub>s</sub>', -L<sub>to</sub>-N (RS) C (O) N (Rs'Rs), -L<sub>to</sub>-N (Rs) SO<sub>2</sub>R<sub>s</sub>', -L<sub>to</sub>-SW<sub>2</sub>N (R<sub>s</sub>R<sub>s</sub>'), -L<sub>to</sub>-N (R<sub>s</sub>)SW<sub>2</sub>N (Rs'R<sub>s</sub>), -L<sub>to</sub>-N (R<sub>s</sub>) S (O) N (Rs'Rs), -L<sub>to</sub>-OS (O) -Rs, -L<sub>to</sub>-BEAR)<sub>2</sub>-Rs, -LA-S (O)<sub>2</sub>OR<sub>s</sub>, -L<sub>to</sub>-S (O) OR<sub>s</sub>, -L<sub>to</sub>-OC (O) ORs, -L<sub>to</sub>-N (R<sub>s</sub>) C (O) ORs', -L<sub>to</sub>-OC (O) N (R<sub>s</sub>R<sub>S</sub>'), -L<sub>to</sub>-N (R<sub>s</sub>) S (O) -R<sub>s</sub>', -L<sub>to</sub>-S (O) N (R<sub>s</sub>R<sub>s</sub>') or -L<sub>to</sub>-C (O) N (R<sub>s</sub>) C (O) -R<sub>s</sub>', in which L<sub>TO</sub> is bond, C ^ -Ce alkylene, C alkenylene<sub>2</sub>-C<sub>6</sub> or C alkynylene<sub>2</sub>-C<sub>6</sub>.
More preferably, R<sub>TO</sub> is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or C ^ -Cs alkyl, C alkenyl<sub>2</sub>-C<sub>6</sub> or C alkynyl<sub>2</sub>-C<sub>6</sub>, each of which, independently, is optionally substituted each time it appears with one or more substituents that are selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or carbocycle of C<sub>3</sub>-C<sub>6</sub> or 3- to 6-membered heterocycle, each of which, independently, is optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, Ci-C alkyl<sub>6</sub>, C alkenyl<sub>2</sub>-C<sub>6</sub>,
<img file="MX339989B_D0253.tif" />
C alkynyl<sub>2</sub>-C<sub>6</sub>, Ci-Cr halogenoalkyl, halogenoafq «« ^ * IB
C<sub>2</sub>-C<sub>6</sub> or halogenoalkynyl of C<sub>2</sub>-C<sub>6</sub>. —
<img file="MX339989B_D0254.tif" />
Rather preferably, R<sub>TO</sub> is halogen, hydroxy mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or C ^ Ce alkyl, C alkenyl<sub>2</sub>-C<sub>6</sub> or C alkynyl<sub>2</sub>-C<sub>6</sub>, each of which, independently, is optionally substituted each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano.
Ls, Ls' and L<sub>s</sub> preferably each is selected independently each time they appear from the link; or C-C alkylene<sub>6</sub>, C alkenylene<sub>2</sub>-C<sub>6</sub> or C alkynylene<sub>2</sub>-C<sub>6</sub>.
A and B can be the same or different, Likewise, L<sub>1</sub> and L<sub>2</sub> they can be the same or different.
In one embodiment of this aspect, A is and is optionally substituted with one or more R<sub>TO</sub>; B is and is optionally substituted with one or more R<sub>TO</sub>; and D is carbocycle of C<sub>5</sub>-C<sub>6</sub> or 5- to 6-membered heterocycle (e.g. phenyl), and is optionally substituted with one or more R<sub>TO</sub>. Preferably, D is
IMPI
<img file="MX339989B_D0255.tif" />
MEXICAN INSTITUTE OF PROPERTY
INDUSTRIAL
<img file="MX339989B_D0256.tif" />
in which R<sub>M</sub> and R<sub>N</sub> they are as defined above. Z<sub>TO</sub> is independently selected each time it appears from O, S, NH, or CH<sub>2</sub>; and Z<sub>2</sub> is independently selected each time it appears from N or CH. and L<sub>2</sub> are each independently Ci-Ce bond or alkylene, and L<sub>3</sub> is bond, Ci-Ce or -C (O) - alkylene, and L<sub>1f</sub> L<sub>2</sub>, and L<sub>3</sub> are each independently optionally substituted with one or more R<sub>L</sub>. Preferably, L · ,, L<sub>2</sub>, and L<sub>3</sub> they are link. -TR<sub>D</sub>'is independently selected each time it appears from -C (O) -L<sub>AND</sub>'-N (R<sub>B</sub>)CABBAGE<sub>S</sub>-R<sub>D</sub>'or -C (O) -Ly'-N (R<sub>B</sub>) C (O) O-Ls-RD '. in which L<sub>AND</sub>'is C- | -C alkylene<sub>and</sub> (for example, -CH<sub>2</sub>-) and optionally substituted with one or more substituents selected from R<sub>L</sub>, and L<sub>s</sub> preferably link. -TR<sub>D</sub>'can also be selected, without limitation, from -C (O) -L<sub>and</sub>'-Ls' '- Rd', —C (O) -L<sub>and</sub>'-O — L<sub>s</sub>-Rd ', -C (O) L<sub>and</sub>'-N (R<sub>b</sub>) -L<sub>s</sub>-Rd ', or -C (O) -L<sub>and</sub>'-N (R<sub>b</sub>)SW)<sub>2</sub>-L<sub>s</sub>-Rd '.
In yet another aspect, the present invention also features compounds of Formula l<sub>c</sub> and pharmaceutically acceptable salts thereof.
IMPI
<img file="MX339989B_D0257.tif" />
<img file="MX339989B_D0258.tif" />
<img file="MX339989B_D0259.tif" />
I-3
LX — L<sub>2</sub>-B
<img file="MX339989B_D0260.tif" />
<img file="MX339989B_D0261.tif" />
Ic in which:
Rnb is Rb!
R<sub>c</sub>'each is independently selected from R<sub>c</sub>;
R<sub>d</sub>'each is independently selected from R<sub>D</sub>;
R<sub>2</sub> and Rs, taken together with the atoms to which they are attached, form a 3- to 12-membered heterocycle which is optionally substituted with one or more R<sub>TO</sub>;
Rs and Ri2, taken together with the atoms to which they are attached, form a 3- to 12-membered heterocycle which is optionally substituted with one or more R<sub>TO</sub>;
A, B, D, X, Ι_<sub>ή</sub>, L<sub>2</sub>, L<sub>3i</sub> T, R<sub>to</sub>,
Rb, Rc, and Rd are as previously described in Formula I.
In this regard, A is preferably C carbocycle.<sub>5</sub>-C<sub>6 </sub>or 5- to 6-membered heterocycle, and is optionally substituted with one or more R<sub>TO</sub>; and B preferably is 8 to 12 membered bicycles (such as
<img file="MX339989B_D0262.tif" />
substituted with one or more R<sub>TO</sub>. is O, S, NH or CH<sub>2</sub>; Z<sub>2</sub> is N or CH; Z<sub>3 </sub>is N or CH; Z<sub>4</sub> is O, S, NH or CH<sub>2</sub>; and W<sub>2</sub>, W<sub>3</sub>, W<sub>4</sub>, W<sub>5</sub> and W<sub>6</sub> are each independently selected from CH or N.
More preferably, A is phenyl (eg,), and is optionally substituted with one or more R<sub>TO</sub>; yy is optionally
<img file="MX339989B_D0263.tif" />
<img file="MX339989B_D0264.tif" />
substituted with one or more R<sub>TO</sub>, in which Z<sub>5</sub>, Z<sub>2</sub>, Z<sub>3</sub>, Z<sub>4</sub>, \ N-¡, \ N<sub>2</sub>, W<sub>3</sub>, W<sub>4</sub>, W<sub>5</sub>, W<sub>6</sub> they are as defined above. Preferably Z<sub>3 </sub>is N and Z<sub>4</sub> is NH. For example, B can be (for example,
<img file="MX339989B_D0265.tif" />
I (for example,
<img file="MX339989B_D0266.tif" />
(for example,
<img file="MX339989B_D0267.tif" />
), and is optionally substituted with one or more R<sub>TO</sub>.
Also preferably, A is carbocycle of C<sub>5</sub>-C<sub>6</sub> (eg, phenyl such as | \ -1) or 5- to 6-membered heterocycle;
and B is
B '(for example,
!), in which
<img file="MX339989B_D0268.tif" />
INSTITUTE McXiCArH J
B 'is selected from carbocycle of C<sub>5</sub>-C<sub>6</sub> d hetexcbmE! members. A and B, independently, are optionally substituted with one or more R<sub>TO</sub>.
D is preferably selected from carbocycle of
C<sub>5</sub>-C<sub>6</sub>, 5- to 6-membered heterocycle, or 6 to 12-membered bicycles, and is optionally substituted with one or more R<sub>TO</sub>. D may also preferably be selected from C ^ Cs alkyl, C alkenyl<sub>2</sub>-C<sub>6</sub> or C alkynyl<sub>2</sub>-C<sub>6</sub>, and is optionally substituted with one or more substituents that are selected from R<sub>L</sub>. More preferably, D is carbocycle of C<sub>5</sub>-C<sub>6</sub>, 5-6 membered heterocycle, or 6-12 membered bicycles, and is substituted with one or more R<sub>m</sub>, in which R<sub>M</sub> is halogen, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano, or —L<sub>s</sub>—Re · Also preferably, D is phenyl, and is optionally substituted with one or more R<sub>TO</sub>. More preferably, D is phenyl, and is substituted with one or more Rm, in which R<sub>m</sub> it is as defined above. Quite preferably,
D is
<img file="MX339989B_D0269.tif" />
in which R<sub>m</sub> is as defined above, and each R<sub>n</sub> is independently selected from R<sub>D</sub> and is preferably hydrogen. One or more of R<sub>N</sub> preferably it can also be halogen such as F.
IMPI
<img file="MX339989B_D0270.tif" />
MEXICAN INSTITUTE
D is also preferably pyridinyl, pwwrolyln thiazolyl, optionally substituted with one or more -Wx. Most preferably, D is pyridinyl, pyrimidinyl, or thiazolyl, and is substituted with one or more R<sub>M</sub>. Rather preferably, D is
Rm <sup>Rn</sup>yS
Ri
<img file="MX339989B_D0271.tif" />
Ri \ y = N <sup>s</sup>\ ^ R<sub>n</sub> in which R<sub>M</sub> is as defined above, and each R<sub>N</sub> is independently selected from R<sub>D</sub> and is preferably hydrogen. One or more of R<sub>N</sub> preferably it may also be halogen such as F. D it is also preferably indanyl, 4,5,6,7tetrahldrobenzo [d] t¡azolllo, benzo [d] thiazolllo, or Indazoliio, and is optionally substituted with one or more R<sub>TO</sub>. More preferably D is indanyl, 4,5,6,7-tetrahydrobenzo [d] thiazolyl, benzo [d] tlazolllo, indazolium, or benzo [d] [1,3] dioxoI-5-it , and is substituted with one or more Rm · Quite preferably, D is
<img file="MX339989B_D0272.tif" />
Preferably R<sub>M</sub> is halogen, hydroxl, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or rent from
100
Ci-C<sub>6</sub>, C alkenyl<sub>2</sub>-C<sub>6</sub> or C alkynyl<sub>2</sub>-C<sub>6</sub>, IMPIOS • INSTITUTO MEXICANO
OF THE PROPERTY which, independently, is optionally susfiTüTdo carfa ^ as it appears with one or more substituents which is, eléóólónan 3— starting from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono , thioxo, formyl or cyano; or carbocycle of C<sub>3</sub>-C<sub>6</sub> or 3- to 6-membered heterocycle, each of which, independently, is optionally substituted each time it appears with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, CrCe alkyl, C alkenyl<sub>2</sub>-C<sub>6</sub>, C alkynyl<sub>2</sub>-C<sub>6</sub>, halogenoalkyl of geno, -Οβ, halogenoalkenyl of C<sub>2</sub>-C<sub>6</sub> or haloalkynyl of More preferably R<sub>M</sub> is halogen, hydroxy, mercapto, amino, carboxy; or C ^ -Ce alkyl, C alkenyl<sub>2</sub>-C<sub>6</sub> or C alkynyl<sub>2</sub>-C<sub>6</sub>, each of which, independently, is optionally substituted each time it appears with one or more substituents that are selected from halogen, hydroxy, mercapto, amino or carboxy. Rather preferably, R<sub>M</sub> is C- | -C alkyl<sub>6</sub> which is optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, or carboxy.
Also preferably, R<sub>M</sub> is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, or cyano; or R<sub>M</sub> is -L<sub>S</sub>-R<sub>AND</sub>, in which L<sub>s</sub> is a bond or alkylene of C ^ Ce, and R<sub>AND</sub> is -N (R<sub>S</sub>R<sub>S</sub>'), -OR<sub>s</sub>, -C (O) R<sub>S</sub>, -C (O) OR<sub>S</sub>, -C (O) N (R<sub>S</sub>R<sub>S</sub>'), -N (R<sub>S</sub>) C (O) R<sub>S</sub>', -N (R<sub>S</sub>) C (O) OR<sub>S</sub>', -N (R<sub>s</sub>)SW<sub>2</sub>R<sub>s</sub>', -SO<sub>2</sub>R<sub>s</sub>, -MR<sub>s</sub>, or
101 , IM Peí
<img file="MX339989B_D0273.tif" />
-P (O) (ORs)<sub>2</sub>, in which R<sub>s</sub> and Rs', for example
MEXICAN INSTITUTE OF PROPERTY. . ,. ,,. , INDUSTRIAL select independently each occurrence from (1) hydrogen or (2) optionally substituted alkyl to each occurrence with one or more halogen, hydroxy, -O-C -, - C alkyl<sub>6</sub> or 3-6 membered heterocycle; or R<sub>M</sub> is C ^ Ce alkyl, C alkenyl<sub>2</sub>-C<sub>6</sub> or C alkynyl<sub>2</sub>-C<sub>s</sub>, each of which, independently, is optionally substituted each time it appears with one or more substituents which are selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or R<sub>M</sub> is carbocycle of C<sub>3</sub>-C<sub>6</sub> or 3- to 6-membered heterocycle, each of which, independently, is optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, C-C alkyl<sub>6</sub> C alkenyl<sub>2</sub>-C<sub>6</sub>, C alkynyl<sub>2</sub>-C<sub>6</sub>, 0-, -06 haloalkyl, C haloalkenyl<sub>2</sub>-C<sub>6</sub>, C halogenoalkynyl<sub>2</sub>-C<sub>6</sub>, -C (0) ORs, or - N (RsRs') More preferably, R<sub>M</sub> is halogen (e.g. fluoro, chloro, bromo, iodo), hydroxy, mercapto, amino, carboxy, or C ^ -Ce alkyl (e.g. methyl, isopropyl, tert-butyl), alkenyl de C<sub>2</sub>-C<sub>6</sub> or C alkynyl<sub>2</sub>-C<sub>6</sub>, each of which, independently, is optionally substituted each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, cyano, or carboxy. For example R<sub>M</sub> is CF<sub>3</sub>, -C (CF<sub>3</sub>)<sub>2</sub>OH, -C (CH<sub>3</sub>)<sub>2</sub>-CN, -C (CH<sub>3</sub>)<sub>2</sub>-CH<sub>2</sub>OH, or -C (CH<sub>3</sub>)<sub>2</sub>-CH<sub>2</sub>NH<sub>2</sub>. Also from
102 preference R<sub>M</sub> is -L<sub>S</sub>-R<sub>AND</sub> in the -N (RsRs'), -O-Rs, -N (Rs) C (O) OR<sub>s</sub>'which L<sub>s</sub> it is
-N (R<sub>s</sub>)SW<sub>2</sub>R<sub>s</sub>’
MEXICAN INSTITUTE OF PROPERTY
-SW<sub>2</sub>tf<sub>s</sub><sup>D</sup>%<sup>WA</sup>-<sup>L</sup>MR
<img file="MX339989B_D0274.tif" />
example in cases where L<sub>s</sub> is a link, R<sub>AND</sub> SS -'N (9ldUII (Ct-Ce) '72 * (for example, -NMe<sub>2</sub>); -N (alkyl (Ci-C<sub>6</sub>) -O-alkyl (C<sub>1</sub>-C<sub>6</sub>)) 2 (for example -N (CH<sub>2</sub>CH<sub>2</sub>OMe)<sub>2</sub>); -N (alkyl (Ci-C<sub>6</sub>)) (alkyl (Ci-C<sub>6</sub>) -OalkylfCj-Cg)) (for example -N (CH<sub>3</sub>) (CH<sub>2</sub>CH<sub>2</sub>OMe)); - O-C- | -C alkyl<sub>6</sub> (eg, -Ο-Me, -O-Et, -O-isopropyl, -O-tert-butyl, -On-hexyl); -O-halogenoalkyl of CiC<sub>6</sub> (for example, -OCF<sub>3</sub>, -OCH<sub>2</sub>CF<sub>3</sub>); -O-aiquilenfCj-CgJ-piperidine (for example, -O-CH<sub>2</sub>CH<sub>2</sub>-1piperidyl); -NfalkylfCTCg ^ CfOJO-Cj-Cg alkyl (e.g., -N (CH<sub>3</sub>) C (O) O-CH<sub>2</sub>CH (CH<sub>3</sub>)<sub>2</sub>), -N (alkyl (C<sub>1</sub>-C<sub>6</sub>))SW<sub>2</sub>-C alkyl<sub>r</sub>C<sub>6 </sub>(for example, -N (CH<sub>3</sub>)SW<sub>2</sub>CH<sub>3</sub>); -SW<sub>2</sub>-alkyl of Cj-Cg (for example, -SO<sub>2</sub>I); -SW<sub>2</sub>-halogenoalkyl of C ^ Cg (for example, -SO<sub>2</sub>CF<sub>3</sub>); or -S-halogenoalkyl of Cj-Cg (e.g. SCF<sub>3</sub>). Also preferably R<sub>M</sub> is -L<sub>s</sub>-Re in which L<sub>s</sub> is Cj-Cg alkylene (e.g. -CH<sub>2</sub>-, -C (CH<sub>3</sub>)<sub>2</sub>-, -C (CH<sub>3</sub>)<sub>2</sub>-CH<sub>2</sub>-) and R<sub>AND</sub> is -OR<sub>s</sub>, -C (O) OR<sub>S</sub>, -N (R<sub>S</sub>) C (O) OR<sub>S</sub>', or -P (O) (ORs) 2- For example R<sub>M</sub> is -alkylene Cj-Cg) O-Rs (for example, -C (CH<sub>3</sub>)<sub>2</sub>-CH<sub>2</sub>-OMe); -alkylene (Ci-C<sub>6</sub>) -C (O) OR<sub>s </sub>(for example, -C (CH<sub>3</sub>)<sub>2</sub>-C (O) OMe); -alkylene (C<sub>1</sub>-Cg) -N (R<sub>s</sub>) C (O) OR<sub>s</sub>'(for example, -C (CH<sub>3</sub>)<sub>2</sub>-CH<sub>2</sub>-NHC (O) OCH<sub>3</sub>); or -alkylenefCj-Cg) P (O) (OR<sub>s</sub>)<sub>2</sub> (for example, -CH<sub>2</sub>-P (O) (OEt)<sub>2</sub>). Also more preferably R<sub>M</sub> is carbocycle of C<sub>3</sub>-C<sub>6</sub> or 3-6 membered heterocycle, each of which, independently, is optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy,
103
<img file="MX339989B_D0275.tif" />
mercapto, amino, carboxy, nitro, oxo, phosphonoiíitTiTOf © & To <w, '
OF THE PROPERTY
INDUSTRIAL formyl, cyano, Ci-C alkyl<sub>6</sub>, C alkenyl<sub>2</sub>-C<sub>6</sub>, C alkynyl<sub>2</sub>-C<sub>6</sub>, C <-C halogenoalkyl<sub>6</sub>, C halogenoalkenyl<sub>2</sub>-C<sub>6</sub>, C halogenoalkynyl<sub>2</sub>-C<sub>6</sub>, -C (O) OR<sub>S</sub>, or -N (R<sub>S</sub>R<sub>S</sub>'). For example R<sub>M </sub>is cycloalkyl (e.g. cyclopropyl, 2,2-dichloro-1-methylcycloprop1-yl, cyclohexyl), phenyl, heterocyclyl (e.g. morpholin-4-yl,
1,1-dioxidothiomorpholin-4-yl, 4-methylpiperazin-1-yl, 4-methoxycarbonylpiperazin-1-yl, pyrrolidin-1-yl, piperidin-1-yl, 4-methylpiperidin-1-yl, 3,5-dimethylpiperidin-1 - yl, 4,4-difluoropiperidin-1-yl, tetrahydropyran-4-yl, pyridinyl, pyridin-3-yl, 6 (dimethylamino) pyridin-3-yl). Rather preferably, R<sub>M</sub> is CiC alkyl<sub>6</sub> which is optionally substituted with one or more substituents that are selected from halogen, hydroxy, mercapto, amino or carboxy (eg, tert-butyl, CF<sub>3</sub>).
X is preferably carbocycle of C<sub>5</sub>-C<sub>6</sub>, 5- to 6-membered heterocycle, or 6 to 12-membered bikes (for example, in which X<sub>3</sub> is N and is directly attached to -L<sub>3</sub>-D), and is optionally substituted with one or more R<sub>TO</sub>. Non-limiting examples of X are described earlier in the present application.
L-ι and L<sub>2</sub> preferably they are, independently, bond or alkyl of C ^ Ce, L<sub>3</sub> preferably selected from
104 bond, Ci-Ce alkylene or -C (O) -, and Li,
<img file="MX339989B_D0276.tif" />
independently optionally substituted with a n n plus R<sub>l</sub>. More preferably, L<sub>2</sub> and L<sub>3</sub> are each independently C ^ -Cs bond or alkylene (eg, -CH<sub>2</sub>- or -CH<sub>2</sub>CH<sub>2</sub>-), and are each independently optionally substituted with one or more R<sub>L</sub>. Quite preferably, L<sub>1f</sub> L<sub>2</sub> and L<sub>3</sub> they are link. L-ι and L<sub>2</sub> They can be the same or different.
R<sub>2</sub> and Rs, taken together with the atoms to which they are attached, preferably form a 5- to 6-membered heterocycle or 6 to 12-membered bicyclo (for example, which is optionally substituted with one or more R<sub>TO</sub>. Rg and R12, taken together with the atoms to which they are attached, preferably form a 5- to 6-membered heterocycle or 6 to 12-membered bicyclo (for example, which is optionally substituted with one or more R<sub>TO</sub>.
-TR<sub>d</sub>', without limitation, can be selected independently each time it appears from -C (O) -L<sub>and</sub>'-R<sub>d</sub>', -C (O) OL<sub>AND</sub>'-R<sub>D</sub>', -C (O) -L<sub>and</sub>'-N (R<sub>b</sub>)CABBAGE<sub>s</sub>-R<sub>d</sub>', -C (O) -L<sub>and</sub>'-N (R<sub>b</sub>) C (O) OL<sub>s</sub>-Rd ', -N (Rb) C (O) -L<sub>and</sub>'-N (R<sub>b</sub>) C (O) -Ls ~ Rd ', -N (R<sub>b</sub>)CABBAGE<sub>and</sub>’_
105
IMPI
N (R<sub>b</sub>) C (O) OL<sub>s</sub>-Rd ', or -N (R<sub>b</sub>) C (O) -Ly' — N (Rb) -L<sub>s</sub>-K8K8 «6¡S
INDUSTRIAL
L<sub>AND</sub>'is each independently Ls', and preferably each is independently alkylene of Γ-Cg (e.g., -CH<sub>2</sub>-) and optionally substituted with one or more substituents selected from R<sub>L</sub>. Preferably, -T-Rd 'is selected independently each time it appears from -C (O) -L<sub>AND</sub>'-M'L<sub>s</sub>-Rd 'or -N (R<sub>b</sub>)CABBAGE<sub>and</sub>'-M'-Ls-Rd' More preferably -TR<sub>D</sub>'is independently selected each time it appears from -C (O) -L<sub>and</sub>'-N (R<sub>b</sub>)CABBAGE<sub>s</sub>-Rd 'or -C (O) -L<sub>and</sub>'-N (R<sub>b</sub>) C (O) OL<sub>s</sub>-Rd 'Preferably, -TR<sub>D</sub>'is independently selected each time it appears from -C (O) -L<sub>AND</sub>'-N (R<sub>B</sub>) C (O) R<sub>d</sub>'or -C (O) -L<sub>AND</sub>'-N (R<sub>B</sub>) C (O) OR<sub>D</sub>', in which L<sub>AND</sub>'preferably each is independently alkylene from Γ-Ο<sub>6</sub> (for example, -CH<sub>2</sub>-) and optionally substituted with one or more substituents selected from R<sub>L</sub>.
Rmb and Rc 'are preferably hydrogen, and R<sub>D</sub>'preferably is selected independently each time it appears from R<sub>AND</sub>. More preferably, R<sub>D</sub>'is independently selected each occurrence from alkyl of CrCe, alkenyl of C<sub>2</sub>-C<sub>6</sub> or C alkynyl<sub>2</sub>-C<sub>6</sub>, each of which, independently, is optionally substituted each time it appears with one or more substituents that are selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl , cyano, carbocycle of C<sub>3</sub>-C<sub>6</sub> or 3-6 membered heterocycle; or carbocycle of C<sub>3</sub>-C<sub>s</sub> or heterocycle of
<img file="MX339989B_D0277.tif" />
106 to 6 members, each of which,
IMPIS de mane ^ ®f «ggtSh is optionally substituted each time it appears with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, C, -C alkyl<sub>6)</sub> C alkenyl<sub>2</sub>-C<sub>6</sub>, C alkynyl<sub>2</sub>-C<sub>6</sub>, Ci-C haloalkyl<sub>6</sub>, C halogenoalkenyl<sub>2</sub>-C<sub>6</sub> or halogenoalkynyl of C<sub>2</sub>-C<sub>6</sub>.
R<sub>to</sub> preferably it is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or CvCe alkyl, C alkenyl<sub>2</sub>-C<sub>6</sub> or C alkynyl<sub>2</sub>-C<sub>6</sub>, each of which, independently, is optionally substituted each time it appears with one or more substituents that are selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or carbocycle of C<sub>3</sub>-C<sub>6</sub> or 3- to 6-membered heterocycle, each of which, independently, is optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, C alkyl<sub>r</sub>C<sub>6!</sub> C alkenyl<sub>2</sub>-C<sub>6</sub>, C alkynyl<sub>2</sub>-C<sub>6</sub>, C- | -C haloalkyl<sub>6</sub>, C halogenoalkenyl<sub>2</sub>-C<sub>6</sub> or halogenoalkynyl of C<sub>2</sub>-C<sub>6</sub>; or -L<sub>TO</sub>-OR<sub>S</sub>, -L<sub>TO</sub>-MR<sub>s</sub>, -L<sub>TO</sub>-C (O) R<sub>S</sub>, -L<sub>TO</sub>-OC (O) R<sub>S</sub>, -L<sub>to</sub>-C (O) OR<sub>s</sub>, -L<sub>to</sub>-N (R<sub>s</sub>R<sub>s</sub>'), -L<sub>to</sub>-S (O) R<sub>s</sub>, -L<sub>to</sub>-SW<sub>2</sub>R<sub>s</sub>, -L<sub>to</sub>-C (O) N (R<sub>s</sub>Rs'), -L<sub>to</sub>-N (R<sub>s</sub>) C (O) R<sub>s</sub>', -L<sub>to</sub>-N (R<sub>s</sub>) C (O) N (R<sub>s</sub>'R<sub>s</sub>),
-L<sub>to</sub>-N (R<sub>s</sub>)SW<sub>2</sub>R<sub>s</sub>', -L<sub>to</sub>-SW<sub>2</sub>N (R<sub>s</sub>R<sub>s</sub>'), -L<sub>to</sub>-N (R<sub>s</sub>)SW<sub>2</sub>N (Rs'Rs)>
-L<sub>to</sub>-N (Rs) S (O) N (R<sub>s</sub>'R<sub>s</sub>), -L<sub>to</sub>-OS (O) -R<sub>s</sub>, -L<sub>to</sub>-BEAR)<sub>2</sub>-R<sub>s</sub>, -L<sub>to</sub>-SW)<sub>2</sub>OR<sub>s</sub>,
107
<img file="MX339989B_D0278.tif" />
-L<sub>to</sub>-S (O) OR<sub>s</sub>, -L<sub>to</sub>-OC (O) OR<sub>s</sub>, -L<sub>to</sub>-N (R<sub>s</sub>) C (O) OR<sub>s</sub>’,
MEXICAN INSTITUTE OF PROPERTY
-L<sub>to</sub>-N (R<sub>s</sub>) S (O) -R<sub>s</sub>', -La-S (O) N (R<sub>s</sub>Rs') OR -L<sub>to</sub>-C (O) N (R<sub>s</sub>) C (© ^ R ^, which L<sub>TO</sub> is bond, C> -C alkylene<sub>6</sub>, alkenylene filled with —σ alkynylene C<sub>2</sub>-C<sub>6</sub>.
More preferably, R<sub>to</sub> is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or Ci-C alkyl<sub>6</sub>, C alkenyl<sub>2</sub>-C<sub>6</sub> or C alkynyl<sub>2</sub>-C<sub>6</sub>, each of which, independently, is optionally substituted each time it appears with one or more substituents that are selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or carbocycle of
C<sub>3</sub>-C<sub>6</sub> or 3-6 membered heterocycle, each of which, independently, is optionally substituted each time it appears with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, C ^ -Ce alkyl, C alkenyl<sub>2</sub>-C<sub>6</sub>, C alkynyl<sub>2</sub>-C<sub>6</sub>, Cé-Ce halogenoalkyl, C halogenoalkenyl<sub>2</sub>-C<sub>6</sub> or halogenoalkyl C<sub>2</sub>-C<sub>6</sub>.
Rather preferably, R<sub>TO</sub> is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or C -, - C alkyl<sub>6</sub>, C alkenyl<sub>2</sub>-C<sub>6</sub> or C alkynyl<sub>2</sub>-C<sub>and</sub>, each of which, independently, is optionally substituted each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano.
108
IMPI
MEXICAN INSTITUTE
<img file="MX339989B_D0279.tif" />
L<sub>s</sub>, L<sub>s</sub>'and Ls are preferably selected independently each time they appear a parttf - of - ejala ££ do alkylene of Οτ-Οβ, alkenylene of C<sub>2</sub>-C<sub>6</sub> or C alkynylene<sub>2</sub>-C<sub>6</sub>.
In one embodiment of this aspect, A is phenyl, and is optionally substituted with one or more R<sub>TO</sub>; and B is
<img file="MX339989B_D0280.tif" />
y is optionally substituted with one or more R<sub>TO</sub>, in which Z, is O, S, NH or GH<sub>2</sub>; and Z<sub>2</sub> is N or CH. D is carbocycle of C<sub>5</sub>-C<sub>6</sub> or 5- to 6-membered heterocycle (e.g. phenyl), and is optionally substituted with one or more R<sub>TO</sub>. Preferably, D is
<img file="MX339989B_D0281.tif" />
in which R<sub>M</sub> and R<sub>N</sub> they are as defined above. L<sub>4</sub> and L<sub>2 </sub>are each independently C, -C bond or alkylene<sub>6l</sub> and L<sub>3</sub> is bond, Ci-C alkylene<sub>6</sub> or -C (O) -, and L ^ L<sub>2</sub>, and L<sub>3</sub> are each independently optionally substituted with one or more R<sub>l</sub>. Preferably Li, L<sub>2</sub>, and L<sub>3</sub> they are link. -TR<sub>D</sub>'is independently selected each time it appears from -C (O) -L<sub>AND</sub>'N (R<sub>b</sub>)CABBAGE<sub>s</sub>-Rd 'or -C (O) -L<sub>and</sub>'-N (R<sub>b</sub>) C (O) OL<sub>s</sub>-R<sub>d</sub>', in which L<sub>AND</sub>'is Ci-C alkylene<sub>6</sub> (for example, -CH<sub>2</sub>-) and optionally substituted with one or more substituents selected from R<sub>L</sub>, and L<sub>s</sub>
109 preferably it is a link. -TR<sub>D</sub>'you can also isseíerecjanaf, of the INDUSTRIAL property
IMPI issetere cjana /
OF INDUSTRIAL PROPERTY limitation, from -C (O) -L<sub>and</sub>'-L<sub>s</sub>-Rd ', -C (O) -L<sub>and</sub>'-OL<sub>s</sub>-R<sub>d</sub>', -C (O) -
<img file="MX339989B_D0282.tif" />
I_<sub>and</sub>'-N (Rb) -L<sub>s</sub>-Rd ', or -C (O) -L<sub>and</sub>'-N (Rb) S (O)<sub>2</sub>-Ls-Rd '.
In yet another aspect, the present invention features compounds of Formula I.<sub>D</sub> and pharmaceutically acceptable salts thereof.
Rn'-T <sup>R5</sup> n
I R2
Rc /
D
I
L-3, A — LX — L<sub>2</sub>—
Ge
Rq? 12
-N.
'T — Rn'
Rc '
Go in which;
Gt and G<sub>2</sub> are each independently selected from carbocycle of C<sub>5</sub>-C<sub>6</sub> or 5- to 6-membered heterocycle, and are each independently optionally substituted with one or more R<sub>TO</sub>;
R<sub>c</sub>'each is independently selected from R<sub>c</sub>;
Rd 'is each independently selected from R<sub>or</sub>;
R<sub>2</sub> and Rs, taken together with the atoms to which they are attached, form a 3- to 12-membered heterocycle which is optionally substituted with one or more R<sub>TO</sub>;
R<sub>g</sub> and Ri2, taken together with the atoms to which they
110 are attached, form a 3 to 12 heterocycle optionally substituted with one or more R<sub>TO</sub>;
Piss
MEXICAN INSTITUTE OF PROPERTY
INDUSTRIAL
<img file="MX339989B_D0283.tif" />
A, B, D, X, Li, L<sub>2</sub>
R<sub>TO</sub>, R<sub>c</sub>, and Rd are as se
<img file="MX339989B_D0284.tif" />
previously described in Formula I.
In this regard, A and B are preferably independently selected from carbocycle of C<sub>5</sub>-C<sub>6</sub> or 5- to 6-membered heterocycle, and are each independently optionally substituted with one or more R<sub>TO</sub>. More preferably, at least one of A and B is phenyl (eg,), and is optionally substituted with one or more R<sub>TO</sub>. Quite preferably, both A and B are each independently phenyl (eg, |), and are each independently optionally substituted with one or more R<sub>TO</sub>.
D is preferably selected from carbocycle of C<sub>5</sub>-C<sub>6</sub>, 5- to 6-membered heterocycle, or 8 to 12-membered bicycles, and is optionally substituted with one or more R<sub>TO</sub>. D may also preferably be selected from C ^ -Ce alkyl, C alkenyl<sub>2</sub>-C<sub>6</sub> or C alkynyl<sub>2</sub>-C<sub>6</sub>, and is optionally substituted with one or more R<sub>L</sub>. More preferably, D is carbocycle of Ο<sub>5</sub>-Ο<sub>6</sub>, 5-6 membered heterocycle, or 6-12 membered bicycles, and is substituted with one or more R<sub>M</sub>, in which R<sub>M</sub> is halogen, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano, or -L<sub>S</sub>-R<sub>AND</sub>. Also preferably, D is phenyl, and is optionally substituted with one or more R<sub>to</sub>. More preferably, D is phenyl, and is substituted with one or more R<sub>M</sub>, in which R<sub>M</sub> it is as defined above. Of
111 quite preferred way, D is
IMPI
MEXICAN INSTITUTE OF INDUSTRIAL PROPERTY
<img file="MX339989B_D0285.tif" />
<img file="MX339989B_D0286.tif" />
or
<img file="MX339989B_D0287.tif" />
in which R<sub>M</sub> is as defined above, and each R<sub>N</sub> is independently selected from R<sub>D</sub> and is preferably hydrogen. One or more of R<sub>N</sub> preferably it can also be halogen such as F.
D is also preferably pyridinyl, pyrimidinyl, or thiazolllo, optionally substituted with one or more R<sub>TO</sub>. More preferably D is pyridinyl, pyrimidinyl, or thiazolyl, and is substituted with one or more R<sub>M</sub>. Rather preferably, D is
Rm
<img file="MX339989B_D0288.tif" />
<img file="MX339989B_D0289.tif" />
<img file="MX339989B_D0290.tif" />
Rh in which R<sub>M</sub> is as defined above, and each R<sub>N</sub> is independently selected from R<sub>D</sub> and is preferably hydrogen. One or more of R<sub>N</sub> preferably they can also be halogen such as F. D is also preferably indanyl, 4,5,6,7-tetrahydrobenzo [d] thiazolyl, benzo [d] thiazolyl, or indazolyl, and is optionally substituted with one or more R<sub>TO</sub>. Most preferably D is indanyl, 4,5,6,7-tetrahydrobenzo [d] thiazolyl, benzo [d] thiazolyl, indazolyl, or benzo [d] [1,3] dioxol-5-yl, and is replaced with one or more
112
R<sub>m</sub>- Quite preferably, D is
MEXICAN INSTITUTE OF PROPERTY
INDUSTRIAL
<img file="MX339989B_D0291.tif" />
<img file="MX339989B_D0292.tif" />
<img file="MX339989B_D0293.tif" />
more R
My is optionally substituted with one or
Preferably R<sub>M</sub> is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxl, phosphono, thioxo, cyano; or C alkyl<sub>1</sub>-C<sub>6</sub>, C alkenyl<sub>2</sub>-C<sub>6</sub> or C alkynyl<sub>2</sub>-C<sub>6</sub>, each of which, independently, is optionally substituted each occurrence with one or more substituents selected from halogen, hydroxl, mercapto, amino, carboxy, nitro, oxo, phosphonoxl, phosphono, tloxo, formllo or cyano; or carbocycle of C<sub>3</sub>-C<sub>6</sub> or 3-6 membered heterocycle, each of which, independently, is optionally substituted each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxl, phosphono, thioxo, formllo, cyano, Ci-C alkyl<sub>6</sub>, C alkenyl<sub>2</sub>-C<sub>6</sub>, C alkynyl<sub>2</sub>-C<sub>6</sub>, halogenoalkyl of Ο -, - Ce, halogenoalkenyl of C<sub>2</sub>-C<sub>6</sub> or C halogenoalkylnyl<sub>2</sub>-C<sub>6</sub>. More preferably, R<sub>M</sub> is halogen, hydroxy, mercapto, amino, carboxy; or Ci-C alkyl<sub>6</sub>, C alkenyl<sub>2</sub>-C<sub>6</sub> or C alkynyl<sub>2</sub>-C<sub>6</sub>, each of which, independently, is optionally substituted each time it appears with one or more substituents that are selected from
113
<img file="MX339989B_D0294.tif" />
<img file="MX339989B_D0295.tif" />
halogen, hydroxy, mercapto, amino or carboxy. Of ______________
INSTITUTO MEXICANO DE LA PROPIEDAD preferred, R<sub>M</sub> is Ct-Cs alkyl which is optionally substituted with one or more substituents selected from * halogen, hydroxy, mercapto, amino or carboxy.
Also preferably, R<sub>M</sub> is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, or cyano; or R<sub>M</sub> is -L<sub>s</sub>-Re, in which L<sub>s</sub> is a bond or alkylene of C-rCs, and Re is -N (R<sub>s</sub>Rs'), -OR<sub>s</sub>, -C (O) R<sub>S</sub>, -C (O) OR<sub>S</sub>, -C (O) N (R<sub>S</sub>R<sub>S</sub>’),
-N (R<sub>s</sub>) C (O) Rs', -N (Rs) C (O) OR<sub>s</sub>', -N (R<sub>s</sub>)SW<sub>2</sub>R<sub>s</sub>', -SO<sub>2</sub>R<sub>s</sub>, -MR<sub>s</sub>, or -P (O) (ORs) 2, in which Rs and Rs' can be selected, for example, each independently, each time they appear from (1) hydrogen or (2) C-alkyl ^ Ce optionally substituted each time it appears with one or more Ci-C halogen, hydroxy, -O-alkyl<sub>6</sub> or 3-6 membered heterocycle; or R<sub>M</sub> is Ci-Cg alkyl, C alkenyl<sub>2</sub>-C<sub>6</sub> or C alkynyl<sub>2</sub>-C<sub>6</sub>, each of which, independently, is optionally substituted each time it appears with one or more substituents that are selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or R<sub>M</sub> is carbocycle of C<sub>3</sub>-C<sub>6 </sub>or 3-6 membered heterocycle, each of which, independently, is optionally substituted each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, C ^ Cg alkyl, C alkenyl<sub>2</sub>-C<sub>6</sub>, C alkynyl<sub>2</sub>-C<sub>6</sub>, Ci-C haloalkyl<sub>6</sub>, C halogenoalkenyl<sub>2</sub>-C<sub>6</sub>,
114
<img file="MX339989B_D0296.tif" />
u M aw * halogenoalkynyl of C<sub>2</sub>-C<sub>6</sub>, -C (O) OR<sub>S</sub>, or - N (R<sub>S</sub>R<sub>S</sub>') .- ^ DfeVftasfcie-teFrÉ <sup>ev</sup> '' 'MEXICAN INSTITUTE
OF THE PROPERTY . „. . INDUSTRIAL preferred, Rm is halogen (eg fluoro, chloro, bromo, iodo)? hydroxy, mercapto, amino, carboxy, or C ^ Ce alkyl (e.g., methyl, isopropyl, tert-butyl), C ^ alkenyl<sub>2</sub>-C<sub>6</sub> or C alkynyl<sub>2</sub>-C<sub>6</sub>, each of which, independently, is optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, cyano, or carboxy. For example R<sub>M</sub> is CF<sub>3</sub>, -C (CF<sub>3</sub>)<sub>2</sub>OH, -C (CH<sub>3</sub>)<sub>2</sub>-CN, -C (CH<sub>3</sub>)<sub>2</sub>-CH<sub>2</sub>OH, or -C (CH<sub>3</sub>)<sub>2</sub>-CH<sub>2</sub>NH<sub>2</sub>. Also preferably R<sub>M</sub> is -L<sub>S</sub>-R<sub>AND</sub> in which L<sub>s</sub> is a link and R<sub>AND</sub> is -N (RsRs'), -O-Rs, -N (Rs) C (O) OR<sub>s</sub>', -N (R<sub>s</sub>)SW<sub>2</sub>R<sub>s</sub>', -SO<sub>2</sub>R<sub>s</sub>, or -SR<sub>s</sub>. For example in cases where Ls is a bond, R<sub>AND</sub> is -N (alkyl (C<sub>1</sub>-C<sub>6</sub>)) 2 (for example, -NMe<sub>2</sub>); -N (rent (C<sub>1</sub>-C<sub>6</sub>) -O-alkyl (C<sub>1</sub>-C<sub>6</sub>))<sub>2</sub> (for example -N (CH<sub>2</sub>CH<sub>2</sub>OMe)<sub>2</sub>); -N ((Ci-C6) alkyl) (alkylene (Ci-Ce) -Oalkyl C ^ Ce)) (for example -N (CH<sub>3</sub>) (CH<sub>2</sub>CH<sub>2</sub>OMe)); -O-Ct-Cs alkyl (eg -Ο-Me, -O-Et, -O-isopropyl, -O-tert-butyl, -On-hexyl); -O-C ^ Ce halogenoalkyl (for example, -OCF<sub>3</sub>, -OCH<sub>2</sub>CF<sub>3</sub>); -O-alkyleneCT-Cej-piperidine (for example, -O-CH<sub>2</sub>CH<sub>2</sub>-1piperidyl); -N (alkyl (Ci-C<sub>6</sub>)) C (O) O-Ci-C alkyl<sub>6</sub> (for example, -N (CH<sub>3</sub>) C (O) O-CH<sub>2</sub>CH (CH<sub>3</sub>)<sub>2</sub>), -N (alkyl (C<sub>1</sub>-C<sub>6</sub>) SO2-C ^ Ce alkyl (for example, -N (CH<sub>3</sub>)SW<sub>2</sub>CH<sub>3</sub>); -SW<sub>2</sub>-Ci-C alkyl<sub>6</sub> (for example, -SO<sub>2</sub>I); -SW<sub>2</sub>-halogenoalkyl of C- | -C<sub>6</sub> (for example, -SO<sub>2</sub>CF<sub>3</sub>); or -S-halogenoalkyl of Ci-C<sub>6</sub> (for example, SCF<sub>3</sub>). Also preferably R<sub>M</sub> is -Ls-Re in which Ls is Ci-C alkylene<sub>6</sub> (for example, -CH<sub>2</sub>-, -C (CH<sub>3</sub>)<sub>2</sub>-, -C (CH<sub>3</sub>)<sub>2</sub>-CH<sub>2</sub>-) and R<sub>AND</sub> is -O-Rs, -C (O) ORs,
115
ΙΚί ΡI
<img file="MX339989B_D0297.tif" />
-N (R<sub>S</sub>) C (O) OR<sub>S</sub>', or -P (O) (OR<sub>s</sub>)<sub>2</sub>For example R<sub>M</sub> es -á'íqEflí ^^ gC OR<sub>s</sub> (for example, -C (CH<sub>3</sub>)<sub>2</sub>-CH<sub>2</sub>-OMe); -alqu¡len (Ci-C<sub>6</sub>) -C (O) ORs (for example, -C (CH<sub>3</sub>)<sub>2</sub>-C (O) OMe); -alkileníCT-CeJ-NÍRsjCXOjORs' (for example, -C (CH<sub>3</sub>)<sub>2</sub>-CH<sub>2</sub>-NHC (O) OCH<sub>3</sub>); or -alkylene (C., - C<sub>6</sub>) P (O) (OR<sub>s</sub>)<sub>2</sub> (for example, -CH<sub>2</sub>-P (O) (OEt)<sub>2</sub>). Also more preferably R<sub>M</sub> is carbocycle of C<sub>3</sub>-C<sub>6</sub> or 3- to 6-membered heterocycle, each of which, independently, is optionally substituted each time it appears with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, CrCe alkyl, C alkenyl<sub>2</sub>-C<sub>6</sub>, C alkynyl<sub>2</sub>-C<sub>6</sub>, haloalkyl of Ο ·, -Ο<sub>6</sub>, C halogenoalkenyl<sub>2</sub>-C<sub>6</sub>, C halogenoalkynyl<sub>2</sub>-C<sub>6</sub>, -C (O) OR<sub>S</sub>, or -N (R<sub>S</sub>R<sub>S</sub>'). For example R<sub>M </sub>is cycloalkyl (e.g. cyclopropyl, 2,2-dichloro-1-methylcycloprop1-yl, cyclohexyl), phenyl, heterocyclyl (e.g. morpholin-4-yl,
1,1-Dioxydothiomorpholin-4-yl, 4-methylpiperazin-1-yl, 4-methoxycarbonylpiperazin-1-yl, pyrrolidin-1-yl, piperidin-1-lio, 4-methylpiperidin-1-yl, 3,5-d¡ methylpiperidin-1-yl, 4,4-difluoropiperidin-1lo, tetrahydropyran-4-yl, pyridinyl, pyridin-3-yl, 6 (dimethylamino) pyridin-3-yl). Rather preferably, R<sub>M</sub> is C-alkyl, -C<sub>and</sub> which is optionally substituted with one or more substituents that are selected from halogen, hydroxy, mercapto, amino or carboxy (eg, tert-butyl, CF<sub>3</sub>).
X is preferably carbocycle of C<sub>5</sub>-C<sub>6</sub>, 5- to 6-membered heterocycle, or 6 to 12-membered pitchforks (for example,
116
IMPI
<img file="MX339989B_D0298.tif" />
MEXICAN INSTITUTE OF PROPERTY
INDUSTRIAL
<img file="MX339989B_D0299.tif" />
in which X<sub>3</sub> is N and is directly attached to -L<sub>3</sub>-D), and is optionally substituted with one or more R<sub>TO</sub>. Non-limiting examples of X are described earlier in the present application.
L-ι and L<sub>2</sub> preferably they are, independently, bond or alkylene of Ο · ι-Ο<sub>6</sub>, L<sub>3</sub> preferably selected from bond, Ci-C alkylene<sub>6</sub> or -C (O) -, and L-ι, L<sub>2</sub>, and L<sub>3</sub> are each independently optionally substituted with one or more R<sub>l</sub>. More preferably, L<sub>1t</sub> L<sub>2</sub> and L<sub>3</sub> are each independently Ci-C bond or alkylene<sub>6</sub> (for example, -CH<sub>2</sub>- or -CH<sub>2</sub>CH<sub>2</sub>-), and are each independently optionally substituted with one or more R<sub>L</sub>. Quite preferably, L<sub>1t</sub> L<sub>2</sub> and
L<sub>3</sub> they are link.
R<sub>2</sub> and R5, taken together with the atoms to which they are attached, preferably form a 5- to 6-membered heterocycle or 6 to 12-membered bicyclo (for example, which is optionally substituted with one or more R<sub>TO</sub>.
R9 and R2, taken together with the atoms to which they are attached, preferably form a 5-6 membered heterocycle
117 or bicycle with 6 to 12 members (for example,
<img file="MX339989B_D0300.tif" />
<img file="MX339989B_D0301.tif" />
IMPI
MEXICAN INSTITUTE, &
OF THE PROPERTY
INDUSTRIAL which is optionally substituted with one or more R<sub>TO</sub>.
Θϊ and G<sub>2</sub> preferably each one is independently selected from
<img file="MX339989B_D0302.tif" />
and are each independently optionally substituted with one or more R<sub>TO</sub> (for example, one or more chlorine or bromine). More preferably, Gi is including any tautomer of r — NH itself), and G<sub>2</sub> es (including any tautomers thereof), and each Gt and G<sub>2</sub> independently is optionally substituted with one or more R<sub>TO</sub> (for example, one or more chlorine or bromine).
-T-Rd ', without limitation, can be independently selected each time it appears from -C (O) -L<sub>AND</sub>'-, -C (O) OLy'-Rd', -C (O) -L<sub>and</sub>'-N (R<sub>b</sub>) C (O) -Ls-Rd ', -C (O) -L<sub>and</sub>'-N (R<sub>b</sub>) C (O) OL<sub>s</sub>-R<sub>d</sub>', - N (Rb) C (O) -L<sub>and</sub>'-N (Rb) C (O) -L<sub>s</sub>-R<sub>d</sub>', -N (Rb) C (O) -L<sub>and</sub>'—N (R<sub>b</sub>) C (O) 0-L<sub>s</sub>R<sub>d</sub>', or -N (R<sub>and</sub>)CABBAGE<sub>AND</sub>'—N (R<sub>s</sub>) -L<sub>s</sub>-R<sub>d</sub>', in which L<sub>AND</sub>'is each independently Ls' and, preferably, each is independently alkylene of C. | -C<sub>6</sub> (for example, -CH<sub>2</sub>-) and
118 one or more substitutes 4eflYek-íq Je
INSTITUTO MEXICANO DE LA PROPERTY,. __ _, INDUSTRIAL preference, -TR<sub>D</sub> is selected from
<img file="MX339989B_D0303.tif" />
which appears to be derived from -CioI-Lv'-M 'optionally substituted with selected from R<sub>L</sub>. Independently every time
L<sub>s</sub>-R<sub>d</sub>'or -N (Rb) C (O) -Ly'-M'-L<sub>s</sub>-R<sub>d</sub>'. Most preferably, -TR<sub>D</sub>'is independently selected each time it appears from -C (O) -Ly'-N (R<sub>b</sub>) C (O) -Ls-Rd 'or -C (O) -L<sub>and</sub>'-N (R<sub>b</sub>) C (O) OL<sub>s</sub>-Rd '. Rather preferably, -TR<sub>D</sub>'is independently selected each time it appears from -C (O) -L<sub>AND</sub>'- N (R<sub>B</sub>) C (O) -R<sub>D</sub>'or -C (O) -Ly'-N (R<sub>b</sub>) C (O) OR<sub>d</sub>', in which L<sub>AND</sub>'preferably each is independently CiC alkylene<sub>6 </sub>(for example, -CH<sub>2</sub>-) and optionally substituted with one or more substituents selected from R<sub>L</sub>.
R<sub>c</sub>'is preferably hydrogen, and R<sub>D</sub>'preferably is selected independently each time it appears from R<sub>AND</sub>. More preferably, R<sub>D</sub>'is independently selected each occurrence from Ci-C alkyl<sub>6</sub>, C alkenyl<sub>2</sub>-C<sub>6</sub> or C alkynyl<sub>2</sub>-C<sub>6</sub>, each of which, independently, is optionally substituted each time it appears with one or more substituents that are selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl , cyano, carbocycle of C<sub>3</sub>-C<sub>6</sub> or 3-6 membered heterocycle; or carbocycle of C<sub>3</sub>-C<sub>6</sub> or 3- to 6-membered heterocycle, each of which, independently, is optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy,
119
<img file="MX339989B_D0304.tif" />
mercapto, amino, carboxy, nitro, oxo, phosphonoxy! f ^ LdR.J
INSTITUTO MEXICANO DE LA PROFIEDAD formyl, cyano, C alkyl<sub>r</sub>C<sub>5</sub> C alkenyl<sub>2</sub>-C<sub>6</sub>, SPfeffffi'fiI
C<sub>2</sub>-C<sub>6</sub>, Cj-Ce halogenoalkyl, halogenoalqi / ernto — ele · € ^ -0¾ · β C halogenoalkynyl<sub>2</sub>-C<sub>6</sub>.
R<sub>to</sub> preferably it is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or C ^ Ce alkyl, C alkenyl<sub>2</sub>-C<sub>6</sub> or C alkynyl<sub>2</sub>-C<sub>6</sub>, each of which, independently, is optionally substituted each time it appears with one or more substituents that are selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or carbocycle of C<sub>3</sub>-C<sub>6</sub> or 3- to 6-membered heterocycle, each of which, independently, is optionally substituted at each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, CiC alkyl<sub>6</sub>, C alkenyl<sub>2</sub>-C<sub>6</sub>, C alkynyl<sub>2</sub>-C<sub>6</sub>, Cj-Ce haloalkyl, C haloalkenyl<sub>2</sub>-C<sub>6</sub> or halogenoalkynyl of C<sub>2</sub>-C<sub>6</sub>; or -L<sub>TO</sub>-OR<sub>S</sub>, -L<sub>TO</sub>-MR<sub>s</sub>, -L<sub>TO</sub>-C (O) R<sub>S</sub>,
-L<sub>to</sub>-OC (O) R<sub>s</sub>, -L<sub>to</sub>-C (O) OR<sub>s</sub>, -L<sub>TO</sub>-N (R<sub>S</sub>R<sub>S</sub>'), -L<sub>to</sub>-S (O) R<sub>s</sub>, -L<sub>to</sub>-SW<sub>2</sub>R<sub>s</sub>, -L<sub>to</sub>-C (O) N (R<sub>s</sub>R<sub>s</sub>'), -L<sub>to</sub>-N (R<sub>s</sub>) C (O) R<sub>s</sub>', -L<sub>to</sub>-N (R<sub>s</sub>) C (O) N (R<sub>s</sub>'R<sub>s</sub>), -L<sub>to</sub>-N (R<sub>s</sub>)SW<sub>2</sub>R<sub>s</sub>', -L<sub>to</sub>-SW<sub>2</sub>N (R<sub>s</sub>R<sub>s</sub>'), -L<sub>to</sub>-N (Rs) SO<sub>2</sub>N (R<sub>s</sub>'R<sub>s</sub>), -L<sub>to</sub>-N (R<sub>s</sub>) S (O) N (R<sub>s</sub>'Rs), -L<sub>to</sub>-OS (O) -R<sub>s</sub>, -L<sub>to</sub>-BEAR)<sub>2</sub>-R<sub>s</sub>, -L<sub>to</sub>-SW)<sub>2</sub>OR<sub>s</sub>,
-L<sub>to</sub>-S (O) ORs, -L<sub>to</sub>-OC (O) ORs, -La-N (R<sub>s</sub>) C (O) OR<sub>s</sub>', -L<sub>to</sub>-OC (O) N (R<sub>s</sub>R<sub>s</sub>'), -L<sub>to</sub>-N (Rs) S (O) -R<sub>s</sub>', -La-S (O) N (R<sub>s</sub>Rs') or -L<sub>to</sub>-C (O) N (R<sub>s</sub>) C (O) -R<sub>s</sub>', in which L<sub>TO</sub> is bond, Ci-C alkylene<sub>6</sub>, C alkenylene<sub>2</sub>-C<sub>6</sub> or
120
IMPL C alkynylene<sub>2</sub>-C<sub>6</sub>.
More preferably, R<sub>TO</sub> is halogen, hydroxy,
MEXICAN INSTITUTE OF INDUSTRIAL PROPERTY
<img file="MX339989B_D0305.tif" />
mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or C - C alkyl<sub>6l</sub> C alkenyl<sub>2</sub>-C<sub>6</sub> or C alkynyl<sub>2</sub>-C<sub>B</sub>, each of which, independently, is optionally substituted each time it appears with one or more substituents that are selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or carbocycle of
C<sub>3</sub>-C<sub>6</sub> or 3-6 membered heterocycle, each of which, independently, is optionally substituted each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, C ^ -Ce alkyl, C alkenyl<sub>2</sub>-C<sub>6</sub>, C alkynyl<sub>2</sub>-C<sub>6</sub>, C, -C halogenoalkyl<sub>6;</sub> halogenoalkenyl of C<sub>2</sub>-C<sub>6</sub> or halogenoalkynyl of C<sub>2</sub>-C<sub>6</sub>.
Rather preferably, R<sub>TO</sub> is halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, cyano; or Ct-Cs alkyl, C alkenyl<sub>2</sub>-C<sub>6</sub> or C alkynyl<sub>2</sub>-C<sub>6</sub>, each of which, independently, is optionally substituted each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano.
L<sub>s</sub>, L<sub>s</sub>'and L<sub>s</sub> preferably they are each independently selected each time they appear from link; or Ci-C alkylene<sub>6</sub>, C alkenylene<sub>2</sub>-C<sub>6</sub> or C alkynylene<sub>2</sub>-C<sub>6</sub>.
121
IMPI
A and B can be the same or different, Ü'eDÍ'áüíB'iEéHSin |
INDUSTRIAL
<img file="MX339989B_D0306.tif" />
L<sub>d</sub> and l_<sub>2</sub> They can be the same or different. _
In one embodiment of this aspect, A, B, and D are each independently phenyl, and each independently is optionally substituted with one or more R<sub>TO</sub>; and Gt
<img file="MX339989B_D0307.tif" />
G<sub>2</sub> it is
<img file="MX339989B_D0308.tif" />
, and each of G! and G<sub>2</sub> preferably, D is
Independent Rm is optionally substituted with one or more R<sub>TO</sub> (for example, one or more chlorine or bromine). Of
<img file="MX339989B_D0309.tif" />
<img file="MX339989B_D0310.tif" />
in which R<sub>M</sub> and R<sub>N</sub> they are as defined above. M and L<sub>2 </sub>are each independently bond or alkylene of and
L<sub>3</sub> is bond, Ci-C alkylene<sub>6</sub> or -C (O) -, and L- ,. L<sub>2</sub>, and L<sub>3</sub> are each independently optionally substituted with one or more R<sub>l</sub>. Preferably L- ,, L<sub>2</sub>, and L<sub>3</sub> they are link. -TR<sub>D</sub>'is independently selected each time it appears from -C (O) -L<sub>AND</sub>'N (R<sub>b</sub>)CABBAGE<sub>s</sub>-Rd 'or -C (O) -L<sub>and</sub>'-N (R<sub>b</sub>) C (O) OL<sub>s</sub><sup>,,</sup>-Rd '. in which L<sub>AND</sub>'is C- | -C alkylene<sub>6</sub> (for example, -CH<sub>2</sub>-) and optionally substituted with one or more substituents selected from R<sub>L</sub>, and L<sub>s</sub> preferably it is a link. —TR<sub>D</sub>'can also be selected, without limitation, from -C (O) -L<sub>and</sub>'-L<sub>s</sub>-Rd '. —C (0) -L<sub>AND</sub>'-0 — L<sub>S</sub>-R<sub>D</sub>', -C (O) 122
L<sub>and</sub>'-N (Rb) -Ls-Rd', or -C (O) -L<sub>and</sub>'-N (Rb) S (O)<sub>2</sub>-Ls-R<sub>d</sub>'. IMPI
MEXICAN INSTITUTE OF PROPERTY
<img file="MX339989B_D0311.tif" />
The present invention also presents the SP'éWip of formulas I, l<sub>TO</sub>, Ib, IC and Id as described in the μ i that 11 LE application (including each modality described in the present application) or salts thereof, except that D is carbocycle of C<sub>3</sub>C<sub>í2</sub> or 3- to 12-membered heterocycle of which is substituted with J and optionally substituted with one or more R<sub>TO</sub>, in which J is carbocycle of C<sub>3</sub>-C<sub>12</sub> or 3- to 12-membered heterocycle and is optionally substituted with one or more R<sub>TO</sub>, or J is -SF<sub>5</sub>. Preferably, D is carbocycle of C<sub>5</sub>-C<sub>6</sub>, 5- to 6-membered heterocycle or 6 to 12-membered bicyclo and is optionally substituted with one or more R<sub>to</sub>, and J is carbocycle of C<sub>3</sub>-C<sub>6</sub> or 3- to 6-membered heterocycle and is optionally substituted with one or more R<sub>to</sub>. More preferably, D is carbocycle of C<sub>s</sub>-C<sub>6</sub> or 5- to 6-membered heterocycle and is optionally substituted with one or more R<sub>to</sub>, and J is carbocycle of C<sub>3</sub>-C<sub>6</sub> or 3- to 6-membered heterocycle and is optionally substituted with one or more R<sub>TO</sub>. Quite preferably, D is phenyl substituted with J and optionally substituted with one or more R<sub>TO</sub>, in which J is carbocycle of C<sub>3</sub>-C<sub>and</sub> or 3- to 6-membered heterocycle and is optionally substituted with one or more R<sub>TO</sub>. The R substituents<sub>to</sub> preferred are as described above. In a j
modality, D is
<img file="MX339989B_D0312.tif" />
in which each R<sub>N</sub> is independently selected from R<sub>D</sub> and preferably it is hydrogen, and
123
J is as defined abovem
J is as defined above and preferably 3 ^ fc3r> <jc _ _. .. MEXICAN INSTITUTE.
C<sub>3</sub>-C<sub>6</sub> or 3 to 6 membered heterocycle optionally '^^ y ^ fi one or more R<sub>TO</sub>. In another embodiment, D is _
INSTITUTO M EXICANO.
<img file="MX339989B_D0313.tif" />
J
<img file="MX339989B_D0314.tif" />
and J is carbocycle of C<sub>3</sub>-C<sub>6</sub> or 3- to 6-membered heterocycle and is optionally substituted with one or more R<sub>TO</sub>.
Likewise, the present invention presents the compounds of formulas I, l<sub>TO</sub>, l<sub>B</sub>, le and Id as described in the present application (including each embodiment described in the present application, as well as in cases where D is carbocycle of O<sub>3</sub>-C<sub>12 </sub>or 3- to 12-membered heterocycle substituted with J and optionally substituted with one or more R<sub>TO</sub> as described above in the present application) or salts thereof, except that X is optionally substituted with one or more R<sub>TO</sub>'. Specific examples of X are as described above, such as in which X<sub>3</sub> is N and is directly attached to -L<sub>3</sub>-D. Each R<sub>TO</sub>'is independently R<sub>TO</sub>; or Ci-C alkyl<sub>10</sub>, C alkenyl<sub>2</sub>-Ci<sub>0</sub> or C alkynyl<sub>2</sub>-C<sub>10</sub>, each of which contains 0, 1, 2, 3, 4 or heteroatoms which are selected from O, S or N and are
124 optionally substituted with one or more R<sub>L</sub>.
R, the MJPsI
MEXICAN INSTITUTE OF PROPERTY
<img file="MX339989B_D0315.tif" />
previously. In one modality, each R<sub>TO</sub>'is ^ cFe ^ man ^ ra independent R<sub>TO</sub>; or C ^ C ^ alkyl, u alkenyl<sub>2</sub>-uj¿ 'δ aiCJU'IMIO of C<sub>2</sub>-C<sub>10</sub>, each of which contains 0, 1, 2, 3, 4 or 5 heteroatoms that are selected from O, S or N and is optionally substituted with one or more substituents that are selected from halogen, hydroxy, mercapto , amino, carboxy, nitro, oxo, phosphonoxl, phosphono, thloxo, formyl or cyano. In other modalities, each R<sub>TO</sub>'is independently selected from R<sub>TO</sub>; or Ci-C alkyl<sub>10</sub>, C alkenyl<sub>2</sub>-Ci<sub>0</sub> or C alkynyl<sub>2</sub>-C<sub>10</sub>, each of which contains 0, 1, 2, 3, 4, or 5 O and is optionally substituted with one or more R<sub>L</sub>. In an additional mode, each R<sub>TO</sub>'is independently selected from C<sub>1</sub>-C<sub>10</sub>. C alkenyl<sub>2</sub>-C<sub>10</sub> or C alkynyl<sub>2</sub>-Ci<sub>0</sub>, each of which contains 0, 1, 2, or 3 O and is optionally substituted with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, tloxo, formllo or cyano.
In another aspect of the invention, each R<sub>TO</sub>'is in a way
Independent R<sub>TO</sub> or - (Rx-Ry) n- (Rx-Ry '), in which N is 0, 1,2, 3, 4; each R<sub>x</sub> is independently O, S or N (R<sub>B</sub>); each R<sub>AND</sub> is independently alkylene of C<sub>;</sub>-C<sub>6</sub>, C alkenylene<sub>2</sub>-C<sub>6</sub> or C alkynylene<sub>2</sub>-C<sub>6</sub> each of which is optionally substituted by one or more substituents which are selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy,
125 phosphono, thioxo, formyl, or cyano; and R<sub>AND</sub>'is de mane
<img file="MX339989B_D0316.tif" />
Ci-C alkyl<sub>6</sub>, C alkenyl<sub>2</sub>-C<sub>6</sub> or Cp alkynyl which is optionally substituted with one or Π3δ S'üstnuyentés which are selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formlló or cyano. R<sub>TO</sub> and Rb are as defined above. In one modality, each R<sub>x</sub> is O. For example, each R<sub>TO</sub>'is selected from - (O-C6 alkylenyl) N- (O-alkyl of Οτ-Οβ), where N is preferably 0, 1, 2 or 3.
Furthermore, the present invention presents the compounds of the formulas I, l<sub>TO</sub>, l<sub>B</sub>, le and Id as described in the present application (including each embodiment described in the present application, as well as cases where D is carbocycle of C<sub>3</sub>-C<sub>12</sub> or 3- to 12-membered heterocycle substituted with J and optionally substituted with one or more R<sub>TO</sub> as described earlier in the present application, or where X is optionally substituted with one or more R<sub>TO</sub>'as described above in the present application), in which:
R<sub>and</sub> is selected independently each time it appears from -OR<sub>s</sub>, -MR<sub>s</sub>, -C (O) R<sub>S</sub>, -OC (O) R<sub>S</sub>, -C (O) OR<sub>S</sub>, -N (RsRs'), -S (O) R<sub>s</sub>, -SO<sub>2</sub>R<sub>s</sub>, -C (O) N (R<sub>s</sub>R<sub>s</sub>'), -N (R<sub>s</sub>) C (O) R<sub>s</sub>’,
-N (R<sub>s</sub>) C (O) N (Rs'Rs).
-N (R<sub>s</sub>)SW<sub>2</sub>Rs'
-SW<sub>2</sub>N (R<sub>s</sub>R<sub>s</sub>’)
-N (R<sub>s</sub>)SW<sub>2</sub>N (R<sub>s</sub>'Rs), -N (R<sub>s</sub>) S (O) N (Rs'R<sub>s</sub>). -OS (O) -R<sub>s</sub>, -BEAR)<sub>2</sub>-R<sub>s</sub>,
-SW)<sub>2</sub>ORs, -S (O) OR<sub>s</sub>, -OC (O) ORs, -N (R<sub>s</sub>) C (O) OR<sub>s</sub>', -OC (O) N (R<sub>s</sub>Rs'), -N (R<sub>s</sub>) S (O) -Rs', -S (O) N (R<sub>s</sub>R<sub>s</sub>'), -P (O) (OR<sub>s</sub>)<sub>2</sub>, or -C (O) N (R<sub>S</sub>) C (O) -R<sub>S</sub>'; or C alkenyl alkyl<sub>2</sub>-C<sub>6</sub> or C alkynyl<sub>2</sub>-C<sub>6</sub>, each one of
126
IMPI
<img file="MX339989B_D0317.tif" />
which, independently, is option * mwít ^ ce¡us
INDUSTRIAL whenever it appears with one or more substituents that are selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl or cyano; or carbocycle of C<sub>3</sub>-C<sub>6</sub> or 3- to 6-membered heterocycle, each of which, independently, is optionally substituted each time it appears with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano, C ^ Cg alkyl, C alkenyl<sub>2</sub>-C<sub>6</sub>, C alkynyl<sub>2</sub>-C<sub>6</sub>, Ci-C haloalkyl<sub>6</sub>, C halogenoalkenyl<sub>2</sub>-C<sub>6</sub>, C halogenoalkynyl<sub>2</sub>-C<sub>6</sub>, C (O) OR<sub>S</sub>, or -N (R<sub>S</sub>R<sub>S</sub>'); and
Rs, Rs', and Rs are each independently selected each time they appear from hydrogen; Ch-Cg alkyl, C alkenyl<sub>2</sub>-C<sub>6</sub> or C alkynyl<sub>2</sub>-C<sub>6</sub>, each of which, independently, is optionally substituted each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl , cyano, -O-C alkyl<sub>r</sub>C<sub>6</sub>, -O-alkyl (Ci-C<sub>6</sub>) CY-Cg -O-alkyl, or 3-6 membered carbocycle or heterocycle; or 3- to 6-membered carbocycle or heterocycle; in coughs each 3-6 membered carbocycle or heterocycle in R<sub>s</sub>, Rs 'or Rs' independently is optionally substituted each occurrence with one or more substituents selected from halogen, hydroxy, mercapto, amino, carboxy, nitro, oxo, phosphonoxy, phosphono, thioxo, formyl, cyano , Ci-Cg alkyl, C alkenyl<sub>2</sub>-C<sub>6</sub>,
127
IMPI C alkynyl<sub>2</sub>-C<sub>6</sub>, halogenoalkyl C ^ -Ce, halo ^ feTíffiWft & W
INDUSTRIAL
<img file="MX339989B_D0318.tif" />
C<sub>2</sub>-C<sub>6</sub> or halogenoalkynyl of C<sub>2</sub>-C<sub>6</sub>.
The compounds of the present invention can be used in the form of salts. Depending on the particular compound, a salt of a compound might be desirable due to one or more of the physical properties of the salt, such as increased pharmaceutical stability under certain conditions or desired solubility in water or oil. In some cases, a salt of a compound can be useful for the isolation or purification of the compound.
In cases where it is intended to administer a salt to a patient, the salt is preferably pharmaceutically acceptable. Pharmaceutically acceptable salts include, but are not limited to, acid addition salts, basic addition salts, and alkali metal salts.
Pharmaceutically acceptable acid addition salts can be prepared from inorganic or organic acids. Examples of suitable inorganic acids include, but are not limited to, hydrochloric, hydrobromic, hydroionic, nitric, carbonic, sulfuric, and phosphoric acids. Examples of suitable organic acids include, but are not limited to, the aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclyl, carboxylic, and sulfonic classes of organic acids. Specific examples of suitable organic acids include acetate, trifluoroacetate, formate, propionate, succinate, glycolate, gluconate, digluconate, lactate, malate, tartaric acid, citrate, ascorbate, glucuronate,
128 maleate, fumarate, pyruvate, aspartate, glutamate
<img file="MX339989B_D0319.tif" />
anthranilic, mesylate, stearate, salicylate, | phenylacetate, mandelate, embonate (pamoatoT meta n á UI folia tu;<sup></sup>ethanesulfonate benzenesulfonate, pantothenate toluenesulfonate, 2-hydroxyethanesulfonate, sufanylate, cyclohexylaminosulfonate, alginic acid, b-hydroxybutyric acid, galactarate, galacturonate, adipate, alginate, bisulfate, butyrate, camphorate, camphorosulfonate, hemisphenophosulfonate, dopecontan-propionosulfate, cyclopentanyl phosphate, heptane-sulfonate nicotinate, 2naphthalsulfonate, oxalate, palmoate, pectinate, persulfate, 3phenylproplonate, picrate, pivalate, thiocyanate, tosylate, and undecanoate.
Pharmaceutically acceptable basic addition salts include, but are not limited to, metal salts and organic salts. Non-limiting examples of suitable metal salts include alkali metal salts (group la), alkaline earth metal salts (group lia), and other pharmaceutically acceptable metal salts. Said salts can be made, without limitation, from aluminum, calcium, lithium, magnesium, potassium, sodium, or zinc. Non-limiting examples of appropriate organic salts can be made from tertiary amines and quaternary amine, such as tromethamine, diethylamine, Ν, Ν'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumine (N-methylglucamine), and procaine . Basic nitrogen-containing groups can be quaternized with agents such as alkyl halides (e.g., methyl, ethyl, propyl, butyl chlorides / bromides / iodides,
129 decyl, lauryl, myristyl, and stearyl), its
<img file="MX339989B_D0320.tif" />
example, dimethyl, diethyl, dibutyl, and dimethyl sulfates)<sup>l</sup>,<sup>N</sup>^ Wt<sup>l</sup>Aralkyl genes (eg, benzyl and phenerne bromides /, and Others. Compounds or salts of the present invention may exist in the form of solvates, such as with water (i.e., hydrates), or with organic solvents (eg, with methanol, ethanol, or acetonitrile to form methanolate, ethanolate, or acetonitrile, respectively).
The compounds or salts of the present invention can also be used in the form of prodrugs. Some prodrugs are aliphatic or aromatic esters obtained from acid groups in the compounds of the invention. Others are aliphatic or aromatic esters of hydroxyl or amino groups in the compounds of the invention. Hydroxyl group phosphate type prodrugs are the preferred prodrugs.
The compounds of the invention may comprise asymmetrically substituted carbon atoms known as chiral centers. These compounds can exist, without limitation, as individual stereoisomers (eg, individual enantiomers or individual diastereomer), mixtures of stereoisomers (eg, a mixture of enantiomers or diastereomers), or racemic mixtures. The compounds identified in the present application as individual stereoisomers are intended to describe compounds that are present in a form that is substantially free of other stereoisomers (e.g.,
130
<img file="MX339989B_D0321.tif" />
<img file="MX339989B_D0322.tif" />
substantially free of other enantiomers or dia _
OF THE PROPERTY
INDUSTRIAL _ the expression substantially free, it is meant that at least
80% of the compound in a composition is the stereoisomers described; preferably, at least 90% of the compound in a composition is the described stereoisomer; and more preferably, at least 95%, 96%, 97%, 98% or 99% of the compound in a composition is the described stereoisomer. In cases where the stereochemistry of a chiral carbon is not specified in the chemical structure of a compound, the chemical structure is intended to encompass compounds that contain any stereoisomer of the chiral center.
The individual stereoisomers of the compounds of this invention can be prepared using a variety of methods known in the art. These methods include, but are not limited to, stereospecific synthesis, chromatographic separation of diastereomers, chromatographic resolution of enantiomers, conversion of enantiomers in an enantiomeric mixture into diastereomers followed by chromatographic separation of the diastereomers and regeneration of the individual enantiomers, and enzymatic resolution.
Stereospecific synthesis typically involves the use of optically pure (enantiomerically pure) or substantially optically pure appropriate materials and synthesis reactions that do not cause racemization or inversion of stereochemistry at the chiral centers. Mixtures of stereoisomers can be prepared
131
IMPI
XICANO, wdf - *
INSTITUTE I res of compounds, including racemic mixtures, synthesis reaction, for example, using chromatographic techniques as appreciated by those skilled in the art. Chromatographic resolution of the enantiomers can be achieved using chiral chromatography resins, many of which are commercially available. In a non-limiting example, the racemate is placed in solution and loaded onto the column containing a chiral stationary phase. The enantiomers can then be separated by HPLC.
Resolution of enantiomers can also be achieved by converting the enantiomers in a mixture into diastereomers by reaction with chiral auxiliaries. The resulting diastereomers can be separated by column chromatography or crystallization / recrystallization. This technique is useful when the compounds to be separated contain a carboxyl, amino or hydroxyl group that can form a salt or covalent bond with the chiral auxiliary. Non-limiting examples of suitable chiral auxiliaries include amino acids, organic carboxylic acids, or chirally pure organosulfonic acids. Once the diastereomers are separated by chromatography, the individual enantiomers can be regenerated. Often times, the chiral auxiliary can be recovered and used again.
Enzymes, such as esterases, phosphatases, or lipases, can be useful for the resolution of enantiomeric derivatives in an enantiomeric mixture. For example, an ester derivative of a
132
<img file="MX339989B_D0323.tif" />
carboxyl group in the compounds that go to s ^ j ^^ Pe ^ jí
OF INDUSTRIAL PROPERTY treat with an enzyme which selectively hydrolyzes only the enantiomers in the mixture. The resulting enantiomerically pure acid can then be separated from the unhydrolyzed ester.
Alternatively, the enantiomeric salts can be prepared in a mixture using any method known in the art, including treatment of the carboxylic acid with an appropriate optically pure base such as alkaloids or phenethylamine, followed by precipitation or crystallization / recrystallization of the enantiomerically pure salts. Appropriate methods for the resolution / separation of a mixture of stereoisomers, including racemic mixtures, can be found in ENANTIOMERS, RACEMATES, AND RESOLUTIONS (Jacques et al., 1981, John Wiley and Sons, New York, NY).
A compound of this invention may possess one or more unsaturated carbon-carbon double bonds. All double bond isomers, such as the cis (Z) and trans (E) isomers, and mixtures thereof, are intended to be encompassed within the scope of a stated compound unless otherwise specified. Furthermore, in cases where a compound exists in various tautomeric forms, a stated compound is not limited to any specific tautomer, but rather is intended to encompass all tautomeric forms.
Some compounds of the invention may exist in different stable conformational forms which are
133 susceptible to separation. The asymmetry of: Mexican institute
OF THE PROPERTY jtól restricted rotations around a single link<sup>or</sup>ss + meS53K¡7 ^ for example due to spherical impediment or dol ciniii<sub>?</sub> p..ori<sub>or</sub> allow the separation of different conformers. The invention encompasses each conformational isomer of these compounds and mixtures thereof.
Some compounds of the invention may also exist in zwitterionic form and the invention encompasses each zwitterionic form of these compounds and mixtures thereof.
The compounds of the present invention are described in general terms in the present application using standard nomenclature. For an indicated compound having asymmetric center (s), it is to be understood that all stereoisomers of the compound and mixtures thereof are encompassed by the present invention unless otherwise specified. Non-limiting examples of stereoisomers include enantiomers, diastereomers, and cis-trans isomers. In cases where an indicated compound exists in various tautomeric forms, the compound is intended to encompass all tautomeric forms. Some compounds are described in the present application using general formulas that include variables (for example, A, B, D, X, L-ι, L<sub>2</sub>, L<sub>3i</sub> Y, Z, T, R<sub>to</sub> or R<sub>b></sub>). Unless specified otherwise, each variable within that formula is defined independently of any other variable, and any variable that occurs more than once in a formula is defined independently of
134
<img file="MX339989B_D0324.tif" />
independent each time it appears. If the porc's as independently selected from<sup>, N</sup>&<sup>J</sup>and<sup>TR</sup>a group of each portion is independently selected ΤΓ6Τ3 otfá. Therefore, each serving may be identical to or different from the other serving or servings.
The number of carbon atoms in a hydrocarbyl moiety can be indicated by the prefix C<sub>x</sub>-C<sub>and</sub>,, in which "x" is the minimum number y "y is the maximum number of carbon atoms in the portion. Thus, for example, "C ^ -Cg alkyl" refers to an alkyl substituent containing 1 to 6 carbon atoms. Continuing the illustration, cycloalkyl of C<sub>3</sub>-C<sub>6 </sub>means a saturated hydrocarbyl ring containing 3 to 6 ring carbon atoms. A prefix appended to a multi-component substituent only applies to the first component immediately preceding that prefix. To illustrate, the term carbocyclylalkyl contains two components: carbocyclyl and alkyl. Hence, for example, carbocyclyl (C<sub>3</sub>-C<sub>6</sub>) - C ^ Cg alkyl refers to a carbocyclyl of C<sub>3</sub>-C<sub>6</sub> attached to the parent molecular moiety through a Cj-Cg alkyl group.
Unless otherwise specified, when a linker element links two other elements in a depicted chemical structure, the leftmost described component of the linker element is attached to the leftmost element in the depicted structure, and the most described component to the right of the linker element is attached to the element to the right in the
135 depicted structure. To illustrate, if the structure
ML<sub>s</sub>'- and M is -N (R<sub>b</sub>) S (O) -, then the quirnlcsT structure is
N (R<sub>b</sub>) S (O) -Ls'-.
<img file="MX339989B_D0325.tif" />
If a linker element in a depicted structure is a link, then the element to the left of the linker element is directly linked to the element to the right of the linker element by a covalent bond. For example, if a chemical structure is represented as -L<sub>s</sub>-ML<sub>s</sub>'- and M is selected as the bond, then the chemical structure will be -L<sub>s</sub>-L<sub>s</sub>'-. If two or more adjacent linker elements in a depicted structure are links, then the element to the left with respect to these link elements is directly attached to the element to the right with respect to these link elements by a covalent bond. For example, if a chemical structure is represented as -L<sub>s</sub>-M-Ls'-M'-L<sub>s</sub>-, and M and L<sub>s</sub>'are selected as bonds, then the chemical structure will be -l_s-M'-Ls-. Similarly, if a chemical structure is represented as -Ls-M-Ls'-M'Ls-, and M, L<sub>s</sub>'and M' are bonds, so the chemical structure will be Ls-Ls-.
When a chemical formula is used to describe a radical, the hyphen (s) indicate the portion of the radical that has the free valency (s). If a radical is described as optionally substituted, the radical can be substituted or unsubstituted. If a portion is described as optionally substituted with up to a particular number of non-hydrogen type radicals, that portion
136 i A-té.vgyjr · may be unsubstituted, or substituted with ήάΙίϊίΜϋϊιοΙ
MEXICAN INSTITUTE OF PROPERTY
<img file="MX339989B_D0326.tif" />
particular of non-hydrogen radicals or even di! PH<sup>ST</sup>^1<sup>L</sup> Maximum number of replaceable positions in the portion that you see. Thus, for example, if a portion is described as a heterocycle optionally substituted with up to three non-hydrogen radicals, then any heterocycle with less than three substitutable positions will be optionally substituted only up to as many non-hydrogen radicals as there are substitutable positions. have the heterocycle. To illustrate, tetrazolyl (which has only one substitutable position) will be optionally substituted with up to one non-hydrogen radical. To continue the illustration, if an amino nitrogen is described as optionally substituted with up to two non-hydrogen type radicals, then a primary amino nitrogen will be optionally substituted with up to two non-hydrogen type radicals, while a secondary amino nitrogen it will optionally be substituted with up to only one non-hydrogen radical.
The term "alkenyl" means a straight or branched hydrocarbyl chain containing one or more double bonds. Each carbon-carbon double bond may have cis or trans geometry within the alkenyl portion, relative to the substituted groups on the carbons of the double bond. Non-limiting examples of alkenyl groups include ethenyl (vinyl), 2-propenyl, 3-propenyl,
1,4-pentadienyl, 1,4-butadienyl, 1-butenyl, 2-butenyl, and 3-butenyl.
137
<img file="MX339989B_D0327.tif" />
The term "alkenylene" refers to divalent unsaturated hydrocarbyl which can be li and ia which has at least one carbon-carbon double bond. Non-limiting examples of alkenylene groups include -C (H) = C (H) -,
-C (H) = C (H) -CH<sub>2</sub>-, -C (H) = C (H) -CH<sub>2</sub>-CH<sub>2</sub>-, -CH<sub>2</sub>-C (H) = C (H) -CH<sub>2</sub>-,
-C (H) = C (H) -CH (CH<sub>3</sub>) -, and -CH<sub>2</sub>-C (H) = C (H) -CH (CH<sub>2</sub>CH<sub>3</sub>)-.
The term "alkyl" means a straight or branched saturated hydrocarbyl chain. Non-limiting examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, pentyl, iso-amyl, and hexyl.
The term "alkylene" indicates a divalent saturated hydrocarbyl chain which can be straight or branched. Representative examples of alkylene include, but are not limited to, -CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-, -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-, and -CH<sub>2</sub>CH (CH<sub>3</sub>) CH<sub>2</sub>-,
The term "alkynyl" means a straight or branched hydrocarbyl chain containing one or more triple bonds. Non-limiting examples of alkynyl include ethynyl, 1-propynyl, 2-propynyl, 3-propynyl, decynyl, 1-butynyl, 2-butynyl, and 3-butynyl.
The term "alkynylene" refers to a divalent unsaturated hydrocarbon group which may be linear or branched and which has at least one carbon-carbon triple bond. Representative alkynylene groups include, by way of example, -CsC-, - C = C-CH<sub>2</sub>-, -C = C-CH<sub>2</sub>-CH<sub>2</sub>-, -CH<sub>2</sub>-C ^ C-CH<sub>2</sub>-, -CeC-CH (CH<sub>3</sub>) - and -CH<sub>2</sub>-CeC-CH (CH<sub>2</sub>CH<sub>3</sub>)-.
I
The term carbocycle or carbocyclic or carbocyclyl is
138
ΤΜ ΡI refers to a saturated ring system (by e¡em¿jj
OF THE PROPERTY VSZ'tYES '
INDUSTRIAL S »<sup>--</sup>»» '' Partially saturated (eg cycloalkenyl or cycloalkynyl) or fully unsaturated (eg aryl) containing zero heteroatomic ring atoms. Ring atoms or ring members are atoms bonded together to form the ring or rings. A carbocyclyl can be, without limitation, a single ring, two fused rings, or rings with a bridge or spiro structure. A substituted carbocyclyl can have either cis or trans geometry. Representative examples of carbocyclyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclo-octyl, cyclopentenyl, cyclopentadienyl, cyclohexadienyl, adamantyl, decahydro-naphthalenyl, octahydroindenyl, cyclohexenyl, phenyl, innyl 1,2,3,4-tetrahydronaphthyl, indenyl, isoindenyl, decalinyl, and norpinanyl. A carbocycle group can be attached to the parent molecular moiety through any substitutable carbon ring atom. In cases where a carbocycle group is a divalent moiety that links two other elements in a depicted chemical structure (such as A in Formula I), the carbocycle group can be attached to the other two elements through any two atoms of replaceable ring. Similarly, in cases where a carbocycle group is a trivalent moiety that links three other elements in a depicted chemical structure (such as X in Formula I), the carbocycle group can be attached to the other three elements through of any three substitutable ring atoms,
139
IMPI respectively. * INSTITUTO M EXICANO
OF THE PROPERTY - INDUSTRIAL
The term carbocyclylalkyl refers to a carbocyclyl group attached to the parent molecular moiety through an alkylene group. For example, carbocyl (C<sub>3</sub>-C<sub>6</sub>) -alty of C! -C<sub>6</sub> refers to a carbocyclyl group of C<sub>3</sub>-C<sub>6</sub> attached to the parent molecular moiety through a C alkylene<sub>t</sub>-C<sub>6</sub>.
The term "cycloalkenyl" refers to a non-aromatic, partially unsaturated carbocyclyl moiety having zero heteroatomic ring members. Representative examples of cycloalkenyl groups include, but are not limited to, cyclobutenyl, cyclopentenyl, cyclohexenyl, and octahydronaphthalenyl.
The term "cycloalkyl" refers to a saturated carbocyclyl group containing zero heteroatomic ring members. Non-limiting examples of cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclo-octyl, decalinyl, and norpinanil.
The halogen prefix indicates that the substituent to which the prefix is attached is substituted with one or more independently selected halogen radicals. For example, Ci-C haloalkyl<sub>6</sub> means a C ^ Ce alkyl substituent in which one or more hydrogen atoms are replaced with independently selected halogen radicals. Non-limiting examples of Οτ-Οβ haloalkyl include chloromethyl, 1-bromoethyl, fluoromethyl, difluoromethyl, trifluoromethyl, and 1,1,1-trifluoroethyl. It should be recognized that if a substituent is
<img file="MX339989B_D0328.tif" />
140 substituted with more than can be identical way).
a halogen radical, said ra
UWUSndAL or different (unless otherwise stated
The term "heterocycle" or "heterocycle" or "heterocyclyl" refers to a saturated (eg, heterocycloalkyl), partially unsaturated (eg, heterocycloalkenyl or heterocycloalkynyl), or fully unsaturated (eg, heteroaryl) ring system in which at least one of the ring atoms is a heteroatom (i.e. nitrogen, oxygen, or sulfur), and the remaining ring atoms are independently selected from the group consisting of carbon, nitrogen, oxygen and sulfur. A heterocycle can be, without limitation, a single ring, two fused rings, or bridged or spiro structured rings. A heterocycle group can be attached to the parent molecular moiety via any substitutable carbon or nitrogen atom or atoms. In cases where a heterocycle group is a divalent moiety that links two other elements in a depicted chemical structure (such as A in Formula I), the heterocycle group can be attached to the other two elements through any two atoms of replaceable ring. Similarly, in cases where a heterocycle group is a trivalent moiety that links three other elements in a represented chemical structure (such as X in Formula I), the heterocycle group can be attached to the other three elements through any three substitutable ring atoms, respectively.
141
A heterocyclyl can be without limitation
<img file="MX339989B_D0329.tif" />
OF INDUSTRIAL PROPERTY
<img file="MX339989B_D0330.tif" />
containing an individual ring. Non-limiting examples of monocycles include furanyl, dihydrofuranyl, tetrahydrofuranyl, pyrrolyl, isopyrrolylo, pyrrolinyl, pyrrolidinyl, imidazolyl, isoimidazolyl, imidazolinyl, imidazolidinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, triazolyl, isoxythiolyl, oxyzolidinyl, triazolyl, tetrazolyl, iso-thiyalyl , isothiazolyl, thiazolinyl, isothiazo I yl, thiazolidinyl, isothiazolidinyl, thiodiazolyl, oxathiazolyl, oxadiazolyl (including 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl (also known as azoximyl), 1,2,5-oxadiazolyl (also known as furazanil), and 1,3,4-oxadiazolyl), oxatriazolyl (including 1,2,3,4oxatriazolyl, and 1 , 2,3,5-oxatriazolyl), dioxazolyl (including 1,2,3-dioxazolyl, 1,2,4-dioxazolyl, 1,3,2-dioxazolyl, and 1,3,4-dioxazolyl), oxathiolanyl, pyranyl (including 1,2-pyranyl and 1,4-pyranyl), dihydropyranyl, pyridinyl, piperidinyl, diazinyl (including pyridazinyl (also known as 1,2-diazinyl), pyrimidinyl (also known as 1,3-diazinyl), and pyrazinyl (also known as 1,4-d¡azinyl)), piperazinyl, triazinyl (including striazinyl (also known as 1,3,5-triazinyl), as well -triazinyl (also known 1,2,4-triazinyl), and v-triazinyl (also known as 1,2,3-triazinyl), oxazinyl (including 1,2,3-oxazinyl, 1,3,2oxazinyl, 1, 3,6-oxazinyl (also known as pentoxazolyl), 1,2,6-oxazinyl, and 1,4-oxazinyl), isoxazinyl (including o-isoxazinyl and p-isoxazinyl), oxazolidiniium, isoxazolidinyl, oxathiazinyl (including 1,2,5-oxathiazinyl or 1,2,6-oxathiazinyl), oxadiazinyl (including 1,4,2142
<img file="MX339989B_D0331.tif" />
INSTITUTO MEXICANO DELA PROPERTY INDUSTRIAL oxadiazinyl and 1,3,5,2-oxadiazinyl), morpholinyl, thiepinyl, thiomorpholinyl, and diazepinyl.
A heterocyclyl can also be, oin limitation ·, - «* ► bicyclo containing two fused rings, such as, for example, naphthyridinyl (including [1,8] naphthyridinyl, and [1,6] naphthyridinyl), thiazolpyrimidinyl, thienopyridinyl , pyrimidopyrimidinyl, pyridopyrimidinyl, pyrazolopyrimidinyl, indolizinyl, pyrindinyl, pyranopyrrolyl, 4H-quinolizinyl, purinyl, pyridopyridinyl (including pyrido [3,4-b] -pi rid in i lo, pyrido [3,2-b] -pyridinyl, and pyridinyl [4,3-b] pyridinyl), plridopylimidine, and pteridinlo. Other non-limiting examples of fused ring heterocycles include benzofused heterocycles, such as indolyl, isoindolyl, indoleninyl (also known as pseudoindolyl), isoindazolyl (also known as benzpyrazolyl or indazolllo), benzazinyl (including quinolinyl (also known as 1-benzazin Lo) and isoquinolinyl (also known as 2-benzazinyl)), benzimidazolllo, phthalazinyl, quinoxalinyl, benzodiazinyl (including cynolinyl (also known as 1,2-benzodiazinyl) and quinazolinyl (also known as 1,3-benzodiazinyl)), benzopyranyl (including chromenyl and sochromenyl), benzothiopyranyl (also known as thiochromenyl), benzoxazolyl, doxazinyl (also known as benzisoxazolyl), anthranilyl, benzodioxolyl, benzodioxanil, benzoxadiazolyl, benzofuranyl (also known as coumaronyl), isobenzofuranyl, benzothienyl (also known as benzothiophenyl, thionaphthenyl, and benzothiofuranyl), isobenzothienyl
<img file="MX339989B_D0332.tif" />
143 isobenzothiophenyl, ¡s <I¡
INSTITUTO MEXICANO ΐζ * DE LA PROPIEDAD Q * benzothiazolyl, benzothiadiazolyl, ± ienc¡midazolyl 2-benzoxazinyl, 2,3,1-benzoxazinyl, and 3,1,4-benzoxazinyl), benzisoxazinyl (including 1,2-benzisoxazinyl and 1,4-benzisoxazinyl), and tetrahydroisoquinolinyl.
A heterocyclyl can also be, without limitation, a spiro ring system, such as, for example, 1,4-dioxa-8azaspiro [4.5] decanyl.
A heterocyclyl can comprise one or more sulfur atoms as ring members; and in some cases, the sulfur atom or atoms oxidize to SO or SO<sub>2</sub>. The nitrogen heteroatom (s) in a heterocyclyl may or may not be quaternized, and may or may not be oxidized to the N-oxide. Furthermore, the nitrogen heteroatom (s) may or may not be N-protected.
______ in a chemical formula refers to a single or double bond.
The term "pharmaceutically acceptable" is used as an adjective to mean that the modified noun is appropriate for use as a pharmaceutical product or as part of a pharmaceutical product.
The term "therapeutically effective amount" refers to the total amount of each active substance that is sufficient to
144
The Mexican INSTITUTE OF INDUSTRIAL PROPERTY shows a significant benefit to the patient, by reducing the viral load.
The term prodrug refers to TRilIvydus of the compounds of the invention which have groups susceptible to chemical or metabolic cleavage and are converted, by solvolysis or under physiological conditions, into the compounds of the invention which are pharmaceutically active in vivo. A prodrug of a compound can be formed in a conventional manner by reaction of a functional group of the compound (such as an amino, hldroxl or carboxy group). Prodrugs often offer advantages of solubility, tissue compatibility, or delayed release in mammals (see, Bungard, H., DESIGN OF PRODRUGS, pp. 7-9, 21-24, Elsevíer, Amsterdam 1985). Prodrugs include acidic derivatives well known to those of skill in the art, such as, for example, esters prepared by reacting the parent acid compound with an appropriate alcohol, or amides that are prepared by reacting the parent acid compound with an appropriate amine. Examples of prodrugs include, but are not limited to, acetate, formate, benzoate or other added derivatives of alcohol or amine functional groups within the compounds of the Invention.
The term "solvate" refers to the physical association of a compound of this invention with one or more solvent molecules, either organic or inorganic. This physical association often includes the formation of hydrogen bonds. In some cases, the
145
<img file="MX339989B_D0333.tif" />
solvate is capable of isolation, for example quaTieRTe-nii olí »r J Γ 'INSTITUTO MEXICANO
OF INDUSTRIAL PROPERTY solvent molecules are incorporated into the crystal lattice of crystalline solid. Solvate encompasses both solution phase solvates and isolated solvates. Examples of solvates include, but are not limited to, hydrates, ethanolates, and methanolates.
The term N-protecting or N-protected group refers to those groups that can protect an amino group against undesirable reactions. Commonly used N-protecting groups are described in Greene and Wuts, PROTECTING GROUPS IN CHEMICAL SYNTHESIS (3<sup>to</sup> ed., John Wiley & Sons, NY (1999). Non-limiting examples of N-protecting groups include acyl groups such as formyl, acetyl, propionyl, pivaloyl, t-butylacetyl, 2-chloroacetyl, 2-bromoacetyl, trifluoroacetyl, trichloroacetyl, phthalyl, onitrophenoxyacetyl, benzoyl, 4-chlorobenzoyl, 4-bromobenzoyl, or 4nitrobenzoyl; sulfonyl groups such as benzenesulfonyl or ptoluenesulfonyl; sulfenyl groups such as phenylsulfenyl (phenylS-) or triphenylmethylsulfenyl (trityl-S-); sulfinyl groups such as p-methylphenylsulfinyl (p-methylphenyl-S (O) -) or t-butylsulfinyl (t-Bu-S (O) -); Carbamate-forming groups such as benzyloxycarbonyl, p-chlorobenzyloxycarbonyl, p-methoxybenzyloxycarbonyl, p-nitrobenzyloxycarbonyl, 2-nitrobenzyloxycarbonyl, pbromobenzyloxycarbonyl, 3,4-dimethoxybenzyloxycarbonyl, 4-dimethoxybenzyloxycarbonyl, 4,5-dimethoxybenzyloxycarbonyl, 4, 4-dimethoxybenzyloxycarbonyl, 2,4-dimethoxybenzyloxycarbonyl, 2,4-dimethoxybenzyloxycarbonyl, 4, 4-dimethoxybenzyloxycarbonyloxy Benzyloxycarbonyl,
3,4,5-trimethoxybenzyloxycarbonyl, 1- (p-biphenylyl) -1-methylethoxycarbonyl,
146
<img file="MX339989B_D0334.tif" />
dimethyl-3,5-dimethoxybenzyloxycarbonyl, benzhydrilojuqg ^ ojrficj, '
INSTITUTO MEXICANO DE LA FROFIEDAD butyloxycarbonyl, di-isopropylmethoxycarbonyl, isopropylowhsawo ethoxycarbonyl, methoxycarbonyl, allyloxycarbonyl, trioloroaxycarbonyl, phenoxycarbonyl, 4-nitro-phenoxycarbonyloxyloxyloxycarbonyloxy-cycloboxycarbonyloxyloxyloxy, cycloboxycarbonyloxycarbonyl Lo, or phenylthiocarbonyl; alkyl groups such as benzyl, pmethoxybenzyl, triphenylmethyl, or benzyloxymethyl; p-methoxyphenyl; and silyl groups such as trimethylsilyl. Preferred N-protecting groups include formyl, acetyl, benzoyl, pivaloyl, t-butyllacetyl, phenylsulfonyl, benzyl, t-butyloxycarbonyl (Boc), and benzyloxycarbonyl (Cbz).
The compounds of the present invention can be prepared using a variety of methods. As a non-limiting example, the compounds of the present invention can be prepared according to Reaction Scheme I starting from compounds of Formula II (eg, n = 0 to 8), of Formula V (X<sub>4</sub> can be, for example, O or NR<sub>TO</sub>, in which R<sub>TO</sub> it is as described above in the present application and preferably is H or R<sub>and</sub> as defined above such as CrC alkyl<sub>6</sub>, 3- to 12-membered carbocycle or heterocycle, -C (O) Rs, -C (O) ORs, C (O) N (R<sub>s</sub>Rs'), -SO<sub>2</sub>N (R<sub>s</sub>Rs'). -SW)<sub>2</sub>OR<sub>s</sub>, -S (O) OR<sub>s</sub>, -S (O) N (R<sub>s</sub>R<sub>s</sub>'), or an appropriate protecting group such as Boc or Fmoc), or of Formula VIII (E may be, for example, 3- to 7-membered carbocycle or heterocycle and is optionally substituted with one or more R<sub>TO</sub>), in which A, B, D, Y, Z and R<sub>TO</sub> they are as described above.
147
1,4-diketones Ii, V, and VIII can be
<img file="MX339989B_D0335.tif" />
1,4-diols using the methods described above in racemic, enantiomerically enriched diols, or 1,4-diols, resulting can be converted to dimesylates III, VI, or IX, or alternatively to ditriflates, ditosylates, or dihalides using the methods described below. Dimesylates III, VI, and IX, ditriflates, ditosylates, or dihalides can be reacted with an amine, including but not limited to, aniline,
3,5-Difluoroaniline, 3,4-difluoroaniline, 4-fluoroaniline, 3-fluoroaniline, 4-trifluoromethylaniline, 4-chloroaniline, heteroarylamines, alkylamines, cycloalkylamines, substituted benzylamines, or allylamine, under the conditions described below to obtain the compounds of the invention. L<sub>1</sub> and L<sub>2</sub> can be easily introduced into formulas II, V and VIII, as appreciated by those skilled in the art in light of the present invention, similarly, DL can be used<sub>3</sub>-NH<sub>2 </sub>instead of D-NH<sub>2</sub>, as appreciated by those skilled in the art.
REACTION SCHEME
IV
148
<img file="MX339989B_D0336.tif" />
As another non-limiting example, the compounds of the present invention can be prepared starting from the compounds of Formula II and Formula III as shown in Reaction Scheme II. 1,4-diketones such as Formula IV can be prepared using known methods (see Nevar, et al., Synthesis: 1259-1262 (2000), such as the reaction of abromoketones such as Formula II with methyl ketones such as
Formula III in the presence of an appropriate Lewis acid such as ZnCl<sub>2</sub> or Ti (OiPr)<sub>4</sub>. IV 1,4-diketones can be reduced to
1,4-diols such as V through the action of NaBH<sub>4</sub>, LiA1H<sub>4</sub>, or DIBAL. Alternatively, enantioselective reduction of 1,4-dicketones such as Formula IV can be achieved by analogy with reported methods (see Chong, et al., Tetrahedron: Asymmetry 6: 409-418 (1995), Li, et al. ., Tetrahedron 63: 8046-8053 (2007), Aldous, et al., Tetrahedron: Asymmetry 11: 2455-2462 (2000),
149
IMPI
Masui, et al., Synlett: 273-274 (1997), Jing, et al., Íhijústuai
347: 1193-1197 (2005), Sato, et al., Synthesis: 1434-1438 (2004)), such as reduction with (-) or (+) - diisopinocamheylchloroborane (DIPchloride), with borane and an oxazaborolidine catalyst, or with asymmetric hydrogenation in the presence of an appropriate ruthenium (II) catalyst, such as [RuCl2 {(R) -BINAP} {(R, R) -DPEN}] (BINAP = 2,2'-b¡s (diarylphosphino ) -1,1'-binaphthyl; DPEN = 1,2-diphenylethylenediamine). The resulting enantiomerically enriched, racemic 1,4-diols, or meso 1,4-diols V can be reacted with methanesulfonyl chloride to provide the Formula VI dimeslate. Alternatively, Formula V can be converted to a ditriflate or ditosylate by the action of ptolenesulfonyl chloride or triflic anhydride, or to a dihalogenide such as a dibromide or dichloride by the action of PPh.<sub>3</sub> in the presence of CCI<sub>4</sub> or CBr<sub>4</sub>, or through the action of SOCI<sub>2</sub>, POCI<sub>3</sub>, or PBr<sub>3</sub>. The dimesylate, ditriflate, ditosylate, or dihalogenide can be reacted with an amine, such as 4-fluoroaniline (as shown for illustration in Reaction Scheme II), with or without a cosolvent such as DMF at room temperature up to 100 ° C, to produce pyrrolidines such as Formula Vil. In addition to 4-fluoroaniline, alternative amines can be reacted with the dimesylate Formula VI, including but not limited to aniline, 3,5-difluoroaniline, 3,4-difluoroaniline, 3-fluoroaniline, 4-trifluoromethylaniline, 4-chloroaniline, heteroarylamines, alkylamines, cycloalkylamines , substituted benzylamines, or allylamine. The money
<img file="MX339989B_D0337.tif" />
150
Formula Vil can be reduced to the diamine FórrrAléVHf-uwij z INSTITUTO MEXICANO
OF THE PROPERTY
INDUSTRIAL - Faith in the presence of NH<sub>4</sub>CI, HCI, or acetic acid, or by treatment with a hydride-type reducing agent, such as sodium borohydride (with or without the addition of a transition metal salt, such as B¡CI<sub>3</sub>, SbCI<sub>3</sub>, NiCI<sub>2</sub>, Cu<sub>2</sub>CI<sub>2</sub>, or CoCI<sub>2</sub>) in a solvent such as ethanol or THF. Alternatively, Formula VII can be reduced to the Formula VIII product by hydrogenation in the presence of an appropriate catalyst, such as a palladium or platinum or Raney nickel catalyst. Formula VIII diamine can be reacted with an appropriately protected proline acid (Boc shown, although Cbz, Troc, or Fmoc may be substituted) in the presence of a peptide coupling reagent, such as EDAC / HOBT, PyBOP , HATU, or DEBPT, in a solvent such as THF, DMF, dichloromethane, or DMSO, with or without the addition of an amine-type base such as Hunig's base, pyridine, 2,6-lutidine, or triethylamine, to obtain the Formula IX. Removal of Boc protecting groups to obtain X can be accomplished by treatment with an acid, such as TFA, HCI, or formic acid. The compounds of the present invention can be prepared by coupling Formula X with an acid of choice using the standard peptide coupling reagents and conditions described above. Alternatively, diamine VIII can be reacted with an N-substituted proline in the presence of a peptide coupling reagent such as EDAC / HOBT, PyBOP, HATU, T<sub>3</sub>P, or DEBPT, in a solvent such as THF, DMF, dichloromethane, or
151
DMSO, with or without the addition of an amine base ^^ rjí J¡
INSTITUTO MEXICANO,, .... <sub>Λ Λ</sub> ,. ,. ... Ot U FRCS'JWA »
Humg, pyridine, 2,6-lutidine, or triethylamine, for 'Obtewer
<img file="MX339989B_D0338.tif" />
compounds of the present invention (Formula XI) -dirootQmontOi
<img file="MX339989B_D0339.tif" />
* * In each Formula within Reaction Scheme II can be in which D is defined above, and such compounds can be easily prepared according to the procedure described in Reaction Scheme II (including making compound XI directly from the compound VIII).
REACTION SCHEME II
<img file="MX339989B_D0340.tif" />
SAW
<img file="MX339989B_D0341.tif" />
<img file="MX339989B_D0342.tif" />
<img file="MX339989B_D0343.tif" />
<img file="MX339989B_D0344.tif" />
152 ag ^ iarrf-iw.Ma, -
<img file="MX339989B_D0345.tif" />
<img file="MX339989B_D0346.tif" />
<img file="MX339989B_D0347.tif" />
As another non-limiting example, the compounds of the present invention can be prepared starting from the compounds of Formula II and Formula III as shown in Reaction Scheme III, in which A, B, D, Y, and Z are as described above, using conditions similar to those described above for the preparation of IV in Reaction Scheme il. Similarly, the resulting 1,4-diketone IV can be reduced to 1,4-diols V using the methods described above for Reaction Scheme II. The resulting racemic, enantiomerically enriched 1,4-diols, or resulting meso 1,4-diols V can be converted to dimesylate VI or alternatively to a ditriflate, ditosylate, or dihalogenide using the methods described above. Dimesylate VI, ditriflate, ditosylate, or dihalogenide can be reacted with an amine, including but not limited to, aniline, 3,5-difluoroaniline, 3,4-difluoroaniline, 4-fluoroaniline, 3153 fluoroaniline, 4-trifluoromethylaniline, 4 -chloroaniline, KMHPI
MEXICAN INSTITUTE Λ- *
.... ...... , ... .DE IA FROHEDAD<sup>v</sup> Alkylamines, cycloalkylamines, substituted benzylamines, 'NeFWd-ar under the conditions described above for the compounds of the invention. Alternatively, compounds such as VIII, in which R is a group such as allyl, 4-methoxybenzyl, or 2,4-dimethoxybenzyl, can be treated with reagents useful for the removal of the R group (rhodium catalyst such as Rh ( Ph<sub>3</sub>P)<sub>3</sub>CI for R = allyl, treatment with an acid such as TFA or HCI for R = 4-methoxybenzyl or 2,4-dimethoxybenzyl, hydrogenolysis with a Pd catalyst for R = substituted benzyl) to generate compounds such as IX. Amine IX can be reacted with an aryl halide or triflate such as X (iodide shown for illustration) using the Buchwald-Hartwig reaction in the presence of a palladium catalyst (such as Pd (OAc)<sub>2</sub> or ps<sub>2</sub>(dba)<sub>3</sub>) and a phosphine ligand (such as triphenylphosphine or Xantfos) and a base (such as sodium bis (trimethylsilyl) amide, sodium tert-butoxide
<img file="MX339989B_D0348.tif" />
potassium, or K<sub>3</sub>PO<sub>4</sub>) to obtain the compounds of the present invention. Alternatively, the compounds of the present invention can be obtained by reacting IX with an aldehyde or ketone through reductive amination in the presence of a hydride-type reducing agent, such as sodium borohydride or sodium cyanoborohydride (with or without the addition of an acid, such as acetic acid) in a solvent such as ethanol, toluene, THF, or dichloromethane. Alternatively, reductive amination may be accomplished through the use of hydrogenation in the presence of a
154
<img file="MX339989B_D0349.tif" />
appropriate catalyst, such as a catalyst
MLXICAN INSTITUTE OF Nickel Raney. Alternatively, amine IX can be reacted with electrophilic reagents, such as alkyl halides, or with aryl electrophiles (appropriately aryl and heteroaryl halides and electron-deficient triflates) through nucleophilic aromatic substitution reactions to obtain the compounds of the present invention.
REACTION SCHEME III
<img file="MX339989B_D0350.tif" />
155
SCHEME III (cont.)
IMPI
MEXICAN INSTITUTE OF THE INDUSTRIAL PROFIEL'AD
<img file="MX339989B_D0351.tif" />
<img file="MX339989B_D0352.tif" />
<img file="MX339989B_D0353.tif" />
As a further non-limiting example, the compounds of the present invention can be prepared starting from the compounds of Formula Ii and Formula III as shown in Reaction Scheme IV, in which X<sub>5</sub> in Formula II and in Formula III it represents a halogen (eg Cl, Br, or F) or a nitro group. 1,4-diketones such as IV can be prepared using known methods described above for the preparation of IV for Reaction Scheme II. 1,4-diketones IV can be reduced to 1,4-diols such as V by the action of NaBH<sub>4</sub>, L¡AIH<sub>4</sub>, or DIBAL. Alternatively, enantioselective reduction of 1,4-diketone such as IV can be achieved using the methods described above for the preparation of V for Reaction Scheme II. The resulting enantiomerically enriched, racemic 1,4-diols, or meso 1,4-diols V can be reacted with methanesulfonyl chloride to provide the dimesylate VI. Alternatively, V can be either a>
156
Convert IMPIf to a ditriflate or ditosylate using the
INDUSTRIAL
<img file="MX339989B_D0354.tif" />
above for Reaction Scheme II. Dimesylate, ditriflate, ditosylate, or dihalogenide can be reacted with an amine including but not limited to aniline, 3,5-difluoroaniline,
3,4-Difluoroaniline, 4-fluoroaniline, 3-fluoroaniline, 4-trifluoromethylaniline, 4-chloroaniline, heteroarylamines, alkylamines, cycloalkylamines, substituted benzylamines, or allylamine to obtain Vil. When X<sub>5</sub> in Formula VII is nitro, nitro groups can be reduced to the tetraamine product IX using Fe in the presence of NH<sub>4</sub>CI, HCI, or acetic acid, or with a hydride-type reducing agent, such as sodium borohydride (with or without the addition of a transition metal salt, such as BiCI<sub>3</sub>, SbCI<sub>3</sub>, NiCI<sub>2</sub>, Cu<sub>2</sub>CI<sub>2</sub>, or CoCI<sub>2</sub>) in a solvent such as ethanol or THF. Alternatively, VII (X<sub>5</sub> = nitro) can be reduced to product IX by hydrogenation in the presence of an appropriate catalyst, such as a palladium or platinum or Raney nickel catalyst. Alternatively, the Vil compounds in which X<sub>5</sub> = halogen can be reacted with ammonia (R = H) or an amine having an appropriate protecting group (R = substituted benzyl such as 4-methoxybenzyl or 2,4-dlmethoxybenzyl or R = allyl). The resulting products VIII can be treated with a reagent useful for the removal of the protecting group R (rhodium catalyst such as Rh (Ph<sub>3</sub>P)<sub>3</sub>CI for R = allyl, treatment with an acid such as TFA or HCI for R = 4-methoxybenzyl or 2,4-dimethoxybenzyl, hydrogenolysis with a Pd catalyst for R = substituted benzyl) to obtain product IX. The
157
IΛ4 Ρ J
Formula IX can be reacted with ui »wit» © -3i © «icde ώκ. -J» »W2.íiTJFftÍ> A appropriately protected (Boc shown, although Cbz, Troc, or Fmoc may be substituted) in presence of a peptide coupling reagent, such as EDAC / HOBT, PyBOP, HATU, or DEBPT, in a solvent such as THF, DMF, dichloromethane, or DMSO, with or without the addition of an amine-type base, such as base of Hunlg, pyridine, 2,6-lutidine, or triethylamine, to obtain X as a mixture of the amide products. Conversion to the benzimidazole compound XI can be achieved by heating X in acetic acid (50-100 ° C). Alternatively, XI can be prepared by reacting IX with an aldehyde, followed by treatment with an oxidant, such as Cu (OAc)<sub>2</sub> or MnO<sub>2</sub> (see Pennlng, et al., Bloorg. Med. Chem. 16: 6965-6975 (2008). After removal of Boc protecting groups from XI (is accomplished by treatment with an acid, such as TFA, HCI, or formic acid), the compounds of the present invention can be prepared by coupling the resulting diamine XII with an acid of choice using the standard peptide coupling reagents and conditions described above for Reaction Scheme II.
F formula within Reaction Scheme IV can be
3)
Zp in which D was defined above, and said
Λ / UV »
<img file="MX339989B_D0355.tif" />
in each replace with compounds they can be easily prepared in accordance with the
158
IMPI procedures described in the Re aechan JtVmexicano Scheme
OF INDUSTRIAL RkOFIEDAD
<img file="MX339989B_D0356.tif" />
<img file="MX339989B_D0357.tif" />
159
Alternatively, IX in the EsqTeMdPfe
MEXICAN INSTITUTE
<img file="MX339989B_D0358.tif" />
It can be prepared from a compound of the FuSWfi ^ ll'eCgSfele shown in Reaction Scheme V. The nnmpimetn vin from Reaction Scheme II can be treated with an acylating agent such as acetyl chloride or acetic anhydride to obtain compound II (Reaction Scheme V). Nitraclon of compound II to provide III can be achieved using known methods, such as treatment with nitric acid or potassium nitrate in the presence of an acid such as sulfuric acid or treatment with NO.<sub>2</sub>BF<sub>4</sub>. Removal of the acetamide protecting group can be accomplished by treatment with Boc anhydride in the presence of DMAP to obtain IV, followed by sequential IV treatment with hydroxide (such as NaOH, KOH, or LIOH) to remove the acetyl group and an acid. strong such as TFA or HCI to remove the Boc protecting group. Nitro groups in V can be reduced to amine groups using the methods described above for Reaction Scheme IV.
F in each formula within Reaction Scheme V can be replaced with
I which D was defined above, and such compounds can be easily prepared according to the procedures described in Reaction Scheme V.
160
<img file="MX339989B_D0359.tif" />
<img file="MX339989B_D0360.tif" />
<img file="MX339989B_D0361.tif" />
<img file="MX339989B_D0362.tif" />
As another non-limiting example, the compounds of the present invention can be prepared starting from the compounds of Formula II as shown in Reaction Scheme VI, in which A, B, D, Y, and Z are as described. previously. A
161 1,4-diketone compounds of Formula II IMPí
INSTITUTO MEXICANO describes in Reaction Scheme III) you can read 'jwwac'
<img file="MX339989B_D0363.tif" />
with an amine, including but not limited to Qniiim<sub>J </sub>difluoroaniline, 3,4-difluoroaniline, 4-fluoroaniline, 3-fluoroaniline, 4-trifluoromethiianiline, 4-chloroaniline, heteroarylamines, alkylamines, cycloalkylamines, substituted benzylamines, or allylamine, under acid catalyzed conditions, such as acetic acid, TFA, formic acid or HCI, to obtain the compounds of the invention.
REACTION SCHEME VI
<img file="MX339989B_D0364.tif" />
As a further non-limiting example, the compounds of the present invention can be prepared from a compound of Formula II as shown in Reaction Scheme Vil. A compound of Formula II, in which R<sub>x</sub> is a halogen, such as bromine, chlorine, or iodine, or a triflate or a nonaphlate, can be converted to a boronic acid or ester such as Formula III, in which R is hydrogen, methyl, ethyl, or a pinacholate ester cyclic. For example, a compound of Formula II can be transformed into a compound of III by treatment with pinacolborane in the presence of a tai catalyst such as, for example,
162 tris (dibenzyl-acetone) palladium (0), and a ligand
<img file="MX339989B_D0365.tif" />
example, tri-t-butylphosphine, in solvents such as ^^ w *<sup>1</sup>- exwwp + 87 tetrahydrofuran, dioxane, or toluene at temperatures ranging -4e * from room temperature to approximately 130 ° C. Alternatively, compound II can be reacted with bis (pinacholate) diboro in the presence of a catalyst such as, for example, Combifos-Pd6 (CombiPhos Catalysts, Inc. (NJ, USA), dichloro [1,1'-bis (diphenylphosphino) ferrocene] palladium (II) dichloromethane adduct, or palladium acetate in the presence of a ligand such as, for example, 2-dicyclohexylphosphino- 2 ', 4', 6'-tri-isopropylbiphenyl (XFos), and a base such as, for example, potassium acetate in solvents such as, for example, toluene, dioxane, tetrahydrofuran, dimethylformamide or dimethyl sulfoxide at temperatures of about 60 to about 130 ° C to obtain compound III. Alternatively, a compound of Formula II can be reacted with an organolithium reagent, such as nBuLi, sec-BuLi, or t-BuLi, followed by reaction with trimethyl borate or triethyl borate, to obtain the compound of Formula lll.
A compound of Formula III in the Scheme of
Reaction VII can be coupled with a compound of Formula IV, in which R<sub>AND</sub> is a halogen, such as bromine, chlorine or iodine, under Suzuki reaction conditions to provide a compound of Formula V. Such conditions include, for example, the use of a palladium catalyst such as, for example, tris (dibenzylideneacetone ) palladium (0), palladium acetate,
163 bis (triphenylphosphine) palladium (ll), tetrakis (triphenylphosphine
<img file="MX339989B_D0366.tif" />
dichloro [1, r-bis (diphephosphino) ferrocene] adduct pal§'df5<sup>kiAL</sup> rv dichloromethane; base such as, for example, cattiuiialu de pulasru; potassium phosphate, potassium t-butoxide, sodium carbonate, cesium carbonate, or cesium fluoride; and solvent such as, for example, toluene, ethanol, water, or tetrahydrofuran, or mixtures thereof which are heated in the temperature range of from about 40 to about 130 ° C.
Removal of the Boc protecting groups from V can be accomplished by treatment with an acid, such as TFA, HCI, or formic acid. The compounds of the present invention such as VI can be prepared by coupling the resulting amino compounds with an acid of choice using standard peptide coupling reagents, such as EDAC / HOBT, PyBOP, HATU, or DEBPT, in such a solvent. such as THF, DMF, dichloromethane, or DMSO, with or without the addition of an amine base such as Hunig's base, pyridine, 2,6-lutidine, or triethylamine. Each R<sub>z</sub> is independently -L<sub>AND</sub>'-M'-R<sub>D</sub> (for example -L<sub>AND</sub>-N (R<sub>B</sub>)CABBAGE<sub>S</sub>-R<sub>AND</sub>), and D, L<sub>3</sub>, Ri, R<sub>2</sub>, Rs, L<sub>AND</sub>, R<sub>b</sub>”, L<sub>s</sub>, Re, L<sub>and</sub>', M' and R<sub>D</sub> they are as defined above.
164
<img file="MX339989B_D0367.tif" />
<img file="MX339989B_D0368.tif" />
As another non-limiting example, the compounds of the present invention can be prepared according to Reaction Scheme VIII starting from the compound of Formula II, initially cutting the diol in oxidative mode followed by subsequent acid hydrolysis of the acetonide. This dialdehyde intermediate is then treated with an aryl boronate or aryl boronic acid (compound IV in which A and Y are as previously described, or compound Vil) and aniline III (in which W is R<sub>M</sub> or J, and R<sub>m</sub> and J are as defined above) which gives as
165 result in the formation of Formula V
<img file="MX339989B_D0369.tif" />
respectively. Formula V can be derivatized by deprotonation of the hydroxyl groups with a strong base such as sodium hydride, butyllithium, or potassium hydride, followed by alkylation with R<sub>s</sub>-halogen. Alternatively, formula VIII can be deprotonated with a strong base (eg sodium hydride) and also alkylated with R<sub>s</sub>-halogen, followed by acid hydrolysis of the phenol protecting groups. Sulfonylation of phenols with nonafluorobutylsulfonyl fluoride in the presence of a neutralizing agent such as potassium carbonate in a polar aprotic solvent such as DMF, followed by heating provides a compound of Formula IX. The boronate of Formula X is produced by heating Formula IX with bis (pinacholate) dlboron in the presence of Xfos and a palladium catalyst, such as Pd2 (dba) 3 and a base such as potassium acetate in an organic solvent such as dioxane. .
Formula X is further derivatized to the final product by heating an appropriately substituted heteroaryl halide in the presence of a palladium catalyst such as PdCl2 (dppf) in the presence of a base such as sodium carbonate in a mixture of toluene and ethanol.
w
R<sub>s</sub> it is as defined above. in each formula inside
<img file="MX339989B_D0370.tif" />
of Reaction Scheme VIII can be replaced with in the
166
<img file="MX339989B_D0371.tif" />
<img file="MX339989B_D0372.tif" />
which D was defined above, and said com
OF THE PROPERTY
INDUSTRIAL _ easily prepare according to the procedures outlined in Reaction Scheme VIII.
REACTION SCHEME VIII
1) Phl (OAc),
2) H +
HO OH<sup>H0 </sup>II
OH sh + 9<sup>H</sup>
CUA h<sub>2</sub>ni »iv
A-GX
HO 'Λ
Oh
V
1) Phl (OAc)<sub>2</sub>
2) H + ° Ά
- V<sub>V</sub>N / = \
QjX<sup>1</sup>
HjN <sup>RO</sup>
R = 4- (CH<sub>3</sub>O) Benzyl
III VII
HO
Oh
VIII
NaH
R<sub>s</sub>-Hallogen
THF / DMF
I.NaH
R<sub>s</sub>-Hallogen
THF / DMF • <<sup>N</sup> /=\
two. H +
3. C<sub>fl</sub>FgSO<sub>2</sub>F KzCOj, DMF Λ
R<sub>Mr</sub>/ r »S
Αα =
X-Phos. Pd2 (dba) 3 KOAc. dioxane t \
Y-Br, Pd °
Xs
NagCOg toluencMEtOH 1: 1 Δ o '
Rs P <sup>s</sup>* s
XI X
Even as another non-limiting example, the compounds of the present invention can be prepared according to Reaction Scheme IX starting from the compounds of Formula II and Formula III. The carboxylic acid of formula III is activated towards coupling using reagents such as isobutyl chloroformate, DCC, EDAC, or HATU in the presence of an organic base,
167
such as di-isopropylethylamine. After the acti dianiline of the Formula II to the reaction, with the intermediate amide, which is heated in acetic acid, preferably at 60 ° C, to obtain the compound of the Formula IV. The benzimidazole of Formula IV is treated with SEM-CI in the presence of a base in an aprotic solvent such as THF, yielding two V-protected benzimidazole regioisomers. Boronate esters VI are produced by heating Formula V with bis (pinacholate) diboro in the presence of a palladium catalyst, such as PdCI2 (dppf), X-Fos, and a base such as potassium acetate in an organic solvent such as dioxane . Heating produces both regioisomers of benzimidazole VI. The Vil diol is cleaved oxidatively followed by subsequent acid hydrolysis of the acetonide. This dialdehyde intermediate is then treated with an aryl boronate VI and aniline VIII (where W is R<sub>M</sub> or J, and R<sub>M</sub> and J are as defined above) resulting in the formation of the 3 benzimidazole regioisomers of Formula IX. Formula X is produced by deprotonation of the hydroxyl groups with a strong base such as sodium hydride, butyllithium, or potassium hydride, followed by alkylation with R<sub>s</sub>-halogen, followed by acid hydrolysis of the protecting groups of pyrrolidine and benzimidazole, preferably by treatment with mineral acid, such as hydrochloric acid in an alcoholic solvent such as methanol. Carboxylic acid R<sub>Z</sub>-COOH is activated towards coupling using reagents such as isobutyl chloroformate, DCC, EDAC, or HATU
168
IMPI,
<img file="MX339989B_D0373.tif" />
in the presence of an organic base, such as di- »etttp« XM & itóSl
DELA NCOflEDAO INOUSTWAl
After activation, Formula X is added to the reaction, with the isolation of Formula XI.
w
<img file="MX339989B_D0374.tif" />
in each formula within Reaction Scheme IX / w and v * can be replaced with v_z in which D is defined above, and such compounds can be readily prepared according to the procedures described in Reaction Scheme IX.
Br.
REACTION SCHEME IX
<td>Vo 0 NT ° = <</td><td>1) HATU DIPEA DMSO 2) HOAc</td><td></td>
<td></td><td>60 ° C</td><td></td>
III W
SEM-CI
NaH
THF
<img file="MX339989B_D0375.tif" />
V
62% Global (both regiolsomers)
<img file="MX339989B_D0376.tif" />
(3 regiolsomers) Boc IX
one. NaH R<sub>s</sub>-Hallogen THFZDMF
two. HCI, MeOH
<img file="MX339989B_D0377.tif" />
X
Pln<sub>s</sub>B<sub>2</sub>
PdClg (dppf)
KOAc
Dioxane
<img file="MX339989B_D0378.tif" />
OR
XI
169
The compounds of the invention of fóJrriVá. in which R<sub>20</sub> is -L<sub>s</sub>'-M'-L<sub>s</sub>-Rd and D is like W ^ 'Wfesc above, can be prepared accordingly<sup>1</sup> with lúa »niétuüus from Reaction Scheme X. The bromoalkyl ketone (1) can be reacted with an arylalkyl ketone (2) using the Lewis acid-mediated conditions, described above in Reaction Scheme II, to obtain diaryldketone (3) . The diketone (3) can be converted to the bisboronate (4) by reaction with bis (pinacholate) diborane in the presence of a base such as potassium acetate, a catalyst such as PdCI<sub>2</sub>(dppf) -CH<sub>2</sub>CI<sub>2</sub>, in a solvent such as DMSO, dimethoxyethane or dioxane with heating between 60-100 ° C. Bisboronate (4) can be converted to intermediate (5) by Suzuki reaction using, analogously, the Suzuki conditions described in Reaction Scheme VII. Intermediate (5) can be converted to (6) by reaction with a D-NH amine<sub>2</sub> under the analogous conditions described in Reaction Scheme VI. For example, the reaction of (5) with D-NH<sub>2</sub> in the presence of an acid such as, but not limited to, TFA, in a solvent such as, but not limited to, toluene and with heating up to 110 ° C can provide the intermediates of the general structure (6). Compounds (6) can be converted to compounds of general formulas (7) and then (8) using, analogously, the methods described in the Reaction Scheme
Vile.
170
<img file="MX339989B_D0379.tif" />
IfiSTF ?. JTO MIX¡CA \ 'O
SAY LA i FOPif ¡xj> íNKJSTKJAI
REACTION SCHEME X
<img file="MX339989B_D0380.tif" />
Intermediates (6) can also be prepared using the route shown in Reaction Scheme XI. Intermediate (3) can be reacted with a D-NH amine<sub>2 </sub>using, in an analogous way, the conditions described in Reaction Schemes VI and X to provide the intermediates (9), which can be converted into (10) using, in an analogous way, conditions like those previously described in the Reaction Scheme X; and (10), in turn, can be converted to compounds (6) using the Suzuki reaction conditions described in Reaction Scheme Vil.
171
REACTION SCHEME XI
IMPI
INSTíTvW ICAWO L »T-í..OVi'f9AP
<img file="MX339989B_D0381.tif" />
<img file="MX339989B_D0382.tif" />
The compounds of the invention of the general formula (15), in which R<sub>2</sub>or is -Ls'-M'-L<sub>s</sub>-Rd and D is as described above, can be prepared according to the methods of Reaction Scheme XII. Compounds (11) can be prepared according to the procedures for converting (3) to (9), using general conditions as described in Reaction Scheme VI, such as reacting an appropriate nitrophenyldketone with an amine D-NH<sub>2</sub> with heating in acetic acid to a temperature of approximately 70 ° C. Compounds (11) can be converted to (12) using the reduction conditions described in Reaction Scheme II. The compounds (12) can be sequentially converted to the compounds of the general formulas (13), (14) and (15) using, in an analogous manner, the methods described above in Scheme a
Reaction II.
172
<img file="MX339989B_D0383.tif" />
The compounds of the general formula (19), in which D is as described above, can be prepared according to the methods of Reaction Scheme XIII. The compounds of the general formula (16) can be converted to the compounds of the general formula (17) using a Buchwald reaction with tert-butyl-2-carbamoylpyrrolidine-1-carboxylate. This Buchwald reaction can be carried out in the presence of a base (for example, cesium carbonate), a palladium catalyst (for example, tris (dibenzylideneacetone) dipalladium (0)), a phosphine-type ligand (for example, 4,5 -bis (diphenylphosphino) -9,9-dimethylxanthene) in solvent such as dioxane with heating to about 80-120 ° C. Intermediate (17) can be reduced to (18) and cyclized to (19) using, analogously, the conditions generally described in Reaction Scheme IV. Composites (19)
173
IMPI can also be made to react as illustrated '<sup>N</sup>& fe ^ £ yS $ & 3u • iííEHJSTWAC
<img file="MX339989B_D0384.tif" />
Reaction IV to provide the compounds of the invention.
XHI REACTION SCHEME
<img file="MX339989B_D0385.tif" />
Compounds of the invention of general formula (23), in which D is as described above, can be prepared according to the methods of Reaction Scheme XIV. Compounds (16) can be reacted with compound (20) using a Buchwald reaction as described in general terms in Reaction Scheme XIII to provide compounds (21). Compounds (21) can be reduced to compounds (22) and cyclized to (23) using, in an analogous manner, the conditions described in general terms in the above reaction schemes.
·_..—.......
174
<img file="MX339989B_D0386.tif" />
<img file="MX339989B_D0387.tif" />
The compounds of the invention of the general formula (29), in which R<sub>2</sub>or is -L<sub>S</sub>'-M'-L<sub>S</sub>-R<sub>D</sub> and D is as described above, they can be prepared according to the methods of Reaction Scheme XV. Compounds of formula (24) can be converted to compounds of formula (25) (Sonogashira reaction) by reaction with trimethylsilylacetylene, a palladium catalyst (for example, bis (triphenylphosphine) palladium (ll) chloride), a copper catalyst (eg, copper (l) iodide), and a base (eg, triethylamine) in which an amine-type base can also be used as a solvent. Compounds (25) can be silyl removed to obtain compounds (26) by reaction with a fluoride source (eg, tetrabutylammonium fluoride) in a solvent such as THF. Compounds (26) can be converted to compounds (27) by formation
175
IMPIfsB of the dianion of (26) with n-butyl-lltium and subsigg reaction ^^^ 'corlan:
INDUSTRIAL
<img file="MX339989B_D0388.tif" />
Weinreb amide (eg N- (tert-butoxycarbonyl) -L-prolin-N methoxy-N'methylamide). This reaction can be carried out in an appropriate solvent such as THF or dimethoxyethane. Compounds (27) can be converted to compounds (28) by reaction with hydrazine in a solvent such as ethanol. Compounds (28) can be converted to compounds (29) using the methods generally described in the above reaction schemes.
REACTION SCHEME XV
<img file="MX339989B_D0389.tif" />
<img file="MX339989B_D0390.tif" />
<img file="MX339989B_D0391.tif" />
The compounds of the invention of the general formula (34), in which R<sub>2</sub>or is -L<sub>s</sub>'-M'-L<sub>s</sub>-Rd and D is as described above, can be prepared according to the methods of Reaction Scheme XVI. Compounds (24) can be converted to compounds (30) by reacting (24) with
176
CO (g) under pressure (approx. 4.22 kg / m<sup>z</sup>) in (SáTeaerfeCitíÍNo
OF THE INDUSTRIAL FROFIEDAD
ΙΜΡΙ páTeaerfeCitíÍNo
FROM INDUSTRIAL FROFIDITY palladium catalyst (eg PdCI<sub>2</sub>(dppf)) in methanol as
<img file="MX339989B_D0392.tif" />
solvent and with heating around 100 ° C. Compounds (30) can be converted to compounds (31) by reaction with hydrazine in a solvent such as methanol with heating to about 60-80 ° C. Compounds (31) can be converted to compounds (32) by reaction with N-Boc-2cyan-pyrrolidine in the presence of a base (e.g. potassium carbonate) in a solvent such as butanol and with heating around 150 ° C with irradiation in a microwave reactor. Compounds (32) can be deprotected to obtain compounds (33) and acylated to obtain (34) using, in an analogous manner, the conditions generally described in the above reaction schemes.
REACTION SCHEME XVI (24)
MeO
<img file="MX339989B_D0393.tif" />
OMe (30)
HjNHN
<img file="MX339989B_D0394.tif" />
(31)
<img file="MX339989B_D0395.tif" />
(33) (34)
177
<img file="MX339989B_D0396.tif" />
Compounds of AaiTOrtaui Invention
INSTITUTO MEXICANO TC LA PROPIEDAD (38), in which R<sub>2</sub>or is -L<sub>s</sub>'-M'-L<sub>s</sub>-Rd and D is like<sup>Ix</sup>s ^ *<sup>l</sup>Described above, they can be prepared according to the Idfe rViéiódóé of Reaction Scheme XVII. Compounds of formula (24) can be converted to compounds (35) by reaction with CuCN in a solvent such as DMF and heating to about 160 ° C with microwave irradiation. Compounds (35) can be converted to compounds (36) by reaction with HCl (g) in anhydrous methanol at 0 ° C with heating to room temperature. Compounds (36) can be converted to compounds (37) by reaction with NH<sub>3</sub>(g) in anhydrous methanol at 0 ° C with warming to room temperature. Compounds (37) can be converted to compounds (38) by reaction with (41) in THF in the presence of a base (eg, potassium carbonate).
REACTION SCHEME XVII
<img file="MX339989B_D0397.tif" />
Compounds of formula (41), in which R<sub>20</sub> it is
-L<sub>s</sub>'-M'-L<sub>s</sub>-Rd, can be prepared using the methods of the
178
Reaction Scheme XVIII. Compounds convert to compounds (40) by sequential reaction of
<img file="MX339989B_D0398.tif" />
(39) with isobutyl chloroformate in THF at 0 ° C followed by diazomethane. Compounds (40) can be converted to compounds (41) by reaction with HBr in acetic acid.
REACTION SCHEME XVIII cAh
N> = °
R20 (39)
<img file="MX339989B_D0399.tif" />
N, (40)
<img file="MX339989B_D0400.tif" />
(48), in which R<sub>20</sub> is -L<sub>s</sub>'-M'-L<sub>s</sub>-Rd and D is as described above, can be prepared according to the methods of Reaction Scheme XIX. Compound (42) can be reacted with compound (43) using, analogously, the Lewis acid-mediated conditions described above in Reaction Scheme II to provide compound (44). Compound (44) can be sequentially converted to diol (45), mesylate (46) and cyclic intermediate (47) using, analogously, the conditions of Reaction Scheme II. Compounds (47) can be converted to compounds (48) by reaction with (20) under Buchwald conditions such as those referred to in Reaction Scheme XIV and described in
179
Reaction Scheme XIII.
IMPI
MEXICAN INSTITUTE OF INDUSTRIAL FROFIEDAD
<img file="MX339989B_D0401.tif" />
REACTION SCHEME XIX
<img file="MX339989B_D0402.tif" />
(48)
The compounds of the invention of the general formula (55), in which R<sub>2</sub>or is -L<sub>s</sub>'-M'-Ls-Rd and D is as described above, they can be prepared according to the methods of Reaction Scheme XX. Diethyl meso-2,5dibromoadipate (49) can be reacted with a D-NH amine<sub>2</sub> in a solvent such as THF, dioxane, or dimethoxyethane with heating to 50-100 ° C to obtain compounds (50). Compounds (50) can be converted to (51) by alkaline hydrolysis with a base (eg, NaOH, KOH) in a mixture of alcohol (eg, methanol, ethanol) and water for the solvent. Compounds (51) can be converted to (52) by first reacting with oxalyl chloride, and treating the intermediate acid chloride with diazomethane at 0 ° C. Compounds (52) can be converted to (53)
180
IMPI
<img file="MX339989B_D0403.tif" />
INSTITUTO MEXICANO, by reaction with aqueous HBr. Compounds<sup>01</sup>^^^^ p convert to compounds (54) by reaction with thiourea in ethanol or similar solvent. Compounds (54) can be converted to compounds (55) using, in an analogous manner, the conditions described above in Reaction Scheme II.
REACTION SCHEME XX
<img file="MX339989B_D0404.tif" />
The compounds of the invention of the general formula (60), in which R<sub>20</sub> is -L<sub>s</sub>'-M'-L<sub>s</sub>-Rd and D is as described above, they can be prepared according to the methods of Reaction Scheme XXI. Compound (56) can be reacted with compound (57) in pyridine with heating to about 135 ° C to form compound (58). Compound (58) can be converted to compounds (59) by
181 reaction of a D-NH amine<sub>2</sub> with POCI<sub>3</sub> Following
IMPI
<img file="MX339989B_D0405.tif" />
and heating to about 200 ° C in 1,2-dichlorobenzene. Compounds (59) can be converted to compounds (60) using, in an analogous manner, the conditions described above in Reaction Scheme VII.
REACTION SCHEME XXI
<img file="MX339989B_D0406.tif" />
<img file="MX339989B_D0407.tif" />
The compounds of the invention of the general formula (66), in which R<sub>2</sub>or is -Ls'-M'-Ls-Rd and D are as described above, can be prepared according to the methods of Reaction Scheme XXII. The compounds of the general formula (61) can be reacted with boron tribromide in dichloromethane at 0 ° C to obtain the compounds (62), which can be subjected to hydrogenation conditions using platinum oxide (II) to obtain the compounds (63). Coupling between compounds (63) and proline derivatives (64) can be carried out using the standard coupling conditions described above to obtain compounds (65), which are
182
ΙΜΡΙ
<img file="MX339989B_D0408.tif" />
^^ petA <sup>Μ £ Χ</sup>'<sup>€ ΑΝ</sup>θ can convert to (66) through the action of azodicaq'feeraíÉat diethyl and triphenylphosphine in THF.
REACTION SCHEME XXII
<img file="MX339989B_D0409.tif" />
The compounds of the invention of the general formula (74), in which R<sub>2</sub>or is -L<sub>s</sub>'-M'-L<sub>s</sub>-Rd and D is as described above, they can be prepared according to the methods of Reaction Scheme XXIII. Compound (67) can be converted to (68) by reduction of the nitro group using tin (ll) chloride in ethanol. Compound (69) can be made from
183
ΙΜ of (68) by peptide coupling with Boc-piwry ^ pM ^ gggu
<img file="MX339989B_D0410.tif" />
heating the resulting amide in acetic acid at 80 ° C. Compound (69) can be reacted with SEM-CI and diisopropylethylamine in dichloromethane to obtain (70), which can be coupled with (71) using a palladium catalyst such as
PXPd using a base such as cesium fluoride in a solvent such as Ν, Ν-dimethylformamide at 100 ° C to obtain (72). Compound (72) can be converted to (73) by reaction with Selectfluor® in a mixture of THF and water, followed by hydrogenation using 3% Pt on charcoal in ethyl acetate and then reduction using sodium borohydride in methanol. Compound (73) can be reacted with methanesulfonyl chloride and triethylamine in dichloromethane at -10 ° C, followed by addition of an amine (H<sub>2</sub>ND) to obtain an intermediate that can be converted to (74) by deprotection using 4N HCl in
1,4-dioxane and then by coupling with R<sub>20</sub>CO<sub>2</sub>H using the peptide coupling procedures described above.
REACTION SCHEME XXIII
Br
Br
NH
Br
N NH<sub>2 </sub>(67)
N (68) (69)
184
KtBes & b:
<img file="MX339989B_D0411.tif" />
The compounds of the invention of the general formula (81), in which R<sub>2</sub>or is -Ls'-M'-L<sub>s</sub>-Rd and D is as described above, can be prepared according to the methods of Reaction Scheme XXIV. Compound (75) can be converted to (76) using SnCI<sub>2</sub> in ethanol. Coupling (76) with (64) using the peptide coupling procedures described above to obtain an amide that can be heated in acetic acid at 100 ° C to obtain (77). Compound (77) can be reacted with SEM-CI and di-isopropylethylamine in dichloromethane to obtain (78), which can be reacted with (71) as described above to obtain (79). Compound (79) can be converted to (80) using Selectfluor® in a mixture of THF and water, followed by hydrogenation with Pt over
185
IMPI
<img file="MX339989B_D0412.tif" />
carbon in ethyl acetate and reduction with bordfflg ^ rtSp'ííl ^ yes
INDUSTRIAL methanol. Compound (80) can be converted to compounds (81) by mesylation with methanesulfonyl chloride and triethylamine at temperatures less than 0 ° C, followed by reaction with primary amine H<sub>2</sub>ND and deprotection using 4N HCl in 1,4-dioxane.
REACTION SCHEME XXIV
<img file="MX339989B_D0413.tif" />
(81)
186
Some amines, D-NH<sub>2</sub>, in the is
MEXICAN INSTITUTE OF PROPERTY
<img file="MX339989B_D0414.tif" />
above are represented by formula (84), '<sup>Nt</sup>5P ™ $ k can be prepared according to the method geιτκidI lllσπΠΓΠΤό éff the Reaction Scheme XXV, in which R<sub>N</sub> is as defined above (e.g. halogen, alkyl, haloalkyl) and R<sub>M </sub>is -N (RsRs') (for example, -NEt<sub>2</sub>), heterocyclyl (eg, pyrrolidin-1-yl, piperidin-1-yl, etc.), or -OR<sub>S</sub> (eg —Ot-butyl, -O-isopropyl, etc.). Fluoronitrobenzenes (82) can be reacted with an appropriate amine in the presence of dibasic potassium phosphate in a solvent such as DMSO optionally with heating to obtain intermediates (83), in which R<sub>M </sub>is -N (R<sub>S</sub>R<sub>S</sub> ) (for example, -NEt<sub>2</sub>) or heterocyclyl (eg pyrrolidin-1-yl, pi perid i n-1-yl, etc.). Fluoronitrobenzenes (82) can also be reacted with alkali metal alkoxides (e.g., potassium t-butoxide) to obtain intermediates (83), in which R<sub>M</sub> is -OR<sub>S</sub> (eg -Ot-butyl, -Oisopropyl, etc.). Intermediates (83) can be converted to (84) using well known nitro group reduction conditions. For example, (83) can be converted to (84) by catalytic hydrogenation using palladium on carbon. Alternatively, (83) can be converted to (84) by reaction with iron / ammonium chloride in THF / methanol / water as solvent. Other conditions for effecting nitro group reduction include those described in the above reaction schemes and those generally known to one of ordinary skill in the art.
187
<img file="MX339989B_D0415.tif" />
In the above reaction schemes, compounds are shown in which an aromatic ring (eg, phenyl) is substituted with groups in a particular regiochemistry (eg, para}. A para-substituted starting material or intermediate provides a product final with para substitution in the above reaction schemes. One skilled in the art understands that substitution in the above reaction schemes of a starting material or intermediate with a different regiochemistry (eg meta) could provide a final product with a different regiochemistry. For example, replacement of a para substituted starting material or intermediate in the above reaction schemes with a meta substituted starting material or intermediate could lead to a meta substituted product.
If a portion described in the present application (for example, -NH<sub>2</sub> or -OH) is not compatible with the synthesis methods, the moiety can be protected with an appropriate protecting group that is stable under the reaction conditions used in the methods.
The protecting group can be removed at an appropriate point in the reaction sequence to provide an intermediate or compound.
188
IMPI desired target. Protecting groups appropriSd ^ g / ^ '/ ^ d ^
INDUSTRIAL to protect or unprotect portions are well known in the art, examples of which can be found in Greene and Wuts, supra. Optimum reaction conditions and reaction times for each individual step may vary depending on the particular reactants used and the substituents present on the reactants used. Solvents, temperatures, and other reaction conditions can be readily chosen by one skilled in the art based on the present invention.
Other compounds of the invention can be prepared in a similar manner in accordance with the above reaction schemes as well as the procedures described in the following examples, as appreciated by those skilled in the art. It should be understood that the above-described reaction schemes and modalities and the following examples are provided by way of illustration, not limitation. Various changes and modifications within the scope of the present invention will become apparent to those skilled in the art from the present disclosure.
The following example compounds are named using either ChemDraw version 9.0 or ACD version 12 (ACD v12). Final compounds for Examples 1-50 are named using ChemDraw unless stated to be named using ACD v12. Final compounds after Example 50 are named using ACD v12. Intermediaries are named using
I
ChemDraw, unless stated to be named using ACD
<img file="MX339989B_D0416.tif" />
189
Some compounds in the following Examples are ν12.
ΙΜΡΙ
MEXICAN INSTITUTE OF PROPERTY
INDUSTRIAL
<img file="MX339989B_D0417.tif" />
purify using reverse phase HPLC. Purification is accomplished using either a C18 or C8 reverse phase column. Compounds are eluted using a gradient of 10-100% acetonitrile in 0.1% aqueous TFA; about 60-100% methanol in 10 mM aqueous ammonium acetate; or about 1095% methanol in 10 mM aqueous ammonium acetate. For purifications carried out with TFA, the product obtained in this way may be in the form of a TFA salt. Compounds can be characterized as the TFA salt or as the free base after neutralization, extraction, and isolation.
Some compounds in the following Examples are purified using normal phase silica gel chromatography including traditional flash chromatography or an automated purification system (e.g. Isco Combi-Flash, Analogix Intelliflash) using prepackaged silica gel columns (Columns Isco gold, 55 or 35 pm silica gel).
Typical solvents for silica gel chromatography include: ethyl acetate in hexanes, diethyl ether in hexanes, THF in hexanes, ethyl acetate in methylene chloride, methanol in methylene chloride, methanol in methylene chloride with NH<sub>4</sub>OH, acetone in hexanes, and methylene chloride in hexanes.
190
EXAMPLE 1
IMPI
MEXICAN INSTITUTE OF INDUSTRIAL PROPERTY
<img file="MX339989B_D0418.tif" />
(2S.2'S) -1.1 '- ((2S.2'S) -2.2' - (4.4 '- ((2S.5S) -1- (4-fluorophenyl) p¡rrol¡d¡n2.5-di -il) bis (4,1-phenylene)) b¡s (azand¡¡l) bis (oxomethyl) bisipyrrolidin-2,1-di-yl)) bis (3,3-di-methyl- Dimethyl 1-oxobutan-2.1-d¡-Ddicarbamate and
(2S, 2<sup>,</sup>S) -1.1<sup>,</sup>- ((2S.2'S) -2.2 '- (4.4<sup>,</sup>- ((2R, 5R) -1- (4-fluorophenyl) pyrro! Idi n-2,5-di-iDbis (4,1 -phenylene Dbistazandiyl) bisfoxomethiien) bisphpyrroledin-2,1-di-yl)) bis (3.3 dimethyl -d¡methyl-1oxobutan-2,1-di-¡Dd¡carbamate
<img file="MX339989B_D0419.tif" />
1,4-Bis (4-nitrophenyl) butane-1,4-dione
Anhydrous zinc (ll) chloride (2.73 g, 20.00 mmol) is stirred in dry benzene (15 ml) while adding
191
IMPI
MEXICAN INSTITUTE
<img file="MX339989B_D0420.tif" />
diethylamine (1.558 ml, 15.00 mmol) and t-butanol mmol), and the resulting mixture was stirred at room temperature for 90 minutes to obtain a cloudy solution. To this mixture 2-bromo-1- (4-nitrophenyl) ethanone (2.44 g, 10.00 mmol) and 1- (4-nitrophenyl) ethanone (2.477 g, 15.00 mmol) are added, and the resulting mixture is stir at room temperature overnight. The mixture is poured into water (50 ml) and extracted with ethyl acetate (3 x 50 ml). The combined organic layers are dried over Na<sub>2</sub>SW<sub>4</sub>, filter and concentrate. The resulting residue is triturated with dichloromethane to obtain an orange solid which is collected by filtration and dried to obtain the title compound (2.0 gm, 61% yield).
EXAMPLE 1B
1,4-b¡s (4-nitrophen ¡l) butan-1,4-diol
To a solution of the product of Example 1A (1.0 g, 3.05 mmol) in anhydrous THF (30 ml) at 0 ° C is added sodium borohydride (0.357 g, 9.44 mmol). The resulting mixture is stirred at 50 ° C overnight. The cold mixture is poured into water, extracted with ethyl acetate, dried over Na<sub>2</sub>SW<sub>4</sub>, filter and concentrate in vacuo. The resulting solid is triturated with dichloromethane to obtain a tan solid which is collected by filtration and dried to obtain the title compound (0.82 gm, 81% yield).
192
EXAMPLE 1C
1,4-bis (4-nitrophenyl) butane-1,4-di-yl dimethanesulfonate
ΙΜΡΪ
MEXICAN INSTITUTE OF INDUSTRIAL PROPERTY
<img file="MX339989B_D0421.tif" />
To a solution of the product of Example 1.B (0.80 g, 2.407 mmol) in CH<sub>2</sub>CI<sub>2</sub> dry (25 ml) at 0 ° C add triethylamine (1,007 ml, 7.22 mmol), followed by dropwise addition of methanesulfonyl chloride (0.469 ml, 6.02 mmol). The resulting mixture is stirred at 0 ° C for 30 minutes, during which time the starting material slowly passes into solution. After stirring an additional 1 hour at 0 ° C, a precipitate begins to form. NH is added<sub>4</sub>Saturated aqueous CI (4 ml), and continue stirring at room temperature for 20 minutes. The mixture is washed with water (2x10 ml), and the organic layer is treated with hexanes (10 ml) to obtain an orange solid that is collected by filtration to obtain the title compound (0.75 gm, 64% yield) .
EXAMPLE 1D
- (4-fluorophenyl) -2.5-b¡s (4-nitrofenit) pyrrolidine
The product of Example 1C (0.6 gm, 1,228 mmol) and 4-fluoroaniline (2.0 ml, 20.82 mmol) are combined and stirred at 50 ° C overnight. The resulting mixture is partitioned between 0.2 N HCI (50 ml) and ethyl acetate (3 x 50 ml), and the combined organic layers are dried with Na<sub>2</sub>SW<sub>4</sub>, filtered and concentrated in vacuo. The crude product is purified by chromatography on silica gel
CM
193 using a solvent gradient of 0-40% of
IJV
<img file="MX339989B_D0422.tif" />
hexane to obtain the title compound as a mixture of the cis and trans isomers (0.5 gm, 100% yield).
EXAMPLE 1E
4.4 '- (1- (4-fluorophenyl) pyrroledin-2,5-di-¡l) dianiline
Iron powder (0.412 g, 7.38 mmol) and a solution of ammonium chloride (0.197 g,
3.69 mmol) in water (1.0 ml). The resulting mixture is stirred at 80 ° C for 45 minutes. The mixture is cooled, filtered through celite, washed with ethanol, and concentrated in vacuo. The crude product is purified by silica gel chromatography using a solvent gradient of 0-100% ethyl acetate in hexanes to obtain the title compound as a mixture of the cis and trans isomers (0.135 gm, 32%).
EXAMPLE 1F (25.2 ^) - 2.2 ^ (4.4 ^ (1 - (4-fluorophen¡l) pyrroledin-2.5-d¡-¡l) b¡s (4.1phenyl) ) bis (azandi-l) bis (oxomethylene) dipyrrolidin-1-d-butyiocarboxylate
To a mixture of the product of Example 1E (0.13 gm, 0.374 mmol), (S) -1- (tert-butoxycarbonyl) pyrrolodin-2-carboxylic acid
194
IMPI
<img file="MX339989B_D0423.tif" />
(0.201 gm, 0.935 mmol) and HATU (0.356 gm, O. ^ W¡ ^ <^^ s DMSO (3 ml) Hunig's base (0.196 ml, 1.123 mmol) is added, and the reaction mixture is stirred at temperature ambient for 90 minutes The mixture is poured into water and extracted with ethyl acetate The organic extract is dried with Na<sub>2</sub>SW<sub>4</sub>, filtered and concentrated in vacuo to obtain a crude product which is purified by silica gel column chromatography, eluting with a solvent gradient of 5-100% ethyl acetate in hexane to obtain the title compound (0.28 gm, 100%).
EXAMPLE 1G (2S, 2'S) -N.N '- (4.4' - (1- (4-fluorophen¡l) p¡rrolidin-2,5-d¡-¡l) b¡s (4,1phenylene)) d¡pyrrol¡din-2-carboxamide
To the product of Example 1F (0.28 gm, 0.377 mmol) in CH<sub>2</sub>CI<sub>2</sub> (2.0 mi) TFA (2.0 mi) is added. The reaction mixture is stirred at room temperature for 45 minutes and concentrated in vacuo. The residue is partitioned into CH<sub>2</sub>CI<sub>2</sub>: 2-PrOH 3: 1 and NaHCO<sub>3 </sub>saturated aqueous. The organic layer is dried over Na<sub>2</sub>SW<sub>4</sub>, filtered, and concentrated to obtain the title compound (0.195 gm, 95% yield).
EXAMPLE 1H (2S, 2'S) -1.1 '- ((2S, 2'S) -2.2' - (4.4 '- ((2S, 5S) -1- (4-fluorophenylipyrrolidin2,5-di -¡L) b¡s (4,1-fen8len)) b¡s (azand¡195 'IMPI
1Ι) βΐ5 (θ2! Οητθ1ίΐΘη) Ν5ίρΗΎοΙίάίη-2 ^ 1_-άΜΙ)) 5ί5 ^ 3Έ «ί« ϊ ^ ΐ! Ϊ́2 {^ '<sup>! ΐΛ</sup>ίΓ
.....-——* <sup>1</sup> 'ί nf f.Á PRCPfEUXiy "
INDUSTRIAL --oxobutan-2.1-d¡-¡l) dimethyl dicarbamate and
(2S.2<sup>,</sup>S) -1.1<sup>,</sup>-i (2S.2<sup>,</sup>S) -2.2<sup>,</sup>-(4.4<sup>,</sup>- (2R.5R) -1- (4-fluorophenyl) pyrrol¡d¡n-2,5-di-yl) b¡s (4,1-phenylen)) b¡s (azandiyl) bis (oxomet ¡Len) bis (p¡rrol¡d¡n-2,1-d¡-yl)) b¡s (3,3-dimethyl-1oxobutan-2,1-di-yl Dimethyl dicarbamate
To a mixture of the product of Example 1G (0.03 gm, 0.055 mmol), (S) -2- (methoxycarbonylamino) -3,3-dimethylbutanoic acid (0.0262 gm, 0.138 mmol) and HATU (0.0526 gm, 0.138 mmol) in DMSO (0.5 ml) Hunig's base (0.029 ml, 0.166 mmol) is added, and the resulting mixture is stirred at room temperature for 90 minutes. The mixture is poured into water (2 ml) and extracted with ethyl acetate (2x2 ml), and the combined organic layers are concentrated and subjected to HPLC purification on a semi-preparative C18 reverse phase column using a gradient of 10-100% acetonitrile in 0.1% aqueous TFA. The trans-substituted pyrrolidine isomer is the first of the 2 stereoisomers to elute, providing the title compound as a 1: 1 mixture of dlastereomers (0.014 gm, 29% yield).
<sup>1</sup>H NMR (TFA salt) (400 MHz, DMSO-D6) δ ppm 0.931.01 (m, J = 4.99 Hz, 18H) 1.62 - 1.68 (m, 2H) 1.81 - 1.93 (m, 6H)
1.94 - 2.04 (m, 2H) 2.09 - 2.20 (m, 2H) 3.54 (s, 6H) 3.59 - 3.69 (m,
H) 3.73 - 3.81 (m, 2 H) 4.18 - 4.24 (m, 2 H) 4.43 (dd, J = 7.81, 5.42
196
Hz, 2 Η) 5.16 (d, 2 Η) 6.20 (dd, J = 9.05, 4.39 Hz «,. 2JH £« # g ^ t<sub>b</sub>
OF THE PROPERTY _
Hz, 2H) 7.09 (d, J = 8.89 Hz, 2H) 7.12 (d, 4H) 7.50 (d.TOfc HzTT<sup>-</sup>
H) 9.99 (s, 2H).
<img file="MX339989B_D0424.tif" />
The title compound shows an EC value<sub>50</sub> less than about 0.1 nM in HCV 1b-Con1 replicon tests in the presence of 5% FBS. The 1b-Con1 replicon test is described below.
EXAMPLE 2 (2S, 2<sup>,</sup>S) -1.1 '- ((2S.2<sup>,</sup>S) -2.2<sup>,</sup>- (4,4 '- ((2S, 5R) -1- (4-fluorophenyl) pyrrolidin2.5-di-yl) bis (4.1-phenylene)) bis (azandiyl) bis (oxomethylene) bis (pyrro-idin- 2,1-di-yl)) bis (3,3-dimethyl-1-oxobutan-2,1-d¡-! Dimethyl idicarbamate
<img file="MX339989B_D0425.tif" />
To a mixture of the product of Example 1G (0.03 gm, 0.055 mmol), (S) -2- (methoxycarbonylamino) -3,3-dimethylbutanoic acid (0.0262 gm, 0.138 mmol) and HATU (0.0526 gm, 0.138 mmol) in DMSO (0.5 ml) Hunig's base (0.029 ml, 0.166 mmol) is added, and the resulting mixture is stirred at room temperature for 90 minutes. The mixture is poured into water (2 ml) and
197 extract with ethyl acetate (2x2 ml) *
IMPI
I.9S
OF INDUSTRIAL PROPERTY
<img file="MX339989B_D0426.tif" />
Combines are concentrated and subjected to HPLC purification on a semi-preparative C18 reversed phase column using a gradient of 10-100% acetonitrile in 0.1% aqueous TFA. The cis-substituted pyrrolidine isomer is the second of the 2 stereoisomers to elute, providing the title compound (0.018 gm, 37% yield).
<sup>1</sup>H NMR (TFA salt) (400 MHz, DMSO-D6) δ ppm 0.93 1.01 (m, J = 3.04 Hz, 18H) 1.75 - 1.94 (m, 6H) 1.94 - 2.05 (m, 2H)
2.11 - 2.22 (m, 2H) 2.31 - 2.35 (m, 1H) 3.54 (s, 6H) 3.61 - 3.70 (m, 2H) 3.74 - 3.83 (m, 2H) 4.22 (d, J = 8.78 Hz, 2H) 4.46 (dd, J = 8.02,
5.42 Hz, 2H) 4.65 (t, 2H) 6.34 (dd, 2H) 6.86 (t, J = 8.89 Hz, 2H) 7.08 (d, 2H) 7.43 (d, J = 7.81 Hz, 4H ) 7.60 (d, J = 8.57 Hz, 4H) 10.05 (s, 2H).
The title compound shows an EC value<sub>50</sub> less than about 0.1 nM in HCV 1b-Con1 replicon tests in the presence of 5% FBS.
EXAMPLE 3 (2S.2<sup>l</sup>S) -1.1 '- ((2S.2'S) -2.2' - (4,4 '- ((2S.5S) -1- (4-fluorophen¡hp¡rrolidin2,5-d¡-¡l) bis ( 4.1-phenylene)) b¡s (azandiyl) b¡s (oxomethyl) bis (pyrrolidin-2,1-di-yl)) bis (3,3-dimethyl-1oxobutan- 2,1-d¡-yl) d¡carbamate of dimetSlo
198
<img file="MX339989B_D0427.tif" />
<img file="MX339989B_D0428.tif" />
ΙΜΡΙ
MEXICAN INSTITUTE OF INDUSTRIAL PROPERTY
<img file="MX339989B_D0429.tif" />
The product from Example 1H is purified by chiral chromatography on a semi-preparatlva AD-H Chiralpak column eluting with a 1: 1 mixture of hexanes: (2: 1 IPA: EtOH). The title compound is the first of the 2 stereoisomers to elute.
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ ppm 0.97 (s, 18H) 1.61 1.67 (m, J = 5.64 Hz, 2H) 1.79 - 1.92 (m, 6H) 1.93 - 2.04 (m, J = 5.86 Hz, 2H) 2.07 - 2.20 (m, J = 6.51 Hz, 2H) 3.54 (s, 6H) 3.59 - 3.69 (m, 2H) 3.71 - 3.83 (m, 2H) 4.21 (d, J = 8.89 Hz, 2H) 4.43 (dd, J = 7.97,
5.37 Hz, 2H) 5.15 (d, J = 6.51 Hz, 2H) 6.20 (dd, 2H) 6.78 (t, J = 8.95 Hz, 2H) 7.13 (d, J = 8.57 Hz, 4H) 7.50 (d, J = 8.57 Hz, 4H) 9.99 (s, 2H).
The title compound shows an EC value<sub>50</sub> less than about 0.1 nM in HCV 1b-Con1 replicon tests in the presence of 5% FBS.
EXAMPLE 4 (2S, 2<sup>,</sup>S) -1.1 * - ((2S.2 * S) -2.2<sup>,</sup>-(4.4<sup>,</sup>- ((2R.5R) -1- (4fluorophenyl) pyrrolidin-2.5-di-yl) bisf4.1-phenylene)) bis (azandiyl) bis (oxomethylene) bi (pyrrolidin-2,1-di-yl)) bis (3.3-dim til-1199
<img file="MX339989B_D0430.tif" />
The product from Example 1H is separated by chiral chromatography on an AD-H Chiralpak semi-preparative column eluting with a 1: 1 mixture of hexanes: (IPA: EtOH 2: 1). The title compound is the second of the 2 stereoisomers to elute.
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ ppm 0.96 (s, 18H) 1.64 (d, J = 5.53 Hz, 2H) 1.78 - 1.93 (m, 6H) 1.94 - 2.06 (m, 2H) 2.09 2.21 (m, 2H) 3.54 (s, 6H) 3.59 - 3.69 (m, 2H) 3.72 - 3.83 (m, 2H)
4.20 (d, J = 8.89 Hz, 2H) 4.43 (dd, J = 7.92, 5.42 Hz, 2H) 5.16 (d, J = 6.29 Hz, 2H) 6.20 (dd, J = 9.16, 4.39 Hz, 2 H) 6.77 (t, J = 8.95 Hz, 2H) 7.12 (d, J = 8.57 Hz, 4H) 7.50 (d, J = 8.57 Hz, 4H) 9.99 (s, 2H).
The title compound shows an EC50 value of less than about 0.1 nM in the HCV 1b-Con1 replicon tests in the presence of 5% FBS.
EXAMPLE 5 (2S, 2'S) -1.1 '- ((2S, 2'S) -2.2' - (4.4 '- ((2S, 5S) -1- (4-fl uoropheni l) p¡ rrolidi n2,5-d¡-¡l) b¡s (4,1-phenylene)) bis (azandiyl) b¡ (oxom t¡len) b¡s (pyrrolidin-2.1-d¡-yl) ) b¡s (1-oxobutan-2.1-di-il) 200
<img file="MX339989B_D0431.tif" />
dimethyl dicarbamate <sup>;</sup> and
(2S, 2<sup>,</sup>S) -1.1 '- (f2S, 2'S) -2.2<sup>,</sup>- (4,4 '- ((2R, 5R) -1- (4fluorophenyl) p¡rrol¡din-2,5-d¡-il) b¡s (4,1-phenylene)) bis (azandiyl ) dimethio) bis (oxomethylene) bis (pyrrolidin-2.1-di-yl)) b¡s (1-oxobutan-2,1-di-yl) dicarbamate
<img file="MX339989B_D0432.tif" />
EXAMPLE 5A
4,4 '- ((2S, 5S) -1 - (4-fluorophenyl) pyrro! Idin-2,5-di-yl | dianiline and 4,4'Í (2R, 5R) -1 - (4-fluorophenyl ) pyrolidin-2.5-di-yl) dianilin
The product from Example 1E is purified by silica gel column chromatography, eluting with a solvent gradient of 0-100% ethyl acetate in hexanes. The title compound elutes as the first of 2 stereoisomers and is obtained as a racemic mixture of trans diastereomers.
201
IMPI
<img file="MX339989B_D0433.tif" />
MEXICAN INSTITUTE <sup>1</sup>H NMR (400 MHz, DMSO-D6) δ ppm 1.57 ^ «β ^ 6
H) 2.36 - 2.42 (m, 2H) 4.86 - 4.91 (m, 4H) 4.96 (d. J = 6.61 Hz. 2 H1
6.17 - 6.25 (m, 2H) 6.47 (d, J = 8.35Hz, 4H) 6.74 (t, 2H) 6.82 (d, J = 8.35Hz, 4H).
EXAMPLE 5B (2S.2'S) -2.2 '- (4.4' - ((2S, 5S) -1- (4-fluorophenyl) prolidene-2.5-diII) bis (4.1 -phenylene )) bis (azandi-yl) bis (oxomethylene) dipyrrolidin-1-carboxylate tert-butyl y (2S, 2'S) -2.2<sup>,</sup>-(4.4<sup>,</sup>- ((2R, 5R) -1- (4-fluorophenyl) pyrorole din-2,5-d ii l) bis (4.1 -phenylene)) bis (azandiyl) bis (oxomethylene) dipyrrolidine-1-carboxylate of ter -butyl
The product of Example 5 A (50 mg, 0.144 mmol) is subjected to the conditions described in Example 1F to obtain the title compound as a 1: 1 mixture of dlastereomers (105 mg, 98%).
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ ppm 1.34 (d, 18H) 1.66 (d, J = 5.10 Hz, 2H) 1.74 - 1.89 (m, 6H) 2.07 - 2.23 (m, 2H) 4.15 4.25 (m, 2H) 5.18 (d, J = 3.47 Hz, 2H) 6.18 - 6.25 (m, 2H) 6.78 (t, J = 8.95 Hz, 2H) 7.14 (d, J = 8.24 Hz, 4 H) 7.51 (t, J = 8.29 Hz, 4H) 9.92 (d, 2H).
EXAMPLE 5C (2S.2<sup>,</sup>S) -NN<sup>,</sup>-(4,4<sup>,</sup>- ((2S, 5S) -1- (4-fluorofer> yl) pyrrolidin-2,5-diyl) bi (4,1-f nilen)) dip¡rrol¡d¡n-2-carboxamide and (2S, 2'S) -N, N '- (4.4'202
WICKED?
((2R.5R) -1- (4-fluorophenyl) pyrrolidin-2.5-d¡-Nsyfaigi
INDUSTRIAL phenylene)) dipyrrolidine-2-carboxamide
The product of Example 5B is subjected to the conditions described in Example 1G to obtain the title compound as a 1: 1 mixture of diastereomers.
EXAMPLE 5D (2S.2<sup>,</sup>S) -1.1 '- ((2S.2<sup>,</sup>S) -2.2<sup>,</sup>-(4.4<sup>,</sup>- ((2S, 5S) -1- (4-fluorophenyl) pyrrolidin2.5-di-¡l) bis (4,1-phenylene)) bis (azandiyl) b¡s (oxomethylene) bis (pyrrole ¡di n-2,1-di-yl)) bis (1-oxobutan-2,1-d¡¡Ddicarbamate of dimethyl and (2S, 2'S) -1.1 '- ((2S, 2'S) -2.2' - ( 4.4 '((2R, 5R) -1- (4-fluorophenyl) p¡rrol¡d¡n-2,5-di-il) b¡s (4,1fen¡len)) bis (azandi-il ) bis (oxomethylene) bis (pyrrole di-n-2,1-di-yl)) bis (1 oxobutan-2,1-di-yl) dimethyl dicarbamate
A mixture of the product of Example 5C (0.102 g, 0.188 mmol), (S) -2- (methoxycarbonylamino) butanoic acid (0.064 g, 0.395 mmol) and HATU (0.150 g, 0.395 mmol) in DMSO (2 ml) was Add Hunig's base (0.099 ml, 0.565 mmol), and the reaction is stirred at room temperature for 45 minutes. The reaction mixture is partitioned between water and ethyl acetate, and the organic layer is dried with Na<sub>2</sub>SW<sub>4</sub>, filter and concentrate in vacuo. The crude product is purified by silica gel column chromatography using a solvent gradient of 0-4% MeOH in
203
IMPI ^
..,. ,. . . ,,. . . , MEXICAN INSTITUTE, dichloromethane to obtain the title compound conw - ^^^ eí
1: 1 stereoisomers (0.158 gm, 94% yield).
1H NMR (400 MHz, DMSO-D6) δ ppm 0.86 - 0.96 (m, 6 H)
1.53 (d, J = 4.34 Hz, 2 H) 1.59 - 1.73 (m, 2 H) 1.80 - 1.96 (m, J = 6.29
Hz, 4H) 1.96 - 2.06 (m, 2H) 2.08 - 2.20 (m, 2H) 3.52 (s, 6H) 3.67 3.79 (m, 2H) 4.12 - 4.23 (m, 2H) 4.42 (dd , J = 8.13, 4.66 Hz, 2 H)
5.16 (d, J = 6.40 Hz, 2H) 6.20 (dd, J = 9.22, 4.45 Hz, 2H) 6.77 (t, J = 8.89 Hz, 2H) 7.12 (d, J = 7.59 Hz, 4H) 7.30 (dd, J = 7.59, 3.25 Hz, 2H) 7.50 (d, J = 8.24 Hz, 4H) 8.16 (s, 2H) 9.95 (s, 2H).
The title compound shows an EC value<sub>50</sub> from about 0.1 to about 1 nM in the HCV 1b-Con1 replicon tests in the presence of 5% FBS.
EXAMPLE 6 (2S, 2'S) -1.1 '- ((2S, 2<sup>l</sup>S) -2.2 '- (4.4<sup>,</sup>- ((2S, 5S) -1- (4-fluorophenyl) plrrolidin2.5-di-yl) bis (4,1-phenylene)) bis (azandii I) bis (oxomethylene) bis (pyrrole idln- Dimethyl 2,1-di-yl)) bis (3-hydroxy-3-methyl-1-oxobutan-2,1-di-i D-dicarbamate and
(2S.2'S) -1.1 '- ((2S.2<sup>,</sup>S) -2.2<sup>,</sup>-(4.4<sup>l</sup>- ((2R.5R) -1- (4fluorophenyl) pyrrolidin-2.5-di-yl) bis (4.1-phenylene)) bis (azandiyl) bis (oxomethyl) bis (pyrrolidin-2,1-di-yl) ) dimethyl b¡s (3-hydroxy-3-methyl-1oxobutan-2,1-d¡-¡l) dicarbamate
204
<img file="MX339989B_D0434.tif" />
To a mixture of the product of Example 5C (0.1 g, 0.185 mmol), (S) -3-hydroxy-2- (methoxycarbonylamino) -3-methylbutanoic acid (0.074 g, 0.388 mmol) and HATU (0.147 g, 0.388 mmol) Hunig's base (0.097 ml, 0.554 mmol) is added to DMSO (2 ml), and the reaction mixture is stirred at room temperature for 45 minutes. The reaction mixture is partitioned between water and ethyl acetate, and the organic layer is dried over Na.<sub>2</sub>SW<sub>4</sub>, filter and concentrate in vacuo. The crude product is purified by silica gel column chromatography using a solvent gradient of 0-4% MeOH in dichloromethane to obtain the title compound as a 1: 1 mixture of stereoisomers (0.162 gm, 97% yield) .
1H NMR (400 MHz, DMSO-D6) δ ppm 1.15 (d, J = 10.19 Hz,
H) 1.64 (d, J = 5.64 Hz, 2H) 1.87 - 1.98 (m, 6H) 2.09 - 2.22 (m, 2
H) 3.55 (s, 6H) 3.58 - 3.66 (m, 2H) 3.66 - 3.74 (m, 2H) 3.83 - 3.92 (m, 2H) 4.37 (s, 2H) 4.44 - 4.50 (m, 2 H) 5.07 (s, 2H) 5.11 (s, 2H)
205
5.17 (d, J = 6.18 Hz, 2H) 6.15 - 6.28 (m, 2H) 6.78
<img file="MX339989B_D0435.tif" />
7.13 (d, J = 8.13 Hz, 4H) 7.51 (d, J = 7.81 Hz, 4H) 8.11 - 8.23 (m, 2H) 9.67 (d, J = 9.11 Hz, 2H).
The title compound shows an EC value<sub>50</sub> less than about 0.1 nM in HCV 1b-Con1 replicon tests in the presence of 5% FBS.
EXAMPLE 7 (2S, 2'S, 3R, 3'R) -1.1 '- ((2S, 2'S) -2.2' - (4.4 '- ((2S.5S) -1- (4fluorophenyl) pyrrolidine -2,5-di-yl) bis (4.1-phenylene)) bis (azandiyl) bis (oxomethylene) b¡s (pyrrrolidin-2,1-di-¡l)) bis (3-methoxy- Dimethyl 1-oxobutan2.1-di-yl) dicarbamate (2S, 2'S, 3R, 3'R) -1,1 '- ((2S, 2<sup>,</sup>S) -2,2 '- (4,4' - ((2R, 5R) -1- (4fluorophenyl) pyrrolidin-2,5-di-yl) bis (4.1-phenylene)) bis (azandiyl) Dimethyl bis (oxomethylene) bis (pyrrolidin-2,1-di-yl)) b¡s (3-methoxy-1-oxobutan-2,1-di-yl) d¡carbamate
<img file="MX339989B_D0436.tif" />
'?
+
OR
F
<img file="MX339989B_D0437.tif" />
206
To a mixture of the product of the Exempl) OWN MtWCA
INDUSTRIAL
<img file="MX339989B_D0438.tif" />
<img file="MX339989B_D0439.tif" />
0.046 mmol), (2S, 3R) -3-methoxy-2 (methoxycarbonylamino) butanoic acid (0.01941 gm, 0.102 mmol) and HATU (0.0439 gm, 0.115 mmol) in DMSO (0.2 ml) Hunig's base (0.024 ml) is added , 0.138 mmol). The mixture is stirred at room temperature for 2 hours, and then poured into water and extracted with ethyl acetate. The organic phase is dried with Na<sub>2</sub>SW<sub>4</sub>, filtered and concentrated in vacuo, and the crude product is purified by chromatography on silica gel using a solvent gradient of 0-5% MeOH in CH<sub>2</sub>CI<sub>2</sub> to obtain the title compound (0.040 gm, 93% yield).
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ ppm 1.09 - 1.31 (m, 6 H)
1.64 (d, J = 5.10 Hz, 2H) 1.83 - 1.93 (m, J = 12.42, 12.42 Hz, 4H) 1.93 - 2.03 (m, 2H) 2.11 - 2.19 (m, 2H) 3.10 - 3.18 ( m, J = 6.94 Hz, 2 H)
3.24 (d, J = 4.99 Hz, 6H) 3.42 - 3.49 (m, J = 10.84, 6.72 Hz, 2H) 3.53 (s, 6H) 3.58 - 3.70 (m, 2H) 3.79 - 3.89 (m, 2 H) 4.26 (t, J = 7.10 Hz, 2
H) 4.41 (dd, J = 7.97, 4.93 Hz, 2 H) 5.16 (d, J = 6.29 Hz, 2 H) 6.20 (dd,
J = 9.11, 4.34 Hz, 2H) 6.78 (t, J = 8.95 Hz, 2H) 7.12 (d, 4H) 7.33 (dd,
J = 7.70, 3.47 Hz, 2H) 7.50 (d, J = 8.13 Hz, 4H) 9.95 (s, 2H).
The title compound shows an EC value<sub>50</sub> from about 0.1 to about 1 nM in the HCV 1b-Con1 replicon tests in the presence of 5% FBS.
207
ΙΜΡΐς
EXAMPLE 8 (2S, 2'S, 3R, 3 'R) -1.1' - ((2S.2'S) -2.2 '- (4.4' - ((2S, 5SI-1- (4 -__
MEXICAN INSTITUTE OF INDUSTRIAL PROPERTY
<img file="MX339989B_D0440.tif" />
Fluorophenyl) p¡rrol¡d¡n-2,5-d¡-yl) bis (4.1-phenyl)) b¡s (azandiyl) b¡s (oxomethylene) b¡s (pyrrol¡din- Dimethyl 2.1-d¡-yl)) b¡s (3-methoxy-1-oxobutan2,1-d¡-yl) d¡carbamate
<img file="MX339989B_D0441.tif" />
The product from Example 7 is purified by chiral chromatography on a semi-preparative AD-H Chiralpak column eluting with a 1: 3 mixture of hexanes: (IPA: EtOH 1: 1). The title compound is the first of the 2 stereoisomers to elute.
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ ppm 1.13 (d, J = 6.18 Hz, 6H) 1.64 (d, J = 5.64 Hz, 2H) 1.82 - 1.93 (m, 4H) 1.95 - 2.04 (m , 2 H)
2.10 - 2.19 (m, 2H) 3.25 (s, 6H) 3.44 - 3.48 (m, 2H) 3.53 (s, 6H)
3.62 - 3.71 (m, 2H) 3.79 - 3.87 (m, 2H) 4.26 (t, J = 7.75 Hz, 2H) 4.41 (dd, J = 7.92, 4.99 Hz, 2H) 5.16 (d, J = 6.51 Hz, 2H) 6.20 (dd, J = 9.16,
4.39 Hz, 2H) 6.78 (t, J = 8.89 Hz, 2H) 7.13 (d, J = 8.57 Hz, 4H) 7.34 (d, J = 7.92 Hz, 2H) 7.50 (d, J = 8.57 Hz , 4H) 9.95 (s, 2H).
The title compound shows an EC value<sub>50</sub> less than about 0.1 nM in HCV 1b-Con1 replicon tests in the presence of 5% FBS.
208
IMPIéÜ
MEXICAN INSTITUTE
OF THE PROPERTY
INDUSTRIAL
EXAMPLE 9 (2S.2'S.3R.3'R) -1.1'-í (2S.2'S) -2.2<sup>,</sup>- (4.4 '- ((2R.5R) -1- (4fluorophen¡l) p¡rrol¡din-2.5-d¡-yl) b¡s (4.1-phenylene)) b¡s (azand¡¡l) dimethyl b¡s (oxomethylene) bis (p¡rrol¡din-2,1-d¡-¡l)) b¡s (3-methox¡-1-oxobutan2,1-di-¡l) dicarbamate
<img file="MX339989B_D0442.tif" />
The product from Example 7 is purified by chiral chromatography on a semi-preparative AD-H Chiralpak column eluting with a 1: 3 mixture of hexanes: (IPA: EtOH 1: 1). The title compound is the second of the 2 stereoisomers to elute.
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ ppm 1.12 (d, J = 6.18 Hz, 6H) 1.64 (d, J = 5.64 Hz, 2H) 1.82 - 1.93 (m, 4H) 1.95 - 2.06 (m , 2 H)
2.10 - 2.21 (m, 2H) 3.24 (s, 6H) 3.42 - 3.48 (m, 2H) 3.53 (s, 6H)
3.61 - 3.73 (m, 2 H) 3.78 - 3.88 (m, 2 H) 4.26 (t, J = 7.75 Hz, 2 H) 4.41 (dd, J = 7.92, 4.99 Hz, 2 H) 5.16 (d, J = 6.18 Hz, 2H) 6.20 (dd, 2H)
6.78 (t, J = 8.89 Hz, 2 H) 7.13 (d, J = 8.46 Hz, 4 H) 7.33 (d, J = 7.81 Hz, 2 H) 7.49 (d, J = 8.46 Hz, 4 H) 9.95 ( s, 2H).
The title compound shows an EC value<sub>50</sub> from about 0.1 to about 1 nM in the tests of
209 HCV 1b-Con1 replicon in the presence of
FBS 'to
IMPI @
WSWTJTD MEXICAN D ΥΦΕ LA PSOriEDAD
INDUSTRIAL
<img file="MX339989B_D0443.tif" />
EXAMPLE 10 (2S.2<sup>,</sup>S) -1.1<sup>,</sup>- ((2S, 2<sup>,</sup>S) -2.2<sup>,</sup>-(4.4<sup>,</sup>- ((2S.5S) -1- (4-fluorophenyl) pyrrolidin2,5-di-yl) bis (4.1-phenylene)) bis (azandii l) bis (oxomethylene) bis (p¡rrol idi n-2,1 -di-i l)) bis (3-meti 1-1 -oxobutan2.1-d¡-yl) dimethyl dicarbamate
Ϊ.
(2S, 2'SM, 1 '- ((2S.2'S) -2,2' - (4,4 '- ((2R.5R) -1- (4fluorophenyl) plrrolid¡n-2.5-di-ihb¡ dimethyl s (4.1-phenylene)) bis (azandiyl) bis (oxomethylene) b¡s (p¡rrolidin-2.1-di-yl)) bis (3-methyl-1-oxobutan2,1-di-ihydrocarbamate
<img file="MX339989B_D0444.tif" />
To a mixture of the product of Example 1G (0.030 g, 0.055 mmol), (S) -2- (methoxycarbonylamino) -3-methylbutanoic acid (0.024 g, 0.14 mmol) and HATU (0.052 g, 0.14 mmol) in DMSO (0.3 mi) Hunig's base (0.024 mi, 0.166 mmol) is added, and the mixture
210
IMPI "
<img file="MX339989B_D0445.tif" />
The resulting mixture is stirred at room temperature and the mixture is partitioned between water and ethyl acetate, and the organic layer is concentrated and subjected to HPLC purification on a semi-preparative C18 reversed phase column using a 10 100% gradient. acetonitrile in 0.1% aqueous TFA. The trans-substituted pyrrolidine isomer is the first of the 2 stereoisomers to elute, providing the title compound as a 1: 1 mixture of dlastereomers (9 mg, 16%).
H NMR (TFA salt) (400 MHz, DMSO-D6) δ ppm 0.85 0.96 (m, 12H) 1.64 (d, J = 5.75 Hz, 2H) 1.82 - 1.92 (m, 6H) 1.95 2.06 (m , 2H) 2.08 - 2.20 (m, 2H) 3.52 (s, 6H) 3.57 - 3.68 (m, 2H)
3.74 - 3.86 (m, J = 5.86 Hz, 2 H) 4.02 (t, J = 8.35 Hz, 2 H) 4.42 (dd, J = 7.92, 4.88 Hz, 2 H) 5.16 (d, J = 6.18 Hz, 2 H) 6.20 (dd, J = 9.16, 4.39 Hz, 2 H) 6.77 (t, J = 8.89 Hz, 2 H) 7.12 (dd, J = 8.51, 1.68 Hz, 4 H) 7.31 (dd, J = 8.24, 3.36 Hz, 2H) 7.50 (d, J = 7.26 Hz, 4H) 9.99 (s, 2H).
The title compound shows an EC value<sub>50</sub> less than about 0.1 nM in VCH 1b-Con1 replicon tests in the presence of 5% FBS.
EXAMPLE 11 (2S, 2'S) -1,1 '- ((2S, 2'S) -2,2' - (4,4 '- ((2S, 5R) -1- (4-fluorophenyl) pyrrolidin2,5-di -il) bis (4.1-phenylene)) bis (azandiyl) bis (oxomethylene) bis (pyrolidin-2,1-di-¡l)) bis (3-meth¡ 1-1-oxobutan2,1-di -L) dimethyl dicarbamate
211
<img file="MX339989B_D0446.tif" />
<img file="MX339989B_D0447.tif" />
IMPI
INSTITUTO MEXICANO DE LA PROriECAD industrial
<img file="MX339989B_D0448.tif" />
To a mixture of the product of Example 1G (0.030 g, 0.055 mmol), (S) -2- (methoxycarbonylamine) -3-methylbutanoic acid (0.024 g, 0.14 mmol) and HATU (0.052 g, 0.14 mmol) in DMSO (0.3 ml) Hunig's base (0.024 ml, 0.166 mmol) is added, and the resulting mixture is stirred at room temperature for 90 minutes. The mixture is partitioned between water and ethyl acetate, and the organic layer is concentrated and subjected to HPLC purification on a semi-preparative C18 reverse phase column using a gradient of 10 100% acetonitrile in 0.1% aqueous TFA. The cis-substituted pyrrolidine isomer is the second of the 2 stereoisomers to elute, providing the title compound (11 mg, 20%).
<sup>1</sup>H NMR (TFA salt) (400 MHz, DMSO-D6) δ ppm 9.35 (s, 2H) 8.26 (s, 2H) 7.77 - 7.83 (m, 4H) 7.68 - 7.73 (m, 4H) 7.01 (t, J = 8.95 Hz, 2H) 6.61 - 6.71 (m, 2H) 6.23 (d, J = 8.35 Hz, 2H) 4.87 4.97 (m, 2H) 4.67 - 4.78 (m, 2H) 4.42 - 4.52 (m, 2H) 3.99 - 4.09 (m, 2H) 3.87 - 3.97 (m, 2H) 3.84 (s, 6H) 1.22 (dd, J = 6.78, 2.11 Hz, 6H)
1.15 (dd, J = 6.72, 2.06 Hz, 6H).
The title compound shows an EC value<sub>50</sub> less than about 0.1 nM in HCV 1b-Con1 replicon tests in the presence of 5% FBS.
212
EXAMPLE 12 ιι wiTirr-nririrr erases ^ ·
IMPI
MEXICAN INSTITUTE OF INDUSTRIAL PROPERTY
<img file="MX339989B_D0449.tif" />
(2S, 2'S) -1.1<sup>,</sup>- ((2S, 2<sup>,</sup>S) -2.2<sup>,</sup>-(4,4<sup>,</sup>- ((2S.5S) -1- (4-fluorophenyl) pyrrolidin2,5-di-yl) bis (4.1 -phenylene)) bis (azand¡¡l) b¡s (oxomet¡len) b¡s dimethyl (p¡rrol¡d¡n-2.1-di-yl)) bis (3-methyl-1-oxobutan2,1-di-¡l) dicarbamate
<img file="MX339989B_D0450.tif" />
<img file="MX339989B_D0451.tif" />
The product from Example 10 is separated by chiral chromatography on a semi-preparative AD-H Chiralpak column eluting with a 1: 1 mixture of hexanes: (2-PrOH: EtOH 2: 1). The title compound elutes as the first of the 2 stereoisomers.
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ ppm 0.84 - 0.97 (m, 12 H)
1.64 (d, J = 5.64 Hz, 2 H) 1.88 (s, 6 H) 1.95 - 2.05 (m, 2 H) 2.08 - 2.19 (m, 2 H) 3.52 (s, 6 H) 3.58 - 3.66 (m, 2 H) 3.76 - 3.85 (m, 2 H) 4.02 (t, J = 8.51 Hz, 2 H) 4.42 (dd, J = 8.02, 4.88 Hz, 2 H) 5.15 (d, J = 6.51 Hz, 2
H) 6.20 (dd, J = 9.16, 4.39 Hz, 2 H) 6.78 (t, J = 8.89 Hz, 2 H) 7.13 (d, J = 8.46 Hz, 4 H) 7.31 (d, J = 8.35 Hz, 2 H) 7.50 (d, J = 8.46 Hz, 4H) 9.99 (s, 2H).
The title compound shows an EC value<sub>50</sub> less than about 0.1 nM in the 1b-Con1 replicon tests of
HCV in the presence of 5% FBS.
213
EXAMPLE 13 «S4WfeUa¡t -« *> V4w
IMPIOS
MEXICAN INSTITUTE OF PROPERTY
INDUSTRIAL f 25.2 ^) - 1.1 ^ ((25.2 ^) - 2.2<sup>;</sup>- (4,4 '- ((2R, 5ft1-4 ^ 4fluorophenyl) p¡rrolid¡n-2,5-di-¡l) b¡s (4,1-phenylen)) b ¡S (azandiyl) bis (oxomethyl) b¡s (p¡rrol¡din-2,1-di-yl)) bis (3-methyl-1-oxobutan5 2,1-di-yl) d Dimethyl carbamate
<img file="MX339989B_D0452.tif" />
<img file="MX339989B_D0453.tif" />
<img file="MX339989B_D0454.tif" />
The product from Example 10 is separated by chiral chromatography on a semi-preparative AD-H Chiralpak column eluting with a 1: 1 mixture of hexanes: (2-PrOH: EtOH 2: 1). The title compound elutes as the second of the 2 stereoisomers.
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ ppm 0.82 - 0.97 (m, 12 H)
1.65 (d, 2H) 1.80 - 2.05 (m, 8H) 2.08 - 2.20 (m, 2H) 3.52 (s, 6H)
3.57 - 3.68 (m, 2H) 3.76 - 3.87 (m, 2H) 4.01 (t, 2H) 4.42 (dd, 2H)
5.16 (d, J = 6.40 Hz, 2 H) 6.20 (dd, J = 9.22, 4.45 Hz, 2 H) 6.77 (t,
J = 8.95 Hz, 2 H) 7.12 (d, J = 8.57 Hz, 4 H) 7.30 (d, J = 8.35 Hz, 2 H)
7.50 (d, J = 8.46 Hz, 4H) 9.98 (s, 2H).
The title compound shows an EC value<sub>50</sub> less than about 0.1 nM in the 1b-Con1 replicon tests of
HCV in the presence of 5% FBS.
214
EXAMPLE 14 (1 S, 1'S) -2.2 '- ((2S, 2 ^) - 2.2 ^ (4.4 ^ ((28.5S) -1- (4-fluorophenyl) pyrroxyinIMPI
MEXICAN INSTITUTE OF INDUSTRIAL FROFIEDAD
<img file="MX339989B_D0455.tif" />
2,5-di-¡l) b¡s (4,1-phenylene)) bis (azandiyl) b¡s (oxomethylene) b¡s (pyrrolidin-2,1-di-yl)) b ¡S (2-oxo-1 - ((R) tetrahydrofuran-3-¡Detan-2,1-d¡-¡l) dimethyl d¡carbamate
and.
(1S.1<sup>,</sup>S) -2,2 '- ((2S.2<sup>,</sup>S) -2.2<sup>,</sup>- (4,4 '- ((2R.5R) -1- (4fluorophenyl) p¡rrolidin-2,5-di-yl) bis (4,1-phenylene)) bis (azandiinbis (oxomethylene) dimethyl bis (pyrrolidin-2,1-di-yl)) bis (2-oxo-1 - ((R) tetrahydrofuran-3-l) ethane-2,1-di-ylidicarbamate
<img file="MX339989B_D0456.tif" />
To a mixture of the product of Example 5C (0.013 g, 0.024 mmol), HATU (0.02275 gm, 0.060 mmol), and (S) -2 (methoxycarbonylamino) -2 - ((R) -tetrahydrofuran-3-yl) acetic acid (0.0107 gm, 0.053 mmol) in DMSO (0.200 ml) Hunig's Base (0.013 ml, 0.072 mmol) is added. The reaction is stirred at room temperature for 2 hours, poured into water, and extracted with ethyl acetate.
215
<img file="MX339989B_D0457.tif" />
<sup>F</sup> IMPI
The organic extract is dried with Na<sub>2</sub>SW<sub>4</sub>, is fiftraP ^ '^ J ^^ íSerttwSaQp? Vacuum, and the crude material is purified on a semi-preparative C18 reverse phase column using a gradient of 10-100% acetonitrile in 0.1% aqueous TFA to obtain the title compound (6.9 mg, 28% yield).
<img file="MX339989B_D0458.tif" />
1H NMR (TFA salt) (400 MHz, DMSO-D6) δ ppm 1.61 1.77 (m, 4H) 1.80 - 1.94 (m, 6H) 1.93 - 2.06 (m, 2H) 2.08 - 2.21 (m, 2 H) 3.44 (dd, J = 8.46, 6.29 Hz, 2H) 3.53 (s, 6H) 3.56 - 3.68 (m, 8H)
3.68 - 3.77 (m, 2H) 3.80 - 3.90 (m, 2H) 4.23 (t, J = 8.84 Hz, 2H) 4.43 (dd, J = 8.02, 4.77 Hz, 2H) 5.16 (d, J = 6.29 Hz, 2H) 6.20 (dd, J = 9.11,
4.45 Hz, 2H) 6.77 (t, J = 8.95 Hz, 2H) 7.13 (d, J = 8.57 Hz, 4H) 7.50 (d, J = 8.57 Hz, 4H) 7.60 (d, J = 7.92 Hz , 2H) 9.98 (s, 2H).
The title compound shows an EC value<sub>50</sub> from about 0.1 to about 1 nM in the HCV 1b-Con1 replicon tests in the presence of 5% FBS.
EXAMPLE 15 (1S, 1<sup>,</sup>S) -2.2 '- ((2S, 2<sup>,</sup>S) -2.2<sup>,</sup>-(4,4<sup>,</sup>- ((2S, 5S) -1- (4-fiuorophenyl) pyrrolidin2,5-d¡-yl) bis (4,1-phenylene)) bis (azand¡20 ¡Bb¡s (oxomethylene) bis (p Dimethyl ¡rrol¡d¡n-2.1-di-yl)) bis (2-oxo-1 - ((R) tetrahydrofuran-3-yl) ethan-2.1-di-yl) dicarbamate
<img file="MX339989B_D0459.tif" />
216
The product of Example 14 is
INDUSTRIAL
<img file="MX339989B_D0460.tif" />
IMPIfe
INDUSTRIAL chiral chromatography on a semi-preparative AD-H column
Chiralpak eluting with a 2: 3 mixture of hexanes: (2-PrOH: EtOH 1: 1). The title compound elutes as the first of the 2 stereoisomers.
<img file="MX339989B_D0461.tif" />
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ ppm 1.59 - 1.78 (m, 4 H)
1.79 - 1.94 (m, 6H) 1.94 - 2.05 (m, 2H) 2.09 - 2.23 (m, J = 5.10 Hz, 2H) 3.44 (dd, J = 8.35, 6.40 Hz, 2H) 3.53 (s, 6H) 3.57 - 3.73 (m, 8H)
3.71 - 3.80 (m, 2 H) 3.81 - 3.89 (m, 2 H) 4.23 (t, J = 8.78 Hz, 2 H) 4.43 (dd, J = 7.97, 4.83 Hz, 2 H) 5.16 (d, J = 6.07 Hz, 2H) 6.16 - 6.24 (m, 2H) 6.78 (t, J = 8.89 Hz, 2H) 7.13 (d, J = 8.57 Hz, 4H) 7.50 (d, J = 8.46 Hz, 4H ) 7.60 (d, J = 8.02 Hz, 2H) 9.98 (s, 2H).
The title compound shows an EC value<sub>50</sub> less than about 0.1 nM in the 1b-Con1 replicon tests of
HCV in the presence of 5% FBS.
EXAMPLE 16 (1S.1<sup>,</sup>S) -2.2<sup>,</sup>- ((2S.2'S) -2.2<sup>,</sup>-(4.4<sup>,</sup>- ((2R.5R) -1- (4fluorophenyl) pyrrolidin-2.5-di-i l) bis (4,1 -phenylene)) bis (azandi20 yl) b¡s (oxomethyl) bis ( Dimethyl pyrrolıdin-2,1-di-¡n) bis (2-oxo-1 - ((R) tetrahydrofuran-3-yl) ethane-2,1-d¡-¡l) d¡carbamate
<img file="MX339989B_D0462.tif" />
217
<img file="MX339989B_D0463.tif" />
IMPT * g>
rl -1 i -lll- · i Λ A · INSTITUTO MEXICANO
The product of Example 14 is used for chiral chromatography on a semi-preparative AD-H Chiralpak column eluting with a 2: 3 mixture of hexanes: (2-PrOH: EtOH 1: 1). The title compound elutes as the second of the 2 stereoisomers.
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ ppm 1.61 - 1.77 (m, 4H) 1.80 - 1.94 (m, 6H) 1.93-2.06 (m, 2H) 2.08 - 2.21 (m, 2H) 3.44 ( dd, J = 8.46, 6.29 Hz, 2H) 3.53 (s, 6H) 3.56 - 3.68 (m, 8H) 3.68 - 3.77 (m, 2H) 3.80 - 3.90 (m, 2H) 4.23 (t, J = 8.84 Hz, 2H) 4.43 (dd,
J = 8.02, 4.77 Hz, 2 H) 5.16 (d, J = 6.29 Hz, 2 H) 6.20 (dd, J = 9.11, 4.45 Hz, 2 H) 6.77 (t, J = 8.95 Hz, 2 H) 7.13 ( d, J = 8.57 Hz, 4H) 7.50 (d, J = 8.57 Hz, 4H) 7.60 (d, J = 7.92 Hz, 2H) 9.98 (s, 2H).
The title compound shows an EC value<sub>50</sub> from about 0.1 to about 1 nM in the HCV 1b-Con1 replicon tests in the presence of 5% FBS.
EXAMPLE 17 (R.2S, 2'S) -N.N '- (4,4' - ((2S, 5S) -1- (4-fluorophenyl) p¡rrol¡d¡n-2,5-di ¡L) b¡s (4,1-phenylene)) b¡s (1 - ((R) -2-phen i l-2- (p¡peridin-1 20 yl) acetylpyrroi¡din-2-carboxam¡ da) and (R, 2S, 2'S) -N, N '- (4,4' - ((2R, 5R) -1- (4-fluorophenyl) pyrrole idin-2,5-di I) bis ( 4,1-phenylene)) bis (1 - ((R) -2-phenyl-2- (piperidin-1-yl) acetyl) pyrrolidine-2-carboxamide)
218
IMPI
<img file="MX339989B_D0464.tif" />
tf<sup>X</sup>
<img file="MX339989B_D0465.tif" />
<img file="MX339989B_D0466.tif" />
<img file="MX339989B_D0467.tif" />
To a mixture of the TFA salt of (R) -2-phenyl-2 (piperidin-1-yl) acetic acid (0.0455 mg, 0.137 mmol), the product of Example 1G (0.030 gm, 0.055 mmol), and HATU (0.0526 gm, 0.138 mmol) in DMSO (0.300 ml) Hunig's base (0.029.0 ml, 0.166 mmol) is added, and the resulting mixture is stirred at room temperature for 2 hours. The mixture is partitioned between water and ethyl acetate, the organic layer is dried over Na<sub>2</sub>SW<sub>4</sub>, filter and concentrate in vacuo. The crude product is subjected to purification with
HPLC on a semi-preparative C18 reversed phase column using a gradient of 10-100% acetonitrile in 0.1% aqueous TFA (8.3 mg, 11%).
<sup>1</sup>H NMR (TFA salt) (400 MHz, DMSO-D6) δ ppm 1.20 1.42 (m, 4H) 1.61 - 2.02 (m, 16H) 2.62 - 2.81 (m, 4H) 3.01 - 3.23 (m, J = 9.32 Hz, 4H) 3.87 - 3.98 (m, 2H) 4.40 - 4.47 (m, J = 8.24 Hz, 2
H) 5.14 - 5.24 (m, 2 H) 5.50 (d, J = 8.78 Hz, 2 H) 6.23 (dd, J = 8.89,
4.34 Hz, 2H) 6.75 - 6.84 (m, 2H) 7.16 (d, J = 7.81 Hz, 4H) 7.48 - 7.59 (m, 12H) 7.62 (d, J = 3.69 Hz, 4H) 9.89 ( s, 2H) 10.17 (s, 2H).
The title compound shows an EC value<sub>50</sub> from 25 about 0.1 to about 1 nM in the jljt tests - ίιίΤ-Γ ..—
219
HCV IMPI replicon 1b-Con1 in the presence of 5% FBS ™? Θ
<img file="MX339989B_D0468.tif" />
Dt THE INDUSTRIAL PROPERTY
<img file="MX339989B_D0469.tif" />
EXAMPLE 18 (R, 2S, 2'S) -N, N<sup>,</sup>-(4.4<sup>,</sup>- ((2S.5R) -1- (4-fluorophenyl) pyrrolidin-2,5-d¡5 ¡l) bis (4,1 -phenyl)) b¡s (1 - ((R) -2 -phenyl-2- (piperid¡n-1¡l) acetyl) p¡rrolidine-2-carboxamide)
<img file="MX339989B_D0470.tif" />
<img file="MX339989B_D0471.tif" />
To a mixture of the TFA salt of (R) -2-phenil-2 (piperidin-1-yl) acetic acid (0.0455 mg, 0.137 mmol), the product of
Example 1G (0.030 gm, 0.055 mmol), and HATU (0.0526 gm, 0.138 mmol) in DMSO (0.300 ml) add Hunig's base (0.029.0 ml, 0.166 mmol), and the resulting mixture is stirred at room temperature for 2 hours. The mixture is partitioned between water and ethyl acetate, the organic layer is dried over Na<sub>2</sub>SW<sub>4</sub>, filter and concentrate in vacuo. The crude product is subjected to HPLC purification on a semi-preparative C18 reverse phase column using a gradient of 10-100% acetonitrile in 0.1% aqueous TFA (8.7 mg, 12%).
<sup>1</sup>H NMR (TFA salt) (400 MHz, DMSO-D6) δ ppm 1.22 25 1.43 (m, 4H) 1.62 - 2.03 (m, J = 80.02 Hz, 16H) 2.08 - 2.18 (m, 2H)
220
<img file="MX339989B_D0472.tif" />
2.62 - 2.85 (m, 4 Η) 3.04 - 3.24 (m, 4 Η) 3.88 DE LA FRCP.'lbAD INDUSTRIAL
4.52 (m, 2H) 4.64 - 4.72 (m, 2H) 5.52 (d, J = 8.24 Hz, 2H) 6.36 (d
J = 9.05, 4.50 Hz, 2 H) 6.88 (t, J = 8.89 Hz, 2 H) 7.41 ~ - '?. é8 (m, 1ff H)'
9.89 (s, 2H) 10.23 (s, 2H).
The title compound shows an EC value<sub>50</sub> less than about 0.1 nM in HCV 1b-Con1 replicon tests in the presence of 5% FBS.
<img file="MX339989B_D0473.tif" />
EXAMPLE 19 (2S, 2<sup>,</sup>S) -1J '- ((2S.2<sup>,</sup>S) -2.2 '- (4.4<sup>,</sup>- (1- (4-fluorophenyl) -1H-pyrroi-2,5-diyl) bis (4,1-phenylene)) bis (azandi-yl) bis (oxomethylenebis (pyrrolidin-2,1di-yl) )) bis (3,3-dimethyl-1-oxobutan-2,1-di-yl) di-methyl carbamate
<img file="MX339989B_D0474.tif" />
EXAMPLE 19A
-f4-fIuorophenyl) -2.5-bis (4-nitrophenyl) -1 H-p8rrol
To a suspension of the product of Example 1A (1.5 g,
4.57 mmol) in acetic acid (22.85 ml) is added 4-fluoroaniline (4.33 ml, 45.7 mmol). The mixture is heated at 70 ° C for 24 hours. After cooling to room temperature the mixture was
221
IIMyPJ Á Dilute with water and ether and stir vigorously to obtain 1.67 g (91%) of the title compound .
MEXICAN INSTITUTE OF INDUSTRIAL FROFIEDAD
<img file="MX339989B_D0475.tif" />
EXAMPLE 19B
4,4 '- (1 - (4-fluorophenyl) -1 H-pyrrole-2,5-d ¡-¡lidian ¡line
To a solution of Example 19A (1,017 g, 2,496 mmol) in ethanol (15 ml) and THF (15 ml) is added iron powder (0.836 g,
14.98 mmol) followed by ammonium chloride (0.401 g, 7.49 mmol) and water (3.75 ml). The reaction mixture is refluxed for 45 minutes. The suspension is filtered through celite, washed with ethanol, the combined filtrate is concentrated and the residue is purified by column chromatography (gradient elution from 30% to 50% EtOAc.hexanes) to provide 1.09 g (77% ) of the title compound.
EXAMPLE 19C (2S, 2'S) -2.2 '- (4,4' - (1 - (4-fluorophenyl) -1 H-pyrrol-2.5-di-yl) bis (4,1phenyl)) bis (azand¡ tert-butyl -yl) bis (oxomethylene) di pyrolidine-1-carboxylate
To a solution of Example 19B (1.09 g, 3.17 mmol) in
DMF (15.87 ml) at room temperature HATU (2.66 g,
6.98 mmol), (S) -1- (tert-butoxycarbonyl) pyrrolidine-2-carboxylic acid (1,503 g, 6.98 mmol), and Hunig's base (2,218 ml, 12.70 mmol).
222
<img file="MX339989B_D0476.tif" />
<img file="MX339989B_D0477.tif" />
Stirring is continued overnight.
OF INDUSTRIAL PROPERTY partitions between water and added EtOAc. The organic phase is washed with brine, dried (Na<sub>2</sub>SW<sub>4</sub>) and concentrates. The residue is purified by column chromatography (gradient elution from 20% to 50% EtOAc / hexanes).
MS (ESI; M + H) m / z = 738.
EXAMPLE 19D (2S.2'S) -NN<sup>,</sup>-(4,4<sup>,</sup>- (1- (4-fluorophenyl) -1H-prrol-2,5-d-yl) bis (4,110 phenylene)) dipyrrolidin-2-carboxamide
To the product of Example 19C (100 mg, 0.136 mmol) in CH<sub>2</sub>CI<sub>2</sub> (2.0 ml) TFA (1.0 ml) is added and the reaction is stirred 1 hour. The mixture is concentrated, the residue is partitioned between water and 25% of
IPA-CHCb and neutralized with NaHCO<sub>3</sub>. The organic layer is dried over Na<sub>2</sub>SW<sub>4</sub>, filtered and concentrated to obtain the title compound as a white solid which is used without further purification.
MS (DCI; M + H) m / z = 538.
EXAMPLE 19E f2S, 2<sup>,</sup>S) -1,1 '- ((2S, 2<sup>,</sup>S) -2.2 '- (4.4<sup>,</sup>- (1- (4-fluorophenH) -1H-pyrrole-2.5-di¡I) bisí4,1-phenylene)) bis (azand¡-il) b¡s (oxomet¡len) b¡s (p¡rrolid¡ n-2,1d ii l)) b¡s (3,3-d, I put 1-1-oxobutan-2,1-di-i di-methyl dicarbonate
223
<img file="MX339989B_D0478.tif" />
To a mix of the Example product<sub>NS</sub>^^<sub>M</sub>^<sub>TO</sub>(K3 ^ 4 ^
OF THE PROPERTY <“» · »_
INDUSTRIAL
0.136 mmol) in CH<sub>2</sub>CI<sub>2</sub> (10 ml) at room temperature Hunig's base (0.070 ml, 0.407 mmol) is added. To this is then added (S) -2-methoxycarbonylamine-3,3-dimethyl-butyric acid (0.054 g, 0.285 mmol) followed by HATU (0.114 g, 0.299 mmol). The mixture is stirred for 2 hours then washed with NaHCO<sub>3</sub> saturated and the organic phase is concentrated and the residue is purified by column chromatography (1% gradient elution from 0% to 3% MeOH-CH<sub>2</sub>CI<sub>2</sub>) to provide the desired compound as a light tan solid.
MS (ESI; M + H) m / z = 881.
H NMR (400 MHz, DMSO-D6) δ ppm 0.96 (s, 18H), 1.811.89 (m, 4H), 1.95-2.00 (m, 2H), 2.11-2.16 (m, 2H), 3.53 (s, 6H),
3.61-3.65 (m, 2H), 3.75-3.79 (m, 2H), 4.20 (d, J = 8.85 Hz, 2H), 4.394.42 (m, 2H), 6.39 (s, 2H) , 6.96 (d, J = 8.69 Hz, 4 H), 7.07-7.10 (m, 4
H), 7.17 (dd, J = 8.70, 8.70 Hz, 2H), 7.41 (d, J = 8.70 Hz, 4H), 10.01 (br s, 2H).
The title compound shows an EC value<sub>50</sub> less than about 0.1 nM in HCV 1b-Con1 replicon tests in the presence of 5% FBS.
EXAMPLE 20 (2S.2'S) -1.1<sup>,</sup>- ((2S, 2'S) -2.2 '- (4.4' - ((2S.5S) -1-phenylengine-2.5-dyl) bis (4.1-phenylene) ) bis (azandi-yl) bis (oxomethylene) bis (pyrrolidin-2,1di-yl)) b¡s (3,3-dim t¡l-1-oxobutan-2.1-d¡-yl) dicarbamate of dimethyl
224
<img file="MX339989B_D0479.tif" />
ΙΜΡΙ
MEXICAN INSTITUTE
V OF PROPERTY <sup>4</sup> INDUSTRIAL (2S, 2'S) -1.1 '- ((2S.2<sup>,</sup>S) -2.2 '- (4.4' - ((2R.5R) -1-phen¡lp¡rrolid¡n-2.5-di-_ ¡l) b¡s (4.1-phenylene)) b¡s (azand¡ -¡L) bis (oxomethyl) b¡s (p¡rrol¡d¡n-2,1d¡-¡l)) bis (3,3-dimethyl-1-oxobutan-2,1-di-¡ l) dim linden dicarbamate
<img file="MX339989B_D0480.tif" />
EXAMPLE 20A
2,5-Bis (4-nitrophenyl) -1-phenyl pyrrole di na
A mixture of the product from Example 1C (50 mg, 0.102 mmol) and aniline (0.2 ml, 2.19 mmol) is stirred at room temperature for 48 hours. The mixture is partitioned between aqueous 1N HCl and ethyl acetate, and the organic layer is dried over Na<sub>2</sub>SW<sub>4</sub>, filter and concentrate in vacuo. The crude product is purified by silica gel column chromatography using a solvent gradient of 0-50% ethyl acetate in hexanes. The title compound is obtained as a yellow solid (19 mg, 48%).
225
EXAMPLE 20B
IMPI
INSTITUTO MEXICANO DE LA PROFIEDAO INDUSTRIAL
<img file="MX339989B_D0481.tif" />
(2S, 2'S) -2.2 '- (4.4' - (1-fen¡lp¡rrol¡din-2.5-d¡-¡l) b¡s (4,1fen¡len)) b¡s (azand¡- yl) b¡s (oxomethylene) d¡pyrrol¡din-1-carboxylate d tert-butyl
The product from Example 20A (19 mg, 0.049 mmol) is subjected to the conditions described in Example 1E. The crude product is subjected to the conditions described in Example 1F to obtain the title compound (33 mg, 93%).
<img file="MX339989B_D0482.tif" />
EXAMPLE 20C (2S.2'S) -1.1 '- ((2S, 2'S) -2.2' - (4,4 '- ((2S.5S) -1-phenylpyrrolidin-2,5-d¡l) b ¡S (4,1-phenylene)) bis (azandi-yl) bis (oxomethyl) b¡s (p¡rrol¡din-2,1d¡-yl)) b¡s (3,3- dimethiium dimethyl 1-1-oxobutan-2,1-di-yl) dicarbamate and
(2S, 2<sup>,</sup>S) -1.1<sup>,</sup>- ((2S.2'S) -2.2 '- (4.4<sup>,</sup>- ((2R.5R) -1-phenylpyrrolidin-2,5-diyl) bis (4,1-phenylene)) b¡s (azandi-yl) bis (oxomethylene) bis (pyrrolidin-2.1 di-i I)) di-methylo bis (3,3-di meth 1-oxobutan-2,1-di-yl) dicarbamate
The product from Example 20B (30 mg, 0.041 mmol) is subjected to the conditions described in Example 1G, and the crude product is subjected to the conditions described in Example 1H. The crude product is subjected to HPLC purification on a semi-preparative C18 reverse phase column using a gradient of 1025 100% acetonitrile in 0.1% aqueous TFA. The pyrrolidine isomer
226 substituted in trans is the first of the 2 stereoisó
<img file="MX339989B_D0483.tif" />
which provides the title compound as a 1: 1 mixture of diastereomers (7mg, 19%).
<sup>1</sup>H NMR (TFA salt) (400 MHz, DMSO-D6) δ ppm 0.95 (d, J = 5.31 Hz, 18H) 1.59 - 1.67 (m, 2H) 1.79 - 1.91 (m, 4H) 1.91 - 2.02 (m, 2H) 2.08 - 2.17 (m, 2H) 3.52 (s, 6H) 3.58 - 3.68 (m, 2H) 3.71 3.82 (m, 2H) 4.19 (d, J = 9.00 Hz, 2H ) 4.42 (dd, 2 H) 5.17 (d, J = 5.64 Hz, 2 H) 6.24 (d, J = 8.35 Hz, 2 H) 6.39 (t, J = 7.37 Hz, 2 H) 6.90 (t, J = 7.92 Hz, 2H) 7.07 (d, 2H) 7.11 (d, 4H) 7.48 (d, J = 8.24 Hz, 4H) 9.98 (s, 2H).
The title compound shows an EC value<sub>50</sub> less than about 0.1 nM in HCV 1b-Con1 replicon tests in the presence of 5% FBS.
EXAMPLE 21 (2S, 2<sup>,</sup>S) -1.1<sup>,</sup>- ((2S, 2<sup>,</sup>S) -2.2<sup>,</sup>- (4.4 '- ((2S.5R) -1-phenylpyrrolidin-2.5-diyl) bis (4.1-phenylene)) bis (azandi-ii) bis (oxomethylene) bis (plrrolidin-2.1di-yl)) bis (3.3 -dimethyl-1-oxobutan-2,1-d¡-¡l) d¡carbamate di methylo
The product from Example 20B (30 mg, 0.041 mmol) was
227
IMPI /
INSTITUTO MEXICANO V is subjected to the conditions described in Example 1G, and the crude product is subjected to the conditions described in —Exomplo 1H — The crude product is subjected to HPLC purification on a semi-preparative C18 inverted phase column using a gradient of 105 100% acetonitrile in 0.1% aqueous TFA. The cis-substituted pyrrolidine isomer is the second of the 2 stereoisomers to elute, providing the title compound (8.5 mg, 24%).
<sup>1</sup>H NMR (TFA salt) (400 MHz, DMSO-D6) δ ppm 0.96 (d, J = 3.25 Hz, 18H) 1.74 - 1.91 (m, 6H) 1.93 - 2.03 (m, 2H) 2.10 - 2.20 (m, 2H) 3.53 (s, 6H) 3.58 - 3.69 (m, 2H) 3.72 - 3.83 (m, 2H) 4.20 (d, J = 8.89 Hz, 2H) 4.45 (dd, J = 7.97 , 5.37 Hz, 2 H) 4.68 (t, J = 5.20 Hz, 2 H) 6.37 (d, J = 8.24 Hz, 2 H) 6.56 (t, J = 7.26 Hz, 2 H) 6.98 (t, J = 7.92 Hz, 2H) 7.07 (d, 2H) 7.42 (d, J = 8.02 Hz, 4H) 7.58 (d, J = 8.57 Hz, 4H) 10.03 (s, 2H).
The title compound shows an EC value<sub>50</sub> less than about 0.1 nM in HCV 1b-Con1 replicon tests in the presence of 5% FBS.
EXAMPLE 22 f1R.1'R) -2.2'-f (2S.2<sup>,</sup>S) -2.2<sup>,</sup>-(4.4<sup>,</sup>- ((2S.5S) -1- (4-fluorophenyl) pyrrolidin-2,5-d¡-yl) bis (4.1-phenylene)) bis (azandiyl) bis (oxomethylene) b¡s (pyrrolidin-2.1-d Dimethyl α-yl)) b¡s (2-oxo-1-phenylethane-2,1-di-yl) dicarbamate (1R.1'R) -2.2<sup>,</sup>- ((2S.2'S) -2.2 '- (4.4<sup>,</sup>- ((2R.5R) -1- (4228
<img file="MX339989B_D0484.tif" />
fluorophenyl) pyrrolidin-2,5-di-yl) b¡s (4.1-phenyl)) bhbsfazantd «f)
- T L-Á
INDUSTRIAL ¡l) b¡s (oxomethylene) bis (pyrrolid¡n-2.1 -d¡-¡l)) bis (2-oxo-1-phenylethan-2,1 di-yl) dimethyl dicarbamate
<img file="MX339989B_D0485.tif" />
The product from Example 5C (25 mg, 0.046 mmol) is subjected to the conditions described in Example 5D, substituting (R) -2- (methoxycarbonylamino) -2-phenylacetic acid for (S) -2 (methoxy) acid. carbonylamino) butanoic, to obtain the title compound as a 1: 1 mixture of diastereomers (42 mg, 48%).
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ ppm 9.83 (s, 2H) 7.67 (d, J = 7.81 Hz, 2H) 7.51 - 7.57 (m, 4H) 7.29 - 7.44 (m, 8H) 7.15 (d,
J = 8.46 Hz, 4 H) 6.74 - 6.83 (m, 2 H) 6.17 - 6.28 (m, J = 9.00, 4.34 Hz,
H) 5.48 (d, J = 7.81 Hz, 2 H) 5.12 - 5.24 (m, 1 H) 4.33- 4.43 (m,
J = 8.13 Hz, 2H) 3.75 - 3.87 (m, 2H) 3.54 (s, 6H) 1.73 - 2.05 (m, 8H)
229
IMPI
Mexican Institute of Industrial Property
<img file="MX339989B_D0486.tif" />
1.62 - 1.70 (m, 2 Η).
The title compound shows an EC value<sub>50</sub> less than about 0.1 nM in HCV 1b-Con1 replicon tests in the presence of 5% FBS.
EXAMPLE 23 (25.2 ^) - 1.1 ^ ((25.2 ^) - 2.2 ^ (4.4 ^ ((25.55) -1- (4 (tr¡fluorometh¡l) phen¡ l) p¡rrol¡d¡n-2,5-di-¡l) bis (4,1-phenylene)) bis (azandiil) b¡s (oxomethyl) b¡s (pirrolid ¡n-2, Dimethyl 1 -d ii l)) bis (3,3-di methyl-1 oxobutan-2,1-d¡-yl) d¡carbamate
AND.
(2S.2<sup>,</sup>S) -1.1<sup>,</sup>- ((2S.2<sup>,</sup>S) -2.2<sup>,</sup>-(4,4<sup>,</sup>- ((2R.5R) -1- (4 (trifluoromethyl) phenyl) pyrrolidin-2.5-di-yl) bis (4,1-phenylene)) bis (azandiyl) bis (oxomethylene) bis (pyrroli di dimethyl n-2,1 -di-yl)) bis (3,3-di methyl-1 oxobutan-2,1-di-yl) dicarbamate
<img file="MX339989B_D0487.tif" />
230
IMPI
EXAMPLE 23A
4,4<sup>,</sup>- (2S.5S) -1-f4- (tr¡fluoromethinphenyl) pyrrole¡d¡n-2,5-cf<sup>t</sup>^ i<sup>;</sup>fí ^ íanrrrña
INSTITUTE .v.ÍX'C ».W0 CilAFW.'DQ
<img file="MX339989B_D0488.tif" />
and 4,4 '- ((2R.5R) -1 - (4- (trifluoromethyl) phenyl) prrroliüin-2.á-qi¡Ddianiline
The product from Example 1C (0.74 g, 1.5 mmol) is subjected to the conditions described in Example 1D, substituting 4-fluoroaniline for 4 (trifluoromethyl) aniline. The product obtained in this way is subjected to the conditions described in Example 1E to obtain the title compound as a racemic mixture of trans-substituted pyrrolidine stereoisomers (0.10 g, 17%).
EXAMPLE 23B (2S.2'S) -N.N'-í4.4 '- ((2S, 5S) -1- (4- (trifluoromethyl) phenyl) pyrrolidin-2.5di-ll) b¡s (4 , 1-phenyl)) d¡p¡rrolidin-2-carboxamida and (2S, 2'S) -N, N '(4.4' - ((2R, 5R) -1- (4- (tr ¡Fluorometh¡l) phen¡l) p¡rrol¡d¡n-2,5-d¡-¡l) bis (4,1phenyl)) d¡rrolid¡n-2-carboxam¡da
The product of Example 23A (0.95 g, 0.24 mmol) is subjected to the conditions described in Example 1F to obtain a solid (0.166 g, 88%), which is dissolved in 4 M HCl in 1,4-dioxane (2 mi), and the resulting mixture is stirred at room temperature for 30 minutes. The resulting mixture is concentrated and dried in vacuo to obtain an HCl salt of the title compound as a 1: 1 mixture of stereoisomers.
231
EXAMPLE 23C
ΙΜΡΪ
INSTITUTO MEXICANO DE LA rRC'HEOAD INDUSTRIAL
<img file="MX339989B_D0489.tif" />
(2S, 2'S) -1.1 ^ ((25.2 ^) - 2.2 ^ (4.4 ^ ((25.55) -1- (4 (trifluoromethyl) phenyl) pyrrolidin-2.5-di-yl) bis (4,1-phenylene)) bis (azandiyl) bis (oxomethylene) bis (pyrrolidin-2.1-di-¡l)) b¡s (3.3-dimethyl-1oxobutan-2,1-di- ¡L) dimethyl dicarbamate
X (2S.2'S) -1.1 '- ((2S.2'S) -2.2<sup>,</sup>-(4.4<sup>,</sup>- ((2R.5R) -1- (4 (tr¡fluoromethyl) phenyl) pyrrolid¡n-2.5-d¡-¡l) b¡s (4,1-phenylene)) bis (azandiyl) bis ( dimethyl oxomethylene) bis (pyrrolidin-2,1-di-yl)) bis (3,3-dimethyl-1-oxobutan-2,1-di-dicarbamate)
The product from Example 23B (58 mg, 0.083 mmol) is subjected to the conditions described in Example 1H to obtain the title compound as a colorless solid (30 mg, 39%).
<sup>1</sup>H NMR (free base) (400 MHz, DMSO-D6) δ ppm 10.03 (s, 2 H) 7.52 (d, J = 8.46 Hz, 4 H) 7.25 (d, J = 8.89 Hz, 2 H) 7.14 (d , J = 7.48 Hz, 4 H) 7.06 - 7.11 (m, 2 H) 6.36 (d, J = 8.35 Hz, 2 H) 5.23 5.33 (m, 2 H) 4.39 - 4.48 (m, 2 H) 4.21 (d , J = 8.46 Hz, 2H) 3.71 - 3.82 (m, 2H) 3.58 - 3.69 (m, 2H) 3.54 (s, 6H) 2.08 - 2.21 (m, 2H) 1.93 2.06 (m, 2H ) 1.76-1.94 (m, 4H) 1.61-1.73 (m, 2H) 0.96 (m, 18H).
The title compound shows an EC value<sub>50</sub> less than about 0.1 nM in HCV 1b-Con1 replicon tests in the presence of 5% FBS.
232
EXAMPLE 24 (25.2 ^ .35.3 ^) - 1.1 ^ ((23.2 ^) - 2.2 ^ (4.4 ^ ((25.55) -1- (4IMPI
Du? Tm 'to a £ d. * 9W, VW.'wi? I ímmotmkm.
<img file="MX339989B_D0490.tif" />
fluorophenyl) p¡ rrol¡din-2,5-d¡-yl) b¡s (4.1 -phenylene)) bis (azand¡¡l) b¡s (oxomethylene) b¡s (p¡rrol¡d¡n Dimethyl -2.1-di-¡l)) bis (3-methyl-1-oxopentan2.1-di-yl) dicarbamate
AND.
(2S.2<sup>,</sup>S.3S<sub>1</sub>3<sup>,</sup>S) -1.1<sup>,</sup>- ((2S.2<sup>,</sup>S) -2.2<sup>,</sup>-(4.4<sup>,</sup>- ((2R.5R) -1- (4fluorophenyl) p¡rrolidin-2,5-di-¡l) bis (4.1-phenyl)) bis (azandiyl) b¡s (oxom eti le n) b is (pyrrolid ¡n-2,1-d¡-¡D) bis (3-methi 1-1-oxopentan2,1 -di-¡l) dimethyl dicarbamate
<img file="MX339989B_D0491.tif" />
The product from Example 1G (20 mg, 0.037 mmol) is subjected to the conditions described in Example 1H, substituting
233
IMPI '(2S, 3S) -2- (methoxycarbonylamino) -3-methylpentanoic acid<sup>DUS</sup>H'S. 4 mg,
0.081 mmol) by (S) -2- (methoxycarphthalamine) -3, odimethylbutanoic acid. The title compound is obtained as a mixture
1: 1 diastereomers (13.5 mg, 41%) after silica gel chromatography (0-5% MeOH / CH<sub>2</sub>CI<sub>2</sub>).
MEXICAN INSTITUTE OF PROPERTY
<img file="MX339989B_D0492.tif" />
<sup>1</sup>H NMR (free base) (400 MHz, DMSO-D6) δ ppm 9.99 (s,
H) 7.50 (dd, J = 8.46, 1.52 Hz, 4 H) 7.36 (dd, J = 8.35, 3.04 Hz, 2 H)
7.13 (dd, J = 8.62, 1.79 Hz, 4 H) 6.78 (t, J = 8.89 Hz, 2 H) 6.20 (dd, J = 9.16, 4.39 Hz, 2 H) 5.16 (d, J = 6.29 Hz, 2 H) 4.43 (dd, J = 7.92, 4.77
Hz, 2H) 4.02 - 4.13 (m, 2H) 3.77 - 3.89 (m, 2H) 3.57 - 3.67 (m, 2H)
3.52 (s, 6H) 2.08 - 2.21 (m, J = 14.96 Hz, 2H) 1.94 - 2.05 (m, 2H)
1.81 - 1.93 (m, J = 5.42 Hz, 4H) 1.60 - 1.79 (m, 4H) 1.42 - 1.57 (m, 2H) 1.04 - 1.18 (m, 2H) 0.89 (t, J = 6.51 Hz, 6H) 0.76 - 0.85 (m, 6H).
The title compound shows an EC value<sub>50</sub> less than about 0.1 nM in HCV 1b-Con1 replicon tests in the presence of 5% FBS.
EXAMPLE 25 (2S, 2'S, 3R.3'R) -1.1 '- ((2S, 2'S) -2.2' - (4.4 '- ((2S, 5S) -1- (420 fluorophenii) pyrrolidin-2,5-di-yl) bis (4.1-phenien)) bis (azandiyl) bis (oxomethylene) bis (p¡rrol¡d¡n-2.1-di-yl)) bis (3-methyl- Dimethyl 1-oxopentan2,1-di-yl) dicarbamate
Z (2S.2<sup>,</sup>S.3R, 3'R) -1.1 '- ((2S, 2<sup>l</sup>S) -2,2 '- (4,4' - ((2R.5R) -1- (4-fluoropheniDpyrrolidin-2,5-d¡-yl) bis (4,1-phenylene)) bi (azandi234 yl ) bis (oxomethiien) b¡s (pyrrolidin-2.1-d¡-¡l)) bis (3-me
<img file="MX339989B_D0493.tif" />
Dimethyl 2.1-dihydrocarbamate
<img file="MX339989B_D0494.tif" />
X
<img file="MX339989B_D0495.tif" />
The product of Example 1G (25 mg, 0.046 mmol) is subjected to the conditions described in Example 1H, substituting (2S, 3R) -2- (methoxycarbonylamino) -3-methylpentane acid (19.2 mg, 0.102 mmol ) by (S) -2- (methoxycarbonylamino) -3,315 dimethylbutanoic acid. The title compound is obtained as a 1: 1 mixture of diastereomers (20.5 mg, 50%) after chromatography with silica gel (0-5% MeOH / CH<sub>2</sub>CI<sub>2</sub>).
<sup>1</sup>H NMR (free base) (400 MHz, DMSO-D6) δ ppm 9.96 (s
H) 7.49 (d, J = 8.35 Hz, 4 H) 7.14 (t, J = 7.43 Hz, 4 H) 6.77 (t, J = 8.89 20 Hz, 2 H) 6.20 (dd, J = 9.11, 4.45 Hz, 2H) 5.16 (d, J = 6.40 Hz, 2H) 4.38
- 4.48 (m, 2H) 4.18 - 4.28 (m, 2H) 3.69 - 3.82 (m, 2H) 3.55 - 3.64 (m, 2H) 3.52 (s, 6H) 2.09 - 2.20 (m, 2H ) 1.95 - 2.05 (m, 2H) 1.72 1.95 (m, 6H) 1.58 - 1.70 (m, J = 5.64 Hz, 2H) 1.40 - 1.55 (m, 2H) 1.06 - 1.18 (m, 2H) 0.79 - 0.91 (m, 12H).
The title compound shows an EC value<sub>50</sub> less
235 of approximately 0.1 nM in the HCV repli tests in the presence of 5% FBS.
<img file="MX339989B_D0496.tif" />
EXAMPLE 26 (2S, 2<sup>,</sup>S) -1,1 '- ((2S, 2'S) -2.2' - (4,4 '- (4,4'-i1- (4-tert-butylphenyl) -1H-pyrrole2,5- di-¡l) b¡s (4,1-phenylene)) bis (1H-im¡m¡dazol-4.2-di-yl)) bis (pyrrolidin2,1-d¡-¡l)) b¡s (3 -methyl-1-oxobutan-2.1-di-yl) di-methylo dicarbamate
<img file="MX339989B_D0497.tif" />
EXAMPLE 26A (S) tert-butyl -2-formylpyrrolidin-1-carboxylate
Oxalyl chloride (5.32 ml, 60.8 mmol) and anhydrous dichloromethane (125 ml) are added to a 500 ml 3-neck flask, oven dried with nitrogen purge, and the solution is cooled to -78 ° C. A solution of anhydrous DMSO (7.30 ml, 103 mmol) in anhydrous dichloromethane (25 ml) is added dropwise from a constant pressure addition funnel over a period of 20 minutes. A solution of tert-butyl (S) -2236 (hydroxymethyl) pyrrolidine-1-carboxylate is added
IMPI
INDUSTRIAL
ZEXIOflNO
ROrlffeAD
<img file="MX339989B_D0498.tif" />
mmol) in anhydrous dichloromethane (50 ml) dropwise from a constant pressure addition funnel over a 20 minute period, then the reaction mixture is stirred at 78 ° C for 30 minutes. Triethylamine (32.6 ml, 234 mmol) is added dropwise through a syringe over a 5 minute period and the thick white mixture is stirred in an ice-water bath for 30 minutes. The reaction is quenched with 10% (w / v) aqueous citric acid (30 ml), pouring the reaction into a separatory funnel with Et<sub>2</sub>O (550 ml) and 10% aqueous citric acid (w / v), the layers separated, and the organic phase washed with water and brine. Dry the organic phase with Na<sub>2</sub>SW<sub>4</sub> anhydrous, filtered, and concentrated to obtain a yellow oil (9.4 g), which is used directly in the next reaction.
EXAMPLE 26B (S) -2- (1 H-m¡dazol-2-yl) p¡rrol¡d¡n-1-carboxylate tert-butyl
The product from Example 26 A (20 g, 100 mmol) is dissolved in methanol (50.2 ml) and ammonium hydroxide (50.2 ml) is added. Giioxal (40% in water; 24.08 ml, 211 mmol) is added dropwise to this solution over the course of 10 minutes. The reaction is stirred at room temperature overnight. The reaction is concentrated under reduced pressure, diluted with 50 ml of water, and then extracted with ethyl acetate. The organic layer is
237 i? '' I ·. V
IMPI washes with brine, dried (Na<sub>2</sub>SW<sub>4</sub>) and are concentratedWg ^ & ^ g ^
INDUSTRIAL tan in color. The solid is treated with ether and concentrated. The solid
<img file="MX339989B_D0499.tif" />
then it is triturated with 2: 1 diethyl ether: hexanes (150 ml) to obtain 17 g of solid, which is used directly in the next reaction.
EXAMPLE 26 C (S) -2- (4,5-dibromo-1H-imidazole-2-¡l) pyrrole-din-1-carboxylic acid tr-butyl ester
N-Bromosuccinimide (108 mmol) is added to a cold solution (0 ° C) of the product of Example 26B (12.05 g, 50.8 mmol) in dichloromethane (200 ml). Allow to stir in an ice bath for 2 hours and then concentrate, dissolve in ethyl acetate (250 ml), wash with water (3 x 150 ml), brine (1 x 100 ml), dry (MgSO<sub>4</sub>) and concentrated to a very dark residue, pursued with dichloromethane / hexanes (1: 1) to obtain a brown solid (-19 g). Triturated solid with ether (-100 ml), filter to isolate a tan solid (13.23 g, 65% yield).
EXAMPLE 26D (S) -2- (5-bromo-1 Hi mi dazol-2-8l) pyrrole id in-1-tertbutyl carboxylate or (S) -2- (4-bromo-1 H-im idazol-2 -¡L) p¡rrolidi n-1-carboxylate of tert-butyl
238
IMPIOUS";
The product from Example 26C (6.25 g. 1 dissolves in dioxane (200 ml) and water (200 ml) in a 1 L round bottom flask equipped with a condenser and glass stopper, add a sodium sulfite solution ( 22.38 g, 174 mmol) in water (200 mL), and heated under reflux with a heating mantle for 16 hours The reaction is a reddish amber homogeneous solution. Cool the reaction to room temperature, remove dioxane and some of the water by rotary evaporation, extract with dichloromethane, wash the combined organic extracts with brine (50 mL), dry over Na<sub>2</sub>SW<sub>4</sub> anhydrous, filtered, and concentrated by rotary evaporation, co-evaporating with 2: 1 hexanes / dichloromethane (100 ml) to obtain a beige foam (4.38 g). Dissolved the foam in dichloromethane (2 ml), added hexanes (2 ml), solution applied to the column, and purified by flash chromatography on silica gel eluting with 30% to 80% ethyl acetate / hexanes to obtain the compound of the title as a white solid (3.48 g).
EXAMPLE 26E
1,4-bis (4-bromophen i I) butane-1,4-dione
To a solution of zinc (ll) chloride (19.62 g, 144 mmol) in benzene (108 ml) are added diethylamine (11.16 ml, 108 mmol) and 2-methylpropan-2-ol (10.32 ml, 108 mmol) and the mixture is stirred at room temperature for 2 hours. 2-bromo239 are added
IMPI
INSTITUTO MEXICANC
1- (4-bromophenyl) ethanone (20.0 g, (72 mmoleg ^^^ j ^ bromophenyl) ethanone (21.48 g, 108 mmol) in one portion, and the mixture was stirred overnight (18 hours). extinguish with H<sub>2</sub>SW<sub>4 </sub>5% (500 ml) and stirred vigorously to induce precipitation of the product, which is collected by vacuum filtration and washed with benzene, water, methanol, then dichloromethane, successively. The product is dried in vacuo to obtain the title compound as a white solid (11.15 g, 39.1% yield).
EXAMPLE 26F
2,5-bis (4-bromophenyl) -1 - (4-tert-butiIphenyl) -1 H-pyrrole
To a solution of the product of Example 26E (4.00 g,
10.10 mmol) in toluene (40 ml) 4-tert-butylaniline (1.81 g,
12.12 mmol) followed by TFA (2.30 g, 20.20 mmol). The mixture is heated at 110 ° C for 2 hours. The mixture is cooled to room temperature and water and diethyl ether are added. Stir for 15 minutes, filter, wash with water and diethyl ether, and dry to provide the title compound as a white solid (4.61 g, 90% yield).
EXAMPLE 26G
- (4-tert-butylphenyl) -2.5-bis (4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) phenyl) -1 H-pyrrole
To a solution of the product of Example 26F (2.32 g, 4.56
240
<img file="MX339989B_D0500.tif" />
mmol) in DMSO (26 ml) at room temperature (pinacholate) diborane (2.54 g, 10.02 mmol), of potassium (5.00 g, 36.4 mmol) and PdCI<sub>2</sub>(dppf) (744 mg, 0.91 mmol). The mixture is degassed and heated to 85 ° C. After 4 hours, the mixture is cooled to room temperature, diluted with dichloromethane, and washed with water followed by brine. The organic phase is dried (Na<sub>2</sub>SW<sub>4</sub>) and concentrates. The residue is dissolved in 20% ethyl acetate: hexanes and filtered through a short plug of silica gel (elution with 20% ethyl acetate: hexanes) and concentrated to obtain the title compound as a solid. light yellow (1.62 g; 59% yield).
EXAMPLE 26H (2S, 2'S) -2.2 '- (4.4<sup>,</sup>-(4,4<sup>l</sup>- (1- (4-tert-butyphenyl) -1H-pyrrole-2,5-diyl) bis (4,1-phenylene)) b¡s (1 H-imidazole-4,2- di-¡l)) d¡pyrrol¡d¡n-1 tert-butyl carboxylate
A mixture of the product from Example 26D (664 mg, 2.10 mmol), the product from Example 26G (1.48 g, 2.45 mmol), 2M sodium carbonate (1400 μΙ, 2.80 mmol), and Pd (dppf) C12 (51.2 mg , 0.070 mmol) in DME (2800 µl) is subjected to microwave irradiation at 140 ° C for 20 minutes. The mixture is diluted with ethyl acetate, then washed with water and brine, and dried over Na<sub>2</sub>SW<sub>4</sub>. The product is purified on silica gel eluting with 30 to 70% ethylorhexane acetate to obtain the title compound.
241 (140 mg; 24% yield).
IMPI
MEXICAN INSTITUTE OF INDUSTRIAL PROPERTY
<img file="MX339989B_D0501.tif" />
EXAMPLE 26I —- (2S.2<sup>l</sup>S) -4,4 '- (4,4' - (1- (4-tert-butylphenyl) -1H-pyrrole-2,5-d¡-¡l) b¡s (4.1phenyl )) b¡s (2- (p¡rrolidin-2-yl) -1 H-imidazole)
To a solution of the product of Example 26H (135 mg, 0.164 mmol) in dichloromethane (2 ml) at room temperature is added TFA (0.60 inl). After 3 hours, the solvent is removed and the residue is partitioned between water and 25% isopropyl alcohol: CHCI<sub>3</sub>; neutralizes with NaHCO<sub>3</sub>. The organic phase is dried (Na<sub>2</sub>SW<sub>4</sub>), filtered and concentrated. The residue is used directly in the next reaction (98 mg; 96% yield).
EXAMPLE 26J (2S, 2'S) -1.1 '- ((2S, 2'S) -2.2' - (4.4 '- (4.4' - (1- (4-tert-butylphenyl) -1H-p¡ rrol2,5-d¡-¡l) b¡s (4,1-phenylen)) b¡s (1H-¡m¡dazol-4,2-d¡-¡l)) b¡s (p Dimethyl ¡rrol¡d¡n2,1-di-yl)) bis (3-methyl-1-oxobutan-2,1-di-yl) dicarbamate
To a solution of the product of Example 26I (98 mg, 0.158 mmol) in DMF (2 ml) at room temperature is added (S) 2- (methoxycarbonylamino) -3-methylbutanoic acid (61 mg, 0.347 mmol), EDAC (66 mg, 0.347 mmol) and 1-hydroxybenzotriazole hydrated (53 mg, 0.347 mmol). After 3 hours, the mixture is transferred to a separatory funnel with ethyl acetate and water. The organic phase
242 «ΟΚΒβΕ
<img file="MX339989B_D0502.tif" />
<img file="MX339989B_D0503.tif" />
concentrated and the residue purified by 1% gradient erosion from 0% to 4% methanokdlchloromephane) to provide the desired material as a light yellow solid (70 mg; 30% yield).
<sup>1</sup>H NMR (MeOH-d4; 400 MHz): δ 7.55-7.30 (m, 6H), 7.256.96 (m, 8H), 6.45 (s, 2H), 5.12 (dd, J = 5.43, 5.43 Hz, 2H) , 4.20 (d, J = 7.26 Hz, 2H), 4.02-3.90 (m, 2H), 3.85-3.80 (m, 2H), 3.64 (s, 6H), 2.36-1.93 (m, 10H), 1.31 (s , 9H), 0.97-0.86 (m, 12H).
The title compound shows an EC value<sub>50</sub> less than about 0.1 nM in HCV 1b-Con1 replicon tests in the presence of 5% FBS.
EXAMPLE 27 (2S, 2<sup>,</sup>S) -1.1<sup>,</sup>- ((2S.2'S) -2.2<sup>,</sup>-(4.4<sup>,</sup>-(4.4<sup>,</sup>- ((2S.3R.4R.5S) -1- (4-fluorophenyl) -3,4-dimethoxypyrrolidin-2.5-di-yl) bis (4,1-phenylenehbisd Himidazol-4,2-d¡-¡l)) dimethyl bis (p¡rrolid¡ n-2,1-di-¡l)) bis (3-methyl-1-oxobutan2,1-di-illdicarbamate
<img file="MX339989B_D0504.tif" />
OR
F
<img file="MX339989B_D0505.tif" />
\
OR·
243
EXAMPLE 27A (2S, 3R, 4R.5S) -2.5-b¡s (4-bromophenyl) -1 - (4-fluorophenU2P] rrolidin-3<sub>¿</sub>4diol
IMPI
INSTITUTO KEX'CANO O £ LA reopn »4D INDUSTSlAl
<img file="MX339989B_D0506.tif" />
A solution of 3,4-O-isopropylidene-D-mannitol (2.24 g, 10.08 mmol) in 2: 1 methanol-dichloromethane (45 ml) is treated with iodobenzene diacetate (7.95 g, 24.19 mmol) followed by stirring at temperature environment for 5 hours. The mixture is concentrated by rotary evaporation and the residue is dissolved in 0.1M aqueous sulfuric acid solution (20.6 ml) followed by stirring at room temperature for 18 hours. The mixture is adjusted to pH 6 by adding solid sodium bicarbonate. The mixture is then treated sequentially with 4-fluoroaniline (1.96 ml, 20.16 mmol), 4-bromophenylboronic acid (3.64 g, 18.14 mmol), and absolute ethanol (40 ml). The mixture is then heated in an oil bath (110 ° C) under reflux for 20 hours. The dark brown mixture is cooled to room temperature and concentrated in vacuo. The residue is dissolved in ethyl acetate (100 ml), washed with water (50 ml), 0.33 M aqueous tribasic potassium phosphate solution (2 x 50 ml), and brine (50 ml). The organic phase is dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated by rotary evaporation to a dark reddish brown oil. The oil is dissolved in dichloromethane-hexanes, concentrated in vacuo, and dried in vacuo to obtain a dark brown foam. Purification by flash gel chromatography of
244
<img file="MX339989B_D0507.tif" />
<img file="MX339989B_D0508.tif" />
silica eluting with a step gradient from SwttSfoia »cl» s <o <sup>1</sup> 1-1- OC LA PfcORKLO • WMSTWAL ethyl acetate / dichloromethane allows the product to be obtained as a yellow solid (1216 g, 24%).
EXAMPLE 27B (2S, 3R.4R.5S) -2.5-b¡s (4-bromophenyl) -1- (4-fluorophenyl) -3,4-dimethoxy pyrrolidine
The product from Example 27A (237 mg, 0.467 mmol) is dissolved in a mixture of THF (3 ml) and DMF (1 ml) under a nitrogen atmosphere and cooled to 0 ° C. Dispersion of 60% sodium hydride in mineral oil (56.1 mg, 1402 mmol) is added in portions and the mixture is stirred at 0 ° C for 15 minutes. Neat iodomethane (65 µl, 1028 mmol) is then added, the cooling bath is removed, and the reaction is stirred at room temperature for 14.5 hours. The reaction is diluted in ethyl acetate (50 ml), washed with saturated aqueous ammonium chloride solution (25 ml), water (2 x 25 ml), and brine (25 ml). The organic phase is dried over anhydrous sodium sulfate, filtered, and the filtrate is concentrated by rotary evaporation. The yellow residue is purified by flash silica gel chromatography eluting with 30% hexanes / dichloromethane to obtain the title compound as a white foam (206 mg, 82%).
245
EXAMPLE 27C
IMPI
MEXICAN INSTITUTE OF PROPERTY
INDUSTRIAL
<img file="MX339989B_D0509.tif" />
(2S, 3R, 4R, 5S) -1 - (4-fluorophen ¡l) -3,4-di methoxy-2,5-bis (4- (4,4,5,5 ^ tetramethyl-1,3 , 2-dioxaborolan-2-yl) phenyl) pyrrolidine
A nitrogen purged flask is charged with the product from Example 27B (204 mg, 0.381 mmol), bis (p¡nacalate) diboron (242 mg, 0.953 mmol), potassium acetate (112 mg, 1143 mmol), and anhydrous dioxane. (2 mi). The mixture is sparged with nitrogen for 30 minutes, the complex 1,1'bis (diphenylphosphino) ferrocene-palladium (II) dichloromethane (31.1 mg, 0.038 mmol) is added, the mixture is sparged again with nitrogen for 5 minutes, and heated in an oil bath at 85 ° O for 6 hours. The reaction is vacuum filtered through a small Icho of Celite 545, the collected solids are washed thoroughly with 5% methanol / dichloromethane, and the filtrate is concentrated in vacuo, dispersing the residue with dichloromethane / hexanes to obtain a solid of cinnamon colour. Purification by flash chromatography on silica gel eluting with 5% ethyl acetate / dichloromethane allows the title compound to be obtained as a salmon colored solid (238 mg, 99%).
EXAMPLE 27D (2S, 2<sup>,</sup>S) -2.2<sup>,</sup>-(4.4<sup>,</sup>-(4.4<sup>l</sup>- ((2S.3R.4R.5S) -1- (4-fluorophenyl) -3.4dimethoxypyrrole¡din-2,5-di-¡l) b¡s (4,1-phenylene)) bis (1 H- imidazole-4.2-diyl)) dipyrrolidine-1-carboxylate dt r-butyl '»Υ'
246
IMPI rga a 5 ml tube for micropnctaps ^. ^^^ -.
.INDÍtSTKlAiL
<img file="MX339989B_D0510.tif" />
Nitrogen was cated with the product of Example 27C (237 mg, 0.377 mmol), the product of Example 26D (298 mg, 0.941 mmol), and a mixture of absolute ethanol (1.5 ml) and toluene (1.5 ml). Sonic energy is applied to obtain a cloudy orange mixture, 1M aqueous sodium carbonate (0.941 ml, 0.941 mmol) is added, and sparged with nitrogen for 20 minutes. The 1,1'bis (diphenylphosphino) ferrocene-palladium (II) dichloride dichloromethane complex (30.8 mg, 0.038 mmol) is added, the mixture is sparged again with nitrogen for 5 minutes, the reaction tube is sealed with a cap of aluminum fold, and heated in a stirred microwave reactor at 100 ° C for 1 hour. The reaction is cooled to room temperature, diluted in ethyl acetate (75 ml), washed with water (2 x 25 ml) and brine (25 ml), the organic phase is dried over anhydrous magnesium sulfate, filtered, and the filtrate is concentrated by flash evaporation to a dark yellow solid. Purification by flash chromatography on silica gel eluting with 4% methanol / dichloromethane allows the title compound to be obtained as a yellow solid (221 mg, 69%).
EXAMPLE 27E fS) -4.4<sup>,</sup>-(4.4<sup>,</sup>- ((2S.3R, 4R.5S) -1- (4-fluorophenyl) -3,4-dimethoxypyrrolidi n-2.5-di-yl) bis (4,1-phenylene)) b¡s (2 - ((S) -pyrrolld¡n-2yl) -1 H-imidazole)
247
<img file="MX339989B_D0511.tif" />
«ISTíTUTO MÉXiCANf».
DELAPUOPIEBAP 4Μ) ψ £ Γ £ Μ.
<img file="MX339989B_D0512.tif" />
A solution of the product from Example 0.174 mmol) in anhydrous dichloromethane (2 ml) under hydrogen is treated with TFA (1 ml) and stirred at room temperature for two minutes. The solvent is removed in vacuo and dispersed with 1:10 dichloromethane-hexanes (3 x 50 ml) to obtain a pale yellow solid (193 mg). The TFA salt of the solid is dissolved in anhydrous methanol (15 ml), treated with dry Amberlite IRA400 (OH) resin (1.66 g, 10 g of wet resin previously washed (Supelco) with deionized water (3 x 25 ml) and methanol (3 x 25 ml), then dried in vacuo), and stirred for 2 hours at room temperature. The mixture is then vacuum filtered, the collected resin is washed thoroughly with methanol, the filtrate is concentrated by rotary evaporation, and the residue is dispersed with 1:10 dichloromethane-hexanes to obtain the title compound as a light yellow solid. (94 mg, 0.145 mmol, 83%).
EXAMPLE 27F (2S, 2<sup>,</sup>S) - 't, 1<sup>,</sup>-ff2S.2<sup>,</sup>S) -2.2 '- (4.4<sup>,</sup>-(4.4<sup>,</sup>- (f2S.3R.4R, 5S) -1-f4fluorophenyl) -3,4-dimethoxy, p¡rrolidin-2,5-di-yl) bis (4,1-phenylene)) bis (1Himidazole-4.2 -di-yl)) b¡s (p¡rrol¡din-2.1-di-yl)) bis (3-methyl-1-oxobutan-2,1-di-yl) dimethyl dicarbamate
In an oven-dried round bottom flask, the product of Example 27E (92 mg, 0.142 mmol) is dissolved in a mixture of DMF (1 ml) and DMSO (1 ml) under nitrogen and the mixture is cooled.
248 solution up to 0 ° C. Sequentially added
<img file="MX339989B_D0513.tif" />
(methoxycarbonylamino) -3-methylbutanoic (53.5 mg, 0.305 mmol), EDAC (61.1 mg, 0.312 mmol), 1-hydroxybenzotrazole hydrated (47.8 mg, 0.312 mmol), and N-methylmorpholine (47 μΙ, 0.426 mmol). The cooling bath is removed and stirred at room temperature for 15 hours. The reaction is diluted with ethyl acetate (50 ml), washed with saturated aqueous sodium bicarbonate solution (25 ml), water (2 x 25 ml), and brine (25 ml). The organic phase is dried over anhydrous magnesium sulfate, filtered, and the filtrate is concentrated by rotary evaporation. Purification by flash chromatography on silica gel eluting with 5% methanol / dichloromethane allows the title compound to be obtained as a pale yellow solid (78 mg, 56%).
<sup>1</sup>H NMR (400 MHz, DMSO-d6) δ ppm 0.86 (dd, J = 17.67,
6.72 Hz, 12H), 0.97 - 1.37 (m, 3H), 1.41 - 2.29 (m, 11H), 3.53 (s, 6H), 3.69 - 3.86 (m, 4H), 4.04 (q, J = 8.02 Hz, 2 H), 4.12 - 4.23 (m, 2 H), 5.07 (d, J = 3.80 Hz, 2 H), 5.35 - 5.48 (m, 2 H), 6.31 (dd, J = 9.16,
4.39 Hz, 2H), 6.74 (t, J = 8.89 Hz, 2H), 7.12-7.71 (m, 12H), 11.53-12.31 (m, 2H).
MS (ESI +) m / z 963 (M + H) +.
The title compound shows an EC value<sub>50</sub> less than about 0.1 nM in HCV 1b-Con1 replicon tests in the presence of 5% FBS.
249
EXAMPLE 28 (2S, 2'S) -1.1 '- ((2S.2'S) -2.2' - (5.5<sup>,</sup>- ((2R.5R) -1- (4-terIMPI
MEXICAN INSTITUTE OF INDUSTRIAL PROPERTY
<img file="MX339989B_D0514.tif" />
buti Ifen ¡l) p¡ rrolidi n-2,5-d¡-¡l) b¡s (1 H-benzofdl ¡m¡dazol-5,2-d¡¡l)) b¡s (p¡rrolid ¡N-2,1-d¡-¡l)) b¡s (3-methyl-1-oxobutan-2.1-d¡iDdicarbamate of dimethyl and (25,2 ^) - 1,1 ^ ((25 , 2 ^) - 2,2 ^ (5,5 ^ ((2S, 5S) -1- (4-tert-but¡phenyl) pyrrol¡d¡n-2,5-d¡-¡l) b¡ s (1Hbenzordl¡midazol-5,2-di-yl)) b¡s (p¡rrol¡din-2,1-d¡-¡l)) b¡s (3-methyl-1oxobutan-2,1- di-yl) di dimethyl carbam ate
<img file="MX339989B_D0515.tif" />
EXAMPLE 28A
1,4-b¡s (4-chloro-3-nitrophenyl) butane-1,4-dione
Zinc chloride (27.4 g, 201 mmol), diethylamine (15.6 ml, 151 mmol) and t-butanol (14.4 ml, 151 mmol) are combined in benzene (151 ml) at room temperature under an atmosphere of
250 t 'nitrogen and stir for 2 hours. Be ag
<img file="MX339989B_D0516.tif" />
nitrophenyl) ethanone (30.1 g, 151 mmol) and 2-b> t; omo-1- (4-chloro-3-
<img file="MX339989B_D0517.tif" />
nitrophenyl) ethanone (28 g, 101 mmol). The mixture is vigorously stirred for 20 hours, and the solid product is collected by filtration and rinsed with benzene, water, methanol, and dichloromethane. The solid is dried in a vacuum oven.
EXAMPLE 28B
1,4-bis (4-chloro-3-nitrophenyl) butane-1,4-diol
The product from Example 28A (5.75 g, 14.48 mmol) is dissolved in ethanol (150 mL) at room temperature and treated with sodium borohydride (1.21 g, 31.9 mmol) portionwise over 5 minutes. The solution is heated to 70 ° C for 1 hour and then cooled to room temperature, quenched with water, extracted with ethyl acetate, dried over sodium sulfate, and concentrated to dryness to obtain 4.81 g (83%) off-white solid.
EXAMPLE 28C
1,4-bis (4-chloro-3-nitrophenyl) butan-1,4-di-yl dimethanesulfonate
The product from Example 28B (4.81 g, 11.99 mmol) and triethylamine (5.85 ml, 42.0 mmol) are dissolved in dichloromethane (80 ml) at room temperature and treated with methanesulfonyl chloride
251
XMPJ
<img file="MX339989B_D0518.tif" />
(2.34 ml, 30.0 mmol) by dripping into the
INSTITUTO MEXICANO DE LA rROFIEOAD minutes. The resulting solution is stirred for 2 hours<sup>1N</sup>Then it is concentrated to dryness and used directly in the next step.
EXAMPLE 28D
1- (4-tert-butylpheniD-2,5-b¡s (4-chloro-3-nitropheni Dpi rrol¡dine
The product from Example 28C (6.6 g, 11.84 mmol) is suspended in DMF (30 ml) and 4-t-butylaniline (18.7 ml, 118 mmol) is added and the solution is heated at 55 ° C for 2 hours then cooled and poured into water and extracted with dichloromethane. The organics are concentrated and the residue is purified by column chromatography on 120g of silica gel, eluting with 05% ethyl acetate / hexanes to obtain 4.41 g (72%) of a thick oil.
EXAMPLE 28E
4.4<sup>!</sup>- (1- (4-tert-but¡lfen¡Dpyrrolidin-2.5-d¡-¡l) b¡s (N- (4-methoxybenz¡l) -2 nitroaniline)
The product from Example 28D (4.41 g, 8.57 mmol) is combined neat with p-methoxybenzylamine (8.93 ml, 68.6 mmol) and heated at 145 ° C for 1 hour. The mixture is diluted with dichloromethane and filtered. The filtrate is washed with 0.5 M HCl, then
252
IMPI NaHCO solution<sub>3</sub> soln, later brine, sW ^ l ^ Owi ^ a
INDUSTRIAL
<img file="MX339989B_D0519.tif" />
purify by chromatography on silica gel with a column of 80 g, eluting with 0-50% ethyl acetate / hexanes to obtain
4.13 g (67%) of a foamy orange solid.
EXAMPLE 28F
4,4 '- (1 - (4-tert-butylphenyl) pyrorole d¡n-2,5-di-yl) bis (N1 - (4-methoxybenzyl) benzene-1,2-diamine)
The product from Example 28E (2 g, 2.79 mmol) is dissolved in a mixture of THF (15 ml), ethanol (15 ml), and ethyl acetate (5 ml) then platinum oxide (0.254 g, 1.12 mmol) is added ) via suspension of THF. The flask is evacuated and purged with nitrogen twice, then evacuated and opened onto a hydrogen balloon. The mixture is stirred at room temperature for 20 hours, then filtered through celite, concentrated, and purified by chromatography on silica gel with a column of 80 g, eluting with 0-40% ethyl acetate / dichloromethane to obtain the first peak of 0.508 g of trans product (28%).
EXAMPLE 28G (2S, 2'S) -2.2 '- (5.5' - (1 -f4-tert-butylphenyl) pyrolidin-2.5-di-¡l) bisf2- (4-methoxybenzylamino) -5.1-phenylene) tert-butyl bis (azandiyl) bis (oxomethylene)) d¡pyrrol¡din-1-carboxylate
253
The product of Example is dissolved
OF INDUSTRIAL PROPERTY mmol) and di-isopropylethylamine (0.674 ml, 3.86 mmol) in DMSO (6 ml) at room temperature and treated with S-Boc-proline (0.319 g,
1.48 mmol) followed by HATU (0.514 g, 1.35 mmol). The solution is stirred for 1 hour at room temperature then diluted with water and the solid product is filtered and purified by chromatography on silica gel with a 40 g column, eluting with 0-50% ethyl acetate in dichloromethane to obtain 0.565 g (84%) of a yellow solid.
EXAMPLE 28H (2S.2'S) -2.2 '- (5,5' - (1- (4-tert-butylphenyl) p¡rrol¡d¡n-2,5-d¡-¡l) b¡s Tert-butyl (2 amino-5,1-phenylene) b¡s (azandi-yl) bis (oxomethylene)) d¡pyrrol¡d¡n-1-carboxylate
The product of Example 28G (0.565 g, 0.538 mmol) is dissolved in dichloromethane (5 ml) and water (0.25 ml) at room temperature and treated with DDQ (0.244 g, 1.076 mmol) in portions within 2 minutes. The mixture is diluted with sodium bicarbonate solution, extracted with dichloromethane, concentrated and purified by chromatography on silica gel with a column of 40 g, eluting with 0-15% methanol / dichloromethane to obtain 0.355 g (81 %) of a yellow solid.
254
<img file="MX339989B_D0520.tif" />
2,5-d1Wfefts (1
EXAMPLE 28I / 2S, 2<sup>,</sup>S) -2,2 '- (5.5' - (1- (4-tert-but¡lfen¡l) p¡rrol¡d¡nbenzord1imidazol-5.2-d¡-yl)) dip¡rrol¡d¡n- 1-carbo ~ yrraTOÜ<sup>,</sup>g ~ reTnrcrttm<sup><Í</sup>
The product of Example 28H is dissolved in pure acetic acid (3 ml) and heated at 72 ° C for 2 hours. The solution is concentrated and then poured into water and the pH is adjusted to ~ 7-8 with sodium bicarbonate. The product is extracted with dichloromethane, concentrated and purified by chromatography on silica gel with a column of 40 g, eluting with 0-5% methanol / dichloromethane to obtain 0.185 g (55%) of a light yellow solid. .
EXAMPLE 28J (S) -5,5 '- (1- (4-tert-butylphenyl) p¡rrolidin-2,5-d¡-¡l) b¡s (2 - ((S) - p¡rrol¡d¡n2-¡l) -1 H-benzoidl ¡medazol)
The product from Example 281 (0.204 g, 0.264 mmol) is dissolved in THF (2 ml) at room temperature and treated with 4M hydrochloric acid in dioxane (2 ml). The mixture is concentrated to dryness and used directly in the next step.
EXAMPLE 28K (2S.2<sup>,</sup>S) -1.1<sup>,</sup>- ((2S, 2<sup>,</sup>S) -2.2<sup>l</sup>- (5,5 '- (f2R, 5R) -1- (4-terbut¡lfen¡l) p¡rrol¡d¡n-2,5-d¡-yl) b¡s (1H-benzordl¡m Dazol-5,2-diII)) bis (pyrolidin-2,1-di-il)) bis (3-m ti 1-1 -oxobufan-2,1-di
255
IMPI (Í2S, 5S) -1 - (4-tert-butylphenyl) p8rrol¡d¡n-2.5-d¡-¡l) b¡s (1 H-
<img file="MX339989B_D0521.tif" />
benzord1¡m¡dazol-5,2-di-8l)) b¡s (p¡rrol¡d¡n-2,1-di-yl)) bis (3-methyl-1-oxobutan-2,1-d ¡-¡L) dimethyl dicarbamate
The product of Example 28J (0.150 g, 0.261 mmol) and d¡-¡soprop¡let¡lam¡na (0.365 ml, 2.09 mmol) are dissolved in DMSO (3 ml) at room temperature and treated with acid (S) - 2 (methoxycarbonylamino) -3-methylbutanoic (0.105 g, 0.601 mmol) followed by HATU (0.204 g, 0.536 mmol). The solution is stirred for 1 hour at room temperature then diluted with water and the solid product is filtered and purified by chromatography on silica gel with a 12 g column, eluting with 0-8% methanol in dichloromethane to obtain 0.143 g (60%) of a yellow solid.
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ ppm 0.75 - 0.92 (m, 12H) 1.07 (s, 9H) 1.64 - 1.76 (m, 2H) 1.85 - 2.04 (m, 6H) 2.12 - 2.26 ( m, 4H) 2.43 (dd, J = 7.75, 4.07 Hz, 2H) 3.53 (s, 6H) 3.76 - 3.87 (m, 4H) 4.04 (dd, J = 11.49, 6.51 Hz, 2H) 5.12 (t, J = 7.59 Hz, 2 H) 5.35 (d, J = 3.25 Hz, 2 H) 6.25 (d, J = 8.46 Hz, 2 H) 6.85 - 6.96 (m, 2 H) 7.07 (t, J = 7.97 Hz, 2H) 7.19 (s, 1H) 7.28 (d, J = 8.35 Hz, 3H) 7.38 (dd, J = 8.19, 1.90 Hz, 1H) 7.46 (d, J = 8.13 Hz, 1H ) 11.97-12.09 (m, 2H).
The title compound shows an EC value<sub>50</sub> less than about 0.1 nM in HCV 1b-Con1 replicon tests in the presence of 5% FBS.
256
EXAMPLE 29 (2S, 2'S) -1.1
- ((2S.2'S) -2.2 '- (5.5' - ((2R, 5R) -1- (4IMPI
MEXICAN INSTITUTE OF INDUSTRIAL PROPERTY
<img file="MX339989B_D0522.tif" />
Fluorophenyl) pyrrolidin-2,5-d¡-¡l) b¡s (1H-benzofd1¡m¡mdazol-5,2-d¡yl)) bis (pyrrole ¡di n-2,1 - di-yl)) bis (3-methii-1-oxobutan-2,1-d¡¡ Ddicarbamate dimethyl and (2S, 2'S) -1.1 '- ((2S, 2'S) -2.2' - ( 5,5 '((2S, 5S) -1- (4-fluorophenii) pyrrolidin-2,5-di-yl) bis (1 Hbenzordlim idazol-5,2-di-ii)) bis (pyrrolidin-2,1 dimethyl -di-yl)) bis (3-methyl-1oxobutan-2,1-di-yl) dicarbamate
<img file="MX339989B_D0523.tif" />
EXAMPLE 29A
2,5-bis (4-cl or ro-3-ni trotenyl) -1- (4-fluorofenyl) pyrrolidine
The product of Example 28C (2.9 g, 5.2 mmol) and 4-fluoroaniline (5.0 inl, 52.0 mmol) are combined, undiluted, and heated at 45 ° C for 20 hours then cooled and poured into water and extracted with dichloromethane. Organics concentrate the
257
ΙΜΡΙ residue is purified by gel chromatography
INDUSTRIAL
<img file="MX339989B_D0524.tif" />
120 g column, eluting with 0-5% ethyl acetate / hexanes to obtain 0.59g (24%) of a thick oil.
EXAMPLE 29B
4,4 '- (1 - (4-f luorophenyl) pyrrole id ¡n-2,5-d i-II) bis (N- (4-methoxy benzyl) -2 nitroaniline)
The product from Example 29 A (0.88 g, 1.86 mmol) is combined with 4-methoxybenzylamine (3.64 ml, 28.0 mmol) and heated at 145 ° C for 1 hour in a microwave reactor. The mixture is diluted with dichloromethane and filtered. The filtrate is concentrated and purified by chromatography on silica gel with a 330 g column, eluting with 0-60% ethyl acetate / hexanes to obtain 0.79g (62%) of an orange foam solid.
EXAMPLE 29C
4,4'-I1 - (4-f luorophenyl) pyrrole Id i n-2,5-d ii l) b¡s (2-neither troa nor line)
The product from Example 29B (0.78 g, 1.15 mmol) is dissolved in dichloromethane (10 ml) at room temperature and treated with TFA (1.8 ml, 23.0 mmol) for 3 hours. The residue is concentrated and partitioned between dichloromethane and sodium bicarbonate solution. Organics are concentrated and purified
<img file="MX339989B_D0525.tif" />
258 *· ___~
IMPI
INSTITUTO MEXICANO DE LA PROPIEDAD by chromatography on silica gel with a column eluting with dichloromethane to obtain 0.218 g (43%) of the trans.
EXAMPLE 29D
4,4 '- (1 - (4-fluorophenyl) pyrrolidin-2.5-di-¡l) dibenzene-1,2-diamine
The product from Example 29C (0.218 g, 0.50 mmol) is dissolved in DMF (5 ml) then platinum oxide (0.226 g, 0.99 mmol) is added through THF suspension. The flask is evacuated and purged with nitrogen twice, then evacuated and opened onto a hydrogen balloon. The mixture is stirred at room temperature for 20 hours. The solution is carried to the next step without purification.
EXAMPLE 29E (2S, 2'S) -2.2 '- (5.5' - (1 - (4-fluorophenyl) p¡rrol¡din-2,5-di-¡l) b¡s (2-am¡ 5,1 -pheni len)) bis (azandi-yl) bis (oxomethylene) di pyrrole idi n-1-tert-butyl carboxylate
The crude solution of the product in DMF from Example 29D is treated with di-isopropylethylamine (0.296 ml, 1.70 mmol) and S-Bocproline (0.192 g, 0.89 mmol) followed by HATU (0.322 g, 0.85 mmol). The solution is stirred for 1.5 hours at room temperature then diluted with water and the solid product is filtered and
259
IMPI
INSTITUTO MEXICANO is purified by silica gel chromatography cof ¥ M ^ g. | Jg gl of 12 g, eluting with 0-3% of methanol in dichloromethane to obtain 0.235 g (72%) of a yellow solid.
<img file="MX339989B_D0526.tif" />
for
EXAMPLE 29F (2S.2'S) -2.2 '- (5,5' - (1- (4-fluorophenyl) p¡rrolidin-2,5-di-¡l) b¡s (1HbenzordIimidazol-5,2-di- L)) tert-butyl dipyrrolidine-1-carboxylate
The product from Example 29E is dissolved in undiluted acetic acid (2 ml) and heated at 60 ° C for 1 hour. The solution is concentrated then poured into water and the pH is adjusted to ~ 7-8 with sodium bicarbonate. The product is extracted with dichloromethane, concentrated and purified by chromatography on silica gel with a 12 g column, eluting with 0-20% ethyl acetate in dichloromethane to obtain 0.124 g (55%) of a colored solid. light yellow.
EXAMPLE 29G (S) -5,5 '- (1 - (4-fluorophenii) p¡rrolidin-2.5-di-yl) bis (2 - ((S) -pyrrolidin-2-yl) -1 H-benzofdlim idazol)
The product from Example 29F (0.120 g, 0.163 mmol) is dissolved in dichloromethane (2 ml) at room temperature and treated with TFA (1 ml). The mixture is concentrated to dryness, dissolved in 25% ISOPROPYL ALCOHOL / dichloromethane and washed with
260
IMPW
INDUSTRIAL
<img file="MX339989B_D0527.tif" />
baking soda solution. The residual solids are dried and the organics are concentrated and dried to obtain the title compound (0.062 g 72% yield) of an off-white solid.
EXAMPLE 29H (2S.2'S) -1.1<sup>,</sup>- ((2S.2<sup>,</sup>S) -2.2 '- (5.5<sup>,</sup>- ((2R.5R) -1- (4-fluorophenyl) pyrrolidin-2,5-di-yl) bis (1H-benzordl¡m¡m¡dazol-5,2-diyl)) bis (pyrrol¡d¡ n- 2,1-di-yl)) bis (3-methi 1-1-oxobutan-2,1-di¡Ddicarbamate dimethyl y (25.2 ^) - 1.1 ^ ((25.2 ^) - 2 , 2 ^ (5,5 ^ ((2S, 5S) -1- (4-fluorophenyl) p¡rrolid¡n-2.5-di-yl) b¡s (1Hbenzofdl ¡m¡dazol-5,2- dimethyl d¡-yl)) b¡s (pyrrolidi n-2,1-di-yl)) bis (3-methi I-1 oxobutan-2,1-di-ylidicarbamate)
The product of Example 29G (0.062 g, 0.116 mmol) and di-isopropylethylamine (0.101 ml, 0.58 mmol) are dissolved in DMSO (2 ml) at room temperature and treated with acid (S) -2 (methoxycarbonylamino) -3- methylbutanoic (0.051 g, 0.289 mmol) followed by HATU (0.092 g, 0.243 mmol). The solution is stirred for 1 hour at room temperature then diluted with water and the solid product is filtered and purified by chromatography on silica gel with a 12 g column, eluting with 0-7% methanol in dichloromethane to obtain 0.021 g (21%) of a yellow solid.
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ ppm 0.78 - 0.90 (m, 12 H)
261
ΙΜΡΙ * §> ^
MEXICAN INSTITUTE
1.70 (s, 2H) 1.87 - 2.03 (m, 6H) 2.13 - 2.26 (m, 4H) 2 ^^^^ 2
H) 3.54 (s, 6H) 3.82 (s, 4H) 4.03 - 4.11 (m, 2H) 5.09 - 5.18 um 2
H) 5.32 - 5.42 (m, 2H) 6.28 (dd, J = 8.89, 4.34 Hz, 2H) 6.70 - 6.80 (m,
H) 7.01 - 7.10 (m, 2H) 7.20 (d, J = 9.32 Hz, 1H) 7.27 - 7.34 (m, 3H)
7.38 (dd, J = 8.13, 2.71 Hz, 1H) 7.45 (d, J = 8.02 Hz, 1H) 12.03 (s, 2H).
The title compound shows an EC value<sub>50</sub> less than about 0.1 nM in HCV 1b-Con1 replicon tests in the presence of 5% FBS.
EXAMPLE 30 (2S.2<sup>,</sup>S) -1.1<sup>,</sup>- ((2S, 2'S) -2.2<sup>,</sup>- (5.5 '- ((2S.5S) -1- (4-fluorophenyl) pyrrolidin2,5-di-yl) bis (1 H-benzord1midazol-5.2-di-yl)) bis (pyrrolidin-2 Dimethyl, 1-diyl)) b¡s (3-methyl-1-oxobutan-2,1-di-yl) dicarbamate
<img file="MX339989B_D0528.tif" />
The product from Example 29H is purified by chiral chromatography on a Chirapak IA column eluting with a mixture of hexane / EtOH / MeOH / 1,2-dichloroethane / diethylamine (25/25/25/25 / 0.1).
• «β
262 TO.
IMPI
MEXICAN INSTITUTE.
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ ppm 0.75 1 *
1.64-1.73 (m, 2H) 1.85-2.03 (m, 6H) 2.12-2.24 (m, 4.H) 2.81
2.90 (m, 2H) 3.52 (s, 6H) 3.76 - 3.87 (m, 4H) 4.01 - 4.09 (m, 2H) 5.08 - 5.16 (m, 2H) 5.34 (q, J = 6.65 Hz, 2 H) 6.26 (dd, J = 9.05, 4.50 Hz, 2 H) 6.67 - 6.78 (m, 2 H) 7.03 (t, J = 8.02 Hz, 2 H) 7.20 (s, 1 H)
7.24 - 7.32 (m, 3H) 7.36 (d, J = 8.13 Hz, 1H) 7.44 (d, J = 7.92 Hz, 1H) 12.01-12.07 (m, 2H).
The title compound shows an EC value<sub>50</sub> less than about 0.1 nM in HCV 1b-Con1 replicon tests in the presence of 5% FBS.
EXAMPLE 31 (2S, 2'S) -1.1 '- ((2S.2'S) -2.2<sup>,</sup>-(5,5<sup>,</sup>- ((2R.5R) -1- (4fluorophenyl) p¡rrol¡d¡n-2,5-di-¡l) b¡s (1H-benzord1¡m¡dazole-5,2-d¡iD) bisfplrrolidin-2.1 -di-iD) bis (3-methyl-1-oxobutan-2.1-di¡Ddicarbamate dimethyl)
<img file="MX339989B_D0529.tif" />
The product from Example 29H is purified by chiral chromatography on a Chirapak IA column eluting with a mixture of hexane / EtOH / MeOH / 1,2-dichloroethane / diethylamine
263 <sup>1</sup>H NMR (400 MHz, DMSO-D6) δ ppm 0.74 - 0.93 (m, 12 H) (25/25/25/25 / 0.1).
IMPI
MEXICAN INSTITUTE OF INDUSTRIAL PROPERTY
<img file="MX339989B_D0530.tif" />
1.69 (t, J = 9.65 Hz, 2H) 1.82 - 2.06 (m, 6H) 2.09 - 2.26 (m, 4H) 3.04 - 3.23 (m, 2H) 3.52 (s, 6H) 3.73 - 3.90 ( m, 4 H) 4.06 (t, J = 8.46 Hz, 2
H) 5.05 - 5.21 (m, 2H) 5.29 - 5.44 (m, 2H) 6.21 - 6.32 (m, 2H) 6.67 6.86 (m, 2H) 7.05 (t, J = 8.78 Hz, 2H) 7.18 (s, 1H) 7.23 - 7.33 (m, 3H) 7.37 (d, J = 8.13 Hz, 1H) 7.45 (d, J = 8.02 Hz, 1H) 12.04 (d, J = 14.96 Hz, 2H ).
The title compound shows an EC value<sub>50</sub> less than about 0.1 nM in HCV 1b-Con1 replicon tests in the presence of 5% FBS.
EXAMPLE 32 (1 R, 4R) -1,4-b¡s (4-nitrophenyl) butan-1,4-diol / τ-λ HO OH / = \ o<sub>2</sub>n- # 2— \) —4 NO<sub>2</sub>
To (S) - (-) - a, adiphenyl-2-pyrrolidinemethanol (2.71 g, 10.70 mmol) THF (80 ml) is added at 23 ° C. The very thin suspension is treated with trimethyl borate (1.44 g, 13.86 mmol) over 30 seconds, and the resulting solution is mixed at 23 ° C for 1 hour. The solution is cooled to 16-19 ° C, and N, N-diethylanilin-borane (21.45 g, 132 mmol) is added dropwise via syringe over 3-5 minutes (caution: vigorous release of H<sub>2</sub>), while the internal temperature remains at
264 . IMPI
16-19 ° C. After 15 minutes, the neglect ceases;
<img file="MX339989B_D0531.tif" />
In a separate container, the product of Example 1A (22.04 g, 95% by weight, 63.8 mmol) is added, followed by THF (80 ml), to form an orange solution. After cooling the suspension to 11 ° C, the borane solution is transferred by cannula into the dione suspension within 3-5 minutes. During this period, the internal temperature of the suspension rises to 16 ° C. After the addition is complete, the reaction is held at 2027 ° C for an additional 2.5 hours. After the reaction is complete, the mixture is cooled to 5 ° C and methanol (16.7 g, 521 mmol) is added dropwise over 5-10 minutes, maintaining an internal temperature <20 ° C (note: vigorous release of H<sub>2</sub>). After the exotherm ceases (approx. 10 minutes), the temperature is adjusted to 23 ° C, and the reaction is mixed until complete dissolution of the solids occurs. Ethyl acetate (300 ml) and 1 M HCl (120 ml) are added, and the phases are partitioned. The organic phase is then washed successively with 1 M HCl (2 x 120 ml), H<sub>2</sub>O (65 ml), and 10% aqueous NaCl (65 ml). Organics are dried with MgSO<sub>4</sub>, filtered, and concentrated in vacuo. Product crystallization occurs during concentration. The suspension is heated to 50 ° C, and heptane (250 ml) is added over the course of 15 minutes. The suspension is then allowed to mix at 23 ° C for 30 minutes and filtered. The wet cake is washed with 3: 1 heptane: ethyl acetate (75 ml), and the orange crystalline solids are dried at 45 ° C for 24 hours to provide the
265 Title compound (15.35 g, 99.3% ee, 61% yield) ^^^ r ^ a ^^ L ^ F is contaminated with 11% of the meso isomer (vs. di isomer).
<img file="MX339989B_D0532.tif" />
EXAMPLE 33 (1S, 4S) -1.4-bis (4-nitrophenyl) butane-1,4-diol
HO OH
The product from Example 1A (30 g, 95% by weight, 91.4 mmol) is subjected to the conditions described in Example 32, substituting (R) - (-) - a, α-diphenyl-2-pyrrolidinemethanol for (S) - (-) - a, adiphenyl-2-pyrrolidinemethanol, to obtain the title compound (20.14 g,> 99.55 ee, 61% yield) which is contaminated with 9.7% of the meso isomer (against the di isomer).
EXAMPLE 34 (2S, 2'S) -1,1 '- ((2S.2'S) -2.2' - (4.4 '- ((2S, 5S) -1- (4-terbuti Ifeni Dpi rrol idin-2,5-di -yl) bis (4,1-phenylene)) bis (azandi I) bis (oxomethyl n) bis (pyrrole ¡di n-2,1-di-i l)) bis (3-meth¡ 1- Dimethyl 1-oxobutan2,1-di-yl) dicarbamate
Ϊ.
(2S.2<sup>,</sup>S) -1.1<sup>,</sup>- ((2S.2<sup>,</sup>S) -2.2 '- (4.4<sup>,</sup>- ((2R.5R) -1- (4-tert-butylphenyl) pyrrolidin-2,5-di-yl) bis (4,1-phenylene)) bis (azandiyl) bis (oxomethylene) bis (pyrrolidi n-2,1 -di-yl)) bis (3-methyl-1-oxobutan2,1-di-iI) d¡carbamate d dimethyl
266
<img file="MX339989B_D0533.tif" />
- (4-te r-buti Ifen yl) -2,5-b¡s (4-nitrophe ni I) pyrrolidine
The product of Example 1C (3.67 g, 7.51 mmol) and 4-tert-butylaniline (11.86 ml, 75 mmol) in DMF (40 ml) are stirred under nitrogen at 50 ° C for 4 hours. The resulting mixture is diluted with ethyl acetate, treated with 1M HCl, stirred for 10 minutes, and filtered to remove solids. The filtered organic layer is washed twice with brine, dried over sodium sulfate, filtered and evaporated. The residue is purified by chromatography on silica gel eluting with ethyl acetate in hexane (5% to 30%) to obtain a solid. The solid is triturated in a minimum volume of 1: 9 ethyl acetate / hexane to obtain a light yellow solid as a mixture of trans and cis isomers (1.21 g, 36%).
267
4,4 '- ((2S.5S) -1- (4-tert-butylphenyl) pyrrolidin-2,5-di-yl) dian1f1<sup>I</sup>i<sup>l</sup>ft<sup>T</sup>to<sup>AI</sup>(¡R ((2R.5RÍ-1 - (4-tert-but¡phenyl) pyrroiid¡n-2,5- (Ji-ll ') clianlíliid
EXAMPLE 34B
IMPI
MEXICAN INSTITUTE OF PROPERTY
<img file="MX339989B_D0534.tif" />
To a solution of the product from Example 34A (1.1 g, 2.47 mmol) in ethanol (20 ml) and THF (20 ml) is added PtO<sub>2</sub> (0.22 g, 0.97 mmol) into a 50 ml pressure bottle and stir under 2.11 kg / cm<sup>2</sup> hydrogen at room temperature for 1 hour. The mixture is filtered through a nylon membrane and evaporated. The residue is purified by chromatography on silica gel eluting with ethyl acetate in hexane (20% to 60%). The title compound elutes as the first of 2 stereoisomers (trans isomer, 0.51 g, 54%).
EXAMPLE 34C (2S, 2'S) -2,2 '- (4.4' - ((2S, 5SI-1- (4-fer / '- but¡ Ifeni l) p¡rrolid¡n-2,5-diii) b ¡S (4.1 -phenylene)) bis (azandi-yl) bis (oxomethylene) dipyrrol¡din-1 tert-butyl carboxylate and (2S.2'S) -2.2 '- (4.4<sup>,</sup>- ((2R, 5R) -1- (4-t-rbutylphenyl) pyrrolidin-2,5-di-yl) bis (4,1-phenylene)) bis (azandiyl) bis (oxomethylene) dipyrrolidin-1 -tert-butyl carboxylate
To a mixture of the product of Example 34B (250 mg,
0.648 mmol), (S) -1- (tert-butoxycarbonyl) pyrrolidine-2-carboxylic acid (307 mg, 1.427 mmol) and HATU (542 mg, 1.427 mmol) in DMSO (10 ml) Hunig's base (0.453 mi, 2.59 mmol). Mix
268 reaction is stirred at room temperature di ^ a ^^ Jp íj | oi
INSTITUTO MEXiCANÍ mixture is partitioned with ethyl acetate and water. The mixture is washed with brine, dried over sodium sulfate, filtered and evaporated. The residue is purified by chromatography on silica gel eluting with ethyl acetate in hexane (10% to 50%) to obtain the title compound (500 mg, 99%).
<img file="MX339989B_D0535.tif" />
EXAMPLE 34D (2S, 2'S) -N, N<sup>,</sup>- (4,4 '- ((2S.5S) -' 1- (4-tert-butiphenyl) pyrroidin-2.5-diyl) bis (4,1-phenyleneDdipyrrolidiη-2-carboxamide and (2S, 2'S) -N. phenylene)) d¡ pyrrolidine-2-carboxamide
To the product of Example 34C (498 mg, 0.638 mmol) in dichloromethane (4 ml) is added TFA (6 ml). The reaction mixture is stirred at room temperature for 1 hour and concentrated in vacuo. The residue is partitioned between CHCI<sub>3</sub>: isopropyl alcohol 3: 1 and NaHCO<sub>3</sub> saturated aqueous. The aqueous layer is re-extracted with CHCI<sub>3</sub>: isopropyl alcohol 3: 1. The combined organic layers are dried over Na<sub>2</sub>SW<sub>4</sub>, filter and concentrate to obtain the title compound (345 mg, 93%).
EXAMPLE 34E
X2S, 2'S) -1.1 ^ ((25.2 ^) - 2.2 ^ (4.4 ^ ((25.5S) -1- (4-tert-butylfin) pyrrolidin-2,5-di-yl ) bis (4,1-phenylene)) bis (azand¡269 ¡l) b¡s (oxomethylene) b¡s (pyrrolidin-2.1-di-yl)) bis (3-me
2,1-di-¡l) dimethyl dicarbamate
<img file="MX339989B_D0536.tif" />
AND.
(2S, 2<sup>,</sup>S) -1.1<sup>,</sup>- ((2S.2'S) -2.2 '- (4.4<sup>,</sup>- ((2R, 5R) -1- (4-tert-butylphenyl) pyrrolidin-2.5-di-yl) bis (4.1 -phenylene)) b¡s (azand¡¡l) bis (oxomethylene) bis (pyrroidi dimethyl n-2,1-di-i l)) bis (3-methyl-1-oxobutan-2,1-di-yl) dicarbamate
The product of Example 34D (29.0 mg, 0.050 mmol), (S) -2- (methoxycarbonylamino) -3-methylbutanoic acid (19.27 mg, 0.110 mmol), EDAC (21.09 mg, 0.110 mmol), HOBT (16.85 mg, 0.110 mmol) and N-methylmorpholine (0.027 ml, 0.250 mmol) are combined in DMF (2 ml). The reaction mixture is stirred at room temperature for 3 hours. The mixture is partitioned with ethyl acetate and water. The organic layer is washed with brine twice, dried over sodium sulfate, filtered, and evaporated. The residue is purified by chromatography on silica gel eluting with ethyl acetate in hexane (50% to 80%) to obtain a solid. The solid is triturated with ethyl acetate / hexane to obtain the title compound (13 mg, 29%).
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ ppm 0.85 - 0.95 (m, 12 H)
1.11 (s, 9H) 1.59 - 1.65 (m, 2H) 1.79 - 2.04 (m, 8H) 2.10 - 2.18 (m, 2H) 2.41 - 2.46 (m, 2H) 3.52 (s, 6H) 3.57 - 3.67 (m, 2H) 3.76 - 3.86 (m, 2H) 4.00 (t, J = 7.56 Hz, 2H) 4.39 - 4.46 (m, 2H) 5.15 (d, J = 7.00 Hz, 2H) 6.17 (d, J = 7.70 Hz, 2H) 6.94 (d, J = 8.78 Hz, 2H) 7.13 (d,
270
J = 7.37 Hz, 4H) 7.30 (d, J = 8.20 Hz, 2H) 7.50 (d, JMPJ
MEXICAN INSTITUTE OF PSOPIEDAD
9.98 (s, 2H). industrial (ESI +) m / z 895 (M + H) +. —-—
The title compound shows an EC value<sub>50</sub> less than about 0.1 nM in HCV 1b-Con1 replicon tests in the presence of 5% FBS.
EXAMPLE 35 (2S, 2<sup>,</sup>S) -1.1<sup>,</sup>- ((2S.2'S) -2.2<sup>,</sup>- (4.4 '- ((2S, 5S) -1- (4-tert-butylphenyl) p¡rrol¡din-2,5-di-yl) b¡s (4.1-phenylene)) b¡s (azandi¡ l) b¡s (oxomethylene) b¡s (p¡rrolidin-2.1-d¡-¡l)) b¡s (3-methyl-1-oxobutan2,1-di-yl) d¡carbamate of dimethyl
<img file="MX339989B_D0537.tif" />
<img file="MX339989B_D0538.tif" />
The product from Example 34E is purified by chiral chromatography on a semi-preparative AD-H Chiralpak column eluting with a 2: 1 mixture of hexane (2: 1 isopropyl alcohol: EtOH). The title compound is the first of the 2 diastereomers to elute.
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ ppm 0.88 (d, J = 6.61 Hz,
H) 0.93 (d, J = 6.72 Hz, 6 H) 1.11 (s, 9 H) 1.63 (d, J = 5.42 Hz, 2 H)
1.80 - 2.04 (m, 8H) 2.09 - 2.19 (m, 2H) 2.44 - 2.47 (m, 2H) 3.52 (s,
271
Η) 3.59 - 3.66 (m, 2 Η) 3.77 - 3.84 (m, 2 Η) 4<sup>θ2</sup>· (T, JJ
MEXICAN INSTITUTE
<img file="MX339989B_D0539.tif" />
4.42 (dd, J = 7.86, 4.83 Hz, 2 H) 5.14 (d, J = 6.18 Hz, n »37 J = 8.67 Hz, 2 H) 6.94 (d, J = 8.78 Hz, 2 H) 7.13 (d, J = 8.46 Hz, 4H) 7.31 (d, J = 8.35 Hz, 2H) 7.50 (d, J = 8.35 Hz, 4H) 9.98 (s, 2H).
The title compound shows an EC value<sub>50</sub> less than about 0.1 nM in VCH 1b-Con1 replicon tests in the presence of 5% FBS.
EXAMPLE 36 (2S, 2<sup>,</sup>S) -1.1 '- ((2S.2<sup>,</sup>S) -2.2<sup>,</sup>-(4.4<sup>,</sup>- ((2R.5R) -1- (4-tert-butylphenyl) pyrrolidin-2,5-di-yl) bis (4,1-phenylene)) bis (azandiyl) bis (oxomethylene) bis (pyrrolidin-2 Dimethyl, 1-di-yl)) bis (3-methyl-1-oxobutan-2,1-di-yl) dicarbamate
<img file="MX339989B_D0540.tif" />
The product from Example 34E is purified by chiral chromatography on a semi-preparative AD-H Chiralpak column eluting with a 2: 1 mixture of hexane: (isopropyl alcohol: EtOH 2: 1). The compound of the. titer is the second of the 2 diastereomers to elute.
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ ppm 0.87 (d, J = 6.51 Hz, 6 H) 0.92 (d, J = 6.72 Hz, 6 H) 1.11 (s, 9 H) 1.63 (d, J = 5.53 Hz, 2H)
272
<img file="MX339989B_D0541.tif" />
H) 4.02 (t, J = 7.26 Hz, 2 H)
J = 6.18 Hz. 2 Hl 6.17
1.82 - 2.04 (m, 8 Η) 2.09-2.18 (m, 2 Η)
Η) 3.58 - 3.67 (m, 2 Η) 3.75 - 3.84 (m 4.43 (dd, J = 7.92, 4.88 Hz, 2 H) 5.14
J = 8.78 Hz, 2 H) 6.94 (d, J = 8.67 Hz, 2 H) 7.12 (d, J = 8.46 Hz, 4 H) 7.31 (d, J = 8.35 Hz, 2 H) 7.49 (d, J = 8.46 Hz, 4H) 9.98 (s, 2H).
The title compound shows an EC value<sub>50</sub> less than about 0.1 nM in HCV 1b-Con1 replicon tests in the presence of 5% FBS.
EXAMPLE 37 (2S.2<sup>,</sup>S) -1.1 '- ((2S, 2'S) -2.2<sup>,</sup>-(4<sub>1</sub>4<sup>,</sup>- ((2S.5S) -1- (4-tertbutylphenyl) pyrrolidin-2.5-di-¡l) b¡s (4,1-phenylene)) bis (azandiii) bis (oxomethien) bis Dimethyl (pyrrolidin-2,1-di-yl)) bis (3-methyl-1-oxobutan2,1-d ¡-¡Ddicarbamate
<img file="MX339989B_D0542.tif" />
EXAMPLE 37A
(S) -2,5-dioxopyrrolidi n-1 -yl 2- (methoxycarbonylamino) -3-methylbutanoate
To a mixture of (S) -2- (methoxycarbonylamino) -3-methylbutanoic acid (19.66 g, 112 mmol) and N-hydroxysuccinimide (13.29g,
273
116 mmol) add ethyl acetate (250 ml), Aj<sub>ST</sub>Pheromeaeía <'· OF PROPERTY *, · INDUSTRIAL cools down to 0-5 ° C. Add d¡-¡soprop¡lcarbod¡-¡mide (13.88 g, 110
<img file="MX339989B_D0543.tif" />
<img file="MX339989B_D0544.tif" />
mmol) and the reaction mixture is stirred at 0-5 ° C for about 1 hour. The reaction mixture is warmed up to room temperature. The solids (di-isopropylurea by-product) are filtered and rinsed with ethyl acetate. The filtrate is concentrated in vacuo to an oil. Isopropyl alcohol (200 ml) is added to the oil and the mixture is heated to about 50 ° C to obtain a homogeneous solution. After cooling, crystalline solids form. The solids are filtered and washed with isopropyl alcohol (3 x 20 ml) and dried to obtain the title compound as a white solid (23.2 g, 77% yield).
EXAMPLE 37B
(S) -1 - ((S) -2-fmethoxycarbonylamino) -3m eti I b uta noi I) pyrrolid i η-2-carboxylic acid
To a mixture of L-proline (4.44 g, 38.6 mmol), water (20 ml), acetonitrile (20 ml) and DIEA (9.5 g, 73.5 mmol) is added a solution of the product from Example 37A (10 g, 36.7 mmol ) in acetonitrile (20 ml) over the course of 10 minutes. The reaction mixture is stirred overnight at room temperature. The solution is concentrated in vacuo to remove acetonitrile. 6N HCl (9 ml) is added to the resulting clear aqueous solution until pH ~
two. The solution is transferred to a separatory funnel and added
274
NaCI at 25% (10 ml) and the mixture is extracted with ace ^ atMAlá · INSTITUTO MEXICANO
OF THE PROPERTY mi), and then again with ethyl acetate (6 x 2¿T mFj<sup>TO</sup>,<sup>L</sup> and the combined extracts are washed with 25% NaCl (2 x 10 ml), the solvent is evaporated until a thick oil is obtained. Heptane is added and the solvent is evaporated to obtain a foam, which is dried under high vacuum. Diethyl ether is added and the solvent is evaporated to obtain a foam, which is dried under high vacuum to obtain the title compound (10.67g) as a white solid.
The compound of Example 37B can also be prepared according to the following procedure:
L-valine (35 g, 299 mmol), 1N sodium hydroxide solution (526 ml, 526 mmol) and sodium carbonate (17.42 g, 164 mmol) are charged to a flask. The mixture is stirred for 15 minutes to dissolve the solids and then cooled to 15 ° C. Methyl chloroformate (29.6 g, 314 mmol) is added slowly to the reaction mixture. The mixture is then stirred at room temperature for 30 minutes. The mixture is cooled to 15 ° C and the pH is adjusted to ~ 5.0 with concentrated HCl solution. 100 ml of 2-methyltetrahydrofuran (2-MeTHF) is added and the pH adjustment continues until the pH reaches ~ 2.0. 150 ml of 2-MeTHF are added and the mixture is stirred for 15 minutes. The layers are separated and the aqueous layer is extracted with 100 ml of 2-MeTHF. The combined organic layer is dried over Na<sub>2</sub>SW<sub>4</sub> anhydrous and filtered, and the Na cake<sub>2</sub>SW<sub>4</sub> It is washed with 50 ml of 2-MeTHF. The product solution is
275
<img file="MX339989B_D0545.tif" />
concentrates to ~ 100 ml, disperses with 120 ml dejll
MEXICAN INSTITUTE OF FROPIEDAD
250 ml of heptanes are slowly charged and then the mixture volume is concentrated to 300 ml. The mixture is heated to <16<sup>n</sup>0 and 160 ml of heptanes are loaded. The mixture is cooled to room temperature in 2 hours, stirred for 30 minutes, filtered and washed with 2-MeTHF / heptanes mixture (1: 7, 80 ml). The wet cake is dried at 55 ° C for 24 hours to obtain 47.1 g of the Moc-L-ValOH product as a white solid (90%).
Moc-L-Val-OH (150 g, 856 mmol), hydrated HOBt (138 g, 899 mmol) and DMF (1500 ml) are charged to a flask. The mixture is stirred for 15 minutes to obtain a clear solution. EDC hydrochloride (172 g, 899 mmol) is charged and mixed for 20 minutes. The mixture is cooled to 13 ° C and (L) -prollna benzyl ester hydrochloride (207 g, 856 mmol) is charged. Triethylamine (109 g, 1079 mmol) is then charged in 30 minutes. The resulting suspension is mixed at room temperature for 1.5 hours. The reaction mixture is cooled to 15 ° C and 1500 ml of NaHCO are charged<sub>3 </sub>6.7% in 1.5 hours, followed by the addition of 1200 ml of water over the course of 60 minutes. The mixture is stirred at room temperature for 30 minutes, filtered and washed with a water / DMF mixture (1: 2, 250 ml) and then with water (1500 ml). The wet cake is dried at 55 ° C for 24 hours to obtain 282 g of product as a white solid (90%).
The resulting solids (40 g) and 5% Pd / Alumina are charged to a Parr reactor followed by THF (160 ml). The reactor is
276
ΙΜΡ<sup>Τ</sup>
<img file="MX339989B_D0546.tif" />
seal and purge with nitrogen (6 x 1.41 kg / cm<sup>2</sup>
INDUSTRIAL followed by a hydrogen purge (6 x 2.11 kg / cm<sup>2</sup> manometric).
The reactor is pressurized to 2.11 kg / cm<sup>2</sup> Manometric with hydrogen and stir at room temperature for approximately 15 hours. The resulting suspension is filtered through a GF / F filter and concentrated to approximately 135 g of solution. Heptane (120 ml) is added, and the solution is stirred until solids form. After an addition of 2-3 hours additional heptane (240 ml) is added dropwise, the suspension is stirred for about 1 hour, the suspension is filtered. The solids are dried to obtain the title compound.
EXAMPLE 37C
Di methanesulf or nato of (1R, 4R) -1,4-bis (4-nitrophenyl) butan-1,4-di-yl
The product from Example 32 (5.01 g, 13.39 mmol) is combined with 2-methyltetrahydrofuran (70 ml) and cooled to -5 ° C, and Ν, Ν-di-isopropylethylamine (6.81 g, 52.7 mmol) is added in a 30 second span. Separately, a solution of methanesulfonic anhydride (6.01 g, 34.5 mmol) in 2-methyltetrahydrofuran (30 ml) is prepared and added to the diol suspension over the course of 3 minutes, keeping the internal temperature between -15 ° C and -25. ° C. After mixing for 5 minutes at -15 ° C, the cooling bath is removed and the reaction is allowed to slowly warm to 23 ° C and mixed for 30 minutes. After
277 the reaction is completed, the crude suspension to the next step.
takes
IMPtJn
INSTITUTO MEXICANO DI LA PROPIEDAD
INDUSTRIAL
<img file="MX339989B_D0547.tif" />
EXAMPLE 37D (2S, 5S) -1- (4-tert-butylphenyl) -2,5-bis (4-nitrophen-Dpyrrolidine
To the crude product solution from Example 37C (7.35 g,
13.39 mmol) 4-tert-butylaniline (13.4 g, 90 mmol) is added to
23 ° C within 1 minute. The reaction is heated to 65 ° C for 2 hours. After completion, the reaction mixture is cooled to 23 ° C and diluted with 2-methyltetrahydrofuran (100 ml) and 1 M HCl (150 ml). After partitioning the phases, the organic phase is treated with 1 M HCl (140 ml), 2-methyltetrahydrofuran (50 ml), and 25% by weight aqueous NaCl (100 ml), and the phases are partitioned. The organic phase is washed with 25% by weight aqueous NaCl (50 ml), dried with MgSO<sub>4</sub>, filtered, and concentrated in vacuo to approximately 20 ml. Additional heptane (30 ml) and 2-methyltetrahydrofuran are added in order to induce crystallization. The suspension is further concentrated, and additional heptane (40 ml) is added slowly and the suspension is filtered, washed with 2-methyltetrahydrofuran: heptane (1: 4, 20 ml). The solids are suspended in MeOH (46 ml) for 3 hours, filtered, and the wet solid is washed with additional MeOH (18 ml). The solid is dried at 45 ° C in a vacuum oven for 16 hours to provide the title compound (3.08 g, 51% yield in 2 steps).
278
EXAMPLE 37E
INDUSTRIAL
4,4 '- ((2S, 5S) -1- (4-tert-buty Ifeni Dpi rrolidi n-2,5-di-yl) diani line
IMPI
MEXICAN INSTITUTE OF FROPIEDAD
<img file="MX339989B_D0548.tif" />
To a 160 ml hydrogenation vessel with Parr shaker is added the product of Example 37D (2 g, 4.49 mmol), followed by 60 ml of THF, and Raney Grace 2800 nickel (1 g, 50% by weight (dry basis) ) under a stream of nitrogen. The reactor is assembled and purged with nitrogen (8 x 1.41 kg / cm<sup>2</sup> gauge) followed by hydrogen purging (8 x 2.11 kg / cm<sup>2</sup> manometric). The reactor is then pressurized to 2.11 kg / cm<sup>2</sup> Manometric measurements with hydrogen and agitation (700 rpm) begins and continues for a total of 16 hours at room temperature. The suspension is filtered by vacuum filtration using a Whatman GF / F glass fiber filter.
Evaporation of the filtrate to obtain a suspension followed by the addition of heptane and filtration produces the crude title compound, which is dried and used directly in the next step.
EXAMPLE 37F (2S, 2'S) -1.1 '- ((2S, 2'S) -2.2' - (4.4 '- ((2S, 5S) -1- (4-terbuti Ifeni l) pi rrol¡ d¡n-2,5-di-yl) b¡s (4,1-phenylene) bis (azandiiDbis (oxomethyleneDbis (pyrrolidin-2,1-di-iD) bis (3-methyl-1- dimethyl oxobutan2,1-di-illdicarbamate
To a solution of the product of Example 37E (1.64 g, 4.25 mmol) in DMF (20 ml), the product of Example 37B (2.89 g, 10.63
279 mmol), and HATU (4.04 g, 10.63 mmol) in DMF ('
<img file="MX339989B_D0549.tif" />
triethylamine (1.07 g, 10.63 mmol), and the solution at room temperature for 90 minutes. 20 ml of water are poured into the reaction mixture, and the white precipitate obtained is filtered, and the solid is washed with water (3x5 ml). The solid is blown dry for 1 hour. The crude material is loaded onto a silica gel column and eluted with a gradient starting with ethyl acetate / heptane (3/7), and ending with pure ethyl acetate. The desired fractions are combined and the solvent is distilled to obtain a very light yellow solid, which is dried at 45 ° C in a vacuum oven with nitrogen purge for 15 hours to obtain the title compound (2.3 g, 61% yield).
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ ppm 0.88 (d, J = 6.61 Hz
H) 0.93 (d, J = 6.72 Hz, 6 H) 1.11 (s, 9 H) 1.63 (d, J = 5.42 Hz, 2 H)
1.80 - 2.04 (m, 8H) 2.09 - 2.19 (m, 2H) 2.44 - 2.47 (m, 2H) 3.52 (s, 6H) 3.59 - 3.66 (m, 2H) 3.77 - 3.84 (m, 2 H) 4.02 (t, J = 8.40 Hz, 2 H)
4.42 (dd, J = 7.86, 4.83 Hz, 2H) 5.14 (d, J = 6.18 Hz, 2H) 6.17 (d, J = 8.67 Hz, 2H) 6.94 (d, J = 8.78 Hz, 2H) 7.13 (d, J = 8.46 Hz, 4 H)
7.31 (d, J = 8.35 Hz, 2H) 7.50 (d, J = 8.35 Hz, 4H) 9.98 (s, 2H).
Alternatively, the product from Example 37E (11.7 g, 85% by weight, 25.8 mmol) and the product from Example 37B (15.45 g, 56.7 mmol) are suspended in EtOAc (117 ml), diisopropylethylamine (18.67 g, 144 mmol) and the solution is cooled to 0 ° C. In a separate flask, 1-propanphosphonic acid cyclic anhydride (T3P®) (46.0 g, 50% by weight is dissolved in EtOAc, 72.2
280
<img file="MX339989B_D0550.tif" />
<img file="MX339989B_D0551.tif" />
mmol) wn EtOAc (58.5 ml), and loaded into an emb
PROPERTY, INDUSTRIAL _ T solution<sub>3</sub>P is added to the reaction mixture dropwise over 3-4 hours and stirred until the reaction is complete. The reaction is warmed to room temperature, and washed with 1M HCl / 7.5% wt NaCl (100 ml), then washed with NaHCO<sub>3</sub> 5% (100 ml), then washed with 5% NaCl solution (100 ml). The solution is concentrated to approximately 60 ml, EtOH (300 ml) is added, and the solution is concentrated to 84 g of solution.
A portion of the EtOH solution of the product (29 g) is heated to 40 ° C, and 134 g of EtOH are added to i 40% by weight in H<sub>2</sub>O. Add a seed suspension in EtOH / H<sub>2</sub>Or at 58% w / w, allow to stir at 40 ° C for several hours, then cool to 0 ° C. The suspension is then filtered, and washed with EtOH / H<sub>2</sub>Or at 58% w / w. The product is dried at 40-60 ° C under vacuum, and then rehydrated by placing a tray of water in the vacuum oven to obtain the title compound.
The title compound shows an EC value<sub>50</sub> less than about 0.1 nM in HCV 1b-Con1 replicon tests in the presence of 5% FBS.
EXAMPLE 38 f2S.2<sup>,</sup>S) -1.1<sup>,</sup>- ((2S.2<sup>,</sup>S) -2.2<sup>,</sup>- (4.4 '- ((2R<sub>1</sub>5R) -1- (4fl uorophenyl) pyrrolid¡n-2.5-di-yl) bis (4,1-phenylene)) bis (azandi¡Dbisloxomethyl n) bis (pyrrolidin-2,1-di-yl)) bis (3.3-dim til-1281
<img file="MX339989B_D0552.tif" />
OF INDUSTRIAL PROPERTY
<img file="MX339989B_D0553.tif" />
di oxobutan-2,1-di-yl) dicarbamate
<img file="MX339989B_D0554.tif" />
EXAMPLE 38A
(1 S, 4S) -1,4-bis (4-nitropheni i) b uta n-1,4-di-yl dimethanesulfonate
The title compound is prepared using the methods of Example 37C, substituting the product of Example 33 for the product of Example 32.
EXAMPLE 38B (2R.5RÍ-1 - (4-fluorophenyl) -2,5-bis (4-nitrophenyl) pyrolidine
The title compound is prepared using the methods of Example 37D, substituting 4-fluoroaniline for 4-tert-butylaniline.
EXAMPLE 38C
4,4 '- ((2R, 5R) -1 - (4-fluorophenyl) pyrrolidin-2,5-d¡-yl) dianiline
To a solution of the product from Example 38B (2.34 g, 5.74 mmol) in 1: 1 ethaneLTHF (60 ml) in a 250 ml stainless steel pressure bottle is added PtO<sub>2</sub> (0.47 g, 2.06 mmol) and the resulting mixture is placed under pressure of H<sub>2</sub> (2.11 kg / cm<sup>2</sup>) and
282 stir at room temperature for 90 minutes. LaJmj ^ jj ^ sJ
MEXICAN INSTITUTE. . . . . . ,. , , OF<sup>THE</sup> PROPERTY ~ _ through a nylon membrane and the filtrate is cut off in vacuum. The crude product is purified by a silica gel column chromatography using a solvent gradient of 065% ethyl acetate in hexanes to obtain the title compound as a solid (0.736 g, 37%).
<img file="MX339989B_D0555.tif" />
EXAMPLE 38D (2S, 2<sup>,</sup>S) -2.2<sup>,</sup>-(4.4<sup>,</sup>- ((2R.5R) -1 - (4-fluorophenyl) pyrrolidin-2,5-di¡l) bis (4.1-phenylene)) b¡s (azandi-¡l) bis (oxomethylene) tert-butyl di pyrrolidine-1 carboxylate
To a solution of the product of Example 38C (3.54 g, 10.19 mmol), (S) -1- (tert-butoxycarbonyl) pyrrolidin-2-carboxylic acid (5.48 g, 25.5 mmol), and HATU ( 9.69 g, 25.5 mmol) in anhydrous NMP (50 ml) add Ν, Ν-di-isopropylethylamine (5.29 ml, 30.6 mmol), and the reaction mixture is stirred at room temperature for 30-45 minutes. The reaction mixture is diluted with water (500 ml). The precipitated product is filtered and washed with water (3 x 100 ml), sodium bicarbonate solution (50 ml), and water (50 ml). The product is dried at 40 ° C for 15 hours. This material (8.5 g) is passed through a pad of silica gel and eluted with ethyl acetate to obtain the white solid product (7.9 g, 99%).
283
IMPI
EXAMPLE 38E (2S, 2<sup>,</sup>S) -N, N<sup>,</sup>- (4,4 '- ((2R.5R) -1- (4-fluorophen¡l) pyrrolid¡níT5-d¡INSTITUTO MEXICANO Dt LA FROEIECaD
<img file="MX339989B_D0556.tif" />
¡L) b¡s (4,1 -phenyl)) dip¡rrol¡d¡n-2-carboxamide
To a solution of the product from Example 38D (7.9 g, 10.65 mmol) in dichloromethane (50 ml), 5M HCl solution in Isopropyl alcohol (50 ml) is added and the reaction mixture is stirred at room temperature for 16 hours. The solvent is evaporated using a rotary evaporator under vacuum and the crude material is dissolved in dichloromethane containing 20% methanol (200 ml). The solution is washed with 5% ammonium hydroxide solution (90 ml), brine (50 ml) and dried over MgSO<sub>4</sub>. The solution is filtered and concentrated to obtain 6.5 g of crude product. This material is recrystallized from ethyl acetate / heptane (8/2) to obtain the title compound (5.0 g, 87% yield).
EXAMPLE 38F (2S.2<sup>,</sup>S) -1.1<sup>,</sup>- ((2S, 2<sup>,</sup>S) -2.2<sup>,</sup>- (4.4 '- ((2R, 5R) -1- (4fluorophenyl) pyrrolidin-2,5-di-yl) bis (4,1-phenylene)) bis (azandiyl) bis (oxomethylene) bis ( pyrrole id in-2,1-di-yl)) dimethyl bis (3,3-dimethyl 1-1 oxobutan-2,1-di-iDdicarbamate
To a solution of the product of Example 38E (4.14 g, 7.64 mmol), (S) -2-methoxycarbonylamino-3,3-dimethyl-butyric acid (3.62 g, 19.11 mmol), and EDAC (3.66 g, 19.11 mmol) in Anhydrous DMF
284 (80 ml) add N, N-di-isopropylethylamine (2.96 g, 22J? 3LMImtfldk) ^ £ Í ^^^
MEXICAN INSTITUTE
DE LA PROHEDAD * the solution is stirred at room temperature for 4 The * reaction mixture is poured into 400 ml of water, and on the left the white color obtained is filtered and washed with water (3 x 50 ml), sodium bicarbonate (50 ml), water (50 ml), and dried at 45 ° C in a vacuum oven with nitrogen purge for 15 hours to obtain 7.0 g of the crude product. The crude material is loaded onto a silica gel column (150g silica) and eluted with a gradient starting with ethyl acetate / heptane (7/3), and ending with ethyl acetate. The desired fractions are combined and the solvent is distilled to obtain a very pale yellow oil, which is ground MTBE / heptane (1: 9) for 1 hour. The white solid obtained in this way is filtered and dried in a vacuum oven with nitrogen purge to obtain 6.1 g of product. The 5.5 g of solid are dissolved in 16 ml of methanol and this solution is added to water (220 ml) in a 500 ml flask. The suspension is stirred for 30 minutes, and the solid is collected by filtration, dried at 45 ° C with nitrogen purge for 15 hours to obtain the title compound (5.4 g).
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ ppm 0.96 (s, 18H) 1.64 (d, J = 5.53 Hz, 2H) 1.78 - 1.93 (m, 6H) 1.94 - 2.06 (m, 2H) 2.09 2.21 (m, 2H) 3.54 (s, 6H) 3.59 - 3.69 (m, 2H) 3.72 - 3.83 (m, 2H)
4.20 (d, J = 8.89 Hz, 2H) 4.43 (dd, J = 7.92, 5.42 Hz, 2H) 5.16 (d, J = 6.29 Hz, 2H) 6.20 (dd, J = 9.16, 4.39 Hz, 2 H) 6.77 (t, J = 8.95 Hz, 2
H) 7.12 (d, J = 8.57 Hz, 4H) 7.50 (d, J = 8.57 Hz, 4H) 9.99 (s, 2H).
285
IMPI
The title compound shows a value
INDUSTRIAL of approximately 0.1 nM in the HCV 1b-Con1 replicon tests in the presence of 5% FBS.
EXAMPLE 39
N- (methoxycarbonyl) -L-valyl-N- (4 - <(2S, 5S) -1 - (4-fluorophenyl) -5-r4- (2f (2S) -1 -rN- (methoxycarbonyl ) -L-valillpyrroliclin-2-yl) -1 H-imidazol-4-yl) phenylp¡rrol¡d¡n-2-yl) phenl) -L-prolinamide (ACD v12)
AND.
N- (methoxycarbon¡I) -L-valyl-N- (4 - ((2R, 5R) -1 - (4-fluorophenyl) -5-f4- (2fí2S) -1-rN- (methoxycarbonyl) - L-valiHpyrrolidin-2-yl} -1 H-imidazol-4iDphenylpyrrolidin-2-iiIfeniΠ-L-prolinamide (ACD v12)
<img file="MX339989B_D0557.tif" />
<img file="MX339989B_D0558.tif" />
EXAMPLE 39A
1- (4-bromophenyl) -4- (4-nitrophenyl) butane-1,4-dione
286
Benzene (108 ml) is added to anhydrous chlorWQ ^^^ j ^ í
INDUSTRIAL
Λ * 1ΚΛ3ΛπΐΚ. · 2 £ Λ. ·. ζ.'Λ4
IMPI
-lorWW »
INDUSTRIAL (19.62 g, 144 mmol), followed by the addition of diethylamine (11.16
<img file="MX339989B_D0559.tif" />
ml, 108 mmol) and 2-methylpropan-2-ol (10.32 ml, 108 mmol) and stir at room temperature for 2 hours. 2-Bromo1- (4-bromophenyl) ethanone (20 g, 72.0 mmol) and 1- (4-nitrophenyl) ethanone (17.83 g, 108 mmol) are added together and the mixture is stirred for 18 hours. 5% aqueous sulfuric acid (50 ml) is added and stirred vigorously, then the product is collected by filtration, rinsed with benzene, water, methanol, dichloromethane and dried under vacuum to provide the product (15.0 g, 58% yield, colorless powder).
EXAMPLE 39B
- (4-bromophenyl) -4- (4-nitrophenyl) butan-1,4-diol
The product from Example 39A (3.64 g, 10.05 mmol) is dissolved in ethanol (67 ml) and sodium borohydride (0.837 g,
22.11 mmol) per servings. After stirring for 1 hour at room temperature, the mixture is filtered through celite and washed with methanol and ethyl acetate and the filtrate is concentrated to a solid. The solid is dissolved in ethyl acetate (200 ml) and extracted with aqueous 1N HCl (200 ml), then brine and the organic layer is dried and concentrated to a colorless oil (3.68 g, 100%) which is used directly in the next reaction.
287
EXAMPLE 39C IMPI
MEXICAN INSTITUTE DF. THE PRül'iEC'AD
1- (4-bromophenyl) -4- (4-nitrophenyl) b dimethanesulfonate<sup>l</sup>Eftff1<sup>></sup>M
<img file="MX339989B_D0560.tif" />
ilo
The product from Example 39B (3.68 g, 10.05 mmol) is dissolved in dichloromethane (167 ml) and the solution is cooled in an ice bath followed by the addition of triethylamine (4.20 ml, 30.1 mmol) and methanesulfonyl chloride (1.96 ml , 25.1 mmol) dropwise. After stirring for 15 minutes, the solution is concentrated to a solid (5.25 g, 100%) that is used directly in the next reaction.
EXAMPLE 39D
2- (4-bromophenyl) -1 - (4-fluorophenyl) -5- (4-nitrophenyl) pyrrolidine
The product from Example 39C (5.25 g, 10.05 mmol) is dissolved in DMF (31 ml) and then 4-fluoroaniline (9.65 ml, 101 mmol) is added and the solution is heated at 50 ° C for 18 hours. The solution is cooled to room temperature and aqueous 1N HCl (100 ml) is added then extracted with ethyl acetate (2 x 200 ml), the combined organic extracts are then washed with brine, dried and concentrated to an oil. amber color to which methanol (10 ml) is added and after 3 hours a yellow solid (1.05 g, 24%) is obtained as the title compound as a 1/1 mixture of trans isomers of pyrrolidine.
288
1- (4-fluorofen yl) -2- (4-nitropheni 1) -5- (4- (4,4,5, S-tetrametH ^ lYS
EXAMPLE 39E
IMPI
MEXICAN INSTITUTE OF PROPERTY
<img file="MX339989B_D0561.tif" />
d¡oxaboroian-2-¡I) fen¡ Dpi rrolidrrw
The product of Example 39D (1.05 g, 2.38 mmol), 4,4,4 ', 4', 5,5,5 ', 5'-octamethyl-2,2' -bi (1,3,2- dioxaborolane) (0.725
2.86 mmol), [1,1'bis (diphenylphosphino) ferrocene] dichloropalladium (ll) (0.194 g, 0.238 mmol), and potassium acetate (0.35 g, 3.57 mmol) in dioxane (20 ml) and then nitrogen gas is bubbled through the solution for 10 minutes, then heated at 100 ° C for 1.5 hours. The solution is cooled to room temperature then filtered through celite and washed with ethyl acetate (20 ml). The filtrate is dried, concentrated, and the residue is purified by silica gel column chromatography, eluting with a solvent gradient of 10-50% ethyl acetate in hexane to obtain the title compound (1.09 g, 94% ) as a yellow solid and a 1/1 mixture of trans stereoisomers.
EXAMPLE 39F (2S) -2- (4- (4- (1- (4-fluoropheniD-5- (4-nitrophenyl) pyrrolidin-2-iDfeniD1 H-imidazole-2-l) pyrrolidine-1-carboxylate of ter -butyl
The product of Example 39E (1.05 g, 2.15 mmol), the product of Example 26D (0.748 g, 2.365 mmol), [1.1'289 atetar * —-
<img file="MX339989B_D0562.tif" />
bis (diphenylphosphino) ferrocene] dichloropaladium (ll) (0 j * 'INSTITUTO MEXICANO in a mixture of toluene (10 ml), ethanol (10 ml) and ^ Wi ^ Jín & ISc 1 N aqueous sodium bicarbonate (2.58 ml, 2.58 mmol) Nitrogen gas is bubbled through the solution for 10 minutes, then heated at 90 ° C for 3 hours. The solution is cooled to room temperature and water (20 ml) is added, then it is extracted with dichloromethane (50 ml), then dried, concentrated and the residue is purified by column chromatography with silica gel, eluting with a gradient of Solvent 0-100% ethyl acetate in hexane to obtain the title compound (0.28 g, 72%) as a yellow solid and a 1/1 mixture of trans stereoisomers.
EXAMPLE 39G (2S) -2- (4- (4- (5- (4-aminophenyl) -1- (4-f luorophenyl jpyrrolid-in-2-yl) phenyl) 1 H-lmidazol-2-yl ) tert-butyl p¡rrol¡d¡n-1-carboxylate
The product of Example 39F (300 mg, 0.502 mmol) is dissolved in ethanol (5 ml) and THF (5 ml) then platinum (IV) oxide (22.8 mg, 0.1 mmol) and a hydrogen balloon are added and the solution stir at room temperature for 2.5 hours. The solution is filtered through celite and washed with methanol (10 ml), then concentrated to obtain the title compound (285 mg, 100%) as a colorless semisolid and a 1/1 mixture of stereoisomers.
290
EXAMPLE 39H
IMPI
MEXICAN INSTITUTE OF INDUSTRIAL PROPERTY
<img file="MX339989B_D0563.tif" />
(2S) -2- (4- (5- (4- (2 - ((S) -1- (tert-butox¡carbon¡l) p¡rrol¡d¡n-2-¡l) -1H¡ tert-butyl midazol-4-yl) phenyl) -1 - (4-fluorophenyl) p¡rrol idin-2yl) phenylcarbamo¡l) pyrrolidin-1-carboxylate
The product of Example 39G (285 mg, 0.502 mmol), (S) -1- (tert-butoxycarbonyl) pyrrolidine-2-carboxylic acid (162 mg, 0.753 mmol), HATU (305 mg, 0.803 mmol) and base are dissolved of Hunig (0.263 ml, 1506 mmol) in DMSO (5 ml) and stirred at room temperature for 1 hour. Dichloromethane (50 ml) is added followed by extraction with water (2 x 50 ml), the organic extract is dried, concentrated and the residue is dissolved in methanol (10 ml) followed by the addition of potassium carbonate (400 mg, 2.89 mmol) and the bright yellow solution is stirred at room temperature for 30 minutes. The solution is then filtered and the filtrate is concentrated to an oil, which is dissolved in a 95/5 mixture of dichloromethane / methanol (50 ml) and extracted with water (20 ml). The organic extract is dried and concentrated to obtain the title product (350 mg, 91%) as a light yellow solid and a 1/1 mixture of stereoisomers.
EXAMPLE 391
(2S) -N- (4- (1- (4-fluorophenyl) -5- (4- (2 - ((S) pyrrolidin-2-D-1H-imidazole-4-iDfeniDpyrrolidi n-2-iDfen¡Dpi rrolidin2-carboxamide
291
<img file="MX339989B_D0564.tif" />
The product of Example 39H (350 mg, 0.458rnmcn (© Jes <sup>r J w</sup> OF THE DEEP!
INDUSTRIAL dissolves in a 4 M solution of hydrochloric acid in dioxane (6 ml) and the solution is stirred at room temperature for 30 minutes then the mixture is concentrated under high vacuum to a solid (approx. 310 mg) as a hydrochloride salt which is use directly in the next reaction.
EXAMPLE 39J
N- (methoxycarbonyl) -L-valyl-N- (4 - ((2S.5S) -1- (4-fluorophenyl) -5-r4- (2f (2S) -1-IN- (methoxycarbonyl) - L-valillP¡rrolidin-2-yl) -1 H-imidazol-4¡nphenylpyrrolidin-2-iDphenyl) -L-prolinamide (ACD v12)
¥.
N- (methoxycarbonyl) -L-valyl-N- (4 - ((2R.5R) -1 - (4-fluorophenyl) -5-r4- (2Í (2S) -1 -rN-ymethoxycarbonyl) -L -valillpyrrolidin-2-yl> -1 H-imidazol-4infeniHpyrrolidin-2-infhenyl) -L-prolinamide (ACD v12)
To a mixture of the product from Example 391 (300 mg, 0.45 mmol), (S) -2- (methoxycarbonylamino) -3-methylbutanoic acid (173 mg, 0.99 mmol), and HATU (428 mg, 1,125 mmol) in DMSO ( 5 ml) Hunig's base (0.786 ml, 4.5 mmol) is added, and the reaction is stirred at room temperature for 1 hour. Dichloromethane (50 ml) is added followed by extraction with water (2 x 25 ml), the organic extract is dried, concentrated and the residue is dissolved in methanol (15 ml) followed by the addition of potassium carbonate (300 mg, 2.17 mmol) and stirred at room temperature for 20
292
<img file="MX339989B_D0565.tif" />
minutes. The solution is an oil, which is dissolved in a 95/5 mixture of dichloromethane / methanol (50 ml) and extracted with water (20 ml). The organic extract is dried and concentrated, and the residue is purified by silica gel column chromatography, eluting with a solvent gradient of 0-25% methanol in dichloromethane to obtain the title compounds (0.13 g, 33% ) as a colorless solid and as a 1/1 mixture of diastereomers.
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ ppm 11.64 (s, 1H), 9.94 (s, 1H), 7.57 (d, J = 8.1 Hz, 2H), 7.47 (m, 3H), 7.33 (d, J = 1.7 Hz, 1H),
7.24 (m, 2H), 7.08 (m, 4H), 6.72 (m, 2H), 6.17 (m, 2H), 5.15 (m, 2H),
5.01 (m, 1H), 4.38 (m, 1H), 4.0 (m, 2H), 3.75 (m, 2H), 3.56 (m, 1H),
3.48 (s, 3H), 3.47 (s, 3H), 2.06 (m, 2H), 1.87 (m, 8H), 1.63 (m, 2H),
0.82 (m, 12H).
The title compound shows an EC value<sub>50</sub> less than about 0.1 nM in VCH 1b-Con1 replicon tests in the presence of 5% FBS.
EXAMPLE 40
N- (methoxycarbonyl) -L-varyl-N- (4-f (2S, 5S) -1- (4-tert-butylphenih-5-r4- (2f (2S) -1-rN- (methoxycarbonin-L- valiHpyrrolidin-2-in-1H-imidazol-4¡Dphenylpyrrolidin-2-yl> phenyl) -L-prolinamide (ACD v12)
AND.
N- (methoxycarbonyl) -L-val¡lN- (4 - ((2R, 5R) -1 - (4-tert-butyphenyl) -5-r4- (2 ((2S) -1-fN - (m-toxycarbonyl) -L-valillpyroiidin-2-yl) -1 H-imidazol-4293 ¡I) fe ni II pyrrol id i n-2-yl> f, nil) -L-prol inamide | Aca ^ fe ; c<sub>to</sub>g
INDUSTRIAL
<img file="MX339989B_D0566.tif" />
<img file="MX339989B_D0567.tif" />
EXAMPLE 40A
2- (4-bromophenyl) -1- (4-tert-butylphenyl) -5- (4-nitrophenyl) pyroiidin
The product from Example 39C (10.86 g, 20.79 mmol), DMF (65 ml) and 4-tert-butylaniline (26.5 ml, 166 mmol) is reacted according to the procedure in Example 39D to provide the title compound ( 5.0 g, 50%, yellow solid) as a mixture of cis and trans stereoisomers of pyrrolidine.
EXAMPLE 40B
- (4-tert-butylphenii) -2- (4-nitrophenyl) -5- (4- (4.4.5,5-tetramethyl-1,3,2d¡oxaborolan-2-¡l) phenyl) pyrrolidine
The product from Example 40A (2.0 g, 4.17 mmol),
294
4<sub>l</sub>4,4<sup>,</sup>)4’,5,5<sub>l</sub>5 ', 5'-octamethyl-2,2'-b¡ (1,3,2-dioxaborolan J mmol), [1,1'-bis (diphenylphosphino) ferrocene] dichloropala<sup>l</sup>9l ® ^^^
0.834 mmol), and potassium acetate (0.614 g, 6.26 mmol) in dioxane (35 ml) are reacted according to the procedure in Example 39E to provide the title compound (1.5 g, 68%, yellow solid ) as a mixture of stereoisomers.
EXAMPLE 40C (2S) -2- (4- (4- (1- (4-tert-butylphenyl) -5- (4-nitrophenyl) pyrrolidin-2-yl) phenyl) 1 H-imidazol- Tert-butyl 2-¡l) p¡rrolid¡n-1-carboxylate
The product of Example 40B (0.7 g, 1.33 mmol), tert-butyl (S) -2 (4-bromo-1 H-imidazol-2-yl) pyrrolidine-1-carboxylate (0.462 g, 1.463 mmol), [ 1,1'-bis (diphenylphosphino) ferrocene] dichloropalladium (ll) (0.109 g, 0.133 mmol) in a mixture of toluene (6 ml), ethanol (6 ml) and an aqueous solution of 1 N sodium bicarbonate (1.6 ml , 1.6 mmol) are reacted according to the procedure in Example 39F to provide the title compound (0.66 g, 78%, yellow solid) as a mixture of stereoisomers.
EXAMPLE 40D (2S) -2- (4- (4- (5- (4-aminophenyl) -1- (4-tert-butylphenyl) pyrrolidin-2I Uphenyl) -1 H-imidazol-2-yl) tert-butiium pyrrolidine-1-carboxylate
295
The product of Example 40C (1.37 g, 2.1
OF THE PROPERTY
INDUSTRIAL f XJX ethanol (10 ml) and THF (10 ml) then platinum (IV) oxide (196 mg, 0.862 mmol) and a hydrogen balloon are added and the solution is stirred at room temperature for 48 hours. The reaction is then worked up according to the procedure in Example 39G to provide the title compound (1.3 g, 100%) as a mixture of stereoisomers.
EXAMPLE 40E (2R) -2- (4- (5- (4- (2 - ((S) -1 - (tert-butoxycarbonyl) pyrrolidin-2-¡l) -1H¡midazole- Tert-Butyl 4-¡l) phenyl) -1 - (4-tert-butylphenyl) pyrrolidin-2-yl) phenylcarbamo¡l) pyrroledin-1-carboxylate
The product of Example 40D (1.3 g, 2,146 mmol), (S) -1- (tert-butoxycarbonyl) pyrrolidine-2-carboxylic acid (1,386 g, 6.44 mmol), HATU (1,305 g, 3.43 mmol) and Hunig's base (1.124 ml, 6.44 mmol) in DMSO (20 ml) are reacted according to the procedure in Example 39H to provide the title compound (1.01 g, 59%) as a mixture of stereoisomers.
EXAMPLE 40F
(2R) -N- (4- (1- (4-tert-butylphenyl) -5- (4- (2 - ((S) p¡rrolidi n-2-yl) -1 H- imidazol-4-i hfeni Dpi rrolidi η-2-yl Henyl Ipyrrolidine2-carboxamide
296
<img file="MX339989B_D0568.tif" />
The product of Example 40E (610 mg, 0.7
OF THE PROPERTY The 2M solution of hydrochloric acid in dioxane (10 ml) is then reacted according to the procedure in Example 391 to provide the title compound (495 mg) as a hydrochloride salt and a mixture of stereoisomers.
EXAMPLE 40G
N- (methoxycarbonyl) -L-val¡lN- (4 - ((2S, 5S) -1- (4-tert-butylphenyl) -5-f4- (2 {(2S) -1-fN- (methoxycarbon¡ nL-valyl1pyrrolid¡n-2-yl) -1H-midazol-4¡l) phen¡npyrrol¡din-2-¡l) phen¡l) -L-prolinamida (ACD v12)
X
N- (methoxycarbon¡l) -L-val¡lN- (4 - {(2R, 5R) -1- (4-tert-butylphenyl) -5-F4- (2f (2S) -1 - [N - (methoxycarbonyl) -L-val¡npyroyin-2-¡l) -1 H-imidazol-4¡Dphenylpyrrolidin-2-yl) phen¡l) -L-prolinamide (ACD v12)
The product from Example 40F (372 mg, 0.617 mmol), (S) -2- (methoxycarbonylamino) -3-methylbutanoic acid (324 mg, 1851 mmol), HATU (821 mg, 2.16 mmol) in DMSO (6 ml) and Hunig's base (1.078 ml, 6.17 mmol) are reacted according to the procedure in Example 39J then the reaction is diluted with acetonitrile and water (0.1% TFA) and purified by reverse phase chromatography (C18), eluting with 10-100% acetonitrile in water (0.1% TFA) to obtain the title compounds (68mg, 12% yield, white solid) as a 1/1 mixture of diastereomers.
297
<img file="MX339989B_D0569.tif" />
H NMR (free base) (400 MHz, DMSO-C
0.96 (m, 12 Η), 1.10 (s, 9 Η), 1.65 (d, J = 6.07 Hz, 2 H
H), 2.07 - 2.20 (m, 3H), 3.52 (s, 3H), 3.53 (s, 3H), 3.58 - 3.66 fm 2H), 3.73 - 3.85 (m, 3H), 3.99 - 4.08 (m, 2H), 4.43 (dd, J = 7.97, 4.93
Hz, 1H), 5.06 (dd, J = 6.99, 2.87 Hz, 1H), 5.17 (d, J = 6.40 Hz, 2H),
6.20 (d, J = 8.89 Hz, 2H), 6.93 (d, J = 8.89 Hz, 2H), 7.14 (dd, J = 8.51,
2.87 Hz, 4 H), 7.30 (t, J = 9.11 Hz, 2 H), 7.37 (d, J = 1.84 Hz, 1 H), 7.50 (d, J = 8.02 Hz, 2 H), 7.61 (d, J = 8.13 Hz, 2H), 9.98 (s, 1H), 11.68 (s,
H).
The title compound shows an EC value<sub>50</sub> less than about 0.1 nM in HCV 1b-Con1 replicon tests in the presence of 5% FBS.
EXAMPLE 41
N- (methoxycarbonyl) -L-val¡lN- (4 - ((2S, 5R) -1 - (4-tert-but¡lfen¡l) -5-r4- (2 <(2S) -1 -rN - (methoxycarbon¡hL-val¡Hp¡rrolid¡n-2-¡D-1 H-imidazol-4¡l) phen¡llp¡rrolid¡n-2-yl} phen¡l) -L-prol¡nam Da (ACD v12)
<img file="MX339989B_D0570.tif" />
To the product of Example 40F (493 mg, 0.818 mmol), (S) -2- (methoxycarbonylamine) -3-methylbutanoic acid (430 mg, 2.454
298 mmol), HATU (1088 mg, 2.86 mmol) in DMSO (8
<img file="MX339989B_D0571.tif" />
teTmjTíz yjtxieXr DE LA PRCPÍEDAD
INDUSTRIAL
<img file="MX339989B_D0572.tif" />
Hunig (1.5 ml, 8.59 mmol) are reacted according to the procedure in Example 39J then the residue is diluted with acetonitrile and water (0.1% TFA) and purified by reverse phase chromatography (C18), eluting with 10- 100% acetonitrile in water (0.1% TFA) to obtain the title compound (80mg, 11% yield, white solid).
<sup>1</sup>H NMR (free base) (400 MHz, DMSO-D6) δ ppm 0.89 1.04 (m, 12 H), 1.20 (s, 9 H), 1.86 - 2.12 (m, 10 H), 2.15 - 2.27 (m, 3 H), 2.43-2.49 (m, 2H), 3.60 (s, 3H), 3.61 (s, 3H), 3.66-3.74 (m, 1H), 3.81-3.393 (m, 2H), 4.06 - 4.15 (m, 2H), 4.52 (dd, J = 7.86, 4.61 Hz, 1H), 4.74 (d, J = 5.20 Hz, 2H), 5.14 (dd, J = 6.99, 3.31 Hz, 1H ),
6.40 (d, J = 8.78 Hz, 2 H), 7.06 - 7.11 (m, 2 H), 7.32 - 7.41 (m, 2 H), 7.47 (d, J = 1.73 Hz, 1 H), 7.51 (d, J = 7.81 Hz, 4 H), 7.65 (d, J = 8.46 Hz, 2 H), 7.77 (d, J = 8.24 Hz, 2 H), 10.10 (s, 1 H), 11.76 (s, 1 H) .
The title compound shows an EC value<sub>50</sub> less than about 0.1 nM in HCV 1b-Con1 replicon tests in the presence of 5% FBS.
EXAMPLE 42 <2S.2<sup>,</sup>S) -1.1<sup>,</sup>- ((2S, 2'S) -2.2<sup>,</sup>-(4,4<sup>,</sup>-(4.4<sup>,</sup>- ((2S.5S) -1- (4-terbut¡lfen¡l) p¡rrolidin-2,5-d¡-yl) bis (4.1-phenylene)) bis (1H-im¡dazole-4 , 2d¡-yl)) bis (p¡rrol¡d¡n-2.1-d¡-¡0) bis (3-methyl-1-oxobutan-2.1-d¡¡Qdicarbamate of dimethyl
AND.
299 (2S, 2'S) -1<sub>i</sub>r - ((2S, 2'S) -2.2 '- (4.4' - (4.4<sup>></sup>- ((2R, 5R) -Jj \ ^<sub>and</sub>p J
INSTITUTO MEXICANO but¡lfenil) p¡rrol¡d¡n-2,5-di-¡Pb¡s (4,1 -phenylene)) bis (1 H-irriictaizorhU
<img file="MX339989B_D0573.tif" />
di-¡l)) b¡s (pyrrole¡d¡n-2,1 -d¡-¡D) b¡s (3-methyl-1 -oxohutafuXlaXÜj-
<img file="MX339989B_D0574.tif" />
1,4-bis (4-bromophenyl) butan-1,4-diol
The product from Example 26E (3.42 g, 8.63 mmol) is subjected to the conditions described in Example 39B to provide the title product (3.45 g, 100% yield, colorless oil).
EXAMPLE 42B
1,4-bis (4-bromophenyl) butan-1,4-di-yl dimethanesulfonate
The product from Example 42A (3.45 g, 8.63 mmol) is subjected to the conditions described in Example 39C to provide the title product (4.8 g, 100%).
300 , 'Λ.ΐζ
EXAMPLE 42C
WICKED
MEXICAN INSTITUTE
2<sub>l</sub>5-bis (4-bromophenyl) -1- (4-tert-butylphenyl) p¡rroFf¿fma<sup>l</sup>T £ AL
The product from Example 42B (5.2 g, 9.35 mmol) is subjected to the conditions described in Example 39D, substituting 4-tert-butylaniline (11.91 ml, 74.8 mmol) for 4-fluoroaniline to provide the title product (3.89 g, 81%) as a mixture of isomers.
EXAMPLE 42D
1- (4-tert-butylphenyl) -2,5-bis (4- (4,4,5,5-tetram eti 1-1,3,2-di oxa borolan2-¡Ufen ¡Dpi rrolidine
The product of Example 42C (3.88 g, 7.56 mmol), 4,4,4 ', 4', 5,5,5 ', 5'-octamethyl-2,2'-b¡ (1,3,2 -dioxaborolane) (6.72 g, 26.5 mmol), [1,1'-bis (diphenylphosphino) ferrocene] dichloropaladium (ll) (0.617 g, 0.756 mmol), and potassium acetate (3.34 g, 34.0 mmol) in dimethoxyethane (70 mi) and nitrogen gas is bubbled through the solution for 10 minutes, then heated at 85 ° C for 1 hour. The solution is cooled to room temperature then filtered through celite and washed with ethyl acetate (20 ml), the filtrate is dried, then concentrated and the residue is purified by silica gel column chromatography, eluting with a solvent gradient of 0-10% ethyl acetate in hexane followed by trituration of the resulting solid with diethyl ether to
301 Obtain the title compound (1.14 g, 25%) co of trans stereoisomers.
<img file="MX339989B_D0575.tif" />
EXAMPLE 42E (2S, 2'S) -2,2 '- (4,4' - (4.4 '- (1- (4-tert-butylphenyl) pyrrolıdin-2.5-di¡l) bis (4.1-phenylene )) bis (1 H-imidazole-4,2-di-¡l)) di pyrrolidine-1 tert-butyl carboxylate
The products of Example 42D are dissolved (0.915 g,
1,506 mmol), the product of Example 26D (1,429 g, 4.52 mmol), [1,1'-bis (diphenylphosphino) ferrocene] dichloropaladium (ll) (0.123 g, 0.151 mmol) in a mixture of toluene (7 ml), ethanol (7 ml) and a 2N aqueous sodium bicarbonate solution (2.64 ml, 5.28 mmol) and nitrogen gas is bubbled through the solution for 10 minutes, then heated at 100 ° C for 3 hours. The solution is cooled to room temperature and water (20 ml) is added, then it is extracted with dichloromethane (50 ml), then dried, concentrated and the residue is purified by column chromatography with silica gel, eluting with a gradient of Solvent 0-80% ethyl acetate in hexane to obtain the title compound (0.93 g, 75%) as a 1/1 mixture of trans stereoisomers.
EXAMPLE 42F
(S) -4.4 hydrochloride salt<sup>,</sup>-(4,4<sup>,</sup>- (1- (4-tert-butylphenyl) pyrrolidin-2,5di-ihbi (4.1-phenylene)) b¡ (2 - ((S) -pyrroIidin-2-yl) -1 H-im idazole)
302
A. .ΜΙι, Ι I ----
<img file="MX339989B_D0576.tif" />
To the product of Example 42E (1.11 g, 1.3 *
INSTITUTO MEXICANO DE LA PROPERTY 4 M solution of hydrochloric acid in dioxane (5 ml)<sup>, Nt</sup>S ^<sup>R1A</sup>It was reacted according to the procedure ea-el-Example 3-04 to provide the title compound (1.12 g) as a hydrochloride salt and a mixture of stereoisomers.
EXAMPLE 42G (25.2<sup>.</sup>5) -1.1 '- ((2S.2<sup>,</sup>S) -2.2<sup>,</sup>-(4,4<sup>,</sup>-(4.4<sup>,</sup>- ((2S, 5S) -1- (4-tert-butylphenyl) pyrrolidin-2.5-di-yl) bis (4,1-phenylene)) bis (1H-imidazol-4.2di-yl)) bis ( Dimethyl pyrrolidin-2.1-di-i l)) bis (3-meth¡ 1-1-oxobutan-2,1-di¡Ddicarbamate
and.
(25.2<sup>.</sup>5) -1.1 '- ((2S, 2<sup>,</sup>S) -2.2<sup>,</sup>-(4.4<sup>,</sup>- (4.4 '- ((2R, 5R) -1- (4-terbut¡phenyl) p¡rrol¡d¡n-2.5-di-¡l) bis (4.1-phenylen)) b¡s (1H -im¡dazol-4,2d¡-¡n) b¡s (p¡rroHdln-2.1-d¡-¡l)) b¡s (3-methyl-1 -oxobutan-2,1 -d¡ Dimethyl Pdicarbamate
To a mixture of the products of Example 42F (1.04 g, 1,662 mmol), (S) -2- (methoxycarbonylamine) -3-methylbutanoic acid (0.728 g, 4.15 mmol), and HATU (1,295 g, 3.41 mmol) in DMSO (20 ml) Hunig's base (2.322 ml, 13.29 mmol) is added, and the reaction is stirred at room temperature for 1 hour. Water (20 ml) is added to form a solid which is dissolved in dichloromethane and purified by column chromatography on silica gel, eluting with a solvent gradient of 0-5% methanol in
303 dichloromethane to obtain a solid that is diluted with water (0.1% TFA) and further purified by reverse phase (C18) WD¿12? mai ^, eluting with 10-100% acetonitrile in water (0.1% TFA) to obtain the compound of the title (92 mg, 6% yield, white solid) as a 1/1 mixture of diastereomers.
<sup>1</sup>H NMR (free base) (400 MHz, DMSO-D6) δ ppm 0.78 0.92 (m, 12 H), 1.09 (s, 9 H), 1.63 - 1.74 (m, 2 H), 1.85 - 2.00 (m, 6 H), 2.05-2.16 (m, 2H), 3.44-3.50 (m, 4H), 3.52 (s, 6H), 3.70 3.82 (m, 4H), 4.02-4.09 (m, 2H), 5.04 (dd, J = 6.67, 3.20 Hz, 2 H),
5.19 (t, J = 6.18 Hz, 2 H), 6.21 (d, J = 8.57 Hz, 2 H), 6.91 (dd, J = 7.16,
1.63 Hz, 2H), 7.14 (dd, J = 8.19, 2.22 Hz, 4H), 7.20 - 7.30 (m, 2H),
7.36 (d, J = 1.19 Hz, 2H), 7.61 (d, J = 8.13 Hz, 4H), 11.67 (d, J = 4.01 Hz, 2H).
The title compound shows an EC value<sub>50</sub> less than about 0.1 nM in HCV 1b-Con1 replicon tests in the presence of 5% FBS.
EXAMPLE 43
<img file="MX339989B_D0577.tif" />
(2S, 2'S) -1.r - ((2S, 2'S) -2.2 '- <4.4' - (4.4 '- ((2R.5R) -1 (4-terbuti Ifenihpyrrole idin-2 , 5-di-yl) bis (4,1-phenylene)) bis (1 H-im dazol-4,2-di-yl)) bis (pyrrolidin-2,1-di-yl)) bis ( Dimethyl 3-methyl-1-oxobutan-2,1-di-illdicarbamate
304
<img file="MX339989B_D0578.tif" />
<img file="MX339989B_D0579.tif" />
ΙΜΡΙ
MEXICAN INSTITUTE OF INDUSTRIAL PROPERTY
<img file="MX339989B_D0580.tif" />
The product from Example 42G is purified by chiral chromatography on a Chirapak IB column eluting with a mixture of hexane / THF / MeOH (80/10/10). The title compound is the first of the 2 diastereomers to elute.
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ ppm 0.78 - 0.92 (m, 12H), 1.09 (s, 9H), 1.63 - 1.74 (m, 2H), 1.85 - 2.00 (m, 6H), 2.05 2.16 (m, 2H), 3.44 - 3.50 (m, 4H), 3.52 (s, 6H), 3.70 - 3.82 (m, 4H), 4.02 - 4.09 (m, 2H), 5.04 (dd , J = 6.67, 3.20 Hz, 2 H), 5.19 (t, J = 6.18 Hz, 2 H), 6.21 (d, J = 8.57 Hz, 2 H), 6.91 (dd, J = 7.16, 1.63 Hz, 2 H),
7.14 (dd, J = 8.19, 2.22 Hz, 4 H), 7.20 - 7.30 (m, 2 H), 7 36 (d, J = 1.1 9 Hz, 2 H), 7 61 (d, J = 8.13 Hz, 4H), 11.67 (d, J = 4.01 Hz, 2H).
The title compound shows an EC value<sub>50</sub> less than approximately 0.1 nM in HCV 1b-Con1 replicon tests in the presence of 5% FBS
EXAMPLE 44 (2S.2<sup>,</sup>S) -1.1<sup>,</sup>- ((2S.2<sup>,</sup>S) -2.2 '- (4.4' - (4.4<sup>,</sup>- ((2S.5S) -1- (4-tert-butylphenyl) pyrrol¡d¡n-2,5-d¡-¡l) b¡s (4,1-phenyl)) bis (1H- ¡M¡dazol-4,2d¡-yl)) b¡s (pyrrolidin-2,1-di-yl)) bis (3-m tyl-1-oxob utan-2,1-di305
<img file="MX339989B_D0581.tif" />
The product from Example 42G is purified by chiral chromatography on a Chirapak IB column eluting with a mixture of hexane / THF / MeOH (80/10/10). The title compound is the second of the 2 diastereomers to elute.
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ ppm 0.78 - 0.92 (m, 12H), 1.09 (s, 9H), 1.63 - 1.74 (m, 2H), 1.85 - 2.00 (m, 6H), 2.05 2.16 (m, 2H), 3.44 - 3.50 (m, 4H), 3.52 (s, 6H), 3.70 - 3.82 (m, 4H), 4.02 - 4.09 (m, 2H), 5.04 (dd , J = 6.67, 3.20 Hz, 2 H), 5.19 (t, J = 6.18 Hz, 2 H), 6.21 (d, J = 8.57 Hz, 2 H), 6.91 (dd, J = 7.16, 1.63 Hz, 2 H),
7.14 (dd, J = 8.19, 2.22 Hz, 4 H), 7.20 - 7.30 (m, 2 H), 7.36 (d, J = 1.19 Hz, 2 H), 7.61 (d, J = 8.13 Hz, 4 H) , 11.67 (d, J = 4.01 Hz, 2H).
The title compound shows an EC value<sub>50</sub> less than approximately 0.1 nM in HCV 1b-Con1 replicon tests in the presence of 5% FBS
EXAMPLE 45 (2S, 2'S) -1.1 '- ((2S, 2'S) -2.2' - (4.4 '- (4.4' - ((2S, 5S) -1- (4fl uorofenihpi rrolidi n-2,5-di-¡l) b¡s (4,1-phenylene)) bis (1 H-imidazol-4,2di-yl)) bis (pyrolidi n-2,1-di-i l )) bi (3-m tyl-1-oxobutan-2,1-di306 dimethyl ddicarbamate
Ϊ.
<img file="MX339989B_D0582.tif" />
MEXICAN INSTITUTE OF PROPERTY
INDUSTRIAL
<img file="MX339989B_D0583.tif" />
(2S, 2'S) -1.1 '- ((2S, 2'S) -2.2' - (4.4<sup>,</sup>- (4.4 '- ((2R,<sup>,</sup>5RM- (4fluorophenyl) pyrrolidin-2.5-di-iDbis (4,1-phenylene)) bis (1H-imidazol-4,2di-yl)) bis (pyrrolidi n-2.1-di-yl)) bis (3 dimethyl -methyl-1-oxobutan-2.1-di¡Ddicarbamate
<img file="MX339989B_D0584.tif" />
EXAMPLE 45A
2.5-b¡s (4-bromophen¡n-1- (4-fluorophenyl) pyrrolod¡na
The product from Example 42B (5.2 g, 9.35 mmol) is subjected to the conditions described in Example 39D to provide the title product (6.41 g, 48%) as a mixture of cis and trans isomers.
307
1- (4-fluorophenyl) -2.5-b¡s (4- (4.4,5,5-tetramethyl-1,3.2-dioxaffire ^ iv3p
EXAMPLE 45B
IMPI
<img file="MX339989B_D0585.tif" />
The product from Example 45A (2.17 g, 4.57 mmol) is subjected to the conditions described in Example 42D and purified by column chromatography on silica gel, eluting with a solvent gradient of 0-15% ethyl acetate in hexane to obtain the title compound (1.65 g, 64%) as a mixture of cis and trans stereoisomers.
EXAMPLE 45C (2S, 2<sup>,</sup>S) -2.2 '- (4.4' - (4.4<sup>,</sup>- (1- (4-fluorophenylpyrrolidin-2,5-di-yl) b¡s (4.1phenylene)) bis (1 H-imidazole-4,2-di-¡l)) d¡pyrrolidin- 1-tert-butyl carboxylate
The product from Example 45B (1.0 g, 1,756 mmol) is subjected to the conditions described in Example 42E to provide the title product (1.0 g, 72%) as a mixture of cis and trans isomers.
EXAMPLE 45D (S) -4.4 '- (4.4<sup>l</sup>- (1- (4-fluorophenyl) pyrrolidin-2.5-di-yl) bis (4.1f nyl n)) bis (2 - ((S) -pyrrol¡din-2-yl) -1 H-im Dazol)
308
<img file="MX339989B_D0586.tif" />
The product of Example 45C disο 'INSTITUTO MEXICANO mmol) is dissolved in dichloromethane (1 ml) and TFA (1 ml) and the s.elution ^ swsBgMt room temperature for 1 hour then the piss is concentrated under high vacuum to obtain a solid that diluted with acetonitrile and water (0.1% TFA) and purified by reverse phase chromatography (C18), eluting with 10-100% acetonitrile in water (0.1% TFA) to obtain the title compound (62 mg, 55% yield) as a 1/1 mixture of trans diastereomers eluting earlier than the cis isomer.
EXAMPLE 45E (2S, 2'S) -1,1 '- ((2S, 2'S) -2.2' - (4.4 '- (4,4' - ((2S, 5S) -1- (4-fluorophenyl) pyrrolidin-2.5-di -yl) bis (4,1-phenylene)) bis (1H-imidazol-4,2di-yl)) bis (pyrrolidin-2,1-di-yl)) bis (3-methyl-1-oxobutan- Dimethyl 2,1-dddicarbamate
JÍ (2S, 2<sup>| l</sup>S) -1.1<sup>,</sup>- ((2S, 2'S) -2.2<sup>,</sup>-(4,4<sup>,</sup>- (4,4 '- ((2R, 5R) -1-f4fluorophenyhpyrrolidin-2,5-di-yl) bis (4,1-phenylenenb¡s (1H-imidazoI-4,2di-yl)) bis (pyrrolid Dimethyl n-2,1-di-yl)) bis (3-methyl-1-oxobutan-2,1-di¡Ddicarbamate
To a mixture of the product of Example 45D (47 mg, 0.08 mmol), (S) -2- (methoxycarbonylamino) -3-methylbutanoic acid (29 mg,
0.168 mmol), and HATU (61 mg, 0.16 mmol) in DMSO (0.8 ml) is added Hunig's base (0.035 ml, 0.2 mmol) is reacted in
309
Example compliance with the procedure in the.
'INSTITUI
D £ THE RESIDUE PROPERTY is diluted with acetonitrile and water (0.1% TFA) and purified by reverse phase chromatography (C18), eluting with ΐϋ-ΐυυ<sup>υ</sup>/ ο acetonitrile in water (0.1% TFA) to obtain the title compound (54mg, 75% yield, white solid) as a 1/1 mixture of diastereomers.
<sup>1</sup>H NMR (free base) (400 MHz, DMSO-D6) δ ppm 11.62 12.13 (m, 2 H), 7.59 - 7.71 (m, J = 8.13 Hz, 3 H), 7.46 - 7.57 (m, J = 8.24 Hz , 1 H), 7.38 (d, J = 1.84 Hz, 2 H), 7.10 - 7.32 (m, 6 H), 6.72 6.83 (m, 2 H), 6.19 - 6.31 (m, 2 H), 5.17 - 5.28 (m, 2H), 5.02 - 5.11 (m, J = 6.72 Hz, 2H), 4.05 (t, J = 8.40 Hz, 2H), 3.71 - 3.85 (m, 4H),
3.53 (S, 6H), 2.05-2.21 (m, 4H), 1.94 (s, 6H), 1.64-1.78 (m, 2H), 0.77-0.95 (m, 12H).
The title compound shows an EC value<sub>50</sub> less than approximately 0.1 nM in HCV 1b-Con1 replicon tests in the presence of 5% FBS
EXAMPLE 46 (2S.2'S) -1.1<sup>,</sup>- ((2S, 2<sup>,</sup>S) -2.2<sup>,</sup>-(4,4’-(4.4<sup>,</sup>- ((2R, 5R) -1- (4-fluorophenyl) pyrrolidin-2,5-d¡-yl) bis (4,1-phenylene)) b¡s (1H-imidazol-4.2d i-yl)) bis ( dimethyl pyrrole i din-2,1-di-i l)) bis (3-methi 1-1-oxobutan-2,1-di¡Ddicarbamate)
310
<img file="MX339989B_D0587.tif" />
IMPI
MEXICAN INSTITUTE
PE INDUSTRIAL PROPERTY
The product from Example 45E is purified by chiral chromatography on a Chirapak IB column eluting with a mixture of hexane / THF / MeOH (85 / 7.5 / 7.5).
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ ppm 11.62 - 12.13 (m, 2 H), 7.59 - 7.71 (m, J = 8.13 Hz, 3 H), 7.46 - 7.57 (m, J = 8.24 Hz, 1 H ),
7.38 (d, J = 1.84 Hz, 2H), 7.10 - 7.32 (m, 6H), 6.72 - 6.83 (m, 2H),
6.19 - 6.31 (m, 2 H), 5.17 - 5.28 (m, 2 H), 5.02 - 5.11 (m, J = 6.72 Hz, 2 H), 4.05 (t, J = 8.40 Hz, 2 H), 3.71 - 3.85 (m, 4H), 3.53 (s, 6H), 2.05 - 2.21 (m, 4H), 1.94 (s, 6H), 1.64 - 1.78 (m, 2H), 0.77 - 0.95 (m, 12 H).
The title compound shows an EC value<sub>50</sub> less than approximately 0.1 nM in HCV 1b-Con1 replicon tests in the presence of 5% FBS
EXAMPLE 47 (2S, 2'S) -1.1 '- ((2S, 2'S) -2.2' - (4.4 '- (4.4' - ((2S, 5S) -1- (4fluorophenyl) pyrrole ¡Din-2,5-di-yl) b¡s (4.1-phenylene Dbis (1H-imidazole-4,2d¡-¡l)) bis (pyrolidi n-2,1-di-yl)) bis ( Dimethyl 3-methyl-1-oxobutan-2,1-diiPdicarbamate
311
<img file="MX339989B_D0588.tif" />
IMPI
MEXICAN INSTITUTE OF INDUSTRIAL PROPERTY
<img file="MX339989B_D0589.tif" />
The product from Example 45E is purified by chiral chromatography on a Chirapak IB column eluting with a mixture of hexane / THF / MeOH (85 / 7.5 / 7.5).
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ ppm 11.62 - 12.13 (m, 2 H), 7.59 - 7.71 (m, J = 8.13 Hz, 3 H), 7.46 - 7.57 (m, J = 8.24 Hz, 1 H ),
7.38 (d, J = 1.84 Hz, 2H), 7.10 - 7.32 (m, 6H), 6.72 - 6.83 (m, 2H),
6.19 - 6.31 (m, 2 H), 5.17 - 5.28 (m, 2 H), 5.02 - 5.11 (m, J = 6.72 Hz, 2 H), 4.05 (t, J = 8.40 Hz, 2 H), 3.71 - 3.85 (m, 4H), 3.53 (s, 6H), 2.05 - 2.21 (m, 4H), 1.94 (s, 6H), 1.64 - 1.78 (m, 2H), 0.77 - 0.95 (m, 12 H).
The title compound shows an EC value<sub>50</sub> less than about 0.1 nM in HCV 1b-Con1 replicon tests in the presence of 5% FBS.
EXAMPLE 48 (2S, 2<sup>,</sup>S) -1.1<sup>,</sup>- ((2S.2<sup>,</sup>S) -2.2 '- (4.4<sup>,</sup>-(4.4<sup>,</sup>- ((2S.3R.4R, 5S) -1- (4-tert-butylphenyl) -3,4-dimethoxypyrrolidin-2,5-di-¡l) b¡s (4,1-phenyl)) dimethyl b¡s (1H¡midazol-4,2-di-yl)) bis (pyrrolid¡n-2.1-di-yl)) bis (3-methyl-1-oxobutan-2,1-di-yl) dicarbamate
312
<img file="MX339989B_D0590.tif" />
EXAMPLE 48A (2S, 3R, 4R, 5S) -2,5-bis (4- (benzyloxy) phenyl-1 - (4-tert-butylphenyl) pyrrolidin-3,4-diol
To a solution of (1 R, 1'R) -1,1 '- ((4R, 5R) -2,2-dimethyl-1,3-dioxolan-4,5-di-yl) diethane-1,2-diol (200 mg, 0.90 mmol) in methanol (6 ml) and dichloromethane (3 ml) add iodobenzene diacetate (696 mg, 2.16 mmol) and the solution is stirred at room temperature for 5 hours. The solution is concentrated and H is added to the residue.<sub>2</sub>SW<sub>4</sub> 0.1 M (4 ml) and continue stirring at room temperature for 18 hours. PH is adjusted to ~ 6 with NaHCO<sub>3</sub> solid, and 4-tert-butylaniline (287 µΙ, 1.80 mmol) is added followed by 4-benzyloxyphenylboronic acid (369 mg, 1.62 mmol) and hexafluoroisopropyl alcohol (4 ml) and stirred at 60 ° C for 2 hours. The solvent is concentrated and the residue is dissolved in ethyl acetate, washed with H<sub>2</sub>OKAY<sub>3</sub>PO<sub>4</sub> 0.33 M, brine, dried (Na<sub>2</sub>SW<sub>4</sub>), filter and concentrate to obtain the crude product which is purified by chromatography on silica gel eluting with 0-20% ethyl acetate / dichloromethane to obtain the title compound
313 (249 mg, 46%).
EXAMPLE 48B
IMPI
MEXICAN INSTITUTE OF INDUSTRIAL PROPERTY
<img file="MX339989B_D0591.tif" />
(2S, 3R, 4R, 5S) -2,5-bis (4- (benzyloxy) phenyl) -1- (4-tert-butylphenyl) -3,4d imethoxypyrrolide
To a solution of the product of Example 48A (200 mg, 0.33 mmol) in THF (2.1 ml) and DMF (0.7 ml) at 0 ° C is added, in portions, sodium hydride, 60% in mineral oil (40.0 mg 1.0 mmol) and continue stirring at 0 ° C for 20 minutes. Iodomethane (0.046 ml, 0.734 mmol) is added and stirring is continued at room temperature overnight. Dilute with ethyl acetate, wash with NH<sub>4</sub>Saturated CI, H<sub>2</sub>O, brine, dries up (Na<sub>2</sub>SW<sub>4</sub>), filtered and concentrated to obtain the crude product which is purified by chromatography on silica gel eluting with 0-20% ethyl acetate / dichloromethane to obtain the title compound (170 mg, 80%).
EXAMPLE 48C
4,4 '- ((2S, 3R, 4R, 5S) -1 - (4-tert-butylphenyl) -3,4-dimethoxypyrrolidin-2,5di-yl) diphenol
To a solution of the product from Example 48B (168 mg, 0.268 mmol) in ethyl acetate (3 ml) is added 10% palladium on carbon (17 mg) and the flask is evacuated and filled with H gas<sub>2</sub>.
314
The solution is stirred under a balloon of H gas<sub>2</sub> du filter through celite, and wash with filtered acetate, concentrate, and azeotrope the residue with ether to obtain the title compound (120 mg, 100%) as a white solid.
<img file="MX339989B_D0592.tif" />
EXAMPLE 48D bis (1,1,2,2,3.3,4,4,4-nonafluorobutan-1-sulfonate) of 4,4 '((2S, 3R, 4R.5S) -1- (4-tert-but ¡Lphen¡U-3,4-dimethoxypyrrolidin-2,5-d¡yl) bis (4,1-phenylene)
To a solution of the product from Example 48C (117 mg, 0.261 mmol) in DMF (1.3 ml) is added K<sub>2</sub>CO<sub>3</sub> (81 mg, 0.588 mmol) and 1,1,2,2,3,3,4,4,4-nonafluorobutan-1-sulfonyl fluoride (0.101 ml, 0.575 mmol) and the solution is stirred at 100 ° C for 1 hour. The cold solution is diluted with ethyl acetate, washed with H<sub>2</sub>O, brine, dries up (Na<sub>2</sub>SW<sub>4</sub>), filter and concentrate to obtain an oil which is purified by chromatography on silica gel eluting with 0-20% ethyl acetate / hexane to obtain the title compound (195 mg, 73.7% yield).
EXAMPLE 48E (2S, 3R, 4R, 5S) -1- (4-tert-butylphenyl) -3,4-dimethoxy-2,5-bis (4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan -2-il) fen¡ l) p¡ rrol ¡dina
315
To a pressure tube is added the
48D (193 mg, 0.191 mmol)
<img file="MX339989B_D0593.tif" />
bi (1,3,2-dioxaborolane) (102 mg, 0.401 mmol), dΙΰΙΰΤ77Π5ΧΙΙ (2,4-isopropylbiphenyl-2-¡l) phosphine (X-Phos) (14.55 mg, 0.031 mmol), potassium acetate (112 mg, 1,145 mmol), and dioxane (1.5 ml) and the solution is degassed with N gas<sub>2</sub> for 30 minutes. Add tris (dibenzyldenacetone) dypal (0) (6.99 mg, 7.63 pmol) is added and degassing is continued for another 10 minutes. The tube is sealed and heated with shaking at 100 ° C overnight. The cold solution is diluted with ethyl acetate, washed with H<sub>2</sub>O, brine, dries up (Na<sub>2</sub>SW<sub>4</sub>), filtered and the filtrate is treated with 3 (mercaptopropyl) -silica gel for 1 hour. The solution is filtered and the solvent is removed to obtain a yellow solid which is purified by chromatography on silica gel eluting with 020% ethyl acetate / hexane to obtain the title compound (99 mg, 78% yield ) as a white solid.
EXAMPLE 48F (2S, 2<sup>,</sup>S) -2.2<sup>,</sup>- (4.4 '- (4.4' - ((2S, 3R, 4R.5S) -1- (4-tert-butylphenyl) -3,4d¡ methoxypyrrolidi n-2,5-d ii l) bis (4 Tert-butyl, 1-phenylene)) bis (1 H-imidazole-4.2-diylDdipi rrolidi n-1 -carboxylate
In a sealed tube, combine the product of Example 48E (97 mg, 0.145 mmol), the product of Example 26D (115 mg, 0.363 mmol), Na<sub>2</sub>CO<sub>3</sub> 1 M (0.363 ml, 0.363 mmol), EtOH (1.0 ml)
316 and toluene (1.0 ml) and the solution is degassed with * ga
<img file="MX339989B_D0594.tif" />
1.1 'minutes. Bis (diphenylphosphino) ferrocenedichloro-palladium (ll) dicloyOmétartTO '- complex (10.63 mg, 0.015 mmol) is added and degassing is continued for an additional 10 minutes. The tube is sealed and heated at 100 ° C for 3 hours. The cold solution is diluted with ethyl acetate, filtered through celite, and the residue is washed with ethyl acetate. The filtrate is concentrated in vacuo and the resulting material is purified by chromatography on silica gel using a 12 g column of silica gel eluting with 0-2% methanol / dichloromethane to obtain the title compound (85 mg, 66.1% yield ).
EXAMPLE 48G (2S.2<sup>,</sup>S) -1.1<sup>></sup>- ((2S.2<sup>,</sup>S) -2.2<sup>,</sup>-(4.4<sup>,</sup>-(4,4<sup>,</sup>- ((2S, 3R, 4R.5S) -1- (4-tertbutylphenyl) -3.4-dimethoxypyrrol¡din-2,5-di-yl) bis (4.1-phenylene)) bis (1Himidazol-4,2-di -¡L)) bis (pyrrolidin-2,1 -d ¡-i I)) bis (3-methyl-1-oxobutan2,1-di-¡l) d¡carbamate of dimethyl
To a solution of the product of Example 48F (83 mg,
0.094 mmol) in dichloromethane (1.0 ml) add TFA (1.0 ml,
12.98 mmol) and the solution is stirred at room temperature for 1 hour. The solvent is concentrated and the residue is subjected to azeotropic distillation 2 times with dichloromethane. The residue is placed under vacuum for 1 hour to remove the final traces of TFA. To this residue (64.2 mg, 0.094 mmol) DMSO (500 µl) is added followed
317
<img file="MX339989B_D0595.tif" />
by acid (S) -2- (methoxycarbonylamino) -3-methylbutanI¡d ^^ (^ RJ
INSTITUTE .MLSíCANQ -LA T'hf .'J · '?,
0.234 mmol), HATU (89 mg, 0.234 mmol) and base of
0.469 mmol). The pH is checked and rte t lunig adioionol is added to adjust the pH to ~ 9. Stirring is continued at room temperature for 1 hour. The solution is diluted with ethyl acetate, washed with H<sub>2</sub>O, brine, dries up (Na<sub>2</sub>SW<sub>4</sub>), filter and concentrate to obtain the crude residue. Purification is run by silica gel chromatography eluting with 0-4% methanol / dichloromethane over 60 minutes to obtain the title compound (7.5 mg, 8.01% yield).
<sup>1</sup>H NMR (400 MHz, CDCI<sub>3</sub>) δ ppm 0.86 (s, 12H) 1.13 (s, 9H) 1.86-2.02 (m, 2H) 2.02-2.12 (m, 2H) 2.12-2.25 (m, 2H) 2.25-2.41 (m, 1H) 2.90-3.17 (m, 2H) 3.43 (s, 6H) 3.53-3.65 (m, 2H) 3.70 (s, 6H) 3.74-3.89 (m, 2H) 4.16-4.26 (m, 2H) 4.26-4.37 (m, 1H) 5.18 -5.26 (m, 2H) 5.26-5.32 (m, 2H) 5.33-5.41 (m, 2H) 6.28 (d, J = 8.78 Hz, 2H) 6.89-6.99 (m, 2H) 7.16 (s, 2H) 7.20 ( s, 2H) 7.22 (s, 2H) 7.26 (s, 4H) 7.30-7.48 (br s, 1H) 7.58-7.82 (br s, 2H) 10.08-10.42 (br s, 1H).
The title compound shows an EC value<sub>50</sub> less than about 0.1 nM in HCV 1b-Con1 replicon tests in the presence of 5% FBS.
EXAMPLE 49 (2S.2<sup>,</sup>S) -1.1<sup>,</sup>- ((2S, 2<sup>,</sup>S) -2,2 '- (5.5' - ((2S.3R.4R, 5S) -1- (4-tert-butyphenyl) 3,4-dimethoxypyrrolıdin-2,5-di-yl) bis (1H-benzord-imidazole-5,2-diyl)) bis (pyrrolidin-2,1-di-yl)) bi (3-methyl-1-oxobutan-2,1-diAatetftK.
318
<img file="MX339989B_D0596.tif" />
IMPI
MEXICAN INSTITUTE OF INDUSTRIAL PROPERTY
<img file="MX339989B_D0597.tif" />
EXAMPLE 49A (S) -2- (2-am i no-5-bromophen i I carbam oi Dpi rrolidi n-1-tert-butyl carboxylate
A solution of 2-amino-4-bromoaniline (6.0 g, 32.1 mmol), Boc-Pro-OH (6.90 g, 32.1 mmol) and HATU (13.42 g, 35.3 mmol) in dry DMSO (160 ml) is treated with di-isopropylethylamine (14.0 ml, 10.4 g, 80 mmol) followed by stirring at room temperature for 18 hours. The mixture is diluted with ethyl acetate and extracted with water (3x) and saturated sodium chloride solution. Drying (Na<sub>2</sub>SW<sub>4</sub>) and vacuum concentration allow to obtain a brown solid which is used directly in the next step.
EXAMPLE 49B (S) -2- (5-bromo-1H-benzord1imidazole-2-¡l) p¡rrolidi n-1-carboxylate of tert-butyl
A solution of the compound of Example 49A in acid
319
Λ.
<img file="MX339989B_D0598.tif" />
glacial acetic acid (75 ml) is heated at 60 ° C for 3 -t '' INSTITUTO MEXICA.N
FROM PROPERTY, INDUSTRIAL is cooled and diluted with toluene and concentrated in vacuo. The remaining acetic acid is removed by azotropic distillation with toluene (2x) and the residue is subjected to chromatography through a 360 g cartridge of silica gel, eluting with 25-75% ethyl acetate in dichloromethane. These procedures allow the product (10.0 g, 85%) to be obtained as a light beige rigid foam.
EXAMPLE 49C (S) -2- (6-bromo-1 - ((2- (trimethylsilyl) ethoxy) methyl) -1 tert-butyl Hbenzordlimidazoi-2-yl) pyrrolidine-1-carboxylate
A solution of the compound from Example 49B (2.25 g, 6.14 mmol) in dry THF (25 ml) is treated with sodium hydride (295 mg of 60% in oil, 177 mg, 7.37 mmol) followed by stirring at room temperature for 1 hour. The solution is then treated with SEM-chloride (1.20 ml, 1.13 g, 6.76 mmol) followed by stirring at room temperature for 18 hours. The mixture is quenched by adding water and the mixture is diluted with ethyl acetate. The mixture is extracted with water and saturated sodium chloride solution. Drying (Na<sub>2</sub>SW<sub>4</sub>) and concentration under vacuum allow an oil to be obtained, which is subjected to chromatography through a 100 g silica gel cartridge, eluting with 20-75% ethyl acetate in hexanes. These procedures allow to obtain the product (2.24 g,
320
73%) as a heavy oil, which solidifies IMPI
INSTITUTO MEXICANO for several days. This mixture of both regioisomeric defiVáííISiRiXfcl is not separated for use in the next step.
<img file="MX339989B_D0599.tif" />
EXAMPLE 49D (S) -2- (6- (4,4,5,5-tetramethyl-1,3,2-d¡oxaborolan-2-¡l) -1 - ((2 (trimethylsilyl) ethoxy) tert-butyl) methyl) -1 H-benzord1imidazol-2-yl) pyrrolodin-1carboxylate
In a resealable pressure tube, a solution of the compound of Example 49C (2.24 g, 4.51 mmol), bis (pinacholate) diboron (1.26 g, 4.96 mmol), and potassium acetate (1.33 g, 13.53 mmol) is degassed. in dry dioxane (23 ml) by sparging with nitrogen for 30 minutes. The solution is treated with 1,1'-bis (diphenylphosphino) ferrocene palladium (II) dichloromethane chloride complex (111 mg, 0.14 mmol) followed by degassing for another 5 minutes. The pressure tube is sealed and heated at 90 ° C for 4 hours. The mixture is cooled and diluted with ethyl acetate, followed by extraction with water and saturated sodium chloride solution. The solution dries (Na<sub>2</sub>SW<sub>4</sub>) and stirred for 1 hour with 3-mercaptopropyl) -silica gel. After filtering and concentrating in vacuo the brown oil is chromatographed through a 100 g cartridge of silica gel, eluting with 15-70% ethyl acetate in dichloromethane. These procedures allow the product (1.99 g, 81%) to be obtained as a rigid white foam.
321
W (45B ».
EXAMPLE 49E (S) -2- (6 - ((2S.3R.4R.5S) -5- (2 - ((S) -1-tert-butoxycarfc
<img file="MX339989B_D0600.tif" />
yl) -1 - ((2- (tr¡methylsilyl) ethoxy¡) methyl) -1 H-benzoidlimidaaol 6 yl) 1 il-4 tert-butylphenyl) -3,4-dihydroxypyrrolidin- Tert-butyl 2-¡l) -1 - ((2 (trimethylsilyl) ethoxy) met¡h-1H-benzoTdl ¡m¡dazol-2-yl) pyrrolidi n-1 carboxylate
A solution of 2,3-O-isopropylidene-D-mannitol (144 mg,
0.65 mmol) and iodobenzene diacetate (501 mg, 1.56 mmol) in methanol-dichloromethane 2: 1 (3 ml) is stirred at room temperature for 5 hours. The mixture is concentrated in vacuo to a white paste and then suspended in 0.1 M sulfuric acid solution (1.0 ml) followed by stirring at room temperature for 18 hours. The pH of the solution is adjusted to 6 by adding solid sodium bicarbonate followed by adding 4-tertbutylaniline (206 μΙ, 193 mg, 1.30 mmol) the product of Example 49D (634 mg, 1.17 mmol) and hexafluoroisopropyl alcohol (2.6 ml). The solution is then heated at 70 ° C for 5 hours. The solution is cooled and concentrated in vacuo. The residue is dissolved in ethyl acetate and extracted with 0.33 M tribasic potassium phosphate solution and saturated sodium chloride solution. Drying (Na<sub>2</sub>SW<sub>4</sub>) and concentration in vacuo allow to obtain a brown oil, which is subjected to chromatography through a 50 g cartridge of silica gel, eluting with 15-85% of ethyl acetate in dichloromethane. These procedures allow to obtain the boronate
322
<img file="MX339989B_D0601.tif" />
recovered (208 mg) as a viscous oil __ _____ ____ <sup>r K</sup> MEXICAN INSTITUTE
FROM THE PROPERTY,,,, _____ INDUSTRIAL, _ column is then re-eluted with 0-20% methanol in dichloromethane to obtain the product (159 mg, 23%) as a solid brownish color.
EXAMPLE 49F (S) -2- (6 - ((2S.3R, 4R, 5S) -5- (2 - ((S) -1- (tert-butoxycarbonyl) pyrrolein-2yl) - 1 - ((2- (trimethylsilyl) ethoxy) methyl) -1 H-benzofdlimidazol-5-yl) -1- (4-tert-butylphenyl) -3.4-dimethoxypyrrolidin- Tert-butyl 2-yl) -1 - ((2 (trimethylsilyl) ethoxy) methyl) -1 H-benzord-imidazol-2-yl) p¡rrolid¡ n-1-carboxylate
A solution of the product from Example 49E (154 mg, 0.14 mol) in dry THF is treated with sodium hydride (13 mg of 60% in oil, 8 mg, 0.33 mmol) followed by stirring at room temperature for 30 minutes. The mixture is treated with methyl iodide (19 µl, 43 mg, 0.30 mmol) followed by stirring at room temperature for 2 hours. The mixture is diluted with ethyl acetate and quenched by adding water. The mixture is extracted with water and saturated sodium chloride solution. Drying (Na<sub>2</sub>SW<sub>4</sub>) and concentration in vacuo allow to obtain a brown oil, which is subjected to chromatography through a 25 g cartridge of silica gel, eluting with 0-15% methanol in dichloromethane. These procedures allow the product (121 mg, 77%) to be obtained as a beige foam.
323
IMPI
EXAMPLE 49G (S) -5.5 '- ((2S.3R, 4R, 5S) -1 -í4-tert-butyphenyl) -3,4-dimethoxypyrrolidin2,5-d i-i l) b ¡S (2 - ((S) -p¡ rrolidi n-2-yl) -1 H-benzordl imidazole)
INSTITUTE HBK & O CELAFKCfifTAO
INDUSTRIAL
<img file="MX339989B_D0602.tif" />
A solution of the compound of Example 49F (111 mg,
0.10 mmol) in ethanol (1 ml) is treated with 4 N hydrochloric acid solution (2.0 ml) followed by heating at 60 ° C for 18 hours. The solution is cooled and concentrated in vacuo with ethanol-toluene mixtures (2x) to obtain the tetrahydrochloride as a light yellow solid. This material is dissolved in methanol (3 ml) and stirred with Amberlyte IRA 400 (OH- form, 1.4 mequiv / g, 577 mg, 0.81 mequiv) for 1 hour. The resin is removed by filtration and the filtrate is concentrated in vacuo to obtain the product (29 mg, 45%) as a light amber glass.
EXAMPLE 49H (2S, 2<sup>,</sup>S) -1.1<sup>,</sup>- ((2S, 2'S) -2.2<sup>,</sup>- (5,5 '- ((2S.3R, 4R, 5S) -1- (4-tert-butylphenyl) 3,4-dimethoxypyrrol idi n-2.5-di-yl) bis (1 H-benzoidl imidazole- Dimethyl 5,2-diyl)) bis (pyrolidin-2,1-di-i l)) bis (3-meth¡ 1-1-oxobutan-2,1-di¡Ddicarbamate)
A solution of the compound of Example 49G (29 mg,
0.046 mmol), hydrated HOBt (18 mg, 0.114 mmol), EDAC (22 mg, 0.114 mmol) and (S) -2- (methoxycarbonylamino) -3-methylbutanoic acid (20 mg, 0.114 mmol) in dry DMF (0.5 ml) at 0 ° C is
324 treat with N-methylmorpholine (15 μΙ, 14 mg, 0.137 mm
MEXICAN INSTITUTE
OF THE FROFITY _ stirring at 0 ° C for 30 minutes and heating<sup>í</sup>RW<sup>TO THE</sup> up to room temperature for 2 hours. The mixture is diluted with δόιΓ ethyl acetate and extracted with water (3x) and saturated sodium chloride solution. Drying (Na<sub>2</sub>SW<sub>4</sub>) and vacuum concentration allow to obtain an oil which is dissolved in methanol and treated with a small amount of potassium carbonate. After stirring for 1 hour, the mixture is filtered and concentrated in vacuo to obtain a yellow oil, which is chromatographed through a 25 g cartridge of silica gel, eluting with 0-15% methanol. in dichloromethane to obtain the product (14 mg, 32%) as a white solid.
<sup>1</sup>H NMR (400 MHz, DMSO-d6) δ 7.39 (m, 4H), 7.30 (m, 4H), 7.07 (t, J = 9.1 Hz, 2H), 6.87 (m, 2H), 6.31 ( d, J = 8.9 Hz, 1H),
5.54 (m, 2H), 5.14 (dd, J = 7.6, 4.6 Hz, 2H), 4.14 (m, 2H), 3.77 (m, 4H), 3.51 (m, 6H), 3.28 (m , 6H), 2.15 (m, 4H), 1.04 (s, 9H), 0.86 (m, 12H).
The title compound shows an EC value<sub>50</sub> from about 0.1 to about 1 nM in the HCV 1b-Con1 replicon tests in the presence of 5% FBS.
EXAMPLE 50 (2S, 2'S) -1.1 '- ((2S, 2'S) -2.2' - (4.4 '- (4.4' - (1- (4- (pentafluoroth) phenil) 1H-pyrrol-2,5-di-yl) bis (4,1-phenylene)) bis (1H-imidazol-4.2-diyl)) bis (pyrrole idin-2,1-di-yl)) bis (3- methi 1-1-oxobutan-2,1-di325 Dimethiium ddicarbamate
<img file="MX339989B_D0603.tif" />
IMPI
INSTITUTO MEXICANO OE La MC'F'EáXW JNÜUJTfUAt
<img file="MX339989B_D0604.tif" />
EXAMPLE 50A
2,5-b¡s (4-bromophenyl) -1 - (4- (pentafl uorothio) phenyl) -1 H-pyrrole
The title compound is prepared from the product of Example 26E using the methods of Example 26F substituting 4-aminophenylsulfur pentafluoride for 4-tert-butylaniline to provide the desired compound.
EXAMPLE 50B
1- (4- (pentafluorothio) phenylD-2,5-b¡s (4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) phenyl) -1 H -pyrrole
The title compound is prepared using the methods of Example 26G by substituting the product of Example 50A for the product of Example 26F to provide the desired compound.
EXAMPLE 50C
2.2 '- (4.4' - (4,4 '- (1- (4- (p-ntafluorothio) f nih-1 H-pyrrole-2,5-di326
IMPI?
i I) bis (4,1 -f nilen)) bis (1 H-imidazole-4.2-di-¡l)) d »priTroNjOlfr ^ 7l
INDUSTRIAL tert-butyl carboxylate
The title compound is prepared using the methods of Example 26H by substituting the product of Example 50B for the product of Example 26G to provide the desired compound.
EXAMPLE 50D
4,4 '- (4,4' - (1 - (4- (pentafl uortio) phenyl) -1 H-pyrrol-2,5-di-yl) bis (4.1phenylene)) bis (2- (pyrrolidine- 2-yl) -1 H-imidazole)
The title compound is prepared using the methods of Example 26I by substituting the product of Example 50C for the product of Example 26H to provide the desired compound.
EXAMPLE 50E (2S, 2<sup>,</sup>S) -1.1<sup>,</sup>- ((2S, 2<sup>,</sup>S) -2.2 '- (4.4<sup>,</sup>- (4,4 '- (1- (4- (pentafluorothio) phenyl) 1H-pyrrol-2,5-di-yl) bis (4,1-pheny | en)) bis (1H-imidazole-4.2 dimethyl -diih) bis (pyrrolidin-2,1-di-yl)) bis (3-methyl-1-oxobutan-2,1-diQdicarbamate
The title compound is prepared using the methods of Example 26J by substituting the product of Example 50D for the product of Example 26I to provide the desired compound.
<sup>1</sup>H NMR (DMSO-d6; 400 MHz): δ 11.75 (br s, 2H), 7.88 (m,
327
<img file="MX339989B_D0605.tif" />
2H), 7.56 (ap. D. J = 8.35 Hz, 4H), 7.45 (br s, 2H>. AgtV ^ FJ)!
:. of depth ___ (ap. d, J = 8.35 Hz, 4H), 6.50 (s, 2H), 5.04 (m, 2H $ '„4.03 (m ^ H), 3.78 (m, 4H), 3.53 (s, 6H), 2.11-1.85 (m, 10H), 0.86 fcr, Chi = b. / 2 *, 6H), 0.82 (d, J = 6.72 Hz, 6H).
The title compound shows an EC value<sub>50</sub> less than about 0.1 nM in HCV 1b-Con1 replicon tests in the presence of 5% FBS.
<img file="MX339989B_D0606.tif" />
EXAMPLE 51 (Γ1 - (4-fluorophenyl) -1 H-pyrrole-2,5-di-¡n bis (benzene-4,1 -d¡¡I carbamo¡l (2S) pyrolidi n-2, Dimethyl 1-di-ylf (2S) -3-meth¡ 1-1-oxobutan-1,2-d¡¡Hubiscarbamate
Example 19D (150 mg) and (S) -2 (methoxycarbonylamino) -3-methylbutanoic acid are processed using the method of Example 19E (substituting DMF as the solvent) to provide the title compound which is purified using gel chromatography of Gradient silica (30-70% EtOAc in hexanes) (70 mg).
<sup>1</sup>H NMR (500 MHz, DMSO-D6) δ 9.76 (s, 2H), 7.16 (d, J =
328
<img file="MX339989B_D0607.tif" />
8.7, 4Η), 7.06 (d, J = 8.4, 2H), 6.92 (t, J = 8.7, 2H), I
MEXICAN INSTITUTE OF PROPERTY
8.9, 2H), 6.71 (d, J = 8.7, 4H), 6.14 (s, 2H), 4.15 '(dd, J
2H), 3.77 (t, J = 8.5, 2H), 3.59 - 3.50 (m, 2H), 3.4TT-3.3 I (lli, 2M),
3.27 (s, 6H), 1.95-1.82 (m, 2H), 1.79-1.52 (m, 8H), 0.67 (d, J = 6.8, 6H), 0.62 (d, J = 6.7, 6H).
MS (ESI; M + H) m / z = 853.
<img file="MX339989B_D0608.tif" />
EXAMPLE 52 (M- (4-fluoro-2-methylphenyl) -1 Hp¡rrol-2,5-d¡-¡nbis {benzene-4,1-d¡ylcarbamoi I (2S) pyrolidin-2, Dimethyl 1-di-yl r (2S) -3,3-dimethyl 1-1-oxobutan-1,2di-ill)) biscarbamate
Example 1A is processed using 4-fluoro-2 methylaniline and the methods of Examples 19A, 19B, 19C, 19D, and 51 ((S) -2- (methoxycarbonylamino) -3,3-dimethylbutanoic acid is used) to provide the title compound.
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ 9.98 (s, 2H), 7.44 - 7.36 (m, 5H), 7.09 - 6.96 (m, 8H), 6.42 (s, 2H), 4.39 (dd, J = 5.5 , 8.1, 2H),
4.19 (d, J = 8.7, 2H), 3.80-3.70 (m, 2H) , 3.65-3.56 (m, 2H), 3.52 (s, 6H), 2.20-2.06 (m, 2H), 1.97-1.91 (m , 2H), 1.90-1.76 (m, 4H),
1.63 (s, 3H), 0.94 (s, 18H).
329
MS (ESI; M + H) m / z = 895
IM ----
<img file="MX339989B_D0609.tif" />
INSTITUTO MfcAíUAr * «J
OF THE PRCPrtÜ'AD C
<img file="MX339989B_D0610.tif" />
EXAMPLE 53 (f (2S, 5S) -1 -r4- (tr¡fl uorometal) fen¡ Ilpyrrole idi n-2,5-di-¡l) b¡ Síbenzen4,1 -di-ylcarbamoi l (2S) pyrrol, din-2,1-di-yl (2S) -3-methyl-1-oxobutane, 1,2-di-ill, dimethyl Ubiscarbamate
EXAMPLE 53A ({(2S, 5S) -1 -í4- (trifluoro rom ethyl) feni II pyrrolid in-2,5-d i-illbisibenc n4,1 -di-i Icarbam oí l (2S) pyrrol i di n Dimethyl -2,1 -di-i ir (2S) -3-methyl-1-oxobutan1,2-di-illbbiscarbamate and (((2R, 5R) -1-r4 (trifluoromethyl) feninpyrrolidin-2,5 -di-nbisfbenzene-4,1-diylcarbamoil (2S) pyrrole idi n-2,1 -d ¡-i ir (2S) -3-meth¡ 1-1-oxobutan-1,2-di Dimethyl IBIbiscarbamate
To a solution of the product of Example 23B (84 mg
0.142 mmol) in DMSO (1.5 ml) add (S) -2 (methoxycarbonylamino) -3-methylbutanoic acid (62.2 mg, 0.355 mmol),
HATU (135 mg, 0.355 mmol), and Hunig's base (0.074 ml, 0.426 mmol), and the resulting mixture is stirred at room temperature for 90 minutes and then partitioned between H<sub>2</sub>O (1 mi) and EtOAc
330
<img file="MX339989B_D0611.tif" />
(2x2 mi). The combined organic layers will dry out Jcj ^ ZLI ^ yes)
INSTITUTE MlX'CA-XO Zl · ·
D £ -IA C * filter and concentrate in vacuo. The drying agent is ^ Wfláf; and crude product is purified by chromatography on silica gel colurrrrra'ccrrr using a solvent gradient of 1-3% MeOH in CH2Cl2 to obtain the title compounds as a mixture
1:1.
EXAMPLE 53B (f (2S, 5S) -1 -r4- (tr¡fluorometh¡i) phen¡npyrrolidin-2,5-d¡-¡Db¡s <benzene10 4,1-di-ylcarbamo¡l (2S) Dimethyl pyrroldin-2,1-di-yl f (2S) -3-methyl 1-1-oxobutan-1,2-di-ylU) biscarbamate
The product from Example 53A is separated on a Chiralpak AD-H column using hexanes :( EtOH: 2-PrOH 1: 1) 1: 1. The title compound is the first component to elute.
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ ppm 0.88 (d, J = 6.61 Hz,
H), 0.93 (d, J = 6.61 Hz, 6H), 1.63 - 1.72 (m, 2H), 1.78 - 2.06 (m, 8H), 2.06 - 2.20 (m, 2H), 3.52 (s, 6H), 3.56 - 3.67 (m, 2H), 3.73 3.86 (m, 2H), 4.03 (t, J = 8.51 Hz, 2H), 4.42 (dd, J = 7.92, 4.88 Hz, 2
H), 5.27 (d, J = 6.61 Hz, 2 H), 6.36 (d, J = 8.67 Hz, 2 H), 7.14 (d, J = 8.57
Hz, 4 H), 7.25 (d, J = 8.89 Hz, 2 H), 7.31 (d, J = 8.35 Hz, 2 H), 7.52 (d, J = 8.57 Hz, 4 H), 10.01 (s, 2 H).
MS (ESI) m / z 906.3 (M + H)<sup>+</sup>.
331
IMPI
<img file="MX339989B_D0612.tif" />
<img file="MX339989B_D0613.tif" />
MEXICAN INSTITUTE OF PROPERTY
INDUSTRIAL
<img file="MX339989B_D0614.tif" />
EXAMPLE 54 (Í (2R, 5R) -1 -r4- (tr¡fluoromethyl) pheniHPyrrolidin-2,5-di-yl> b¡sfbenc n4,1 -di-ylcarbamoi l (2S) pyrrole id i n-2, Dimethyl 1 -d¡-¡lí (2S) -3-methyl-1-oxobutan1,2-di-¡ll)) b¡scarbamate
The product from Example 53A is separated on a Chiralpak AD-H column using hexanes: (EtOH: 2-PrOH 1: 1) 1: 1. The title compound is the second component to elute.
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ ppm 0.87 (d, J = 6.61 Hz, 6 H), 0.92 (d, J = 6.72 Hz, 6 H), 1.64 - 1.74 (m, 2 H), 1.78 - 2.06 (m, 8H), 2.06-2.22 (m, 2H), 3.52 (s, 6H), 3.56-367 (m, 2H), 3.75 3.86 (m, 2H), 3.97-4.08 (m , 2 H), 4.37 - 4.48 (m, 2 H), 5.28 (d, J = 6.51 Hz, 2 H), 6.36 (d, J = 8.78 Hz, 2 H), 7.14 (d, J = 8.57 Hz, 4 H),
7.25 (d, J = 8.89 Hz, 2H), 7.30 (d, J = 8.24 Hz, 2H), 7.52 (d, J = 8.57 Hz, 4H), 10.01 (s, 2H).
MS (ESI) m / z 906.3 (M + H) <sup>+</sup> .
332
<img file="MX339989B_D0615.tif" />
EXAMPLE 55 (r (2R, 5S) 4- (4-fluorophenyl) p¡rrol¡din-2,5-di-¡Hbisf benzene-3,1-di¡lcarbamoyl (2S) p¡rrolidin-2, 1-di-yl (2S) -3,3-dimethyl-1-oxobutan-1,2di-¡H)) dimethyl biscarbamate
EXAMPLE 55A
1,4-bis (3-nitrophenyl) butane-1,4-dione
Anhydrous zinc (ll) chloride (5.42 g, 39.7 mmol) in dry benzene (50 ml) is stirred under nitrogen while diethylamine (3.10 ml, 29.8 mmol) and t-butanol (2.85 ml, 29.8 mmol) are added. The resulting mixture is stirred at room temperature for 90 minutes to obtain a cloudy solution. To this is added 1- (3-nitrophenyl) ethanone (4.97 g, 29.8 mmol) followed by 2-bromo-1- (3-nitrophenyl) ethanone (5.00 g, 19.87 mmol) and the resulting mixture is allowed to stir at room temperature during mixing. night. Subsequently, a large portion of the benzene is removed by decantation. The resulting mixture is then treated with acid
333
ΙΜ 5% sulfuric (25 ml) in a separatory funnel »g» «g ^ Jggg ^
<img file="MX339989B_D0616.tif" />
it drains. The organic phase is washed with water (2 x 25 ml). A third wash results in an emulsion. The contents of the funnel are poured into a large volume of water (750 ml) to which sodium chloride is added and the oil-in-water mixture is rapidly stirred. Methanol (75 ml) is added in portions to treat and disperse the oil and promote solidification of the product. After almost forty-eight hours of stirring the product solidifies and is collected by vacuum filtration. The filter cake is washed with water, air dried first and then in a vacuum oven at 55 ° C to provide the title compound (5.85g, 90% yield) as a pale yellow solid that is used directly. in the next step.
EXAMPLE 55B
1,4-bis (3-nitrophenyl) butan-1,4-diol
Sodium borohydride (0.6173 g, 17.74 mmol) is added to a suspension of Example 55A (2.71 g, 8.26 mmol) in ethanol (150 ml) and stirred at room temperature for 3 hours. The reaction is quenched with water (~ 50 ml) and concentrated to a paste which is dissolved in 1: 1 MeOH: THF. This suspension is filtered through a plug of celite and concentrated. The residue is dissolved in toluene and heated with stirring to form a white paste which is then subjected to sonic energy and scraped until a filterable solid is formed. This is filtered, rinsed with toluene
334
<img file="MX339989B_D0617.tif" />
DELA INDUSTRIAL PROPERTY and dried under vacuum to obtain 2.84 g (100%) of the title as an off-white solid.
MS (DCI) m / z 350 (M + NH<sub>4</sub>)<sup>+</sup>.
EXAMPLE 55C
1,4-bis (3-nitrophenyl) butan-1,4-d¡-yl dimethansuIfonate
Methanesulfonyl chloride (0.3 ml, 3.87 mmol) is added dropwise to a cold solution (0 ° C) of Example 55B (0.5089 g, 1531 mmol) and triethylamine (0.65 ml, 4.66 mmol) in THF (10 ml). The reaction is removed from the ice bath and stirred at room temperature for 30 minutes. The solvent is removed in vacuo to provide the title compound as a solid that is used without further purification.
EXAMPLE 55D
- (4-fluorophenyl) -2,5-bis (3-nitrophenyl) pyrrolidine
Example 55C (0.733 g, 1.5 mmol) is mixed with 4-fluoroaniline (1.5 ml, 15.63 mmol) and DMF (3 ml). The reaction is stirred at 50 ° C for 24 hours. The reaction mixture is partitioned between EtOAc and water. The organic portion is washed with water (2x), brine (1x), dried (MgSO<sub>4</sub>), concentrates. Purification by flash chromatography (silica gel, 050% EtOAc / Hexanes). The material is dissolved in EtOAc and washed
335 uaj
<img file="MX339989B_D0618.tif" />
with 1 M HCl (2x) to remove the aniline resid
MEXICAN INSTITUTE OF PROPERTY
NaHCO<sub>3</sub> Aqueous saturated (1x) and brine (1x) dried (MgSO ^ and concentrated to obtain the title compound as mine 1111? LI trans and cis isomers (0.45 g, 73%).
EXAMPLE 55E
3,3 '- (1 - (4-fluorophenyl) pyrrolodin-2,5-di-¡l) dianiline
A suspension of Pd / C (0.0527 g, 0.050 mmol) in THF (2 ml) is added to a solution of Example 55D (0.45 g, 1.105 mmol) in THF (7 ml) / EtOH (7 ml) under N<sub>2</sub>. The flask is purged with H<sub>2</sub> and stirred under 1 atmosphere of H<sub>2</sub> for 20 hours. The reaction is filtered through a plug of celite, rinsed with -100 ml (EtOH: THF 1: 1) and the solvent is removed in vacuo. The material is used without further purification.
MS (DCI) m / z 348 (M + H)<sup>+</sup>.
EXAMPLE 55F (2S.2<sup>,</sup>S) -2.2 '- (3.3<sup>,</sup>- ((2S.5R) -1- (4-fluorophenii) pyrrolid¡n-2.5-di¡l) bis (3.1-phenylene)) b¡s (azandi-yl) b¡s (oxometh¡len) d¡ tert-butyl pyrrolidine-1 carboxylate
Di-isopropylethylamine (0.8 ml, 4.58 mmol) is added to a mixture of Example 55E (0.382 g, 1.1 mmol), (S) -1- (tert-butoxycarbonyl) pyrrolidine-2-carboxylic acid (0.5950 g, 2.76 mmol) and
336
IMPI
HATU (0.9196 g, 2.419 mmol) in dichloromethand<sup>Nsl</sup>(<sub>;</sub><sup>r</sup>|<sup>,</sup>g'jí ¥ ^ l ^ ® ínJI.sjKíai reaction is stirred at room temperature for 1 hour, diluted with dichloromethane, washed with water (2x), brine (1x), dried (MgSO<sub>4</sub>) and concentrated to obtain a brown residue. Dissolve the residue in ether, apply sonic energy, and filter to obtain the title compound as a tan solid. The trans isomers remain in the ether solution and are described later in Example 83.
LC / MS Rt 2.27 m / z 742 (M + H)<sup>+</sup>.
EXAMPLE 55G (2S, 2<sup>,</sup>S) -N, N '- (3.3<sup>,</sup>- ((2S, 5R) -1- (4-fluoropheniI) p¡rrolidin-2,5-dii Ubis (3,1 -phenyleneDdipyrrolidi η-2-carboxamide
TFA (3 ml, 38.9 mmol) is added to a solution of Example 55F (0.4033 g, 0.544 mmol) in dichloromethane (10 ml). After 90 minutes the reaction is concentrated. The residue is sequentially dissolved in and concentrated in vacuo from the following solvents: dichloromethane (2x), methanol (2x), and ether (1x). This semisolid is dissolved in dichloromethane and washed with NaHCO<sub>3 </sub>saturated aqueous (2x) water (1x) brine (1x) dry (MgSO<sub>4</sub>) and filter to provide the title compound.
LC / MS Rt 1.31 m / z 542 (M + H)<sup>+</sup>.
<img file="MX339989B_D0619.tif" />
337
IMPI
<img file="MX339989B_D0620.tif" />
EXAMPLE 55H
KIXXAI'O INSTITUTE> χ ·<sup>, Ι!</sup>'' ϊ £<sup>!</sup> (f (2R, 5S) -1 - (4-fluorophenyl) pyrrolidin-2,5-d¡-yl1bis (benfi ^ t ^ 3jMj¿ ^ i> ^ T<sup>and</sup> i lcarbamoyl (2S) pyrolidi n-2,1-di-ylf (2S) -3.3-dimethyl-1-or di-yl1)) dimethyl biscarbamate
Di-isopropylethylamine (0.5 ml, 2.86 mmol) is added to a mixture of Example 55G, (S) -2-methoxycarbonylamino-3,3-dimethyl-butyric acid (0.2600 g, 1.374 mmol) and HATU (0.4527 g, 1.191 mmol) in dichloromethane (15 ml). The reaction is stirred at room temperature for 18 hours. The reaction is diluted with dichloromethane, washed with water (2x), brine (1x), dried (MgSO<sub>4</sub>), concentrate and purify by flash chromatography (silica gel, 0-30% EtOAc / dichloromethane) to obtain 0.14 g (30%) of the title compound.
<sup>1</sup>H NMR (400 MHz, DMSO-d6) δ 0.96 (s, 9H), 0.98 (s, 9H), 2.06 - 1.71 (m, 8H), 2.25 - 2.07 (m, 2H), 2.42 (t, J = 7.1 , 2H), 3.54 (d, J = 3.2, 6H), 3.72 - 3.59 (m, 2H), 3.86 - 3.72 (m, 2H), 4.22 (d, J = 8.9, 2H), 4.51 - 4.37 (m, 2H), 4.69 (t, J = 11.9, 2H), 6.42 - 6.28 (m, 2H),
6.96-6.83 (m, 2H), 7.08 (t, J = 8.5, 2H), 7.39-7.18 (m, 4H), 7.76- 7.54 (m, 4H), 10.03 (d, J = 9.8, 2H).
MS (ESI) m / z 884 (M + H)<sup>+</sup>, 882 (MH)<sup>+</sup>.
<img file="MX339989B_D0621.tif" />
338
EXAMPLE 56
IMPI
INSTITUTO MEXICANO DE LA PSCHEDA3 KMenuAt
<img file="MX339989B_D0622.tif" />
(f1- (4-chlorophenyl) -1H-pyrrole-2,5-di-inbis (benzene-4,1-diylcarbamoyl (2S) p¡rrolidi n-2,1-di-iir (2S) -3-met Dimethyl l-1-oxobutan-1,2-di¡HDbiscarbamate
Example 1A is processed using 4-chloroaniline and the methods of Examples 19A, 19B, 19C, 19D, and 51 to provide the title compound (72 mg).
<sup>1</sup>H NMR (400 MHz, DMSO-d6) δ 10.00 (s, 2H), 7.45 - 7.36 (m, 6H), 7.31 (d, J = 8.3, 2H), 7.04 (d, J = 8.4, 2H), 6.96 (d, J = 8.6, 4H), 6.39 (s, 2H), 4.44 - 4.37 (m, 2H), 4.06 - 3.99 (m, 2H), 3.85 - 3.74 (m, 2H), 3.67 - 3.56 (m, 2H), 3.52 (s, 6H), 2.20-2.06 (m, 2H), 2.04 1.79 (m, 8H), 0.92 (d, J = 6.7, 6H), 0.88 (d, J = 6.7, 6H).
MS (ESI; M + H) m / z = 869.
<img file="MX339989B_D0623.tif" />
EXAMPLE 57 (ri- (4-fluorophenyl) -1H-p¡rrole-2,5-d¡-¡nbis {benzene-3,1-d¡ylcarbamo¡l (2S) p¡rrol¡din-2,1 -di-iir (2S) -3-m ti 1-1 -oxobutan-1,2-d i339! L * Α.Λ-WÓ · dimethiium illDbiscarbamate
IMPI
MEXICAN INSTITUTE OF INDUSTRIAL PROPERTY
<img file="MX339989B_D0624.tif" />
Example 55A is processed using the methods of Examples 19A, 19B, 19C, 19D, and 19E to provide the title compound.
<sup>1</sup>H NMR (400 MHz, DMSO-d6) δ 0.99 - 0.84 (m, 12H), 2.05 - 1.76 (m, 8H), 2.22 - 2.05 (m, 2H), 3.53 (s, 6H), 3.70 - 3.56 (m , 2H), 3.88-3.71 (m, 2H), 4.11-3.93 (m, 2H), 4.42 (dd, J = 4.9, 7.9, 2H), 6.40 (s, 2H), 6.54 (d, J = 7.9, 2H), 7.18-6.98 (m, 6H), 7.34 (dd, J = 8.3, 15.4, 4H), 7.55 (s, 2H), 9.96 (d, J = 11.2, 2H).
MS (ESI) m / z 852 (M + H)<sup>+</sup>.
<img file="MX339989B_D0625.tif" />
EXAMPLE 58 (<1-f4- (trifluoromethyl) phenyl1-1H-pyrrol-2,5-di-yl) bis {benzene-4,1-diylcarbamoyl (2S) pyrrolidin-2,1-di-i ir (2S Dimethyl) -3-meth, 1-1-oxobutan-1,2-diiHbbiscarbamate
EXAMPLE 58A
2,5-bis (4-nitrophenyl) -1- (4- (trifluoromethyl) phenyl) -1 H-pyrroi
340
IMPI
4 (trifluoromethyl) aniline (1.9 ml, 15 mmol) is added to a suspension of the product of Specimen (3.05 mmol) in acetic acid (30 ml). The mixture is heated at 170 ° C for 15 minutes under microwave irradiation. The cold mixture is diluted with water and diethyl ether and stirred vigorously for 15 minutes and the suspension is filtered. The crude product is purified by chromatography on silica gel eluting with a solvent gradient of 0-30% ethyl acetate in hexane. The product-containing fractions are combined and concentrated under reduced pressure and then triturated with diethyl ether to obtain the title compound (110 mg, 8% yield).
<img file="MX339989B_D0626.tif" />
EXAMPLE 58B (<1- [4- (trifiuoromethyl) phenyl1-1 H-pyrrol-2,5-di-yl} bis <benzene-4,1-diylcarbamoii (2S) pyrrolidin-2.1-di-i ir (2S) Dimethyl -3-methy 1-1-oxobutan-1,2-diHBbiscarbamate
Example 58A is processed using the methods of Examples 19B, 19C, 19D, and 51 to provide the title compound (44 mg).
<sup>1</sup>H NMR (400 MHz, DMSO-d6) δ 10.01 (s, 2H), 7.71 (d, J =
8.6, 2H), 7.42 (d, J = 8.7, 4H), 7.31 (d, J = 8.2, 2H), 7.22 (d, J = 8.3, 2H), 6.95 (d, J = 8.6, 4H), 6.43 (s, 2H), 4.39 (dd, J = 5.2, 8.1, 2H), 4.03 (d, J = 8.3, 2H), 3.85 - 3.75 (m, 2H), 3.66 - 3.56 (m, 2H), 3.52 ( s, 6H), 2.18-2.08 (m, 2H), 2.01-1.79 (m, 8H), 0.92 (d, J = 6.7, 6H),
341
0.87 (d, J = 6.6, 6H).
I ίνϊ ΡI
MS (ESI; M + H) m / z = 903.
INSTITUTO MEXICANO DELA FRCnEDrtD
INDUSTRIAL
<img file="MX339989B_D0627.tif" />
H
<img file="MX339989B_D0628.tif" />
EXAMPLE 59 {(2S) -1-F (2S) -2- (4- (4 - [(2R<sub>l</sub>5S) -5- (4- {2 - [(2S) -1 - {(2S) -2rfmethoxycarbonyl) aminoT-3-methylbutanoyl} pyrrolidin-2-iH-1H¡m¡dazol-4-yl) fen ¡L) -1-phenylpyrrol¡d¡n-2-illphenyl) -1 H-imidazol-2-yl) pyrroledin-1-¡H-3-methyl-1-oxobutan-2-iI) methyl carbamate
<img file="MX339989B_D0629.tif" />
EXAMPLE 59A (2S.2'S) -2.2 '- (4.4' - (4.4<sup>,</sup>- (1-phenylpyrrolidin-2,5-di-yl) b¡s (4,1phenylene)) bis (1H-imidazol-4,2-di-yl)) dipyrrolidin-1-carboxylic ester
Example 42B and aniline are processed using the
342
IMPI
<img file="MX339989B_D0630.tif" />
methods of Examples 39D, 42D, and 42E to provideP<sup>T</sup>i ^ $ ^ ®) ge
INDUSTRIAL of the title as a mixture of stereoisomers.
MS (ESI) m / z 770 (M + H) +.
EXAMPLE 59B
4,4 '- ((2R, 5S) -1-phenylpyrrolidin-2,5-di-yl1d¡benzene-4,1-di-¡l) bisph2i (2S) -pyrrol¡d¡n-2 -H-1 H-imidazole) (ACD v12)
To the product from Example 59A (30 mg, 0.039 mmol) dimethoxyethane (1.5 ml) and a solution of 4N hydrochloric acid in dioxane (3 ml) are added and the resulting solution is stirred at room temperature for 1.5 hours. Then the solvent is removed in vacuo and the resulting residue is diluted with acetonitrile and water (0.1% TFA) and purified by reverse phase chromatography (C18), eluting with 10-100% acetonitrile in water (0.1% TFA ) to obtain 9.8 mg (44%) of the title compound and 8.5 mg of a mixture of the trans diastereomers (MS (ESI) m / z 570 (M + H) +) which is further processed as described in Example 89 For the title compound: MS (ESI) m / z 570 (M + H) +.
EXAMPLE 59C ((2S) -1-r (2S) -2- (4-f4-F (2R.5S) -5- (4- (2-r (2S) -1 - ((2S) -2r ( methoxycarbonyl) aminol-3-methylbutano¡l) pyrrolidin-2-¡H-1 Him idazol-4-yl) phenyl) -1-phenylpyrrolidin-2-yl1phenyl1-1 H-imidazol-2-yl) pyrrolidin-1- ill-3-methyl-1-oxobutan-2-yl) methyl carbamate
343
The product from Example 59B (9.8 mg, (S) -2- (methoxycarbonylamino) -3,3-dimethylbutanoic acid (5.4 mg,
<img file="MX339989B_D0631.tif" />
0.031 mmol) and HATU (10.3 mg, 0.027 mmol) in DMSO (1 ml) Hunig's base (0.017 ml, 0.098 mmol) is added, and the reaction mixture is stirred at room temperature for 1 hour. The reaction mixture is partitioned between water and ethyl acetate, and the organic layer is dried over MgSO<sub>4</sub>, filter and concentrate in vacuo. The crude product is purified by reverse phase chromatography (C18), eluting with 10-100% acetonitriium in water (0.1% TFA) to obtain 4.5 mg (41%) of the title compound.
<sup>1</sup>H NMR (TFA salt) (400 MHz, DMSO-D6) δ ppm 14.50 (bs, 2H), 7.99 (s, 2H), 7.78 (m, 4H), 7.65 (m, 4H), 7.32 ( m, 2H), 7.02 (t, J = 8.0 Hz, 2 H), 6.63 (t, J = 7.4 Hz, 1 H), 6.40 (d, J = 8.2 Hz, 2 H), 5.11 (t, J = 6.9 Hz, 2H), 4.83 (m, 2H), 4.10 (t, J = 7.7 Hz, 2H), 3.82 (m, 6H), 3.48 (s, 6H), 2.40 (m, 2H) , 2.08 (m, 2H), 2.00 (m, 6H),
1.85 (m, 2H), 0.85 (m, 2H), 0.80 (m, 12H).
MS (ESI) m / z 884 (M + H) +.
<img file="MX339989B_D0632.tif" />
EXAMPLE 60 (f (2S, 5S) -1- (4-t r-butylf n¡l) p¡rrol¡d¡n-2,5-di-¡Hb¡sf b ncen-4,1-d¡
344
ΙΜΡΙ6 ilcarbamo¡l (2S) pyrrolid¡n-2,1-d¡-¡ir (2S) -3<sub>Í</sub>3-dimethyl-<sup>l</sup>1<sup>to</sup>OÍXatmtáh- #;
l <sup>L</sup>-'¿USTIUAV d¡-ill}) dimethyl b¡scarbamate
<img file="MX339989B_D0633.tif" />
EXAMPLE 60A (r (2S, 5S) -1 - (4-tert-butylphenyl) p¡rrolid¡n-2,5-di-¡nbisfbenzene-4,1-d¡¡lcarbamoyl (2S) pyrrolidin -2,1-di-iirí2S) -3.3-dimethyl-1-oxobutan-1,2di-¡H)) dimethyl biscarbamate
Ϊ.
(r (2R, 5R) -1- (4-tert-butylphenyl) pyrrolidin-2,5-di-¡Hb¡s (benzene-4,1-diylcarbamoyl (2S) pyrroli din- Dimethyl 2,1-di-i ir (2S) -3,3-dimethyl 1-1-oxob utan-1,2di-illUbiscarbamate
The product of Example 34D (29.0 mg, 0.05 mmol), (S) -2- (methoxycarbonylamino) -3,3-dimethylbutanoic acid (20.81 mg, 0.110 mmol), EDC (21.09 mg, 0.110 mmol), HOBT (16.85 mg, 0.110 mmol) and N-methylmorpholine (0.027 ml, 0.250 mmol) are combined in DMF (2 ml). The mixture is stirred at room temperature for 3 hours. The reaction mixture is partitioned between ethyl acetate and water. The organic layer is washed with brine twice, dried over sodium sulfate, filtered, and evaporated. The residue is purified by chromatography on silica gel eluting with ethyl acetate / hexane (50% to 80%) to obtain the title compound (32 mg, 69%) as a mixture of trans diastereomers.
345
EXAMPLE 60B
IMPI
MEXICAN INSTITUTE OF INDUSTRIAL PROPERTY
<img file="MX339989B_D0634.tif" />
(H2S, 5S) -1- (4-tert-but¡lfen¡l) p¡rrol¡d¡n-2,5-di-yl1b¡s (benzene-4,1 -d¡¡lcarbamo¡l ( Dimethyl 2S) pyrroled¡ n-2,1-di-ir (2S) -3,3-d¡methyl 1-1 -oxobutan-1,2di-ylTUbiscarbamate
The product from Example 60A is purified by chiral chromatography on a semi-preparative AD-H Chiralpak column eluting with a 3: 1 mixture of hexane: (2: 1 IPA: EtOH). The title compound is the first of the 2 diastereomers to elute.
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ ppm 0.97 (s, 18H) 1.11 (s, 9H) 1.60 - 1.65 (m, 2H) 1.79 - 1.91 (m, 4H) 1.94 - 2.03 (m, 2H)
2.10 - 2.18 (m, 2H) 2.44 - 2.50 (m, 2H) 3.54 (s, 6H) 3.59 - 3.67 (m, 2H) 3.71 - 3.82 (m, 2H) 4.21 (d, J = 8.89 Hz, 2H) 4.43 (dd, J = 7.92,
5.42 Hz, 2 H) 5.14 (d, J = 6.40 Hz, 2 H) 6.18 (d, J = 8.89 Hz, 2 H) 6.94 (d, J = 8.78 Hz, 2 H) 7.08 (d, J = 8.78 Hz , 2H) 7.13 (d, J = 8.57 Hz, 4H)
7.50 (d, J = 8.46 Hz, 4H) 9.99 (s, 2H).
MS (ESI +) m / z 923 (M + H) +.
<img file="MX339989B_D0635.tif" />
EXAMPLE 61 (f (2R, 5R) -1- (4-t r-butylf ni Dpi rrol idi n-2,5-di-yl1bisf benzene-4,1 -di346
i lcarbamoyl (2S) pyrrole i di n-2,1-di-yl (2S) -3,3-di methyl-;
dimethyl di-ylTDbiscarbamate
<img file="MX339989B_D0636.tif" />
OF INDUSTRIAL FFOPILTY
<img file="MX339989B_D0637.tif" />
The product from Example 60A is purified by chiral chromatography on a semi-preparative AD-H Chiralpak column eluting with a 3: 1 mixture of hexane: (2: 1 IPA: EtOH). The title compound is the second of the 2 diastereomers to elute.
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ ppm 0.96 (s, 18H) 1.11 (s, 9H) 1.60 - 1.66 (m, 2H) 1.78 - 1.92 (m, 4H) 1.94 - 2.04 (m, 2H) 2.08 - 2.19 (m, 2H) 2.42 - 2.50 (m, 2H) 3.54 (s, 6H) 3.59 - 3.67 (m, 2H) 3.74 - 3.81 (m, 2H) 4.20 (d, J = 8.89 Hz, 2 H) 4.43 (dd, J = 7.97, 5.37 Hz, 2 H) 5.15 (d, J = 6.29 Hz, 2 H) 6.17 (d, J = 8.89 Hz, 2 H) 6.94 (d, J = 8.89 Hz, 2H) 7.07 (d, J = 8.89 Hz, 2H) 7.13 (d, J = 8.46 Hz, 4H) 7.50 (d, J = 8.57 Hz, 4H) 9.99 (s, 2H ).
MS (ESI +) m / z 923 (M + H) +.
<img file="MX339989B_D0638.tif" />
EXAMPLE 62 f (2S) -1 -r (2S) -2- (4- {4-r (2R, 5S) -1 - (4-fiuorophenyl) -5- (4-f2-F (2S) -1 -F (2S) 2-F (methoxycarbonyl) aminol-3-methylbutano¡l) pyrrol¡din-2-in-1H¡m¡mdazol-4-¡IKenyl) pyrrolidin-2-yl1phenyl-1H-imidazoi-2 -ii) pyrrolidin347
<img file="MX339989B_D0639.tif" />
ΪΜΡΙ
1-yn-3-methyl-1-oxobutan-2-¡l) carbamate
EXAMPLE 62A
4,4<sup>,</sup>-frf2R, 5S) -1- (4-fluorophenyl) pyrrolidin-2,5-di-indibenze-4,1-diyl) bis {2-y (2S) -pyrrolidin-2-iΠ-1 H-imidazole ) (ACD v12)
The product of Example 45C (0.15 g, 0.190 mmol) in CH<sub>2</sub>CI<sub>2</sub> (1 ml) is treated with TFA (1 ml), and the resulting mixture is stirred at room temperature for 1 hour and then concentrated in vacuo. The crude product is purified by column chromatography on C18 silica using a solvent gradient of 10 100% CH<sub>3</sub>CN in 0.1% aqueous TFA. The desired cis-pyrrolidine isomer is the second of the 2 components to elute. The fractions containing the pure cis isomer are combined and concentrated in vacuo. The residue is partitioned between NaHCO<sub>3</sub> aqueous saturated and a 3: 1 mixture of CH<sub>2</sub>CI<sub>2</sub>: 2-PrOH (3x). The combined organic layers are dried over Na<sub>2</sub>SW<sub>4</sub>, filter and concentrate in vacuo to obtain the title compound (32 mg, 28%).
EXAMPLE 62B f (2S) -1-r (2S) -2- (4- {4-r (2R<sub>1</sub>5S) -1- (4-fluorophenyl) -5- (4- (2-r (2S) -1-f (2S) 2-r (methoxycarbonyl) amino1-3-methylbutane<sup>,</sup>) p¡rrolid¡n-2-in-1 H¡m¡dazol-4-yl) fen¡np¡rrol¡d¡n-2-¡Hfen¡l) -1 H-im¡dazol-2-yl ) p¡rrolidin1-¡H-3-methyl-1-oxobutan-2-¡l> methyl carbamate
348
IM
<img file="MX339989B_D0640.tif" />
The product of Example 62A (32 mg'NST ^ c is subjected to the method described in Example 5D, substituting (S) 2- (methoxycarbonylamino) -3-methylbutanoic acid for (S) -2 (methoxycarbonylamino) butanoic acid, to obtain the title compound (34mg, 69%).
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ ppm 0.78 - 0.93 (m, 12H), 1.78 - 2.24 (m, 12H), 2.37 - 2.46 (m, 2H), 3.54 (s, 6H), 3.68 3.87 (m, 4H), 4.66 - 4.79 (m, 2H), 5.02 - 5.13 (m, 2H), 6.39 (dd, J = 9.16, 4.50 Hz, 2H), 6.81 - 6.92 (m, 2H), 7.23-7.34 (m, 2H), 7.39-780 (m, 12H), 11.67-12.12 (m, 2H).
MS (ESI) m / z 902.7 (M + H)<sup>+</sup>.
EXAMPLE 63 r (2S) -1 - ((2S) -2- [4- (4-f (2R, 5S) -5- (4- {2-r (2S) -1 - {(2S) -2r (methoxycarbonyl) amino1-3-methylbutanoyl) p¡rrol¡d¡n-2-¡n-1Himidazol-4-¡l} phenyl) -1-F4- (trifluoromethyl) phenylHpyrrolidin-2-¡ Methyl l) phenyl) 1H-imidazol-2-inpyrrolidin-1-yl) -3-methyl-1-oxobutan-2-l1carbamate
349
EXAMPLE 63A (2R.5S) -2.5-bis (4-bromophenyl) -1 - (4- (trifluoromethyl) phenyl) pyrrolidine
WICKED
MEXICAN INSTITUTE OF PROPERTY
INDUSTRIAL
<img file="MX339989B_D0641.tif" />
The product from Example 42B (11.13 g, 20.0 mmol) and 4 (trifluoromethyl) aniline (Aldrlch, 32.2 g, 200 mmol) are combined in DMF (50 ml), stirred at 50 ° C under nitrogen for 16 hours, cooled and they concentrate. The residue is diluted with ethyl acetate, treated with 1M HCl, stirred for 10 minutes, and filtered to remove solids. The organic layer of the filtrate is washed with brine, dried (Na<sub>2</sub>SW<sub>4</sub>), filtered and concentrated. The residue is purified by flash chromatography (silica gel, 0 to 1% ethyl acetate / hexane) to obtain the title compound (1.0 g, 10%) as the second stereoisomer to elute.
MS (ESI +) m / z 526 (M + Hf.
EXAMPLE 63B r (2S) -1 - ((2S) -2-r4- (4-f (2R, 5S) -5- (4- {2-r (2S) -1 - ((2S) -2r ( methoxycarbon¡l) amino1-3-met¡lbutanoinp¡rrol¡d¡n-2-¡n-1H¡m¡mdazol-4-yl> phenyl) -1-f4- (tr¡fluoromethyl) phenylHpyrrolidin-2-yl > phenyl) methyl 1H-imidazole-2-np¡rrolidin-1-yn-3-methyl-1-oxobutan-2-iHcarbamate
The product from Example 63A (1.0 g, 1.90 mmol) is processed using the methods described in Examples 42D, 42E, 42F, and 42G to obtain the title compound.
350
IΜ ΡI <sup>1</sup>Η NMR (free base) (400 MHz, DMSO-TO ^ Mfé-ICSÉ #
INDUSTRIAL (m, 12H) 1.83-2.18 (m, 14H) 3.54 (s, 6H) 3.79 (d, J = 6.18 Hz, 3H)
3.97 - 4.15 (m, 3H) 4.87 (d, J = 4.88 Hz, 2H) 5.02 - 5.14 (m, 2H) 6.54 (d, J = 8.67 Hz, 2H) 7.15 - 7.80 (m, 14H ) 11.56-12.30 (m, 2H).
MS (ESI +) m / z 953 (M + H) <sup>+</sup> .
<img file="MX339989B_D0642.tif" />
EXAMPLE 64 f (2S) -1-R2S) -2- (4-f4-r (2R, 5S) -1- (4-tert-butylphenyl) -5- (4-f2-r (2S) -1f ( 2S) -2-r (methoxycarbonyl) amino1-3-methiibutanoiDpyrroledin-2-iH-1 Hyidazol-4-yl) phenyl) pyrrole idi n-2-illfeni IV-1 H-imidazol-2-i Dpi rrol idi n1 -ill-3-methyl-1-oxobutan-2-iDcarbamate methyl
EXAMPLE 64A
Bis trifluoroacetate salt of (2S, 2'R) -2,2 '- (4,4' - (4,4 '- (1- (4-terbuti Ifeni I jpyrrole id¡ n-2,5-di-yl ) bis (4,1-phenylene)) bis (1 H-imidazole)
Example 42C is processed using the methods of Examples 42D, 42E, and 42F to provide a mixture of cis / trans pyrrolidine isomers. The mixture of stereoisomers dissolves in 10
351
IMPI mi of 80% (0.1% TFA / water): 20% CH<sub>3</sub>CN
INDUSTRIAL column of 13 g of C18 silica. The column is eluted with a gradient of 0.1% TFA (aq.): CH<sub>3</sub>CN; 80/20 to 50:50 over the course of 25 minutes, yielding the cis stereoisomer of the title compound as a light yellow solid trifluoroacetate salt,
88.6 mg, 58%.
<img file="MX339989B_D0643.tif" />
EXAMPLE 64B n2S) -1-H2S) -2- (4- (4-n2R, 5S) -1- (4-tert-but¡lfen¡l) -5- (4- (2-r (2S) - 1f (2S) -2-r (methoxy carbon yl) amine nol-3-methylbutanoi Dpi rrolıdin-2-iH-1 Himidazol-4-yl> phenyl) pyrrolidin-2-infenin-1 H-imidazole -2-yl) pyrrolidin
Methyl 1-ill-3-methyl-1-oxobutan-2-yl) carbamate
The product from Example 64A is dissolved in 1 ml of DMF and added dropwise to a cold solution (0-5 ° C) containing (S) -2- (methoxycarbonylamino) -3-methylbutanoic acid (0.41 g, 0.232 mmol), HOBt (0.036 g, 0.232 mmol), EDAC (0.045 g, 0.232 mmol) and 4-methylmorpholine (0.138 g, 0.150 ml, 1.364 mmol) in 0.5 ml of DMF. The pH of the solution is measured and found to be 8. The reaction is stirred a total of 3.5 hours in the ice bath. The reaction mixture is diluted with 50 ml of EtOAc and washed with NaHCO<sub>3</sub> 10%, NaCl 10%, dried with Na<sub>2</sub>SW<sub>4</sub>(s) anhydrous, it is filtered and the solvent is removed in vacuo leaving a pinkish oil. The oil dissolves in 5 ml of CH<sub>2</sub>CI<sub>2</sub> and applied to a 12 g column of silica gel. The column elutes with a
352 CH gradient<sub>2</sub>CI<sub>2</sub>/ MeOH, 99/1 to 94/6 in one laps <
which produces the title compound as a white solid,
12.5 mg, 11%. —-
<img file="MX339989B_D0644.tif" />
KtOi & 'ZU-tiL <sup>1</sup>H NMR (400 MHz, DMSO-D6) d ppm 0.85 (s, 12H) 1.13 (s, 9H) 1.95 (s, 6H) 2.15 (s, 4H) 2.50 (s, 3H) 3.43 (s , 1H) 3.54 (s,
H) 3.80 (s, 4H) 4.05 (s, 2H) 4.70 (s, 2H) 5.07 (s, 1H) 6.36 (d,
J = 8.78 Hz, 2H) 7.01 (s, 2H) 7.28 (s, 2H) 7.47 (s, 6H) 7.70 (s, 4H)
11.71 (s, 2H) 12.09 (s, 2H).
ESI +: 940.8
<img file="MX339989B_D0645.tif" />
EXAMPLE 65 n2SM-R2S) -2- (4- (4-r5- (4- (2-r (2S) -1 - {(2S) -2r (methoxycarbonyl) amino1-3-methylbutanoiRpyrrolidin-2 -ill-1H¡midazol-4-¡l) phen¡l) -1 -f eni 1-1 Hp¡rrol-2-illfen¡l) -1 H-imidazol-2¡l) p¡rrol¡d¡ methyl n-1-¡n-3-methyl-1-oxobutan-2-¡l) carbamate
EXAMPLE 65A (2S, 2'R) -2.2 '- (4.4' - (4.4 '- (1-phenyl-1H-p¡rrole-2,5-d¡-¡l) b¡ t-rbutyl s (4.1phenylene)) bis (1 H-midazol-4,2-d¡-yl)) d¡pyrrol¡d¡n-1-carboxylate
353
<img file="MX339989B_D0646.tif" />
IMPI
MEXICAN INSTITUTE
OF THE PROPERTY
Example 26E and aniline uffRfSYWo were processed by methods of Examples 19A, 26G, and 26H to provide the title compound (150 mg).
EXAMPLE 65B (S) -4,4 '- (4,4' - (1-feni 1-1 Hp¡rrol-2.5-di-¡l) b¡s (4.1-phenylene)) bis (2- ((S) p¡rrolidi n-2-yl) -1 H-imidazole)
To a suspension of the product of Example 65A (186 mg, 0.243 mmol) in dioxane (5 ml) is added HCl / dioxane (5 ml, 20 mmol). The mixture is stirred for 30 minutes and then concentrated under reduced pressure to provide the title compound as a hydrochloride salt.
EXAMPLE 65C <(2S) -1-r (2S) -2- (4-f4-r5- (4- (2-r (2S) -1-f (2S) -2r (methoxycarbonyl) aminol-3-methyl butanoiDpi rrolidin-2-ill-1H¡midazol-4-ylHenyl) -1-phenyl 1-1 H-pyrrol-2-illphenyl} -1 H-imidazol-2-yl) pyrrolidin-1-ill-3-methyl-1 - Methyl oxobutan-2-ylIcarbamate
A solution consisting of N1 ((ethylimino) methylene) -N3 hydrochloride, N3-dimethylpropan-1,3-diamine (90 mg, 0.47 mmol), 1 H-benzo [d] [1,2,3] hydrated triazol-1-ol (72 mg, 0.47 mmol), (S) -2- (methoxycarbonylamino) -3-methylbutanoic acid (82 mg, 0.47 mmol) and 4-methylmorpholine (0.28 ml, 2.6 mmol) in DMF (1.6 >
354
IMPI
INSTITUTO MEXICANO CE LA FROFIEDAD INDUSTRIAL
<img file="MX339989B_D0647.tif" />
e) is cooled in an ice bath. To this mixture a solution of the product of Example 65B (150 mg, 0.2 150 mmol) in DMF (0.5 ml) is added dropwise. Additional 4-methylmorpholine is added to the mixture until the pH is adjusted to 8. The reaction is stirred for 3.5 hours and then the ice bath is removed and the reaction is stirred for an additional 16 hours. Water is then added to the reaction mixture and the resulting precipitate is recovered by filtration. The residue is washed with copious amounts of water followed by diethyl ether. The crude product is purified by chromatography on silica gel eluting with a solvent gradient of 0-5% methanol in CH<sub>2</sub>CI<sub>2</sub> to provide the title compound.
<sup>1</sup>H NMR (400 MHz, DMSO-d6) δ 12.12 - 11.64 (m, 2H)
7.57 - 7.45 (m, 4H), 7.42 - 7.36 (m, 2H), 7.36 - 7.29 (m, 3H), 7.29 7.05 (m, 4H), 7.04 - 6.91 (m, 4H), 6.54 - 6.43 (m, 2H), 5.06 - 4.96 (m, 2H), 4.06 - 3.96 (m, 2H), 3.84 - 3.67 (m, 4H), 3.52 (s, 6H), 2.17 - 1.80 (m, 10H), 0.91 - 0.76 ( m, 12H).
MS (ESI; M + H) m / z = 881.
F
<img file="MX339989B_D0648.tif" />
O \
355 ν
EXAMPLE 66
H2SM-f (2S) -2-r4- (4-f (2S, 5S) -5- <4-f2-K2SM-f (2S) -2IMPI
INSTITUTO MEXICANO ΠΪ LA PFOPIEOAO INPVSTIUAL
<img file="MX339989B_D0649.tif" />
rtmethoxycarboni l) amino1-3-methylbutano¡l) pyrrole ¡din-2-ill-1H¡m¡mdazol-4-¡l) phen¡l) -1 -r4- (trifluoromet¡nfen¡llp¡rrol¡din- Methyl 2-¡llphenyl) 1H-im¡dazol-2-¡n Pyrrolid i n-1 -yl) -3-methyl-1-oxobutan-2-¡l] carbamate
EXAMPLE 66A (2R, 5R) -2,5-b¡s (4-bromophenyl) -1- (4- (trifluoromethyl) phenyl) pyrrolidine
X (2S.5S) -2.5-bis (4-bromophenyl) -1 - (4- (trifluoromethyl) phenyl) pyrrolidine
The product from Example 42B (11.13 g, 20.0 mmol) and 4- (trifluoromethyl) aniline (32.2 g, 200 mmol) are combined in DMF (50 ml). The mixture is stirred at 50 ° C under nitrogen overnight. The reaction mixture is evaporated and the residue is diluted with ethyl acetate, treated with 1M HCl, stirred for 10 minutes, and filtered to remove the solid. The organic layer of the filtrate is washed with brine, dried over sodium sulfate, filtered and evaporated. The residue is purified by chromatography on silica gel eluting with ethyl acetate / hexane (0 to 1%). Title compounds (500 mg, 5%) elute as the first of 2 stereoisomers and are obtained as a mixture of trans diastereomers.
356
EXAMPLE 66B (2R, 5R) -2.5-b¡s (4- (4.4.5.5-tetramethyl-1,3.2-dioxaborolan-2-iPfen¡PI Μ Ρ I
MEXICAN INSTITUTE OF INDUSTRIAL PROPERTY
<img file="MX339989B_D0650.tif" />
- (4- (trifiuorometiDfeniDpi rrolidin
AND.
(2S, 5S) -2.5-b¡s (4- (4.4.5,5-tetramethyl-1. 3,2-d¡oxaborolan-2-¡DfeniP1 - (4- (trifluorometiPfeniPpi rrolidi na
The products of Example 66A (500 mg, 0.952 mmol), bis (pinacholate) dyboror (725 mg, 2.86 mmol), potassium acetate (374 mg, 3.81 mmol) and bis (triphenylphosphine) palladium chloride (II) (66.8 mg, 0.095 mmol) are combined in 1,2-dimethoxyethane (10 ml). The mixture is purged with nitrogen for 15 minutes and stirred at 85 ° C for 2 hours. The reaction mixture is partitioned between ethyl acetate and 1M HCl. The organic layer is washed with saturated sodium bicarbonate, brine, dried over sodium sulfate, filtered, and evaporated. The residue is purified by chromatography on silica gel eluting with hexane to ethyl acetate / hexane (10%) to obtain a solid which is triturated with dichloromethane / hexane (1: 3) to obtain the title compounds (370 mg, 63%).
EXAMPLE 66C (2S.2<sup>,</sup>S) -2.2<sup>,</sup>- (4.4 '- (4,4' - ((2R, 5R) -1- (4 (trifluoromethiDfeni Dpi rrolidi n-2,5-di-i Dbis (4,1-phenylene)) bis (1 Him¡ tert-butyl dazol-4,2-di-¡D) dipyrrolidine-1-carboxylate
Ϊ.
357 «Exemjtr:
(2S, 2'S) -2.2 '- (4.4' - (4.4 '- ((2S, 5S) -1- (4J-U __
--- - - -’-'-<sup>1</sup>-INST-UTC MEXICAN '
LA? LOí ElDAl) (tr¡fluoromethyl) phenyl) pyrrol¡d¡n-2,5-di-yl) bis (4.1-phenyinUbis / TH¡midazol-4,2-di-¡h) di pyrrolidin-1 - carboxylate Π'6ΐ5ΊΓ-Β IUIIO
<img file="MX339989B_D0651.tif" />
The products of Example 66B (257 mg, 0.415 mmol), the product of Example 26D (341 mg, 1,079 mmol), tribasic potassium phosphate (352 mg, 1,660 mmol) and 1,1'-bis (diter-butylphosphine dichloride ) palladium ferrocene (27.0 mg, 0.041 mmol) are combined in THF (4.5 ml) / water (1.5 ml). The mixture is purged with nitrogen for 15 minutes and stirred at 70 ° C for 6 hours. The reaction mixture is partitioned between ethyl acetate and saturated sodium bicarbonate. The organic layer is washed with brine, dried over sodium sulfate, filtered, and evaporated. The residue is purified by chromatography on silica gel eluting with methanol / dichloromethane (1% to 3%) to obtain the title compounds (286 mg, 82%) as a solid.
EXAMPLE 66D (S) -4.4<sup>,</sup>- | 4,4'-l2R, 5R) -1 - (4- (trifluoromethihphenyl) pyrrolidin-2.5-diyl) bis (4,1-phenylene)) bis (2-f (S) -pyrrolidi n-2- ¡L) -1 H-imidazole)
AND.
Is) -4.4<sup>,</sup>-|4.4<sup>,</sup>-l (2S, 5S) -1- (4- (trifluoromethyl) phenyl) PÍrrolidin-2,5-diyl) bis (4,1-phenylene)) bis (2 - ((S) -pyrrolidi η-2 -i h-1 H-imidazole)
To the products of Example 66C (385 mg, 0.459 mmol)
358 ildMalo I
MEXICAN INSTITUTE OF PRCFIEDAD ambi d'rf<sup>í</sup>t<sup>J</sup>and<sup>TR1</sup>d<sup>l</sup>U ran
<img file="MX339989B_D0652.tif" />
in dioxane (6 ml) 4 M hydrochloric acid e 40.0 mmol is added) and the reaction is stirred at temperature 1 hour. The solvent is evaporated under high vacuum to the title compounds (approx. 360 mg) as the hydrochloride salts.
EXAMPLE 66E
K2SM-f (2S) -2-r4- (4 - {(2S, 5S) -5- (4- (2-H2S) -1-f (2S) -2r (methoxycarbon¡l) aminol-3-met ¡Lbutanoyl) p¡rrol¡d¡n-2-in-1Himidazol-4-yl) phenyl) -1 -r4- (trifluoromethyl) phenylpyrrolidi n-2-yl) phenyl) 1H-i midazol-2-i II pyrrolidin Methyl -1-yl) -3-methyl-1-oxobutan-2-illcarbamate and
H2S) -1 - {(2S) -2-r4- (4 - {(2R, 5R) -5- (4- (2-r (2S) -1 - {(2S) -2Kmethoxycarbonyl) ami nol- 3-methylbutanoyl) pyrolidin-2-yl] -1 Himidazol-4-yl) phenyl) -1 -r4- (trifluoromethyl) phenyl-1-pyrrolidin-2-yl) phenyl) 1H-imidazol-2 methyl-ylpyrrolidin-1-yl) -3-methyl-1-oxobutan-2-ncarbamate
The product of Example 66D (360 mg, 0.459 mmol), (S) -2- (methoxycarbonylamino) -3-methylbutanoic acid (161 mg, 0.919 mmol), 4-methylmorpholine (0.404 ml, 3.68 mmol), hydrochloride N1 - ((ethylimino) methylene) -N3, N3-dimethylpropan-1,3-diamine (194 mg, 1,011 mmol) and 1 H-benzo [d] [1,2,3] triazol-1-ol hydrated (155 mg, 1011 mmol) are combined in DMF (10 ml). The mixture is stirred at room temperature for 20 hours. The reaction mixture is
359 partitions between ethyl acetate and water. The layer
IMPI or rg aiFWi © ac & e \; laiva
OF THE PP.OHfPAD
INDUSTRIAL
<img file="MX339989B_D0653.tif" />
saturated sodium bicarbonate, brine twice, dry over sodium sulfate, filter, and evaporate. The residue is purified by chromatography on silica gel eluting with methanol / dichloromethane (1% to 6%) to obtain the title compounds (223 mg, 51%) as a solid.
EXAMPLE 66F r (2S) -1 - <(2S) -2-r4- (4-f (2S, 5S) -5- (4- {2-H2S) -1-í (2S) -2f (methoxycarbon¡ l) amino1-3-methylbutanoyl) pyrrolidin-2-ill-1Himidazol-4-yl> phenyl) -1 -r4- (trifluoromethyl) phenylpyrrolidin-2-yl> phenyl) 1H-imidazol-2-ilpyrrolid Methyl n-1-¡l} -3-methyl-1-oxobutan-2-iHcarbamate
The product from Example 66E is purified by chiral chromatography on a Chiralpak IB column eluting with a mixture of hexane / THF / methanol (8/1/1). The title compound is the first of the 2 diastereomers to elute.
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ ppm 0.78 - 0.90 (m, 12 H)
1.71 - 1.77 (m, 2H) 1.86 - 2.02 (m, 6H) 2.09 - 2.18 (m, 4H) 2.51 2.54 (m, 2H) 3.53 (s, 6H) 3.74 - 3.84 (m, 4H ) 4.04 (t, J = 8.35 Hz, 2 H) 5.06 (dd, J = 6.83, 3.14 Hz, 2 H) 5.28 - 5.41 (m, 2 H) 6.41 (d, J = 8.67 Hz, 2 H) 7.12 - 7.33 (m, 8H) 7.36-7.72 (m, 6H) 11.62 12.13 (m, 2H).
MS (ESI +) m / z 953 (M + H) +.
360
IMPI
F
<img file="MX339989B_D0654.tif" />
/
MEXICAN INSTITUTE OF INDUSTRIAL PROPERTY
<img file="MX339989B_D0655.tif" />
EXAMPLE 67 r (2S) -1-f (2S) -2-r4- (4-f (2R, 5R) -5- (4- <2-R2S) -1-f (2S) -2r (methox¡ carbon¡l) am¡no1-3-meth¡lbutano¡l) pyrrol¡d¡n-2-¡n-1 H¡midazol-4-¡l) phenyl) -1 -r4- (tr¡fluorometh¡l ) Methyl) phenyllpyrrolidin-2-i) phenyle) 1 H-imidazol-2-ill pyrrolidin-1 -iR-3-methyl-l-oxobutan-2-incarbamate
The product from Example 66E is purified by chiral chromatography on a Chiralpak IB column eluting with a mixture of hexane / THF / methanol (8/1/1). The title compound is the second of the 2 diastereomers to elute.
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ ppm 0.79 - 0.91 (m, 12 H)
1.71 - 1.77 (m, 2H) 1.88 - 2.01 (m, 6H) 2.08 - 2.17 (m, 4H) 2.51 2.54 (m, 2H) 3.53 (s, 6H) 3.74 - 3.82 (m, 4H ) 4.05 (t, J = 8.40 Hz, 2H) 5.00 - 5.13 (m, 2H) 5.29 - 5.40 (m, 2H) 6.40 (d, J = 8.57 Hz, 2H)
7.12 - 7.31 (m, 8H) 7.36 - 7.72 (m, 6H) 11.52-12.15 (m, 2H).
MS (ESI +) m / z 953 (M + H) +.
361
<img file="MX339989B_D0656.tif" />
/
IMPI
MEXICAN INSTITUTE OF FROPIEDAD
INDUSTRIAL
<img file="MX339989B_D0657.tif" />
EXAMPLE 68
R2S) -1-r (2S) -2- (4- <4-R2R.5S) -1- (4-cyclopropylphenyl) -5- (4- {2-R2S) -1K2S) -2-Rmethoxycarbonyl ) am¡no1-3-methylbutanoyl} p¡rrolid¡n-2-¡n-1H¡m¡dazol-4-¡l) phen¡l) p¡rrol¡d¡n-2-¡llfen¡l) Methyl -1 H-imidazol-2-yl) pyrrolidin-ii1-3-methyl-1-oxobutan-2-ylIcarbamate
EXAMPLE 68A
2.5-b¡s (4-bromophenyl) -1 - (4-cyclopropyl) p¡rrol¡d¡na
The product from Example 42B (3.14 g, 5.64 mmol) and 4-cyclopropllaniline (6.01 g, 45.2 mmol) are combined in DMF (20 ml). The mixture is stirred at 50 ° C under nitrogen for 3 hours. The reaction mixture is partitioned between 1M HCl and ethyl acetate. The organic layer is washed with brine three times, dried over sodium sulfate, filtered, and evaporated. The residue is purified by chromatography on silica gel eluting with ethyl acetate / hexane (0.5% to 1%) to obtain the title compound (2.12 g, 76%) as a mixture of stereoisomers as a sticky solid.
362
ΙΜΡΙ
EXAMPLE 68Β
MEXICAN INSTITUTE OF PROPERTY
INDUSTRIAL
<img file="MX339989B_D0658.tif" />
- (4-cyclopropyl) -2.5-b¡s (4- (4.4,5,5-tetramethyl-1,3.2d¡oxaborolan-2-¡l) phenyl) pyrrolidine
The product of Example 68A (2.12 g, 4.26 mmol), bis (pinacholate) biboro (3.25 g, 12.79 mmol), potassium acetate (1.674 g, 17.05 mmol) and bis (triphenylphosphine) palladium (ll) chloride (0.299 g , 0.426 mmol) are combined in 1,2-dimethoxyethane (40 ml). The mixture is purged with nitrogen for 15 minutes and stirred at 85 ° C for 2 hours. The reaction mixture is partitioned between ethyl acetate and 1M HCl. The organic layer is washed with saturated sodium bicarbonate, brine, dried over sodium sulfate, filtered, and evaporated. The residue is purified by chromatography on silica gel eluting with hexane to ethyl acetate / hexane (10%) to obtain a solid which is triturated with diethyl ether / hexane (1/3) to obtain the title compound (1.05, 42 %) as a mixture of stereoisomers as a white solid.
EXAMPLE 68C (2S, 2<sup>,</sup>S) -2.2<sup>,</sup>-(4.4<sup>,</sup>-(4,4<sup>,</sup>- (1- (4-cyclopropylphenyl) pyrrolidin-2,5-diyl) bis (4,1-phenylene)) bis (1 H-imidazol-4,2-di-yl)) dipyrrolidine-1-carboxylate tert-butyl
The product from Example 68B (1.04 g, 1,759 mmol), the product from Example 26D (1,446 g, 4.57 mmol), PdCI<sub>2</sub>(dppf) (0.129
363 g, 0.176 mmol) and 1.0 M sodium carbonate (4.57
IMPI
INDUSTRIAL
<img file="MX339989B_D0659.tif" />
I are combined in the mixed solvent of ethanol (5 ml) / toluene (5 ml). The mixture is purged with nitrogen for 15 minutes and stirred at 80 ° C for 2 hours. The reaction mixture is partitioned between ethyl acetate and saturated sodium bicarbonate, brine, dried over sodium sulfate, filtered, and evaporated. The residue is purified by chromatography on silica gel eluting with methanol / dichloromethane (1% to 3%) to obtain the title compound (1.28 g, 90%) as a mixture of stereoisomers as a solid.
EXAMPLE 68D (S) -4,4 '- (4.4' - ((2R, 5S) -1 - (4-cyclopropylphenyl) pyrrolidin-2.5-diyl) bis (4,1-phenylene)) bis (2 - ((S) -pyrrolidin-2-H) -1 H-imidazole)
The product from Example 68C (1.27 g, 1568 mmol) is dissolved in dichloromethane (12 ml). The mixture is cooled to 0 ° C and trifluoroacetic acid (8 ml, 104 mmol) is added slowly. The mixture is warmed to room temperature and stirred for 1 hour. The solvent is evaporated and the residue is purified by chromatography on silica gel eluting with methanol / dichloromethane (1% to 10%). The title compound (310 mg, 32%) elutes as the second of the 2 stereoisomers.
EXAMPLE 68E <(2S) -1-r (2S) -2- (4-f4-r (2R.5S) -1- (4-cyclopropylphenyl-5- (4- {2-r (2S) -l. ((2S) -2-r (methox¡carbon¡l) am¡no1-3-methyl lbutano¡l} pyrrole¡d¡n-2-¡H-1 H¡m¡dazol-4-¡l} phenyl ) methyl) pyrrolidin-2-infenin-1H-amidazol-2-yl) pyrrolidin-1-ill-3-methyl-1-oxobutan-2-iIjcarbamate
364
IMPI
MEXICAN INSTITUTE OF INDUSTRIAL PROPERTY
<img file="MX339989B_D0660.tif" />
The product of Example 68D (90 mg, 0.148 mmol), (S) -2- (methoxycarbonylamino) -3-methylbutanoic acid (51.7 mg, 0.295 mmol), 4-methylmorpholine (0.130 ml, 1.181 mmol), N1- hydrochloride ((ethylimino) methylene) -N3, N3-dimethylpropan-1,3-dimine (62.2 mg, 0.325 mmol) and 1 H-benzo [d] [1,2,3] triazol-1-ol hydrate (49.7 mg, 0.325 mmol) are combined in DMF (10 ml). The mixture is stirred at room temperature for 2 hours. The reaction mixture is partitioned between ethyl acetate and water. The organic layer is washed with saturated sodium bicarbonate, brine twice, dried over sodium sulfate, filtered, and evaporated. The residue is purified by chromatography on silica gel eluting with methanol / dichloromethane (1% to 4%) to obtain the title compound (40 mg, 29%) as a solid.
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ ppm 0.39-0.47 (m, 2H) 0.71 - 0.78 (m, 2H) 0.82 - 0.92 (m, 12H) 1.65 - 1.72 (m, 1H) 1.82 2.03 (m, 8H) 2.09 - 2.17 (m, 4H) 2.40 - 2.45 (m, 2H) 3.54 (s, 6H)
3.75 - 3.83 (m, 4H) 4.02 - 4.09 (m, 2H) 4.64 - 4.75 (m, 2H) 5.035.11 (m, 2H) 6.32 (d, J = 8.67 Hz, 2H) 6.73 ( d, J = 8.35 Hz, 2H) 7.29 (d, J = 8.02 Hz, 2H) 7.37 - 7.81 (m, 10H) 11.47-12.17 (m, 2H).
365
<img file="MX339989B_D0661.tif" />
EXAMPLE 69 f (2S) -1-r (2S) -2- (4-f4-r (2S, 5SM- (4-tert-but¡lfen¡n-5- (4-f2-H2S) -1i ( 2S) -2-r (methoxy carbon yl) aminol-3.3-di meth Ib uta noi Dpi rrol idin-2, 11-1 H-imidazol-4-illfeniDpyrro! Din-2-iUfen i 11-1 H-imidazole Methyl -2¡Dpi rrol id i n-1 -ill-3,3-dimethyl-1-oxobutan-2-yl} carbamate
EXAMPLE 69 A (1 R, 4R) -1.4-bis (4-bromophenyl) buta n-1,4-diol
To (S) - (-) - alpha, alpha-diphenyl-2-pyrrole dinmethanol (3.81 g, 15.04 mmol) THF (140 ml) is added at 23 ° C. The thin suspension is treated with trimethyl borate (2.189 ml, 19.63 mmol) to form a clear solution. After stirring for 1.5 hours, the solution is cooled to 10-15 ° C, and NN-diethylaniline-borane (33.1 ml, 186 mmol) is added over the course of 5-10 minutes via syringe. A slight exotherm and evolution of H are observed<sub>2</sub>. In a
366 Separate containers are loaded Example 26E
<img file="MX339989B_D0662.tif" />
OF INDUSTRIAL PROPERTY
<img file="MX339989B_D0663.tif" />
mmol), followed by THF (140 ml), to form a suspension. The suspension is cooled to 10 ° C. The cold Forano solution is transferred by cannula to the dione suspension over the course of approximately 5 minutes, maintaining the internal temperature <25 ° C. After the transfer is complete, the suspension is kept at 15 ° C for 5 minutes and then the temperature is kept at 23 ° C for 3 hours. After the reaction is complete, the solution is cooled to 5 ° C, and methanol (31.6 ml, 780 mmol) is added slowly to maintain a temperature <20 ° C (note: vigorous evolution of hydrogen). The cloudy solution is mixed for an additional 1 hour to ensure complete extinction. The cloudy solution is diluted with EtOAc (500 ml) and 1 M HCl (220 ml). The phases are separated, and the organic phase is washed successively with 1 M HCl (2 x 220 ml), H<sub>2</sub>O (110 ml), and 25% aqueous NaCl (110 ml). The organic layer is concentrated in vacuo, then dissolved in EtOAc, filtered, concentrated, and crystallized with EtOAc / hexane to provide the title compound (16.92 g, 100% ee, 47% isolated yield).
EXAMPLE 69B (2S, 5S) -2,5-b¡s (4-bromophenyl) -1 - (4-tert-butylphenyl ') pyrrolidine
To a mixture of the product of Example 69A (0.60 g, 1,500 mmol) in CH<sub>2</sub>CI<sub>2</sub> anhydrous (15 ml) at 0 ° C add Et<sub>3</sub>N (0.627 mi,
367
4.50 mmol), and the resulting mixture is stirred IMPIOS
INSTITUTO MEXICANO Λ.ίβιίΓ '<sup>0</sup>'minutes until a cold homogeneous solution is obtained, add methanesulfonyl chloride (0.292 ml, 3.75 mmol) by dropwise, and the resulting mixture is stirred at 0 ° C for 1.5 hours until the reaction is complete as determined by TLC (EtOAc: hexanes 1: 1). The solvent is removed under vacuum to obtain a solid, which is dried under vacuum. The solid is dissolved in anhydrous DMF (5 ml), and 4-tert-butylaniline (2.39 ml, 15 mmol) is added. The resulting mixture is stirred at 40 ° C for 4 hours and then partitioned between aqueous 1N HCl (30 ml) and EtOAc (30 ml).
The organic layer is washed with H<sub>2</sub>O and dried with Na<sub>2</sub>SW<sub>4</sub>. The drying agent is filtered off, the solvent is removed in vacuo, and the crude product is purified by silica gel column chromatography using a solvent gradient of 0-20% EtOAc in hexanes. The title compound is obtained as a colorless solid (0.71 g, 92%). The spectrum of<sup>1</sup>H NMR indicates that this material is an 87:13 mixture of trans: cis pyrrolidine isomers.
EXAMPLE 69C (2S, 5S) -1- (4-tert-butHfenin-2,5-bis (4- (4.4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) phenyl) pyrrolidine
The product from Example 69B (0.71 g, 1.38 mmol) is subjected to the conditions described in Example 42D to obtain the title compound as a colorless solid (0.56 g, 66%).
368
IMPI
EXAMPLE 69D (2S, 2'S) -2.2 '- (4.4' - (4.4 '- ((2S.5S) -1- (4-tert-butylphenyl) p¡rroli'áin- ^ 5-dT MEXICAN INSTITUTE OF THE FROPíED / VO
<img file="MX339989B_D0664.tif" />
tert-butyl yl) bis (4,1-phenylene)) bis (1 H-imidazole-4,2-di-¡l)) dipyroiiain-i carboxylate
The product from Example 69C (0.55 g, 0.91 mmol) is subjected to the conditions described in Example 42E to obtain the title compound (0.27 g, 36%).
EXAMPLE 69E fS) -4.4<sup>,</sup>-(4,4<sup>,</sup>- ((2S, 5S) -1- (4-tert-butylphenyl) pyrrolidin-2,5-d¡-yl) bis (4,1phenylene)) bis (2 - ((S) -pyrrolidin- 2-yl) -1 H-imidazole)
A solution of the product of Example 69D (0.27 g, 0.33 mmol) in a 1: 1 mixture of CH<sub>2</sub>CI<sub>2</sub>: TFA (4 ml) stir at room temperature for 40 minutes and then concentrate in vacuo. The residue is partitioned between NaHCO<sub>3</sub> aqueous saturated and a 3: 1 mixture of CH<sub>2</sub>CI<sub>2</sub>: 2-PrOH (2x), and the combined organic layers are dried over Na<sub>2</sub>SW<sub>4</sub>. The drying agent is filtered off, and the solvent is removed in vacuo to obtain the title compound as an amorphous solid (0.18 g, 87%).
EXAMPLE 69F f (2S) -1-H2S) -2- (4- (4-r (2S.5S) -1- (4-tert-butylphenyl) -5- (4- {2-r (2S ) -1f (2S) -2-Rmethoxycarbon¡l) ann¡no1-3,3-d¡methylbutanoyl) p3Trol¡d¡n-2369 yl1-1H-imidazol-4-¡Dphen¡l) pyroiidin-2 -illfeniD-1H
<img file="MX339989B_D0665.tif" />
Dpi rrol i di n-1 -¡ll-3.3-dimethyl-1-oxobutan-2-¡Ilcarbamate of methyl
To a mixture of the product from Example 69E (0.10 g, 0.16 mmol) and (S) -2- (methoxycarbonylamino) -3,3-dimethylbutanoic acid (76 mg, 0.40 mmol) in anhydrous DMSO (1.6 ml) is added HATU ( 152 mg, 0.40 mmol) and Hunig's base (84 yl, 0.48 mmol). The resulting mixture is stirred at room temperature for 90 minutes, and then partitioned between H<sub>2</sub>O (5 ml) and EtOAc (2x5 ml). The combined organic layers are concentrated in vacuo, and the residue is dissolved in MeOH (1 ml). K is added to the solution<sub>2</sub>CO<sub>3</sub> solid (1-2 mg) and the resulting mixture is stirred at room temperature for 30 minutes. The mixture is filtered and concentrated in vacuo, and the crude product is purified by column chromatography on silica gel using a solvent gradient of 0-5% MeOH in CH<sub>2</sub>CI<sub>2</sub> to obtain the title compound (0.12 g, 78%).
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ ppm 0.94 (s, 18H), 1.10 (s, 9H), 1.63 - 1.77 (m, 2H), 1.84 - 2.25 (m, 10H), 3.55 ( s, 6H),
3.66 - 3.87 (m, 2H), 4.16 - 4.28 (m, 2H), 5.03 - 5.12 (m, 2H), 5.15 5.28 (m, 2H), 6.22 (d, J = 8.46 Hz, 2H ), 6.93 (d, J = 8.67 Hz, 2 H), 7.07 (d, 2 H), 7.15 (d, J = 8.13 Hz, 4 H), 7.23 (d, 1 H), 7.38 (d, J = 1.41 Hz, 2H), 7.52 (d, 1H), 7.62 (d, J = 8.02 Hz, 4H), 11.66-12.10 (m, 2H).
MS (ESI) m / z 969.1 (M + H)<sup>+</sup>.
370
<img file="MX339989B_D0666.tif" />
EXAMPLE 70 (f (2S, 3R, 4R, 5S) -1 - (4-fluorophenyl) -3,4-d¡methoxypyrrol¡din-2,5-d¡inbisfbenzene-4,1-di-¡lcarbamoyl Dimethyl (2S) pyrrolidin-2.1-di-iir (2S) -3-m til1 -oxobutan-1.2-di-ill)) b¡scarbamate
EXAMPLE 70A
4,4 '- ((2S, 3R, 4R, 5S) -1- (4-fluorophenyl) -3,4-di hydroxy pyrrole idi n-2,5-diyl) bis (4,1-phenylene dicarbamate of ter -butyl
A solution of 3,4-O-isopropylidene-D-mannitol (444 mg, 2.0 mmol) in 2: 1 methanol-dichloromethane (8 ml) is treated with iodobenzene diacetate (1.54 g, 4.79 mmol) followed by stirring at temperature environment for 5 hours. The mixture is concentrated in vacuo to remove organic solvents, and the residue is suspended in 0.1M sulfuric acid solution (4 ml) followed by stirring at room temperature for 18 hours. The mixture is adjusted to pH 6 by adding solid sodium bicarbonate. The mixture is then treated sequentially with 4-fluoroaniline (383 µl, 444 mg, 4.00 mmol), 4- (tert-butoxycarbonylamino) phenylboronic acid
371
IMPI
INSTITUTO MEXICANO (853 mg, 3.60 mmol) and alcohol hexafluoro¡soprop¡l¡¿ó '; (& GfíkL). mixture is heated to 50 ° C for 2 hours. The anliirion is; Cool and concentrate in vacuo. The mixture is dissolved in ethyl acetate and extracted with water, 0.33 M tribasic potassium phosphate solution, and saturated sodium chloride solution. Drying (Na<sub>2</sub>SW<sub>4</sub>) and concentration in vacuo allows to obtain a brown solid, which is subjected to chromatography through a cartridge of 100 g of silica gel, eluting with 5-70% of ethyl acetate in dichloromethane. These procedures allow the title compound (770 mg, 67%) to be obtained as an almost white solid.
<sup>1</sup>H NMR (400 MHz, CDCI<sub>3</sub>) δ 7.35 (d, J = 8.3 Hz, 4 H),
7.11 (d, J = 8.4 Hz, 4 H), 6.67 (t, J = 8.8 Hz, 2 H), 6.51 (s, 2 H), 6.22 (dd, J = 9.1, 4.3 Hz, 2 H), 5.15 (d, J = 6.3 Hz, 2H), 4.26 (d, J = 5.7 Hz, 2H), 1.51 (s, 18H).
MS + ESI m / z (rel abundance) 580 (100, M + H), 602 (15, M + Na), 1159 (18, 2M + H).
EXAMPLE 70B
(2S, 3R.4R, 5S) -2,5-bis (4- (tertbutoxycarbonylamino) phenyl) -1- (4-fluorophenyl) pyrrolidin-3,4-di-yl diacetate
A solution of the compound of Example 70A (314 mg,
0.54 mmol), triethylamine (227 μl, 164 mg, 1.65 mmol), and DMAP (13 mg, 0.11 mmol) in 1: 1 ethyl acetate-tetrahydrofuran (2.8 ml) is treated with acetic anhydride (128 μΙ, 138 mg, 1.35 mmol) followed
<img file="MX339989B_D0667.tif" />
372
KúaaftíSÍW ·· ». · '* <sub>h</sub> IMPI ,,
OF INDUSTRIAL PROPERTY
<img file="MX339989B_D0668.tif" />
by stirring at room temperature for 1 treat with water followed by stirring at room temperature for 30 minutes. The mixture is diluted with ethyl acetate and extracted with water, saturated sodium bicarbonate solution, and saturated sodium chloride solution. Drying (Na<sub>2</sub>SW<sub>4</sub>) and concentration in vacuo allow to obtain the title compound (330 mg, 92%) as a cream-colored solid, pure enough for later use.
<sup>1</sup>H NMR (400 MHz, CDCI<sub>3</sub>) δ 7.32 (d, J = 8.4 Hz, 4 H), 7.07 (d, J = 8.5 Hz, 4 H), 6.66 (t, J = 8.8 Hz, 2 H), 6.47 (s, 2 H), 6.25 (dd, J = 9.2, 4.3 Hz, 2 H), 5.53 (dd, J = 5.5, 1.9 Hz, 2 H), 5.46 (d, J =
7.2 Hz, 2H), 1.83 (s, 6H), 1.51 (s, 18H).
MS + ESI m / z (rel abundance) 664 (100, M + H).
EXAMPLE 70C
(2S, 3R, 4R, 5S) -2,5-bis (4-aminophenyl) -1- (4-fluorophenyl) pyrroUd¡n-3,4-di-yl diacetate dihydrochloride
A solution of 4N hydrogen chloride in dioxane (8 ml) is treated with the compound of Example 70B (136 mg, 0.21 mmol) followed by stirring at room temperature for 2 hours. (During this time, the mono-deprotection of the product begins to precipitate, and about 4 ml of dichloromethane is added to accelerate the reaction by solubilizing the mono-hydrochloride). Excess ether is added to the mixture and the product is collected by filtration and washed with ether. After
373
<img file="MX339989B_D0669.tif" />
IMPI
INSTITUTO MEXICANO drying in a vacuum oven at 50 ° C for 18 ffótjS9 ^ £ 1gs procedures allow to obtain the title compound (92 mg, _
84%) as an off-white powder.
<sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 7.28 (m, 8 H), 6.81 (t, J =
8.9 Hz, 2H), 6.33 (m, 2H), 5.63 (m, 2H), 5.51 (dd, J = 5.5, 1.9 Hz, 2
H), 1.79 (s, 6H).
EXAMPLE 70D (2S, 3R, 4R.5S) -2,5-b¡s (4-aminophenyl) -1 - (4-fluorophenii) pyrrolidine-3,4diol
In a 25 ml round bottom flask, dissolve Example 70C (160.5 mg, 0.299 mmol) in MeOH (3 ml), add potassium carbonate (165 mg, 1.197 mmol), and stir at 25 ° C for 1.5 hours. The solids are filtered, washed with MeOH, and the filtrate is concentrated by rotary evaporation to dryness. Purify by flash chromatography (silica gel, Alltech Extract-Clean 10 g column, 8% MeOH / CH<sub>2</sub>CI<sub>2</sub>) to obtain the title compound as a yellow solid (85mg, 75%).
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ ppm 4.10 - 4.19 (m, 2 H),
4.73 (d, J = 2.71 Hz, 2H), 4.80 - 4.88 (m, 2H), 4.84 (s, 4H), 6.21 (dd,
J = 9.22, 4.55 Hz, 2 H), 6.45 (d, J = 8.35 Hz, 4 H), 6.72 (t, J = 8.95 Hz, 2
H), 6.77 (d, J = 8.24 Hz, 4H).
MS (DCI +) 380 (M + H) <sup>+</sup> .
374
EXAMPLE 70E
IMPI
MEXICAN INSTITUTE OF THE FRORIEOAD
<img file="MX339989B_D0670.tif" />
INDUSTRIAL
4,4 '- ((2S, 3R, 4R, 5S) -1- (4-fluorophen¡D-3,4-dimethoxypyrrolidin-2.5-di
Idianiline
In an oven dried 25 ml round bottom flask, dissolve the product from Example 70D (83.6 mg, 0.220 mmol) in anhydrous THF (3 ml) under nitrogen, cool to 0 ° C in an ice water bath , NaH dispersion at 60% by weight in mineral oil (18.51 mg, 0.463 mmol) is added, and it is stirred at 0 ° C for 15 minutes. Iodomethane (0.028 ml, 0.441 mmol) is then added via microsyringe and stirred at 0 ° C for 1 hour, then at 25 ° C for 3 hours. The solvent is removed by rotary evaporation and the residue is dried under vacuum. Purify by flash chromatography (silica gel, Alltech Extract-Clean 10 g column, gradient 1% to 2% MeOH / CH<sub>2</sub>CI<sub>2</sub>) to obtain the title compound as a yellow solid (59mg, 66%).
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ ppm 3.25 (s, 6H), 3.92 4.17 (m, 2H), 4.91 (s, 4H), 5.07 - 5.24 (m, 2H), 6.28 (dd , J = 9.16,
4.50 Hz, 2H), 6.47 (d, J = 8.46 Hz, 4H), 6.73 (t, J = 8.95 Hz, 2H), 6.86 (d, J = 8.35 Hz, 4H).
MS (DCI +) m / z 408 (M + H)<sup>+</sup>.
EXAMPLE 70F (2S, 2'S) -2.2 '- (4.4' - ((2S, 3R, 3R, 5S) -1- (4-f luorophenyl) -3.4375
IMPIOS d¡methoxypyrrol¡din-2.5-d¡-yl) bis (4,1-phenylenemJTsra ^ aug¡S¿ ^ ¿^<sub>Jr</sub>z<sup>;</sup>>
FROM INDUSTRIAL PROPERTY tert-butyl yl) bis (oxomethylene) dipyrrolidine-1-carboxylate
In a 10 ml round bottom flask, dissolve the product of Example 70E (57 mg, 0.140 mmol) in anhydrous DMSO (1.2 ml) under nitrogen, add (S) -1- (tert-butoxycarbonyl) pyrrolidin-2- acid. carboxylic acid (76 mg, 0.350 mmol), HATU (137 mg, 0.350 mmol), and diisopropylethylamine (0.073 ml, 0.420 mmol), and the bright yellow solution is stirred at 25 ° C for 1 hour. The reaction is diluted with EtOAc (50 mL), washed with H<sub>2</sub>O (3 x 25 ml) and brine (15 ml), the organic phase is dried over MgSO<sub>4</sub> anhydrous, filtered, and concentrated by rotary evaporation to a yellow residue. Purify by flash chromatography (silica gel, column
Alltech Extract-Clean 10g, 3% MeOH / CH<sub>2</sub>CI<sub>2</sub>) to obtain the title compound as a yellow solid (118 mg).
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ ppm 1.29 (s, 11H), 1.39 (s, 7H), 1.72 - 1.95 (m, 6H), 2.08 - 2.25 (m, 2H), 3.29 ( s, 6H), 3.35 - 3.49 (m, 3H), 4.12 (d, J = 0.87 Hz, 2H), 4.15 - 4.29 (m, 2H), 5.30 20 5.45 (m, 2H), 6.28 (dd, J = 9.22, 4.45 Hz, 2 H), 6.75 (t, J = 8.89 Hz, 2
H), 7.19 (d, J = 8.35 Hz, 4H), 7.50 (t, J = 8.89 Hz, 4H), 9.70-10.14 (m, 2H).
MS (APCI +) m / z 802 (M + H)<sup>+</sup>.
376
EXAMPLE 70G
IMPI
MEXICAN INSTITUTE OF INDUSTRIAL PROHEDAD
<img file="MX339989B_D0671.tif" />
(2S, 2'S) -N, N '- (4.4' - ((2S.3R, 4R.5S) -1- (4-fluoropheni D-3,4-dimethoxypyrrolidin-2,5-di-yl) b ¡S ((4,1-phenylene)) dipyrrolidine-2-carboxamide
The product from Example 70F (112 mg, 0.140 mmol) is dissolved in CH<sub>2</sub>CI<sub>2</sub> anhydrous (1 ml) under nitrogen, add TFA (1 ml), and stir at 25 ° C for 30 minutes. The solvent is removed by rotary evaporation, redissolved in CH<sub>2</sub>CI<sub>2</sub>/ hexanes 1: 5 v / v, and concentrate in vacuo. The residue is dissolved in EtOAc (50 ml), washed with NaHCO<sub>3</sub> aqueous saturated (2 x 15 ml), the organic phase is dried over MgSO<sub>4</sub> anhydrous, filtered, and concentrated by rotary evaporation to obtain the title compound as a yellow solid (72 mg, 84%).
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ ppm 1.57 - 1.69 (m, 4 H),
1.70 - 1.85 (m, 2H), 1.96 - 2.10 (m, 2H), 2.82 - 2.95 (m, 4H), 3.28 (s, 6H), 3.66 (dd, J = 8.84, 5.58 Hz, 2 H), 4.07 - 4.17 (m, 2 H), 5.30 5.49 (m, 2 H), 6.28 (dd, J = 9.16, 4.39 Hz, 2 H), 6.75 (t, J = 8.89 Hz, 2 H), 7.18 (d, J = 8.57 Hz, 4H), 7.56 (d, J = 8.57 Hz, 4H), 9.90 (s, 2H).
MS (ESI +) m / z 602 (M + H)<sup>+</sup>.
EXAMPLE 70H (r (2S.3R.4R, 5S) -1- (4-fluorophenyl) -3,4-dimethoxypyrrol¡d¡n-2,5-diylbisfbencen-4,1 -di-i lea rbam oil (2S) pyrrol idin-2,1 -di-i lff2S) -3-m tii1-oxobutan-1,2-di-illUbiscarbamate
377
<img file="MX339989B_D0672.tif" />
IMPI
INSTITUTO .MEXICANO: DE LA PLOFIEDAD
The product of Example 7OG (69.3 mg, Ό.115 ηβ8) dissolves in anhydrous DMF (1.2 ml) under nitrogen, is * eilfi Id liasla 0<sup>n</sup>C, then (S) -2 (methoxycarbonylamino) -3-methylbutanoic acid (50.4 mg, 0.288 mmol), HOBT monohydrate (44.1 mg, 0.288 mmol), EDAC (56.3 mg, 0.288 mmol), and N-methylmorpholine are added sequentially (0.038 mi, 0.346 mmol). The cooling bath is removed and stirred at 25 ° C for 13 hours. The reaction is diluted with EtOAc (50 mL), washed with NaHCO<sub>3</sub> saturated aqueous (25 ml), H<sub>2</sub>O (2 x 25 mi), and brine (25 mi). The organic phase is dried over MgSO<sub>4</sub> anhydrous, filtered, and concentrated by rotary evaporation. Purify by flash chromatography (silica gel, 2.5 cm x 15 cm, 6% MeOH / CH<sub>2</sub>CI<sub>2</sub>) to obtain the title compound as a white solid (48mg, 85%).
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ ppm 0.88 (d, J = 6.61 Hz, 6 H), 0.93 (d, J = 6.72 Hz, 6 H), 1.80 - 2.05 (m, 8 H), 2.08 - 2.22 (m, 2H), 3.28 (s, 6 | h), 3.52 (s, 6H), 3.56 - 3.69 (m, 2H), 3.77 - 3.88 (m, 2H), 4.03 (t, J = 8.51 Hz, 2H), 4.07 - 4.16 (m, 2H), 4.43 (dd, J = 7.97,
4.83 Hz, 2H), 5.29 - 5.44 (m, 2H), 6.27 (dd, J = 9.22, 4.45 Hz, 2H),
6.75 (t, J = 8.89 Hz, 2 H), 7.17 (d, J = 8.46 Hz, 4 H), 7.31 (d, J = 8.46 Hz, 2 H), 7.49 (d, J = 8.57 Hz, 4 H ), 9.99 (s, 2H).
MS (ESI +) m / z 408 (M + H)<sup>+</sup>.
378 aserasxz:
<img file="MX339989B_D0673.tif" />
(R2S, 3R, 4R, 5S) -1- (4-fluorophenyl) -3,4-d¡methoxypyrrol¡din-2,5-d¡¡nb¡s <benzene-4,1 -di -¡ Ica rbam o¡ l (2S) pyrrole id ¡n-2,1 -d¡-¡IH2S) -3,3-dimethyl-1-oxobutan-1,2-di-ylT)) dimethyl biscarbamate
The product from Example 70D (58.5 mg, 0.097 mmol) is dissolved in anhydrous DMF (1 ml) under nitrogen, cooled to 0 ° C, then (S) -2 (methoxycarbonylamino) -3.3 acid is added sequentially di-methylbutanoic (46.0 mg, 0.243 mmol), HOBt monohydrate (37.2 mg, 0.243 mmol), EDAC (47.5 mg, 0.243 mmol), and 4-methiimorpholine (0.032 ml, 0.292 mmol). The cooling bath is removed and stirred overnight at 25 ° C for 16 hours. The reaction is diluted with EtOAc (50 mL), washed with NaHCO<sub>3 </sub>saturated aqueous (25 ml), H<sub>2</sub>O (2 x 25 ml), and brine (25 ml) The organic phase is dried over MgSO<sub>4</sub> anhydrous, filtered, and concentrated by rotary evaporation. Purify by flash chromatography (silica gel, 2 5 cm x 15 cm, 4% MeOH / CH<sub>2</sub>CI<sub>2</sub>) to obtain the title compound as a cream colored solid (66mg, 72%).
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ ppm 0 .96 (s, 18 H), 1.79
379
- 1.94 (m, 4 Η), 1.94 - 2.06 (m, 2 Η), 2.10 - 2.22 (m
<img file="MX339989B_D0674.tif" />
Η), 3.54 (s, 6 Η), 3.58 - 3.70 (m, 2 Η), 3.71 - 3.86 (m, 2 Η), 4.06 4.15 (m, 2 Η), 4.21 (d, J = 8 89 Hz, 2 H), 4.44 (dd, J = 7 92, 5.31 Hz, 2
H), 5.31 - 5.39 (m, 2 H), 6.27 (dd, J = 9.22, 4.45 Hz, 2 H), 6.75 (t, J = 8.89 Hz, 2 H), 7.08 (d, J = 8.78 Hz, 2H), 7.17 (d, J = 8.57 Hz, 4H),
7.49 (d, J = 8.57 Hz, 4H), 9.99 (s, 2H)
MS (ESI +) m / z 945 (M + H)
Ύ<sup>1</sup> or
<img file="MX339989B_D0675.tif" />
EXAMPLE 72 (ri- (4-tert-butylphenyl) -1H-pyrrole-2.5-di-illbis <benzene-4,1-di -ylcarbamoyl (2S) pyrrolidin-2,1-di-ylf (2S) - Dimethyl 3-methyl-1-oxobutan-1,2-diylIHbiscarbamate
EXAMPLE 72A
4,4 '- (1- (4-tert-butylphenyl) -1H-pyrrol-2,5-di-yl) dianiline
Example 1A is processed using the methods generally described in Examples 26F and 19B to provide the title compound.
MS (ESI, M + H) m / z = 382.
380
EXAMPLE 72B (2S.2<sup>,</sup>S) -2.2<sup>,</sup>-(4.4<sup>,</sup>- (1- (4-tert-butylfenin-1H-pyrrole-2.5-di-iDbis (4.1IMPI
MEXICAN INSTITUTE OF INDUSTRIAL PROPERTY
<img file="MX339989B_D0676.tif" />
phenylene) bis (azandi-yl) bis (oxomethylene)) di pyrrolidi n-1-carboxylate d tert-butyl
To a solution of the product from Example 72A (0.310 g, 0.813 mmol) in DMF (5 ml) is added (S) -1- (tert-butoxycarbonyl) pyrrolidine-2-carboxylic acid (0.385 g, 1.79 mmol) 1-hydroxybenzotriazole hydrate (0.274 g ; 1.79 mmol) and N- (3-dimethylaminopropyl) -N'-ethylcarbodi-imide hydrochloride (0.343 g, 1.79 mmol) and the mixture was stirred overnight. The mixture is poured into water and CH is extracted.<sub>2</sub>CI<sub>2</sub>. The organic extract is dried (Na<sub>2</sub>SW<sub>4</sub>), filtered and concentrated to obtain a crude product that is purified by trituration with ether to obtain 325 mg (51%) of the title compound.
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ 1.25 (s, 24H) 1.83 (s, 6H) 2.15 (s, 2H) 3.45 (m, 4H) 4.18 (s, 2H) 6.40 (s, 2H) 6.98 (s, 6H)
7.37 (s, 6H) 9.98 (s, 2H).
EXAMPLE 72C (2S.2<sup>,</sup>S) -N, N<sup>,</sup>- (4.4 '- (1- (4-tert-butylphenyl) -1H-pyrrole-2.5-di-ihbis (4.1phenylene)) di pyrrolidi η-2-carboxam ida
To a solution of the product of Example 72B (0.325 g, 0.419 mmol) in CH<sub>2</sub>CI<sub>2</sub> (5 ml) at room temperature add
381
IMPI
INDUSTRIAL
<img file="MX339989B_D0677.tif" />
TFA (1.0 ml) and continue stirring for 5 hours ^ TiTbiaME.etaGCi
DE LA rl OflEDAD concentrates and the residue is partitioned between water and 25% isopropyl alcohol -CHCI<sub>3</sub>. The organic phase is dried (Na<sub>2</sub>SW<sub>4</sub>), filter and concentrate to provide the title compound that is used directly in the next reaction.
MS (DCI; M + H) m / z = 576.
EXAMPLE 72D (F1 - (4-tert-butylphenih-1H-pyrrole-2.5-di-illbisfbencen-4.1-di10 ¡lcarbamoyl (2S) pyrrolidin-2.1 -di-ylf (2S) -3-methyl-1-oxobutan-1 Dimethyl, 2-diylTUbiscarbamate
The product of Example 72C and the product of (S) -2 (methoxycarbonylamino) -3-methylbutanoic acid are processed using the method described in Example 72B. The crude residue is purified by silica gel chromatography (1% elution gradient from 0% to 4% MeOH / CH<sub>2</sub>CI<sub>2</sub>) to provide 129 mg (35%) of the title compound.
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ 0.89 (s, 12 H) 1.25 (s, 9
H) 1.89 (s, 6H) 1.98 (s, 2H) 2.13 (s, 2H) 3.52 (s, 6H) 3.61 (s, 2H)
3.80 (s, 2H) 4.00 (s, 2H) 4.39 (s, 2H) 6.38 (s, 2H) 6.95 (s, 6H)
7.34 (s, 8H) 9.96 (s, 2H).
382
<img file="MX339989B_D0678.tif" />
EXAMPLE 73 r (2S) -1 - {(2S) -2-í4- (4- {5- (4- {2 - [(2S) -1 - {(2S) -2f (methoxy carbon i Dam i nol-3-methyl butane i Dpi rrol idi η-2-i 11-1H10 imidazol-4-inpheniD-1-f4- (methylsulfoniDphenyl1-1H-pyrrole-2-iDfeniD1 H-imidazol-2-ΪΠ pyrrole id ¡n Methyl -1 -¡D-3-methyl-1-oxobutan-2-iDcarbamate
Example 26E and 4- (methylsulfonyl) aniline are processed using the methods of Examples 26F, 26G, 26H, 65B, and 65C to provide the title compound (78mg).
<sup>1</sup>H NMR (400 MHz, DMSO-d6) δ 12.17 - 11.67 (m, 2H),
7.92 - 7.82 (m, 2H), 7.62 - 7.49 (m, 4H), 7.48 - 7.40 (m, 2H), 7.39 - 7.15 (m, 4H), 7.08 - 6.92 (m, 4H), 6.59 - 6.47 (m, 2H), 5.08 - 4.99 (m,
2H), 4.08 - 3.98 (m, 2H), 3.84 - 3.69 (m, 4H), 3.53 (s, 6H), 3.24 (d, J = 1.9, 3H), 2.20 - 1.81 (m, 10H), 0.91 - 0.77 (m, 12H).
MS (ESI; M + H) m / z = 959.
383
<img file="MX339989B_D0679.tif" />
EXAMPLE 74 f (2S) -1-r (2S) -2- (5-í4-I1- (4-cyclohexylphenyl-5- (4- (2-r (2S) -1 - {(2S) -2F ( methox¡carbon¡l) aminol-3-methylbutano¡l) pyrrolidin-2-ill-1Himidazol-5-¡Dfeni D-1 H-pyrrol-2-i I1phenyl) -1 H-im ¡dazol-2-i Methyl dpi rrolidi n1-yl1-3-methyl-1-oxobutan-2-yl) carbamate
EXAMPLE 74A
2,5-bis (4-bromophenyl) -1- (4-cyclohexyphenyl) -1 Hp¡rrol
The product from Example 26E and 4-cyclohexylaniline (Alpha) are processed using the method described in Example 26F to provide 1.23 g (91%) of the title compound.
<sup>1</sup>H NMR (400 MHz, benzene-D6) δ I.09 (s, 5H) 1.60 (s, 5H) 2.14 (s, 1H) 6.52 (s, 2H) 6.67 (s, 4H) 6.84 ( s, 4H) 7.11 (s, 4H).
EXAMPLE 74B
- (4-cyclohexylpheniP-2.5-b¡s (4- (4,4,5,5-tetramethyl-1,3,2-dioxaboroian-2-yl) feniD-1 H-pyrrole
384
He
IMPI product of Example 74A is proce ^^ $$$ ^
INDUSTRIAL
<img file="MX339989B_D0680.tif" />
method described in Example 26G to provide 1.58 g (60%) of the title compound.
MS (ESI; M + H) m / z = 630.
EXAMPLE 74C (2S, 2'S) -2.2<sup>,</sup>-(5,5’-(4.4<sup>,</sup>- (1- (4-cyclohexylphenyl) -1H-pyrrole-2,5-diyl) bis (4,1-phenylene)) bis (1 H-imidazol-5,2-di-yl)) tert-butyl dipyrrolidine-1 carboxylate
A solution of the product of Example 74B (0.400 g, 0.635 mmol) and the product of Example 26D (0.442 g, 1.40 mmol) in toluene (3 ml) and ethanol (3 ml) is treated with 1 M sodium carbonate (2 ml). ) followed by the complex 1,1'-bis (diphenylphosphino) palladium (ll) ferrocenedichloride dichloromethane (0.052 g, 0.064 mmol), the mixture is degassed (3 x vacuum / N purge<sub>2</sub>) and then heated at 90 ° C for 4 hours. The reaction is concentrated and the residue is partitioned between 25% isopropyl alcohol -CHCI<sub>3</sub>. The organic phase is dried (Na<sub>2</sub>SW<sub>4</sub>) is concentrated and the residue is dissolved in ether, subjected to sonic energy, filtered and dried to obtain 499 mg (93%) of the title compound.
MS (ESI; M + H) m / z = 848.
EXAMPLE 74D (S) -5,5 '- (4,4' - (1- (4-cyclohexylph ηιΠ-í H-pyrrole-2,5-d¡-yl) bi (4.1385 phenyle)) bis (2 - ((S) -pyrrolidin-2-yl) -1 H-imi
<img file="MX339989B_D0681.tif" />
OF INDUSTRIAL PROPERTY
<img file="MX339989B_D0682.tif" />
The product from Example 74C is processed using the method described in Example 19D to provide the title compound.
MS (ESI; M + H) m / z = 648.
EXAMPLE 74E ((2S) -1-r (2S) -2- (5-f4-M- (4-cyclohex¡lfen¡l) -5- (4- (2-r (2S) -1- R2S) -2í (methoxycarbonyl) amino1-3-methylbutano¡l} p¡rrol¡d¡n-2-¡l1-1H¡midazol-5-¡l) phen¡ l) -1 Hp¡ rrol-2 -¡ Ufe n¡l) -1 H-¡midazol-2-¡l) p¡rrol¡d¡n1 -¡l1-3-methyl-1 -oxobutan-2-ll) methyl carbamate
To a solution of the product from Example 74D (0.190 g, 0.293 mmol) in DMF (5 ml) is added (S) -2 (methoxycarbonylamino) -3-methylbutanoic acid (0.113 g, 0.645 mmol), hydrated 1-hydroxybenzotriazole (0.099 g; 0.645 mmol) and N- (3-dimethylaminopropyl) -N'-ethylcarbod¡ -imida hydrochloride (0.124 g, 0.645 mmol) and the mixture was stirred for 3 hours. The mixture is poured into water and CH2CI2 is extracted. The organic layer is concentrated and the residue is purified by chromatography (gradient elution from 0% to 4% MeOH-CH<sub>2</sub>CI<sub>2</sub>) to provide 100 mg (35%) of the title compound.
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ 0.84 (d, J = 6.62 Hz, 6H) 0.87 (d, J = 6.72 Hz, 6H) 1.20 (m, 2H) 1.35 (m, 4H) 1.78 (m, 4 H)
386
1.92 (m, 6H) 2.10 (m, 4H) 3.52 (s, 6 5.03 (m, 2H) 6.47 (m, 2H) 6.99 (m, 6
7.41 (m, 2H) 7.51 (m, 4H) 11.74 (s, 2
<img file="MX339989B_D0683.tif" />
H) 3.76 (m, 4-M1W <sup>one v</sup> MEXICAN INSTITUTE
OF THE PROPERTY
H) 7.18 (m, 3 H) Z'ff'fm
<img file="MX339989B_D0684.tif" />
H).
<img file="MX339989B_D0685.tif" />
EXAMPLE 75 f (2S) -1-r (2S) -2- (5- {4-ri- (4-cyclohexylphenyl) -5- (4- {2-r (2S) -1-f (2S) - 2I (methoxycarbonyl) amino 1-3,3-dimethylbutanoyl) pyrrolid¡ n-2-¡H-1 Himidazol-5-¡l) phenyl) -1 H-pyrrole-2-illphenyl) -1 H-im idazol-2- i Dpi rrolidi n15 1-ill-3,3-dimethyl-1-oxobutan-2-yl) methyl carbamate
The product of Example 74D and (S) -2-methoxycarbonylamino-3,3-dimethyl-butyric acid (Org. Process Res. Develop. 2008, 12, 69) are processed using the method described in Example
74E to provide 165 mg (57%) of the title compound.
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ 0.86 - 0.96 (m, 18 H)
1.23 (m, 2H) 1.36 (m, 4H) 1.78 (m, 4H) 1.88-2.00 (m, 4H) 2.10 (m, 4H) 3.54 (s, 6H) 3.77 (m, 4H ) 4.21 (m, 2H) 5.05 (m, 2H) 6.46 (s, 2H) 6.96 - 7.03 (m, 6H) 7.19 (m, 2H) 7.38 - 7.55 (m, 7H) 7.70 (d , J = 8.35 Hz, 1H) 7.97 (d, J = 8.46 Hz, 1H) 11.76 (s, 2H).
387 <sup>:</sup> «ΊΚ'Λ5Γ3ΤςΛ.Λί *
<img file="MX339989B_D0686.tif" />
ΙΜΡϊ
MEXICAN INSTITUTE OF INDUSTRIAL FROFIEDAD
<img file="MX339989B_D0687.tif" />
EXAMPLE 76
N- (methoxy carbon ¡l) -L-val i lN- (4-f 1 - (4-tert-buti Ifen yl) -5-r4- (2-f (2S) -1 [N- (methox¡ carbonyl) -L-val¡llpi rrolidin-2-yl) -1 H-im¡dazol-5-¡l) phenyl110 1 Hp¡ rrol-2-¡l) phenyl) -L-prol inamide
EXAMPLE 76A
2- (4-bromophenyl) -1 - (4-tert-butylphenyl) -5- (4-nitrophenyl) -1 Hp¡rrole
TFA (0.6 ml, 7.79 mmol) is added to a mixture of the product from Example 39A (1.2335 g, 3.41 mmol) and 4-tert-butylaniline (0.8 ml, 5.07 mmol) in toluene (30 ml) and heated to 110 ° C for 17 hours. The cold reaction mixture is poured into ether / water and stirred until a nice solid forms. The mixture is filtered to obtain the title compound.
<sup>1</sup>H NMR (400 MHz, BENZENE-D6) δ 1.02 (s, 9H), 6.48 (d,
J = 3.8, 1H), 6.52 (d, J = 3.8, 1H), 6.63 (d, J = 8.5, 2H), 6.80 (d, J =
8.5, 2H), 6.84 (d, J = 8.9, 2H), 6.89 (d, J = 8.5, 2H), 7.10 (d, J = 8.5,
2H), 7.70 (d, J = 8.9, 2H).
388
EXAMPLE 76B
N- (methoxycarbonl) -L-vali lN- (4- (1 - (4-tert-butylphenyl) -5-r4- (2-f (2S) -1 IMPI
MEXICAN INSTITUTE OF INDUSTRIAL FROFIEDAD
<img file="MX339989B_D0688.tif" />
fN- (methoxycarbonih-L-valylpyrrolidin-2-ylI-1H-imidazol-5-yl) phenyl11H-pyrrole-2-¡l) phenyl) -L-prolineamide
Example 76A is processed sequentially using the methods of Examples 19B, 55F, 39E (reaction temperature = 85 ° C), 39F, 55G, and 26J (reaction solvent = dichloromethane) to provide the title compound (0.14 g).
<sup>1</sup>H NMR (400 MHz, METHANOL-D4) δ 0.94 (ddd, J = 21.1, 19.5, 6.7, 12H), 1.30 (s, 10H), 2.36 - 1.92 (m, 10H), 3.63 (s, 6H), 3.76 - 3.67 (m, 1H), 3.89 - 3.78 (m, 1H), 4.02 - 3.89 (m, 2H), 4.19 (d, J = 7.9, 2H), 4.50 (dd, J = 8.1, 5.3, 1H), 5.11 (dd, J = 7.6, 5.5, 1H), 6.39 (d, J = 3.7, 1H), 6.43 (d, J = 3.6, 1H), 7.01 (dt, J = 28.2, 8.3, 6H),
7.20 (s, 1H), 7.40 (ddd, J = 19.1, 11.9, 5.7, 6H).
MS (ESI) m / z 913 (M + H)<sup>+</sup>.
<img file="MX339989B_D0689.tif" />
EXAMPLE 77
N- (methoxycarbonyl) -L-val¡lN- (4- {5-r4- (2-f (2S) -1 -ΓΝ (methoxycarbonyl) -L-vaiillpyrrolidin-2-ylI-1H-imidazol-5 -yl) phenyl-1-r4389 (pentafluoro-lambda ~ 6-sulfanyl) phenyl-1 H-pjrr prolinamide
<img file="MX339989B_D0690.tif" />
Example 39A and 4-aminophenylsulfurpentafluoride are processed sequentially using the methods of Examples 76A, 19B, 55F, 39E (reaction temperature = 85 ° C), 39F, 55G, and 26J (reaction solvent = DMF) to provide the title compound (0.36 g).
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ 0.86 (ddd, J = 6.9, 15.8, 21.6, 12H), 2.04 - 1.76 (m, 7H), 2.24 - 2.04 (m, 3H), 3.53 (d, J = 3.0, 6H), 3.61 (dd, J = 6.7, 16.0, 1H), 3.88 - 3.67 (m, 3H), 4.03 (dd, J = 8.3, 14.1, 2H), 4.40 (dd, J = 5.0, 8.0, 1H), 5.12 - 4.92 (m, 1H), 6.49 (ddd, J = 3.6, 14.2, 18.1, 2H), 7.09 - 6.84 (m, 4H), 7.38 - 7.12 (m, 4H), 7.50 - 7.38 (m , 3H), 7.58 (dd, J = 8.3, 16.7, 2H), 7.89 (t, J = 8.7, 2H), 10.01 (d, J = 20.9, 1H), 12.16-11.66 (m, 1H).
MS (ESI) m / z 983 (M + H) <sup>+</sup> , 981 (MH) <sup>+</sup> .
<img file="MX339989B_D0691.tif" />
Ό
390
EXAMPLE 78
IMPIíS
MEXICAN INSTITUTE OF FRCzHEDAO
INDUSTRIAL
<img file="MX339989B_D0692.tif" />
R2S) -1-r (2S) -2- (5- {3-M- (4-tert-butylphenyl) -5- (4- <2-K2S) -1-R2S) -2F (methoxycarboniPamino1- 3-methylbutanoiDpyrrolidin-2-ill-1Himidazoi-5-iDfeniD-1 H-pyrrole-2-i HfeniD-1H-inriidazol-2-i Dpi rrolidi n1-yl ~ | -3-methyl-1-oxobutan -2-¡l} methyl carbamate
2,4'-Dibromoacetophenone and 3'bromoacetophenone are processed sequentially using the methods of
Examples 26E, 26F, 26G, 74C, 19D, and 74E to provide the title compound (232mg).
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ 0.81 - 0.91 (m, 12 H)
1.25 (s, 9H) 1.93 (m, 4H) 2.11 (m, 4H) 3.53 (s, 6H) 3.78 (m, 4H) 4.04 (m, 2H) 5.03 (m, 2H) 6.49 (m, 2H) 6.90 - 7.08 (m, 5H) 7.11 7.21 (m, 1H) 7.27 - 7.55 (m, 9H) 7.71 (d, J = 8.35 Hz, 1H) 7.94 - 8.01 (m, 2H) 11.72 (br s, 2H).
<img file="MX339989B_D0693.tif" />
EXAMPLE 79
R2S) -1-r (2S) -2- (4-f4-r (2R.3S, 4S, 5R) -1- (4-t r-butylpheniD-3.4391
<img file="MX339989B_D0694.tif" />
dimethoxy-5- (4- (2 - [(2 $) -1 -f (2S) -2-f (methoxycarbonylXamrhkOT-j7,
DE LA FP.OPíEC-AD INDUSTRIAL methyl butanoi Dpi rrolidin-2-i 11-1 H-imidazol-4-yl) phenyl) pyrrolid¡n-2¡Hfen¡D-1 H-imidazol-2-yl) pyrrolidin- Methyl 1 -¡Π-3-methyl-l-oxobutan-2iDcarbamate
EXAMPLE 79A
1,2: 3,4: 5.6-tri-O-isopropylidene-L-man itol
A solution of L-manonic acid γ-lactone (9.87 g, 55 4 mmol) in methanol (150 ml) at 0 ° C is treated with lithium borohydride (2.1 g, 97 mmol) over the course of 30 minutes. After the addition is complete, the mixture is warmed to room temperature for 30 minutes. The mixture is then treated carefully with a solution of hydrogen chloride in dioxane (4 N, 2 ml). The solution is then concentrated under vacuum, first on a rotary evaporator and then under high vacuum (0.3 mm Hg) while heating with a heat gun to remove the last traces of methanol. The solid obtained is then suspended in acetone (50 ml) and treated with 2,2-dimethoxypropane (41 ml, 34.6 g, 332 mmol) and a solution of hydrogen chloride in dioxane (4 N, 42 ml, 166 mmol) followed by stirring at room temperature for 18 hours. The mixture is concentrated in vacuo to approximately 20% of the original volume, and the inhomogeneous mixture is added to saturated sodium bicarbonate solution (200 ml) followed by stirring for 48 hours. The precipitate is collected by filtration and
392
ΪΜΡ
INDUSTRIAL
<img file="MX339989B_D0695.tif" />
wash with water and air dry. The white solid «OT <s @ MCl¡ <aueí<sup>J</sup> OF THE PROPERTY in ethanol (absolute, 175 ml) and filtered through celite to remove particulate matter. The solution is cooled to -78 ° C to effect crystallization. The solid is collected by filtration, and the stock solutions are concentrated to approx. half the volume, and cooled back down to -78 ° C. The second crop of crystals is collected by filtration and washed with ethanol. After drying in a vacuum oven at 50 ° C for 3 hours, these procedures allow the title compound (9 88 g, 59%) to be obtained as a fluffy white solid.
<sup>1</sup>H NMR (400 MHz, CDCI<sub>3</sub>) δ 4.19 (dt, J = 6.0, 3.0 Hz, 2
H), 4.08 (dd, J = 8.3, 6.4 Hz, 2H), 3.99 (m, 2H), 3.95 (m, 2H), 1.43 (s, 6H), 1.39 (s, 6H), 1.36 (s, 6H).
MS (+ ESI) m / z (rel abundance) 303 (100, M + H), 320 (43, M + NH4).
EXAMPLE 79B
3,4-O-isopropylidene-L-mannitol
The compound of Example 79A (9.88 g, 32.7 mmol) is suspended in 60% (v / v) acetic acid in water (150 ml) on a 1 L round bottom and the flask is placed on the rotary evaporator and made Spin in the heating bath at 45 ° C for 1.5 hours. The temperature of the heating bath is reduced to 40 ° C and a pipe is connected to the rotary evaporator to the heating pump.
393
<img file="MX339989B_D0696.tif" />
OF THE EMPTY INDUSTRIAL PROPERTY. The mixture is concentrated under pressure of ap {mm Hg to a wet solid. This material is diluted with dichloromethane (100 ml) and stirred at room temperature for 10 minutes. The solution is filtered through celite, and the filtrate is concentrated in vacuo. The residue is dissolved in toluene and concentrated in vacuo (2x) to remove residual acetic acid. The white solid is then triturated with ether (60 ml) and collected by filtration. After drying in a vacuum oven for 18 hours, these procedures allow the title compound (2.46 g, 34%) to be obtained as a white solid.
<sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 5.07 (d, J = 4.5 Hz, 2 H),
4.45 (t, J = 5.7 Hz, 2 H), 3.86 (dd, J = 4.9, 1.5 Hz, 2 H), 3.54 (ddd, J = 10.9, 5.5, 3.1 Hz, 2 H), 3.48 (d, J = 4.6 Hz, 2H), 3.37 (m, 2H),
1.28 (s, 6H).
EXAMPLE 79C (2R, 3S.4S, 5R) -1- (4-tert-butylphenyl) -2.5-bis (4- (4-methoxybenzyloxy) phenyl) -p¡rrolid¡ n-3,4-diol
To a solution of Example 79B (1.0 g, 4.5 mmol) in CH<sub>3</sub>OH (12.0 mi) and CH<sub>2</sub>CI<sub>2</sub> (6.0 ml) iodobenzene diacetate (3.48 g, 10.8 mmol) is added and the solution is stirred at room temperature for 5 hours. The solvent is removed in vacuo and H is added to the residue.<sub>2</sub>SW<sub>4</sub> 0.1 M (4 ml) and the solution is stirred at room temperature for 18 hours. PH is adjusted to ~ 6 with
394
Τϊ * γ <-ιτ ^ ιιγ .-- | ·<sub>π</sub>
<img file="MX339989B_D0697.tif" />
NaHCO<sub>3</sub> solid, and 4-tert-butylaniline (1.43 ml.
INSTITUTO MEXICANO DE LA PROPERTY followed by 4- (4-methoxybenzyloxy) phenylboronic acid (2.09 ^ - ^ - 8.
mmol) and hexafluoroisopropyl alcohol (8 ml). The reaction — heat at 50 ° C for 2 hours, cool, and the solvent is removed under vacuum leaving the aqueous layer which contains a considerable amount of solid material. The mixture is diluted with H<sub>2</sub>O and add K<sub>3</sub>PO<sub>4</sub> 0.33 M and the mixture stirred vigorously. The resulting white solid is collected by filtration and dried in a vacuum oven to obtain the title compound (1.49 g,
2.26 mmol, 50%).
<sup>1</sup>H NMR (400 MHz, DMSO-d6) δ ppm 1.10 (s, 9H) 3.75 (s, 6H) 4.21 (s, 2H) 4.95 (s, 2H) 5.02 (d, J = 6.9 Hz, 2H) 5.75 (s , 2H) 6.20 (d, J = 8.9 Hz, 2H) 6.85-6.97 (m, 10H) 7.05 (d, J = 8.6 Hz, 4H) 7.37 (d, J = 8.7 Hz, 4H).
EXAMPLE 79D (2R, 3S, 4S, 5R) -1- (4-tert-butylphenyl) -3.4-dimethoxy-2.5-bis- (4- (4-methoxybenzyloxy) phenyl) pyrrolidine
To a solution of Example 79C (1.49 g, 2.26 mmol) in THF (17 ml) and DMF (5.7 ml) at 0 ° C is added, in portions, NaH, 60% in mineral oil (0.27 g, 6.77 mmol) and the mixture is stirred at 0 ° C for 20 minutes. Iodomethane (0.31 ml, 4.97 mmol) is added and the reaction mixture is stirred at room temperature for 18 hours, diluted with EtOAc, washed with NH<sub>4</sub>Saturated CI, H<sub>2</sub>Or, and
395 brine, dried (Na<sub>2</sub>SW<sub>4</sub>), it is filtered and the solvent is obtained to obtain an oily product. The oil is diluted with a<sup>D</sup>AC<sup>K</sup>ntida <
minimum ether and the oil begins to solidify and the compound aei
<img file="MX339989B_D0698.tif" />
title is isolated as a colorless solid (1.55 g, 2.25 mmol, 100%).
<sup>1</sup>H NMR (400 MHz, CDCI<sub>3</sub>) δ ppm 1.16 (s, 6H) 3.44 (s, 6H)
3.82 (s, 6H) 4.12-4.17 (m, 2H) 4.94 (s, 4H) 5.22 (dd, J = 5.2, 1.63 Hz, 2H) 6.29 (d, J = 8.9 Hz, 2H) 6.88-7.00 (m, 10H) 7.12 (d, J = 8.6 Hz, 4H)
7.34 (d, J = 8.6 Hz, 4H).
MS (ESI) m / z 688 (M + H)<sup>+</sup>.
EXAMPLE 79E
4,4 '- ((2R.3S, 4S, 5R) -1- (4-tert-butylphenyl-3,4-dimethoxypyrrolidin-2,5di-i hdiphenol
To a solution of Example 79D (1.55 g, 2.25 mmol) in CH<sub>2</sub>CI<sub>2</sub> (9 ml) add trifluoroacetic acid (9 ml, 117 mmol) and continue stirring at room temperature for 1 hour. The solvent is removed and the crude residue is dissolved in EtOAc / NaHCO<sub>3 </sub>saturated 1: 1. The organic layer is separated, washed with brine, dried (Na<sub>2</sub>SW<sub>4</sub>), filtered and the solvent is removed in vacuo to obtain the title compound (1.0 g, 2.23 mmol, 99%).
MS (ESI) m / z 448 (M + H)<sup>+</sup>.
EXAMPLE 79F
4,4 '- ((2R, 3S, 4S, 5R) -1- (4-tert-butyl nih-3,4-dimethoxypyrrolidine-2,5396
IΜ ΡI d¡-yl) bis (4,1-phenylene) bis (1,1,2.2,3,3,4,4,4-nonaflu<sup>s</sup>¿'Fe? KuW «r> 1 ^
INDUSTRIAL sulfonate)
To a solution of Example 79E (1.0 g, 2.23 mmol) in DMF (12 ml) is added K<sub>2</sub>CO<sub>3</sub> (0.695 g, 5.0 mmol) and fluoride
1,1,2,2,3,3,4,4,4-nonafluorobutan-1-sulfonyl (0.86 ml, 4.9 mmol) and the solution was stirred at 100 ° C for 1 hour. The cold solution is diluted with EtOAc, washed with H<sub>2</sub>O, brine, dries up (Na<sub>2</sub>SW<sub>4</sub>), filtered and the solvent is removed in vacuo to obtain the crude product which is purified by flash chromatography on silica gel eluting with 0-20% EtOAc / hexane to obtain the title compound (1.63 g, 1.61 mmol, 72%).
<sup>1</sup>H NMR (400 MHz, CDCI<sub>3</sub>) δ ppm 1.17 (s, 9H) 3.42 (s, 6H)
4.10 (dd, J = 5.3, 1.90 Hz, 2H) 5.30 (dd, J = 5.2, 1.9 Hz, 2H) 6.19 (d, J = 8.8 Hz, 2H) 6.99-7.03 (m, 2H) 7.21-7.29 (m , 8H).
MS (ESI) m / z 1012 (M + H) <sup>+</sup> .
EXAMPLE 79G (2R, 3S.4S, 5R) -1- (4-tert-butylphenyl) -3.4-dimethoxy-2,5-b¡s (4- (4.4.5,5-tetramethyl-1,3, 2-d¡oxaborolan-2-yl) phen¡l) p¡rrol¡d¡na
In a pressure tube, combine Example 79F (216 mg, 0.21 mmol), 4,4,4 ', 4', 5,5,5 ', 5'-octamethyl-2,2'-b¡ ( 1,3,2-dioxaborolane) (114 mg, 0.45 mmol), dicyclohexyl (2 ', 4', 6'-triisopropylbiphenyl-2-¡l) phosphine (16.3 mg, 0.034 mmol), acetate
397
RaassEZscAsx¿- ^ i potassium (126 mg, 1.28 mmol) and dioxane (2 ml)
<img file="MX339989B_D0699.tif" />
ítit jtc kexicat OF INDUSTRIAL FRCPIEDAD
<img file="MX339989B_D0700.tif" />
degass with N<sub>2</sub> gas for 30 minutes. Tris (dibenzylideneacetone) dipalladium (0) (7.8 mg, 8.54 mmol) is added and degassing is continued for 10 minutes. The tube is sealed and heated at 100 ° C for 30 minutes. The cold solution is diluted with EtOAc, washed with H<sub>2</sub>O, brine, dries up (Na<sub>2</sub>SW<sub>4</sub>), filtered and the filtrate is treated with 3-mercaptopropyl modified silica gel for 1 hour, filtered and the solvent is removed in vacuo to obtain the title compound (143 mg, 100%).
EXAMPLE 79H (2S.2'S) -2.2 '- (4.4' - (4.4'-n2R, 3S.4S, 5R) -1- (4-tert-but¡lfen¡l) -3,4dimethoxy¡ p¡rrol¡d¡n-2,5-d¡-¡l) b¡s (4.1-phenylene) bisí1H-¡m¡mdazol-4.2-d¡¡l)) d¡ pyrrolidi n-1-carboxylate tert-butyl
In a pressure tube, combine Example 79G (140 mg, 0.21 mmol), (S) -tert-butyl-2- (4-bromo-1 H-imidazol-2-yl) pyrrolidine-1-carboxylate (Example 26D) (166 mg, 0.524 mmol), Na<sub>2</sub>CO<sub>3</sub> 1 M (0.524 ml, 0.524 mmol), EtOH (1 ml), and toluene (1 ml) and the mixture is degassed with N<sub>2</sub> gas for 30 minutes. Complex is added
1,1'-bs (diphenylphosphine) ferrocene-dichloropalladium (ll) dichloromethane (15.3 mg, 0.021 mmol) and degassing is continued for 10 minutes. The tube is sealed and heated at 100 ° C for 3 hours, then stirred at room temperature for 16 hours. The solution is diluted with EtOAc, filtered through celite, and the filtrate is washed with
<img file="MX339989B_D0701.tif" />
<img file="MX339989B_D0702.tif" />
398 brine, dried (Na<sub>2</sub>SW<sub>4</sub>), is filtered and the solvent ^ S ^ / Hl ^ Bi
INDUSTRIAL EMPTY. Purify by flash chromatography on silica gel eluting with 0-100% EtOAc / hexane to obtain the title compound (119 mg, 0.135 mmol, 64%).
<sup>1</sup>H NMR (400 MHz, CDCI<sub>3</sub>) δ ppm 1.13 (s, 9H) 1.49 (s, 18H) 1.88-2.02 (m, 2H) 2.06-2.22 (m, 4H) 2.99 (s, 2H) 3.33-3.48 (m, 4H) 3.43 (s, 6H ) 4.23 (s, 2H) 4.96 (d, J = 5.3 Hz, 2H) 5.29 (d, J = 6.9 Hz, 2H) 6.29 (d, J = 8.9 Hz, 2H) 6.94 (d, J = 8.4 Hz, 2H ) 7.13-7.29 (m, 8H).
MS (ESI) m / z 886 (M + H)<sup>+</sup>.
EXAMPLE 79I {(2S) -1-r (2S) -2- (4-f4-r (2R.3S, 4S, 5R) -1- (4-tert-butylphenin-3,4-dimethoxy-5- (4-f2 - [(2S) -1 - ((2S) -2-r (methoxycarbonyl) amlnob3-methylbutane) p¡rrolidin-2-in-1 H-imidazol-4-infenihpyrrole i methyl di n-2¡llphen¡l> -1 H-imidazol-2-¡l) pyrrol¡d¡n-1-iH-3-methyl-1-oxobutan-2¡Rcarbamate
To a solution of Example 79H (30 mg, 0.034 mmol) in CH<sub>2</sub>CI<sub>2</sub> (1 ml) add trifluoroacetic acid (1 ml) and the solution is stirred at room temperature for 1 hour. The solvent is removed in vacuo and then dissolved in DMSO (0.5 ml). Ν, Ν-Diisopropylethylamine is added until pH 9-10, then (S) -2 (methoxycarbonylamine) -3-methylbutanoic acid (14.8 mg, 0.085 mmol) is added followed by HATU (32 mg 0.085 mmol) and the solution is stirred at
399
OF THE industrial PROPERTY
<img file="MX339989B_D0703.tif" />
room temperature for 1 hour. The EtOAc solution is washed with H<sub>2</sub>O, brine, dries up (Na<sub>2</sub>SW<sub>4</sub>), it is filtered and the solvent is removed under vacuum. The residue is dissolved in CH<sub>3</sub>OH (2 mi), K is added<sub>2</sub>CO<sub>3</sub> solid and stir at room temperature for 30 minutes. The solid is filtered and the filtrate is concentrated in vacuo and the residue is purified by flash chromatography on silica gel eluting with 0-5% CH<sub>3</sub>OH / CH<sub>2</sub>CI<sub>2 </sub>to obtain the title compound (21.6 mg, 0.022 mmol, 63%).
<sup>1</sup>H NMR (400 MHz, CDCI<sub>3</sub>) δ ppm 0.85 (s, 12H) 1.13 (s,
9H) 1.82-2.03 (m, 2H) 2.02-2.24 (m, 4H) 2.32 (br s, 2H) 3.04 (br s, 2H) 3.43 (s, 6H) 3.53-3.65 (m, 2H) 3.70 (s, 6H) 3.75-3.90 (m, 2H)
4.22 (s, 2H) 4.31 (d, J = 15.7 Hz, 2H) 5.16-5.33 (m, 4H) 5.37 (d, J = 9.1 Hz, 2H) 6.29 (d, J = 8.9 Hz, 2H) 6.94 (s , 2H) 7.16 (s, 2H) 7.22 (d, J = 8.0 Hz, 4H) 7.31-7.52 (m, 2H) 7.60-7.87 (m, 2H) 10.26 (s, 1H) 10.64 (s, 1H).
MS (ESI) m / z 1000 (M + H)<sup>+</sup>.
<img file="MX339989B_D0704.tif" />
EXAMPLE 80 r (2S) -1-f (2S) -2-r5- (4- (1-r4- (dimethylamino) phenyl1-5- (4- (2-r (2S) -1400 f (2S) -2-r (methoxycarbon¡l) amino1-3-methylbutanoii) PM; ftohájw<sub>1</sub>r,
OF INDUSTRIAL PROPERTY
<img file="MX339989B_D0705.tif" />
¡Midazol-5-¡l) phen¡l) -1 H-pyrrole-2-¡Ufen ¡H-1 H-imidazol-2-illpyroiidin1-yl) -3-meth¡ 1-1-oxobutan-2-incarbamate methyl
Example 26E and N, Nd, methyl-pphenylenediamine are processed using sequentially the methods of
Examples 76A, 39E, 39F, 55G (25% isopropyl alcohol / chloroform is used for extraction), and 26J (reaction solvent = dichloromethane) to provide the title compound (5.6 mg).
<sup>1</sup>H NMR (400 MHz, DMSO-d6) δ 0.94 - 0.75 (m, 12H), 2.04 - 1.78 (m, 6H), 2.21 - 2.03 (m, 4H), 2.89 (s, 6H), 3.38 (s, 1H ), 3.53 (s, 6H), 3.84 - 3.68 (m, 3H), 4.10 - 3.96 (m, 2H), 5.04 (dd, J = 2.9, 6.7, 2H), 6.53 - 6.37 (m, 2H), 6.70 - 6.54 (m, 2H), 7.12 - 6.85 (m, 6H), 7.33- 7.12 (m, 2H), 7.46 - 7.34 (m, 2H), 7.60 - 7.46 (m, 4H), 12.11 11.64 (m, 2H ).
MS (ESI) m / z 923 (M + H)<sup>+</sup>.
<img file="MX339989B_D0706.tif" />
EXAMPLE 81 (r (2S, 5S) -1- (4-fiuorophenyl) pyrrolidin-2,5-di-inbis (benzene-4,1-diylcarbamoiir (2S, 4S) -4-hydroxypyrrolidin-2,1-di ylir (2S) -3,3-dimtyl-1401 oxobutan-1,2-di-IIU) b¡scarbamate
Ϊ.
dtaXMPI
-iw! »<sup>,</sup>riTOTP> .Ex¡CANo
OF THE INDUSTRIAL PROPERTY
<img file="MX339989B_D0707.tif" />
(R2R.5R) -1 - (4-fluorophenyl) p¡rrol¡d¡n-2.5-di-illbisT6 ~ eh¿éh-4, 'l-fll-— ¡Icarbamoil f (2S, 4S) - Dimethyl 4-h¡d roxy pyrrolid¡n-2,1-di-Π1 H2S) -3,3-d¡methyl 1-1 oxobutan-1,2-di-iin) biscarbamate
EXAMPLE 81A
(2S, 4S) -1 - (tert-butoxycarbonyl) -4-hydroxypropyl din-2-carboxylic acid
To a solution of (2S, 4S) -4-hydroxypyrrolidine-2-carboxylic acid (3.9 g, 29.7 mmol) in THF (26.7 ml) and water (13.3 ml) is added di-tert-butyl dicarbonate (7.14 g, 32.7 mmol ) and sodium hydroxide (2.0 N, 22.9 ml, 45.8 mmol) and the mixture was stirred at room temperature overnight. 10% citric acid (50 ml) is then added to the mixture followed by EtOAc and extraction with water and brine. The organic extract is dried, filtered and concentrated to obtain 5.31 g (77%) of the title compound.
MS (ESI) m / z 232 (M + H) +.
EXAMPLE 81B
(2S, 4S) -1- (tert-butoxycarbonyl) -4- (tert-butyldimethylsilyloxy) pyrrolidine-2-carboxylic acid
To a solution of Example 81A (5.31, 22.96 mmol) and imidazole (7.82 g, 115 mmol) in dichloromethane (106 ml) and DMF (21.3
402 mi) add tert-butyldimethylsilyl chloride (7.61 g, OTJS;
Industrial IMPI
<img file="MX339989B_D0708.tif" />
the mixture is stirred at room temperature overnight. Water (425 ml) is then added to the mixture and the solution is extracted with EtOAc and the organic extract is concentrated to a residue that is dissolved in 25% EtOAc and 75% hexanes then it is extracted with brine and the organic extract is concentrates to a solid. The resulting solid is dissolved in methanol (65 ml) and water (85 ml) then lithium hydroxide monohydrate (1.93 g, 46 mmol) is added and the solution is stirred at room temperature for 2 hours. After this, water (106 ml) and a 1 N aqueous hydrochloric acid solution are added until a pH of 2. The mixture is then extracted with a mixture of 25% EtOAc and 75% hexanes, the organic extract is dry, filter and concentrate to a colorless solid.
MS (ESI) m / z 346 (M + H) +.
EXAMPLE 81C (3S, 3'S, 5S .5'S) -5.5 '- (4.4' - ((2S, 5S) -1- (4-fluoropheni Dpi rrol idin-2,5-diiDbis (4.1-phen¡ len)) bis (azandi-iDbis (oxomethylene) bis (3- (tert-butyl dimethylsilyloxy) pyrrolidin-1-carboxylic acid tert-butyl ester
¥.
(3S, 3<sup>,</sup>S.5S.5<sup>,</sup>S) -5.5<sup>,</sup>- (4.4 '- ((2R.5R) -<sup><</sup>tert-butyl l- (4-fluoropheniDpyrrolidin-2,5-diiDbis (4.1-phenylene)) bis (azandi-yl) bis (oxomethylene) bis (3- (tert-butyldimethylsilyloxy) pyrrolidi n-1-carboxylate
403
The product of Example 81B (149 product of Example 5A (50 mg, 0.144 using the method described in Example (51%) of the title compound as diastereomers.
<img file="MX339989B_D0709.tif" />
mg, 0.4 mmol) are processed 1F to obtain / 4 mg a 1: 1 mixture of
OF INDUSTRIAL PROPERTY
MS (ESI) m / z 1002 (M + H) +.
EXAMPLE 81D (2S.2<sup>,</sup>S.4S.4<sup>,</sup>S) -N, N '- (4.4<sup>,</sup>- ((2S, 5S) -1- (4-fluorophenyl) p¡rrol¡din-2,5di-yl) bis (4,1-phenylene)) bis (4-hydroxy pyrrole idi η-2-carboxam go) (2S, 2<sup>,</sup>S.4S, 4'S) -N, N<sup>,</sup>- (4Í4<sup>,</sup>- ((2R, 5R) -1- (4-fluorophenyl) pyrrolidin-2i5di-yl) bis (4,1-phen ylene)) bis (4-hydroxy pyrrole ¡di η-2-carboxam ¡da)
The product from Example 81C (74 mg, 0.074 mmol) is dissolved in trifluoroacetic acid (4 ml), water (0.2 ml) and dichloromethane (0.2 ml) and the mixture is stirred at room temperature for 3 hours. After this the mixture is concentrated to an oil which dissolves in 75% CHCI<sub>3</sub> and 25% isopropyl alcohol then extracted with a saturated aqueous solution of sodium bicarbonate, the organic extract separated, dried, filtered and concentrated to a colorless solid.
MS (ESI) m / z 574 (M + H) +.
404
IMPI
EXAMPLE 81 E (H2S, 5S) -1- (4-fluorophenyl) p¡rrolid¡n-2.5-d¡-¡nb¡s (bencen-4.1 -d¡ MEXICAN INSTITUTE OF PROPERTY
INDUSTRIAL ¡lcarbamoiir (2S, 4S) -4-h¡drox¡p¡rrol¡d¡n-2.1 -d¡-¡nr (2S) -3,3-dimethyl-1 oxobutan-1,2-di-¡ID) dimethyl biscarbamate
X (R2R, 5R) -1- (4-fluorophenyl) p¡rrol¡d¡n-2,5-di-¡nbis <benzene-4.1 -d¡ylcarbamoiir (2S.4S) -4-hydroxypyroiidin-2, Dimethyl 1-d¡-ylirf2S) -3,3-dimethyl-1oxobuta n-1,2-d¡-¡HUbiscarbamate
To the product of Example 81D (40 mg, 0.072 mmol), (S) -2- (methoxycarbonylamino) -3,3-dimethylbutanoic acid (34.1 mg, 0.18 mmol) and HATU (60.2 mg, 0.158 mmol) in DMSO (3 ml ) Hunig's base (0.063 ml, 0.36 mmol) is added, and the reaction mixture is stirred at room temperature for 1 hour. The reaction mixture is partitioned between water and ethyl acetate, and the organic layer is dried over MgSO<sub>4</sub>, filter and concentrate in vacuo. The crude product is purified by silica gel column chromatography using a solvent gradient of 0-10% MeOH in dichloromethane to obtain the title compound as a 1: 1 mixture of stereoisomers (21 mg, 32% yield) .
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ ppm 9.94 (s, 2H), 7.44 (d, J = 8.4 Hz, 4H), 7.07 (m, 6H) 6.74 (t, J = 8.9 Hz, 2 H), 6.15 (dd, J = 9.1, 4.4 Hz, 2 H), 5.26 (dd, J = 6.1, 3.3 Hz, 2 H), 5.11 (d, J = 5.5 Hz, 2 H), 4.33 (t, J = 7.8 Hz, 2H), 4.19 (m, 2H), 4.07 (m, 2H), 3.93 (m, 2H), 3.48 (s, 6H), 2.34 (m, 2H), 1.66 ( m, 2H), 1.59 (m, 2H), 1.20 (m,
405
Η), 0.91 (m, 18 Η).
ΙΜΡΪ6
<img file="MX339989B_D0710.tif" />
MEXICAN INSTITUTE OF INDUSTRIAL PROPERTY
<img file="MX339989B_D0711.tif" />
EXAMPLE 82 (í (2S, 5S) -1 - (3-fluorophenyl) p¡rrolidin-2.5-di-yl1 bis (benzene-4,1 -d¡10 ¡lcarbamo¡l (2S) p¡rrol¡din- Dimethyl 2,1-di-iir (2S) -3.3-d8methyl-1-oxobutan-1,2di-ill)) biscarbamate
Ϊ.
(n2R, 5R) -1- (3-fluorophen¡l) p¡rrol¡d¡n-2.5-d¡-¡l1bis (benzene-4,1-d¡¡lcarbamo¡i (2S) pyrrole¡din- Dimethyl 2,1-d¡-ylf (2S) -3,3-dimethylt-oxobutan-1,215 di-ylBIbiscarbamate
Example 1C and 3-fluoroaniline are processed sequentially using the methods of Examples 1D, 1E, 1F, 1G, and 1H to provide the title compounds. The trans diastereomers are separated from the cis diastereomer at the 4,4 '- (1- (3-fluorophenyl) pyrrolidin-2,5-di-yl) dianiline step. Data for the title compounds:
<sup>1</sup>H NMR (free base) (400 MHz, DMSO-d<sub>6</sub>) δ ppm 0.96 (d, J = 2.17 Hz, 18 H), 1.75 - 1.92 (m, 7 H), 1.93 - 2.05 (m, 2 H), 2.10 25 2.21 (m, 2 H), 2.31 - 2.44 ( m, 2H), 3.43-3.51 (rn, 4H), 3.53 (s, 6H),
406
WICKED
3.59 - 3.73 (m, 6 Η), 3.73 - 3.82 (m, 2 Η), 4.21 (d,
INDUSTRIAL *
4.46 (dd, J = 7.92, 5.31 Hz, 2 H), 4.70 (t, J = 4.66 Hz, 2 H), 6.07 (d,
J = 12.90 Hz, 1 H), 6.19 (dd, J = 8.35, 1.63 Hz, 1 H), 6.37 (dt, J = 8.35, 2.06 Hz, 1 H), 6.97 - 7.05 (m, 2 H), 7.08 (d, J = 8.67 Hz, 2H), 7.41 (d, J = 7.26 Hz, 4H), 7.60 (d, J = 8.57 Hz, 4H), 10.07 (s, 2H).
MS (ESI) m / z 885 (M + H)<sup>+</sup>.
<img file="MX339989B_D0712.tif" />
(R2S, 5S) -1- (4-fluorophen¡l) p¡rrol¡d¡n-2.5-d¡-¡Hb¡s (benzene-3.1-d¡¡lcarbamo¡l (2S) pyrrolid¡ n- 2,1-di-i I r (2S) -3,3-di methyl 1-1-oxobutan-1,2di-iH>) dimethyl biscarbamate
Ϊ.
(f (2R, 5R) -1- (4-fluorophenyl) pyrroiidin-2,5-d¡-yl-bisibenzene-3,1-d¡¡lcarbamoyl (2S) p¡rrolidin-2,1-di-iir (2S ) Dimethyl) -3,3-dimethyl-1-oxobutan-1,2di-illDbiscarbamate
407
Kiamarr.t ^ sas
EXAMPLE 83A (2S, 2'S) -2.2 '- (3,3 ^ ((28.eS) -1- (4-fluorophenyl) p¡rrol¡din-2,5-diIMPI
MEXICAN INSTITUTE OF INDUSTRIAL PROPERTY
<img file="MX339989B_D0713.tif" />
¡L) bis (3,1-phenylene)) bls (azand¡-¡l) b¡s (tert-butyl oxomethylene T3i pyrrolidine-1-carboxylate
Ϊ.
(2S.2'S) -2.2<sup>,</sup>-(3,3<sup>,</sup>-í (2R.5R) -1- (4-fluoropheni Dpi rrolidi n-2,5-di¡l) bis (3.1 -phenylene)) b¡s (azand¡-¡l) bis (oxomethylene) d¡pyrrole D¡n-1 tert-butyl carboxylate
The ether fraction from the Example 55F treatment is purified using flash chromatography (silica gel, 0-30% EtOAc / dichloromethane) to obtain the title compound as a mixture of trans diastereomers.
MS (ESI) m / z 742 (M + H)<sup>+</sup>.
EXAMPLE 83B (Í (2S, 5S) -1 - (4-fluorofen ¡Dpi rrolidi n-2,5-d ¡-i llbisfben ce n-3,1 -d¡i lcarbamo¡lf2S) p¡ rrolidi n-2 Dimethyl, 1-di-i ir (2S) -3,3-di methyl 1-1-oxobutan-1,2di-iHDbiscarbamate
Ϊ.
(f (2R, 5R) -1- (4-fluorophenyl) pyrrol¡d¡n-2,5-d¡-¡nb¡s (benzene-3,1-d¡ylcarbamoyl (2S) pyrrolidin-2 Dimethyl, 1-di-iir (2S) -3,3-dimethii-1-oxobutan-1,2di-ill)) biscarbamate
408
I jMí¡Pn
<img file="MX339989B_D0714.tif" />
The product from Example 83A was processed .______
Mexican INSTITUTE OF PROPERTY methods described in Examples 55G and 55H for '© tStfeYier title compound (0.18 g, 27%).
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ 0.97 (d, J = 4.5, 18H),
1.73-1.60 (m, 2H), 1.92-1.75 (m, 5H), 2.05-1.92 (m, 3H), 2.23 2.05 (m, 2H), 3.54 (d, J = 1.5, 6H), 3.71-3.59 ( m, 2H), 3.85-3.71 (m, 2H), 4.21 (d, J = 8.9, 2H), 4.50 - 4.37 (m, 2H), 5.14 (d, J = 5.7,
2H), 6.30 - 6.19 (m, 2H), 6.85 - 6.75 (m, 2H), 6.88 (d, J = 7.7, 2H),
7.09 (d, J = 8.7, 2H), 7.23 (t, J = 7.9, 2H), 7.40 - 7.30 (m, 2H), 7.58 (d, J = 8.1, 2H), 10.07 - 9.96 (m, 2H) .
MS (ESI) m / z 884 (M + H)<sup>+</sup>, 882 (MH) <sup>+</sup> .
<img file="MX339989B_D0715.tif" />
EXAMPLE 84 (r (2S, 5S) -1 - (4-methylphenii) pyrrolidin-2,5-di-illbisfbenzene-4,1-di¡lcarbamo¡l (2S) p¡rrole idin-2,1- dimethyl di-yl r (2S) -3-meth¡ 1-1-oxobutan-1,2-di¡llHbiscarbamate
Y (r (2R, 5R) -1- (4-methylphenyl) pyrrolidin-2,5-di-811bisfbenzene-4,1-di-lcarbamoyl (2S jpyrrole idi n-2,1-di- ilf (2S) -3-methy 1-1 -oxobutan-1,2-diillDbi carbamate d dimtyl
409
MEXICAN INSTITUTE
The title compound is prepared ui
IMPI
INSTITUTO MEXICANO procedures described for the syntheses of Examples 34A, 34B,
<img file="MX339989B_D0716.tif" />
34C, 34D, and 34E, substituting 4-methylaniline for 4-tert-butylaniline.
<sup>1</sup>H NMR (500 MHz, DMSO-D6) δ ppm 0.85 - 0.90 (m, 6H), 5 0.90 - 0.95 (m, 6H), 1.61 - 1.65 (m, 2H), 1.82 - 2.01 (m, 8 H), 2.03 (s, 3H), 2.09 - 2.16 (m, 2H), 3.52 (s, 6H), 3.58 - 3.66 (m, 2H), 3.77 - 3.84 (m, 2H), 4.02 (t, 2H), 4.40 - 4.45 (m, 2H), 5.14 (d, J = 6.6 Hz, 2H), 6.13 - 6.18 (m, 2H), 6.72 (d, J = 8.4 Hz, 2 H), 7.08 - 7.14 (m, 4
H), 7.29-7.34 (m, 2H), 7.46-7.51 (m, 4H), 9.98 (s, 2H).
MS m / z 852.3 (M + H) <sup>+</sup> .
<img file="MX339989B_D0717.tif" />
EXAMPLE 85 (f (2S, 5S) -1 - (4-chlorophenyl) pyrrolidin-2,5-d¡-yl1b¡s (benzene-4,1-di¡Icarbamoi l (2S) p¡rrol id¡ Dimethyl n-2,1-di-iir (2S) -3-methyl-1-oxobutan-1,2-di20 ylUlbiscarbamate
I (r (2R.5R) -1- (4-chlorophenyl) p¡rrolid¡n-2.5-di-¡llb¡s (benzene-4,1-d¡ylcarbamoyl (2S) pyrrolid¡n-2.1-d Dimethyl ¡-iir (2S) -3-methyl-1-oxobutan-1,2-di¡IlDbiscarbamate
410
EXAMPLE 85A
1-f 4-cl or rofenyl) -2,5-bisf4-nitrofenyl) pyrrolidine
IMPI "
MEXICAN INSTITUTE OF PROPERTY
INDUSTRIAL
<img file="MX339989B_D0718.tif" />
The product from Example 1B (0.50 g, 1.51 mmol) is suspended in CH<sub>2</sub>CI<sub>2</sub> (15 mi). Triethylamine (0.626 ml, 4.51 mmol) is added at 0 ° C, the resulting mixture is stirred for 30 minutes, and methanesulfonyl chloride (0.293 ml, 3.76 mmol) is added. The mixture is stirred at room temperature for 1 hour and then concentrated in vacuo to obtain a light yellow solid. The solid is dissolved in DMF (6 ml), 4-chloroaniline (1.92 g, 15.05 mmol) is added, and the resulting mixture is stirred at 50 ° C overnight. The mixture is partitioned between EtOAc and aqueous 1N HCl, and the organic layer is dried over Na<sub>2</sub>SW<sub>4</sub>, filter and concentrate in vacuo. The crude product is purified by silica gel column chromatography using a solvent gradient of 0-12% EtOAc in hexane to obtain the title compound (0.226 g, 35%).
EXAMPLE 85B
4,4 '- (trans-1 - (4-chlorophenyl) pyrrodin-2.5-d¡-yl) diani li na
To a solution of the product of Example 85A (0.214 g,
0.505 mmol) in EtOH (2.52 ml) and THF (2.52 ml) add platinum (IV) oxide (0.115 g, 0.505 mmol), and the resulting mixture is stirred at room temperature under 1 atmosphere of H<sub>2</sub> All night long.
The mixture is filtered through celite, and the filtrate is concentrated
411
IMPI empty. The crude product is purified by
INDUSTRIAL column with silica gel using a solvent gradient of Ο-
<img file="MX339989B_D0719.tif" />
* 2% EtOAc in hexane to obtain a mixture of the title compound and some dechlorinated product (4,4 '- (trans-1-phenylpyrrolidin-2,5d ii l) d ia n i i na).
EXAMPLE 85C (R2S, 5S) -1 - (4-chlorophenyl) pyrrolidin-2.5-di-llbis (benzene-4.1-diylcarbamoyl (2S) pyrrolidi n-2,1-d ii IH2S) -3-methyl-1-oxobutan-1,2-diyl1>) dimethyl biscarbamate
AND.
(r (2R, 5R) -1- (4-chlorophenyl) pyrrolidin-2.5-di-illbis (benzene-4,1-diylcarbamoyl (2S) p¡rrolidi n-2,1-di-yl r Dimethyl (2S) -3-methyl-1-oxobutan-1,2-diylBbiscarbamate
A mixture of the product of Example 85B is subjected to the procedures described in Examples 34C, 34D, and 34E to obtain the free title compounds of the dechlorinated product.
<sup>1</sup>H NMR (TFA salt) (400 MHz, DMSO-D6) δ ppm 0.84 0.89 (m, 6H), 0.89 - 0.94 (m, 6H), 1.61 - 1.66 (m, 2H), 1.80 - 2.03 ( m, 8H), 2.06-2.18 (m, 2H), 3.51 (s, 6H), 3.56-365 (m, 2H), 3.74
- 3.84 (m, 2 H), 4.01 (t, J = 8.4 Hz, 2 H), 4.36 - 4.44 (m, 2 H), 5.16 (d, J = 6.3 Hz, 2 H), 6.21 (d, J = 8.9 Hz, 2H), 6.93 (d, J = 9.0 Hz, 2H), 7.08
- 7.13 (m, 4H), 7.26 - 7.31 (m, 2H), 7.46 - 7.51 (m, 4H), 9.99 (s, 2
H).
412
MS m / z 872.3 (M + H)<sup>+</sup>.
IMPI
INSTITUTO MEXICANO DE LA fSC?; £ DAD INDUSTRIAL
<img file="MX339989B_D0720.tif" />
<img file="MX339989B_D0721.tif" />
EXAMPLE 86 (Γ (25,55) -1 - (4-bromophenyl) p¡rrol¡d¡n-2.5-d¡-¡l1 bisfbenzene-4,1 -d¡¡lcarbamo¡l (2S) p¡rrole Dimethyl din-2,1-di-iir (2S) -3-methyl-1-oxobutan-1,2-diITHbiscarbamate
K (F (2R.5R) -1- (4-bromophenyl) p¡rrolidin-2.5-di-illbisfbenzene-4,1-d¡ylcarbamoyl (2S) pyrrolidin-2,1-di-iir (2S) -3 dimethyl-methii-1-oxobutan-1,2-diylhbiscarbamate
EXAMPLE 86A
- (4-bromophenyl) -2.5-bis (4-nitrophenyl) pyrolidine
The product from Example 1C (0.7 g, 1,433 mmol) and 4-bromo aniline (2.54 g, 14.33 mmol) are suspended in DMF (6 ml) and stirred at 50 ° C overnight. The resulting mixture is partitioned between ethyl acetate (100 ml) and water (50 ml). The organic phase is washed with 1N HCl (2 x 50 mL) followed by a brine wash then dried over MgSO<sub>4</sub>, filter and concentrate. The crude product is purified by chromatography on silica gel
413 using a solvent gradient of 2-50% hexane to obtain the title compound stereoisomers (74.4mg, 11% yield)
IMPI of aoetaitOM £ TeAi £> ti
OF INDUSTRIAL FROFITY as a mixture
<img file="MX339989B_D0722.tif" />
EXAMPLE 86B (2S.2<sup>,</sup>S) -N.N '- (4.4<sup>,</sup>- (1- (4-bromophenyl) pyrrolidin-2<sub><</sub>5-di-yl) bis (4,1phenylene)) dipyrrolodin-2-carboxamide
Example 86A is processed using the methods of Examples 1E, 1F, and 1G to provide the title compound as a mixture of stereoisomers.
EXAMPLE 86C (ri- (4-bromophenyl) pyrrolidin-2.5-d¡-inbisfbencen-4,1-diylcarbamo¡l (2S | p¡rrolidi n-2,1-d¡-¡lf (2S) -3-methyl Dimethyl -1-oxobutan-1,2-di¡nUbiscarbamate
The product from Example 86B (78.0 mg, 0.129 mmol) is combined with EDAC (67.0 mg, 0.347 mmol), 1-hydroxybenzotriazole hydrate (49.0 mg, 0.323 mmol) and (S) -2 (methoxycarbonylamino) -3-methylbutanoic acid ( 61.0 mg, 0.346 mmol) in dimethylformamide (1.4 ml) at room temperature under a nitrogen atmosphere. Di-isopropylethylamine (0.113 ml, 0.645 mmol) is added to this solution. The mixture is allowed to stir overnight at room temperature followed by partitioning between ethyl acetate (20
414
IMPI
<img file="MX339989B_D0723.tif" />
mi) and water (5 mi). The organic phase is washed with 3¾¾ then dried with MgSO<sub>4</sub>, filtered and evaporated to dryness. The crude product is chromatographed using HPLC (C<sub>18</sub>) reverse phase which provides the title compound as a 1: 1 mixture of diastereomers (trans) (0.045g, 38% yield) as an off-white solid.
H NMR (free base) (400 MHz, DMSO-D6) δ ppm 0.72 1.03 (m, 12H) 1.65 (s, 2H) 1.79 - 2.19 (m, 11H) 3.52 (s, 6H) 3.58 3.67 ( m, 2H) 3.75-3.86 (m, 2H) 3.95-4.09 (m, 2H) 4.43 (dd,
J = 7.92, 4.88 Hz, 2H) 5.08 - 5.25 (m, 2H) 6.19 (d, J = 8.89 Hz, 2H)
7.06 (d, J = 8.89 Hz, 2 H) 7.12 (d, J = 7.16 Hz, 4 H) 7.31 (dd, J = 8.29,
3.96 Hz, 2H) 7.51 (dd, J = 8.46, 1.52 Hz, 4H) 10.00 (s, 2H).
MS ESI (+) m/z@916.6 (M + H) +.
<img file="MX339989B_D0724.tif" />
EXAMPLE 87 f (2SM-K2S) -2- {5-rf2S, 5S) -1- (4-fluorophenyl) -5- (2-H2S) -1 - ((2S) -2r (methoxycarboniPamino1-3.3-dimethylbutanoi Dpi rrolidi η-2-i H-1 Hbenz¡midazol-5-¡l) p¡rrol¡d¡n-2-¡H-1 H-benzim idazoi-2-i Dpi rrolidi n-1 25 ¡11-3.3 -dim til-1-oxobutan-2-iDcarbamate dm linden
1Α2ΛΓ. ·.
<img file="MX339989B_D0725.tif" />
415
ΙΜΡΪ
MEXICAN INSTITUTE
DELA FROF. 'AGE x INDUSTRIAL ((2S) -1-r (2S) -2-f5-r (2R, 5R) -1- (4-fluorophenin-5-¿2-r / 9R) -1 -f / 2S) -2r (methox8carbon¡l) am¡no1-3.3-d¡met¡lbutano¡l) pyrrol¡d¡n-2-¡H-1 Hbenzim¡dazol-5-yl) pyrrolidin-2- methyl iH-1H-benzimidazol-2-yl? p¡rrol¡din-1 ¡II-3,3-di methyl-1-oxobutan-2-i llcarbamate
The product of Example 29G (0.045 g, 0.084 mmol), (S) -2-methoxycarbonylamine-3,3-dimethyl-butyric acid (0.037 g, 0.193 mmol), 4-methylmorpholine (0.037 ml, 0.336 mmol), 1Hbenzo [d] [1,2,3] triazol-1-ol hydrate (0.028 g, 0.185 mmol) and hydrochloride of N1 - ((ethylmethyl) -N3, N3- Dimethylpropan-1,3-diamine (0.035 g, 0.185 mmol) are combined in 2 ml of DMF and stirred for 2 hours. The reaction mixture is partitioned between EtOAc and water. The organic layer is washed 3X20 ml with brine, dried (Na<sub>2</sub>SW<sub>4</sub>), filtered and concentrated. The crude material is flash chromatographed on a 4 g Isco Gold silica cartridge eluting with 1.5-8% MeOH in methylene chloride. A second preparative C18 reverse phase chromatography eluting with 9: 1 water / acetonitrile -> 100% acetonitriium gives the title compounds (29 mg, 28%; mixture of trans diastereomers) as a light tan powder.
<sup>1</sup>H NMR (TFA salt) (400 MHz, DMSO-d<sub>6</sub>) δ 0.84 - 0.95 (m, 18H) 1.21 - 1.46 (m, 4H) 1.75 - 2.27 (m, 8H) 3.56 (s, 6H) 3.86 (t, J = 5.26 Hz, 4H) 4.22 ( dd, J = 8.57, 4.45 Hz, 2 H) 5.15 - 5.24 (m, 2
H) 5.53 (d, J = 4.88 Hz, 2 H) 6.30 (dd, J = 9.11, 4.34 Hz, 2 H) 6.75 416
6.83 (m, 2 Η) 7.29 (d, J = 8.57 Hz, 2 H) 7.35 (d, J = (d, J = 7.92 Hz, 2 H) 7.69 (d, J = 7.37 Hz, 2 H).
MS (ESI +) m / z 879 (M + H)<sup>+</sup>.
<img file="MX339989B_D0726.tif" />
OF THE INDUSTRIAL rfcOrEO.AD
<img file="MX339989B_D0727.tif" />
<img file="MX339989B_D0728.tif" />
EXAMPLE 88 (R2S, 5S) -1 - (4-methoxyphenyl) p¡rrol¡d¡n-2.5-d¡-¡Hb¡s (benzene-4,1-d¡ylcarbamo¡l (2S) pyrrolid Dimethyl ¡n-2,1 -di-¡lf (2S) -3-methyl-1-oxobutan-1,2-d¡¡Hubiscarbamate
Ϊ.
(r (2R, 5R) -1- (4-methoxyphenyl) pyrrolidin-2,5-di-yl1b¡sfbenzene-4,1-dii lcarbamoyl (2S) pyrrole di n-2,1-di-i IR2S) Dimethiium -3-methyl-1-oxobutan-1,2-diillDbiscarbamate
The title compound is prepared using the procedures described for the syntheses of Examples 34A, 34B, 34C, 34D, and 34E, substituting 4-methoxyaniline for 4-tert-butylaniline.
<sup>1</sup>H NMR (TFA salt) (400 MHz, DMSO-D6) δ ppm 0.85 0.90 (m, 6H), 0.90 - 0.95 (m, 6H), 1.60 - 1.66 (m, 2H), 1.81 - 2.04 ( m, 8H), 2.08-2.19 (m, 2H), 3.52 (s, 9H), 3.57-3.66 (m, 2H), 3.77-3.85 (m, 2H), 4.02 (t, 2H ), 4.39 - 4.46 (m, 2 H), 5.12 (d, J = 6.3 Hz, 2 H), 6.18 (d, J = 9.0 Hz, 2 H), 6.56 (d, J = 9.0 Hz, 2 H) , 7.09 - 7.15 (m,
417
Η), 7.28 - 7.34 (m, 2 Η), 7.46 - 7.52 (m, 4 Η), 9.9
MS m / z 868.5 (M + H)<sup>+</sup>.
<img file="MX339989B_D0729.tif" />
<img file="MX339989B_D0730.tif" />
EXAMPLE 89
R2S) -1-R2S) -2- (4- (4-R2S, 5S) -5- (4- (2-R2S) -1-R2S) -2r (methoxycarbonyl) amino1-3-methyl butane i Dpi rrol idin-2-¡n-1 Him¡dazol-4-yl> fen¡D-1-phenyl pyrrolidi n-2-infeniD-1 H-imidazol-2¡hpirrol¡din-1 -¡l1 Methyl -3-methyl-1-oxobutan-2-iDcarbamate
X
R2S) -1 -R2S) -2- (4- {4 - [(2R, 5R) -5- (4- {2-R2S) -1 -R2S) -2 [(methoxycarbonyl) amino1-3 -methylbutane¡ Dpi rrol ¡din-2-ϊΠ-Ι H¡midazol-4-¡Pphenyl) -1-phenylpyrrolidi n-2-¡l1fen¡D-1 H-imidazol-2ii) pyrrolid¡n-1 -iΠ Methyl -3-methyl-l-oxobutan-2-iDcarbamate
The trans diastereomers obtained in Example 59B (8.5 mg, 0.0107 mmol), (S) -2- (methoxycarbonylamino) -3-methylbutanolic acid (4.67 mg, 0.027 mmol) and HATU (8.9 mg, 0.023 mmol) in DMSO (1 ml) Hunig's base (0.015 ml, 0.085 mmol) is added, and the reaction mixture is stirred at room temperature for 1 hour. The reaction mixture is partitioned between water and
418 ethyl acetate, and the organic layer is dried over concentrated Mg in vacuo. The crude product is purified by reverse phase chromatography (C18), eluting with 10-100% acetonitrile in water (0.1% TFA) to obtain 5.0 mg (53%) of the title compound as a mixture of trans diastereomers.
<sup>1</sup>H NMR (TFA salt) (400 MHz, DMSO-D6) δ ppm 14.45
<img file="MX339989B_D0731.tif" />
(bs, 2H), 7.97 (s, 2H), 7.66 (m, 4H), 7.38 (m, 4H), 7.31 (d, J = 7.4 Hz, 2H), 6.92 (t, J = 7.6 Hz, 2H), 6.43 (m, 1H), 6.28 (d, J = 8.1 Hz, 2H), 5.37 (m, 2H), 5.09 (t, J = 6.7 Hz, 2H), 4.09 (t , J = 7.7 Hz, 2H), 3.81 (m, 6H), 3.53 (s, 6H), 2.40 (m, 2H), 2.08 (m, 2H), 2.02 (m, 6H),
1.85 (m, 2H), 0.85 (m, 2H), 0.80 (m, 12H).
MS (ESI) m / z 884 (M + H) +.
<img file="MX339989B_D0732.tif" />
EXAMPLE 90 ((2S, 5S) -1- (b¡phenyl-4-¡l) p¡rrol¡d¡n-2,5-d¡-¡llbis (benzene-4J-d¡¡lcarbamoyl (2SÍP ¡Rrol¡dln-2,1-d¡-¡ir (2S) -3-methyl-1-oxobutan-1,2-di¡ITH biscarbamate
and.
(r (2R.5R) -1-fbipheniI-4-yl) p¡rrol¡din-2.5-di-¡llbisfbencen-4,1-d¡¡lcarbamoyl (2S) pyrrol¡d¡n-2.1-d¡ -¡Lf (2S) -3-methyl-1-oxobutan-1,2-d¡419 u'iiiiJ
<img file="MX339989B_D0733.tif" />
DimethyltWrmiTomexican Ubiscarbamate
OF THE PROPERTY
INDUSTRIAL
The product of Example 86C (24.9 mg, 0.027 mmol) dissolved in a solution of THF (1 ml) and water (0.3 ml) is combined in a microwave tube with phenylboronic acid (6.90 mg, 0.054 mmol), tribasic potassium phosphate (13.37 mg, 0.063 mmol) and palladium 1,1'-bis (di-tert-butylphosphino) ferrocene dichloride (1.42 mg,
2.17 pmol). The tube is sealed and nitrogen is bubbled through it at room temperature for five minutes. All gas connections are subsequently removed and the reaction vessel is immersed in a 50 ° C oil bath and heated for two and a half hours. The contents of the tube are partitioned between ethyl acetate (5 ml) and brine (1 ml). The organic phase is washed with brine (2 x 1 ml) then dried over MgSO<sub>4</sub>, filter and concentrate. The crude product is purified by silica gel chromatography eluting with 5% EtOAc-hexane and advancing to (75% EtOAc-hexane) + 3% methanol to provide the title compound as a 1: 1 mixture of diastereomers ( trans) (18.6 mg, 75% yield) as a cream colored solid.
1H NMR (400 MHz, DMSO-D6) δ ppm 0.76 - 0.99 (m, 12H) 1.67 (s, 2H) 1.77 - 2.19 (m, 11H) 3.52 (s, 6H) 3.58 - 3.65 (m, 2H) 3.74 - 3.86 (m, 2H) 3.96-4.08 (m, 2H) 4.44 (d, J = 4.99 Hz, 2H)
5.25 (s, 2H) 6.35 (d, J = 8.02 Hz, 2H) 7.17 (d, J = 7.26 Hz, 5H) 7.24 7.34 (m, 6H) 7.45 (d, J = 7.92 Hz, 2H ) 7.52 (d, J = 7.81 Hz, 4H) 10.00 (s, 2H).
420
<img file="MX339989B_D0734.tif" />
EXAMPLE 91
R2S) -1-r (2S) -2- (5 - <(2S, 5S) -5-f2-H2S) -1-f (2S) -2r (methoxycarbon¡l) am¡no1-3- met¡lbutano¡l) p¡rrol¡d¡n-2-¡H-1 Hbenzim ¡dazol-5-¡l) -1 -F4- (trlfluoromethyl) phenylPi rrolid¡n-2-¡D-1 Hbenzimidazole- Methyl 2-yl) pyrrolidin-1 -¡H-3-methyl-1-oxobutan-2¡Dcarbamate
AND.
R2S) -1-F (2S) -2- (5-R2R.5R) -5-r2-r (2S) -1-f (2S) -2r (methoxycarboniDamino1-3-methylbutanoiDpyrrolidin-2-IL1-1Hbenzimidazole- 5-iR-1 -r4- (tr¡fluoromet¡Dphenyl1p¡rrol¡d¡n-2-¡D-1 Hbenzimidazol-2-iDpi rrolidi n-1 -ill-3-methi 1-1 -oxobutan-2iPcarbamate of methyl
EXAMPLE 91 A
(2S, 2'S) -2,2 '(6.6' - (1- (4- (trifluoromethyl) phen i Dpi rrolidi n421 chloride
2,5-d¡-¡l) b¡s (1 H-benzoMI imidazole-6,2-d¡
ΙΜΡΙβ
INSTITUTO MEXICANO YU? **
-i I)) dipir Potií¿ & jlSÍS
<img file="MX339989B_D0735.tif" />
Example 28C and 4-trifluoromethylaniline are processed using the methods of Examples 28D-28J to provide the title compound as a mixture of cis and trans stereoisomers.
EXAMPLE 91B f (2S) -1-r (2S) -2- (5-f (2S, 5S) -5- (2-f (2S) -1 - {(2S) -2r (methoxycarbonyl) am inol-S-methylbutanoiRpyrrolidin-Z-in-l Hbenzimidazol-5-yl) -1 -r4- (trifluoromethyl) phenylpyrrol¡d¡n-2-¡l) -1 Hbenzim idazol-2-yl) pyrrole idin- Methyl 1-yl1-3-methyl-1-oxobutan-2¡Rcarbamate
AND.
H2S) -1-r (2S) -2- (5-í (2R, 5R) -5-r2-r (2S) -1-r (2S) -2r (methoxycarbonyl) aminol-3-metllbutane l) p¡rrol¡din-2-¡H-1Hbenz¡midazol-5-¡D-1-F4- (tr¡fluorometh¡l) phenylpyrrol¡d¡n-2-iD-1 Hbenci midazol-2-¡ I) methyl pyrrole idin-1 -¡Π-3-methy 1-1-oxobutan-2ipcarbamate
The product of Example 91A (1: 1 mixture of cis and trans isomers), 0.018 g, 0.027 mmol), HOBt (0.013 g, 0.082 mmol), EDAC (0.016 g, 0.082 mmol) and acid (S) -2- ( Methoxycarbonylamino) 3-methylbutanoic (0.014 g, 0.082 mmol) are combined in a 20 ml round bottom flask and dissolved in 1 ml of DMF a. -,, _ν ·. ___
422
<img file="MX339989B_D0736.tif" />
IMPI
INSTITUTO MEXICANO DE LA PROFLEDAJJ 'at room temperature, 4-methylmorpholine (0.015 "WFjw.1 mmol) is added and the resulting slightly other brown solution is stirred at room temperature for 2 hours. The reaction mixture is analyzed by LC-MS and determined to be complete. The reaction mixture is diluted with 50 ml of EtOAc, washed with NaHCO<sub>3</sub> 10% and 10% NaCl, dried with Na<sub>2</sub>SW<sub>4</sub>(s) anhydrous, filter and the solvent is removed in vacuo leaving the title compound as a light brown solid. The material is purified by preparative HPLC on a Phenomenex Luna C8 (2) 5 um 100A AXIA column (30mm x 75mm). A gradient of acetonitrile (A) and 0.1% trifluoroacetic acid in water (B) is used, at a flow rate of 50 ml / minute (0-0.5 minutes 10% A, 0.5-7.0 minutes of linear gradient of 10 -95% A, 7.0-10.0 minutes 95% A, 10.0-12.0 minutes linear gradient 95-10% A). The product fractions are collected and evaporated in vacuo to dryness leaving the title compound as a tan solid, (11 mg, 44%) and a mixture of trans diastereomeric isomers.
1H NMR (TFA salt) (400 MHz, DMSO-D6) d ppm 0.67 0.94 (m, 12H) 1.95 (m, 18H) 3.79 - 3.89 (m, 6H) 4.10 (s, 2H) 5.19 ( s, 1H) 5.64 (s, 2H) 6.45 (s, 2H) 7.28 (s, 4H) 7.47 (s, 4H) 7.69 (s, 4H), 12.1 (b, 2H).
ESI + (m / z): 900.6, ESI- (m / z): 898.8.
423
<img file="MX339989B_D0737.tif" />
IMPI
INSTITUTO MEXICANO DE La?! Industrial OPIE5aD
<img file="MX339989B_D0738.tif" />
EXAMPLE 92 (R2S, 5S) -1- (4-hydrox¡fen¡ l) p¡rrol¡din-2,5-d¡-¡llb¡sf benzene-4,1-diifcarbamoyl (2S) pyrrolidin Dimethyl -2,1-di-iir (2S) -3-methif-1-oxobutan-1,2-diIIIDbiscarbamate
AND.
(r (2R, 5R) -1- (4-hydroxyphenii) pyrrolidin-2,5-d¡-iiIb¡s <benzene-4,1-diylcarbamoyl (2S) pyrrolidi n-2,1-di- i ir (2S) -3-methyl-1-oxobutan-1,2-diIIlDbiscarbamate dimethyl
To a solution of the product of Example 88 (0.050 g, 0.058 mmol) in CH<sub>2</sub>CI<sub>2</sub> (1 ml) at -78 ° C add a 1.0 M solution of boron tribromide in CH<sub>2</sub>CI<sub>2</sub> (0.29 ml, 0.29 mmol). The resulting dark red solution is stirred at -78 ° C for 4 hours, and then warmed to room temperature and washed with water. The organic layer is dried over sodium sulfate, filtered, and concentrated in vacuo. The crude product is purified by silica gel column chromatography using a solvent gradient of 0-7.5% MeOH in CH<sub>2</sub>CI<sub>2</sub> to obtain the title compound (5.5 mg, 12%) as a mixture of trans diastereomers.
1H NMR (400 MHz, DMSO-D6) δ ppm 0.86 - 0.90 (m, 6 H),
424
0.90
2.19
4.02
6.08
7.29
9.96
- 0.95 (m, 6 Η), 1.58 - 1.63 (m, 2 Η), 1.82 - Z.XJ ^ PhJ,
DE EA Ι-Ι, ΟηϊΓΑΠ --- (m, 2H), 3.52 (s, 6H), 3.58 - 3.66 (m, 2H), 3.77 - 2H)
<img file="MX339989B_D0739.tif" />
(t, J = 8.5 Hz, 2H), 4.40 - 4.46 (m, 2H), 5.08 '(d, J = 6.'TTTz7Z1T)', (d, J = 8.8 Hz, 2H), 6.38 ( d, J = 8.8 Hz, 2 H), 7.08 - 7.13 (m, 4 H), - 7.34 (m, 2 H), 7.45 - 7.51 (m, 4 H), 8.27 (d, J = 1.2 Hz, 1 H), (s, 2H).
MS m / z 854.4 (M + H)<sup>+</sup>.
<img file="MX339989B_D0740.tif" />
EXAMPLE 93
U (2S, 5S) -1 -r4- (propan-2-¡l) fen¡Hp¡rrol¡d¡n-2.5-d¡-¡l) b¡s (bencen-4.1d¡-ilcarbamoyl (2S ) dimethyl p¡rrol¡din-2.1-d¡-iir (2S) -3-met¡ 1-1 -oxobutan-1,2-di-ylTDbiscarbamate
X (((2R, 5R) -1-í4- (propan-2-¡l) fen¡np¡rrol¡d¡n-2.5-d¡-yl) bis {benzene-4,1di-¡lcarbamo8l (2S ) P¡rrole idin-2.1-di-¡ir (2S) -3-meth¡ 1-1-oxobutan-1,2di-illDbIScarbamate dimethyl
The title compound is prepared as a mixture of trans diastereomers using the procedures described for the syntheses of Examples 34A, 34B, 34C, 34D, and 34E, substituting 4425
IMPI
INSTITUTO MEXICANO isopropylaniline by 4-tert-butylaniline. 'industrial
1H NMR (TFA salt) (400 MHz, DMSO-ΠΑ) 5 nnm 0 85 0.90 (m, J = 5.8, 5.8 Hz, 6 H), 0.90 - 0.96 (m, 6 H), 1.02 - 1.06 (m, 6H), 1.60 - 1.65 (m, 2H), 1.81 - 2.04 (m, 8H), 2.08 - 2.19 (m, 2H), 2.56 - 2.65 (m, 1H) „3.52 (s, 6H ), 3.58 - 3.66 (m, 2H), 3.76 - 3.85 (m, 2H), 4.02 (t, J = 8.3 Hz, 2H), 4.40 - 4.45 (m, 2H), 5.14 (d, J = 6.5 Hz, 2H), 6.15 - 6.20 (m, 2H), 6.79 (d, J = 8.7 Hz, 2H), 7.09 - 7.16 (m, 4H), 7.29 - 7.34 (m, 2H) , 7.47-7.52 (m, 4H), 9.97 (s, 2H).
MS m / z 880.5 (M + H)<sup>+</sup>.
<img file="MX339989B_D0741.tif" />
<img file="MX339989B_D0742.tif" />
EXAMPLE 94 í (2S) -1-H2S) -2- (4- <4-r (2S.5S) -1- (4-fluorophenin-5- (4- (2-r (2S) -1 -n2S) 2-r (methoxycarbon¡l) am¡no1-3,3-d¡methylbutane¡Rp¡rrolid¡n-2-¡H-1 Himidazol-4-¡l> feninp¡rrolidin-2-yl1fenii) Methyl -1 H-imidazol-2-yl) pyrrolidin-iH-3,3-dimethyl-1-oxobutan-2-l) carbamate
AND.
f (2S) -1-r (2S) -2- (4-I4-n2R, 5R) -1-í4-fluorophenyl) -5- (4-f2-R2S) -1 - {(2S) 2 -Rmethoxycarbonyl) aminol-3,3-dimethylbutanoyl) p¡rrolidin-2-¡ll-1 H¡midazol-4-yl) phenyl) p¡rrolidin-2-¡l1phenyl} -1 H- Methyl dazol-2-yl) pyrrolidin-iH-3,3-dimethyl-1-oxobutan-2-yl} carbamate
426
<img file="MX339989B_D0743.tif" />
IMPI
The product from Example 45D (28 mg, O.ISWj ^ moígs is subjected to the conditions described in Example 45E, substituting (S) -2- (methoxycarbonylamino) -3,3-dimethylbutanoic acid for (S) 2- ( methoxycarbonylamino) -3-methylbutanoic, to obtain the title compound (18 mg, 41%) as a mixture of diastereomers.
1H NMR (TFA salt) (400 MHz, DMSO-D6) δ ppm 0.86 (s, 9H), 0.87 (s, 9H), 1.70 - 1.81 (m, 2H), 1.94 - 2.25 (m, 6 H), 2.34-2.44 (m, 2H), 3.55 (s, 6H), 3.72-3.95 (m, 4H), 4.19 (d, J = 8.7 Hz,
H), 5.09 (t, J = 7.2 Hz, 2 H), 5.35 (d, J = 6.1 Hz, 2 H), 6.26 (dd, J = 9.1,
4.4 Hz, 2 H), 6.81 (t, J = 8.9 Hz, 2 H), 7.29 (d, J = 8.0 Hz, 2 H), 7.37 (d,
J = 7.2 Hz, 4H), 7.68 (dd, J = 7.8, 5.4 Hz, 4H), 7.97 (s, 2H), 14.46 (br s, 2H).
MS m / z 930.8 (M + H)<sup>+</sup>.
<img file="MX339989B_D0744.tif" />
H2S) -1-n2S) -2- (4-f4-r (2S, 5SM- (4-cyclopropylphenyl) -5- (4- <2-r (2S) -1f (2S) -2-nmethoxycarbon ¡L) am¡no1-3-met¡lbutanoi Dpi rrol ¡di n-2-¡11-1Himidazol-4-infhenyl) pyrrole idin-2-illfenii) -1 H-imidazol-2-yl) pyrrolid¡n1- L1-3-methyl-1-oxobutan-2-yl) methyl carbamate
427
<img file="MX339989B_D0745.tif" />
IMPI
INSTITUTO MEXICANO oelaitofiioao y INDUSTRIAL f (2S) -1- | ~ (2S) -2- (4- (4-r (2R.5R) -1- (4-cyclopropylfeni + F-6 (1 f2 R2SM— f (2S) -2-r (methoxycarbon¡ham i no1-3-methylbutanoyl} p¡rrolidi n-2-ill-1 H¡m¡dazol-4-¡l) fen i I) pyrrol ¡din- 2-¡l1phenyl} -1 H-im ¡dazoI-2-i Dpi rrolidi n1-¡Π-3-methyl-l-oxobutan-2-yl> methyl carbamate
EXAMPLE 95A (S) -4,4 '- (4,4' - ((2R, 5R) -1 - (4-cyclopropylphenyl) pyrrolidin-2,5-diyl) bis (4,1-phenylene)) bis (2 - ((S) -pyrrolidin-2-yl) -1 H-imidazole)
Ϊ.
(S) -4.4 '- (4,4' - ((2S, 5S) -1- (4-cyclopropylphenyl) p¡rrol¡d¡n-2,5-d¡yl) bis (4.1 -phenylene)) bis (2 - ((S) -pyrrolidin-2-ii) -1 H-imidazole)
The product from Example 68C (1.27 g, 1568 mmol) is dissolved in dichloromethane (12 ml). The mixture is cooled to 0 ° C and trifluoroacetic acid (8 ml, 104 mmol) is added slowly. The mixture is warmed to room temperature and stirred for 1 hour. The solvent is evaporated and the residue is purified by chromatography on silica gel eluting with methanol / dichloromethane (1% to 10%). The title compound elutes as the first of 2 stereoisomers and is obtained as a mixture of trans diastereomers (510 mg, 53%).
428
EXAMPLE 95B
IMPI
INSTITUTO MEXICANO DE lA FEOfiíOA »tK & JSTíilAL
<img file="MX339989B_D0746.tif" />
((2S) -1-I (2S) -2- (4-I4-r (2S, 5S) -1- (4-cyclopropylfer> N) -5- (4- {2-r (2S) -1f (2S) -2-r (methoxy carbon i ham i nol-3-m eti Ibutanoyl Ipyro lid i η-2-i 11-1H¡m¡m¡dazol-4-ylIphenyl) pyrrolid¡n-2-¡l1phenylI-1 Methyl Hi midazol-2-yl) pyrrolid i n1 -yl1-3-methyl-1-oxobutan-2-ylIcarbamate
Y í (2S) -1-r (2S) -2- (4-f4-r (2R, 5R) -1- (4-cyclopropiiphenyl) -5- (4- {2-r (2S) -1 ( (2S) -2-r (methoxycarbonyl) aminoI-3-methylbutanoi IIpyrrolidin-2-¡n-1 Him¡dazol-4-ylIphenyl) pyrrolidin-2-yl1phenylI-1H-imidazol-2-yl) pyrrolidin1 - methyl ill-3-methyl-l-oxobutan-2-ylIcarbamate
The product of Example 95A (150 mg, 0.246 mmol), (S) -2- (methoxycarbonylamino) -3-methylbutanoic acid (86 mg, 0.492 mmol), 4-methylmorpholine (0.216 ml, 1.968 mmol), hydrochloride of N1- ((ethylimino) methylene) -N3, N3-dimethylpropan-1,3-dimine (104 mg, 0.541 mmol) and 1 H-benzo [d] [1,2,3] triazol-1-ol hydrate (83 mg, 0.541 mmol) are combined in DMF (10 ml). The mixture is stirred at room temperature for 2 hours. The reaction mixture is partitioned between ethyl acetate and water. The organic layer is washed with saturated sodium bicarbonate, brine twice, dried over sodium sulfate, filtered, and evaporated. The residue is purified by chromatography on silica gel eluting with methanol / dichloromethane (1% to 4%) to obtain the title compound (78 mg, 34%) as a solid.
1H NMR (400 MHz, DMSO-D6) δ ppm 0.35 - 0.41 (m, 2H)
<img file="MX339989B_D0747.tif" />
429
ΙΜΡΙ
MEXICAN INSTITUTE
0.65 - 0.72 (m, 2H) 0.81 - 0.92 (m, 12H) 1.58 - 1.64 (^ «$ 3 ·
I. 72 (m, 2H) 1.86 - 2.03 (m, 6H) 2.07 - 2.17 (m, 4H) 2.24 - 2.30 (m, 2H) 3.53 (s, 6H) 3.74 - 3.82 (m, 4 H) 4.04 (t, J = 7.86 Hz, 2H) 5.06 (dd, J = 6.72, 2.93 Hz, 2H) 5.14 - 5.26 (m, 2H) 6.19 (d, J = 8.67 Hz, 2H) 6.64 (d, J = 8.24 Hz, 2H) 7.10 - 7.30 (m, 6H) 7.34 - 7.69 (m, 6H)
II. 64-12.11 (m, 2H).
MS (ESI +) m / z 924.8 (M + H) +.
<img file="MX339989B_D0748.tif" />
EXAMPLE 96 (r (2R, 5R) -1- (4-cyclopropylphenyl) p¡rrolid8n-2,5-di-illbisfbencen-4.1di-ylcarbamoyl (2S) pyrrolid8n-2.1-di-ylF (2S) -3-meth -1-oxobutan-1,2d¡-¡IT)) dimethyl b¡scarbamate
Example 38A and 4-cyclopropylaniline are processed sequentially using the methods of Examples 34A, 34B, 34C, 66D, and 66E to provide the title compound (62 mg).
<sup>1</sup>H NMR (400 MHz, DMSCW<sub>6</sub>) δ 0.36 - 0.46 (m, 2 H) 0.63 0.77 (m, 2 H) 0.87 (d, J = 6.61 Hz, 6 H) 0.92 (d, J = 6.72 Hz, 6 H) 1.52 2.46 (m, 15 H ) 3.52 (s, 6H) 3.57 - 3.66 (m, 2H) 3.75 - 3.85 (m, 2H)
430
ΙΜΡΪ
<img file="MX339989B_D0749.tif" />
MEXICAN INSTITUTE
4.02 (t, J = 8.46 Hz, 2H) 4.42 (dd, J = 8.02, 4.88 Hz, 2 * Ίί39ίΜ4 J = 6.40 Hz, 2H) 6.14 (d, J = 8.78 Hz, 2H) 6.65 (d. J = 8.67 Hz, 2 H)
7.10 (d, J = 8.57 Hz, 4H) 7.30 (d, J = 8.35 Hz, 2H) 7.48 (d, J = 8.57 Hz, 4H) 9.97 (s, 2H).
MS (APCI) m / z 878 (M + H)<sup>+</sup>.
<img file="MX339989B_D0750.tif" />
EXAMPLE 97 f (2S) -1-r (2S.4S) -2-f5-H2S.5S) -1- (4-fluorophenyl) -5- (2-H2S, 4S) -4hydroxy-1-if2S ) -2-rfmethoxycarbonyl) amino-3-methylbutanoiDpyrrolidin-2-i Π-1 H-benzim idazol-5-i Dpi rrolid i η-2-i Π1 H-benzimidazol-2-iD-4-h id roxy pyrrolidi n-1-iH-3-methi 1-1-oxobutan-2-l) methyl carbamate or
AND.
ph2S) -1-rí2S.4S) -2-f5-rí2R, 5R) -1-í4-fluorophenyl) -5- (2-rí2S.4S) -4-hydroxy-1 - ((2S) -2-f (methoxycarbonyl ) aminoT-3methylbutanoi Dpi rrol ¡din-2-II1-1 H-benzim¡dazol-5-¡Pp¡rrol¡din-2-¡11H-benzimidazol-2-iD-4-hydroxypyrrolidin-1-ill-3 methyl-1-oxobutan-2-P-carbamate
431
<img file="MX339989B_D0751.tif" />
IMPI
MEXICAN INSTITUTE OF INDUSTRIAL PROPERTY
<img file="MX339989B_D0752.tif" />
EXAMPLE 97A
(2S.4S) -1- (tert-butoxycarbonyl) -4- (terbuti Idimeti Isi liloxy) pyrole idi η-2-carboxylic acid
(2S, 4S) -1- (tert-butoxycarbonyl) -4-hydroxypyrrolidine-2-carboxylic acid (5.31 g, 22.96 mmol) and imidazole (7.82 g, 115 mmol) are combined in dichloromethane (106 ml) and dimethylformamide (22 ml). ) at room temperature and treated with portionwise addition of tert-butylchlorodimethylsilane (7.61 g, 50.5 mmol). The mixture is stirred for 18 hours then diluted with water and extracted with ethyl acetate and concentrated to provide the title compound.
EXAMPLE 97B
The product from Example 29D (0.906 g, 2.62 mmol) is processed as in Examples 29E, 29F, 29G, and 29H, substituting S-Boc-proline for Example 97A in step 29E to obtain the title compounds (0.012 g , 13%).
1H NMR (400 MHz, DMSO-D6) δ ppm 0.69 - 0.85 (m, 12H) 1.27 - 1.39 (m, 1H) 1.53 (dt, J = 21.31, 6.64 Hz, 1H) 1.71 (s, 4H )
1.80 - 1.90 (m, 2H) 2.02 (d, J = 7.70 Hz, 2H) 2.54 - 2.62 (m, 2H) 3.53
432
IMPI
INSTITUTO MEXICANO DE LA TRCflEDAD INDUSTXIAi.
<img file="MX339989B_D0753.tif" />
IIiLpUD i JUAjL (s, 6H) 3.68 (t, J = 10.63 Hz, 2H) 3.93 - 4.00 (m, 2H) 4.39 (s, 2H)
5.13 (s, 2H) 5.38 (s, 2H) 6.19 - 6.38 (m, 4H) 6.74 (d, J =? .8O Hz, '7H) 7.08 (s, 2H) 7.21 - 7.36 (m , 4H) 7.40-7.51 (m, 2H) 12.21 12.38 (m, 2H).
MS TFA + m / z 882.5 (M + H) +.
or
N
<img file="MX339989B_D0754.tif" />
EXAMPLE 98 (Í (2R, 5R) -1 -r4- (morphol ¡η-4-i Ufe ni Hp¡ rrolidi n-2,5-d¡-i llbisfbenc n4.1 -d¡-¡lcarbamoyl (2S) p¡rrol¡din-2.1-d¡-¡ir (2S) -3.3-d¡ meth 1-1 oxobutan-1,2-di-yl1>) dimethyl b¡scarbamate
EXAMPLE 98A
4- (4 - ((2R, 5R) -2,5-bls (4-ni trofeni Dpi rrol ¡di n-1 -ll) phen¡ Dmorpholine
The product from Example 38A and 4-morpholinoaniline are processed using the method described in Example 1D using NMP for the solvent to obtain the title compound.
MS (ESI) m / z 475 (M + H)<sup>+</sup>.
433
EXAMPLE 98B iMPir
INSTITUTO MEXICANO CE LA ».ΟΠ £ ΡΛΙ»
INiXiSTSIAI.
<img file="MX339989B_D0755.tif" />
4,4'-í (2 R, 5R) -1-í4-morpholinophen¡l) p¡rrolidi n-2,5-d¡-¡l Idianiline ^
The product from Example 98A in tetrahydrofuran (20 ml) is added to Ra-Ni (wet with water, A-7000, 0.8 g, 12.63 mmol) in a 50 ml pressure bottle and stirred for 2 hours at room temperature under 2.11 kg / cm<sup>2</sup> hydrogen. The mixture is filtered through a nylon membrane and concentrated to obtain the title compound (0.31 g, 44%).
MS (DCI) m / z 415 (M + H)<sup>+</sup>.
EXAMPLE 98C (2S, 2<sup>,</sup>S) -2.2<sup>,</sup>- (4.4 '- ((2R.5R) -1 -f4-morphoiinophenyl) pyrolidi n-2,5-diyl) bis (4,1-phenylene)) b¡síazand¡-¡Dbis (oxomethien ) tert-butyl dipyrroledin-1 carboxylate
The product of Example 98B is processed using sequentially the methods of Examples 55F, 55G, and 26J (with (S) -2- (methoxycarbonylamino) -3,3-dimethylbutanoic acid) to obtain the compound of titer (0.13 g).
H NMR (400 MHz, DMSO-D6) δ 0.93 (d, J = 20.5, 17H),
1.92-1.79 (m, 4H), 2.05-193 (m, 3H), 2.21-2.08 (m, 2H), 2.43 (t, J = 6.1, 3H), 2.84-2.75 (m, 4H), 3.54 (s , 6H), 3.68-3.58 (m, 6H),
3.83-3.70 (m, 2H), 4.20 (d, J = 8.9, 2H), 4.43 (dd, J = 7.9, 5.3, 2H),
5.12 (d, J = 6.3, 2H), 6.17 (d, J = 9.1, 2H), 6.60 (d, J = 9.1, 2H), 7.07
434 (d, J 2H).
8.8, 2H), 7.11 (d, J = 8.5, 4H), 7.48 (d, J
IMPI
<img file="MX339989B_D0756.tif" />
Impurity:
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ 1.63 (d, J = 5.6, 2H), 3.17 (d, J = 5.3, 3H), 4.09 (q, J = 5.3, 1H).
MS (ESI) m / z 952 (M + H +).
<img file="MX339989B_D0757.tif" />
(r (2S, 5S) -1- (4-r6- (dimethylamno) pyrid¡n-3-¡Hphenyl) pyrrol¡d¡n-2.5-d¡illbis {benzene-4.1 -d ¡-¡Lcarbamo¡l (2S) p¡rrolidin-2,1-d¡-¡IH2S) -3-methyll1-oxobutan-1,2-d¡-¡l1)) dimethyl b¡scarbamate
Ϊ.
(f (2R.5R) -1- {4-r6- (d¡met¡lam¡no) p¡r¡din-3-¡Hfen¡l) p¡rrol¡d¡n-2,5-d 20 ¡llbisfbencen-4,1 -di-ylcarbamoyl (2S) pyrrolidin-2,1 -dl-iir (2S) -3-m tyl1-oxobutan-1,2-d¡-¡n)) blscarbamate dimethyl
EXAMPLE 99A
5- (4- (2.5-bis (4-nitrophenyl) pyrrol¡d¡n-1-¡l) f nil) -N, Nd¡met¡lp¡r¡din-2 «
435 amine
IMPI
MEXICAN INSTITUTE OF INDUSTRIAL PROPERTY
<img file="MX339989B_D0758.tif" />
The product from Example 86A (25.7 mg, 0.055 mmol) is combined in a microwave tube with 6- (dimethylamine) pyridin-3-ylboronic acid (17.49 mg, 0.105 mmol), potassium tribasic phosphate (24.70 mg, 0.116 moles) and palladium 1,1'-bis (di-tert-butylphosphino) ferrocene dichloride (2,504 mg, 3.84 pmol). The tube is sealed and a solvent mixture of THF (2 ml) and water (0.6 ml) is added by syringe. The reaction mixture is sparged with nitrogen at room temperature for three minutes during which time the solution turns black. Chromatographic analysis indicates that the reaction is complete. The contents of the microwave tube are partitioned between brine (3 ml) and ethyl acetate (3 ml). The water is extracted and the organic phase is dried with MgSO<sub>4</sub>, filter and concentrate. The crude product is purified by silica gel chromatography from 2 to 20% ethyl acetate in hexane to provide the title compound (26.8 mg, 96% yield) as an orange solid as a mixture of stereoisomers.
MS ESI (+) m / z @ 510.4 (M + H) +.
EXAMPLE 99B
4,4 '- (1- (4- (6- (d¡met¡ lam¡no) p¡r¡d¡n-3-¡l) phenyl) p¡ rrolidi n-2,5-d¡¡ hdianiline
The product from Example 99A (26.8 mg, 0.053 mmol) was
<img file="MX339989B_D0759.tif" />
436
IMPI
INSTITUTO MEXICANO DE LA FROPIEDAD dissolves in THF (526μΙ) in a round bottom flask. Bi ^ Wíl subsequently adds ethanol (526 μΙ) which gives a yellow precipitate as a result. Platinum (IV) oxide (3.16 mg, 0.014 mmol) is added to this suspension. The flask is capped with a septum and the contents are degassed under vacuum three times. Hydrogen is introduced by balloon and the mixture is allowed to stir at room temperature for two and a half hours. The reaction mixture is vacuum filtered through a plug of sand and celite, which is rinsed with THF and methanol until the filtrate is uv (-). The filtrate is concentrated in vacuo to provide the title compound in quantitative yield as a white solid as a mixture of stereoisomers.
MS ESI (+), m / z @ 450.7 (M + H) +.
EXAMPLE 99C (2S, 2<sup>,</sup>S) -2.2<sup>,</sup>- (4.4 '- (1- (4- (6- (dimethylamino) pyridin-3-yl) phenyl) pyrrolidin-2,5-di-yl) bis (4.1-phenylene)) bis (azandiII) bis (oxomethylene ) di pyrrole id tert-butyl n-1-carboxylate
The product from Example 99B (23.83 mg, 0.053 mmol) is reacted with (S) -1- (tert-butoxycarbonyl) pyrrolidin-2-carboxylic acid (27.8 mg, 0.129 mmol) as described in Example 1F with minor modification. The crude product is recovered by partitioning the reaction mixture between ethyl acetate (10 ml) and water (3 ml). The organic phase is washed with water (3x3 ml), dried
437
<img file="MX339989B_D0760.tif" />
MEXICAN INSTITUTE
OF THE 2ROEIED.AD. , λ.
in gertodeiAilit with MgSO<sub>4</sub>, filter and concentrate. Chromatography using a 2-100% Ha otyl ρπ hexane solvent gradient provides the title compound (32.6mg, 73% yield) as a cream colored solid as a mixture of stereoisomers.
EXAMPLE 99D (2S, 2'S) -N, N '- (4.4<sup>!</sup>- (1- (4- (6- (dimethylamno) p¡r¡d¡n-3¡l) phenyl) pyrrole ¡d¡n-2,5-di-¡l) bis ( 4,1 -phenylene)) dipyrrolidin-2carboxamide
The product from Example 99C (32.6 mg, 0.039 mmol) is reacted with trifluoroacetic acid (0.071 ml, 0.927 mmol) as described in Example 1G to provide the title compound (22.5 mg, 90% yield) as a solid. cream colored as a mixture of stereoisomers.
EXAMPLE 99E (í (2S, 5S) -1 -f4-f6- (dimethylamine) p¡r¡d¡n-3-¡l1phenyl) p¡rrol¡din-2,5-diylbisf benzene-4 Dimethyl, 1 -di-¡lcarbamo¡l (2S) p¡rrolidi n-2,1 -di-i li (2S) -3-m tyl-1-oxobutan-1,2-di-iH)) biscarbamate
AND.
(r (2R, 5R) -1-f4-f6- (dimethylamino) pyridin-3-imphenyl) pyrrolidin-2,5-diyl bis (benzene-4,1-di-alcarbamoil (2S) pyrrol¡d¡ n-2,1-di-i li (2S) -3-m tyl1-oxobutan-1,2-di-¡H)) dimethyl biscarbamate
438
IMPI *
MEXICAN INSTITUTE
The product of Example 99D (22.5 mg, 0.03?><sup>AND</sup> mwwí 's) reacts with (S) -2- (methoxy-carbonyllamine) i 3 <methylbutanoic acid (19.41 mg, 0.111 mmol) as described in Example 86C. Chromatography on silica gel (10% ethyl acetate / 90% hexane to 100% ethyl acetate / 4% methanol) provides the title compound (14.5 mg, 43.3% yield), a yellow solid. -orange that darkens a bit on standing, like a 1: 1 mixture of trans diastereomers.
1H NMR (400 MHz, DMSO-D6) δ ppm 0.77 - 0.99 (m, 12H) 1.67 (s, 2H) 1.76 - 2.24 (m, 11H) 2.98 (s, 6H) 3.52 (s, 6H ) 3.58 - 3.65 (m, 2H) 3.76 - 3.90 (m, J = 9.54 Hz, 2H) 3.95 - 4.11 (m, 2H)
4.36 - 4.47 (m, 2H) 5.19 - 5.27 (m, 2H) 6.30 (s, 2H) 6.58 (d, J = 9.00 Hz, 1H) 7.17 (t, J = 8.08 Hz, 4H) 7.30 (d, J = 8.02 Hz, 3H) 7.52 (d, J = 7.37 Hz, 4H) 7.57 - 7.63 (m, 1H) 7.63 - 7.68 (m, 1H) 7.91 (s, 1H)
8.18 - 8.22 (m, 1H) 10.00 (s, 2H).
MS ESI (+) m / z @ 959.4 (M + H) +.
<img file="MX339989B_D0761.tif" />
<img file="MX339989B_D0762.tif" />
EXAMPLE 100 f <f 2R, 5R) -1-r4- (methyls ulfoni Dfeni II pyrrolidi n-2,5-di-i Rbisfbenc n4,1-di-ylcarbamoi l (2S) pyrrole idi n-2,1- di-i ir (2S) -3,3-dim til-1439
IMPI oxobutan-1,2-d¡-¡ID) b¡scarbamate of
INDUSTRIAL
<img file="MX339989B_D0763.tif" />
Example 38A and 4- (methylsulfonic) aniline are processed sequentially using the methods of Examples 98A, 98B, 55F, 55G, and 26J (with (S) -2- (methoxycarbonylamino) - acid 3,3-dimethylbutanoic, reaction solvent = dichloromethane) to provide the title compound (55mg).
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ 0 96 (d, J = 5.1, 18H),
1.24 (s, 1H), 1.69 (d, J = 5.7, 2H), 2.04-1.74 (m, 7H), 2.22-2.07 (m, 2H), 2.98 (s, 3H), 3.54 (s, 6H), 3.70 - 3.58 (m, 2H), 3.83 - 3.70 (m, 2H), 4.20 (d, J = 8.9, 2H), 4.43 (dd, J = 7.8, 5.4, 2H), 5.32 (d, J = 6.1, 2H), 6.39 (d, J = 9.0, 2H), 7.08 (d, J = 8.8, 2H), 7.15 (d, J = 8.6, 4H),
7.43 (d, J = 9.0, 2H), 7.53 (d, J = 8.6, 4H), 10.03 (s, 2H).
MS (ESI) m / z 966 (M + Na)<sup>+</sup>, 943 (MH)<sup>+</sup>.
<img file="MX339989B_D0764.tif" />
EXAMPLE 101 (H2S, 5S) -1 -f4-r6- (tnorfol¡n-4-yl) pyridin-3-illphenyl) p¡rrol¡din-2,5-d¡¡IIb¡s (benzene- 4,1 -d¡-ylcarbamo¡l (2S) p¡rrol¡d¡n-2.1-di-iir (2S) -3-m til1-oxobutan-1,2-di-iITUbiscarbamate d dimethyl
440
<img file="MX339989B_D0765.tif" />
IMPI and INSTITUTO MEXICANO
DELA ΓΚΟΡΙΕΓΛΟ
INDUSTRIAL (r (2R, 5R) -1-f4-r6- (morpholin-4-yl) pyridin-3-infhenyl) p¡rrolid¡n-2,5-di¡llbisf benzene-4,1 -di dimethyl -i lcarbamoil (2S) pyrrolidin-2,1-di-iir (2S) -3-m til1-oxobutan-1,2-di-iHl) biscarbamate
Example 86A and 4- (5- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) pyridin-2-l) morpholine are processed sequentially using the methods of Examples 99A, 99B, 1F, 1G, and 86C to provide the title compound as a 1: 1 mixture of trans diastereomers.
1H NMR (free base) (400 MHz, DMSO-D6) δ ppm 0.78 1.00 (m, 12H) 1.67 (s, 2H) 1.75 - 2.20 (m, 11H) 3.36 - 3.41 (m, 4H)
3.52 (s, 6H) 3.57 - 3.65 (m, 2H) 3.65 - 3.72 (m, 4H) 3.79 (s, 2H) 4.02 (s, 2H) 4.36 - 4.48 (m, 2H) 5.24 ( s, 2H) 6.32 (d, J = 7.70 Hz, 2H) 6.78 (d, J = 9.00 Hz, 1H) 7.12 - 7.18 (m, 4H) 7.21 (d, J = 8.78 Hz, 2H) 7.31 (d, J = 8.35 Hz, 2H) 7.52 (d, J = 7.48 Hz, 4H) 7.63 - 7.69 (m, 1H) 8.22 - 8.27 (m, 1H) 10.00 (s, 2H).
<img file="MX339989B_D0766.tif" />
(f (2S, 5S) -1 -r4- (pyridin-3-yl) pheni II pyrrolidi n-2,5-di-yl) bisfbenc n-4,1441 di-ylcarbamoyl (2S) pyrrolidin-2.1 -di -iir (2S) -3-md¡-¡H »dimethyl b¡scarbamate
Ϊ.
OF INDUSTRIAL FROFITY
<img file="MX339989B_D0767.tif" />
ff (2R.5R) -1-r4- (pyridin-3-yl) phenyl1pyrrolidin-2,5-di-yl) bis {benzene-4,1d¡-ylcarbamoyl (2S) pyrrolidin- Dimethyl 2,1-di-¡ir (2S) -3-methyl-1-oxobutan-1,2d¡-iH)) biscarbamate
Example 86A and pyridin-3-ylboronic acid are processed sequentially using the methods of Examples 99A, 99B, 1F, 1G, and 86C to provide the title compound as a 1: 1 mixture of trans diastereomers (35.8 mg) .
1H NMR (free base) (400 MHz, DMSO-D6) δ ppm 0.71 1.05 (m, 11H) 1.68 (s, 2H) 1.87 (s, 8H) 2.06 - 2.21 (m, 2H) 3.52 (s , 6H) 3.56 - 3.67 (m, 2H) 3.80 (s, 2H) 4.02 (d, J = 1.73 Hz, 2H) 4.43 (dd, J = 7.97, 4.93 Hz, 2H) 5.26 (d, J = 6.29 Hz, 2 H) 6.37 (d, J = 7.92 Hz, 2 H) 7.17 (dd, J = 8.57, 1.95 Hz, 4 H) 7.28 - 7.36 (m, 5 H) 7.52 (d, J = 7.81 Hz, 4H) 7.82 - 7.87 (m, 1H) 8.36 (dd, J = 4.72, 1.36 Hz, 1H)
8.69 (s, 1H) 10.00 (s, 2H).
MS ESI (+) m / z @ 915.6 (M + H) +.
<img file="MX339989B_D0768.tif" />
442
EXAMPLE 103 r (2S.3SM - ((2S) -2-r5- (4-f (2S, 5SM- (4-tert-but¡lfen¡l) -5-r4- (2-f (2S) - 1fN- (methoxycarbonii) -Q-methyl-D-threonylpyrrolidin-2-yl> -1 H-imidazoT
IMPI
MF.XIC.AN INSTITUTE OF INDUSTRIAL RRORITY
<img file="MX339989B_D0769.tif" />
Methyl 5-¡Dphenyl pyrrole ¡din-2-¡l) phenyl) -1 H-imidazol-2-ιΠ p¡ rrol id ¡n-1-yl) -3-methoxy-1-oxobutan-2-ill carbamate
AND.
r (2S, 3S) -1-í (2S) -2-r5- (4-K2R.5R) -1- (4-tert-butylphenyl) -5-r4- (2 - <(2S) - 1rN- (methoxycarbonyl) -O-methyl-D-threon¡Hpyrrolidin-2-¡II-1H-imidazol5-i Dphenyl pyrrole idi n-2-yl} fen¡D-1 H-im¡dazol-2-8llpyrrolidin- Methyl 1-l-3-methox-1-oxobutan-2-l-carbamate
The product from Example 201A (0.122 g, 0.639 mmol), and HOBt (0.098 g, 0.639 mmol) are combined and dissolved in 2 ml of DMF then cooled in an ice bath at 0-5 ° C. EDAC (0.123 g, 0.639 mmol) is added to this solution followed by 4-methylmorpholine (0.211 ml, 1.917 mmol) and the mixture is stirred for 5 minutes, then the mixture of the products of Example 42F (0.2 g, 0.320 mmol) is added dropwise ), in DMF (2 ml) with a DMF wash (1 ml). The pH of the solution is adjusted with additional 4-methylmorpholine (0.1 ml, 0.96 mmol) and the mixture is stirred for a total of 90 minutes in the ice bath. The reaction mixture is analyzed by LC-MS at 90 minutes and the reaction is determined to be complete. The reaction mixture is diluted with 100 ml of EtOAc and washed with 25 ml of water. The layers are separated and the aqueous layer is extracted with another 100 ml of EtOAc. Organic extracts
443
<img file="MX339989B_D0770.tif" />
combined are washed with NaHCO<sub>3</sub> 10% and NaGI IM / P4
MEXICAN INSTITUTE OF PROPERTY with Na<sub>2</sub>SW<sub>4</sub>(s) are anhydrous, filtered and the solvent is removed by leaving a purple oil. The oil fell on 10 days CH<sub>2</sub>CI<sub>2</sub> and applied to a 12 g column of silica gel. The column is eluted with a gradient of CH<sub>2</sub>CI<sub>2</sub>/ MeOH, 99/1 to 95/5 over 25 minutes. The title compounds are isolated as a light yellow solid, 60mg, 19%.
1H NMR (400 MHz, DMSO-D6) d ppm 0.86 (m, 2H) 1.00 1.18 (m, 15H) 1.27 (m, 2H) 1.70 (m, s H) 1.99 (m, 2H) 2.15 (m , 4 H)
3.18 (d, J = 10.08 Hz, 6H) 3.54 (s, 6H) 3.81 (m, 4H) 4.27 (m, 2H) 5.06 (m, 2H) 5.21 (d, 2H) 6.21 (d , 2H) 6.94 (d, 2H) 7.17 (d, 2H)
7.29 (d, 2H) 7.38 (d, J = 1.73 Hz, 2H) 7.51 (d, 2H) 7.62 (d, J = 8.02 Hz, 2H) 11.68 (s, 2H), 12.01 (m, 2H).
ESI +: 972.6.
<img file="MX339989B_D0771.tif" />
EXAMPLE 105 ((2S) -1-n2S) -2- (3-f4-r (2S, 5S) -1- (4-tert-but¡lfen¡l) -5- (4-f5-H2S) - 1 ((2S) -2-f (methoxycarbonyl) amine nol-3-methyl butanoi Dpi rrolidi n-2-¡D-1 Hpyrazol-3-¡Df ni Dpi rrolidi η-2-i llf ni D-1 H-pyrazol-5-yl) pyrolidi n-1 444
<img file="MX339989B_D0772.tif" />
¡H-3-methyl-1-oxobutan-2-yl) carbamate dt ^ rijVfil | p J
INSTITUTO MEXICANO DE LA FΡ.ΟΓ51 DAD y INDUSTRIAL {(2S) -1-H2S) -2- (3-f4-K2R, 5R) -1- (4-ter-but¡lfen + H - $ - 444C-r (2S) .l - ((2S) -2-r (methoxycarbonyl) am¡no1-3-methylbutane¡l) p¡rrol¡d¡n-2-iH-1Hp¡ razol-3-¡ Ufen ¡Dpi rrol idi n-2-illfen ¡l) -1 H-pyrazole-5-¡Dpi rrol ¡di n-1¡Π-3-methyl-l-oxobutan-2-yl) methyl carbamate
EXAMPLE 105 A
1- (4-tert-buti Ifeni l) -2.5-b¡s (4 - ((trimetiisii¡l) et¡ ni Dfeni I) pyrrole ¡dine
To an oven-dried microwave tube (Size M, 5 ml) purged with nitrogen, add the product of Example 42C (340 mg, 0.662 mmol), bis (triphenylphosphine) palladium (ll) dichloride (18.60 mg, 0.026 mmol ), THF (2 ml), and triethylamine (2 ml). Stir at room temperature for 5 minutes, then add copper (L) iodide (2.52 mg, 0.013 mmol), the yellow mixture is stirred for 2 minutes, then bubble nitrogen through it for 15 minutes. Trimethylsilylacetylene (0.374 ml, 2.65 mmol) is added, the tube is sealed with an aluminum fold-over cap, and heated in an oil bath at 70 ° C for 20 hours. The reaction is cooled to room temperature, fresh bis (triphenylphosphine) palladium (ll) dichloride (18.60 mg, 0.026 mmol) and copper (l) iodide (2.52 mg, 0.013 mmol) are added, additional trimethylsilylacetylene (0.374 ml) is added. 2.65 mmol), and heating is continued at 80 ° C for 24 hours. The
445
<img file="MX339989B_D0773.tif" />
Reaction is cooled to room temperature, (50 ml), washed with H<sub>2</sub>O (2 x 25 ml) and organic brine dried over MgSO<sub>4</sub> anhydrous, fixed, - and concentrated by rotary evaporation to a light tan foam (470 mg). Purify by flash chromatography (silica gel, 2.5 cm x 10 cm, 2% Et<sub>2</sub>0 / hexanes) to obtain the title product as a yellow foam (324 mg, 89%) as a mixture of stereoisomers.
MS (ESI +) m / z 548 (M + H)<sup>+</sup>.
EXAMPLE 105B
1- (4-tert-butüphenyl) -2,5-b¡s (4-eth¡n¡lfen¡l) pyrrole¡d¡na
The product from Example 105A (322 mg, 0.588 mmol) is dissolved in anhydrous THF (5 ml) under nitrogen, 1 M TBAF in THF (1.322 ml, 1322 mmol) is added, and stirred at 25 ° C for 30 minutes. The reaction darkens immediately after addition and remains brown throughout the reaction. The solvent is removed by rotary evaporation, the residue is dissolved in Et<sub>2</sub>O (50 mi), wash with H<sub>2</sub>O (2 x 25 ml) and brine (25 ml), the organic phase is dried over MgSO<sub>4</sub> anhydrous, filtered, and concentrated by rotary evaporation to a light tan foam (289 mg). Purify by flash chromatography (silica gel, 3.8 cm x 14 cm, 20% CH<sub>2</sub>CI<sub>2</sub>/ hexanes) to the title compound as a foam of
446 light yellow color (176 mg, 74%) stereoisomers.
com
ΊΜΡΤ
INSTITUTO MEXICANO ¡> e LA INDUSTRIAL PROPERTY
<img file="MX339989B_D0774.tif" />
MS (ESI +) m / z 404 (M + H)<sup>+</sup>.
EXAMPLE 105C is) -3.3 '- (4.4' - (1- (4-tert-butylphenyl) p¡rrolid¡n-2,5-di-¡l) b¡s (1 - ( 4,1 phenylene)) bis (1 - (N-Boc- (S) -pyrrolidin-2-yl) prop-2-in-1 -one
In a flame-dried 10 ml round bottom flask, dissolve the product from Example 105B (94.3 mg, 0.234 mmol) in anhydrous THF (2 ml) under nitrogen and cool to 78 ° C, slowly add n- 1.6 M BuL¡ in hexanes (0.365 ml, 0.584 mmol) by dropping through a gas-tight syringe, and the yellow-green solution is stirred for 1 hour at -78 ° C. In a separate flame-dried 10 ml round bottom flask, purged with nitrogen, prepare a solution of N- (tert-butoxycarbonyl) -1-proline N'-methoxy-N'-methylamide (166 mg, 0.631 mmol) in Anhydrous THF (1 ml), and cool to -78 ° C. Add the dianion mixture dropwise through a gas-tight syringe equipped with a 16-gauge needle to the Weinreb's amide solution and stir at -78 ° C for 30 minutes, the dry ice-acetone bath is replace with an ice-water bath, and stir at 0 ° C for 1 hour. Remove the cooling bath and stir at room temperature for 1 hour, the cloudy yellow mixture turns into a dark yellow solution. The
447 reaction is stopped with NH<sub>4</sub>Aqueous CI saturated «j (^ | -np, js with Et<sub>2</sub>O (2 x 25 mi), the ethereal extracts comtíYFTSa2) ÍSwSéíS! 9a
INDUSTRIAL
<img file="MX339989B_D0775.tif" />
H<sub>2</sub>O (2 x 25 ml) and brine (25 ml), the organic phase is dried over MgSO<sub>4</sub> anhydrous, filtered, and concentrated by rotary evaporation to a yellow oil (214 mg). Purify by flash chromatography (silica gel, Alltech Extract-Clean 10 g column, 5% to 7% EtOAc / CH gradient<sub>2</sub>CI<sub>2</sub>) to obtain the title compound as a yellow solid (77 mg, 41%) as a mixture of stereoisomers.
MS (ESI +) m / z 798 (M + H)<sup>+</sup>, 1595 (2M + H)<sup>+</sup>.
EXAMPLE 105D (2S.2'S) -2.2<sup>,</sup>-(3.3<sup>,</sup>-f4.4<sup>,</sup>- (1- (4-tert-butylphenyl) pyrrolidin-2,5-diyl) bisph4.1-phenylene)) bisph1H-pyrazoI-5.3-di-iD) dipyrrolidine-1-carboxylate
The product of Example 105C (75 mg, 0.094 mmol) is dissolved in anhydrous absolute EtOH (1 ml) under nitrogen, hydrazine hydrate (0.023 ml, 0.235 mmol) is added, and the yellow solution is stirred at room temperature for 1 hour. The solvent is removed by rotary evaporation, the yellow oil is subjected to azeotropic distillation with toluene (2x5 ml), can be dissolved in CH<sub>2</sub>CI<sub>2</sub>/ hexanes 1: 5 v / v, concentrate, and the light yellow solid is dried in vacuo. Purify by flash chromatography (silica gel, 2.5 cm x 15 cm, 4%
448
MeOH / CH<sub>2</sub>CI<sub>2</sub>) to obtain the title compound
<img file="MX339989B_D0776.tif" />
<img file="MX339989B_D0777.tif" />
4EWÍANC DELA INDUSTRIAL PROPERTY
<img file="MX339989B_D0778.tif" />
white (59 mg, 76%) as a mixture of stereoisomers.
MS (ESI +) m / z 826 (M + H) +, 848 (M + Na)<sup>+</sup>.
EXAMPLE 105E (S) -3.3<sup>,</sup>-i4.4<sup>,</sup>- (1- (4-tert-butylphenyl) pyrrolıdin-2.5-di-yl) bis (4.1phenyl)) b¡s (5 - ((S) -pyrrol idi n-2-¡ l) -1 H-pyrazole
The product from Example 105D (57.5 mg, 0.070 mmol) is dissolved in CH<sub>2</sub>CI<sub>2</sub> anhydrous (2 ml) under nitrogen, add TFA (1 ml, 12.98 mmol), and stir at 25 ° C for 30 minutes. The solvent is removed by rotary evaporation, the residue is dissolved in CH<sub>2</sub>CI<sub>2</sub>/ hexanes 1: 5 v / v, concentrate to a yellow residue, and dry in vacuo (83 mg). The TFA salt is dissolved in anhydrous MeOH (7 ml) under nitrogen, treated with Amberlite IRA-400 (OH) resin (750 mg, -15 equivalents of OH 'based on -1.4 mequivalents / g of dry resin ) pre-washed (H<sub>2</sub>O and MeOH) and dry and stir at 25 ° C for 2 hours. The resin is vacuum filtered on a Büchner funnel and washed thoroughly with MeOH. The filtrate is concentrated by rotary evaporation, the residue is dissolved in CH<sub>2</sub>CI<sub>2</sub>/ hexanes 1: 5 v / v, and concentrate in vacuo to obtain the title compound as a light yellow solid (41 mg, 94%) as a mixture of stereoisomers.
MS (ESI +) m / z 626 (M + H)<sup>+</sup>, 1251 (2M + H)<sup>+</sup>.
449
IMPI
EXAMPLE 105F
INSTITUTO MEXICANO ((2S) -1-r (2S) -2- (3- (4-f (2S, 5S) -1- (4-tert-butylfhenyl) -5-r4 ^ ggfí, ^ 5
<img file="MX339989B_D0779.tif" />
n2S) -2-r (methox¡carbon¡l) am¡no1-3-met¡lbutane¡llp¡rrol¡din-2-iH-1 Hp¡ razol-3-i Ufen il) pyrrol id i n- Methyl 2-¡Ufen ill-1 Hp¡ razo l-5-i Dpi rrol id ¡n-1il1-3-methyl-1-oxobutan-2-ylIcarbamate
Y f (2S) -1-r (2S) -2- (3-f4-H2R, 5R) -1- (4-tert-butylphenyl) -5- (4-f5-r (25) -1 <( 2S) -2-r (methoxycarbon yl) aminol-3-methyl butanoyl | p¡rrolidi n-2-ill-1 H-pyrazol-3-yl) phenyl) pyrrolidin-2-illphenyl) -1 H-pyrazole- Methyl 5-yl) pyrrolidin-1111-3-methyl-1-oxobutan-2-ylIcarbamate
In a nitrogen purged oven dried 10 ml round bottom flask, dissolve the product of Example 105E (39.7 mg, 0.063 mmol) in anhydrous DMF (1 ml) and cool to 0 ° C. (S) -2 (methoxycarbonylamino) -3-methylbutanoic acid (23.89 mg, 0.136 mmol), hydrated HOBt (21.37 mg, 0.140 mmol), EDAC (27.3 mg, 0.140 mmol), and N-methyl are added sequentially. lmorpholine (0.021 ml, 0.190 mmol). The cooling bath is removed and the dark yellow solution is stirred at 25 ° C for 1 hour. The reaction is diluted with EtOAc (50 mL), washed with H<sub>Z</sub>O (3 x 25 ml) and brine (25 ml), the organic phase is dried over MgSO<sub>4</sub> anhydrous, filtered, and concentrated by rotary evaporation to a light peach colored solid (63 mg). The crude material is dissolved in CH2CI2 and purified by flash chromatography (silica gel, 2.5 cm x 10 cm, 5%
450
MeOH / CH<sub>2</sub>CI<sub>2</sub>) to obtain a mixture of productj J l ^^? ^
INSTITUTO MEXICANO (34 mg, 94% purity). The residue dissolves in DM8>, | v / v (2 ml) and purify by HPLC RP-C<sub>1 B</sub> (Waters Prep LC. 40mm module with Nova Pak HR C cartridge<sub>18</sub> 6 pm 40 x 100 mm Prep Pak) eluting with a 30 minute gradient of 90:10 0.1% TFA in H<sub>2</sub>O / AcCN up to 100% AcCN at 20 ml / minute. The fractions containing a mixture of the trans diastereomers are concentrated by rotary evaporation, the residue is dissolved in CH<sub>2</sub>CI<sub>2</sub>/ hexanes 1: 5 v / v and evaporate (5 times), and dry in vacuo to obtain the title compounds as a cream colored solid (12 mg, 16%).
<sup>1</sup>H NMR (TFA salt) (400 MHz, DMSO-D6) δ ppm 0.76 0.94 (m, 12 H), 1.10 (s, 9 H), 1.13 - 1.31 (m, 3 H), 1.71 (d, J = 5.42 Hz, 2H), 1.82 - 2.17 (m, 9H), 3.53 (s, 6H), 3.70 - 3.85 (m, 4H), 4.05 (t, J = 8.08 Hz, 2H), 5.09 - 5.19 (m, 2 H), 5.26 (d, J = 5.96 Hz, 2 H), 6.22 (d, J = 8.78 Hz, 2 H), 6.39 (d, J = 1.30 Hz, 2 H), 6.94 (d , J = 8.67 Hz, 2H), 7.20-7.31 (m, 6H), 7.62 (d, J = 7.92 Hz, 4H).
MS (ESI +) m / z 940 (M + H)<sup>+</sup>.
<img file="MX339989B_D0780.tif" />
451
EXAMPLE 106; IMPIOS f (2S> -1 -r (2S) -2-I3- <4-r (2R.SS) -1 - (4-tert-butylfenlt) -S> W? Ifem «) - f
INDUSTRIAL f (2S) -2-r (methoxycarbonyl) amino1-3-methylbutanoyl) pyrrolodin-2-¡ll-1 Hpyrazol-3-¡l) phenyl) pyrroledin-2-¡Hfen¡l) -1 Methyl H-pyrazol-5-yl) p¡rrolid¡n-1¡n-3-methyl-1-oxobutan-2-iDcarbamate
From the preparative HPLC separation of Example 105F the title compound (cis) is obtained as a yellow solid (16 mg, 21%).
<sup>1</sup>H NMR (TFA salt) (400 MHz, DMSO-D6) δ ppm 0.77 0.93 (m, 12 H), 1.14 (s, 9 H), 1.17 - 1.31 (m, 2H), 1.80 - 2.18 (m, 11H), 3.35 (d, J = 8.02 Hz, 1H), 3.54 (s, 6H), 3.72 - 3.85 (m, 4H), 4.06 (t, J = 8.29 Hz, 2H), 4.71 - 4.79 (m, 2H), 5.13 - 5.20 (m, 2H), 6.35 (d, J = 8.78 Hz, 2H), 6.43 (s, 2H), 7.03 (d, J = 8.78 Hz, 2H ), 7.28 (d, J = 8.35 Hz, 2H), 7.55 (d, J = 8.24 Hz, 4H), 7.71 (d, J = 7.59 Hz, 4H).
MS (ESI +) m / z 940 (M + H)<sup>+</sup>.
<img file="MX339989B_D0781.tif" />
((2S) -1-r (2S) -2- (3-f4-ri- (4-tert-butylphenyl) -5- (4- (5-r (2S) -1 - ((2S) -2f (m tox¡carbon¡l) am¡no1-3-mt¡lbutano¡l) pyrrol¡d¡n-2-¡H-1 H452 pyrazol-3-yl) phenyl) -1 Hp¡rrol-2 -IIphenyl) -1 H-pyrazol INSTITUTQ MEXICANO ill-3-methyl-1-oxobutan-2-yl) carbamate of
<img file="MX339989B_D0782.tif" />
In a nitrogen purged 5 ml oven dried round bottom flask, dissolve the product from Example 105E (5.1 mg, 8.15 pmol) in anhydrous DMF (400 µl) and cool to 0 ° C. (S) -2- (methoxycarbonylamino) -3-methylbutanoic acid (3.07 mg, 0.018 mmol), hydrated HOBt (2.75 mg, 0.018 mmol), EDAC (3.51 mg, 0.018 mmol), and N-methylmorpholine (2.69) are added sequentially. μΙ, 0.024 mmol). The cooling bath is removed and the dark yellow solution is stirred at 25 ° C for 18 hours. The reaction is diluted in EtOAc (50 mL), washed with H<sub>2</sub>O (2 x 10 inl) and brine (10 ml), the organic is dried over MgSO<sub>4</sub> anhydrous, filtered, and concentrated by rotary evaporation to a yellow solid (9.6 mg). Dissolve in MeOH / DMSO 1: 1 v / v (1.5 ml) and purify by HPLC RP-C<sub>18</sub> (Waters Prep LC, 40mm module with Nova Pak HR C cartridge<sub>18</sub> 6 pm 40 x 100 mm Prep Pak) eluting with a 30 minute gradient of 90:10 0.1% TFA in H<sub>2</sub>O / AcCN up to 100% AcCN at 20 ml / minute. The pure fractions are concentrated by rotary evaporation, azeotropically distilled with toluene (25 ml), the residue is dissolved in CH<sub>2</sub>CI<sub>2</sub>/ hexanes 1: 5 v / v and evaporate (3 times), then dry in vacuo to obtain the title compound as an off-white solid (2.5 mg, 25%).
<sup>1</sup>H NMR (TFA salt) (400 MHz, DMSO-D6) δ ppm 0.76 453
0.92 (m, 12 Η), 1.27 (s, 9 Η), 1.80 - 2.15 (m, 10 ΓΜ4ΡΪ
MEXICAN INSTITUTE
3.69 - 3.84 (m, 4H), 4.05 (t, J = 8.24 Hz, 2H), 5.08
6.39 (s, 2H), 6.53 (s, 2H), 7.06 (dd, J = 8.29, 2.H.).,. 7 [alpha] fi (rl, J = 8.35 Hz, 2H), 7.37 (d, J = 8.46 Hz, 2H), 7.44-7.55 (m, 4H), 12.92 (s, 2H).
<img file="MX339989B_D0783.tif" />
<img file="MX339989B_D0784.tif" />
N- (methoxycarbonyl) -L-val¡lN- (4-r (2S.5R) -5- (4-frN- (methoxy carbonyl) L-val¡Ham i no} fen¡l) - 1 -í4-r6- (morpholin-4-¡l) py¡d¡n-3¡l1fen¡l) p¡rrol¡din-2-¡l1phenyl) -L-prol¡namide
AND.
N- (methoxycarbonyl) -L-valyl-N- {4-rf2R.5S) -5- (4- (fN- (methoxycarbonyl) L-valylamino) phenyl) -1- f4-i6- (morpholin-4-¡l) pir¡d¡n-3¡Hfen¡l) py rrolid¡n-2-¡llfen¡l} -L-prolinamide
EXAMPLE 108 A
4- (5- (4- (2,5-b¡s (4-nitrofen ¡Dpi rrolidi n-1-i Dfeni Dpi ridi n-2¡Pmorpholine
454
In a microwave tube (size 1, 2oJnJVÍ<sup>or</sup>j ^<sup>to</sup>J<sup>c</sup>^^^ M '<sup>>;</sup>^ eemvm. «« zitoMo íj
... ... efUHMMiw »C * rii? li1¡r nitrogen and sealed with a rubber septum, the
Example 86A (160 mg, 0.342 mmol) and 4- [5- (4,4,5 -, '& totfa-methyl' 1<sub>l</sub>).to.<sub>Í</sub>.2i -.............
dioxaborolan-2-¡l) pyridin-2-yl] morpholine (153 mg, 0.512 mmol) in THF (6 ml), add a solution of potassium phosphate (176 mg, 0.803 mmol) in water (2 ml ), and the reaction solution is sparged with nitrogen for 5 minutes. Palladium 1,1'-bis (di-tert-butylphosphino) ferrocene dichloride (12.02 mg, 0.018 mmol) is added and stirred at 25 ° C for 15 minutes. During this procedure, the reaction rapidly darkens to a brown color. The reaction is diluted with EtOAc (50 ml), washed with brine (10 ml), the organic phase is dried over MgSO<sub>4</sub> anhydrous, filtered, and concentrated by rotary evaporation. The residue is dissolved in CH<sub>2</sub>CI<sub>2</sub> and purified by flash chromatography (silica gel, Alltech Extract-Clean 10 g column, 20% EtOAc / CH<sub>2</sub>CI<sub>2</sub>) to obtain the title compound as a solid (176 mg, 93%) as a mixture of stereoisomers.
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ ppm 1.82 - 1.94 (m, 2H),
2.53 - 2.62 (m, 2H), 3.37 - 3.47 (m, 4H), 3.64 - 3.74 (m, 4H), 5.03 (t, J = 5.37 Hz, 2H), 6.40 (d, J = 8.89 Hz, 2H), 6.82 (d, J = 9.00 Hz, 1H), 7.34 (d, J = 8.78 Hz, 2H), 7.69 (dd, J = 8.84, 2.55 Hz, 1H), 7.83 (d , J = 8.78 Hz, 4H), 8.28 (d, J = 8.78 Hz, 4H), 8.29-8.31 (m, 1H).
MS (ESI +) m / z 552 (M + H)<sup>+</sup>.
455
EXAMPLE 108B IMPI
MEXICAN INSTITUTE
4,4 '- (1 - (4- (6-morphol and nopyridin-3-yl) fenihpi rrolidi
<img file="MX339989B_D0785.tif" />
A 100 ml round bottom flask is charged with the product of Example 108A (174.7 mg, 0.317 mmol), partially dissolved in THF (12.50 ml) and absolute EtOH (2.50 ml), evacuated with the domestic vacuum and the flask is filled with nitrogen, then platinum (IV) oxide (14.38 mg, 0.063 mmol) is added, the flask is evacuated in the domestic vacuum and filled with hydrogen from a balloon, the evacuation / filling cycle is repeated 3 times, and the heterogeneous reaction mixture is vigorously stirred under hydrogen (1 atm). After 2 hours, the reaction is charged with additional platinum (IV) oxide (14.38 mg, 0.063 mmol) and continued vigorous stirring under hydrogen at 25 ° C. After 5 hours, additional platinum (IV) oxide (14.38 mg, 0.063 mmol) is added. The reaction mixture is then vacuum filtered through a bed of Celite 545 on a Büchner funnel, the filter pad is washed with CHCI<sub>3</sub> (100 mi) and CHCI<sub>3</sub> hot (2 x 50 mL), and the filtrate is concentrated by rotary evaporation to obtain the title compound as a yellow solid (101 mg, 65%) as a mixture of stereoisomers. <sup>1</sup>H NMR (400 MHz, DMSO-D6) δ ppm
1.71-1.87 (m, 2H), 2.24-2.31 (m, 1H), 3.37-3.45 (m, 4H), 3.64 3.74 (m, 4H), 4.57 (t, J = 4.99 Hz, 2H ), 4.95 (s, 4H), 6.42 - 6.53 (m, 3H), 6.57 (d, J = 8.35 Hz, 4H), 6.76 - 6.89 (m, 2H), 7.15 (d, J = 8.35
Hz, 4H), 7.26 (d, J = 8.78 Hz, 2H), 7.68 (dd, J = 8.84, 2.44 Hz, 1H),
456
<img file="MX339989B_D0786.tif" />
EXAMPLE 108C (2S) -1 - (4- (5- (4-am¡nophen¡l) -1- (4- (6-morpholinopyridin-3¡l) fen¡ Dpi rrol ¡d¡n-2 -¡ Dphenylam ¡no) -3-m ethi methyl 1-1-oxobutan-2ylcarbamate
In a nitrogen purged 5 ml oven dried round bottom flask, the product of Example 108B (70 mg, 0.142 mmol) and (S) -2- (methoxycarbonylamino) -3-methylbutanolic acid (26.2 mg, 0.150) are dissolved. mmol) in anhydrous DMSO (1.5 ml), HATU (58.6 mg, 0.150 mmol) and di-isopropylethylamine (0.050 ml, 0.285 mmol) are added, and the dark yellow solution is stirred at 25 ° C for 15 minutes. The reaction is diluted with MeOH (1.5 ml) and purified by RP-C HPLC<sub>18</sub> (Waters Prep LC, 40mm module with Nova Pak HR C cartridge<sub>18</sub> 6 pm 40 x 100 mm Prep Pak) eluting with a 30 minute gradient of 95: 5 0.1% of
TFA in H<sub>2</sub>O / AcCN up to 25:75 0.1% TFA in H<sub>2</sub>O / AcCN, then
457
<img file="MX339989B_D0787.tif" />
Di La? FcOf H.TAD INDUSTRIAL minutes at 100% AcCN at 20 ml / minute. The frag &
concentrated by rotary evaporation (35 ° water bath) to a small volume, partitioning between 20% of ¡PrOH / CHCI<sub>3</sub> (50 mi), and NaHCO<sub>3</sub> saturated aqueous (15 ml), the layers are separated, the organic extract is dried over MgSO<sub>4</sub> anhydrous, filtered, and concentrated by rotary evaporation to obtain the title compound as a light yellow solid (48 mg, 52%). 1H NMR shows that the material is a ~ 3: 1 trans: cis mixture.
MS (ESI +) m / z 649 (M + H)<sup>+</sup>, 1297 (2M + H)<sup>+</sup>.
EXAMPLE 108D
N- (methoxycarbon¡l) -L-val¡lN- (4-R2S, 5R) -5- (4- (fN- (methoxycarbon¡l) L-valiHam¡no) fenll) -1- {4-r6- (morpholin-4-¡l) p¡r¡d¡n-3¡ Ufen ¡l) pyrrol¡din-2-iHfeni'l) -Lp rol ¡nam ¡da-ACD v12
AND.
N- (methoxycarbonyl) -L-valll-N- {4-r (2R, 5S) -5- (4- {rN- (methoxycarbonyl) L-valinamino) phenyl) -1-f4- i6- (morpholin-4-yl) pyridin-3¡ Hfen I Dpi rrol idin-2-lllfen iR-L-prol i nam ida ACD v12
In a nitrogen purged oven dried 5 ml round bottom flask, dissolve the 3: 1 trans / cis mixture of Example 108C (44 mg, 0.068 mmol) and the product of Example 37B (20.31 mg, 0.075 mmol) in Anhydrous DMSO (1 ml), HATU (29.2 mg, 0.075 mmol) and di-isopropylethylamine (0.024 ml, 0.136 mmol) are added, and the yellow solution is stirred at 25 ° C for 30
458
ΛβΛϊ1 £. ·. · Β33ί— «iSAJIALk
<img file="MX339989B_D0788.tif" />
minutes. The reaction is diluted with MeOH (1 iR ^ uT <y<sub>M</sub>E «« NoP
OF INDUSTRIAL FRCPIETY by HPLC RP-C<sub>18</sub> (Waters Prep LC, 40mm module with Nova Pak HR cartridge Ο<sub>Ί8</sub> 6 pm 40 x 100mm Prep Pak) eluting with a 30 minute gradient of 95: 5 0.1% TFA in H<sub>2</sub>O / AcCN up to 25:75 0.1% TFA in H<sub>2</sub>O / AcCN, then 10 minutes at 100% AcCN at 20 ml / minute. It is determined by<sup>1</sup>H NMR that the compound eluting the earliest (18.8 mg, 31%) are the trans diastereomeric diastereomers. The fractions of the last elution peak are concentrated by rotary evaporation (35 ° C water bath) to a small volume, partitioning between 20% of ¡PrOH / CHCI<sub>3</sub> (50 mi) and NaHCO<sub>3</sub> saturated aqueous (15 ml), the layers are separated, the organic phase is dried over MgSO<sub>4</sub> anhydrous, filtered, and concentrated by rotary evaporation to obtain a 2: 3 trans: cis mixture as an off-white solid (10 mg). The mixture is dissolved in 1: 1 v / v MeOH / DMSO (1.5 ml) and purified by HPLC RP-Ci<sub>8</sub> (Phenomenex Luna C column<sub>8</sub>(2) 5 pm 100 A AXIA (30 mm x 75 mm)) eluting with a gradient of 90:10 NH<sub>4</sub>10 mM OAc: MeOH to 100% MeOH to obtain the title cis compounds as a light beige solid (2 mg, 3%).
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ ppm 0.85 - 0.98 (m, 12H), 1.77 - 2.06 (m, 7H), 2.09 - 2.21 (m, 1H), 2.36 - 2.45 (m, 1H ),
3.37-3.42 (m, 4H), 3.51 (s, 3H), 3.53 (s, 3H), 3.59-3.70 (m, 6H),
3.75 - 3.86 (m, 1H), 3.95 (t, J = 8.13 Hz, 1H), 4.02 (t, J = 8.57 Hz, 1
H), 4.44 (dd, J = 8.19, 4.72 Hz, 1 H), 4.73 (s, 2 H), 6.43 (d, J = 8.89 Hz, 2 H), 6.80 (d, J = 8.89 Hz, 1 H ), 7.27 (d, J = 8.78 Hz, 2 H), 7.29 - 7.38
459 (m, 2 Η), 7.44 (dd, J = 8.57, 2.71 Hz, 4 H), 7.54 - ϊΙΑίΙ, © Ϊ)
INSTITUTO MEXICANO D £ LA 7ΛΟΠΓ DAD (dd, J = 8.89, 2.49 Hz, 1 H), 8.27 (d, J = 2.49 Hz, 1 H), 10.0W * W * MS (ESI +) m / z 903 (M + H)<sup>+</sup>, 92O "~ (M ^ NH4)<sup>J</sup>7 (M + AcCN + NH4)<sup>+</sup>.
<img file="MX339989B_D0789.tif" />
<img file="MX339989B_D0790.tif" />
f (2S) -1-r (2S) -2-f5-r (2R, 5R) -1- (4-tert-butylphenyl) -5- {2 - [(2S) -1 - {(2S) - 2r (methoxycarbonyl) amino1-3-methylbutanoiDpyrrolidin-2-ill-1Hbenzimidazol-5-yl) pyrrolidin-2-in-1 H-benzim idazol-2-yl) pyrrolidi n-1 ill-3-methyl Methyl -1-oxobutan-2-iDcarbamate
EXAMPLE 109 A
2-bromo-1- (4-chloro-3-nitrophen) full none
Method a
To a flask equipped with a magnetic stir bar and under an atmosphere of N<sub>2</sub> 4'-chloro-3'nitroacetophenone (10.0 g, 50.1 mmol) and THF (100 ml) are added. To this stirring mixture, phenyltrimethylammonium tribromide (19.78 g, 52.6 mmol) is added portionwise over the course of a
460 15 minute period. The resulting mixture after
<img file="MX339989B_D0791.tif" />
hourly monitoring by LCMS. After that, it is filtered and the resulting solids are washed with EtOAc. The organic solution is then concentrated, H<sub>2</sub>O and NaHCO<sub>3</sub> 10% aqueous and washed with EtOAc (2 x 300 mL). The combined organic layers are then washed with brine, dried (MgSO<sub>4</sub>), filtered and concentrated. The residue material is then subjected to purification by crystallization (the material is dissolved in 100 ml of EtOAc and hexanes are slowly added until it becomes cloudy 10 is allowed to stand for a few hours) to obtain 9.81 g (70%) of 2- bromo-1 - (4-chloro-3-nitrophenyl) ethanone as an off-white solid.
1H NMR (500 MHz, DMSO-D6) δ ppm 5.00 (s, 2 H) 7.98 (d, J = 8.54 Hz, 1 H) 8.24 (dd, J = 8.54, 2.14 Hz, 1 H) 8.61 (d, J = 1.98
Hz, 1H).
Method b
In a 500 ml round bottom flask add 1- (4-chloro-3-nitrophenyl) ethanone (11.98 g, 60 mmol) in benzene (75 ml) 20 to obtain a white suspension. Bromine (9.59 g, 60.0 mmol) is added dropwise over 5 minutes to obtain a deep red solution. Stir for 1 hour to obtain a yellow solution which is concentrated in vacuo to a yellow solid. Recrystallize with hexane / ethyl acetate 9: 1 to obtain 2-bromo-1 - (4-chloro-3-nitrophenyl) ethanone
461
IMPI
INSTITUTE f-.EKICATO DE LA ι · Λ0ΗΙΡλϊ> (ÍOUÍTidAL
<img file="MX339989B_D0792.tif" />
like yellow needles.
EXAMPLE 109B
1,4-bis (4-chloro-3-nitrophenyl) butane-1,4-dione
Zinc (II) chloride (14.68 g, 108 mmol) is added to toluene (81 ml), then diethylamine (8.35 ml, 81 mmol) and tert-butanol (7.73 ml, 81 mmol) are added and the resulting heterogeneous solution is stir at room temperature for about 2 hours. After this, Example 109A (15.0 g, 53.9 mmol) and 4'-chloro-3'-nitroacetophenone (16.13 g, 81 mmol) are added to the solution in one portion, and the resulting mixture is stirred at room temperature for 42 hours). The reaction is then quenched with 5% aqueous sulfuric acid (500 mL) and stirred vigorously to induce solid formation. The resulting solid is filtered in vacuo, then washed with toluene, water, and methanol successively. The solid is then added to a hot ethyl acetate solution and the resulting heterogeneous solution is stirred for 30 minutes and then the solid is collected and dried overnight in a vacuum oven to provide 16.6 g (78%) of the title compound.
<sup>1</sup>H NMR (400 MHz, DMSO-d6) δ 8.61 (d, J = 1.9 Hz, 2H),
8.27 (dd, J = 8.4, 1.9 Hz, 2H), 7.96 (d, J = 8.3 Hz, 2H), 3.48 (s, 4H).
462
EXAMPLE 109C J p J
INSTITUTO MEXICANO (1 S, 4S) -1.4-b¡s (4-chloro-3-nitrophen¡l) butan-'T,<sup>L</sup>4wd ^ ¿il ^
(R) - (+) - alpha, alpha-d¡phenyl-2-p¡rrol¡d¡nmethanol 5 (1.08 g, 4.28 mmol) is dissolved in 70 ml of THF at room temperature in a dry flask under nitrogen and timetllo borate (650 ul,
5.54 mmol) by dripping. The resulting solution is stirred for 1 hour. The solution is cooled in a cold bath to -10 ° C and Ν, Ν-diethylaniline borane (9.18 ml, 51.6 mmol) is added dropwise with some bubbling. After 15 minutes, this solution is transferred to an addition funnel and added dropwise to 1,4b¡s (4-chloro-3-nitrophenyl) butane-1,4-dione (Example 109B) ( 10.0 g, 25.2 mmol) suspended in 200 ml of THF and cooled to ~ 10 ° C. Bubbling is observed. After the addition, the mixture is stirred at room temperature for 4 hours. The mixture is cooled in an ice bath and 30 ml of MeOH is added dropwise until bubbling ceases, then the mixture is allowed to stir at room temperature for 30 minutes. The mixture is filtered to remove traces of unreacted insoluble SM. The filtrate is concentrated, poured into 1M HCl and extracted with ethyl acetate, dried over sodium sulfate; Concentrate to obtain the title compound (9.9g, 99%) as a yellow waxy solid. Qurial HPLC e. . > 99.9% (RR diol is undetectable).
<sup>1</sup>H NMR (400 MHz, DMSO-d6) δ 7.94 (d, J = 1.9 Hz, 2H),
7.69 (d, J = 8.4 Hz, 2H), 7.60 (dd, J = 8.4, 1.9 Hz, 2H), 4.65 (m, 2H),
463
1.62 (m, 4H).
IMPI
MEXICAN INSTITUTE OF INDUSTRIAL PROPERTY
<img file="MX339989B_D0793.tif" />
is processed as in
EXAMPLE 109D
The product of Example 109C
Examples 113A, 113B, 113C, and 113D, substituting 4-t-butylaniline for
4-cyclohexyllanin in procedure step 113A to obtain 0.212 g (22%) of the title compound.
1H NMR (400 MHz, DMSO-D6) δ ppm 0.74 - 0.92 (m, 12 10 H) 1.07 (s, 9 H) 1.69 (d, J = 4.01 Hz, 2 H) 1.86 - 2.05 (m, 6 H) 2.13 2.24 (m, 4H) 2.54 (d, J = 2.60 Hz, 2H) 3.51 - 3.56 (m, 6H) 3.81 (s, 4H) 4.05 (t, J = 8.13 Hz, 2H) 5.09 - 5.18 (m, 2H) 5.35 (d, J = 3.47 Hz, 2H) 6.25 (d, J = 8.78 Hz, 2H) 6.86 - 6.96 (m, 2H) 7.07 (t, J = 7.81 Hz, 2 H) 7.20 (s, 1H) 7.26 - 7.32 (m, 3H) 7.38 (d, J = 8.24 Hz, 1H) 7.46 (d, 15 J = 8.24 Hz, 1H) 11.98 - 12.08 (m, 2 H).
MS TFA + m / z 889.
<img file="MX339989B_D0794.tif" />
EXAMPLE 110 f (2S) -1 -r (2S) -2-f5-H2S.5S) -1 - (4-t r-but¡lfen¡l) -5- {2-R2S) -1-f ( 2S) -2464
<img file="MX339989B_D0795.tif" />
r (methoxycarbonyl) amino1-3-methyl butanoiPpi rrotjkÁlE ^ lIl
MEXICAN INSTITUTE
OF THE PROPERTY benzim ¡dazol-5-il) p¡ rrolidi n-2-¡H-1 H-benzim ¡ά3ΖοΙ-2-ϋ) ΐ? Ι77 # 1ίάΓη ^ ¡Π-3-methyl-l-oxobu tan- 2-llcarba mato ~ tte tubíHo—
The product from Example 28K is purified by chiral chromatography on a Chirapak IA column eluting with a mixture of hexane / methanol / tetrahydrofuran (3: 1: 1) to obtain the title compound.
1H NMR (400 MHz, DMSO-D6) δ ppm 0.78 - 0.91 (m, 12H) 1.07 (s, 9H) 1.64 - 1.73 (m, 2H) 1.89 - 2.00 (m, 6H) 2.12 - 2.23 ( m, 4H) 3.14 - 3.24 (m, 2H) 3.52 (s, 6H) 3.76 - 3.85 (m, 4H) 4.05 (td, J = 8.38, 2.33 Hz, 2H) 5.07 - 5.16 (m, 2H) 5.30 - 5.39 (m, 2H)
6.23 (d, J = 8.78 Hz, 2 H) 6.90 (ddd, J = 8.95, 4.72, 4.55 Hz, 2 H) 7.06 (t, J = 9.22 Hz, 2 H) 7.17 (s, 1 H) 7.23 - 7.31 (m, 3H) 7.37 (d, J = 8.13 Hz, 1H) 7.44 (d, J = 8.24 Hz, 1H) 12.02 (d, J = 23.42 Hz, 2H).
MS ESI + m / z 888 (M + H) +.
<img file="MX339989B_D0796.tif" />
EXAMPLE 111 (r (2S, 5S) -1 - (4-tert-buty Ifenyl) pyrrolid i n-2,5-d ii II bisfbenzene-4,1 -d¡¡lcarbamo¡l (3S) -2- azab¡c¡cloí2.2.11 heptan-3,2-d¡-¡ir (2S) -3-methyl-1 oxobutan-1,2-d¡-¡ll}) b¡ carbamate d dim linden
465
<img file="MX339989B_D0797.tif" />
Η> = Ο Μ— <
IMPI
INSTITUTO MEXICANO DELAFKOF'EDAO INDUSTRIAL
<img file="MX339989B_D0798.tif" />
Ν.
/ ° ί:> ο /
EXAMPLE 111Α
(3S) -2 - ((S) -2- (methoxycarbonylamino) -3-methylbutano¡l) -2azabicyclof2.2.1Iheptan-3-carboxylic acid
Ethyl (3S) -2-azabicyclo [2.2.1] heptan-3-carboxylate (1.25 g, 7.39 mmol), (S) -2- (methoxycarbonylamino) -3-methylbutanoic acid (1.42 g, 8.13 mmol) are combined , di-isopropylethylamine (6.45 inl,
36.9 mmol), and HATU (2.95 g, 7.76 mmol) in dimethylformamide (40 ml) at room temperature and stir for 2 hours. The solution is diluted with water and the product is filtered and dried. The dry ester (1.0 g, 3.06 mmol) is dissolved in water (15 ml) and ethanol (15 ml) and treated with sodium hydroxide (0.5 g, 12.5 mmol) at room temperature for 17 hours. The solution is washed with the ester then the aqueous is neutralized with concentrated HCl to pH 7 and the product is extracted with ethyl acetate, dried over sodium sulfate, and concentrated to obtain the title compound as a waxy solid.
EXAMPLE 111 B (Í (2S.5S) -1 - (4-tert-butylphenyl) pyrrolidin-2,5-di-inbis (benzene-4,1-diylcarbamoylf3S) -2-azabichlor2.2.nh ptan -3,2-di-iiR2S) -3-m ti 1-1466 easasESK oxobutan-1,2-d ii ΠΏ biscarbamate
-=<sup>1</sup>—MEXICAN INSTITUTE OF THE PROPERTY
INDUSTRIAL
<img file="MX339989B_D0799.tif" />
The product of Example 37E (0.05g, 0.13 mmol), the product of Example 111A (0.097 g, 0.324 mmol), diisopropylethylamine (0.113 ml, 0.648 mmol), and HATU (0.104 g, 0.272 mmol) are combined in dimethylformamide (2 ml) at room temperature and stir for 3 hours. The solution is poured into brine, extracted with ethyl acetate, concentrated, and purified by a 12 g combi-flash silica column, eluting with 0-6% methanol in dichloromethane to obtain the title compound as a solid. .
1H NMR (400 MHz, DMSO-D6) δ ppm 0.91 (d, J = 6.72 Hz, 6 H) 0.98 (d, J = 6.72 Hz, 6 H) 1.11 (s, 9 H) 1.32 (d, J = 8.89 Hz, 2H)
1.36 - 1.46 (m, 2H) 1.59 - 1.74 (m, 6H) 1.76 - 1.84 (m, 2H) 1.90 (td,
J = 13.88, 6.94 Hz, 2H) 2.01 - 2.09 (m, 2H) 2.40 - 2.47 (m, 2H) 2.60 (d, J = 1.19 Hz, 2H) 3.52 (s, 6H) 3.94 (s , 2H) 4.04 - 4.15 (m, 2H)
4.46 (s, 2H) 5.15 (d, J = 6.51 Hz, 2H) 6.17 (d, J = 8.78 Hz, 2H) 6.94 (d, J = 8.78 Hz, 2H) 7.13 (d, J = 8.57 Hz, 4H) 7.22 (d, J = 8.46 Hz, 2H)
7.49 (d, J = 8.57 Hz, 4H) 9.95 (s, 2H).
<img file="MX339989B_D0800.tif" />
467
I * »* · *! *» MkMi.Xl.CTaf ·· —2 »
EXAMPLE 112 I Al Ρ I $ 3 ^
INSTITUTE ΜίΧΙΓΑΝΟ T?
nt the W; fr »tD.<sub>TO</sub>0 V ((2S1-1 -r (2S) -2- (4- (4-R2R, SR) -1 - (4-tert-butylphen¡D-5- (4-<sup>r</sup>fg-<sup>K</sup>fy<sup>t</sup>2S1 ((2S) -2-f (methox¡carbon¡D (methyl) am ino1-3-methiibutan ~ OtD pii i ulielin ..... 2-i 11-1 H-im¡dazol-4-¡Pfenl Dpi rrolidin-2-i UfeniD-l H-imidazole-2¡Dpyrrol8din-1 -ΐΠ-3-methyl-l-oxobutan-2-ylImethylcarbamate of m-linden
The product from Example 126H is processed as in Examples 42B-42G, substituting (S) -2 (methoxycarbonyl (methyl) amino) -3-methylbutanoic acid for (S) -210 (methoxycarbonylamino) -3-methylbutanoic acid in step 42G, to obtain 0.07g (40%) of the title compound as a white solid.
1H NMR (free base) (400 MHz, DMS0-D6) δ ppm 0.76 (d, J = 6.61 Hz, 6 H) 0.83 (d, J = 6.51 Hz, 6 H) 1.09 (s, 9 H) 1.63 - 1.75 (m, 2H) 1.86 - 2.00 (m, 4H) 2.03-2.21 (m, 6H) 2.77 (s, 6H) 3.10 - 3.22 (m, 4H) 3.63 (s, 6H) 3.74 - 3.84 (m, 2H) 4.98 - 5.07 (m, 2H) 5.16 5.23 (m, 2H) 6.21 (d, J = 8.78 Hz, 2H) 6.88 - 6.96 (m, 2H) 7.15 (d,
J = 8.24 Hz, 4 H) 7.22 (d, J = 8.35 Hz, 1 H) 7.36 (d, J = 1.52 Hz, 2 H)
7.51 (d, J = 8.24 Hz, 1H) 7.61 (d, J = 8.13 Hz, 4H) 11.70 (s, 2H).
MS ESI + m / z 968.7 (M + H) +; MS ESI + m / z 968.7 (M + H) +.
<img file="MX339989B_D0801.tif" />
468
<img file="MX339989B_D0802.tif" />
EXAMPLE 113 IMPI
ΪΝΠΤΠΓΓΟ MEXICAN
OF THE PROPERTY
R2S) -1-r (2S) -2- (5-R2R, 5R) -1- (4-cyclohex¡lfen¡l) -5-íCT ^ -r
2-r (methoxycarbon¡l) am¡no1-3-met¡lbutano¡l) pyrrolldin-2-t ITHTT<sup>7</sup> benzim ¡dazol-5-¡l} p¡rrol¡d¡n-2-¡n-1 H-benzim¡dazol-2-yl) p¡rrolidin-1 ¡l1-3-methyl-1-oxobutan-2 -¡L) methyl carbamate
EXAMPLE 113A (2R<sub>1</sub>5R) -2.5-bis (4-chloro-3-nitrophenyl) -1 - (4-cyclohexyphenyl) pyrolidine
The product from Example 109C (2.0 g, 4.99 mmol) and triethylamine (1.51 ml, 14.96 mmol) are dissolved in dichloromethane (50 ml) and cooled in an ice bath. Methanesulfonyl chloride (0.855 ml, 10.97 mmol) in dichloromethane (2 ml) is added dropwise and the resulting mixture is stirred at room temperature for 2 hours. The solution is concentrated to dryness and dissolved in dimethylformamide (8 ml). 4-Cyclohexylaniline (5.24 g, 29.9 mmol) is added and the solution is heated to 65 ° C for 2 hours then it is poured into 1M HCl and extracted with dichloromethane, concentrated, and purified by a combi-flash silica column. 80 g, eluting with 0-20% ethyl acetate in hexanes to obtain 1.38 g (51%) of the title compound.
469 asaaee ^ ssacst
IMPI
INSTITUTO MEXICANO M LA THORIFDAD INDUSTRIAL
<img file="MX339989B_D0803.tif" />
, Q ^ ° O, Ο'9-Tr ΛΛο<sup>ΗΝ</sup>Υ), ΧχΥ<sup>ΝΗ</sup>ο £ Λ
Ο, Ν YZ ^^ NO,
EXAMPLE 113B (2S, 2'S) -2,2 '- (4,4' - ((2R.5R) -1- (4-cyclohexylphenyl) plrroiidin-2.5-diyl) b¡s (2-nitro-4 Tert-butyl, 1-phenylene)) bis (azandi-yl) bis (oxomethylene) dipyrrolidin1-carboxylate
The product from Example 113A (1.29 g, 2.39 mmol), tert-butyl (S) 2-carbamoylpyrrolidine-1-carboxylate (1.53 g, 7.16 mmol), cesium carbonate (2.33 g, 7.16 mmol), 4,5bis (diphenylphosphino) -9,9-dimethylxanthene (0.33 g, 0.573 mmol), and tris (d¡benzylideneacetone) dipalladium (0) (0.328 g, 0.358 mmol) are combined in dioxane (18 ml) and nitrogen sparged through the solution for 15 minutes, then the flask is capped with a reflux condenser and the solution is heated at 100 ° C for 8 hours. After filtering through celite and concentrating, the residue is purified by an 80 g combi-flash silica column, eluting with 0-20% ethyl acetate in dichloromethane to obtain 1.71 g (80%) of the title compound .
470
ΙΜΡϊ
MEXICAN INSTITUTE OF INDUSTRIAL PROPERTY ^<sup>Λ</sup>°<sup>ΗΝ</sup>Χ) ·· ΧΧΤ<sup>ΝΗ</sup>°<sup>ΛσΧ</sup>
Η, Ν \ _ / NH,
EXAMPLE 113C (2S, 2'S) -2.2 '- (4,4' - ((2R, 5R) -1- (4-cyclohexylfen ¡l) p¡ rrol ¡d¡n-2,5-di ¡Pb¡s (2-am¡no-4.1-phenylenePbisiazandi¡l) b¡s (oxomethylene) dipyrrolidine-1-carboxylic acid tert-butyl ester
The product from Example 113B (1.71 g, 1.91 mmol) is dissolved in tetrahydrofuran (10 ml) and ethanol (10 ml) at room temperature and treated with platinum (IV) oxide (0.11 g, 0.48 mmol). The flask is evacuated and opened onto a hydrogen balloon and stirred for 18 hours then filtered through celite and concentrated to obtain the title compound.
EXAMPLE 113D
K2S) -1-n2S) -2-f5-r (2R.5R) -1- (4-cyclohex¡lfen¡l) -5-í2-r (2S) -1-f (2S) 2-r ( methoxycarbon¡l) am¡no1-3-met¡lbutano¡l) pyrrol¡d¡n-2-¡n-1Hbenzim idazol-5-¡Dpi rrolidi n-2-ill-1 H-benzimidazol-2-i Dpi rrolidi n-1 ¡Π-3-methyl-l-oxobutan-2-¡D-methyl carbamate
Example 113C is processed using the methods of Examples 281, 28J, and 28K to provide the title compound.
471
1Η NMR (400 MHz, DMSO-D6) δ ppm O.IeM) JH wrrmrTo msocaw ^ οε la - somo.ÁO
H) 1.03- 1.29 (m, 6H) 1.55 - 1.74 (m, 7H) 1.84 - 2.06 (m.'T'W ^ .rT- ^ 2.25 (m, 6H) 3.53 (s, 6H) 3.81 (s, 4H) 4.02 - 4.-t3 ~ trn7-2 H) '&: & 8 .........
5.18 (m, 2H) 5.32 - 5.38 (m, 2H) 6.24 (d, J = 8.57 Hz, 2H) 6.68 - 6.77 (m, 2H) 7.06 (t, J = 7.54 Hz, 2H) 7.19 (s, 1H) 7.26 - 7.32 (m, 3H)
7.37 (d, J = 8.24 Hz, 1H) 7.45 (d, J = 8.35 Hz, 1H) 11.98-12.05 (m, 2H).
<img file="MX339989B_D0804.tif" />
EXAMPLE 114 {(2S) -1-r (2S) -2- (6-f (2R.5R) -5-i2-r (2S) -14 (2S) -2ffmethoxycarbonyl) amno1-3-methylbutanoyl ) p¡rrol¡d¡n-2-yl1-1 Hbenzim¡dazol-5-yl1-1-r4- (4-methylpiperaz8n-1-¡l) phenylp¡rrol¡d¡n-2-¡l11H-benc Methyl midazol-2-yl) pyrrolidin-1-ill-3-methyl-1-oxobutan-2-ylcarbamate
The product from Example 109C (1.0 g, 2.49 mmol) is processed as in Examples 113A-113D, substituting 4- (4472
<img file="MX339989B_D0805.tif" />
<img file="MX339989B_D0806.tif" />
methylpiperazin-1-yl) aniline for 4-cyclohexylaniline in ejC- ίΤΠθ from Example 113A and substituting Raney nickel in tetrahydrofuran for platinum (IV) oxide in tetrahydrofuran and ethanol in the procedure of Example 113C to obtain 0.028 g (50%) of the title compound as a solid.
1H NMR (400 MHz, DMSO-D6) δ ppm 0.77 - 0.90 (m, 12H) 1.65 - 1.72 (m, 2H) 1.85 - 2.04 (m, 8H) 2.13 (s, 3H) 2.15 - 2.23 ( m, 4H) 2.32 (s, 2H) 2.77 (s, 6H) 3.54 (s, 6H) 3.82 (d, J = 4.66 Hz, 4H) 4.02 - 4.08 (m, 2H) 5.09 - 5.18 (m, 2H) 5.28 - 5.37 (m, 2H) 6.23 (d, J = 8.78 Hz, 2H) 6 54 (ddd, J = 9.00, 4.66, 4.55 Hz, 2H) 7.02 - 7.08 (m, 2H) 7.19 (s, 1H) 7.26 - 7.31 (m, 3H) 7.36 (d, J = 8.13 Hz, 1H)
7.44 (d, J = 8.35 Hz, 1H) 12.01 (s, 2H).
MS ESI + m / z 556 (M + H) +.
<img file="MX339989B_D0807.tif" />
EXAMPLE 115 <(2S) -1-r (2S) -2- {6-r (2R.5R) -1- (1,3-benzot¡azol-2-¡l) -5- {2-r (2S) -1 {(2S) -2-r (methox8carbonyl) ami nol-3-methii butanoi Rpyrrole id in-2-yl1-1 Hbenzymidazol-5-yl) pyrrolidin-2-¡H-1H-benc ¡Midazol-2-¡l) p¡rrolidin-1¡Π-3-methyl-l-oxobutan-2-¡Rcarbamate of methyl
473
EXAMPLE 115A (2R, 5R) -1-allyl-2.5-bis (4-chloro-3-nitrophenidpyrrolidine
IMP I
MEXICAN INSTITUTE OF INDUSTRIAL PROPERTY
<img file="MX339989B_D0808.tif" />
The product from Example 109C (5.0 g, 12.46 mmol) and allylamine are processed as in Example 113A to obtain 1.5 g (39%) of the title compound as a thick oil.
EXAMPLE 115B (2R, 5R) -2,5-bis (4-chloro-3-n itrofen ¡Dpi rrol ¡di na
The product from Example 115A (2.0 g, 4.74 mmol) is dissolved in acetonitrile (40 ml) and water (4 ml) and treated with tris (triphenylphosphine) rhodium (I) chloride (0.219 g, 0.237 mmol). The mixture is heated to 100 ° C and nitrogen is bubbled through the solution for 3 hours. The mixture is partitioned between a 5% sodium bicarbonate solution and ethyl acetate, then the organics are concentrated and the product is purified by an 80 g combiflash silica column eluting with dichloromethane to obtain 1.33 g (74%) of the compound of the Title.
EXAMPLE 115C
2-f (2R.5R) -2.5-bis (4-chloro-3-nitropheniDpyrrolidin-1-iDbenzordIthiazole
The product of Example 115B (0.335 g, 0.877 mmol), 2-bromobenzo [d] thiazole (0.281 g, 1.32 mmol), 0.08 g of
474 (essbzuA:
'^ S
<img file="MX339989B_D0809.tif" />
yriTwe'MKiÍANoí. ^ 4
OF INDUSTRIAL PROPERTY tr¡s (dibenzylideneacetone) d¡palladium (0) (0.088 mmol g, 0.088 mmol), and sodium tert-butoxide (0.126 g, 1.32 mmol) are combined in dioxane (8 ml) and nitrogen is bubbled in through the solution for 10 minutes. The tube is sealed and heated at 100 ° C for 18 hours. The reaction mixture is partitioned between brine and dichloromethane and the organics are concentrated and purified by a 24 g combi-flash silica column, eluting with 1: 1 hexanes: dichloromethane, followed by 100% dichloromethane to obtain 0.165 g (37 %) of the title compound.
EXAMPLE 115D f (2S) -1-H2S) -2-f6-r <2R, 5R) -1- (1,3-benzothiazol-2-yl) -5- (2-r (2S) -1f (2S ) -2-f (methoxycarbon ¡l) am i nol-3-methylbutanoi l) p¡ rrol ¡di n-2-¡H-1 Hbenzimidazol-5-¡l> pyrrole¡d¡n-2-¡ H-'l H-benzimidazole-2-¡Dpyrrolidin-1 ¡Π-3-methyl 1-1-oxobutan-2-¡P-methyl carbamate
The product from Example 115C is processed as in Examples 113B, 113C, and 113D to obtain 0.040 g (38%) of the title compound.
1H NMR (400 MHz, DMSO-D6) δ ppm 0 74 - 0 88 (m, 12H) 1.76 - 1.84 (m, 2H) 1.85 - 1.94 (m, 3H) 1.95 - 2.07 (m, 4H) 2.14 2.26 (m, 4H) 2.61 - 2.71 (m, 2H) 3.53 (s, 6H) 3.76 - 3.85 (m, 4H) 4.05 (t, J = 8.51 Hz, 2H) 5.10 - 5.18 (m , 2H) 6.90 (t, J = 7.54 Hz, 2H) 7.07 - 7.16 (m, 3H) 7.22 - 7.35 (m, 4H) 7.40 (d, J = 8.13 Hz, 2H) 7.47 (d, J = 8.35 Hz, 1H) 7.52-7.59 (m, 1H) 12.07 (s, 2H).
475
MS ESI + m / z 889
<img file="MX339989B_D0810.tif" />
IMPI
INSTITUTO MEXICANO DE LAPROFltDAO INDUSTRIAL
<img file="MX339989B_D0811.tif" />
EXAMPLE 116 <(2S) -1-r (2S) -2-I6-H2R, 5R) -5-f2-r (2S) -1-f (2S) -2ffmetoxic r bon¡ham¡no1-3-methylbutane ¡Ilpyrrole id ¡n-2-yl] -1Hbenzimidazol-5-ylI-1 - (4,5,6,7-tetrahydro-1,3-benzot¡azol-2¡l) p¡rrolid¡n-2- ¡L1-1 H-benzimidazol-2-¡l) pyrrole¡din-1-iH-3-methyl-1-oxobutan-2-ylIcarbamate of methyl
EXAMPLE 116A
(S) -pyrroledin-2-carboxamide hydrochloride salt
To tert-butyl (S) -2-carbamoylpyrrolidine-1-carboxylate (29.8 g, 139 mmol) a 4 N solution of HCl in dioxane (209 ml, 836 mmol) is added and the resulting mixture is stirred at room temperature for 18 hours. The mixture is then concentrated and triturated with diethyl ether then vacuum filtered and dried in vacuo to provide 21.6 g (104%) of the title product as a colorless solid.
agaaw .:
476
EXAMPLE 116B
(S) -2- (methoxycarbonylamine) -3-methylbutanoic acid
<img file="MX339989B_D0812.tif" />
To (S) -2-amino-3-methylbutanoic acid (57 g, 487 mmol) dissolved in dioxane (277 ml) is added a 2N aqueous sodium hydroxide solution (803 ml, 1606 mmol) followed by dropwise addition of methyl chloroformate (75 ml, 973 mmol) over the course of 1 hour which causes heating of the solution to occur. After the addition, the mixture is heated at 60 ° C for 22 hours, then cooled and extracted with dichloromethane (400 ml). The resulting aqueous layer is cooled in an ice bath then 12N hydrochloric acid is added dropwise until the pH is 2. The resulting mixture is stirred at 0 ° C for 2 hours then the resulting solid is vacuum filtered and dried. in a vacuum oven to provide 80 g (94%) of the title compound as a colorless solid.
H NMR (400 MHz, DMSO-d6) δ 12.50 (bs, 1H), 7.34 (d, J = 8.6 Hz, 1H), 3.84 (dd, J = 8.6, 6.0 Hz, 1H), 3.54 (s, 3H) , 2.03 (m,
1H), 0.86 (t, J = 7.0 Hz, 6H).
,OR
EXAMPLE 116C (S) -1 - ((S) -2-carbamoylpyrrolidi n-1 -yl) -3-methyl-1-oxobutan-2477 ylcarbamate methyl
<img file="MX339989B_D0813.tif" />
I
INSTITUTO MEXICANO BE LAFROHIOaD INDUSTRIAL
<img file="MX339989B_D0814.tif" />
To the product of Example 116A (21 product of Example 116B (29.1 g, benzo [d] [1,2,3] triazol-1-ol hydrate (27.6 g, 180 mmol), N1 - ((ethylimino) methylene hydrochloride) -N3, N3-dimethylpropan-1,3-diamine (34.6 g, 180 mmol) and 4-methylmorpholine (63.5 ml, 578 mmol) is dissolved in dichloromethane (960 ml) and stirred at room temperature for 18 hours. The resulting solution is then concentrated to a residue, then water is added and the solution is extracted with a solution of 25% isopropanol in chloroform (2 x 2000 ml) the organic layer is washed with brine then the organic extract is dried over MgSO<sub>4</sub>Then it is concentrated to a yellow oil which is purified by column chromatography eluting with a gradient of 0-10% methanol in dichloromethane to provide 25 g (64%) of the title compound as a colorless solid.
<sup>1</sup>H NMR (400 MHz, DMSO-d6) δ 7.28 (m, 2H), 6.81 (s, 1H), 4.24 (dd, J = 8.1, 4.4 Hz, 1H), 4.00 (t, J = 8.4 Hz, 1H) , 3.75 (m, 1H), 3.55 (m, 1H), 3.50 (s, 3H), 2.02 (m, 1H), 1.97 (m, 2H), 1.80 (m, 2H), 0.92 (d, J = 6.7 Hz, 3H), 0.86 (d, J = 8.6 Hz, 3H).
.6 g, 144 mmol), the
166 mmol). 1 HOUR-
<img file="MX339989B_D0815.tif" />
478
IMPI
EXAMPLE 116D
INSTITUTO MEXICANO r> E la> Kcmr? AO 1NDVSTWAL
<img file="MX339989B_D0816.tif" />
2 - ((2R, 5R) -2,5-b¡s (4-chloro-3-nitrophen¡l) pyrrole¡d¡n-1 -yl) -4,5,6,7tetrahydrobenzordithiazole '~
The product from Example 109C (0.80 g, 1.489 mmol) and
4,5,6,7-tetrahydrobenzo [d] thiazol-2-amine are processed using the method of Example 113A to obtain 0.375 g (50%) of the title compound.
<img file="MX339989B_D0817.tif" />
EXAMPLE 116E (K2R.5R) -1 - (4,5,6,7-tetrahydro-1,3-benzot¡azol-2-¡l) pyrrole¡d¡n-2,5d¡-¡nb¡s ((2-n ¡Trobencen-4.1 -di-¡l) carbamo¡l (2S) p¡rrol¡d¡n-2,1-diir (2S) -3-methyl-1-oxobutan-1,2-di dimethyl -iHUbiscarbamate (ACD v12))
The product from Example 116D (0.375 g, 0.722 mmol) is processed as in Example 113B, substituting the product from Example 116C for tert-butyl (S) -2-carbamoylpyrrolidin-1-carboxylate. to obtain 0.59 g (83%) of the title compound.
479
<img file="MX339989B_D0818.tif" />
IMPIAS »/
-Ο<sub>γ</sub>Ν ^ /<sub>(</sub> ™ ο Ζθγ<sup>Ν</sup> me
INSTITUTO MEXICANO D5 ΙΑ ΡΓ (.ΟΠΓΟΛΠ
INDUSTRIAL / UrOW?
h<sub>2</sub>n \ _y nh<sub>2</sub> To or
<img file="MX339989B_D0819.tif" />
EXAMPLE 116F (R2R, 5R) -1- (4,5,6,7-tetrahydro-1,3-benzothiazol-2-¡l) pyrrolidin-2,5d¡-¡llb¡s ((2-am i nobenzene Dimethyl -4,1-di-¡l) carbamoil (2S) p¡rrolidin-2,1-diir (2S) -3-methyl-1-oxobutan-1,2-di-ylD) biscarbamate (ACD v12))
The product from Example 116E (0.59 g, 0.596 mmol) is dissolved in tetrahydrofuran (15 ml) and treated with suspension of Raney nickel in water (0.25 ml). The flask is evacuated and opened onto a hydrogen balloon and stirred at room temperature for 1 hour. The solution is filtered through a plug of silica and concentrated to dryness to obtain the title compound.
EXAMPLE 116G f (2SI-1 -r (2S) -2- <6-f (2R, 5R) -5-f 2-f (2S) -1 -f (2S) -2r (methoxycarbonamino1- 3-methylbutanoinp¡rrohd¡n-2-iH-1Hbenzim idazol-5-i 1) -1- (4,5,6,7-tetrahydro-1,3-benzot¡azol-2-yl) pyrrolidin- Methyl 2-iyl-1 H-benzimidazol-2-yl) p¡rrolid¡n-1-¡Π-3-methyl-loxobutan-2-yl) carbamate
480
The product of Example 116F (0.55 g, 0.5
<img file="MX339989B_D0820.tif" />
dissolve in toluene (6 ml) and treat with acetic acid (0.34 ^^^. 92 mmol) and heat at 65 ° C for 4 hours. Concentrate to dryness and purify by 12 g combi-flash silica column, eluting with 0-6% methanol in dichloromethane to obtain 0.245 g (48%) of the title compound.
1H NMR (400 MHz, DMSO-D6) δ ppm 0.78 - 0.92 (m, 12
H) 1.53-1.61 (m, 4H) 1.67-1.75 (m, 2H) 1.88-2.07 (m, 6H) 2.15 2.27 (m, 6H) 2.41-2.47 (m, 2H) 2.59 (d, J = 1.63 Hz, 2H) 3.54 (s, 6H) 3.79 - 3.87 (m, 4H) 4.07 (t, J = 8.57 Hz, 2H) 5.12 - 5.20 (m, 2H)
5.38 - 5.46 (m, 2 H) 7.05 (dd, J = 12.79, 9.00 Hz, 2 H) 7.22 - 7.33 (m, 4 H) 7.39 (d, J = 8.46 Hz, 1 H) 7.46 (d, J = 8.46 Hz, 1H) 12.06 (d, J = 6.83 Hz, 2H).
MS ESI + m / z 893.5.
<img file="MX339989B_D0821.tif" />
°> NH “Ib
EXAMPLE 117 f (2S) -1-r (2S) -2- (4-f4-r (2S.3R, 4R, 5S) -1- (4-tert-butylphenyl) -3.4-diethoxy5- (4- (2-r (2S) -1 - ((2S) -2-Rmethox¡carbon¡l) am¡no1-3methi I butanoi l) p¡rrol id i n-2-¡Π-1 H- imidazol-4-¡l) fen¡ l) p¡ rrol i din-2il1phenyl) -1 H-imidazol-2-iDpyrrolidin-1 -il1-3-methyl-1-oxobutan-2481 ¡D-carbamate dm linden
IMPI
MEXICAN INSTITUTE OF INDUSTRIAL PROPERTY
<img file="MX339989B_D0822.tif" />
3.4-O-isopropylidene-D-mannitol is processed using the methods of Examples 79C, 79D, 79E, 79F, 79G, 79H, and 79I to provide the title compound, in which iodoethane is used in the O- step. alkylation (method of Example 79D) in place of iodomethane.
<sup>1</sup>H NMR (400 MHz, CDCI<sub>3</sub>) δ ppm 0.86 (t, J = 7.4 Hz, 12H) 1.04 (t, J = 7.0 Hz, 6H) 1.13 (s, 9H) 1.85-2.03 (m, 4H) 2.03-2.13 (m, 2H) 2.13-2.24 (m, 2H) 2.24-2.40 (m, 2H) 3.03 (m, 2H) 3.54-3.89 (m, 9H) 3.69 (d, J = 1.7 Hz, 6H) 4.25 (d, J = 5.3 Hz, 2H) 4.31 (br s, 2H) 5.19-5.29 (m, 4H) 5.36 (br s, 2H) 6.28 (d, J = 8.8 Hz, 2H) 6.90-6.98 (m, 4H) 7.12-7.23 (m, 6H).
MS (ESI) m / z 1029 (M + H)<sup>+</sup>.
<img file="MX339989B_D0823.tif" />
EXAMPLE 118 n2S) -1-r (2S) -2- (5-R2R, 5R) -5-f2-H2S) -1-R2S) -2f (methoxycarbonyl) amino-3-methylbutanoyl) p¡ rrolid¡n-2-ill-1 Hb ncim¡dazol-5-yl) -1 -Γ6- (ρϊrrolidin-1-pyridin-3-illpyrrol¡din-2-yl> 482
Hb nc¡midazol-2-ii) pyrrolid¡n-1 -¡Η-3-m til ¡Ijcarbamate of methyl
-l-txMuPnL
MEXICAN INSTITUTE OF INDUSTRIAL PROPERTY
<img file="MX339989B_D0824.tif" />
EXAMPLE 118A
5- nitro-2- (p¡ rrolidi n-1 -iDpyridine
To a suspension of 2-chloro-5-nitropyridine (10 g, 63.1 mmol) in EtOH (100 ml) at room temperature, pyrrolidine (15.72 ml, 189 mmol) is added and the mixture is heated at 70 ° C for 18 hours. The cold solution is concentrated in vacuo and the residue is partitioned between CH<sub>2</sub>CI<sub>2</sub> and in 1 M NaOH. The organic layer is dried (Na<sub>2</sub>SO4), filtered and the solvent is removed in vacuo to obtain the title compound (9.52g, 78%).
MS (ESI) m / z 194 (M + H)<sup>+</sup>.
EXAMPLE 118B
6- (p¡rrolidi n-1 -ii) pyridin-3-amine
The material from Example 118A (9.52 g, 49.3 mmol) is dissolved in THF (50 ml) and DMF (40 ml) and added to a pressure bottle containing Raney 2800 nickel, suspended in water (45%) (9.52 g , 162 mmol) is stirred for 2 hours at 2.11 kg / cm<sup>2</sup> low H<sub>2 </sub>gas. The solution is filtered through a nylon membrane, washed with CH<sub>3</sub>OH and the filtrate is concentrated in vacuo to obtain the title compound (7.78 g, 97%).
483 <sup>1</sup>H NMR (400 MHz, OMSO-d6) δ ppm 1.
<img file="MX339989B_D0825.tif" />
3.17-3.29 (m, 4H) 4.30 (s, 2H) 6.25 (d, J = 8.7, 1H), 6.90
8.7, 1H), 7.55 (d, J = 2.6, 1H). - * --- ~~
MS (ESI) m / z 164 (M + H)<sup>+</sup>.
EXAMPLE 118C (2S, 2'S) -2.2 '- (5.5' - ((2R, 5R) -1- (6- (pyrrol¡d¡n-1-¡l) pir¡d¡n-3 ¡Dpyrrole ¡di n-2,5-di-i Dbisí 1 H-benzofd1imidazole-5,2-di-iDdi pyrrole ¡di n1-tert-butyl carboxylate
Example 118B and Example 109C are processed sequentially using the methods of Examples 113A, 113B, 116F, and 28I to provide the title compound.
EXAMPLE 118D f (2S) -1 -r (2S) -2- (5 - {(2R, 5R) -5- {2-H2S) -1 -f (2S) -2-phimethoxycarboni Pami nol-3-methylbutanoiPpyrrolidi n- 2-yl1-1 Hbenzimidazol-5-¡n-1-r6- (p¡ rrolidi n-1-i Dpi ridin-3-illPÍ rroiidin-2-iD1 H-benzim idazol-2-i Dpi rrolidi n-1- methyl iii-3-methii-1-oxobutan-2¡Dcarbamate
To a solution of Example 118C (741 mg, 0.94 mmol) in dioxane (4 ml) is added 4 M HCl in dioxane (4.0 ml) and the solution is stirred at room temperature for 30 minutes. The solvent is removed in vacuo and the residue is dissolved in DMF (9.4 ml). It is added
484
<img file="MX339989B_D0826.tif" />
Ν, Ν-di-isopropylethylamine (0.99 ml, 5.65 mmol) s ^ JMLpoI
MEXICAN INSTITUTE
DE LA ΓΤΟΡΙΕΟΑΟ (S) -2- (methoxycarbonyl-amino) -3-methylbutanoic (379 mmol), HOBT (331 mg, 2.16 mmol), and EDO — f4T5<sup>-</sup>'-nig; -2? t6 mmol) and stirred at room temperature for 18 hours. Pour into EtOAc, wash with H<sub>2</sub>O, brine, dries up (Na<sub>2</sub>SW<sub>4</sub>), filtered and the solvent is removed under vacuum to obtain the crude product which is purified by flash chromatography on silica gel eluting with 0-6% CH<sub>3</sub>OH / CH<sub>2</sub>CI<sub>2 </sub>to obtain the title compound (165 mg, 0.183 mmol, 19%).
1H NMR (400 MHz, DMSO-d6) δ 0.73-0.95 (m, 12H) 1.662.27 (m, 12H) 3.09 (br s, 5H) 3.53 (s, 6H) 3.81 (br s, 4H) 4.06 (t , J = 8.4 Hz, 2H) 5.13 (br s, 2H) 5.33 (br s, 2H) 6.12 (br s, 1H) 6.64 (br s, 1H) 7.00-7.47 (m, 10H) 12.02 (s, 2H) .
MS (ESI) m / z 903 (M + H)<sup>+</sup>.
<img file="MX339989B_D0827.tif" />
EXAMPLE 119
4- {4-f (2R, 5R) -2,5-b¡s (2 - ((2S) -1-rN- (methoxycarbon¡l) -Lval¡npyrrolid¡n-2-yl) - Methyl 1 H-benzimidazol-5-yl) pyrrolidin-1 -ΙΙΊ-2-fluorophenyl) piperazine-1-carboxylate
485
EXAMPLE 119A IMPIOS
INSTITUTE MtX'OAN'O
D £ LA? £ <>? ÍEDAO t. ww ^^ gMjJKa?
- (2-fluoro-4-nitrophenyl) piperazine ¡ndotaiai
1,2-Difluoro-4-nitrobenzene (2.0 ml, 18.07 mmol) is added dropwise to a hot solution of piperazine (7.78 g, 90 mmol) in DMSO (40 ml). The solution is stirred at 70 ° C for 2 hours, cooled to room temperature, diluted with EtOAc, washed with H<sub>2</sub>O, brine, dries up (Na<sub>2</sub>SW<sub>4</sub>), filter and remove the solvent in vacuo to obtain the title compound (4.05 g, 17.98 mmol, 100%).
<sup>1</sup>H NMR (400 MHz, CDCI<sub>3</sub>) δ ppm 3.03-3.09 (m, 4H) 3.263.29 (m, 4H) 6.91 (t, J = 8.8 Hz, 1H) 7.91 (dd, J = 13.1, 2.6 Hz, 1H) 7.96-8.01 (m, 1H) ).
MS (ESI) m / z 226 (M + H)<sup>+</sup>.
EXAMPLE 119B
Methyl 4- (2-fluoro-4-nitrophenyl) piperazin-1-carboxylate
Ί
To a solution of Example 119A (4.0 g, 17.76 mmol) in dioxane (40 ml) at 0 ° C 2M NaOH (29.3 ml, 58.6 mmol) is added followed by dropwise addition of methyl chloroformate (2.75 ml, 35.5 mmol ). The solution is warmed to room temperature and stirred for 2 hours. Dilute with EtOAc and add 1N HCl until all solid dissolves, the phases are separated, and the organic phase is washed with 1N HCl, H<sub>2</sub>Or, brine, be
486
Dry IMPI (Na<sub>2</sub>SW<sub>4</sub>), it is filtered and the solvent is removed at ¥ f§y $$ ^ $$> t
INDUSTRIAL
<img file="MX339989B_D0828.tif" />
the title compound (4.69 g, 16.56 mmol, 93%).
H NMR (400 MHz, CDCI<sub>3</sub>) δ ppm 3.20-3.31 (m, 4H) 3.623.71 (m, 4H) 3.75 (s, 3H) 6.92 (t, J = 8.8 Hz, 1H) 7.93 (dd, J = 12.9, 2.6 Hz, 1H) 7.98 -8.02 (m, 1H).
MS (ESI) m / z 284 (M + H)<sup>+</sup>.
EXAMPLE 119C
Methyl 4- (4-amino-2-fluorophenyl) piperazin-1-carboxylate
To a solution of Example 119B (3.0 g, 10.59 mmol) in EtOAc (40 ml) is added 10% palladium on carbon (300 mg) and the solution is stirred under a H balloon.<sub>2</sub> gas for 1.5 hours. The solution is filtered through Celite, the catalyst is washed with EtOAc, and the filtrate is concentrated in vacuo to obtain the title compound (2.68g, 10.59mmol, 100%).
EXAMPLE 119D
4- {4-K2R, 5R) -2,5-bis (2-f (2S) -1-rN- (nrietox¡carbon¡l) -Lval¡npyrrolid¡n-2-¡l) -1H-benc ¡M¡dazol-5-¡l) p¡rrol¡d¡n-1-¡ll-2fiuorophenylpiperazine-1-methyl carboxylate
Example 119C and Example 109C are processed sequentially using the methods of Examples 113A113C, 26I, and 118D to provide the title compound.
487 ; · 5Κ *, · ύκ ·? Χ-: γ · τι
<img file="MX339989B_D0829.tif" />
<img file="MX339989B_D0830.tif" />
Ή NMR (400 MHz, DMSO-dO) δ ppmi
OF THE INDUSTRIAL CV PROPERTY
1.69 (br s, 2H) 1.82-2.07 (m, 7H) 2.10-2.28 (m, 4H) 2.61-2.73 (rn, 5
3.54 (s, 6H) 3.56 (s, 3H) 3.82 (br s, 4H) 3.99-4.1 Ππΐ, J> H) 5.1) 9-5. W (m, 2H) 5.29-5.41 (m, 2H) 6.01-6.13 (m, 2H) 6.61-6.72 (m, 1H) 7.06 (s, 2H) 7.20 (s, 1H) 7.29 (d, J = 9.1 Hz , 3H) 7.38 (d, J = 8.1 Hz, 1H)
7.46 (d, 1H) 12.04 (s, 2H).
MS (ESI) m / z 993 (M + H)<sup>+</sup>.
<img file="MX339989B_D0831.tif" />
EXAMPLE 120 ((2S) -1-r (2S) -2-f5-r (2R.5RI-1-r3-fluoro-4- (morpholin-4-¡l) phen¡n-5- (2r (2S) -1-f (2S) -2-r (methoxycarbon¡nam¡no1-3-met¡lbutane¡np¡ rrol idi n2-ΪΠ-1 H-benzim idazol-5-inpyrrolidin-2-iH-1 Methyl H-benzim idazol-2-yl) pyrrolidin-1-yl1-3-methyl-1-oxobutan-2-illcarbamate
A suspension of morpholine (4.72 ml, 4.72 g, 54.2
EXAMPLE 120A
4- (2-Fluoro-4-nitrophenyl) morpholin
488 mmol) and dibasic potassium phosphate
OF INDUSTRIAL PROPERTY
<img file="MX339989B_D0832.tif" />
(9.44 g,
<img file="MX339989B_D0833.tif" />
DMSO (27 ml) is treated with 3,4-difluoronitrobenzene (3.0 ml, 4.31 g,
27.1 mmol) is heated at 60 ° C for 18 hours. The solution is cooled and diluted with ethyl acetate and extracted with water (3x) and saturated sodium chloride solution. Drying (Na<sub>2</sub>SW<sub>4</sub>) and concentration in vacuo allows the title compound (6.32 g, approx. 100%) to be obtained as a yellow solid.
<sup>1</sup>H NMR (400 MHz, CDCI<sub>3</sub>) δ 8.00 (ddd, J = 9.0, 2.6, 0.9 Hz, 1 H), 7.92 (dd, J = 13.1, 2.6 Hz, 1 H), 6.92 (t, J = 8.8 Hz, 1 H),
3.88 (m, 4H), 3.29 (dd, J = 5.5, 4.0 Hz, 4H).
MS + DCI m / z (rel abundance) 227 (10, M + H), 244 (100, M + NH4).
EXAMPLE 120B
3-fluoro-4-morpholnoanilin
A solution of the compound of Example 120A (2.26 g, 10.00 mmol) in ethyl acetate (35 ml) is treated with 10% palladium on carbon (300 mg) followed by hydrogenation under a pressure atmosphere for 6 hours. The mixture is filtered through celite and concentrated in vacuo to obtain the title compound as a white solid.
EXAMPLE 120C
4- (4 - ((2R.5R1-2.5-b¡ (4-chloro-3-nitrofnil) p¡ rrol ¡d¡n-1-yl) -2489 fluorof niDmorpholine
IMPI
INSTITUTE - / EXfCANO DE LA rnO? '£ OAÍ> íh'DVSTWAt
<img file="MX339989B_D0834.tif" />
A solution of the compound of Fj ^ mpin mac (? QQ q, 4.99 mmol) and triethylamine (4.17 ml, 3.03 g, 29.9 mmol) in dry dichloromethane (25 ml) at 0 ° C is treated with methanesulfonyl chloride (1.17 ml, 1.71 g, 14.96 mmol) followed by stirring at 0 ° C for 30 minutes. The solution is warmed to room temperature and then concentrated in vacuo. The residue is combined with the compound of Example 120B and N, Nd¡methylanine (1.26 ml, 1.21 g,
9.98 mmol) and dissolved in dry DMF (14 ml) followed by heating at 50 ° C for 2 hours. The solution is cooled and diluted with ethyl acetate, followed by extraction with water (3x) and 1N hydrochloric acid solution (2x) and saturated sodium chloride solution. Drying (Na<sub>2</sub>SW<sub>4</sub>) and concentration in vacuo allows to obtain an orange oil, which is subjected to chromatography through a 340 g silica gel cartridge, eluting with 1080% ethyl acetate in hexanes. These procedures allow the title compound (1.39 g, 50%) to be obtained as a stiff orange foam.
<sup>1</sup>H NMR (400 MHz, CDCI<sub>3</sub>) δ 7.92 (m, 2H), 7.58 (m, 9H),
7.31 (dd, J = 8.3, 2.1 Hz, 2H), 6.69 (s, 1H), 5.99 (m, 2H), 5.20 (d, J = 7.1 Hz, 2H), 3.79 (m, 4H ), 2.92 (m, 6H), 2.54 (m, 2H), 1.88 (m, 2H).
EXAMPLE 120D (2R, 2'R) -1,1'-R2S, 2'S1-2.2 '- (4,4' - (f2R.5R) -1- (3-fluoro-4490 morpholinophenyl) pyrrole ¡d¡ n-2.5-di-yl) bi (2-nitr ΧΑΪΡΙ
DE ¿A FÁOFIEDAD fen¡len)) b¡s (azand¡-¡l) bis (oxometh¡len) b¡s (pyrrol¡d¡n-2.1-di-ihypheisO ^ meth 1-1-oxobutan-2.1- di-indicate dimethyl bamate
<img file="MX339989B_D0835.tif" />
In a microwave tube, a suspension of Example
120C (1.39 g, 2.48 mmol), the compound of Example 116C (2.02 g, 7.43 mmol), Xantfos (129 mg, 0.22 mmol) and cesium carbonate (2.42 g, 7.43 mmol) in dioxane (14 ml) is degassed by sparged with nitrogen for 30 minutes. The mixture is treated with tris (dibenzylideneacetone) dipalladium (0) (68 mg, 0.074 mmol) followed by degassing for another 5 minutes. The microwave tube is sealed and the mixture is heated at 100 ° C for 2 hours. The mixture is cooled and diluted with ethyl acetate and extracted with water (3x) and saturated sodium chloride solution. The solution dries (Na<sub>2</sub>SW<sub>4</sub>) and stir overnight with 3- (mercaptopropyl) -silica gel. Filtration and concentration under vacuum allow a solid to be obtained, which is subjected to chromatography through a 340 g cartridge of silica gel, eluting with 0-10% methanol in dichloromethane. These procedures allow the title compound to be obtained as an orange solid.
<sup>1</sup>H NMR (400 MHz, DMSO-d6) δ ppm 0.80-0.90 (m, 12H)
1.74 (br s, 2H) 1.82-2.03 (m, 10H) 2.08-2.20 (m, 2H) 2.71-2.81 (m, 4H) 3.52 (s, 6H) 3.62 (m, 4H) 3.76 (s, 2H) 4.02 (m, 2H) 4.50 (d, J = 4.4 Hz, 2H) 5.39 (s, 2H) 6.04-6.19 (m, 2H) 6.72-6.81 (m, 1H) 7.32 (d,
J = 8.4 Hz, 2H) 7.47-7.60 (m, 4H) 7.80 (d, J = 1.5 Hz, 2H) 10.41 (s, 2H).
491 .CAT.
MS (ESI) m / z 1031 (M + H)
IMPI
MEXICAN INSTITUTE OF INDUSTRIAL FLCTIEDáD
<img file="MX339989B_D0836.tif" />
EXAMPLE 120E —-----------— (2S, 2'S) -1.1 '- ((2S, 2'S) -2.2' - (4.4 '- ((2R, 5R) -1- (3-fluoro-45 morpholinophenyl) p¡rrol¡d¡n-2.5-d¡-¡l) b¡s (2-amino-4,1 phenylene) bis (azandi-yl ) dimethyl bis (oxomethylene) bis (p¡rrol¡d¡ n-2,1 di-i l) bis (3-methyl-1-oxobutan-2,1-d¡-ddicarbamate
To a solution of Example 120D (640 mg, 0.621 mmol) in EtOH (4 ml) and THF (4 ml) is added PtO<sub>2</sub> (35 mg) and the solution is stirred under a balloon of H<sub>2</sub> gas for 16 hours. The solution is filtered through Celite and washed with EtOAc. The filtrate is concentrated in vacuo to obtain the title compound (322 mg, 0.332 mmol,
53%).
EXAMPLE 120F
R2S) -1-r (2S) -2-f5-r (2R.5R) -1-r3-fluoro-4- (morphoiin-4-yl) fenin-5- {2f (2S) -1 - {( 2S) -2-r (methoxycarbonyl) amino 1-3-methylbutanoyl) pyrroled¡n2-iH-1H-benzim¡dazol-5-¡l} p¡rrolidin-2-iH-1 H-benzimidazole-220 methyl yl) pyrrolidin-1-yl1-3-methyl-1-oxobutan-2-yl) carbamate
Glacial acetic acid (0.057 ml, 0.99 mmol) is added to a solution of Example 120E (320 mg, 0.33 mmol) in toluene (1.5 ml) and the solution is stirred at 50 ° C for 3 hours. The cold solution is concentrated in vacuo and azeotropically distilled 2 times.
492 h ^ Adll<sup>1</sup> 11 f / Ι F Ί ilKTrariBBV *
<img file="MX339989B_D0837.tif" />
with toluene. The crude product is purified by means of j ^ jijfcjr
INSTITUTO MEXICANO flash vaporization on silica gel eluyend6<sup>HE/</sup>d ^ OSCH3OH / CH2Cl2 to obtain the title compound (100 mg, Ql.1.Q, Z mmol, 32%).
<sup>1</sup>H NMR (400 MHz, DMSO-d6) δ ppm 0.72-0.92 (m, 12H)
1.69 (br s, 2H) 1.81-2.10 (m, 8H) 2.11-2.28 (m, 4H) 2.64-2.78 (m, 4H)
3.54 (s, 6H) 3.59 (s, 4H) 3.73-3.92 (m, 4H) 4.06 (s, 2H) 5.02-5.21 (m, 2H) 5.36 (s, 2H) 6.03-6.14 (m, 2H) 6.60- 6.73 (m, 1H) 7.00-7.15 (m, 2H) 7.15-7.37 (m, 4H) 7.36-7.61 (m, 2H) 12.06 (br s, 2H).
MS (ESI) m / z 935 (M + H)<sup>+</sup>.
<img file="MX339989B_D0838.tif" />
EXAMPLE 121 n2S) -1 - {(2S) -2-f5- (4 - {(2S.3R.4R, 5S) -1- (4-tert-butylphenyl) -5- {4- (2rf2S) -1 - (f2S) -2-f (methox¡carbon¡l) am¡no1-3-meth¡lbutanoyl) pyrroid¡d¡n2-ΪΠ-1 H-imidazole-5-¡l) fenll) -3.4-b¡ sr2- (2methoxyethoxy) ethoxy] p¡rrol¡d¡n-2-¡l) phenyl) -1 H-im¡dazol-2-iH pyrrolidi n1-yl) -3-methyl-1 methyl-oxobutan-2-OHcarbamate
3.4-O-isopropylidene-D-mannitol is processed using in
493 iwiHiftuafciags »· tsvn sequentially forms the methods of Examples 79C
<img file="MX339989B_D0839.tif" />
<img file="MX339989B_D0840.tif" />
INDUSTRIAL
<img file="MX339989B_D0841.tif" />
(2-methoxyethoxy) ethane as the alkylating agent with addition of sodium iodide), 79E-79G, 79H (18 hour reaction time), 66D, and 66E to provide the title compound (46 mg) as a solid of light yellow color.
<sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 7.60 (d, J = 7.9 Hz, 4 H),
7.50 (d, J = 8.4 Hz, 2H), 7.38 (s, 2H), 7.29 (d, J = 8.6 Hz, 2H), 7.19 (s, 4H), 6.90 (m, 2H), 6.27 (d, J = 8.6 Hz, 2 H), 5.37 (s, 2 H), 5.07 (d, J = 3.6 Hz, 2 H), 4.32 (s, 2 H), 4.06 (m, 2 H), 3.78 (d, J = 6.0 Hz,
two H), 3.66 (d, J = 4.2 Hz, 4H), 3.53 (s, 6H), 3.17 (s, 6H), 2.10 (m, 4
H), 1.93 (m, 4H), 1.07 (s, 9H), 0.86 (m, 12H).
MS (+ ESI) m / z (rel abundance) 1177 (100, M + H), 1199 (5, M + Na).
<img file="MX339989B_D0842.tif" />
<(2S) -1-H2S) -2- (5-f4-r (2S, 3R, 4R, 5S) -1- (4-tert-butylphenyl) -5- (4- (2H2S) -1- { (2S) -2-f (methoxy carbon yl) am i ηοΊ-3-methyl butanoyl} pyrrole id i n2-IH-1 H-imidazole-5-ii) fenii) -3,4-bis (3-methoxypropoxy ) pyrrolidin-2yl-phenyl> -1H-imidazol-2-ii) pyrolidi n-1 -¡n-3-methyl-1-oxobutan-225 illcarbamate of m-linden
494
3,4-O-isopropylidene-D-mannit ^ are processed sequentially by the methods of Examples 79C, methoxypropane as the alkylating agent with addition of sodium iodide), 79E-79H, 66D, and 66E to provide the title compound.
<sup>1</sup>H NMR (400 MHz, DMSO-d<sub>s</sub>) δ 7.60 (s, 4 H), 7.52 (m, 2
H), 7.37 (m, 2H), 7.30 (m, 4H), 7.18 (d, J = 7.1 Hz, 4H), 6.91 (m, 2
H), 6.24 (m, 2H), 5.40 (m, 2H), 5.06 (m, 2H), 4.31 (m, 2H), 4.11 (m, 2H), 3.78 (s, 4H) , 3.66 (m, 4H), 3.56 (m, 10H), 3.14 (m, 14H),
2.14 (m, 6H), 1.94 (d, J = 3.5 Hz, 8H), 1.43 (m, 6H), 1.07 (s, 10H), 0.89 (d, J = 6.1 Hz, 6H), 0.84 (d, J = 5.9 Hz, 6H).
<img file="MX339989B_D0843.tif" />
f (2S) -1-rf2S) -2-f5-f4-H2S, 3R, 4R, 5S) -1-f4-tert-butylphenyl) -5- (4-f2 [(2S) -1 -f (2S) -2-rfmethoxScarboniham¡no1-3-methylbutanoyl) pyrrole¡d¡n2-in-1H-¡midazol-5-¡l} phen¡l) -3.4-b¡s (2-methoxyethoxy) p ¡Rrol¡din-2¡Hfen¡l) -1 H-¡midazol-2-¡l) p¡rrol¡d¡n-1-¡H-3-methyl-1-oxobutan-2¡Dcarbamate of methyl
3.4-O-isopropylden-D-mannitol is processed using in
495 sequentially the methods of Examples 79
<img file="MX339989B_D0844.tif" />
J Ai P-3r
MEXICAN INSTITUTE OF PROPERTY
<img file="MX339989B_D0845.tif" />
methoxyethane as the alkylating agent with addition of sodium phosphate), 79E, 79F, 79G, and 79H, where 5 * ~ 5l ..... Example — ΤΤββ 'replaces (S) -2- (4 tert-butyl -bromo-1H-imidazol-2-yl) pyrrolidin-1-carboxylate in applying the method of Example 79H, to provide the title compound (43 mg) as a light beige solid.
<sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 7.60 (d, J = 8.0 Hz, 4 H),
7.47 (m, 2H), 7.37 (m, 2H), 7.27 (m, 4H), 7.19 (s, 4H), 6.90 (d, J =
8.6 Hz, 2H), 6.26 (d, J = 8.7 Hz, 2H), 5.37 (s, 2H), 5.06 (d, J = 3.7
Hz, 2H), 4.30 (s, 2H), 4.03 (m, 2H), 3.79 (s, 4H), 3.66 (m, 6H),
3.53 (s, 6H), 3.25 (m, 6H), 3.12 (s, 6H), 2.13 (m, 4H), 1.94 (m, 6
H), 1.07 (s, 9H), 0.89 (d, J = 6.6 Hz, 6H), 0.84 (d, J = 6.6 Hz, 6H).
MS + ESI m / z (rel abundance) 1088 (100, M + H).
<img file="MX339989B_D0846.tif" />
<img file="MX339989B_D0847.tif" />
EXAMPLE 124 ((2S) -1-r (2S) -2-f6- <f2R, 5R) -5-f2 - [(2S) -1-ff2S) -2f (methoxycarbonyl) aminoT-3-methylbutanoiDpyrrolidin-2- in-1H25 b ncimidazol-6-in-1-fe- (morpholin-4-yl) p¡r¡d¡n-3-inpyrrol¡din-2-yl) 496
H-benzim¡dazol-2-ll) pyrrolldin-1 -¡H-3-methyl illcarbamate of methyl in> 111 uv / ntAlKANE
Dt THE PROPERTY
INDVSTSJAl
<img file="MX339989B_D0848.tif" />
<img file="MX339989B_D0849.tif" />
Example 109C and Example 154B are processed using the methods of Examples 113A, 113B, 116F, 281 (reaction carried out at 50 ° C for 4 hours), 66D, and 66E to provide the title compound (120 mg) as a light beige solid.
<sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 12.03 (s, 1 H), 7.46 (d, J = 8.2 Hz, 1 H), 7.45 (s, 1 H), 7.31 (d, J = 6.4 Hz, 3 H), 7.21 (s, 1 H ),
7.06 (t, J = 8.0 Hz, 2H), 6.64 (m, 1H), 6.49 (m, 1H), 5.36 (d, J = 6.2
Hz, 2H), 5.13 (s, 2H), 4.04 (m, 2H), 3.77 (m, 3H), 3.55 (m, 9H),
3.04 (s, 4H), 2.19 (s, 3H), 1.95 (m, 5H), 1.73 (s, 3H), 0.82 (m, 12H).
<img file="MX339989B_D0850.tif" />
EXAMPLE 125 í (2S) -1-H2S) -2- (5- (4-M- (2.3-d¡h¡dro-1H-innder> -5-¡l) -5- (4-f2- r (2S) -1f (2S) -2-r (methoxycarbonl) amino1-3-methylbutanoyl) pyrroldin-2-ill-1Him¡dazol-5-yl) phenil) -1H-p¡rrol-2-¡Hphenyl) -1H-¡m¡dazol-2-¡l) pyrrolid¡n25 1-¡n-3-methyl-1-oxobutan-2-iDcarbamate of m-tyl
497
<img file="MX339989B_D0851.tif" />
IMPI
<img file="MX339989B_D0852.tif" />
Example 26E and 5-aminoindane are projae-san
DE LA íVli.DAIi) [NWSXIíMl.
the methods of Examples 76A, 39E, 39F, 55G, and 26J (reaction solvent = dichloromethane) to provide the title compound (0.1446 g).
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ 0.91 - 0.79 (m, 12H),
2.18 - 1.87 (m, 12H), 2.74 (t, J = 6.7, 2H), 2.86 (t, J = 6.8, 2H), 3.53 (s, 6H), 3.84 - 3.68 (m, 4H), 4.10 - 3.98 (m, 2H), 5.03 (dd, J = 6.8,
2.9, 2H), 6.54 - 6.40 (m, 2H), 7.10 - 6.86 (m, 5H), 7.22 - 7.13 (m, 2H), 7.33- 7.22 (m, 2H), 7.45 - 7.35 (m, 2H), 7.53 (dd, J = 13.7, 8.5, 4H),
11.70 (s, 1H), 12.07-11.96 (m, 1H).
MS (ESI) m / z 920 (M + H)<sup>+</sup>, 918 (MH)<sup>+</sup>.
<img file="MX339989B_D0853.tif" />
<img file="MX339989B_D0854.tif" />
EXAMPLE 126 r (2S) -1-f (2S) -2-r5- (4 - {(2R.5R) -5- (4- <2-H2S) -1-f (2S) -2r (methoxycarbonyl) aminoI-3-methylbutanoyl) pyrroiidin-2-yn-1Himidazol-5-yl) phenyl) -1-T4- (pentafluoro-lambda ~ 6-sulfanyl) phenylpyroiidin-2-yl) phenyl) -1H-imidazol- Methyl 2-illpyroiidin-1-yl) 3-methyl-1-oxobutan-2-illcarbamate
498
IMPI
<img file="MX339989B_D0855.tif" />
EXAMPLE 126A
(S) -2- (methoxycarbonylamino) -3-methylbutanoic acid
INSTITUTO MBOCAüC L »f LA WlOPtea · ®« βουή »
<img file="MX339989B_D0856.tif" />
A mixture of (S) -2-amino-3-methylbutanoic acid (10.0 5 g, 85.0 mmol), NaOH (3.41 g, 85.0 mmol) and NaHCO<sub>3</sub> (4.7 g, 44.4 mmol) in H<sub>2</sub>O (85 ml) is cooled to 0 ° C. A mixture of methyl chloroformate (7.3 ml, 94.0 mmol) dissolved in Et<sub>2</sub>O (40 ml) to the aqueous mixture and stir for 20 hours reaching room temperature. The mixture is adjusted to pH 2.0 with
HCI (cone.). The mixture is extracted with CH<sub>2</sub>CI<sub>2</sub> (3 x 100 ml) and then dried (MgSO<sub>4</sub>), filter and concentrate to obtain 7.5 g (50%) of the title compound.
MS (ESI) m / z 176 (M + H)<sup>+</sup>.
EXAMPLE 126B (S) tert-butyl -2-formylpyrrolldine-1-carboxylate
A mixture of oxalyl chloride (14.1 ml, 161 mmol) in CH<sub>2</sub>CI<sub>2</sub> (331 ml) is cooled to -75 ° C. Dimethyl sulfoxide (19.4 ml, 273 mmol) in CH<sub>2</sub>CI<sub>2</sub> (70 ml) over 30 minutes followed by stirring at -75 ° C for an additional 15 minutes. At -75 ° C tert-butyl (S) -2 (hydroxymethyl) pyrrolidine-1-carboxylate (25.0 g, 124 mmol) in CH2Cl2 (132 ml) is added slowly over the course of one hour, followed by an additional 15 minutes shaking. Afterwards, still at -75 ° C, • t.,
499
<img file="MX339989B_D0857.tif" />
<img file="MX339989B_D0858.tif" />
IMPI is added Et<sub>3</sub>N (87 ml, 621 mmol) in one lap ^ '^^^ ATOi followed by another 15 minutes of stirring. The mixture is then
1.41 »« ^ wwMiwMwaaftira.T.OT.n stir at 0 ° C for 90 minutes. The mixture is quenched with 10% aqueous citric acid at 0 ° C. The mixture is diluted with citric acid at
10% aqueous and partitions. The organic is washed with H<sub>2</sub>Or (5 x 150 mi) and brine. The organic is then dried (MgSO<sub>4</sub>), filter and concentrate to obtain 24.7g (100%) of the title compound.
MS (ESI) m / z 200 (M + H)<sup>+</sup>.
<img file="MX339989B_D0859.tif" />
EXAMPLE 126C (S) -2- (1H-imidazole-2-¡l) pyrrolidine-1-carboxylic acid tert-butyl ester
<img file="MX339989B_D0860.tif" />
A mixture of Example 126B (24.7 g, 124.0 mmol) and 15 NH<sub>4</sub>OH (62.0 ml, 497 mmol) in methanol (62 ml) is stirred at 0 ° C followed by slow addition of hydrated glyoxal (29.9 ml, 262 mmol) over the course of 10 minutes. The mixture is stirred for 16 hours at room temperature. The mixture is concentrated, diluted with H<sub>2</sub>O and extracted with EtOAc (3 x 200 mL). The organic is then dried (MgSO<sub>4</sub>), filtered and concentrated. Purification by trituration with tBuOMe allows to obtain 15.5g (53%) of the title compound.
MS (ESI) m / z 238 (M + H)<sup>+</sup>.
EXAMPLE 126D (S) -2- (4,5-dibromo-1H-amidazol-2-yl) pyrrolldine-1-carboxylate dt r-
<img file="MX339989B_D0861.tif" />
500 butyl
A mixture of Example 126C (15.5 g, 65.4 mmol) in CH<sub>2</sub>CI<sub>2</sub> (260 ml) is stirred at 0 ° C followed by portionwise addition of 1-bromopyrrolidine-2,5-dione (24.5, 137.0 mmol) over the course of 10 minutes. The mixture is stirred at 0 ° C for 90 minutes. The mixture is concentrated, diluted with EtOAc (600 mL), and washed with H<sub>2</sub>O (3 x 200 ml) and brine. The organic is then dried (MgSO<sub>4</sub>), filtered and concentrated. Purification by trituration with Et<sub>2</sub>Or allows to obtain 24.9 g (96%) of the title compound.
MS (ESI) m / z 396 (M + H)<sup>+</sup>.
EXAMPLE 126E (S) -2- (5-bromo-1H-amidazol-2-yl) pyrolidin-1-tert-butyl carboxylate
To a mixture of Example 126D (12.5 g, 31.5 mmol) in dioxane (400 ml) and H<sub>2</sub>Or (400 ml) add a solution of Na<sub>2</sub>SW<sub>3 </sub>(43.7 g, 347 mmol) in H<sub>2</sub>O (400 ml) and heated under reflux for 21 hours. The mixture is concentrated to half volume and extracted with CH<sub>2</sub>CI<sub>2</sub> (3 x 200 ml). The organic is then washed with brine, dried (MgSO<sub>4</sub>), filtered and concentrated. Purification by trituration (CH<sub>2</sub>CI<sub>2</sub>, tBuOMe, and hexanes) allows to obtain 5.2 g (52%) of the title compound.
MS (ESI) m / z 317 (M + H)<sup>+</sup>.
itanax;
501
EXAMPLE 126F
I2W
<img file="MX339989B_D0862.tif" />
INSTITUTE My «C AMO D £ LA Ζ # Ο« ίΛύΤ »
(S) -5-Bromo-2- (pyrrolidin-2-¡l) -1 H-imidazole hydrochloride
A mixture of Example 126E (5.0 g, 15.8 mmol) in 4M HCl / dioxane (40 ml) is allowed to stir for one hour. The mixture is concentrated to obtain 3.99 g (100%) of the title compound.
MS (ESI) m / z 217 (M + H)<sup>+</sup>.
EXAMPLE 126G (S) -1 -í (S) -2- (5-bromo-1 H-imidazol-2-iDpi rrolidin-1-yl) -3-methyl 1-1 oxobutan-2-yl-carbamate
A mixture of Example 126F (3.99 g, 15.8 mmol),
Example 126A (2.77 g, 15.8 mmol), N- (3-dimethylamnopropyl) -N'-ethylcarbodi-imide hydrochloride (3.63 g, 19.0 mmol), 1-hydroxy-benzotriazole hydrate (2.90 g, 19.0 mmol) and N-methylmorpholine ( 12.2 ml, 111.0 mmol) in DMF (150 ml) is allowed to stir overnight. The mixture is diluted with H<sub>2</sub>O and extracted with EtOAc (3 x 300 mL). The organic is washed with H<sub>2</sub>Or and brine. The organic is then dried (MgSO<sub>4</sub>), filtered and concentrated. Purification by chromatography (silica gel, 75% EtOAc in hexanes) gives 5.2 g (88%) of the title compound.
<sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ ppm 0.79 (dd, J = 6.67,
3.63 Hz, 6H), 1.84-1.96 (m, 3H), 2.02-2.14 (m, 2H), 3.51 (s, 3H), 3.66-380 (m, 2H), 3.96-4.03 (m , 1H), 4.91-4.99 (m, 1H), 7.06
502
<img file="MX339989B_D0863.tif" />
(d, J = 1.52 Hz, 1 H), 7.26 (d, J = 8.46 Hz, 1 H), 12.C
MS (ESI) m / z 373 (M + H) *. ___
EXAMPLE 126H (1S, 4S) -1,4-b ¡s (4-bromophenyl) buta n-1,4-diol
(1S, 4S) -1,4-bis (4-bromophenyl) butane-1,4-diol is prepared using the method of Example 69A and (R) -alpha, alpha-diphenyl-2-pyrrolidine-methanol).
<img file="MX339989B_D0864.tif" />
Br
Br
EXAMPLE 1261 (2R.5R) -2,5-bis (4-bromophenyl) -1 - (4-sulfur-pentafluorurophenyl) pyrrolidine
A solution of methanesulfonic anhydride (2.95 ml, 23.02 mmol) in 2-Me THF (15 ml) is cooled in an ice / salt bath to ~ 0 ° C. To this cold solution a solution of Example 126H (4.0524 g, 10.13 mmol) and N, N-di-isopropylethylamine (5.5 ml, 31.8 mmol) in 2-Me THF (40 ml) is added dropwise over the course of 40 minutes. The reaction slowly warms up to 20 ° C. at this time 4-aminophenylsulfur pentafluoride (7.1238 g,
503
IMPI
INSTITUTO MEXICANO Ψ2 nte<sup>M</sup>WO & sS
32.5 mmol) and the mixture was heated to 38 ° C during the reaction, cooled and partitioned between EtOAc and cold water. The organic ion was washed with water (2x), brine (1x) and concentrated. Purification by flash chromatography (silica gel, EtOAc / hexane) gives the title compound (1.95 g, 33%). LC / MS Rt 2.38 m / z 584 (M + H)<sup>+</sup>.
EXAMPLE 126J (2R, 5R) -1 - (4-az uf repe ntafluoru rof eni l) -2,5-bis (4- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2 -¡L) phenyl) pyrrolidine
The product from Example 1261 is processed using the method described in Example 39E to obtain the title compound (1.67 g, 74%).
MS (ESI) m / z 678 (M + H)<sup>+</sup>.
EXAMPLE 126K r (2S) -1 - ((2S) -2-r5- (4 - ((2R, 5R) -5- (4- <2-r (2S) -1 - ((2S) -2y ( methoxycarbonyl) amno1-3-mettllbutanol) p¡rrol¡d¡n-2-iH-1Himidazol-5-H) fenll) -1-r4- (pentafluoro-lambda ~ 6— sulfani Dphenyl pyrrolidin Methyl -2-i HfeniD-l Hi mi dazol-2-i ll py rrolidin-1 -yl) 3-methyl-1-oxobutan-2-illcarbamate
The product from Example 126J and Example 126G are processed using the method described in Example 39F to obtain the title compound (0.75 g, 30%).
504
IMPI
MEXICAN INSTITUTE <sup>1</sup>H NMR (400 MHz, DMSO-d6) δ 0.85 (dd<sup>OF</sup>^ w¿¡ ^,
12H), 2.26-1.66 (m, 14H), 3.53 (s, 6H), 3.87 - & ·. · 63 (m, 1H), 4,143.91 (m, 2H), 5.06 (dd, J = 3.0, 6.7, 2H ), 5.34 (s, 2H), 6.34 (d, J =
9.1, 2H), 7.17 (d, J = 8.2, 4H), 7.26 (dd, J = 8.4, 17.3, 2H), 7.75 7.34 (m, 8H), 12.22-11.46 (m, 2H).
MS (ESI) m / z 1010 (M + H)<sup>+</sup>, 1008 (MH)<sup>+</sup>.
<img file="MX339989B_D0865.tif" />
<img file="MX339989B_D0866.tif" />
EXAMPLE 127 r (2S) -1 - ((2S) -2-r5- (4-f1-r4- (azepan-1-¡l) phenyl-5- (4- (2-I (2S) -1- {(2S) -2r (methoxycarbonyl) amino1-3-methylbutane¡np¡rrol¡d¡n-2-ill-1H¡m¡mdazol-5-¡l) phen¡ l) -1 Hp¡rrol-2- methyl yl) phenyl) -1 H-imidazol-2-lllpyrrolidin-yl) -3-methyl-1-oxobutan-2-illcarbamate
Example 26E and 4- (1-azepanyl) aniline are processed using the methods of Examples 76A, 39E, 39F, 55G, and 26J (reaction solvent = dichloromethane) to provide the title compound (6.1 mg).
MS (ESI) m / z 977 (M + H)<sup>+</sup>.
505
<img file="MX339989B_D0867.tif" />
EXAMPLE 128 {(2S) -1-r (2S) -2- (5- {4 - [(2R, 5R) -1- (4-cyclohex8phenyl) -5- (4-f2-r (2S) -1 {(2S) -2-Rmethoxycarbonyl) aminol-3-methylbutane¡npyrroltdin-2-¡H-1 H¡m¡dazol-5-iDfeniDp¡ rrolidi n-2-illfeni D-1 H-imidazole-2- i Dpi rrolidi n1 -il1-3-methyl-1-oxobutan-2-iD-methyl carbamate
Example 126H and 4-cyclohexylanine are processed using the methods of Examples 1261, 126J, and 126K to provide the title compound (0.14 g).
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ 0.85 (dd, J = 16.6, 6.9, 12H), 1.32 - 1.06 (m, 8H), 1.65 (dd, J = 19.1, 6.2, 7H), 2.27 - 1.82 ( m, 13H), 3.53 (s, 6H), 3.78 (d, J = 6.8, 2H), 4.10 - 3.95 (m, 2H), 5.06 (dd, J = 6.9, 3.1, 2H), 5.19 (t, J = 6.7, 2H), 6.21 (d, J = 8.7, 2H), 6.76 (dd, J ± 8.6, 3.7, 2H), 7.19 - 7.08 (m, 4H), 7.34 - 7.19 (m, 2H), 7.37 ( d, J = 1.8, 1H<sup>1</sup>), 7.50 (t, J = 11.3, 1H), 7.65-7.57 (m, 3H), 11.68 (s, 1H), 12.10-11.93 (m, 1H).
MS (ESI) m / z 966 (M + H)<sup>+</sup>.
506
IMPI
MEXICAN INSTITUTE OF PROPERTY
INDUSTRIAL
<img file="MX339989B_D0868.tif" />
<img file="MX339989B_D0869.tif" />
/
EXAMPLE 129 ((2S) -1-r (2S) -2- (4-chloro-5- {4-r (2R, 5R) -5- (4-f4-chloro-2-r (2S) -1 -f (2S) 2-Rmethoxycarbon¡ l) am¡noI-3-met¡ Ibutanoi Dpi rrolidi η-2-i 11-1Himidazol-5-illfeni l) -1 - (4-c¡ciohex¡lfen¡l) p¡rroI¡d¡n-2-¡nfen¡ll-1 Him idazol-2-i Dpi rrol idi n-1-ill-3-methyl-1-oxobutan-2-i methyl Ilcarbamate
N-chlorosuccinimide (0.046 g, 0.342 mmol) is added to a solution of the product of Example 128 (0.1435 g, 0.149 mmol) in dichloromethane (7 ml) and stirred at room temperature for 17 hours. The reaction is diluted with dichloromethane and washed with NaHCO<sub>3 </sub>aqueous saturated (2x) and concentrated. The residue is purified by flash chromatography (silica gel, MeOH / dichloromethane) then by preparative HPLC to obtain the title compound (20.4 mg, 13%).
H NMR (free base) (400 MHz, DMSO-D6) δ 0.94 - 0.73 (m, 12H), 1.39 - 0.99 (m, 8H), 1.75 - 1.41 (m, 6H), 2.27 - 1.77 (m, 12H) , 3.53 (s, 6H), 3.86-3.66 (m, 3H), 4.08-3.96 (m, 2H), 5.11 507
IMPI
MEXICAN INSTITUTE
4.89 (m, 2H), 5.30 - 5.12 (m, 1H), 5.55 - 5.33 (m, 1
8.7, 1H), 6.88-6.67 (m, 2H), 6.94 (dd, J = 4.3, 8_4_1H). 7.42-7.02 (m, 6H), 7.56-7.42 (m, 3H), 7.61 (t, J = 8.5, 1H), 11.68 (d, J = 10.7, 1H), 12.49-12.26 (m, 1H).
MS (ESI) m / z 1034 (M + H)<sup>+</sup>.
<img file="MX339989B_D0870.tif" />
<img file="MX339989B_D0871.tif" />
EXAMPLE 130
I ~ (2S) -1 - {(2S) -2- [5- (4 - ((2R, 5R) -5- (4- {2-r (2S) -1 - ((2S) -2r ( methoxycarboninaminoI-3-methylbutanoyl) p¡rrolidin-2-iH-1Himidazol-5-yl) phenyl) -1 -r4- (morpholin-4-¡l) phen¡Hp¡rrol¡d¡n-2-¡ Bphenyl) -1 H¡midazol-2-inpyrrolidin-1 -¡l) -3-methyl-1-oxobutan-2-¡Hcarbamate d methyl
Example 126H and 4-morpholinoaniline are processed sequentially using the methods of Examples 1261, 39E, 39F, 391, and 26J (reaction solvent = dichloromethane) to provide the title compound (0.16 g).
<sup>1</sup>H NMR (300 MHz, DMSO-D6) δ 0.86 (dd, J = 12.2, 6.6,
508
12Η), 1.77
2.45 - 2.39
6Η), 3.67 5.06 (dd, J 6.58 (dd, J 7.37 (d, J =
ΙΜΡΙβ
- 1.55 (m, 2H), 2.03- 1.77 (m, 6H), 2.21¾ ^
<img file="MX339989B_D0872.tif" />
(m, 1H), 2.58-2.54 (m, 1H), 2.82-2.74 (m, 4H), 3.53 (s,
3.57 (m, 4H), 3.77 (d, J = 6.1, 3H), 4.04 (t, J = 8.3, 2H), = 6.7, 3.0, 2H), 5.18 (t, J = 5.0, 2H), 6.22 ( d, J = 9.0, 2H), = 9.0, 1.9, 2H), 7.14 (d, J = 8.4, 4H), 7.32 - 7.17 (m, 3H),
1.8, 2H), 7.55-7.41 (m, 1H), 7.63 (t, J = 10.0, 4H), 11.68 (s, 1H), 12.15-11.90 (m, 1H).
MS (ESI) m / z 969 (M + H)<sup>+</sup>.
<img file="MX339989B_D0873.tif" />
EXAMPLE 131 r (2S) -1 - {(2S) -2-r4-chloro-5- (4-f (2R.5R) -5- (4- {4-chloro-2-r (2S) -1 - {(2S) 2-r (methoxycarbon¡l) am¡nol-3-methylbutano¡l> p¡rrol¡d¡n-2-iH-1Him¡dazol-5-¡l) phenyl) -1 - [4- (pentafluoro-lambda ~ 6-sulfanihfen¡Hp¡rrol¡d¡n-2-¡Dfen¡h-1H-im¡dazole-2-¡npyrrolid¡n-1 -¡Π3-methyl-1 - methyl oxobutan-2-OHcarbamate
The product from Example 126K is processed using the method described in Example 129. The mixture of monochlorinated and chlorinated products is purified by reverse phase HPLC.
509
I Αί ΡI
INSTITUTO MEXICANO to obtain the title compound (90.9 mg, 19%). <sup>Of the</sup>iu ^ ™ a?
<sup>1</sup>H NMR (free base) (500 MHz, DMsn-üfi) δ 0 84 (dd, J =
6.8, 16.1, 12H), 2.23-1.70 (m, 13H), 3.53 (s, 6H), 3.85 - 3.66 (m, 4H), 4.02 (ddd, J = 4.8, 10.8, 16.1, 3H), 5.05 - 4.91 (m, 2H), 5.43 (d, J = 5.8, 2H), 6.36 (d, J = 9.1, 2H), 7.28 (d, J = 8.4, 2H), 7.34 (d, J = 8.3, 4H), 7.46 (d, J = 9.4, 2H), 7.72-7.58 (m, 4H), 12.43 (s, 2H).
MS (ESI) m / z 1078 (M + H)<sup>+</sup>.
<img file="MX339989B_D0874.tif" />
EXAMPLE 132 r (2S) -14 (2S) -2-r4-chloro-5- (44 (2R, 5R) -5- (4- {2-r (2S) -1-f (2S) -2r ( methoxycarbonl) amino1-3-methylalbutanoyl) pyrrolidin-2-yl1-1 H¡m¡dazol-5-¡l) phenyl) -1-r4- (pentafluoro-lambda ~ 6— sulfanihfen¡np¡ rrol¡d¡n-2-¡Dphenyl) -1H-¡m¡dazol-2-¡l] pyrrole ¡di n-1-yl> 3-methyl-1-oxobutan-2-illcarbamate of methyl
The product from Example 126K is processed using the method described in Example 129. The mixture of monochlorinated and dichlorinated products is purified by reverse phase HPLC to obtain the title compound (33.3 mg, 7%).
IMPI
MEXICAN INSTITUTE
D-D6f<sup>AND</sup>&OR&?-
<img file="MX339989B_D0875.tif" />
510 <sup>1</sup>H NMR (free base) (500 MHz, (m, 12H), 2.24-1.63 (m, 13H), 3.53 (d, J = 1.2, 1 "R-3 68 (m.
4H), 4.10-3.98 (m, 2H), 5.02-4.93 (m, 1H), 5.06 (dd, J = 3.2, 7.1,
1H), 5.48 - 5.30 (m, 2H), 6.35 (d, J = 9.1, 2H), 7.21 - 7.10 (m, 2H),
7.36-7.21 (m, 4H), 7.58-7.38 (m, 4H), 7.73- 7.59 (m, 4H), 12.50-11.65 (m, 2H).
MS (ESI) m / z 1044 (M + H)<sup>+</sup>, 1042 (MH)<sup>+</sup>.
<img file="MX339989B_D0876.tif" />
r (2S) -1-ff2S) -2-r5- (4-R2R, 5R) -5-f4-f2-f (2S) -1-R2S) -2í (methoxy carbon i Dam i ηοΤ-3-methyl butane i Dpi rrol id i n-2-iD-1Himidazole-5-¡Dfen¡D-1-r6- (piper¡din-1-¡Dpir¡d¡n-3-illP¡rrol¡d¡n-2 ¡Pfen¡l) -1 H-imidazol-2-illpyrrol¡din-1 -¡P-3-methyl-1-oxobutan-2¡ll methyl carbamate
Example 126H and 6- (piperidin-1-yl) pyridin-3-amine are processed using sequentially the methods of Examples 1261, 39E, 39F, 391, and 26J (reaction solvent = dichloromethane) to provide the compound of the title (91.4 mg).
ιι yry.
<img file="MX339989B_D0877.tif" />
IMPI 'MEXICAN INSTITUTE
OF THE PROPERTY <sup>1</sup>H NMR (400 MHz, DMSO-D6) δ 0.85 (dt,
12H), 1.24 (s, 2H), 1.44 (s, 6H), 1.70 (d, J = 5.2Γ211), 2.-Θ4 1.82 (m,
6H), 2.23-2.04 (m, 4H), 3.21-3.03 (m, 4H), 3.53 (s, 6H), 3.87-367 (m, 4H), 4.12-3.96 (m, 2H), 5.06 (dd, J = 3.2, 7.0, 2H), 5.20 (t, J =
6.8, 2H), 6.49 (dd, J = 3.1, 9.1, 1H), 6.60 (dd, J = 2.9, 9.2, 1H), 7.20 7.10 (m, 4H), 7.33- 7.20 (m, 3H), 7.38 ( d, J = 1.8, 2H), 7.51 (t, J =
10.4, 1H), 7.64 (dd, J = 8.1, 15.7, 3H), 11.69 (s, 1.4H), 12.06 (t, J =
32.1, 0.6H).
<img file="MX339989B_D0878.tif" />
EXAMPLE 134
Í (2S) -1 -r (2S) -2- (6 - ((2R, 5R) -5- (2 - [(2S) -1 - {(2S) -2f (methoxycarbonyl) amino1-3-methylbutanoyl ) pyrrolidin-2-ill-1Hbenz¡midazol-6-¡l) -1-f6- (p¡perid¡n-1-¡l) pir¡d¡n-3-illp¡rrol¡d¡n-2 -¡L} 1 H-benzim idazol-2-yl) pyrrole idi n-1-i Π-3-methyl 1-1-oxobu tan-2iDcarbamate methyl
Example 109C and 6- (piperidin-1-yl) pyridin-3-amine are processed sequentially using the methods of Examples
512 ϊΐ
<img file="MX339989B_D0879.tif" />
113Α, 113Β, 116F (reduction with Ni-Ra is performed under SS pressure for 120 minutes at 2.11 kg / cm<sup>2</sup> at temperature _ . ambient), 281 (reaction carried out at 50 ° C for 4 hours), 39I, and 26J (reaction solvent = dichloromethane) to provide the title compound (71 mg).
<sup>1</sup>H NMR (400 MHz, METHANOL-D4) δ 0.89 (ddd, J = 6.5,
20.7, 26.0, 12H), 1.62-1.43 (m, 6H), 2.48-180 (m, 13H), 2.72 2.60 (m, 2H), 3.10-2.97 (m, 4H), 3.64 (s, 6H), 3.93 - 3.78 (m, 2H),
4.09-3.94 (m, 2H), 4.22 (d, J = 7.3, 2H), 5.21 (dd, J = 5.2, 7.6, 1H),
5.44 - 5.30 (m, 2H), 6.50 (d, J = 9.1, 1H), 6.83- 6.71 (m, 1H), 7.59- 7.15 (m, 7H).
MS (ESI) m / z 916 (M + H)<sup>+</sup>, 914 (MH)<sup>+</sup>.
EXAMPLE 135
R2S) -1 - ((2S) -2-r5- (4- <1-f6- (4,4-difluoropiperidin-1-yl) pyridin-3-¡ll-5 (4- (2-r (2S ) -1-f (2S) -2-r (methoxycarbon¡l) am¡no1-3m ethyl b uta noill pyrrole ¡di n-2-yl1-1H-im idazol-5-i Ufe ni l) - 1H-pyrrole-2¡l) f nyl) -1H-imidazol-2-inpyrrolidin-1-yl) -3-m thi-1-oxobutan-2513
IMPI
INSTITUTO MEXICANO ¡Hcarbamate de methyl
EXAMPLE 135A
2- (4,4-d¡fl uoropi perid ¡n-1 -ii) -5-n ¡tro pyridine
To a suspension of 2-chloro-5-nitropyridine (5 g, 31.5 mmol) and 4,4-difluoropiperidine hydrochloride (4.97 g) in ethanol (40 ml) at room temperature is added N, N-di-isopropylethylamine (12.00 ml, 69.4 mmol) and the mixture is heated at 70 ° C for 18 hours. The reaction is concentrated, partitioned between CH2CI2 and 1M NaOH. The organic phase is concentrated and purified by chromatography (elution with 2% MeOH-CH2C12 then 3% MeOH-CH2Cl2) to provide the title compound as a yellow oil.
MS (DCI) m / z 261 (M + NH<sub>4</sub>)<sup>+</sup>.
EXAMPLE 135B
6- (4,4-d ifl uoropi peri di n-1 -ihpyridi n-3-amine
The product from Example 135A (4.56 g, 18.75 mmol) and THF (20 ml) / DMF solvent are added to Ni-Ra 2800, aqueous suspension (4.56 g, 78 mmol) in a 250 ml SS pressure bottle and stirred for 2 hours at 2.11 kg / cm<sup>2</sup> and room temperature. The mixture is filtered through a nylon membrane and washed with MeOH. The filtrate is concentrated and dried under vacuum to obtain the
OF INDUSTRIAL FROFITY
<img file="MX339989B_D0880.tif" />
514
IMPI
MEXICAN INSTITUTE DF. THE PROPERTY
<img file="MX339989B_D0881.tif" />
title compound (3.40 g, 85%).
INDUSTRIAL.
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ 2.03 - 1.88 (m, 4H), 3.49 - 3.38 (m, 4H), 4.61 (s, 2H), 6.73 (d, J = 8.8, 1H), 6.93 (dd , J = 2.9?
8.8, 1H), 7.61 (d, J = 2.6, 1H).
MS (ESI) m / z 214 (M + H<sup>+</sup>).
EXAMPLE 135C
5- (2,5-bis (4- (2 - ((S) -pyrrolidin-2-yl) -1 H-imidazol-5-yl) phenyl) -1 H-pyrrol1 -¡ I) -2 - (4,4-d¡fluoropiperid¡ n-1 -il) p¡ rid i na
TFA (0.046 ml, 0.596 mmol) is added to a mixture of the product of Example 138B (0.2114 g, 0.298 mmol) and the product of Example 135B (0.095 g, 0.447 mmol) in toluene (2.98 ml). The mixture is heated at 110 ° C for 18 hours. The reaction is cooled and additional TFA (0.023 mL, 0.298 mmol) is added and stirred for another hour. The solvent is removed under reduced pressure and azeotropically distilled with toluene to obtain the title compound.
EXAMPLE 135D f (2S) -1-f (2S) -2-f5- (4- (1-r6- (4,4-d¡fluorop¡per¡per¡n-1 -il) py¡d¡n -3-iH-5 (4- <2-r (2S) -1 - ((2S) -2-r (methoxycarbonyl) amino1-3methi Ibutanoi l) p¡rrol id in-2-¡H-1 H-imidazol-5-¡l) phen ¡I) -1 H-plrrole-2¡l) phenyl) -1 H-im ¡dazol-2-¡H pyrrole ¡dín-1-¡l) -3-methyl -1-oxobutan-2 yl carbamate dm linden
515
<img file="MX339989B_D0882.tif" />
• j
The product of Example 135C is pr <Je ^ [ijí? L¡j £
INSTITUTO MEXICANO method described in Example 26J to obtain the<sup>E1</sup>or ^ well
<img file="MX339989B_D0883.tif" />
Title.
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ 0.94 - 0.73 (m, 12H), 2.03 - 1.82 (m, 10H), 2.20 - 2.04 (rn, 4H), 3.53 (s, 6H), 3.64 (s, 4H ),
3.86 - 3.69 (m, 4H), 4.04 (dd, 2H), 5.04 (dd, J = 3.0, 7.0, 2H), 6.53 6.39 (m, 2H), 6.93 - 6.79 (m, 1H), 7.06 (d, J = 8.4, 3H), 7.13 (dd, J =
10.9, 19.3, 1H), 7.30 - 7.21 (m, 2H), 7.39 - 7.30 (m, 1H), 7.42 (d, J =
1.7, 1H), 7.48 - 7.43 (m, 1H), 7.66 - 7.49 (m, 4H), 7.85 (dd, J = 2.7,
9.7, 1H), 12.16-11.64 (m, 2H).
MS (ESI) m / z 1000 (M + H)<sup>+</sup>, 998 (MH)<sup>+</sup>.
<img file="MX339989B_D0884.tif" />
EXAMPLE 136 f (2S) -1 -r (2S) -2- (4-f4-r5- (4-f 2-f (2S) -1 -f (2S) -2rimethoxycarbonyl) amino1-3-methylbutane¡l ) p¡rrolidin-2-ill-1H8midazol-4-iHfenin-1 -f4-H-trifluoromethyl) suiphoninphenyl> -1 H-pyrrole-2iHphenyl) -1 H-im idazoi-2-yl) pyroiidin-1-iH -3-methy 1-1-oxobutan-2¡Rcarbamate dm linden
516
EXAMPLE 136A
2,5-b¡s (4-bromophenyl) -1 -f4-ftr¡fluorometh¡lsulfon¡l) phen¡l) -<sup>N</sup>Ptf ^ Irro
IMPI
MEXICAN INSTITUTE OF PROFIECAD
<img file="MX339989B_D0885.tif" />
To a suspension of the product of Example 26E (0.60 g,
1.52 mmol) and 4- (trifluoromethylsulfonic) anyline (0.51 g, 2.27 mmol) in toluene (12 ml), a 1 N solution of titanium (IV) chloride (1.6 ml, 1.6 mmol) in toluene is added. The mixture is stirred overnight at room temperature and then heated under reflux for 3 hours. The cold mixture is filtered and the solid residue is suspended in a mixture of water and diethyl ether. The solid is diluted with water and ether and stirred vigorously for 15 minutes. The mixture is filtered and then washed thoroughly with diethyl ether to obtain the title compound as a crude mixture which is used in subsequent reactions without further purification (0.60 g, 68% crude yield).
EXAMPLE 136B (2S) -1-H2S) -2-f4- <4-f5-f4-f2-R2S) -1- <f2S) -2ffmethoxycarboniDam inoI-3-methylbuta no¡ Dpi rrol ¡din-2-ΙΠ- 1 H¡m¡dazol-4-¡Pphenyl) -1 -f4-r (tr¡fluoromethyl) sulfonyl1phene¡D-1 H-pyrrole-2¡llpheniP-1 H-im¡dazol-2-yl) p¡rrole ¡D¡n-1-¡Π-3-methyl-l-oxobutan-2¡D methyl carbamate
Example 136A is processed sequentially using the methods of Examples 26G, 26H, 65B, and 65C to
517 provide the title compound (90 mg).
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ 12.20
IMPI
MEXICAN INSTITUTE OF INDUSTRIAL FRCF1EDAD
11.68 (m, 2H),
<img file="MX339989B_D0886.tif" />
8.17 - 8.04 (m, 2H), 7.63 - 7.42 (m, 8H), 7.31 - 7.15 (m, 2H), 7.02 6.90 (m, 4H), 6.64 - 6.53 (m, 2H), 5.08 - 4.97 (m, 2H), 4.05 - 3.97 (m,
2H), 3.83-3.69 (m, 4H), 3.53 (s, 6H), 2.18-1.79 (m, 10H), 0.90 0.78 (m, 12H).
<img file="MX339989B_D0887.tif" />
EXAMPLE 137
H2S) -1 - {(2S) -2-r4- (4-I1-r4- (2-cyanopropan-2-inphenyl1-5- (4-f2-R2S) -1 <(2S) -2-f (methoxycarbonyl) amino1-3-methyl butanoi Hpi rrolidin-2-¡11-1Himldazol-4-yl Ifen ¡11-1 H-pyrrol-2-yl) phenyl) -1 H-¡m ¡dazol-2 -¡Hp¡rrol¡din20 1-yl) -3-methyl-1-oxobutan-2-illcarbamate of methyl
Example 26E and 2- (4-aminophenyl) -2-methylpropanonitril are processed sequentially using the methods of Examples.
26F, 26G, 26H, 65B, and 65C to provide the title compound (100mg).
518
3BESZSS2U <sup>1</sup>H NMR (400 MHz, DMSO-D6) δ 12.15 -Ι<sup>ι</sup>Μ<sup>θ</sup>Ρί
MEXICAN INSTITUTE
7.58 - 7.44 (m, OH), 7.44 - 7.36 (m, OH), 7.30 - 7.12
6.91 (m, OH), 6.55 - 6.42 (m, OH), 5.06 - 4.96 (m, OH), 4.02 (t, J ™ 8.3, OH), 3.81 - 3.67 (m, OH), 3.52 (s, OH ), 2.15-1.82 (m, OH), 1.65 (s, OH), 0.90-0.74 (m, 1H).
MS (ESI; M + H) m / z = 948.
<img file="MX339989B_D0888.tif" />
EXAMPLE 138 f (2S) -1-r (2S) -2- (4- (4-ri- (3-tert-but¡lfen¡l) -5- (4- {2-r (2S) -1 -f (2S) -2r (methoxycarbon¡l) am ino1-3-methylbutanoyl) pyrrolidin-2-yl1-1 Himidazol-4-¡l) phen¡l) -1H-p8rrol-2-infen¡D-1 H methyl -imidazol-2-yl) pyrroiidin1-yl-3-methyl 1-1-oxobutan-2-iRcarbamate
EXAMPLE 138A
1,4-bis (4- (4.4.5.5-tetramethyl-1,3,2-dioxaborolan-2-yl) phenyl) butane 1,4-dione
To a solution of the product of Example 26E (2.00 g, 5.05 mmol), bis (pinacholate) diborane (3.85 g, 15.15 mmol), acetate
519 potassium (1,982 g, 20.20 mmol) in dimethoxyethane nor
<img file="MX339989B_D0889.tif" />
INSTITUTO MEXICANO DELA PROPERTY
<img file="MX339989B_D0890.tif" />
INDUSTRIAL room temperature the PdCI adduct is added<sub>2</sub>(dppf) -CH<sub>2</sub>CI<sub>2</sub> (0.412 g, 0.505 mmol) and the mixture is degassed (purge with N<sub>2</sub>). The mixture is heated under reflux for 1 hour. The cold mixture is filtered through celite and washed with ethyl acetate. The filtrate is washed with water, brine and dried (Na<sub>2</sub>SW<sub>4</sub>). After filtration and removal of the solvent, the residue is purified by chromatography (80 g column; gradient elution from 0% to 40% ethyl acetate hexanes) to provide the title compound (2.22 g; 90%) as a white solid.
<sup>1</sup>H NMR (CDCI<sub>3</sub>; 400 MHz): δ 8.02 (AA'XX ', J = 8.24 Hz, 4H), 7.91 (AA'XX', J = 8.13 Hz, 4H), 3.47 (s, 4H), 1.36 (s, 24H).
<img file="MX339989B_D0891.tif" />
(2S.2'S) -2,2'-f (1,4-dioxobutan-1,4-d¡-¡l) b¡s (benzene-4.1-di-¡l-1 Himidazol-5,2-d ¡-¡Md¡p¡rrol¡d¡n-1-carboxylate of di-tert-butyl
A solution of the product of Example 138A (2.22 g, 4.53 mmol), PdCI adduct<sub>2</sub>(dppf) -CH<sub>2</sub>CI<sub>2</sub> (0.37 g, 0.45 mmol),
520 1 M sodium carbonate (18 ml, 18 mmol) and the prod
JtMEi
INSTITUTE MEXICA!
MEXICAN INSTITUTE OF PROPERTY
<img file="MX339989B_D0892.tif" />
26D (4.30 g, 13.6 mmol) in ethanol (23 ml) / toluene (^ T ^ mt) is degassed (purge with N<sub>2</sub>) and heated in a bath of aceife at 90<sup>or</sup>u all night long. The cold mixture is concentrated and the residue is partitioned between water and ethyl acetate. The organic phase is concentrated and the residue is purified by chromatography (gradient elution from 30% to 100% ethyl acetate-hexane) to provide the title compound (1.90 g, 59%) as a light tan solid.
<sup>1</sup>H NMR (DMSO-d<sub>6</sub>; 400 MHz): δ 12.06 (m, 2H), 8.04-7.96 (m, 4H), 7.89-7.78 (m, 4H), 7.69 (m, 2H), 4.85-4.75 (m, 2H), 3.53 (m, 2H), 3.35 (m, 4H), 2.24-1.87 (m, 10H), 1.39 (br s, 8H), 1.14 (br s, 10H).
MS (ESI; M + H) m / z = 709.
EXAMPLE 138C (S) -4.4 '- (4.4' - (1- (3-tert-but¡ Ifeni l) -1 H-pyrrole-2,5-di-iDbis (4.1phenyl)) b ¡S (2-f (S) -pyrrolidin-2-¡l) -1 Hi midazole)
To a solution of the product of Example 138B (180 mg,
0.25 mmol) and 3-tert-butylanine (57 mg, 0.38 mmol) in toluene (2.0 ml) add trifluoroacetic acid (39 µl 0.50 mmol). The mixture is heated at 110 ° C overnight. Trifluoroacetic acid (0.4 ml) is added to the cold mixture and the mixture is stirred for 1 hour at room temperature. The mixture is concentrated under pressure
521
<img file="MX339989B_D0893.tif" />
reduced. The residue is partitioned between isoprop ^ gp alcohol,<sub>T</sub>^ i ^ éX ^
OF INDUSTRIAL PROPERTY
CHCI3 and saturated sodium bicarbonate solution. The organic layer
<img file="MX339989B_D0894.tif" />
separated and dried with Na<sub>2</sub>SW<sub>4</sub>, filter, and concentrate under reduced pressure to provide the title compound.
EXAMPLE 138D {(2S) -1-r (2S) -2- (4-r4-M- (3-tert-but¡lfen¡l) -5- (4- {2-r (2S) -1- f (2S) -2Rm ethoxy char my nol-3-methyl butanoyl} p¡rrolidi n-2-¡H-1 Him¡dazol-4-illfen¡l) -1 H-pyrrole-2-¡Ufen ¡11 -1 H-im idazol-2-i Dpi rrolidi n1-¡Π-3-methi 1-1-oxobutan-2-illcarbamate methyl
A solution consisting of N1 ((ethylimino) methyllen) -N3, N3-dimethylpropan-1,3-diamine hydrochloride (109 mg, 0.57 mmol), 1 H-benzo [d] [1,2, 3] hydrated triazole-1-o I (87 mg, 0.57 mmol), (S) -2- (methoxycarbonylamino) -3-methylbutanoic acid (100 mg, 0.57 mmol) and 4-methylmorpholine (0.14 ml, 1.0 mmol ) in DMF (2.6 ml) is cooled in an ice bath. To this mixture is added the product from Example 138C (161 mg, 0.26 mmol). Additional 4-methylmorpholine is added to the mixture until the pH is adjusted to 8. The reaction is stirred for 3.5 hours and then the ice bath is removed and the reaction is stirred for an additional 16 hours. Water is then added to the reaction mixture and the resulting precipitate is recovered by filtration. The residue is washed with copious amounts of water followed by diethyl ether. The crude product is purified by chromatography on silica gel eluting with a
522
IMPI
<img file="MX339989B_D0895.tif" />
solvent gradient 0-5% methanol in CH<sub>2</sub>CI<sub>2</sub> BairaT <praaiveer
DE LAPFOPIfTY [NDUSTRIAL Title compound (15 mg, 6% yield).
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ 12.04 - 11.65 (m, 2H),
7.57 - 7.45 (m, 4H), 7.43 - 7.35 (m, 2H), 7.33 - 7.08 (m, 5H), 7.05 6.91 (m, 4H), 6.79 (t, J = 7.5, 1H), 6.53 - 6.40 ( m, 2H), 5.05-4.99 (m, 2H), 4.02 (t, J = 8.3, 2H), 3.82-3.68 (m, 4H), 3.56-3.47 (m, 6H),
2.18-1.79 (m, 10H), 1.09 (s, 9H), 0.89-0.75 (m, 12H).
MS (ESI; M + H) m / z = 937.
<img file="MX339989B_D0896.tif" />
EXAMPLE 139 f (2S) -1-r (2S) -2- (4-í4-n- (4-cyclopropylphenyl) -5- (4-f2-r (2S) -1-f (2S ) -2r (methoxycarbonyl) am i noI-3-methylbutane¡ Ilpyrrole idin-2-¡ll-1 H¡midazol-4-yl1phenyl) -1 H-pyrrole-2-ylIphen¡n-1 H-imidazol-2-i Dpi rrol idi n1-¡ll-3-methyl-1-oxobutan-2-¡l) methyl carbamate
EXAMPLE 139A
Tetrakis (2,2,2-trifiuoroacetate) of (S) -4,4 '- (4,4' - (1- (4-cyclopropylphenyl) -1 H-pyrroi-2,5-di-ihbis (4.1 -f nyl n)) bis (2 - ((S) 523 p¡rrolidin-2-¡l) -1 H-imidazole)
IMPI
MEXICAN INSTITUTE OF INDUSTRIAL PROPERTY
<img file="MX339989B_D0897.tif" />
To a solution of the product of Example 138B (0.30g 0.43 mmol) and 4-cyclopropylene line (85 mg, 0.64 mmol) in toluene (3.4 ml) is added trifluoroacetic acid (65 µΙ 0.85 mmol). The mixture is heated at 110 ° C overnight. Trifluoroacetic acid (1.0 ml) is added to the cold mixture and the mixture is stirred for 1 hour at room temperature. The mixture is concentrated under reduced pressure and then triturated with diethyl ether to provide the title compound (0.42g, 28% yield).
EXAMPLE 139B {(2S) -1-r (2S) -2- (4- {4-n- (4-cyclopropylphenyl) -5- (4-f2-K2S) -1-f (2S) -2r (methoxycarbonyl) am¡nol-3-methyl butano¡l) pyrrol¡din-2-¡n-1 H¡ medazol-4-¡Ufen ii) -1H-p¡ rrol-2-i Ufen ¡ Methyl 11-1 H-¡midazol-2-¡l) p¡rrol¡d¡n1 -H1-3-methyl-1-oxobutan-2-yl1carbamate
The title compound is prepared using the methods of Example 138D by substituting the product of Example 139A for the product of Example 138C to provide the title compound (150 mg, 40% yield).
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ 12.09 - 11.63 (m, 2H),
7.56 - 7.46 (m, 4H), 7.44 - 7.35 (m, 2H), 7.30 - 7.11 (m, 2H), 7.07 6.88 (m, 8H), 6.54 - 6.39 (m, 2H), 5.07 - 4.97 (m, 2H), 4.03 (t, J =
8.3, 2H), 3.83-3.66 (m, 4H), 3.52 (s, 6H), 2.18-1.79 (m, 10H), 1.26
524
- 1.19 (m, 1H), 0.98 - 0.90 (m, 2H), 0.90
- 0.74 (m, (m, 2H).
<img file="MX339989B_D0898.tif" />
MS (ESI; M + H) m / z = 921.
<img file="MX339989B_D0899.tif" />
EXAMPLE 140 r (2S) -1 - ((2S) -2-r5-bromo-4- (4- (1- (4-cyclopropyl) -5-r4- (2-f (2S) - 1rN- (methoxycarbonyl) -L-valiHp8rrolidin-2-yl) -1 H-im ¡dazol-4-i Ufen ill1 H-pyrrole-2-¡Bfenii) -1 H-im idazol-2-¡ll pyrrolidin Methyl -1 -ii} -3-methyl-1oxobutan-2-illcarbamate
To a suspension of the product of Example 139 (47 mg,
0.051 mmol) in CH<sub>2</sub>CI<sub>2</sub> (0.5 ml) a mixture of 1bromopyrrole-d¡n-2,5-dione (9.1 mg, 0.051 mmol) in CH<sub>2</sub>CI<sub>2</sub> (0.5 mi). The mixture is stirred overnight at room temperature then concentrated under reduced pressure and triturated with diethyl ether to provide a mixture of brominated compounds that undergoes reverse phase HPLC purification eluting with a gradient of 10-100% CH<sub>3</sub>CN in 0.1% aqueous trifluoroacetic acid to
525 obtain the title compound (8 mg, 13% ren <sup>1</sup>H NMR (TFA salt) (400 MHz, DM
<img file="MX339989B_D0900.tif" />
ITVMAkrw aiviA OF INDUSTRIAL PROPERTY
<img file="MX339989B_D0901.tif" />
1H), 12.44 (s, 1H), 7.97 (s, 1H), 7.62 - 7.48 (m, 4H), 7.31 (d, J = 8.4, 1H), 7.24 (d, J = 8.5, 1H), 7.18 - 7.08 (m, 4H), 7.09-7.00 (m, 4H),
6.61 (d, J = 3.7, 1H), 6.57 (d, J = 3.7, 1H), 5.07 (t, J = 7.0, 1H), 4.98 - 4.91 (m, 1H), 4.08 (t, J = 7.9, 1H), 4.02 (t, J = 8.3, 1H), 3.90 - 3.67 (m, 4H), 3.52 (s, 3H), 3.51 (s, 3H), 2.18 - 1.83 (m, 10H), 1.22 (s, 1H), 1.01 - 0.93 (m, 2H), 0.89 - 0.72 (m, 12H), 0.70 - 0.62 (m, 2H).
MS (ESI; M + H) m / z = 1000.
<img file="MX339989B_D0902.tif" />
EXAMPLE 141
H2SM-r (2S) -2- (5-bromo-4- <4-r5- (4- (5-bromo-2-r (2S) -1 - ((2S | -2r (methoxycarbonyl) am No 1-3-met! Lbutanoyl) pyrrolldin-2-in-1 H¡m¡dazol-4-ylHenyl) -1- (4-cyclopropyl) -1 H-pyrrole-2-Hfen¡l ) -1H¡midazol-2-¡l) p¡rrol¡d¡n-1-¡Π-3-methyl-l-oxobutan-2-¡l) methyl carbamate
The title compound is formed as a product
526 in Example 140. The product mix jsj ^ ope | e
INSTITUTO MEXICANO purification with reverse phase HPLC eluting with 10-100% CH<sub>3</sub>CN in 0.1% aqueous trifluoroacetic acid to obtain the title compound (15mg, 23% yield).
<sup>1</sup>H NMR (TFA salt) (400 MHz, DMSO-D6) δ 12.43 (s, 2H), 7.54 (dd, 4H), 7.25 (d, J = 8.4, 2H), 7.15 - 7.08 (m, 4H), 7.08 7.00 (m, 4H), 6.55 (s, 2H), 4.99 - 4.89 (m, 2H), 4.02 (t, J = 8.3, 2H), 3.82 - 3.68 (m, 4H), 3.51 (s, 6H) , 2.22 - 2.03 (m, 4H), 2.00 - 1.81 (m, 6H), 1.27 - 1.19 (m, 1H), 1.02 - 0.92 (m, 2H), 0.90 - 0.77 (m, 12H), 0.70 - 0.61 ( m, 2H).
MS (ESI; M + H) m / z = 1078.
<img file="MX339989B_D0903.tif" />
<img file="MX339989B_D0904.tif" />
f (2S) -1-r (2S) -2- (4-f4-r5- (4-f2-K2S) -1-f (2S) -2nmethoxycarboni l) am ¡notT-3-met¡ I butane ¡ Dpi rrol id ¡n-2-¡H-1 H¡m¡dazol-4-¡l) phenyl) -1- (4-tr¡t¡lfen¡l) -1H-p¡rrol-2-¡Hfen ¡L) -1H-¡m¡m¡dazol2-¡l) pyrrole idin-1-¡H-3-methyl-1-oxobutan-2-¡l} carbamate dm linden
527 wgEaKas;
EXAMPLE 142A
Tetrakis (2,2,2-trifluoroacetate) de (S) -4,4M4,4M1 - (4-trftffijqgw? I)
Hpyrrol-2,5-di-yl) bis (4,1-phenylene)) bis (2 - ((S) -pyrr »44-din-2.yl) -1 H imidazole)
IMPI
MEXICAN INSTITUTE
<img file="MX339989B_D0905.tif" />
The title compound is prepared using the methods of Example 139A by substituting 4-trithi I aniline for 4-cyclopropylaniline to provide the title compound.
EXAMPLE 142B ((2S) -1-r (2S) -2- (5-bromo-4-f4-r5- (4- (5-bromo-2-r (2S) -1 - ((2S) -2r (methoxycarbon¡DaminoI-3-methylbutanoyl) pyrrolidin-2-¡n-1Himidazol-4-ii) phenyl) -1- (4-cyclopropylphenyl) -1 H-pyrrol-2-ylIphenyl) -1 H¡m¡dazol- Methyl 2-yl) pyrrol¡d¡n-1-¡n-3-methyl-1-oxobutan-2-¡l) carbamate
The title compound is prepared using the methods of Example 138D by substituting the product of Example 142A for the product of Example 138C to provide the title compound (71 mg, 43% yield).
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ 12.15 - 11.69 (m, 2H),
7.61 - 7.48 (m, 4H), 7.46 - 7.37 (m, 2H), 7.35 - 7.15 (m, 11H), 7.10 - 6.91 (m, 14H), 6.55 - 6.44 (m, 2H), 5.11 - 5.00 (m, 2H), 4.03 (t, J = 8.5, 2H), 3.86 - 3.70 (m, 4H), 3.52 (s, 6H), 2.21 - 1.83 (m, 10H), 0.92 - 0.76 (m, 12H).
528
<img file="MX339989B_D0906.tif" />
{(2S) -1-r (2S) -2- (5-bromo-4- {4-4-bromo-5- (4-f5-bromo-2-r (2S) -1 ((2S) - 2-r (methoxycarbon¡l) am¡nol-3-met¡lbutano¡l) p¡rrol¡d¡n-2-¡ll-1 H¡midazol-4-yl) phen¡l) -1- ( 4-cyclohex¡phenyl) -1 Hp¡rrol-2-¡Hfen¡l} -1 H¡m¡dazol-2-¡l) p¡rrol¡d¡n-1-¡ll-3-methyl -1-oxobutan-2-¡l) methyl carbamate
To a suspension of the product of Example 74 (100 mg, 0.10 mmol) in CH<sub>2</sub>CI<sub>2</sub> (1.0 ml) at -78 ° C a mixture of 1bromopyrrol¡d¡n-2,5-d¡one (59 mg, 0.33 mmol) in CH<sub>2</sub>CI<sub>2</sub> (1.0 mi). The mixture is stirred for 3 hours, warmed to room temperature then concentrated under reduced pressure and triturated with diethyl ether to provide the title compound (103 mg, 83% yield).
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ 12.47 (s, 1H), 11.02 (s, 1H), 7.54 (d, J = 26.1, 4H), 7.29 - 6.98 (m, 10H), 6.71 (s, 1H ), 5.01 529
4.90 (m, 2H), 4.02 (t, J = 8.1, 2H), 3.86 - 3.67 (m, 4JI ^ Jp
MEXICAN INSTITUTE
2.18 - 1.58 (m, 16H), 1.35 - 1.20 (m, 5H), 0.90 - 0.76
<img file="MX339989B_D0907.tif" />
MS (ESI; M + H) m / z = 1200.
<img file="MX339989B_D0908.tif" />
[(2S) -1 - ((2S) -2- [4- (4- (5- (4- (2-F (2S) -1 - ((2S) -2r (methoxycarbonl) amino1 -3-met¡lbutane¡np¡rrol¡d¡n-2-¡n-1 H¡m ¡dazol-4-yl) phen ¡I) -1 -r6- (piperid¡n-1 -il) p ¡R¡d¡n-3-¡ll-1 H-pyrrole-2¡l) phenyl) -1 H-¡mi dazol-2-iH Pyrrolidin-1-yl> -3-methyl-1-oxobutan-2 yl carbamate methyl
EXAMPLE 144A
5-nitro-2- (piper¡din-1-¡l) pyridine
Piperidine (206 ml, 2.08 mol) is added to a suspension of 2-chloro-5-nitropyridine (100 g, 632 mmol) in ethanol (2000 ml) at room temperature and the mixture is heated at 60 ° C for minutes . The cold mixture is concentrated and the residue is dissolved in
530
CH<sub>2</sub>CI<sub>2</sub> then washed with NaHCO<sub>3</sub> saturated and brine.
<img file="MX339989B_D0909.tif" />
dries up (Na<sub>2</sub>SW<sub>4</sub>), filtered, and concentrated to provide - ^^ bt ^ X
INDUSTRIAL title as a yellow solid (130.4 g, 99% yield).
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ 8.94 (d, J = 2.9, 1H),
8.17 (dd, J = 9.6, 2.9, 1H), 6.93 (d, J = 9.6, 1H), 3.79 - 3.73 (m, 4H),
1.69-1.64 (m, 2H), 1.61-1.51 (m, 4H).
EXAMPLE 144B
Tert-butyl 6- (piperdin-1-¡l) pyridin-3-ylcarbamate
To a solution of the product from Example 144A (130.4 g, 629 mmol) and di-tert-butyl dicarbonate (165 g, 755 mmol) in ethanol (750 ml) is added PtO<sub>2</sub> (5.4 g, 24 mmol). The mixture is pressurized at 2.81 kg / cm<sup>2</sup> with H<sub>2</sub> and stir overnight at room temperature. To ensure complete reaction, add PtO<sub>2</sub> additional (3.2 g, 14 mmol) and the pressurized mixture is heated at 50 ° C for 1 hour. The mixture is then filtered, concentrated under reduced pressure, and absorbed onto silica gel and placed on top of a 10.16 to 12.70 cm plug of silica in a 3000 ml sintered glass funnel. The material is eluted with 15% diethyl ether in CH<sub>2</sub>CI<sub>2</sub> and the filtrate is concentrated under reduced pressure and the residue is triturated with boiling hexanes. Additional product is recovered after concentrating the filtrate, which is then subjected to chromatography on silica gel eluting with 10% diethyl ether in
531
CH2CI2. The appropriate fractions are collected
IMPT> -; Λ 'Sai
<img file="MX339989B_D0910.tif" />
. -,,. . -, INSTITUTO MEXICANO are then ground with boiling hexanes. The two lavender colors are combined to provide the title compound (100 g, 57% yield).
<sup>1</sup>H NMR (400 MHz, DMSO) δ 9.02 (bs, 1H), 8.11 (s, 1H),
7.63-7.54 (m, 1H), 6.74 (d, J = 9.1, 1H), 3.42-3.37 (m, 4H), 1.57-1.49 (m, 6H), 1.45 (9, 1H).
EXAMPLE 144C
6- (plperldin-1-yl) pyridin-3-amine dihydrochloride
The product from Example 144B (1.00 g, 3.62 mmol) is slowly added to 4M hydrochloric acid (10 ml, 40 mmol) and stirred at room temperature. After stirring overnight, ether is added and the solid is filtered. Dry in a vacuum oven to a white solid (0.817 g, 84%).
<sup>1</sup>H NMR (400 MHz, methanol-d4) δ 1.77 (s, 6H), 3.65 (s, 4H), 7.41 (d, J = 9.8 Hz, 1H), 7.70 (d, J = 2.6 Hz, 1H), 7.79 (dd, J = 2.7, 9.8 Hz, 1H).
EXAMPLE 144D
5- (2.5-bis (4- (2 - ((S) -pyrrol¡d¡n-2-yl) -1 H-imidazol-4-¡l) phenyl) -1 H-pyrrol1-i D-2-Piperidin-1-Dpyridine
To a solution of the product of Example 138B (0.20 g,
532
0.28 mmol) and the product of Example 144C (0.11 g, 0 · Ϊ2 ^ | ^ ι ^^ 1)
INSTITUTO MEXICANO 7?
OF THE PROPERTY in toluene (2.8 ml) add TFA (22 μΙ, 0.28 mmol). The mixture is stirred at 110 ° C for 3 hours. TFA (0 · .5 · —-.......— ml) is added to the cold mixture and the mixture is stirred for 1 hour at room temperature.
The solvent is then removed under reduced pressure and triturated with diethyl ether and dried to obtain 0.31 g of the desired compound as a TFA salt.
<sup>1</sup>H NMR (DMSO-d<sub>6</sub>; 400 MHz): δ 9.78 (br s, 2H), 7.84 (d,
J = 2.71 Hz, 1H), 7.75 (s, 2H), 7.67 (AA'XX ', J = 8.34 Hz, 4H), 7.35 (dd,
J = 9.11, 2.71 Hz, 1H), 7.18 (AA'XX ', J = 8.46 Hz, 4H), 6.79 (d, J = 9.11 Hz, 1H), 6.53 (s, 2H), 4.79 (apparent t, J = 7.81 Hz, 2H), 3.4-3.2 (m,
4H), 2.44-2.36 (m, 2H), 2.25-1.98 (m, 6H), 1.65-1.45 (m, 6H).
EXAMPLE 144E
H2S) -1 - {(2S) -2-r4- (4-f5- (4- (2-r (2S) -1 - ((2S) -2f (methoxycarbon ¡l) aminol-3-met ¡L butanoi l> p¡ r rol idin-2-ΪΠ-1H¡midazol-4-yl) fen¡ l) -1 -Γβ-fpiperidin-l -il) py¡d¡n-3-¡H-1 H-pyrrol-2-yl> phenyl) -1 H-¡mi dazol-2-i II methyl pyrrolidin-1-yl> -3-methyl-1-oxobutan-2¡ll carbamate
To a hydrochloride solution of N1 - ((ethylimino) methylene) N3, N3-dimethylpropan-1,3-diamine (0.17 g, 0.89 mmol), 1Hbenzo [d] [1,2,3] triazole-1- Hydrated ol (0.14 g, 0.89 mmol), (S) 2- (methoxycarbonylamino) -3-methylbutanoic acid (0.16 g, 0.89 mmol) in DMF (1.0 ml) 4-methylmorpholine (0.3 ml, 2.7 mmol) is added. Is
533 .mrya.
The mixture is stirred at room temperature for
INSTITUTO MEXICANO DE LA rkORIEDAD is then added to a solution of the product of the ExempM ™ ^ (0.31 g, 0.25 mmol) and 4-methylmorpholine (0.2 ml, -4 -.- 8 mmoloo> on ........- —DMF (0.7 ml). After stirring 4 hours, water is added to this mixture and the solid is collected by filtration then washed with water and diethyl ether. The residue is purified on silica gel eluting with 60% THF / hexanes to provide 100 mg of the title compound.
<sup>1</sup>H NMR (400 MHz, DMSO) δ 12.17 - 11.70 (m, 2H), 7.84 7.76 (m, 1H), 7.64 - 7.50 (m, 4H), 7.49 - 7.40 (m, 2H), 7.31 - 7.02 (m, 7H), 6.76 - 6.69 (m, 1H), 6.52 - 6.41 (m, 2H), 5.09 - 5.01 (m, 2H), 4.04 (t, J = 8.3, 2H), 3.83 - 3.71 (m, 4H), 3.53 (s, 6H), 3.50 - 3.44 (m, 4H), 2.18 - 2.04 (m, 4H), 2.03 - 1.86 (m, 6H), 1.61 - 1.46 (m, 6H), 0.90 - 0.79 (m, 12H ).
MS (ESI; M + H) m / z = 965.
<img file="MX339989B_D0911.tif" />
EXAMPLE 145 f (2S) -1-r (2S) -2- (4-f4-r5- (4-f2-r (2S) -1 - {(2S) -2f (m toxiccarbonDam ¡nol-3-mt ¡Lbutano¡l) p¡rrol ¡d¡n-2-¡H-1 H534 lm¡dazol-4-¡Pphenyl) -1 -f4-r (tr¡fl uorometh¡l) sulfan ¡l1fenU} -1hjk- ^> ^
INDUSTRIAL
<img file="MX339989B_D0912.tif" />
illfeniD-1 H-imidazol-2-yl) p¡rrolidin-1 -¡Π-3-methyl-l-oxobutan-2 · Methyl Pcarbamate
Example 138B and 4- (trifluoromethylthio) aniline are processed using the methods of Examples 139A and 138D to provide the title compound (19 mg).
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ 12.18 - 11.65 (m, 2H), 7.73 - 7.63 (m, 2H), 7.60 - 7.48 (m, 4H), 7.45 - 7.39 (m, 2H), 7.31 7.15 ( m, 4H), 7.06 - 6.92 (m, 4H), 6.58 - 6.46 (m, 2H), 5.08 - 5.00 (m, 2H), 4.03 (t, J = 8.4, 2H), 3.85 - 3.69 (m, 4H ), 3.53 (s, 6H), 2.23 1.79 (m, 10H), 0.93-0.77 (m, 12H).
MS (ESI; M + H) m / z = 981.
<img file="MX339989B_D0913.tif" />
EXAMPLE 146
R2S) -1-rí2S) -2-f4- (4-r5- (4-f2-r (2S) -1-ff2S) -2rímethoxycarboniDam inol-3-methyl butanoi l) p¡rrol ¡di n-2- ¡H-1 H¡m¡dazol-4-¡Dfen¡D-1- (2-methyl-1,3-benzot¡azol-5-yl) -1 H-pyrrole-2illf n¡P-1 H- imidazole-2-¡Dpi rrol ¡di n-1-i Π-3-m ti 1-1-oxobutan-2535
• ..VtáA'-íL
IMPI
MEXICAN INSTITUTE OF INDUSTRIAL PROPERTY
<img file="MX339989B_D0914.tif" />
Methyl 2-meth libe nzoidlti azole, Rcarbamate
Example 138B and dihydrochloride
5-amine are processed using the methods of Examples 139A and 138D to provide the title compound (19 mg).
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ 12.04 - 11.63 (m, 2H), 8.02 - 6.85 (m, 15H), 6.58 - 6.45 (m, 2H), 5.07 - 4.96 (m, 2H), 4.02 (t , J = 8.4, 2H), 3.86 - 3.67 (m, 4H), 3.53 (s, 6H), 2.75 (s, 3H), 2.21 1.78 (m, 10H), 0.93 - 0.76 (m, 12H).
MS (ESI; M + H) m / z = 952.
<img file="MX339989B_D0915.tif" />
(4- (2.5-bisr4- (2 - ((2S) -1-rN- (methox8carbonyl) -L-valillp¡rrolidin-2-yl) 1 H-lm ¡dazol-4-yl) fen ¡11-1 Hp¡rrol-1-yl) benzyl) diethyl phosphonate
Example 138B and diethyl 4-aminobenzylphosphonate are processed using the methods of Examples 139A and 138D to provide the title compound.
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ 12.19 - 11.63 (m, 2H),
536
7.56
6.91
8.4,
2.22. 7.44 (m, 4H), 7.42 - 7.34 (m, 2H), 7.32 - 7.1
<img file="MX339989B_D0916.tif" />
15TH
OF INDUSTRIAL PROPERTY (m, 6H), 6.53 - 6.40 (m, 2H), 5.10 - 4.98 (m, 2H), 4.03 (t, J = 2H), 3.91 - 3.67 (m, 8H), 3.53 (s, 6H), 3.23 (d, J = 21.8, 2H), - 1.80 (m, 10H), 1.15 - 1.04 (m, 6H), 0.92 - 0.77 (m, 12H).
MS (ESI; M + H) m / z = 1031.
<img file="MX339989B_D0917.tif" />
EXAMPLE 148 ((2S) -1-K2S) -2- (4- {4-n- (1H-indazol-6-¡l) -5- (4- (2-r (2S) -1 - (( 2S) -2f (methoxy carbon ¡l) am¡nol-3-methi Ibutanoi Dpi rrolidi n-2-yl1-1H¡m idazol-4-i Ríen ¡l) -1 Hp¡rrol-2-illfen¡D- 1 H-¡midazol-2-i Dpi rrol idi n1-iΠ-3-methi 1-1-oxobutan-2-¡l} methyl carbamate
Example 138B and 1 H-indazol-6-amine are processed using the methods of Examples 139A and 138D to provide the title compound (24 mg).
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ 13.08 - 12.99 (m, 1H), 12.05 - 11.62 (m, 2H), 8.13 - 8.04 (m, 1H), 7.74 - 7.66 (m, 1H), 7.54 7.42 ( m, 4H), 7.41 - 7.34 (m, 2H), 7.31 - 7.09 (m, 3H), 7.05 - 6.77 (m, 5H), 6.58 - 6.47 (m, 2H), 5.06 - 4.97 (m, 2H), 4.02 (t, J = 8.4, 2H),
3.83 - 3.66 (m, 4H), 3.53 (s, 6H), 2.20 - 1.78 (m, 10H), 0.89 - 0.76 (m,
537
Tf.fJ-LZ · - · '
<img file="MX339989B_D0918.tif" />
EXAMPLE 149 r (2S) -1 - ((2S) -2-r4- (4-f1-r3-fluoro-4- (p¡per¡din-1-¡I) phen¡n-5- (4- {2U2S) -1 -í (2S) -2-f (methox¡carbon¡l) am¡noT-3-met¡lbutano¡l) p¡rrol¡d¡n2-¡H-1 H-¡m¡ methyl dazol-4-yl) phenyl) -1H-p¡rrol-2-¡l) phenyl) -1H-m¡mdazol-2 ylpyrrolidin-l-oxobutan-2-8ll carbamate
Example 138B and 3-fluoro-4- (piperdin-1-yl) anin are processed using the methods of Examples 139A and 138D to provide the title compound.
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ 12.15 - 11.69 (m, 2H),
7.62 - 7.49 (m, 4H), 7.48 - 7.39 (m, 2H), 7.32 - 7.15 (m, 2H), 7.12 6.77 (m, 7H), 6.52 - 6.42 (m, 2H), 5.08 - 4.99 (m, 2H), 4.04 (t, J =
8.4, 2H), 3.84 - 3.70 (m, 4H), 3.53 (s, 6H), 3.01 - 2.89 (m, 4H), 2.19 1.82 (m, 1 OH), 1.68 - 1.43 (m, 6H), 0.92 - 0.75 (m, 12H).
MS (ESI; M + H) m / z = 982.
538
<img file="MX339989B_D0919.tif" />
IMPI
INSTITUTO MEXICANO DE LA ('λΟΠΕΟΛΠ INDUSTRIAL
<img file="MX339989B_D0920.tif" />
EXAMPLE 150
H2S) -1-f (2S) -2-r4- (4- (1-r4- (hexyloxy) phenin-5- (4-f2-r (2S) -1 - <(2S) - 2Hm ethoxycarbon¡l) am¡no1-3-m ethyl butanoyl Ipyro lid i η-2-il-1Him idazol4-ülfen¡l) -1 Hp¡rrol-2-yl1phenii) -1 H-imidazol-2-iylpyroiidin1 methyl-i-3-methyl-1-oxobutan-2-incarbamate
Example 138B and 4- (hexyloxy) anine are processed using the methods of Examples 139A and 138D to provide the title compound (15 mg).
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ 12.12 - 11.67 (m, 2H),
7.59 - 7.48 (m, 4H), 7.45 - 7.39 (m, 2H), 7.30 - 7.13 (m, 2H), 7.08 20 6.96 (m, 6H), 6.90 - 6.83 (m, 2H), 6.52 - 6.42 (m , 2H), 5.07 - 5.01 (m,
2H), 4.04 (t, J = 8.5, 2H), 3.92 (t, J = 6.4, 2H), 3.83-3.70 (m, 4H),
3.53 (s, 6H), 2.19-1.83 (m, 10H), 1.73-1.63 (m, 2H), 1.45-1.21 (m, 6H), 0.92-0.77 (m, 15H).
MS (ESI; M + H) m / z = 981.
539
<img file="MX339989B_D0921.tif" />
EXAMPLE 151 (4- (3-tert-butyl-2,5-bisr4- (2-f (2S) -1-rN- (methoxycarbonyl) -Lvali H-pyrrole-din-2-yl) -1 H-imidazole -4-¡l) fenin-1 H-pyrro 1-1 ¡diethyl DbenzDphosphonate
The title compound is formed as an additional product from Example 147. The product mixture is purified by chromatography on silica gel eluting with a solvent gradient of 0-5% methanol in CH<sub>2</sub>CI<sub>2</sub> to provide the title compound.
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ 11.68 (d, J = 13.5, 2H), 7.55 - 7.39 (m, 5H), 7.37 - 7.23 (m, 3H), 7.21 - 6.90 (m, 8H), 6.43 (s,
1H), 5.07-4.99 (m, 2H), 4.06-3.97 (m, 2H), 3.83-3.58 (m, 8H),
3.53 (s, 6H), 3.07 (d, J = 21.5, 2H), 2.20-1.81 (m, 10H), 1.15 (s,
9H), 0.98 (t, J = 7.0, 6H), 0.90 - 0.78 (m, 12H).
MS (ESI; M + H) m / z = 1087.
540
<img file="MX339989B_D0922.tif" />
EXAMPLE 152 r (2S) -1 - ((2S) -2-F4- (4- (1-r4- (2,2-dichloro-1-methylcyclopropyl) fenin-5 (4 - {2-r (2S) -1 - ((2S) -2-r (methox¡carbon¡l) am¡no1-3methylbutano¡l) p¡rrol¡d¡n-2-¡l1-1 H- ¡Midazol-4-¡l) phen¡l) -1 H-pyrrole-2¡Rfenih-I H-imidazol-2-illpyrrolidin-1-yl) -3-methyl-1-oxobutan-2¡ll methyl carbamate
Example 138B and 4- (2,2-dichloro-1-methylcyclopropyl) aniline are processed using the methods of Examples 139A and 138D to provide the title compound (36 mg).
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ 12.18 - 11.68 (m, 2H),
7.55 - 7.42 (m, 4H), 7.41 - 7.22 (m, 6H), 7.17 - 6.90 (m, 6H), 6.57 - 6.44 (m, 2H), 5.08 - 5.00 (m, 2H), 4.03 (t, J = 8.3, 2H), 3.86-3.69 (m, 4H), 3.53 (s, 6H), 2.22 (t, J = 8.5, 1H), 2.18-1.81 (m, 10H), 1.79-1.72 (m, 1H), 1.65 (s, 3H), 0.92-0.77 (m, 12H).
MS (ESI; M + H) m / z = 1003.
541
<img file="MX339989B_D0923.tif" />
EXAMPLE 153 f (2S) -1 -f (2S) -2-r4- (4-f1-r4- (1,1,1,3.3,3-hexafluoro-2-hydroxypropan2-¡l) fenin-5- ( 4- {2-r (2S) -1-f (2S) -2-f (methoxycarbonyl) am¡nol-3metNbutanoyl) pyrrolidin-2-¡H-1 H-im idazol-4-i Rfen i D -1 H-pyrrole-2-yl) phenyl) -1 Hi midazol-2-ι'Π pyrrolidin-1-i 11-3-methyl-1-oxobutan-2¡H methyl carbamate
Example 138B and 2- (4-aminophenyl) -1,1,1,3,3,3 hexafluoropropan-2-ol are processed using the methods of Examples 139A and 138D to provide the title compound (45 mg).
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ 12.08 - 11.71 (m, 2H),
8.80 (s, 1H), 8.01 - 7.37 (m, 8H), 7.33- 7.13 (m, 4H), 7.06 - 6.89 (m, 4H), 6.57 - 6.47 (m, 2H), 5.03 (d, J = 6.8 , 2H), 4.03 (t, J = 8.4, 2H),
3.77 (d, J = 6.2, 4H), 3.53 (s, 6H), 2.21 - 1.80 (m, 10H), 0.92 - 0.76 (m, 12H).
MS (ESI; M + H) m / z = 1047.
542
<img file="MX339989B_D0924.tif" />
ΙΜΡΙ
MEXICAN INSTITUTE OF INDUSTRIAL PROPERTY
<img file="MX339989B_D0925.tif" />
EXAMPLE 154
H2S1-1 -f (2S) -2-r4- (4- (5- (4-f2-R2S) -1 -R2S1-2f (methoxycarb ni l) amine nol-3-methylbutanoylpyrrolidi n-2- ¡11-1H¡midazol-4-yl) phen¡l) -1 -r6- (morpholin-4-yl) pyridin-3-ill-1H-pyrro I-2i Ufe ni 11-1 H methyl-imidazol-2-illpyrrolidin-y-y-3-methyl-1-oxobutan-2-11 carbamate
EXAMPLE 154A
4- (5-ni tropirid i η-2-ill morpholine
The title compound is prepared using the methods of Example 144A substituting piperidine for morpholine to provide the title compound.
EXAMPLE 154B
6-morpholinop¡rid¡n-3-am ¡na
To a solution of the product of Example 154A (12.5, 59.5
543 mmol) in THF (150 ml) a suspension * is added.<sup>J</sup><sup>1</sup> \ / σ «r ~ INSTITUTO MEXICANO
OF THE PROPERTY
INDUSTRIAL
2800, (12.5 g, 212 mmol) in a 50 mT7 SS pressure bottle
The mixture is pressurized (H<sub>2</sub>, 2.11 kg / cm<sup>2</sup>) and stirred for 2 hours at room temperature. The mixture is filtered and then concentrated under reduced pressure to provide the title compound.
EXAMPLE 154C r (2S) -1-f (2S) -2-r4- (4-f5- (4- (2-r (2S) -1-y (2S) -2r (methoxycarbonyl) aminol-3 -methylbutanoyl) p¡rrol¡din-2-i 11-1 H¡midazol-4-¡l} phen¡l) -1-r6- (morpholin-4-¡l) pyrid¡n-3 -il1-1 H-pyrrole-2¡nphenyl) -1 H-imidazol-2-i Ilpyrrole id i n-1 -IΠ-3-methyl 1-1-oxo butane-2¡ll carbamate
Example 138B and Example 154B are processed using the methods of Examples 139 A and 138D to provide the title compound.
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ 12.16 - 11.69 (m, 2H), 7.89 - 7.80 (m, 1H), 7.63 - 7.50 (m, 4H), 7.50 - 7.40 (m, 2H), 7.39 7.02 ( m, 7H), 6.80 - 6.71 (m, 1H), 6.52 - 6.41 (m, 2H), 5.10 - 5.00 (m, 2H), 4.04 (t, J = 8.7, 2H), 3.85 - 3.72 (m, 4H ), 3.69-3.59 (m, 4H),
3.53 (s, 6H), 3.45-3.37 (m, 4H), 2.20-1.82 (m, 10H), 0.94-0.77 (m, 12H).
MS (ESI; M + H) m / z = 967.
544
IMPI
OR.
<img file="MX339989B_D0926.tif" />
Ό /
MEXICAN INSTITUTE OF INDUSTRIAL PROPERTY
<img file="MX339989B_D0927.tif" />
EXAMPLE 155 f (2S) -1 -T (2S) -2- (4-í4-ri- <6-rb¡s (2-methoxyethyl) am¡no1p i ri di n-3-¡1) -5- (4 <2-H2S) -1 - <(2S) -2-r (methoxycarbonl) aminoT-3-methylbutanoyl) pyrroiidin-2-yl1-1 H-imidazol-4-¡l) phen¡l ) -1 H-pyrrol-2ii1phenyl-1 Hi mi dazol-2-yl) pyrrolidin-1-yl-3-methyl-1 -oxo bu tan-2, methyl Ucarbamate
EXAMPLE 155A
NN-bis (2-methoxyethyl) -5-nitropyridin-2-amine
The title compound is prepared using the methods of Example 144A by substituting piperidine for bis (2-methoxyethyl) -amine to provide the title compound.
EXAMPLE 155B
N2, N2-bis (2-methoxyetil) p¡r¡d¡n-2.5-diamine
Example 155A is processed using the methods of
545
Example 154B to provide the title compound.
IMPI
INSTITUTO MEXICANO CE LA INDUSTRIAL PROPERTY
<img file="MX339989B_D0928.tif" />
EXAMPLE 155C _________ f (2S) -1 -r (2S) -2- (4- (4-ri-f6-ib¡s (2-methox¡ethyl) am¡no1p¡r¡d¡n-3-¡ l} -5- (4 <2-r (2S) -1 - ((2S) -2-r (methoxy carbon ¡Daminol-3methyl butanoi Dpi rrol idin-2-il-1H-¡m¡ dazol-4-¡Ufen ¡D-1 H-pyrrole-2iHphenyl) -1 H-imidazol-2-i Dpi rrol idin-1 -i II-3-methi 1-1 -oxobutan-2¡D methyl carbamate
Example 138B and Example 155B are processed using the methods of Examples 139A and 138D to provide the title compound.
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ 12.17 - 11.67 (m, 2H),
7.86 - 7.77 (m, 1H), 7.63 - 7.49 (m, 4H), 7.49 - 7.38 (m, 2H), 7.34 - 7.20 (m, 3H), 7.20 - 7.03 (m, 4H), 6.64 - 6.56 (m, 1H), 6.52 - 6.40 (m, 2H), 5.09 - 5.00 (m, 2H), 4.04 (t, J = 8.2, 2H), 3.84 - 3.69 (m, 4H), 3.65 - 3.57 (m, 4H), 3.53 (s, 6H), 3.47-3.40 (m, 4H), 3.21 (s, 6H),
2.20-1.84 (m, 10H), 0.84 (m, 12H).
MS (ESI, M + H) m / z = 1013.
<img file="MX339989B_D0929.tif" />
546
IMPI
Mexican Institute of Industrial Property
ÍÍ2S)
H2S) -2- (4- {4-M
EXAMPLE 156 (2-tert-butylphenyl) -5- (4- (2 [(2S) f (2S) -2r (methoxycarbonyl) amino1-3-methylbutanoyl) pyrrolidin-2-iH-1 H¡m Dazol-4-¡l) phen¡l) -1H-p¡rrol-2-¡nfen¡l) -1H-¡m¡mdazol-2-yl) p¡rrol¡d¡n1-yl1-3-methyl- 1-oxobutan-2-ll> methyl carbamate
Example 138B and 2-tert-butylaniline are processed using the methods of Examples 139A and 138D to provide the title compound (10 mg).
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ 12.07 - 11.64 (m, 2H),
7.61-7.11 (m, 12H), 7.06-6.93 (m, 4H), 6.65-6.49 (m, 2H), 5.08 4.97 (m, 2H), 4.04 (t, J = 7.2, 2H), 3.82-3.69 ( m, 4H), 3.53 (s, 6H),
2.17-1.83 (m, 10H), 0.92-0.77 (m, 21H).
MS (ESI, M + H) m / z = 937.
<img file="MX339989B_D0930.tif" />
EXAMPLE 157 r (2S) -1-f (2S) -2-f4- (4- (1-r4- (1,4-d¡oxa-8-azaesp¡ror4.51dec-8¡I) fn¡l1 -5- (4- (2-r (2S) -1 - ((2S) -2-r (methoxycarbonyl) aminoT-3547 methylbutanoyl> pyrrolidin-2-ill-1H-imidazole- 4-¡l} terftlJL-l ± i-JpirXo
MEXICAN INSTITUTE OF PROFIECAD
<img file="MX339989B_D0931.tif" />
INSTITUTO MEXICANO DE LA PRGFIcCAD il) phenyl) -1 H-¡midazol-2-ill pyrrole ¡di n-1-yl} -3-m ethyl-1 -ox¿<sup>J</sup>bfffd'n-2 ^ 'll methylcarbamate —'——
Example 138B and 4- (1,4-dioxa-8-azaspiro [4.5] decan-8yl) aniline are processed using the methods of Examples 139A and 138D to provide the title compound (156 mg).
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ 12.06 - 11.65 (m, 2H),
7.59 - 7.46 (m, 4H), 7.44 - 7.36 (m, 2H), 7.30 - 7.13 (m, 2H), 7.09 6.96 (m, 4H), 6.90 (ρ, 4H), 6.53 - 6.39 (m, 2H) , 5.08-4.98 (m, 2H), 4.04 (t, J = 8.4, 2H), 3.90 (s, 4H), 3.86-3.71 (m, 4H), 3.53 (s, 6H),
3.29-3.20 (m, 4H), 2.19-1.83 (m, 10H), 1.73-1.64 (m, 4H), 0.93 0.77 (m, 12H).
MS (ESI; M + H) m / z = 1022.
<img file="MX339989B_D0932.tif" />
oxobutan-1,2-di-in)) dimethyl b¡scarbamate
EXAMPLE 158 (ri- (4-tert-but¡phenyl) pyrrol¡d¡n-2.5-d¡-¡llb¡s {benzene-4.1-d¡-¡lmethanedi-ilcarbam oil (2S) pyrrol id i n -2,1-di-yl R2S) -3-methyl-1 548
EXAMPLE 158A IMPI
MEXICAN INSTITUTE
4,4 '- (1 - (4-tert-but¡lfen¡l) p¡rrol¡din-2,5-di-¡l) d¡beh¿t¿h¡, trtyo SS-SM
A solution of Example 42C (2.0 g, 3.9 mmol) and copper (1) cyanide (1.047 g, 11.69 mmol) in DMF (19 ml) is heated in a microwave for 7 hours at 160 ° C. After this, the mixture is poured into water (700 ml) and then concentrated, ammonium hydroxide (40 ml) is added and the solution is extracted with EtOAc. The organic extract is dried, filtered, concentrated and the residue is purified by flash chromatography (silica gel, EtOAc / hexanes) to obtain 1.23 g (78%) of the title compound.
MS (ESI) m / z 406 (M + H) +.
EXAMPLE 158B
4,4 '- (1- (4-tert-butylphenyl) p¡rrolidin-2.5-di-¡l) bis (4,1-phenylenedimethanamine
Lithium aluminum hydride (0.236 g, 6.21 mmol) is added to a solution of Example 158A (0.63 g, 1554 mmol) in THF (21 ml) then stirred at room temperature for 20 minutes and at 70 ° C for 1 hour. The mixture is then cooled in an ice bath and a saturated aqueous ammonium chloride solution is added followed by extraction with EtOAc and the organic layer is extracted with Rochelle's solution. The organic solution dries
549 then, filter and concentrate to obtain comp MS (ESI) m / z 414 (M + H) +.
<img file="MX339989B_D0933.tif" />
EXAMPLE 158C (ΙΊ - (4-tert-butylphenyl) pyrrolidin-2.5-di-iHbis <benzene-4,1 -dilmethanedi-8lcarbamoyl (2S) pyrrole idi n-2,1-di-¡l [ Dimethyl (2S) -3-meth 1-oxobutan-1,2-di-i ITDbiscarbamate
The product of Example 158B (45 mg, 0.109 mmol), the product of Example 37B (62.2 mg, 0.228 mmol) and HATU (91 mg, 0.239 mmol) in DMSO (3 ml) is added Hunig's base (0.095 ml, 0.544 mmol), and the reaction mixture was stirred at room temperature for 1 hour. The reaction mixture is partitioned between water and dichloromethane, and the organic layer is dried over MgSO<sub>4</sub>, filter and concentrate. Purification by flash chromatography (silica gel, 0-10% methanol / dichloromethane) gives 55 mg (55%) of the title compound as a mixture of stereoisomers.
1H NMR (400 MHz, DMSO-D6) δ ppm 8.11 (m, 2H), 7.08 (s, 2H), 6.95 (m, 8H), 6.74 (d, J = 8.8 Hz, 2H), 5.97 (d, J = 8.7 Hz, 2H), 5.01 (m, 2H), 4.15 (m, 4H), 4.05 (m, 4H), 3.80 (m, 2H), 3.31 (s, 6H), 2.40 (m, 2H), 1.90 (m, 2H), 1.85 (m, 4H), 1.80 (m, 4H), 0.95 (s, 9H), 0.70 (m, 2H), 0.65 (m , 12H).
MS (ESI) m / z 923 (M + H) +.
550
<img file="MX339989B_D0934.tif" />
EXAMPLE 159 í (2S) -1-h2S) -2- (4- {4-r (3S, 5R) -4- (4-tert-but¡lfen¡l) -5- (4-f2-K2S) -1f (2S) -2-r (methoxycarbonyl) amino1-3-methylbutanoyl} p¡rrol¡d¡n-2-¡H-1 H¡mi dazol-4-phenyl) thiomorpholin-3-i Ufen yl> -1 H-imidazol-2¡l) pyrrolidin-1-iH-3-methii-1-oxobutan-2-yl} methyl carbamate
EXAMPLE 159A
2,2'-thiobisd - (4-brom ofe ni Peta nona)
A solution of 2-bromo-1- (4-bromophenyl) ethanone (27.8 g, 100 mmol) is dissolved in acetone, the solution is cooled in an ice bath then sodium sulfide nonahydrate (12.01 g, 50 mmol) is added dissolved in water (100 ml) by dripping over 45 minutes. The resulting solution is stirred an additional 2 hours at room temperature, the solid that forms in the reaction is collected and then washed with water then ethanol and dried in a vacuum oven to provide 18.5 g (43%) of the title compound .
551
IMPI
EXAMPLE 159B
MEXICAN INSTITUTE OF EA PROPERTY
2.2<sup>,</sup>-thiob¡s (1 - (4-bromophenyl) ethanol) <sup>indu</sup>strial
<img file="MX339989B_D0935.tif" />
Sodium borohydride (0.972 g, 25.7 mmol) is added portionwise to a solution of Example 159A (5.0 g, 11.68 mmol) in ethanol (78 ml) and the mixture is stirred at room temperature for 20 minutes. After this the solution is concentrated, then a 1N aqueous hydrochloric acid solution (100 ml) is added and extracted with EtOAc. The organic extract is dried, filtered and concentrated to 5.05 g (100%) of a colorless solid as the title compound.
EXAMPLE 159C
N, N '- (2.2<sup>!</sup>-tio b¡s (1- (4-brom of nilleta n-2,1-di-yl)) bis (4-tertbutylanil i na)
To a solution of Example 159B (5.05 g, 11.68 mmol) in THF (145 ml) and dichloromethane (145 ml) is added triethylamine (4.86 ml, 35.1 mmol) and the mixture is cooled in an ice bath. To this solution methanesulfonyl chloride (2,276 ml, 29.2 mmol) is added dropwise followed by stirring at 0 ° C for an additional 30 minutes followed by concentration at room temperature to a residue. The resulting residue is dissolved in DMF (39 ml) followed by the addition of 4-tert-butylaniline (18.62 ml, 117 mmol) and the mixture is heated at 50 ° C for 5 hours. After this acid is added
552
<img file="MX339989B_D0936.tif" />
1 N aqueous hydrochloric acid followed by extraction with
INSTITUTO Mexicano organico is dried, filtered and concentrated. Purification of flash chromatography (gel / -qn EtOAc / hexanes) gives 2.67 g (42%) of the title compound.
EXAMPLE 159D
3,5-b¡s (4-bromophen¡D-4- (4-tert-but¡lfen¡l) thiomorpholin
Silica gel (1.0 g) is added to a solution of Example 159C (350 mg, 0.504 mmol) in toluene (5 ml) which has been dehydrated by heating at 180 ° C in a vacuum oven for 3 hours, and trifluoromethanesulfonic acid (0.045 ml, 0.504 mmol) and heated at 100 ° C for 3 hours. After cooling to room temperature, dichloromethane is added and the silica gel is filtered off and the solution is extracted with semi-saturated aqueous sodium bicarbonate solution. The organic extract is dried, filtered and concentrated to obtain 220 mg (80%) of the title compound as a mixture of isomers.
MS (ESI) m / z 546 (M + H) +.
EXAMPLE 159E
4- (4-tert-butylphenyl) -3,5-b¡s (4- (4.4.5,5-tetramethyl-1,3.2-d¡oxaborolan2-¡l) phenyl) t¡ omorpholine
553
IM
The product of Example 159D (200 mg, O'.3fFFg ^ i ^ & $ ¡s
<img file="MX339989B_D0937.tif" />
Process using the method described in Example 42D to provide 105 mg (45%) of the title compound as a mixture of isomers.
MS (ESI) m / z 640 (M + H) +.
EXAMPLE 159F (2S.2<sup>,</sup>S) -2.2<sup>,</sup>-(4.4<sup>,</sup>- (4.4 '- (4- (4-tert-butylfhenyl) thiomorpholin-3.5-d¡¡l) bis (4.1-phenylene)) bis (1 H-imidazole-4,2-d¡-¡l) ) tert-but8lo dipyrrolidin-1 carboxylate
The product from Example 159E (190 mg, 0.297 mmol) and the product from Example 26D (282 mg, 0.891 mmol) are processed using the method described in Example 42E to provide 110 mg (43%) of the title compound as a mixture. of isomers.
MS (ESI) m / z 859 (M + H) +.
EXAMPLE 159G
4- (4-tert-butylphenyl) -3.5-b¡s (4- (2 - ((S) -pyroiidin-2-yl) -1 H-imidazol-4¡DpheniDthiomorpholine
To the product of Example 159F (110 mg, 0.128 mmol) dimethoxyethane (5 ml) and a 4N solution of hydrochloric acid in dioxane (5 ml) are added and the resulting solution is stirred at room temperature for 1 hour. The solvent is then removed in vacuo and the resulting residue is diluted with acetonitrile and water (0.1% TFA) and
554 purified by phase chromatography
Inverse IMPI (OM ^^^ eh
INDUSTRIAL
<img file="MX339989B_D0938.tif" />
with 10-100% acetonitrile in water (0.1% TFA) to obtain 12 mg (14%) of the title compound as a mixture of stereoisomers.
MS (ESI) m / z 658 (M + H) +.
EXAMPLE 159H f (2S) -1-r (2S) -2- (4- <4-r (3S, 5R) -4- (4-tert-but¡lfen¡l) -5- (4- {2 -r (2S) -1í (2S) -2-rfmethox ¡carbon yl) am¡nol-3-methi Ib uta no¡ l | p¡ rrol ¡din-2-¡Π-1Himidazol-4-¡l) feni l) thiomorpholin-3-¡Hfen¡ 11-1 H-imidazoi-2¡l) p¡rrol¡d¡n-1-¡ll-3-methyl-1-oxobutan-2-¡l) methyl carbamate
The product of Example 159G (10 mg, 0.015 mmol), (S) -2- (methoxycarbonylamine) -3-methylbutanoic acid (5.86 mg, 0.033 mmol) and HATU (12.71 mg, 0.033 mmol) in DMSO (0.5 ml) is added Hunig's base (0.013 ml, 0.076 mmol), and the reaction mixture is stirred at room temperature for 1.5 hours. The reaction mixture is partitioned between water and dichloromethane, and the organic layer is dried over MgSO.<sub>4</sub>, filter and concentrate in vacuo. The crude product is redissolved in methanol (5 ml) then potassium carbonate (50 mg) is added then stirred at room temperature for 20 minutes, the solids are removed by filtration, the filtrate is concentrated and purified by chromatography ( silica gel, 0-10% methanol / dichloromethane) to obtain 7 mg (47%) of the title compound.
555
1Η NMR (400 MHz, DMSO-D6) δ ppm 11 Instituto Mexicano 'DE LA PROPIEDAD
<img file="MX339989B_D0939.tif" />
(m, 2H), 7.32 (m, 4H), 7.23 (m, 4H), 6.85 (m, 4H), 5.OTfrn,<sup>L</sup> 2
4.38 (m, 2H), 4.02 (m, 2H), 3.75 (m, 4H), 3.52 (s? 6H} '/' jjjq (m, '2H), 2.66 (m, 2H), 2.08 (m, 4H), 1.91 (m, 4H), 0.97 (s, 9H), 0.82 (m, 12H).
MS (ESI) m / z 973 (M + H) +.
<img file="MX339989B_D0940.tif" />
EXAMPLE 160 ((2S) -1-r (2S) -2- (4- <4-r (3S.5S) -4- (4-tert-but¡lfen¡l) -5- (4- <2 -H2S) -1P2S) -2-f (methox¡ca rbon i Pam i nol-3-methyl butanoi Dpi rrolidi n-2-¡l1-1 H¡m¡dazol-4-¡Pfen¡Dt¡omorfol¡n -3-¡nfen¡P-1 H-imidazol-2¡l) p¡rrolidin-1-¡n-3-methyl-1-oxobutan-2-¡Pcarbamate methyl and
n2S) -1-H2S) -2- (4-f4-r (3R.5R) -4- (4-tert-butylphenyl) -5- (4- {2-r (2S) -1f (2S) - 2-f (methoxycarbon¡Pam¡nol-3-methylbutane¡Ppyrrolid¡n-2-¡ll-1H¡m¡dazol-4-¡Pfen¡l) thiomorphol¡n-3-¡nfen¡P-1 H- imidazol-Σι Dpi rrolidi n-1-i II-3-m ethyl-1-oxobutan-2-yl} methyl carbamate
The product of Example 159E (100 mg, 0.156 mmol), the
556
<img file="MX339989B_D0941.tif" />
product of Example 126G (146 mg, 0.391 rrtm [1, r-bis (diphenylphosphine) ferrocene] dichloropalladium (li).
adduct (25.5 mg, 0.031 mmol) in a mixture - toluene <-9<sup>F</sup>TrTt) T'ethanol (3 ml) and a 1 N aqueous sodium bicarbonate solution (0.469 ml, 4.69 mmol) and nitrogen gas is bubbled through the solution for 10 minutes, then heated at 80 ° C for 18 hours. The solution is cooled to room temperature and water (20 ml) is added then it is extracted with dichloromethane (50 ml), then it is dried, concentrated and the residue is purified by reversed phase chromatography (C18), eluting with 10-100 % acetonitrile in water (0.1% TFA) to obtain 8.5 mg (6%) of the title compound as a mixture of stereoisomers.
1H NMR (free base) (400 MHz, DMSO-D6) δ ppm 11.70 (bs, 2H), 7.64 (m, 4H), 7.45 (m, 2H), 7.37 (m, 4H), 7.28 (m , 2H),
7.01 (m, 2H), 6.46 (d, J = 8.7 Hz, 2H), 5.38 (m, 2H), 5.07 (m, 2H),
4.03 (m, 2H), 3.52 (s, 6H), 3.10 (m, 2H), 2.12 (m, 4H), 1.91 (m, 4
H), 1.12 (s, 9H), 0.86 (m, 12H).
MS (ESI) m / z 973 (M + H) +.
557 rwwrri li¡.ay<sub>TO</sub>
EXAMPLE 161 f (2S) -1-r (2S1-2- (4- <4-I4- (4-tert-butylphenyl) -5- (4-f2-r (2S) -1 - ((2S ) -2IMPI
INSTITUTO M EXJ CANO ΟΪ LA FRCritDAO INDUSTRIAL
<img file="MX339989B_D0942.tif" />
R-methoxycarboni l) am ¡no1-3-methylbutanoyl) p¡rrol ¡din-2-ill-l Him¡dazol-4-yl) phenyl) -1.1 -dioxydothiomorphol i n-3-¡llphen¡l) -1 H- imidazol 2-yl) pyrrolidin-1-yl-3-methyl-y-oxobutan-2-¡l> methyl carbamate
<img file="MX339989B_D0943.tif" />
EXAMPLE 161A
3,5-bis (4-bromophenyl) -4- (4-tertbutylphenyhthiomorphoiin (ACD v12) 1,1-dioxide
A solution of Example 159D (850 mg, 1.56 mmol) in a mixture of acetone (15 ml), water (5 ml) and THF (5 ml) is added to a solution of osmium tetraoxide (2.5% in tert-butanol, 0.587 ml, 0.047 mmol) and the mixture is stirred at room temperature for 1.5 hours. The solution is then diluted with water and extracted with EtOAc, the organic extract is dried, filtered and concentrated to obtain 900 mg (100%) of the title compound.
MS (ESI) m / z 578 (M + H) +.
558
EXAMPLE 161B
IMPI
<img file="MX339989B_D0944.tif" />
INSTIT ^ O MEXICANO OE LA Π0ΠΓ4Ι) <(2S) -1-r (2S) -2- (4- (4-r4- (4-tert-butylphenyl) -5- (4- (2-r (2S) ^ -n2S) r (methoxycarbon¡l) amino1-3-met¡lbutane¡Rp¡rro4ietin 2 iP 4H-¡m¡mdazol-4-¡l) phen¡ P-1,1-dioxidothiomorpholi n-3-illfeni P -1 H-imidazol2-¡l) p¡rrol¡d¡n-1-¡l1-3-methyl-1-oxobutan-2-yl) methyl carbamate
Example 161A is processed sequentially using the methods of Examples 42D, 42E, 159G, and 159H to provide the title compound as a mixture of trans stereoisomers.
1H NMR (400 MHz, DMSO-D6) δ ppm 11.73 (bs, 2H),
7.64 (m, 4H), 7.55 (m, 2H), 7.44 (m, 4H), 7.24 (m, 2H), 7.04 (m, 2H), 6.60 (m, 2H), 5.48 (m , 2H), 5.06 (m, 2H), 4.04 (m, 2H), 3.78 (m, 6H), 3.52 (s, 6H), 2.11 (m, 4H), 1.92 (m, 6H ), 1.13 (s, 9H), 0.92 (m, 12H).
<img file="MX339989B_D0945.tif" />
EXAMPLE 162 <(2S) -1-r (2S) -2- (4-I4-F (2R, 5R) -1- (4-cyclopropylene) -5- (4- <2-r ( 2S) -1 ((2S) -2-f (methoxycarbonyl ami nol-3-methyl butanoi l) p¡rrol i din-2-111-1H559 im i dazol-4-i) fen ¡Dpi rro Ii di n-2-i Ufe n ¡Π-1H-i measure JMH
ÜOUSTKUU.
1-¡Π-3-methi 1-1-oxobutan-2-¡Pea rbamate
<img file="MX339989B_D0946.tif" />
The product from Example 95B is purified by chiral chromatography on a Chiralpak IB column eluting with a mixture of hexane / THF / methanol (85/10/5). The title compound is the first of the 2 diastereomers to elute.
1H NMR (400 MHz, DMSO-D6) δ ppm 0.33 - 0.43 (m, 2H)
0.65 - 0.72 (m, 2H) 0.79 - 0.91 (m, 12H) 1.56 - 1.64 (m, 1H) 1.66 1.72 (m, 2H) 1.84 - 2.03 (m, 6H) 2.06 - 2.19 (m, 4H) 3.53 (s, 6H)
3.73 - 3.84 (m, 4H) 4.04 (t, J = 8.35 Hz, 2H) 5.06 (dd, J = 6.89, 3.09 Hz, 2H) 5.14 - 5.23 (m, 2H) 6.19 (d, J = 8.67 Hz, 2H) 6.60 - 6.67 (m, 2H) 7.09 - 7.31 (m, 6H) 7.34 - 7.68 (m, 6H) 11.62-12.11 (m, 2H).
MS (ESI +) m / z 924.6 (M + H)
<img file="MX339989B_D0947.tif" />
<(2S) -1-f (2S) -2-f5-r (2R, 5R) -1- (4-cyclopropylphenyl) -5- {2-r (2S) -1-f (2S) 2-r (methoxycarbon¡ l) am ¡no '| -3-methylbutane¡Pp¡rrol¡d¡n-2-¡H-1 Hbenclm i dazol-5-yl) pyrrole idi n-2-¡H-1 H-benzimidazole -2-yl) pyrrolid¡n-1 560 ¡l1-3-methyl-1 -oxobutan-2-¡Dea rbam ato de
OF INDUSTRIAL PROPERTY
<img file="MX339989B_D0948.tif" />
Example 109C and 4-cyclopropylaniline are processed sequentially using the methods of Examples 113A (cyclization reaction carried out at room temperature overnight), 113B, 113C, 28I (reaction carried out at 50 ° C for 3 hours), 28J, and 66E to provide the title compound (122mg) as a solid.
1H NMR (400 MHz, DMSO-D6) δ ppm 0.32 - 0.39 (m, 2H) 0.63-0.69 (m, 2H) 0.77 - 0.90 (m, 12H) 1.53- 1.61 (m, 1H) 1.66 1.74 (m, 2H) 1.86 - 2.04 (m, 8H) 2.14 - 2.23 (m, 4H) 3.54 (s, 6H)
3.78 - 3.87 (m, 4H) 4.00 - 4.07 (m, 2H) 5.10 - 5.18 (m, 2H) 5.31 5.39 (m, 2H) 6.22 (d, J = 8.67 Hz, 2H) 6.57 - 6.65 (m, 2H) 7.00 - 7.07 (m, 2H) 7.16 - 7.32 (m, 4H) 7.36 (d, J = 8.13 Hz, 1H) 7.44 (d, J = 8.24 Hz, 1H) 11.97 - 12.27 (m, 2H),
MS (ESI +) m / z 872.5 (M + H) +
<img file="MX339989B_D0949.tif" />
or
561
EXAMPLE 164 f (2S) -1 -r (2S) -2- (5-f (2R, 5R) -5-f2-R2S) -1 -f (2S) -2IMPI
MEXICAN INSTITUTE OF INDUSTRIAL FBOriEDAD
<img file="MX339989B_D0950.tif" />
í (methoxycarbonyl) amno1-3-methilbutane) p¡rrol id¡n-2-¡l1-1 Idbe nci medazol-5-i 11-1 -r4- (morpholin-4 -¡L) feniHp¡rrol idi η-2-i 11-1Hbertcim ¡dazol-2-¡l) p¡rrolid¡n-1 -¡Π-3-methyl-l-oxobutan-2¡ll methylcarbamate
Example 109C and 4-morpholinoanin are processed using sequentially the methods of Examples 113A (cyclization reaction carried out at room temperature overnight), 113B, 113C, 28I (reaction carried out at 50 ° C). for 2 hours), 28J, and 28K to provide the title compound (100mg) as a solid.
1H NMR (400 MHz, DMSO-D6) δ ppm 0.76 - 0.91 (m, 12H) 1.66 - 1.72 (m, 2H) 1.87 - 2.03 (m, 8H) 2.15 - 2.22 (m, 4H) 2.72 2.78 (m, 4H) 3.53 (s, 6H) 3.57 - 3.62 (m, 4H) 3.78 - 3.86 (m, 4H) 4.00 - 4.12 (m, 2H) 5.09 - 5.18 (m, 2H) 5.30 - 5.37 (m, 2H) 6.25 (d, J = 8.78 Hz, 2H) 6.52 - 6.59 (m, 2H) 7.05 (t, J = 7.54 Hz, 2H) 7.18 7.32 (m, 4H) 7.36 (d, J = 8.13 Hz, 1H) 7.44 (d, J = 8.24 Hz, 1H) 11.91-12.28 (m, 2H).
MS (ESI +) m / z 917.5 (M + H) +.
562
<img file="MX339989B_D0951.tif" />
EXAMPLE 165 (fí2R, 5R) -1 - {4-r6- (morpholin-4-¡l) p¡r¡din-3-¡llfen¡Dpyrrolid¡n-2.5-d¡¡Hb¡sf (2-am ¡Nobenzen-4,1-di-¡l) carbamoiif2S) p¡rrol¡d¡n-2,1-di¡ir (2S) -3-methyl-1-oxobutan-1,2-di- dimethyl illPbiscarbamate
EXAMPLE 165A (2R, 5R) -2.5-b¡s (4-chloro-3-nitrophenyl) -1- (4-iodophenyl) pyrrolidine
Example 109C (3.34 g, 6.0 mmol) and 4-iodoaniline (7.88 g, 36.0 mmol) are processed using the method of Example 113A in which the reaction is allowed to proceed for 4 days at room temperature to provide the title compound ( 2.01 g, 57%) as a yellow solid.
EXAMPLE 165B
4- (5- (4 - ((2R, 5R) -2.5-b¡s (4-chloro-3-nitropheml) pyrrolidi n-1 yl) phen¡l) pyrid¡n-2-¡l) morphol¡ na
563
IMPI ^^
The product of 165A (1.869 g, 3.2 mntoI tetramethyl-1,3,2-dioxaborolan-2-yl) pyridin-2-yl) morform (0.929 g, 3.20 mmol), potassium phosphate (1.359 g, 6.40 mmol ), trls (d¡benz¡l¡denacetone) d¡pallad¡o (0) (0.029 g, 0.032 mmol) and
1,3,5,7-tetramethyl-6-phenyl-2,4,8-trioxa-6-phospha-adamant (0.028 g, 0.096 mmol) are combined in THF (18 ml) / water (6 ml). The mixture is purged with nitrogen for 15 minutes and stirred at room temperature for 24 hours. The reaction mixture is partitioned between ethyl acetate and saturated sodium bicarbonate. The organic layer is washed with brine, dried over sodium sulfate, filtered, and evaporated. The residue is purified by chromatography on silica gel eluting with ethyl acetate / hexane (20% to 40%) to obtain the title compound (1.01 g, 51%) as a solid.
EXAMPLE 165C (2S.2<sup>,</sup>S) -1.1<sup>,</sup>- ((2S.2'S) -2.2<sup>,</sup>-(4.4<sup>,</sup>- ((2R.5R) -1- (4- (6-morpholinopyridin3-¡l) phenyl) pyrrolidin-2,5-d¡-¡Pbis (2-nitro-4,1-phenylene)) bis (azand¡ L) bis (oxomethylen) bisfpi rrolidin-2,1-di-yl)) bis (3-methyl-1-oxobutan-2,1-di-yl) d¡carbamate dimethyl
The product from Example 165B (683 mg, 1.10 mmol), the product from Example 116C (895 mg, 3.30 mmol), casium carbonate (1004 mg, 3.08 mmol), tris (d¡benz¡l¡denacetone) d¡palladium (0) (60.4 mg, 0.066 mmol) and (9,9-dimethyl-9H-xanthen-4,5-diII) bis (d¡phenylphosphine) (115 mg, 0.198 mmol) are combined in dioxane
564
<img file="MX339989B_D0952.tif" />
(15 mi). The mixture is purged with nitrogen for xlJVfoixiutb
INSTITUTO WÍKICANO Dt LA 3'LOntPAD stir at 100 ° C for 3 hours. The mixture is partitioned with ethyl and saturated sodium bicarbonate. The organic layer is washed with brine, dried over sodium sulfate, filtered and evaporated. The residue is purified by chromatography on silica gel eluting with methanol / dichloromethane (1% to 3%) to obtain the title compound (631 mg, 53%) as a solid.
EXAMPLE 165D (R2R, 5R) -1 -f4-f6- (morpholin-4-8l) pyridin-3-¡llfen¡l> pyrroledin-2.5-d¡¡Hb¡sf (2-aminobencen-4 Dimethyl, 1-d¡-¡hcarbamoyl (2S) pyrrolid¡n-2,1-di¡ir (2S) -3-methyl-1-oxobutan-1,2-di-¡H}) b¡scarbamate
The product from Example 165C (628 mg, 0.576 mmol) and 2800 Ni-Ra (628 mg) are combined in THF (40 ml). The mixture is hydrogenated at 2.11 kg / cm<sup>2</sup> During 4 hours. The mixture is filtered and the filtrate is evaporated. The residue is purified by chromatography on silica gel eluting with methanol / dichloromethane (2% to 5%) to obtain the title compound (590 g, 99%) as a solid.
1H NMR (400 MHz, DMSO-D6) δ ppm 0.88 (d, J = 6.61 Hz,
H) 0.91 (d, J = 6.72 Hz, 6H) 1.62 - 1.69 (m, 2H) 1.82 - 2.04 (m, 8H)
2.10 - 2.20 (m, 2H) 2.52 - 2.56 (m, 2H) 3.37 - 3.41 (m, 4H) 3.52 (s,
H) 3.56-3.62 (m, 2H) 3.65-3.70 (m, 4H) 3.78-3.85 (m, 2H)
3.98 - 4.07 (m, 2H) 4.36 - 4.44 (m, 2H) 4.87 (s, 4H) 5.06 (d, J = 6.32
Hz, 2H) 6.36 (d, J = 8.78 Hz, 2H) 6.42 (d, J = 8.02 Hz, 2H) 6.57 (d,
565
<img file="MX339989B_D0953.tif" />
J = 1.19 Hz, 2 H) 6.78 (d, J = 8.89 Hz, 1 H) 6.96 (d,
7.23 (d, J = 8.78 Hz, 2 H) 7.36 (d, J = 8.24 Hz, 2 H) 7.68 (dd, J = 8.78,
2.49 Hz, 1H) 8.27 (d, J = 2.49 Hz, 1H) 9.24 (s, 2H).
MS (ESI +) m / z 1030.6 (M + H) +.
<img file="MX339989B_D0954.tif" />
{(2S) -1-r (2S) -2-f5-r (2R, 5R) -5- (2-r (2S) -1 - <(2S) -2Tim ethoxy rboni ham i nol-3-m ethi I butane ¡Dpi rrol ¡din-2-i 11-1Hbenzim¡dazol-5-yl> -1- (4-r6- (morpholin-4-¡l) pyridin-3illphenyl) pyrrolidin-2-ill- Methyl 1H-benzimidazol-2-yl) pyrrolidin-1-yn-3-methyl1-oxobutan-2-Rcarbamate
The product from Example 165D (520 g, 0.505 mmol) and acetic acid (0.087 ml, 1.514 mmol) are combined in toluene (10 ml). The mixture is stirred at 50 ° C for 4 hours. The solvent is evaporated and the residue is purified by chromatography on silica gel eluting with methanol / dichloromethane (2% to 5%) to obtain the title compound (309 mg, 62%) as a solid.
566
INSTITUTO MEXICANO OT LA PROPERTY IKD'JSTM / .L .21 (m. 2 H) 2.
<img file="MX339989B_D0955.tif" />
1Η NMR (400 MHz, DMSO-D6) δ ppm H) 1.70 - 1.76 (m, 2H) 1.84 - 2.05 (m, 8H) 2.14 - 2
2.60 (m, 2H) 3.34 - 3.39 (m, 4H) 3.53 (s, 6H) 3.62 - 3.6S (m, 4H) '
3.75 - 3.87 (m, 4H) 4.02 - 4.08 (m, 2H) 5.06 - 5.17 (m, 2H) 5.40 5 5.47 (m, 2H) 6.40 (d, J = 8.67 Hz, 2H) 6.75 ( d, J = 8.89 Hz, 1 H) 7.02 7.20 (m, 4 H) 7.25 (s, 1 H) 7.28 (d, J = 8.46 Hz, 2 H) 7.34 (s, 1 H) 7.39 (d, J = 8.13 Hz, 1 H) 7.47 (d, J = 8.24 Hz, 1 H) 7.60 (d, J = 8.60 Hz, 1 H)
8.21 (s, 1H) 11.96-12.11 (m, 2H);
MS (ESI +) m / z 994.5 (M + H) +.
<img file="MX339989B_D0956.tif" />
R2S) -1-R2S) -2-r5- (4- {5- (4- {2-R2S) -1-R2S) -2RmethoxycarboniPam ¡nol-3-methylbutane ¡PP¡ rrol idin-2-¡ H-1 Himidazol-5-¡Dfeni l) -1-Γ4-ί pipe rid ¡n-1-¡Dfeni Π-1 Hp¡ rrol-2-i Dfeni I) 20 1H-i midazol-2-illpi rrol ¡ methyl din-1 -iP-3-methyl-1-oxobutan-2-llcarbamate
Example 26E and 4-p¡per¡d¡noan¡l¡na (Maybridge) are processed using sequentially the methods of the Examples
26F, 26G, 74C, 19D, and 74E to provide the title compound (106
567
ΪΜΡΙ m α) INSTITUTO MEXICANO <sup>to</sup> 'DE LA PROTIEDXJ'
INDUSTRIAL <sup>1</sup>H NMR (400 MHz, DMSO-D6) δ 0.83 (d, J = 6.73 Hz, 6 H)
0.87 (d, J = 6.73 Hz, 6H) 1.50 - 1.62 (m, 6H) 1.90 - 2.15 (m, 10H)
3.13 (m, 4H) 3.53 (s, 6H) 3.77 (m, 4H) 4.04 (m, 2H) 5.04 (m, 2H)
6.47 (m, 2H) 6.80-7.35 (m, 10H) 7.42 (m, 2H) 7.53 (m, 4H) 11.73 (s, 2H).
<img file="MX339989B_D0957.tif" />
<img file="MX339989B_D0958.tif" />
f (2S) -1 -f (2S) -2-F5- (4- <5- (4- (2-r (2S) -1 -í (2S) -215 Km ethoxy carbon ¡l) am i ηοΊ -3-m ethyl butane ¡l) p¡ rrol id i n-2-¡II-1Himidazole-5-¡nphenyl) -1-r4- (trlcyclor3.3.1.1 ~ 3,7 ~ ldec-1 -il) methyl phenyl1-1Hp8rroi-2-yl) phenyl) -1 H-imidazol-2-illpyrrolidin-1-ih-3-methyl-1-oxobutan-2-illcarbamate
Example 26E and 4- (1-adamantanyl) aniline hydrochloride (Enamine) are processed using sequentially the methods of Examples 26F, 26G, 74C, 19D, and 74E to provide the title compound (320 mg) .
<sup>1</sup>H NMR (400 MHz, methanol-D4) δ 0.91 (m, 12H) 1.75 25 2.35 (m, 25H) 3.64 (s, 6H) 3.84 (m, 2H) 4.00 (m, 2H) 4.20 ( m, 2H)
568 (m, 2H) 6.48 (s, 2H) 7.02 (m, 6H) 7.31 (m, '4 72 (d, J = 8.13 Hz, 1H) 7.82 (d, J = 8.24 Hz, 1H) .;
MEXICAN INSTITUTE OF PROPERTY
INDUSTRIAL
<img file="MX339989B_D0959.tif" />
<img file="MX339989B_D0960.tif" />
EXAMPLE 169
H2S) -1 -f (2S) -2-r5- (4-f5- (4-f 2-H2S) -1 -f (2S) -2-phmethoxycarboni l) amino1-3-methylbutanoyl) pyrrolıdin -2-¡11-1H¡mi dazol-5-yl) fe η ¡I) -1-r4- (morphol i η-4-yl Ifeni 11-1 H-pyrrole-2-yllphenyl) 1 H-imidazole- Methyl 2-iHpyrrolidin-1-yl-3-methyl-l-oxobutan-2-illcarbamate
Example 26E and 4-morpholinoanine (Aldrich) are processed sequentially using the methods of Examples 26F, 26G, 74C, 19D, and 74E to provide the title compound (133 mg).
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ 0.83 (d, J = 6.83 Hz, 6 H) 0.87 (d, J = 6.61 Hz, 6 H) 1.88 - 2.17 (m, 10 H) 3.11 (m, 4 H ) 3.53 (s, 6H) 3.70 - 3.80 (m, 8H) 3.97 - 4.08 (m, 2H) 5.04 (m, 2H) 6.41 - 6.51 (m, 2H) 6.84 - 7.35 (m, 10H ) 6.93-7.02 (m, 6H) 11.71-12.03 (m, 2H).
569
<img file="MX339989B_D0961.tif" />
EXAMPLE 170
H2S) -1-r (2S) -2- (5-bromo-4- {4-r (2S, 5S) -5- (4- (5-bromo-2-r (2S) -1 ((2S ) -2-r (methoxycarbonyl) aminol-3-methylbutanoyl) p¡rrolidin-2-iH-1H¡m¡dazol-4-yl) phenyl) -1 - (4-tert-butylphenyl) pyrrole ¡D¡n-2-illphenyl) -1Himidazol-2-¡l) p¡rrol¡din-1 -ΙΠ-3-methyl-l-oxobutan-2-¡l) methyl carbamate
To a solution of Example 44 (0.100 g, 0.106 mmol) in CH<sub>2</sub>CI<sub>2</sub> (5 ml) at room temperature N-bromosuccinimide (0.019 ml, 0.223 mmol) is added. After 15 minutes, the reaction is washed with NaHCO<sub>3</sub> saturated and concentrated. The residue is purified by chromatography (1% gradient elution from 0% to 4% MeOH-CH<sub>2</sub>CI<sub>2</sub>; 12 g column) to provide 60 mg (51%) of the title compound as a light yellow solid.
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ 0.8 (d, J = 6.61 Hz, 6 H) 0.87 (d, J = 6.56 Hz, 6 H) 1.11 (s, 9 H) 1.72 - 1.75 (m, 2 H ) 1.87 - 1.98 (m, 7H) 2.10 - 2.15 (m, 5H) 3.53 (s, 6H) 3.70 -3.75 (m, 4H) 4.00 = 4.06 (m, 2H) 4.96 - 5.00 (m, 2H) 5.27 - 5.35 (m, 2H) 6.24 (d, J = 8.78 Hz, 2H) 6.97 (d, J = 8.78 Hz, 2H) 7.24 - 7.35 (m, 6H) 7.60 - 7.65 (m ,
570
Η) 12.41 (m, 2 Η).
IMPI instituto kexícv «o D £ LA ΓΙ! ΟΠ £ Γ> ΑΟ INPUSTMAt
<img file="MX339989B_D0962.tif" />
<img file="MX339989B_D0963.tif" />
EXAMPLE 171 f (2S) -1-r (2S) -2- (5-f4-r (2S, 5S) -1- (4-tert-butylphenii) -5- (4- <5-r (2S) -1f (2S) -2-r (methoxycarbonyl) am¡nol-3-methyl butane yl> p¡rrol¡din-2-yl1-4H1.2.4- tr¡azol-3-inphenyl) pyrrolidin-2-yl1phenyl > -4H-1,2,4-tr¡azol-3ii) p¡rrol¡d¡n-1 -¡H-3-methyl-1-oxobutan-2-illcarbamate
AND.
{(2S) -1-H2S) -2- (5-f4-r (2R.5R) -1- (4-tert-but¡lfen¡l) -5- (4- {5 - [(2S) -1 {(2S) -2-r (methox¡carbon¡l) am¡no1-3-met¡lbutano¡l) pyrrole¡d¡n-2-¡H-4H1.2.4- tr¡azol-3- ¡L) phen¡l) p¡rrol¡d¡n-2-¡Hfen¡l) -4H-1,2,4-tr¡azol-3-yl) pyrrolidin-1 -¡ll-3-methyl- Methyl 1-oxobutan-2-illcarbamate
EXAMPLE 171A
4,4 '- (1 - (4-tert-buty Ifeni l) p¡rrol ¡din-2.5-di-¡l) d¡ dimethyl benzoate
A mixture of Example 42C (0.5 g, 0.974 mmol), Et<sub>3</sub>N (0.407 ml, 2.92 mmol) and [1,1'B¡s (d¡phenophosphine) ferrocene] d¡chloropallad¡o (ll) (71.3 mg, 0.097 mmol) in methanol (20 ml) were subject to a monoxide atmosphere
ΙΙ · ι ---- τ-η-ι - ^ -. Τ - »^ -
571
ΙΜΡΙ ^^, carbon gas (4.22 kg / cm<sup>2</sup>) for 24 hours at 10t ^ Si * is filtered through celite and concentrated. Purification by chromatography (silica gel, 25% EtOAc in hexanes) gives 396 mg (86%) of the title compound.
MS (ESI) m / z 472 (M + H)<sup>+</sup>.
EXAMPLE 171B
4,4 '- (1 - (4-tert-butylphenyl I) pyrolidin-2.5-d¡-yl) d¡benzoh idrazide
A mixture of Example 171A (350 mg, 0.742 mmol) and hydrazine (0.140 µl, 4.45 mmol) in methanol (10 ml) is refluxed for 72 hours. The mixture is concentrated to obtain 350 mg of the title compound as a mixture of stereoisomers.
MS (ESI) m / z 472 (M + H)<sup>+</sup>.
EXAMPLE 171C (2S, 2'S) -2.2 '- (5.5' - (4.4 '- (1- (4-tert-butylphenyl) pyrrolidin-2,5-diyl) b¡s (4.1 -phenylene)) bis (4H-1,2,4-triazol-5,3-di-yl)) dipyrrolidin-1 tert-butyl carboxylate
A mixture of Example 171B (105 mg, 0.223 mmol), (S) -1-N-Boc-2-cyano-pyrolidine (175 mg, 0.891 mmol), and K<sub>2</sub>CO<sub>3 </sub>(9.23 mg, 0.067 mmol) in n-butanol (0.5 ml) is heated at 150 ° C for 90 minutes in a microwave. The mixture is diluted with EtOAc and then washed with H<sub>2</sub>Or and brine. The organic then dries
572 (MgSO<sub>4</sub>), filtered and concentrated. The pu rif a .INE & OM
ΙΜΡΙ • OSSTÁS'JÍO to ClBtQ /. í kOTH & Cpl .ΙΝΒΜΕΠΙΛίΛ.
chromatography (silica gel, 90% EtOAc in hexanes) allows
<img file="MX339989B_D0964.tif" />
Obtain 59 mg (32%) of the title compound as a mixture of stereoisomers.
MS (ESI) m / z 829 (M + H)<sup>+</sup>.
EXAMPLE 171D
(S) -5.5 Pentahydrochloride<sup>,</sup>-f4,4<sup>,</sup>-f1-f4-tert-but¡lfen¡l) p¡rrol¡d¡n-2,5di-¡l) b¡s (4.1-phenylene)) b¡s (3 - ((S} -p¡rrolld¡ n-2-¡l) -4H-1,2,4-triazole)
A mixture of Example 171C (59 mg, 0.071 mmol) in HCl 4 / dioxane (2 ml) is allowed to stir for one hour. The mixture is concentrated to obtain 58 mg (100%) of the title compound as a mixture of stereoisomers.
MS (ESI) m / z 628 (M + H)<sup>+</sup>.
EXAMPLE 171E f (2S) -1-r (2S) -2- (5- {4-r (2S, 5S) -1- (4-tert-but¡lfen¡l) -5- (4- {5 -r (2S) -1f (2S) -2-rfmethox¡carbonyl) aminoT-3-meth¡lbutano¡l} p8rrol¡d¡n-2-¡H-4H1.2.4- tr¡azol-3-i Ufen i Dpi rrolidi n-2-¡Hfenll) -4H-1,2,4-triazol-3¡l) p¡rrolidln-1-¡H-3-methyl-1-oxobutan-2-¡l) methyl carbamate li ((2S) -1-r (2S) -2- (5-f4-K2R, 5R) -1- (4-tert-butylphenll) -5- (4-f5-n2S) -1f (2S) - 2-ffmethox¡carbonll) am¡nol-3-methyl butanoi l) p¡ rroll din-2-lll-4H1.2.4- triazol-3-¡l) f níllpyrrolidin-2-¡llf n¡l) - 4H-1,2,4-triazole-3573
IMPI yl) pyrrolidin-1-yl1-3-methyl-1-oxobutan-2-yl) carbamaitoiTdieMai¡elH
-' *- <sup>J</sup>: -DtUÍ HJÍÍ'ItC-Rg ['vDUÍTí.'AL
<img file="MX339989B_D0965.tif" />
A mixture of Example 171D (58 mg, 0.071 mmol), (S) -2- (methoxycarbonylamino) -3-methylbutanoic acid (25 mg, 0.142 mmol), N- (3-dimethylaminopropyl) -N'- hydrochloride Ethylcarbodi-imide (30 mg, 0.157 mmol), 1-hydroxy-benzotriazole hydrated (24 mg, 0.157 mmol) and N-methylmorpholine (78 µl, 0.712 mmol) in DMF (1 ml) is allowed to stir overnight. The mixture is diluted with EtOAc. The organic is then washed with H<sub>2</sub>Or and brine. The organic is then dried (MgSO<sub>4</sub>), filtered and concentrated. The compound is subjected to HPLC purification on a semi-preparative C18 reversed phase column using a gradient of 10-100% acetonitrile in 0.1% aqueous TFA to obtain both title compounds of Example 171 (24mg, 70%) which elute first (trans isomers) and the title compound of Example 172 which elute second (Cis isomer).
<sup>1</sup>H NMR (free base) (400 MHz, DMSO-d<sub>6</sub>) δ ppm 0.27 (d, J = 6.72 Hz, 2 H), 0.71 (dd, J = 6.61, 2.49 Hz, 2 H), 0.78 - 0.95 (m, 9 H), 1.03 (d, J = 6.07 Hz, 12 Η), 1.09 (s, 9H), 1.22 (s, 2H), 1.65 - 1.77 (m,
H), 1.82-2.30 (m, 10H), 3.52 (s, 6H), 3.57-3.66 (m, 1H), 3.71 3.92 (m, 3H), 4.00-4.16 (m, 2H), 5.07 - 5.15 (m, 1H), 5.25 - 5.34 (m, 2H), 5.65 (d, J = 4.88 Hz, 1H), 6.21 (dd, J = 8.73, 3.20 Hz, 2H),
6.94 (dd, J = 8.78, 2.82 Hz, 2H), 7.16 - 7.46 (m, 6H), 7.83 - 7.92 (m,
H), 14.01 (s, 1H).
MS (ESI) m / z 943 (M + H)<sup>+</sup>.
574
<img file="MX339989B_D0966.tif" />
EXAMPLE 172 f (2S) -1-r (2S) -2- (5- {4-F (2R.5S) -1- (4-tert-but¡lfen¡l) -5- (4-f5- r (2S) -110 f (2S) -2-r (methoxycarbonyl) am¡no1-3-met¡lbutano¡l> p¡rrolidin-2-¡n-4H1.2.4-tr¡azol-3-infen¡ l) p¡rrolid¡n-2-yl1phenyl> -4H-1,2,4-tr¡azol-3¡l) p¡rrol ¡di n-1 -¡Π-3-methi 1-1-oxob uta n-2-ITca rba methyl matte
The title compound, Example 172, is the second compound to elute described in the procedures for Example 171E. The procedure makes it possible to obtain 21 mg (61%) of the title compound (cis isomer).
<sup>1</sup>H NMR (free base) (400 MHz, DMSO-d<sub>and</sub>) δ ppm 0.27 (d, J = 6.29 Hz, 2 H), 0.71 (d, J = 6.61 Hz, 2 H), 0.81 - 0.96 (m, 9 H), 1.03 (d, J = 6.07 Hz, 12 H ), 1.12 (s, 9H), 1.22 (s, 2H), 1.82 - 2.30 (m, 12H), 3.52 (s, 6H), 3.72 - 3.91 (m, 4H), 4.03- 4.17 ( m, 2H), 4.33 (d, J = 4.23 Hz, 1H), 4.73 - 4.83 (m, 2H), 5.09 - 5.18 (m, 2H), 6.33 (d, J = 8.78 Hz, 2H ), 7.03 (dd, J = 8.78, 3.04 Hz, 2 H), 7.29 (d, J = 7.70 Hz, 1 H), 7.57 - 7.69 (m, 4 H), 7.92 - 8.01 (m, 4 H), 13.84 (s, 2H),
MS (ESI) m / z 943 (M + H)
575
<img file="MX339989B_D0967.tif" />
EXAMPLE 173 f (2S) -1 -H2S) -2- (2- (4-H2S.5S) -1 - (4-tert-butylphenyl) -5- (4- (4-H2S) -1 ((2S ) -2-r (methoxycarbonii) amino1-3-methylbutanoyl> p¡rrolidin-2-ill-1 H¡m¡dazol-2-¡l) phen¡ l) p¡rrolidi n-2-hpheni l) -1 H-im¡dazol-4-i Dpi rrolidi n1-ill-3-methyl-1-oxobutan-2-¡l} methyl carbamate
Y f (2S) -1-r (2S) -2- (2-f4-r (2R, 5R) -1- (4-tert-butylphenyl) -5- (4- (4-f (2S) - 1 <(2S) -2-r (methoxycarbonyl) aminol-3-methylbutano¡l) pyrrolidin-2-ill-1Him idazol-2-yl) phenyl Dpi rrolidi n-2-yl1phenyl) -1 H-imidazole- Methyl 4-i Dpi rrolidi n1-¡H-3-methyl-1-oxobutan-2-¡Dcarbamate
EXAMPLE 173A
4,4 '- (1 - (4-tert-but¡lfen¡Dpyrrolid¡n-2.5-d¡-¡Dd¡benzon¡trile
A mixture of Example 42C (1.0 g, 1,948 mmol) and CuCN (523 mg, 5.84 mmol) in dimethylformamide (9.5 ml) is heated at 160 ° C for 4.5 hours in a microwave. The mixture is poured into a dimethylamine / H mixture<sub>2</sub>O (1/10) and extract with EtOAc (3 x 150 ml) · The combined organics are washed with H<sub>2</sub>Or and
576 brine. The organic after dries (MgSO4), iNss ^ '£ fit ^ a ^ gy'
IMPI concentrates. Purification by chromatography (silica gel, 20%
<img file="MX339989B_D0968.tif" />
EtOAc in hexanes) yields 395 mg (50%) of the title compound.
MS (ESI) m / z 406 (M + H)<sup>+</sup>.
EXAMPLE 173B
Dimethyl 4,4 '- (1 - (4-tert-butylphenyl) p¡rrolidin-2.5-d¡-¡l) dimethylbenzimidate
A mixture of Example 173A (0.5 g, 1,233 mmol) in anhydrous MeOH (12 ml) at 0 ° C is bubbled with an excess amount of HCl (g) for 45 minutes. The mixture is then stirred at room temperature for 24 hours and then concentrated to obtain the title compound.
EXAMPLE 173C
4,4 '- (1 - (4-tert-butylphenyl) pyrrolldin-2.5-d¡-yl) dibenzimidam Ida
A mixture of Example 173B (0.579 g, 1.233 mmol) in anhydrous MeOH (12 ml) at 0 ° C is bubbled with an excess amount of NH<sub>3</sub> (g) for 45 minutes. The mixture is then stirred at room temperature for 24 hours and then concentrated and subjected to purification by chromatography (reversed phase C18 column using 10-100% acetonitrile in TFA grade.
577 <.w:
0.1% aqueous)
IMPI to obtain the compound of the 'INDUSTRIAL
<img file="MX339989B_D0969.tif" />
mixture of trans isomers; the Cis isomer is discarded.
MS (ESI) m / z 440 (M + H)<sup>+</sup>.
EXAMPLE 173D (S) -1 -f (S) -2- (2-diazoacetyl) pyrrolid¡n-1 -¡I) -3-m ethi 1-1-oxobutan-2-ylcarbamate methyl
A mixture of Example 37B (100 mg, 0.367 mmol) and Et<sub>3</sub>N (154 µΙ, 1,102 mmol) in tetrahydrofuran (4 ml) at 0 ° C is added-butyl chloroformate (50 µΙ, 0.386 mmol). The mixture is then stirred at 0 ° C for 30 minutes followed by the addition of excess diazomethane in Et<sub>2</sub>O. The mixture is slowly brought to room temperature over the course of 3 hours. The mixture is then concentrated and diluted with EtOAc. The organic is then washed with NaHCO<sub>3</sub> saturated aqueous and brine. The organic dries (MgSO<sub>4</sub>), filtered and concentrated. Purification by chromatography (silica gel, 100% EtOAc) gives 82 mg (75%) of the title compound:
MS (ESI) m / z 297 (M + H)<sup>+</sup>.
EXAMPLE 173E (S) -1 - ((S) -2- (2-bromoacetyl) p¡rrol ¡d ¡n-1-¡l) -3-met¡ 1-1-oxo butane-2¡Icarbamate methyl
578
IMPI
A mixture of Example 173D (70 mg,
INDUSTRIAL
<img file="MX339989B_D0970.tif" />
HOAc (0.6 ml) at room temperature 48% HBr (80 µl, 0.709 mmol) is added. The mixture is stirred at room temperature for 1 hour. The mixture is poured into ice / H<sub>2</sub>O and extracted with CH<sub>2</sub>CI<sub>2</sub> (3 x 75 mi). The organic dries (Na<sub>2</sub>SW<sub>4</sub>), filter and concentrate to obtain 63 mg (76%) of the title compound.
MS (ESI) m / z 350 (M + H) <sup>+</sup> .
EXAMPLE 173F {(2S) -1-r (2S) -2- (2- {4-r (2S, 5SM- (4-tert-butUfen¡l) -5- (4- {4-r (2S) -1 ((2S) -2-r (methoxycarbon¡Uam¡no1-3-met¡lbutano¡l) p¡rrol¡din-2-¡H-1Himidazol-2-yl} feni hpirroldin-2-¡ Hphenyl) -1 H-imidazol-4-¡l) pyrolidin-1-i H-3-methyl-1-oxobutan-2-yl) methyl carbamate
I f (2S) -1-r (2S) -2- (2- <4-r (2R.5R) -1- (4-tert-butylphenyl) -5- (4-í4-r (2S) - 1f (2S) -2-r (methoxycarbon¡l) am¡no1-3-methylbutanoyl) pyrrolidin-2-yn-1Himidazol-2-yl) phen¡l) p¡rrolid¡n-2-¡llfen¡ l) Methyl -1 H-imidazol-4-yl) p¡rrolidin1-¡Π-3-methy 1-oxobutan-2-¡l) carbamate
A mixture of Example 173E (59.6 mg, 0.171 mmol), Example 173C (25 mg, 0.057 mmol) and K<sub>2</sub>CO<sub>3</sub> (65 mg, 0.470 mmol) in tetrahydrofuran (1 ml) is refluxed for 4 hours. The mixture is diluted with CH<sub>2</sub>CI<sub>2</sub> and washed with H<sub>2</sub>Or and brine. The organic is then dried (MgSO<sub>4</sub>), filtered and concentrated. The compound is subjected to HPLC purification on a column of
579
<img file="MX339989B_D0971.tif" />
semi-preparative C18 inverted phase using a
YL'ICANO INSTITUTE
100% acetonitrile in 0.1% aqueous TFA to obtain ^.
(6.7%) of the title compound of Example 173 (Trano isomers) · .--—<sup>1</sup>H NMR (free base) (400 MHz, DMSO-d<sub>6</sub>) δ ppm 0.78 5 0.89 (m, 12 H), 1.09 (s, 9 H), 1.68 - 1.74 (m, 4 H), 1.88 - 2.04 (m, 8
H), 3.52 (s, 6H), 3.70 - 3.78 (m, 4H), 4.04 (t, J = 8.19 Hz, 2H), 5.07 (t, J = 4.61 Hz, 2H), 5.26 (s , 2 H), 6.21 (d, J = 8.46 Hz, 2 H), 6.82 (s, 2 H), 6.93 (d, J = 8.67 Hz, 2 H), 7.22 (d, J = 8.89 Hz, 2 H ), 7.26 (d, J = 8.13 Hz, 4 H), 7.78 (d, J = 8.13 Hz, 4 H), 7.82 (d, J = 7.70 Hz, 2 H), 12.11 10 12.20 (m, 2 H) .
MS (ESI) m / z 941 (M + H)<sup>+</sup>.
<img file="MX339989B_D0972.tif" />
((2S) -1-r (2S) -2-f6-r (2R.5R) -5-f2-r (2S) -1 - {(2S) -2r (methoxycarbon¡l) am¡no '| -3-methylbutano¡l) p¡rrol¡d¡n-2-¡n-1 Hbenzim idazol-6-yl) -1 - (6-methoxypyridi n-3-¡l) p¡rrol ¡ d¡n-2-¡H-1 Hbenzim¡dazol-2-¡l) p¡rrol¡d¡n-1 -¡ll-3-methyl-1-oxobutan-2¡P methyl carbamate
580
Example 109C and 6-methoxypyridin-3- £
<img file="MX339989B_D0973.tif" />
using sequentially the methods of Examples 113A (dichloromethane is used as the solvent and cyclization is carried out at room temperature overnight), 165C, 113C, and 166 to provide the title compound which is purified by HPLC on a semi-preparative C18 reversed phase column using a gradient of 10-100% acetonitrile in 0.1% aqueous TFA to obtain 27 mg of the title compound <sup>1</sup>H NMR (free base) (400 MHz, DMSO-d<sub>6</sub>) δ ppm 0.76 0.86 (m, 12 H), 1.69 - 1.76 (m, 2 H), 1.84 - 2.04 (m, 4 H), 2.13 - 2.22 (m, 4 H), 2.52 - 2 60 (m, 2 H), 3.52 (s, 6H), 3.55 (s, 3H), 3.76 - 3.85 (m, 4H), 4.05 (t, J = 8.40 Hz, 2H), 5.08 - 5.16 (m, 2H ), 5.31 - 5.41 (m, 2 H), 6.36 - 6.45 (m, 2 H), 6.74 (dd, J = 9.00, 3.04 Hz, 2 H), 7.05 (t, J = 8.57 Hz, 2 H), 7.15 - 7.24 (m, J = 17.02 Hz, 3 H), 7.28 (d, J = 8.46 Hz, 2 H), 7.31 (s, 1 H), 7.37 (d, J = 8.13 Hz, 1 H), 7.45 (d, J = 8.13 Hz,
H), 12.03 (s, 2H),
MS (ESI) m / z 864 (M + H)<sup>+</sup>
<img file="MX339989B_D0974.tif" />
'<
<sup>:</sup>OR
581
EXAMPLE 175 f (2S) -1 -r (2S) -2- (6-n2R, 5R) -1-re (dimet¡lam¡noH> iriel¡na-Hl “5'f2 ··
IMPI
MEXICAN INSTITUTE OF INDUSTRIAL PROPERTY
<img file="MX339989B_D0975.tif" />
Í (2S) -1 - ((2S) -2-í (methoxycarbonyl) am¡no1-3-methylbutano¡l) p¡rrol¡d¡n2-ÍH-1 H-benzim¡dazole-e -¡L) p¡rrol¡din-2-¡ll-1 H-benzimidazol-2 ylpyrrolidin-1 -¡ll-3-methyl-1-oxobutan-2-yl) methyl carbamate
EXAMPLE 175 A
NN-d¡metll-5-n¡trop¡r¡d¡n-2-am¡na
A mixture of 2-chloro-5-nitropyridine (5.0 g, 31.5 mmol) and 40% solution of dimethylamine (10.66 g, 95 mmol) in ethanol (40 ml) is heated at 75 ° C for 1 hour The mixture is cooled to room temperature, diluted with CH2CI2 and washed with NaHCO<sub>3 </sub>saturated aqueous (3 x 100 mL) and brine. The organic dries (MgSO<sub>4</sub>), filter and concentrate to obtain 5.27 g (100%) of the title compound.
MS (ESI) m / z 168 (M + H)<sup>+</sup>
EXAMPLE 175B
N<sup>2</sup>.N<sup>2</sup>-dimethylp¡ridi n-2,5-d¡amine
A mixture of Example 175A (5.27 g, 31.5 mmol) and Raney nickel (5.27 g, 90 mmol) in tetrahydrofuran (60 ml) is subjected to an atmosphere (2.11 kg / cm<sup>2</sup>) of hydrogen gas for 2 hours at room temperature. The mixture is filtered and concentrated
582 to obtain 4.3 g (100%) of the title compound. MS (ESI) m / z 138 (M + H)<sup>+</sup>.
IMPI
INSTITUTO MEXICANO DE LA ΓΕΟΓΤΕΓΑΟ INDUSTRIAL
<img file="MX339989B_D0976.tif" />
EXAMPLE 175C <(2S) -1 -r (2S) -2- (6-f (2R.5R) -1 -r6- (d¡met¡lamlno) p¡r¡dirt-3-iH-5- ( 2r (2S) -1-f (2S) -2-r (methoxycarbon¡l) aminoI-3-meth¡lbutane¡ Dpi rrolidi n2-ÍI1-1H-benzi m¡dazol-6-¡l) p¡rrol id Methyl ¡n-2-¡11-1 H-benzimidazol-2yl} plrrol¡din-1-¡ll-3-methll-1-oxobutan-2-illcarbamate methyl
Example 175B is processed using the methods referred to or described in Example 174 to provide the title compound (8.5 mg).
<sup>1</sup>H NMR (free base) (400 MHz, DMSO-d<sub>6</sub>) δ ppm 0.75 0.86 (m, 12 H), 1.71 (d, J = 4.99 Hz, 2 H), 1.86 - 2.05 (m, 6 H), 2.12 15 2.23 (m, 3 H), 2.55 (s, 2 H), 2.70 (s, 6H), 3.16 (s, 2H), 3.52 (s, 6H),
3.81 (s, 3H), 4.05 (t, J = 8.35 Hz, 2H), 5.09 - 5.18 (m, 2H), 5.33 (d, J = 5.53 Hz, 2H), 6.33 (d, J = 9.00 Hz, 1H), 6.63 (dd, J = 9.05, 2.98 Hz, 1H), 7.04 (d, J = 7.70 Hz, 2H), 7.19 - 7.31 (m, 4H), 7.34 - 7.48 (m , 2H), 12.02 (s, 2H).
MS (ESI) m / z 877 (M + H)<sup>+</sup>.
583
<img file="MX339989B_D0977.tif" />
<img file="MX339989B_D0978.tif" />
EXAMPLE 176
R2SI-1-R2S) -2- {6-H2R.5R) -1- (6-tert-butylpyridin-3-¡l) -5-f2-R2S) -1 10 R2S) -2-r (methoxycarbon¡ l) aminol-3-methylbutanoiPpyrrol¡d¡n-2-¡ll-1 Hbenzim¡dazol-6-yl> pyrrolidi n-2-811-1 H-benzimidazol-2-yl) p¡rrol idi n Methyl -1 yl 1-3-methyl-1-oxobutan-2-iRcarbamate
6-tert-Butylpyridin-3-amine is processed using the methods referred to or described in Example 174 to provide the title compound (62.5 mg) of the title compound.
<sup>1</sup>H NMR (free base) (400 MHz, DMSCW<sub>6</sub>) δ ppm 0.74 0.88 (m, 12H), 1.08 (s, 9H), 1.68 - 1.77 (m, 2H), 1.83 - 2.04 (m, 7
H), 2.12 - 2.23 (m, 4 H), 2.53 - 2.61 (m, 2 H), 3.16 (d, J = 5.20 Hz, 2
H), 3.52 (s, 6H), 3.76 - 3.85 (m, 4H), 4.00 - 4.11 (m, 3H), 5.08 5.16 (m, 2H), 5.37 - 5.46 (m, 2H), 6.54 - 6.61 (m, 1H), 6.88 - 6.96 (m, 2H), 7.08 (t, J = 9.00 Hz, 2H), 7.20 (s, 1H), 7.25 - 7.31 (m, 3H) ,
7.39 (d, J = 8.13 Hz, 1 H), 7.47 (d, J = 8.24 Hz, 1 H), 7.60 (d, J = 3.25
Hz, 1H), 12.04 (d, J = 27.76 Hz, 2H).
MS (ESI) m / z 890 (M + H)<sup>+</sup>.
584
<img file="MX339989B_D0979.tif" />
ΙΜΡΙ
INSTITUTO MEXICANO D £ LA INDUSTRIAL PROPERTY
<img file="MX339989B_D0980.tif" />
EXAMPLE 177 f (2S) -1-H2S) -2- (6-f (2S.5S) -5- (2-H2S) -1-f (2S) -2im ethoxycarbon and I lamino! -3-methyl butane il) p¡ rrol Id ¡n-2-¡Π-1 Hbencim ¡dazol-6-¡H-1-í6- (piperid¡n-1 -i Dpi ridin-3-ι'Π pyrrole i din-2- i I) methyl 1 H-benzimidazol-2-yl) pyrrolidin-1-yl-3-methyl-1-oxobutan-2¡Dcarbamate
EXAMPLE 177A
5 - ((2S, 5S) -2.5-b¡s (4-chloro-3-nitrophenyl) p¡rrol¡d¡ n-1 -yl) -2- (piperidin1-ylpyridine
(1 R, 4R) -1,4-bis (4-chloro-3-nitrophenyl) butan-1,4diol (which is prepared using (S) - (+) - alpha, alpha-diphenyl-2-p Rolidinemethanol and the method of Example 109C) (0.60 g, 1.5 mmol) using the method described in Example 182A to obtain the title compound (0.41 g, 50%).
585
EXAMPLE 177B (2S, 2'S) -1.1 '- ((2S.2 ^) - 2.2 ^ (4.4 ^ ((25.55) -1 - (6- (p¡pericITn-T-<sup>L</sup>
IMPI
<img file="MX339989B_D0981.tif" />
INSTITUTE ΜΓΧίΟΛΝΟ DE LA rROFJEOAD
<img file="MX339989B_D0982.tif" />
¡L) b¡s (oxomet¡len) b¡s (p¡rrol¡din-2,1-d¡-yl)) b¡s (3-methyl-1-oxobutan2,1-d¡-¡Ddicarbamate dimethyl
The product from Example 177A (0.20 g, 0.369 mmol) is combined with the product from Example 116C (0.30 g, 1.1Ί mmol), cesi carbonate (0.336 g, 1.03 mmol), Xantfos (38 mg, 0.066 mmol) and tr ¡S (d¡benz¡l¡denacetone) d¡pallad¡o (20.3 mg, 0.022 mmol). Anhydrous 1,4-dloxane (3.7 ml) is added, and the mixture is sparged with N<sub>2</sub> gas for 15 minutes. The resulting mixture is stirred in a sealed tube at 100 ° C for 2 hours. The mixture is cooled to room temperature, diluted with water, and extracted with ethyl acetate. The organic extract is washed with brine, dried (NaSO4), filtered, and concentrated. Purification by flash chromatography twice (silica gel, 0-10% MeOH / CH<sub>2</sub>CI<sub>2</sub>) allows to obtain the title compound (235 mg, 60%).
EXAMPLE 177C (2S.2<sup>,</sup>S) -1.1<sup>,</sup>- ((2S, 2<sup>,</sup>S) -2.2<sup>,</sup>-(4.4<sup>,</sup>- ((2S.5S) -1- (6- (piperid¡n-1¡ l) p¡ r¡d¡n-3-¡l) p¡ rrol ¡di n-2,5-d¡-il ) b¡s (2-am ¡no-4,1 fen¡len)) b¡s (azand¡-il) b¡s (oxomet¡len) b¡s (p¡rrol¡d¡n-2, 1 -d¡-¡l)) bis (3m tyl-1-oxobutan-2,1-d¡-¡ddicarbamate of dim linden
586
To a solution of the product of Example
<img file="MX339989B_D0983.tif" />
0.234 mmol) in ethanol (1.2 ml) and tetrahydrofuran (I) Ke adds platinum (IV) oxide (13.29 mg, 0.059 mmol). The mixture is placed under a hydrogen atmosphere for approximately 1 hour. The mixture is filtered through celite, washed with methanol, and concentrated. Purification by flash chromatography (silica gel, 0-10% MeOH / CH<sub>2</sub>CI<sub>2</sub>) allows to obtain the title compound (186 mg, 84%).
EXAMPLE 177D f (2S) -1-r (2S) -2- (6-f (2S, 5S) -5- <2-r (2S) -1-R2S) -2r (methoxycarbonyl) am¡no1-3 -meth¡lbutano¡l) p¡rrol¡d¡n-2-ill-1 Hbenzim¡dazol-6-yl) -1-i6- (p¡perid¡n-1-¡l) p¡r¡d¡n -3-inp¡rrolid¡n-2-yl) 1H-benzim idazol-2-yl) p¡rrolidin-1 -¡Π-3-methy 1-1 -oxobuta n-2¡D methyl carbamate
To a solution of the product of Example 177C (113 mg,
0.119 mmol) in toluene (1.2 ml) acetic acid (34 μΙ, 0.593 mmol) and 3A molecular sieves are added. The mixture is heated at 60 ° C for 2 hours. The reaction is cooled to room temperature and diluted with ethyl acetate. The organic phase is washed with NaHCO<sub>3</sub> saturated aqueous, dried (Na<sub>2</sub>SW<sub>4</sub>), filtered and concentrated. The crude product is purified by reverse phase HPLC (C18) using a solvent gradient of 10-90% CH<sub>3</sub>CN in water (0.1% TFA). The fractions containing the
587 desired product are combined and concentrated to ΤΜΡΪ
INSTITUTO MEXICANO participates between NaHCO<sub>3</sub> saturated aqueous, and organic dried (Na<sub>2</sub>SW<sub>4</sub>), filter and concentrate to obtain the title compound (9 mg, 8%).
<img file="MX339989B_D0984.tif" />
1H NMR (400 MHz, DMSO-D6) δ ppm 0.78 - 0.85 (m, 7 H),
0.87 (dd, J = 6.7, 3.0 Hz, 6H), 1.23 (s, 1H), 1.43 (s, 6H), 1.72 (s, 2
H), 1.97 (s, 5H), 2.18 (s, 3H), 3.09 (s, 4H), 3.30 (s, 2H), 3.53 (d, J = 1.5 Hz, 6H), 3.81 ( s, 4H), 4.07 (s, 2H), 5.13 (s, 2H), 5.33 (s, 2
H), 6.48 (d, J = 4.4 Hz, 1H), 6.59 - 6.64 (m, 1H), 7.05 (s, 2H), 7.22 (s, 1H), 7.25 - 7.34 (m, 4H ), 7.37 (s, 1H), 7.44 (s, 1H), 12.06 (s, 2H).
MS (ESI) m / z 916 (M + H) <sup>+</sup> .
<img file="MX339989B_D0985.tif" />
EXAMPLE 178 ((2S) -1-r (2S) -2- (6-f (2R.5R) -5- (2-r (2S) -1 - {(2S) -2r (methoxycarbon¡l ) am¡no1-3-methylbutanoyl) p¡rrolid¡n-2-¡n-1 Hbenzim¡dazol-6-IP-1 -re- (trifluoromethyl) pyrid¡n-3-¡np¡rrolld¡n -2-¡l) 1H-benzim ¡dazol-2-¡I) pyrrole ¡din-1 -¡ll-3-methyl-1-oxobutan-2¡Pcarbamate dm linden
588
Example 109C and 5-amino-2- (trifluoro processed using sequentially the methods
182A, 177B, 177C, and 177D to provide the compound of the lUl'CJ ”1H NMR (400 MHz, DMSO-D6) δ ppm 0.79 - 0.89 (m, 15
<img file="MX339989B_D0986.tif" />
MEXICAN INSTITUTE OF PFCrIFPAD
H), 1.61 (s, 4H), 1.97 (s, 6H), 2.19 (s, 5H), 3.50-3.58 (m, 7H),
3.82 (s, 4H), 3.99 - 4.10 (m, 2H), 5.15 (s, 2H), 6.89 - 6.98 (m, 2H),
7.19 (s, 1H), 7.26-7.34 (m, 4H), 7.36 (d, J = 8.2Hz, 1H), 11.94 (d, J = 12.9Hz, 2H).
MS m / z 901 (M + H)<sup>+</sup>.
<img file="MX339989B_D0987.tif" />
EXAMPLE 179
N- (methoxycarbon yl) -L-valyl-N- <4-f (2S, 5S) 1 -f4-tert-butylphenyl) -5-f2f (2S) -1 -rN- (methoxycarbonyl ) -L-valiHpyrrol¡d¡n-2-yl) -1 Hbenc¡m¡dazol-5-¡l) pyrrol¡d¡n-2-¡Hfen¡l) -L-prol¡nam¡da
AND
N- (methoxycarbonyl) -L-valyl-N- (4-r (2R, 5R) -1- (4-tert-butylphenyl) -5- (2Í (2S) -1-fN- (methoxy carbon ¡L) -L-val i II pyrrhid ¡n-2-¡l) -1 Hb ncimidazol-S-illpirr lidin-2-illfeniD-L-prolinamide
589
IMPI
EXAMPLE 179A
MEXICAN INSTITUTE
-f4-chloro-3-nitrophenyl) -4- (4-nitrophenyl) butan-1
<img file="MX339989B_D0988.tif" />
To a mixture of zinc chloride (39.1 g, 287 mmol) in benzene (215 ml), diethylamine (22.24 ml, 215 mmol) and 2-methylpropan-2-ol (20.57 ml, 215 mmol) are added. The resulting mixture is stirred at room temperature for 2 hours, and 2-bromo-1- (4-nitrophenyl) ethanone (35.0 g, 143 mmol) and 1- (4-chloro-3-nitrophenyl) are added in one portion. ) ethanone (42.9 g, 215 mmol). The resulting mixture is stirred at room temperature overnight. H is added<sub>2</sub>SW<sub>4</sub> 5% aqueous (50 ml) and stirred vigorously to induce precipitation. The resulting solid is collected by filtration and washed successively with benzene, water, methanol, and CH<sub>2</sub>CI<sub>2</sub>. The solid is dried in vacuo to obtain the title compound.
EXAMPLE 179B
1- (4-chloro-3-nitrophenyl) -4- (4-nitrophenyl) butane-1,4-diol
To a solution of the product of Example 179A (10.0 g,
27.6 mmol) in EtOH (220 ml) add sodium borohydride (2,190 g, 57.9 mmol) in several portions over the course of 1 hour. The resulting mixture is stirred at room temperature for 1 hour, filtered through celite, and concentrated in vacuo. The residue is dissolved in EtOAc and washed with aqueous 1N HCl. The organic layer is dried over Na<sub>2</sub>SW<sub>4</sub>, filtered and concentrated in vacuo to obtain the
590 title compound (9.29 g, 92%).
EXAMPLE 179C: IMPI ζ MEXICAN INSTITUTE OF INDUSTRIAL PROPERTY
<img file="MX339989B_D0989.tif" />
1- (4-tert-but¡lfen¡l) -2- (4-chloro-3-nitrophen¡l) -5- (4nitrophenylDpyrrolldine
To a solution of the product of Example 179B (9.29 g, 25.3 mmol) in CH<sub>2</sub>CI<sub>2</sub> anhydrous (200 ml) at 0 ° C add triethylamine (10.53 ml, 76 mmol), followed by dropwise addition of methanesulfonyl chloride (4.93 ml, 63.3 mmol). The resulting mixture is stirred at 0 ° C for 2 hours, and then concentrated in vacuo. The resulting solid is dissolved in anhydrous DMF (70 ml), 4-tert-butylaniline (40.4 ml, 253 mmol) is added, and the resulting mixture is stirred at 50 ° C for 1 hour. The resulting mixture is cooled to room temperature and poured into ice cold 1N aqueous HCl (500 mL) to obtain a yellow precipitate. The precipitate is collected by filtration and dried to obtain the title compound (13.2 g).
EXAMPLE 179D
4- (1- (4-tert-butylfen¡B-5- (4-nitrophenyl) p¡rrolidin-2-¡l) -N- (4-methoxybenzl) -2-nitroanil Na
The product from Example 179C (13.2 g, 27.5 mmol) and 4-methoxybenzylamine (18 ml, 139 mmol) are combined and stirred at
591
145 ° C for 1.5 hours. The mixture is cooled h
<img file="MX339989B_D0990.tif" />
environment, and CH is added<sub>2</sub>CI<sub>2</sub>. The precipitate resulted.
The filtrate is washed successively with aqueous 1N HCl-y. Saturated aqueous NaHCOj. The organic layer is dried over Na<sub>2</sub>SW<sub>4</sub>, filter and concentrate in vacuo. The crude product is purified by silica gel column chromatography using a solvent gradient of 0-25% EtOAc in hexane to obtain the title compound (5.0 g, 31%).
EXAMPLE 179E
4- (5- (4-am i nofen ¡l) -1- (4-tert-but¡ Ifen i I) pyrrolidi n-2-yl) -N1- (4-methoxy benzyl) benzene-1,2-diam i na
To a solution of the product of Example 179D (2.74 g,
4.72 mmol) in EtOH (25 ml) and THF (25 ml) add platinum (IV) oxide (0.5 g, 2.2 mmol). The resulting mixture is stirred at room temperature under 1 atmosphere of H<sub>2</sub> All night long. The mixture is filtered through celite, washed with methanol, and the filtrate is concentrated in vacuo. The crude product is purified by silica gel column chromatography using a solvent gradient of 0-45% EtOAc in hexane to obtain the title compound (1.74 g, 71%).
EXAMPLE 179F (2S) -2- (4- (5- (3 - ((S) -1 -it r-butoxycarboni I) pyrrolidi n-2592 carboxamido) -4- (4-methoxybenzlamine) phenyl)
<img file="MX339989B_D0991.tif" />
butylphen ¡Dpi rrolidi n-2-yl) phenylcarbamo¡ Dpi rrol ¡di n-1 -carboMpha'io gfe tert-butyl
To a mixture of the product of Example 179E (1.74 g, 3.33 mmol), (S) -1 - (tert-butoxycarbonyl) pyrroledin-2-carboxylic acid (1.793 g, 8.33 mmol) and HATU (3.17 g, 8.33 mmol ) in DMSO (33 ml) Hunig's base (1746 ml, 10.00 mmol) is added. The resulting mixture is stirred at room temperature for 1 hour and partitioned between H<sub>2</sub>O and CH<sub>2</sub>CI<sub>2</sub>. The organic layer is dried over Na<sub>2</sub>SW<sub>4</sub>, filter and concentrate in vacuo. The crude product is purified by silica gel column chromatography using a solvent gradient of 0-25% EtOAc in hexane to obtain the title compound (2.1 g, 69%).
EXAMPLE 179G (2S) -2- (4- (5- (4-amino-3 - ((S) -1 - (tert-butoxy carbon i Dpi rrol idi n-2 carboxamido) phenyl) -1- (4- tert-butylphenyl) p¡rrol¡d¡n-2¡DphenylcarbamoiDpyrrolidine-1-carboxylate tert-butyl
To a solution of the product of Example 179F (1.06 g,
1.16 mmol) in CH<sub>2</sub>CI<sub>2</sub> (40 mi) and H<sub>2</sub>Or (2 ml) 2,3-dichloro5,6-dclane-1,4-benzoqulnone (DDQ) (0.316 g, 1,393 mmol) is added in several portions. The mixture is stirred at room temperature for minutes and washed with NaHCO<sub>3</sub> saturated aqueous. The organic layer
593 dries with Na<sub>2</sub>SW<sub>4</sub>, filtered and concentrated to the 'INDUSTRIAL
IMPI
Crude INDUSTRIAL is purified by column chromatography with gel
<img file="MX339989B_D0992.tif" />
silica using a solvent gradient of 0-25% EtOAc in hexane to obtain the title compound (0.53 g, 57%).
EXAMPLE 179H (2S) -2- (4- (5- (2-US) -1 - (tert-butoxycarbon¡l) p¡rrol¡d¡n-2-¡l) -1Hbenzord1im¡dazol-5-yl Tert-butyl) -1 - (4-tert-butylphenyl I) pyrrole idi n-2¡Dphenylcarbamoyl) pyrroledin-1-carboxylate
A solution of the product from Example 179G (0.526 g, 0.662 mmol) in acetic acid (4.73 ml, 83 mmol) is stirred at 65 ° C for 1 hour. The resulting mixture is partitioned between CH<sub>2</sub>CI<sub>2</sub> and NaHCO<sub>3</sub> saturated aqueous. The organic layer is dried over Na<sub>2</sub>SW<sub>4</sub>, filter and concentrate in vacuo. The crude product is purified by silica gel column chromatography using a solvent gradient of 0-2.5% MeOH in CH<sub>2</sub>CI<sub>2</sub> to obtain the title compound (0.23 g, 45%).
EXAMPLE 1791 (S) -N- (4 - ((2S, 5S) -1- (4-tert-butylphen¡D-5- (2 - ((S) -pyrrol¡d¡n-2-iP-1Hbenzord-imidazole -5-yl) pyrrolidin-2-yl) phenyl Ppyrrolidine-2-carboxam ida
Y (S) -N- (4 - ((2R.5R) -1- (4-tert-butylphenyl) -5- (2 - ((S) -pyrrolidIN-2-yl) -1Hbenzofdlim idazol-5 -il) p¡rrol¡din-2-8l) phenyl) pyrrole idine-2-carboxam ida
594
IMPI
To a solution of the product of Example 17SW,<sup>2 </sup>0.389 mmol) in CH<sub>2</sub>CI<sub>2</sub> (3 ml) TFA (2.5 ml) is added, and the resulting mixture is stirred at room temperature for 1.5 hours. The mixture is concentrated in vacuo, and the crude product is purified by reverse phase HPLC (C18) using a solvent gradient of 10-100% acetonitrile in H<sub>2</sub>O (0.1% TFA). The trans-pyrrolidine isomer elutes before the cis-pyrrolidine isomer. The fractions containing the trans isomer are concentrated in vacuo, and the residue is partitioned between CH<sub>2</sub>CI<sub>2</sub> and NaHCO<sub>3</sub> saturated aqueous. The organic layer is dried over Na<sub>2</sub>SW<sub>4</sub>, filter, and concentrate in vacuo to obtain the title compound (83mg, 37%).
EXAMPLE 179J
N- (methoxycarbonyl) -L-val¡lN- {4-r (2S, 5S) 1- (4-tert-butylphenyl) -5- (2f (2S) -1 - [N- (methox ¡Carbonyl) -L-valillpyrrol¡din-2-¡l> -1 Hbenzimidazole-5-¡l) pyrrol¡di n-2-¡nfen¡l) -L-prol¡namide and
N- (methoxycarbonyl) -L-valyl-N- (4-r (2R, 5R) -1 - (4-tert-butylphenH) -5- (2f (2S) -1 -rN- (methoxycarbonii) - L-valillpyroidin-2-iD-1 Hbenc¡m¡dazol-5-yl) p¡rrol¡d¡n-2-¡Hfen¡l) -L-prol¡nam ¡da
To a mixture of the product of Example 1791 (83 mg, 0.144 mmol), (S) -2- (methoxycarbonylamino) -3-methylbutanoic acid (63 mg,
0.361 mmol), and HATU (0.137 g, 0.361 mmol) in DMSO (1.5 ml) add Hunig's base (0.101 ml, 0.578 mmol), and the mixture
595
IMPI
RQírétcfkacXPe
<img file="MX339989B_D0993.tif" />
resulting is stirred at room temperature for 1 tso + aebacme
OF THE INDUSTRIAL PROPERTY is divided between CH<sub>2</sub>CI<sub>2</sub> and H<sub>2</sub>O. The organic layer is dried with
Na<sub>2</sub>SW<sub>4</sub>, filter and concentrate in vacuo. The crude product is purified by silica gel column chromatography using a solvent gradient of 0-3.5% MeOH in CH<sub>2</sub>CI<sub>2 </sub>to obtain the title compounds (80mg, 60%).
1H NMR (400 MHz, DMSO-D6) δ ppm 0.74 - 0.99 (m, 12H), 1.09 (s, 9H), 1.59 - 1.73 (m, 2H), 1.81 - 2.05 (m, 6H), 2.07 2.24 (m, 2H), 3.50 - 3.56 (m, 6H), 3.58 - 3.67 (m, 1H), 3.76 - 3.85 (m, 2H), 3.99 - 4.10 (m, 2H), 4.43 (dd, J = 8.0, 4.9 Hz, 1 H), 5.08 5.16 (m, 1 H), 5.16 - 5.25 (m, 1 H), 5.26 - 5.37 (m, 1 H), 6.21 (d, J = 8.8 Hz, 2H), 6.88 - 6.97 (m, 2.5H), 7.00 - 7.08 (m, 1H), 7.11 - 7.20 (m, J = 5.7 Hz, 2.5H), 7.21 - 7.34 (m, 2H), 7.37 (dd, J = 8.2, 2.0 Hz, 0.5 H), 7.45 (d, J = 8.3 Hz, 0.5 H), 7.50 (d, J = 8.3 Hz, 2 H), 9.98 (s,
H), 12.01 (m, 1H).
MS m / z 891.6 (M + H)<sup>+</sup>.
<img file="MX339989B_D0994.tif" />
• or \
o =
596
EXAMPLE 180
IMPI
MEXICAN INSTITUTE OF THE I ROPIEDAD INDUSTRIAL
<img file="MX339989B_D0995.tif" />
f (2S) -1-H2S) -2- (4- {4-r (2R, 5RM- (4-tert-but¡lfen¡l> -5- (4- {5-chloro-2K2S1-1 - ((2S) -2-r (methoxycarbonyl) am¡nol-3-methylbutano¡l} pyrolidi n2-HI-1 H-imidazol-4-illphenyhpyrrolidin-2-yl-phenyl) -5-chloro-1 Himidazol-2-ii) pyrroiidin-1 -¡Π-3-methi 1-1 -oxobutan-2-¡lcarbamate d methyl
To a solution of the product of Example 43 (114 mg, 0.121 mmol) in CH<sub>2</sub>CI<sub>2</sub> (1.2 ml) N-chlorosuccinimide (54 mg, 0.41 mmol) is added, and the resulting mixture is stirred at room temperature for 9 hours. The mixture is diluted by CH<sub>2</sub>CI<sub>2</sub> and washed with NaHCO<sub>3</sub> saturated aqueous. The organic layer is dried over Na<sub>2</sub>SW<sub>4</sub>, filtered, and concentrated in vacuo. The crude product is subjected to reverse phase HPLC (C18) using a solvent gradient of 40% -100% acetonitrile in water (0.1% TFA). The fractions containing the desired product are combined and concentrated in vacuo. The residue is purified on a preparative TLC plate, eluting with 3% MeOH in CH<sub>2</sub>CI<sub>2</sub> to obtain the title compound (3.5 mg, 3%).
1H NMR (400 MHz, DMSO-D6) δ ppm 0.80 - 0.92 (m, 12H), 1.11 (s, 9H), 1.72 (d, J = 5.0 Hz, 2H), 1.87 - 2.04 (m, 6 H), 2.05 2.23 (m, 2H), 3.53 (s, 6H), 3.72 - 3.82 (m, 2H), 4.04 (t, J = 8.4 Hz, 2H), 4.98 (dd, J = 6.8 , 3.5 Hz, 2 H), 5.29 (dd, J = 3.5, 2.5 Hz, 2 H), 6.23 (d, J = 8.8 Hz, 2 H), 6.96 (d, J = 8.8 Hz, 2 H), 7.27 (d, J = 8.6 Hz, 2 H),
7.32 (d, J = 8.2 Hz, 4H), 7.61 (d, J = 8.1 Hz, 4H), 12.41 (s, 2H).
597
<img file="MX339989B_D0996.tif" />
EXAMPLE 181
U2S) -1-r (2S) -2- (4-f4-n2R, 5R) -1- (4-tert-butii-2-chlorophenyl) -5- (4-f5chloro-2-r (2S) - 1-f (2S) -2-r (methoxycarbonyl) aminol-3m eti I butane! Dpi rrol id i η-2-i 11-1 H-im¡dazol-4-¡llfen¡l) pyrrole¡d Methyl n-2inpheniD-5-chloro-1H-imidazol-2-yl) p¡rrolidin-1-yl] -3-methyl-1-oxobutan-2-illcarbamate
The product from Example 43 (114 mg, 0.121 mmol) is subjected to the procedure described in Example 180 to obtain the title compound (4.7 mg, 4%).
1H NMR (TFA salt) (400 MHz, DMSO-D6) δ ppm 0.78 20 0.89 (m, 12 H), 1.05 (s, 9 H), 1.85 - 1.97 (m, 10 H), 2.04 - 2.18 (m , 4H), 3.52 (s, 6H), 3.69 - 3.81 (m, 4H), 4.03 (t, J = 8.3 Hz, 2H), 4.95 (dd, J = 7.0, 4.0 Hz, 2H) , 5.53 (d, J = 7.5 Hz, 2H), 6.91 - 6.95 (m, 1H),
6.96 - 7.02 (m, 2H), 7.26 (d, J = 8.5 Hz, 2H), 7.30 - 7.41 (m, 4H),
7.49 (d, J = 7.6 Hz, 4H), 12.34 (s, 2H).
MS m / z 1045.1 (M + H) \
598
<img file="MX339989B_D0997.tif" />
[(2S) -1-f (2S) -2-f4- (4 - ((2S, 5S) -5- (4- {2 - [(2S) -1 - ((2S) -2f (methoxycarbonyl) am ¡nol-3-methyl butanoi Dpi rrol ¡d¡n-2-¡H-1 H¡m¡ dazol-4-¡l) fe ni I) -1-T6- (p¡ peridin-1 -yl) pir¡din-3-lllpyrrolid¡n-2¡l) phen¡l) -1 Hi m idazol-2-i II pyrrole ¡di n-1-yl) -3-m eti 1-1 -oxobutan-2¡ methyl llcarbamate
EXAMPLE 182A
5 - ((2S.5S) -2.5-bis (4-bromophenyl) p¡rrol¡din-1 -i I) -2- (pipe rid i n-1 ¡Dpyridine
To a suspension of the product of Example 69A (0.50 g,
1.25 mmol) in CH<sub>2</sub>CI<sub>2</sub> anhydrous (12 ml) at 0 ° C add Et<sub>3</sub>N (0.52 ml, 3.75 mmol), followed by methanesulfonyl chloride (0.243 ml,
3.12 mmol). The resulting mixture is stirred at 0 ° C for 90 minutes and then evaporated to dryness. The solid is dissolved in anhydrous DMF (10 ml), and Example 144C (1108 mg, 6.25 mmol) is added. The resulting mixture is stirred at 40 ° C overnight, and partitioned between aqueous 0.2N HCl and EtOAc. The organic layer is
599 dry with Na<sub>2</sub>SW<sub>4</sub>, filter and concentrate in vacuo.
<img file="MX339989B_D0998.tif" />
<img file="MX339989B_D0999.tif" />
OF THE PROPERTY
INDUSTRIAL is purified by silica gel column chromatography using a solvent gradient of EtOAc and hexane to obtain the title compound (107 mg, 16%).
EXAMPLE 182B
H2S) -1-f (2S) -2-r4- (4-f (2S, 5S) -5- (4-f2-r (2S) -1-f (2S) -2y (methoxycarbonDam ¡No1-3-met¡lbutano¡l) p¡rrolidin-2-ill-1 H¡m¡dazol-4-¡l) phenyl) -1 -F6- (p¡peridin-1 -¡l) p¡ rid ¡n-3-¡II pyrrole idi n-2¡l) phen¡l) -1 H-imidazol-2-ίΠ pyrrole id ¡n-1 -yl) -3-methyl-1 -oxobuta n- 2II methyl carbamate
The product of Example 182A is subjected to the procedures described in Examples 42D, 42E, 42F, and 42G to obtain the title compound.
1H NMR (free base) (400 MHz, DMSO-D6) δ ppm 0.80 0.94 (m, 12H), 1.24 (s, 4H), 1.44 (s, 6H), 1.89 - 2.04 (m, 6H) , 2.07 - 2.20 (m, 4H), 3.12 (s, 4H), 3.53 (s, 6H), 3.77 (d, J = 6.7 Hz, 2H), 4.05 (t, J = 8.4 Hz, 2 H), 5.06 (dd, J = 6.7, 3.0 Hz, 2 H), 5.19 (d, J = 6.4 Hz, 2 H), 6.45 - 6.53 (m, 1 H), 6.56 - 6.63 (m, 1 H) , 7.15 (d, J = 8.2 Hz, 4 H), 7.21 - 7.32 (m, 4 H), 7.38 (d, J = 1.8 Hz, 2 H), 7.62 (d, J = 8.0 Hz, 4 H), 11.69 (s, 2H),
MS m / z = 968.8 (M + H)<sup>+</sup>
600
IMPI
MEXICAN INSTITUTE OF PROPERTY
INDUSTRIAL
<img file="MX339989B_D1000.tif" />
Ρ
F • F
OR
<img file="MX339989B_D1001.tif" />
/
EXAMPLE 183 r (2S) -1 - {(2S) -2-r4- (4 - {(2S.5S) -5- (4- <2-K2S) -1 - <(2S) -2r (methox¡ carbon¡l) aminol-3-met¡lbutano¡l) p¡rrol¡din-2-yl1-1 Him¡dazol-4-¡l) phen¡l) -1 -r6- (tr¡fluorometh¡l) pyrid¡n-3-¡l1pyrrol¡d¡n-2¡l) fenll) -1 H-¡m¡dazol-2-IHp¡rrol¡d¡n-1-yl) -3-methyl-1 methyl-oxobutan-2Hcarbamate
EXAMPLE 183A
5 - ((2S.5S) -2.5-bis (4-bromophenyl) pyrolidin-1 -ll) -2 (trifluoromethi Dpi ridine
The product from Example 69A (1.0 g, 2.5 mmol) is subjected to the procedure described in Example 182A, substituting 6 (trifluoromethyl) pyridin-3-amine for Example 144C, to obtain the title compound (0.13 g, 10 %).
EXAMPLE 183B [(2S) -1-f (2S) -2- [4- (4 - ((2S, 5S) -5- (4-f2-r (2S) -1-f (2S) -2r ( methoxycarbon¡l) am¡noT-3-methylbutanoyl) pyrrolid¡n-2-¡H-1Himidazol-4-H) phen¡l) -1-re (trifluoromethyl) pyrid¡n-3-¡ Hpirrolidin-2601 ¡l> phenyl) -1 H-im¡dazol-2-¡llp¡rrolid¡n-1 -¡l) -3-meti 1-1 ιιοχτΟιΒΓμ $ »ι> ε> 2 · a ... ....... i «. u | 'K (J! TET / Ai>
INDUSTRIAL Methyl Hcarbamate
<img file="MX339989B_D1002.tif" />
The product of Example 183A is subjected to the procedures described in Examples 42D, 42E, 42F, and 42G to obtain the title compound.
1H NMR (TFA salt) (400 MHz, DMSO-D6) δ ppm 0.75 0.91 (m, 12H), 1.84 (d, J = 5.6 Hz, 2H), 1.96 - 2.10 (m, 6H), 2.11 2.20 (m, J = 10.8, 5.5 Hz, 2H), 3.54 (s, 6H), 3.76 - 3.91 (m, 4H), 4.10 (t, J = 7.9 Hz, 2H), 5.11 (t, J = 6.8 Hz, 2 H), 5.56 (d, J = 5.1 Hz, 2 H),
6.74 (dd, J = 8.8, 2.5 Hz, 1 H), 7.32 (d, J = 8.5 Hz, 2 H), 7.41 (d, J = 7.8
Hz, 4 H), 7.44 - 7.48 (m, J = 8.8 Hz, 1 H), 7.71 (d, J = 8.2 Hz, 4 H), 7.76 (d, J = 2.5 Hz, 1 H), 7.97 (s , 2H), 14.50 (s, 2H).
MS m / z 953.6 (M + H)<sup>+</sup>.
<img file="MX339989B_D1003.tif" />
EXAMPLE 184 f (2S) -1 -r (2S) -2- (6-f (2R, 5R) -5-f2-H2S) -1 - <(2S) -2í (methoxycarbonl) amino) -3-methylbutanoyl) p¡rrolidin-2-ill-1 Hbenzimidazol-6-ίΠ-Ι -í2- (piper¡din-1-¡l) p¡r¡m¡d¡n-5-¡Hp¡rrolid ¡N-2-¡l1602
IMPI
H-benzimidazol-2-yl) pyrrolidin-1-ill-3-methyl-1 -oxo & uVan ^ i »R-methyl carbamate _
<img file="MX339989B_D1004.tif" />
EXAMPLE 184A
2- (pipe rid ¡n-1 -yl) pyrimid¡n-5-amine
Piperidine (2.79 ml, 28.2 mmol) is added to a suspension of 2-chloro-5-nitropyrimidine (1.5 g, 9.40 mmol) in EtOH (15 ml), and the resulting mixture is refluxed for 2 hours . The cold mixture is concentrated in vacuo, and the residue is partitioned between CH<sub>2</sub>CI<sub>2</sub> and NaHCO<sub>3</sub> saturated aqueous. The organic layer is dried over Na<sub>2</sub>SW<sub>4</sub>, filter and concentrate in vacuo to obtain a solid (1.65 g, 84%). The solid is placed in a 250 ml stainless steel pressure bottle and dissolved in THF (20 ml). Ni-Raney 2800 aqueous suspension (1,650 g, 28.1 mmol) is added, and the mixture is stirred at room temperature for 2 hours under H<sub>2</sub> gas at a pressure of 2.11 kg / cm<sup>2</sup>. The mixture is filtered through a nylon membrane and concentrated in vacuo to obtain the title compound (1.4 g, 99%).
EXAMPLE 184B
5 - ((2R, 5R) -2,5-bis (4-chloro-3-nitrophen¡l) p¡rrol¡din-1 -il) -2- (piperid¡n1 -ihpirim id ¡na
The product from Example 109C (1.09 g, 2.72 mmol) was <sup>603</sup> '
IMPI
INSTITUTO MEXICANO DE LA PROriEDAD submits to the conditions described in Example 182A, suálftliyón
<img file="MX339989B_D1005.tif" />
Example 184A by Example 144C, to obtain gf-eompueoto of the title (0.59 g, 40%).
EXAMPLE 184C f (2S) -1-H2S) -2- (6 - ((2R, 5R) -5- (2-r <2S) -1 - ((2S) -2rtmethoxy carbon ¡l) amlno1-3- Methyl butaño ¡Dpi rrol ¡di n-2-¡11-1Hbenzim i dazol-6-111-1 -i2- (p¡per¡d¡n-1 -il) p¡ r¡mid¡n-5 -¡Np¡rrolid¡n-2-i Π1 H-benzim idazol-2-yl) p¡rrolidin-1-ill-3-methy 1-1-oxobutan-2¡D methyl carbamate
The product of Example 184B is subjected to the procedures described in Examples 177B, 177C, and 177D to obtain the title compound.
1H NMR (TFA salt) (400 MHz, DMSO-D6) δ ppm 0.71 0.91 (m, 12H), 1.24 (s, 2H), 1.32 - 1.41 (m, 4H), 1.44 - 1.52 (m, 2H), 1.82 (d, J = 5.1 Hz, 2H), 1.92 - 2.26 (m, 12H), 3.86 (s, 6H), 4.12 (t, J = 8.0 Hz, 2H), 5.20 ( dd, J = 8.0, 5.2 Hz, 2 H), 5.54 (d, J = 6.2 Hz, 2 H), 7.33 (d, J = 8.3 Hz, 2 H), 7.40 (d, J = 7.8 Hz, 2 H ), 7.51 (s, 2H),
7.57 - 7.61 (m, 2H), 7.72 (d, J = 8.3 Hz, 2H).
MS m / z 917.5 (M + H)<sup>+</sup>.
<img file="MX339989B_D1006.tif" />
EXAMPLE 185 ((2S) -1-r (2S) -2- (5- {4-f (2S, 5S) -5- (4- {2-f (2S) -1 - {(2S) -2Γ (ιτιethoxycarbon¡I) am ¡nol-3-met¡Ibutano¡ l} p¡ rrol ¡din-2-¡11-1Himidazol-5-yl) feni i) -1 - (4-r6- (morpholin-4- ¡L) p¡r¡d¡n-3¡ Ufe ni l) p¡ rrol i di n-2-¡Ufen ¡11-1 H-im idazol-2-H) pi rro lid i n-1 -i Methyl II-3-methyl-1-oxobutan-2-yl) carbamate and
f (2S) -1-H2S) -2- (5- (4-r (2R, 5R) -5- (4- <2-n2S) -1 - <(2S) -2r (methoxycarbon8l) aminol-3 -methylbutanoyl) pyrolid i n-2-i 11-1 Himidazol-5-illphenyl) -1- (4-r6- (morphoiin-4-yl) pyridin-3illphenyl> p¡rrolidin-2- methyl illfenin-1 H-im idazol-2-yl) pyrrolidin-1-yl-3-methyl-1-oxobutan-2-illcarbamate
EXAMPLE 185A
2,5-bis (4-bromophenyl) -1- (4-iodophenyl) pyrroleine
The product from Example 42B (1.39 g, 2.499 mmol) in DMF (6.25 ml) is treated with 4-iodoaniline (Aldrich, 4.38 g, 19.99
605
IMPIgfca mmol), heat at 40-50 ° C for two hours, s
INDUSTRIAL dilutes in EtOAc. The EtOAc layer is washed 3 X 50 ml with 1 M HCl, with water, brine, dried (Na<sub>2</sub>SW<sub>4</sub>), filtered and concentrated. Purification by flash chromatography on an ISCO cartridge with 40 g of silica eluting with 0-20% EtOAc in hexane allows the title compound to be obtained as a tan foam as a mixture of stereoisomers (0.96 g, 66%) .
MS (ESI) m / z 584 (M + H)<sup>+</sup>.
EXAMPLE 185B
4- (5- (4- (2,5-b¡s (4-bromophenyl) p¡rrol¡d¡ n-1-yl) phen¡l) p¡ ridin-2¡Dmorpholine
The product from Example 185A (0.1 g, 0.171 mmol), -4- (5 (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) pyridin-2-yl) morpholine (0.050 g, 0.171 mmol), potassium phosphate (0.028 ml, 0.343 mmol), tris (dibenzylideneacetone) dipalladium (0) (1,570 mg, 1,715 pmol) and
1,3,5,7-tetramethyl-6-phenyl-2,4,8-trioxa-6-phosphaadamante (1,504 mg,
5.14 pmol) are combined in THF (1.2 ml) / water (0.4 ml). The mixture is sparged with nitrogen for 15 minutes, diluted in EtOAc, washed with 1M sodium bicarbonate, brine, dried (Na<sub>2</sub>SW<sub>4</sub>), filtered and concentrated. Purification by flash chromatography on an Isco cartridge with 12 g of silica eluting with 20-70% EtOAc in hexane allows the title compound to be obtained as a cream colored powder (91 mg, 86%). %).
606
MS (ESI) m / z 620 (M + H)<sup>+</sup>.
IMPI
INSTITUTO MEXICANO DE LA PRCFIEDÁD INDUSTRIAL
<img file="MX339989B_D1007.tif" />
EXAMPLE 185C <(2S) -1-R2S) -2- (5-f4-R2S.5S) -5- (4-f2-R2S) -1-R2S) -2Rmethoxycarbonyl) amino1-3-methylbutanoyl) pyrrolid in -2-i 11-1Himidazol-5-¡l) phenyl) -1-f4-f6- (morpholin-4-¡l) pyrid¡n-3iHfenii) pyrrolid¡n-2-yl1fenii) -<sup>,</sup>l H-imidazoi-2-yl) pyrrole ¡din-Ι-ίΠ-3-m tyl1-oxobutan-2-¡l) methyl carbamate
Y f (2S) -1-R2S) -2- (5-f4-R2R, 5R) -5- (4- (2-R2S) -1-R2S1-2Rmethoxycarbonyl) amino1-3-methylbutanoii> pyrolidi n-2-ill-1 H¡midazol-5-¡llfeni l) -1 -f4-r6- (morpholin-4-yl) pyridin-3illphenyl) pyrrolidin-2-¡nphenil) -1 Methyl H-imidazol-2-yl) pyrrolidin-1-yl-3-methyl-1-oxobutan-2-l) carbamate
The product from Example 185B is processed as described in Example 42D, 42E, 42F, and 42G to obtain the title compounds.
<sup>1</sup>H NMR (free base) (400 MHz, DMSO-d<sub>6</sub>) δ 0.77 - 0.94 (m, 12H) 1.71 - 2.47 (m, 16H) 3.36 - 3.42 (m, 4H) 3.53 (s, 6H) 3.63 - 3.71 (m, 4H) 3.74 - 3.84 (m , 3H) 4.00 - 4.08 (m, 1H) 4.79 (d,
J = 4.23 Hz, 1H) 5.02 - 5.11 (m, 2H) 5.24 - 5.32 (m, 1H) 6.37 (d,
J = 8.89 Hz, 1 H) 6.49 (d, J = 8.78 Hz, 1 H) 6.79 (dd, J = 14.91, 8.95 Hz,
H) 7.12-7.78 (m, 15H) 8.23-8.31 (m, 1H) 11.64-12.11 (m, 2H).
MS (ESI) m / z 1046 (M + H) <sup>+</sup> .
607 or" ·"* *·
<img file="MX339989B_D1008.tif" />
<img file="MX339989B_D1009.tif" />
EXAMPLE 186
I (2S) -1-r (2S) -2- (4-f4-H2S.5S) -1- (4-cyclopropylphenyl) -5- (4- (2-R2S) -110 f (2S) -2-r (methoxycarbon¡l) am¡no1-3-meth¡lbutanoyl} p¡rrolidin-2-¡H-1 Himidazol-4-¡l) phenyl) pyrrolid¡n-2-¡nphenyl> - 1 Hi midazol-2-¡Dpi rrolidi n 1 -ill-3-methyl-1-oxobutan-2-iDcarbamate methyl
The product from Example 95B is purified by chiral chromatography on a Chiralpak IB column eluting with a mixture of hexane / THF / methanol (85/10/5). The title compound is the second of the 2 diastereomers to elute.
1H NMR (400 MHz, DMSO-D6) δ ppm 0.35 - 0.42 (m, 2H) 0.65 - 0.73 (m, 2H) 0.80 - 0.92 (m, 12H) 1.58 - 1.65 (m, 1H) 1.67 20 1.71 (m, 2H) 1.87 - 2.02 (m, 6H) 2.07 - 2.17 (m, 4H) 3.53 (s, 6H)
3.70 - 3.85 (m, 4H) 4.05 (t, J = 8.35 Hz, 2H) 5.06 (dd, J = 6.72, 2.82 Hz, 2H) 5.16 - 5.25 (m, 2H) 6.19 (d, J = 8.67 Hz, 2H) 6.64 (d, J = 8.57 Hz, 2H) 7.09 - 7.32 (m, 6H) 7.36 - 7.69 (m, 6H) 11.60-12.09 (m, 2H).
MS (ESI +) m / z 924.6 (M + H).
608
<img file="MX339989B_D1010.tif" />
EXAMPLE 187 (i (2R, 5R) -1 - (3-r6- (morpholin-4-¡l) pyr¡din-3-yl1phenyl) pyrrolodin-2,5-diyl1bisf (2-aminobenzene Dimethyl -4,1-di-¡l) carbamoyl (2S) p¡rrolidin-2,1-di¡H72S) -3-methyl-1-oxobutan-1,2-d¡-¡H}) biscarbamate
EXAMPLE 187A (2R.5R) -2.5-b¡s (4-chloro-3-nitrophenyl) -1 - (3-iodophen¡l) p¡rrol¡dine
The mesylate from Example 109C (4.17 g, 7.48 mmol) in DMF (15 mL) is treated with 3-iodoaniline (Aldrich, 7.2 mL, 59.8 mmol), stirred at room temperature for 48 hours, and diluted with EtOAc. The EtOAc layer is washed 3 X 50 ml with 1 M HCl, with water, brine, dried (Na<sub>2</sub>SW<sub>4</sub>), filtered and concentrated. Purification by flash chromatography on an Isco cartridge with 300 g of silica eluting with 10-30% EtOAc in hexane gives the title compound as a bright yellow foam (2.6 g, 60%).
MS (ESI) m / z 584 (M + H)<sup>+</sup>.
609
EXAMPLE 187B
4- (5- (3 - ((2R.5R) -2,5-bis (4-chloro-3-nitrophen¡l) p¡rrolidin-1 yl) fen¡ Dpi ridin-2-¡Dmorpholin
IMPI Mexican institute DE LA? R.Or¡EOAD
IS'D'JSTr.lA !.
<img file="MX339989B_D1011.tif" />
The product from Example 187A (1.4 g, 2,396 mmol), 4- (5 (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-¡l) pyridin -2-¡l) morpholin (0.695 g, 2.396 mmol), potassium phosphate (1.017 g, 4.79 mmol), tr¡s (d¡benzylideneacetone) d¡pallad¡o (0) (0.022 g, 0.024 mmol ) and
1,3,5,7-tetramethyl-6-phenyl-2,4,8-trioxa-6-phosphaadamante (0.021 g, 0.072 mmol) are combined in THF (18 ml) / water (6 ml) . The mixture is sparged with nitrogen for 15 minutes, stirred for 6 hours, diluted in EtOAc, washed with 1M sodium bicarbonate, brine, dried (Na<sub>2</sub>SW<sub>4</sub>), filtered and concentrated. Purification by flash chromatography on an Isco cartridge with 120 g of silica eluting with 20-60% EtOAc in hexane allows the title compound to be obtained as a yellow glass (1.1 g, 74%).
MS (ESI) m / z 620 (M + H)<sup>+</sup>.
EXAMPLE 187C (R2R.5R) -1-f3-r6- (morpholin-4-iDpyridine-3-inpheniDpyrrolidin-2,5-diylbisf (2-aminobenzene-4,1-di-¡Dcarbamoyl (2S) pyrrolidin Dimethyl -2.1 -di¡lf (2S) -3-methyl-1-oxobutan-1,2-di-¡ID) biscarbamate
The product from Example 187B (0.5 g, 0.806 mmol), was
610 processed using the methods in Examples, 1
FROM INDUSTRIAL PROPERTY obtain the title compound (400 mg, 45% two steps).
<img file="MX339989B_D1012.tif" />
<sup>1</sup>H NMR (400 MHz, DMSO-d<sub>and</sub>) δ 0.89 (dd, J = 11.82, 6.61 Hz, 12 H) 1.35 - 2.22 (m, 14 H) 3.36 - 3.46 (m, 8 H) 3.52 (s, 6 H) 3.56 - 3.86 (m, 4 H) 3.97 - 4.43 (m, 4H) 4.85 (s, 4H) 5.09 (s, 2H) 6.25 (d, J = 7.26 Hz, 1H) 6.42 - 6.51 (m, 3H) 6.58 (s, 2H ) 6.66 (d, J = 7.59 Hz,
H) 6.81 (d, J = 8.78 Hz, 1 H) 6.95 - 7.02 (m, 3 H) 7.36 (d, J = 8.35 Hz,
H) 7.51 (dd, J = 8.73, 2.33 Hz, 1H) 8.12 (d, J = 2.06 Hz, 1H) 9.23 (s, 2H).
MS (ESI) m / z 1031 (M + H) *.
<img file="MX339989B_D1013.tif" />
EXAMPLE 188 ((2S) -1-K2S) -2- (5-r (2R, 5R) -5- (2-n2S) -1-n2S) -2f (methoxycarbonl) amnol-3 -meth¡lbutano¡l) p¡rrol¡d¡n-2-¡H-1Hbenz¡midazol-5-iD-1-f3-f6- (morpholin-4-¡l) pyridin-3¡ Ufen ¡ Dpi rrol id¡n-2-yl1-1 H-benz8midazol-2-¡l) pyrroledin-1-8ll-3-methyl1-oxobutan-2-yl> methyl carbamate
The product from Example 187C (0.4 g, 0.388 mmol) was
611 Treat with acetic acid (0.089 ml, 1.553 mmol) in
<img file="MX339989B_D1014.tif" />
at 50 ° C for 4 hours, cool and concentrate. The Ves ^ uo * ^ dissolves in EtOAc, washed with bicarbonate of 550IO ai — Γ0%, brine, dried (Na<sub>2</sub>SW<sub>4</sub>), filtered and concentrated. Purification by flash chromatography on an Isco Gold cartridge with 12 g of silica eluting with 1-6% MeOH in dichloromethane gives the title compound (183 mg, 45%).
<sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 0.71 - 0.90 (m, 12 H) 1.62
- 2.28 (m, 14H) 3.37 - 3.43 (m, 4H) 3.53 (s, 6H) 3.64 - 3.68 (m, 4H)
3.80 (s, 4H) 4.05 (t, J = 8.35 Hz, 2H) 5.08 - 5.19 (m, 2H) 5.48 (s, 2H) 6.29 (d, J = 8.02 Hz, 1H) 6.54 - 6.64 (m, 2H) 6.76 (d, J = 8.89 Hz, 1
H) 6.93 (d, J = 4.66 Hz, 1 H) 7.11 (d, J = 8.13 Hz, 2 H) 7.23 - 7.30 (m, 3
H) 7.34-7.40 (m, 2H) 7.46 (s, 2H) 8.05 (s, 1H) 12.01 (s, 2H).
MS (ESI) m / z 995 (M + H) \
<img file="MX339989B_D1015.tif" />
EXAMPLE 189 r (2S, 3R) -1-f (2S) -2-r (4 - ((2S.5S) -1- (4-tert-butylphenyl) -5-r4 - ((r (2S) - 1 ((2S) -2-r (methoxycarbonyl) amino1-3-methylbutanoyl) pyrolidin-2yl1carbonyl) amino) phenyl1pyrrolidin-2-yl) f niDcarbamoiHpyrrolidin-1 612 iD-3-methox -1-oxobutan-2-lllcarbamate d
IA4> PI
MEXICAN INSTITUTE OF INDUSTRIAL PROPERTY
<img file="MX339989B_D1016.tif" />
EXAMPLE 189A --—— (S) -2- (4 - ((2S, 5S) -1- (4-tert-butylphenyl) -5- (4 - ((S) -1 - ((S) Tert-butyl -2 (methoxycarbonylamino) -3-methylbutanoyl) pyrrolidin-2carboxamdolfen ¡l) p¡rrol¡din-2-yl) phenylcarbamo¡l) pyrrolid¡n-1 carboxylate
To a solution of the product of Example 213 (33 mg, 0.052 mmol) in anhydrous DMSO (0.5 ml) is added (S) -1- (terbutoxycarbonl) p¡rrol¡d¡n-2-carboxylic acid ( 13.3 mg, 0.062 mmol), HATU (23.5 mg, 0.062 mmol) and Hunig's base (18 μΙ, 0.10 mmol). The resulting mixture is stirred at room temperature for 90 minutes and then partitioned between H<sub>2</sub>O and EtOAc. The organic layer is dried over Na<sub>2</sub>SW<sub>4</sub>, filtered, and concentrated in vacuo. The crude product is purified by silica gel column chromatography using a solvent gradient of 0-10% MeOH in CH<sub>2</sub>CI<sub>2</sub> to obtain the title compound (33mg, 76%).
EXAMPLE 189B
K2S.3RM-f (2S) -2-H4-n2S.5S) -1- (4-tert-but¡lfeml) -5-r4- (U (2S) -1f (2S) -2-r (methoxycarbon ¡L) am¡no1-3-methylbutanoyl) p¡rrol¡d¡n-2yl1carbon¡l) amino) phenylpyrrolid¡n-2-¡l) phenyl) carbamo¡llpi rrolidin-1 ¡U-3-methoxy-1 methyl-oxobutan-2-illcarbamate
613
A solution of the product from Example IMlBJ
MEXICAN INSTITUTE *
Dt THE PROPERTY
0.036 mmol) in a 1: 1 mixture of CH<sub>2</sub>CI<sub>2</sub>: TFA (0.4 ml) ^ é '^ á ^' lta at ~ room temperature for 45 minutes. The mixture is cleaned in vacuo, and the residue is partitioned between NaHCO<sub>3</sub> aqueous saturated and EtOAc (2x). The combined organic layers are dried over Na<sub>2</sub>SW<sub>4</sub>, filter and concentrate in vacuo to obtain a solid. The solid is subjected to the procedure described in Example 189A (27 mg), substituting (2S, 3R) -3-methoxy-2 (methoxycarbonylamino) butanoic acid for (S) -1- (terbutoxycarbonyl) pyrrolidine-2-carboxylic acid , to obtain the title compound (17mg, 52%).
1H NMR (400 MHz, DMSO-D6) δ ppm 0.85 - 0.97 (m, 6H), 1.08 - 1.19 (m, 12H), 1.60 - 1.66 (m, 2H), 1.80 - 2.05 (m, 8H ), 2.08 - 2.20 (m, 2H), 3.25 (s, 3H), 3.42 - 3.50 (m, 2H), 3.52 (s, 3H), 3.53 (s, 3H), 3.58 - 3.72 ( m, 2H), 3.76 - 3.87 (m, 2H), 3.98 - 4.06 (m, 1H), 4.26 (t, J = 7.81 Hz, 1H), 4.38 - 4.46 (m, 2H), 5.15 (d, J = 6.40 Hz, 2 H), 6.17 (d, J = 8.78 Hz, 2 H), 6.94 (d, J = 8.89 Hz, 2 H), 7.13 (d, J = 8.24 Hz, 4 H) , 7.32 (t, J = 8.84 Hz, 2 H), 7.49 (dd, J = 8.57, 2.06 Hz, 4 H), 9.96 (d, J = 15.51 Hz, 2H).
MS (ESI) m / z 910.6 (M + H) \
614
<img file="MX339989B_D1017.tif" />
EXAMPLE 190 (ri- (4-tert-but¡lfen¡l) p¡rrolid¡n-2.5-di-¡Hbis (benzene-4<sub>1</sub>1-d¡¡Icarbonylhydrazi na-2,1-di-i lcarbonyl (2S) p¡rrol id i n-2,1 -di-iir (2S) -3methyl-1-oxobutan-1,2-d¡ -¡Ni) dimethyl biscarbamate)
To a solution of the product of Example 171B (50 mg, 0.106 mmol) and the product of Example 37B (72 mg, 0.27 mmol) in anhydrous DMSO (1 ml) are added HATU (100 mg, 0.27 mmol) and Hunig's base ( 56 pl, 0.32 mmol). The resulting mixture is stirred at room temperature for 90 minutes, and then partitioned between H<sub>2</sub>O and EtOAc (2x). The combined organic layers are dried over Na<sub>2</sub>SW<sub>4</sub>, filtered, and concentrated in vacuo. The crude product is purified by silica gel column chromatography using a solvent gradient of 0-10% MeOH in CH<sub>2</sub>CI<sub>2 </sub>to obtain the title compound (68mg, 65%) as a mixture of cis and trans stereoisomers.
1H NMR (400 MHz, DMSO-D6) δ ppm 0.81 - 0.98 (m, 12
H), 1.08-1.17 (m, 9H), 1.64-1.77 (m, 2H), 1.78-2.06 (m, 8H),
2.07 - 2.22 (m, 2H), 3.50 - 3.55 (m, 6H), 3.58 - 3.69 (m, 2H), 3.70 615
<img file="MX339989B_D1018.tif" />
<img file="MX339989B_D1019.tif" />
3.83 (m, 2 Η), 3.96 - 4.08 (m, 2 Η), 4.38 - 4.49 (m, J
DELA INDUSTRIAL PROPERTY
4.76 - 4.87 (m, 0.7 H), 5.28 - 5.40 (m, 1.3 H), 6.14 - 6.33 (m, 2 H),
6.92 - 7.08 (m, 2 H), 7.27 - 7.38 (m, J = 8.02 Hz, 5 H), 7.62 (d, J = 8.35 Hz, 1 H), 7.79 - 7.96 (m, 4 H), 9.87 - 9.98 (m, 2H), 10.31-10.44 (m, 2H).
MS (ESI) m / z 981.1 (M + H)<sup>+</sup>.
<img file="MX339989B_D1020.tif" />
EXAMPLE 191 f (2S) -1-r (2S) -2- (5-f4-H2S, 5S) -1- (4-tert-butylphenyl) -5-f2-n2S) -1-f (2S ) 2-I (methoxycarbonyl) am ¡no1-3-methylbutane ¡Dp¡ rrolidin-2-ill-1 Hbenzimidazol-6-¡Dpyrrol¡d¡n-2-iHphenyl) -1 H-imidazole-2-¡ Methyl dpyrrolidin1-ill-3-methyl-1-oxobutan-2-yl) carbamate
AND.
((2S) -1-r (2S) -2- (5-f4-r (2R, 5R) -1- (4-tert-butylphenyl) -5- <2-r (2Sí-1 - {(2S ) 2-r (methoxycarbonyl) amino1-3-methylbutanoyl Pyrrolidin-2-in-1 Hbenzim ¡dazol-6-yl) p¡rrolid¡n-2-i Uphenyl) -1 H-imidazol-2-i Dpyrrolidin1- i Π-3-methyl-l-oxobutan-2-illcarbamate d methyl
616
EXAMPLE 191A
- (4-bromophenyl) -4- (4-chloro-3-nitrophen ¡l) butane-1,4-dione
IMPI
INSTITUTO MEXICANO Dt La PkO?; EDaO INDUSTRIAL
<img file="MX339989B_D1021.tif" />
Zinc chloride (2.73 g, 20 mmol) anhydrous benzene (10 ml) is treated followed by diethylamine (1.55 ml, 15 mmol) and terbutanol (1.4 ml, 15 mmol) and the resulting suspension is stirred at room temperature for 1.75 hours until all solids dissolve. To the cloudy suspension, 4'-chloro-3'-nitroacetophenone is added followed by 2,4'-dibromoacetophenone and the resulting light yellow suspension is stirred at room temperature for 68 hours. The resulting thick white suspension is treated with 25 ml of 5% aqueous sulfuric acid with stirring and the resulting suspension is filtered. The solid is washed with water (50 ml), MeOH (50 ml) and CH<sub>2</sub>CI<sub>2</sub> (50 ml), then dried under vacuum at room temperature for 1 hour and at 55 ° C for 5 hours which yields the title compound as a white solid, 3.4 g, 86%.
EXAMPLE 191B
1- (4-bromophenyl) -4- (4-chloro-3-nitrophenyl) butane-1,4-diol
The product from Example 191 A (4.62 g, 11.65 mmol) is mixed with EtOH (100 ml) and the resulting suspension is treated portionwise over five minutes with NaBH<sub>4</sub> solid (0.97 g,
25.6 mmol). The resulting foamy suspension churns and
617 heat under reflux for 1 hour. The reaction was consr
<img file="MX339989B_D1022.tif" />
by LC-MS. The reaction mixture is cooled to room temperature and concentrated in vacuo to an oily residue. The residue dissolves in CH<sub>2</sub>CI<sub>2</sub> and applied to an 80 g column of silica gel. The column is eluted with a hexane / acetone gradient, 90/10 to 20/80 over a 32 minute period. The product containing fractions are combined and concentrated in vacuo to yield the title compound as a white solid, 3.14 g, 67%.
EXAMPLE 191C
1- (4-bromophenyl) -4- (4-chloro-3-nitrophenyl) butan-1,4-di-yl dimethanesulfonate
The product from Example 191B (3.14 g, 7.84 mmol) is dissolved in 70 mL of CH<sub>2</sub>CI<sub>2</sub> and cooled in an ice-acetone bath to -10 ° C. Triethylamine (3.82 mL, 27.4 mmol) is added dropwise to the cold solution, followed by dropwise addition of methanesulfonyl chloride (1.53 mL, 19.59 mmol) in 20 mL of CH<sub>2</sub>CI<sub>2 </sub>within 10 minutes. The resulting clear solution is stirred in the cold for 90 minutes. The reaction is considered complete by LC-MS analysis and the solvent is removed in vacuo leaving a light yellow solid as the title compound, (4.36 g, 100%), which is used directly in the next reaction.
618
t ... ya.gai ¿
EXAMPLE 191D IMPI
INSTITUTO MEXICANO DE LA I'FCHEDaD
2- (4-bromophenyl) - '1- (4-tert-butylphenyl-5- (4-chloro-3<sup>|</sup>sp-<sup>Tk: AL</sup> Nitrophenidpyrrolidine — The light yellow solid, obtained in Example 191C (4.36 g, 7.84 mmol) is treated with DMF (15 mL) followed by dropwise addition of 4-tert-butylaniline (12.47 mL, 78 mmol), then Place in a 52 ° C oil bath and stir for a total of 12 hours. The reaction mixture is concentrated in vacuo to an oily residue. The mixture is diluted with 100 ml of EtOAc and washed with 50 ml of 0.5 M HCl. The aqueous layer is back extracted with 100 ml of EtOAc. The combined organic extracts are washed with NaHCO<sub>3</sub> 10%, NaCl 10%, dried with Na<sub>2</sub>SW<sub>4</sub>(s) are anhydrous, filtered and the solvent is removed in vacuo, leaving a reddish oil. The oil dissolves in CH<sub>2</sub>CI<sub>2</sub> (10 ml) and apply to an 80 g column of silica gel. The column is eluted with a gradient of hexane / acetone, 90/10 to 30/70 over the course of 32 minutes. The title compound is isolated as a 1: 1 mixture of cis and trans-pyrrolidine isomers, 3.13 g, 75%.
EXAMPLE 191E
4- (5- (4-bromophenyl) -1- (4-tert-butylphenyl) pyrrolidin-2-yl) -N- (2,4-dimethoxybenzyl) -2-nitroan ylin
<img file="MX339989B_D1023.tif" />
The product from Example 191D (1.1 g, 2.14 mmol) was
619 treat with 2,4-dimethoxybenzylamine (3.22 ml
21:41 am I read? X
INSTITUTO MEXICANO Ct LA fRC'.UFCAD
<img file="MX339989B_D1024.tif" />
The resulting suspension is heated to 140 ° C (oil bath) '(ftrFSffteΎ hour. The homogeneous red reaction mixture lesions its concentration in vacuo which leaves a red oil. The oil is diluted with 30 ml of CH2Cl2 , the solid is filtered and the filtrate is applied to a column of 120 g of silica gel The column is eluted with CH<sub>2</sub>CI<sub>2</sub> within 25 minutes. The fractions are combined and concentrated in vacuo to yield the title compound as an orange foamy solid as a mixture of stereoisomers (1.18 g).
EXAMPLE 191F
4- (5- (4-bromophenyl) -1- (4-tert-butylphenyl) pyrrolıd¡n-2-yl) -N1- (2,4-dimethoxy benzyl) benzene-1,2- diamine
The product from Example 191E (1.18 g, 1831 mmol) is dissolved in a mixture of THF (10 ml): EtOH (10 ml): EtOAc (10 ml), treated with PtO<sub>2</sub> (42 mg) and evacuate 10 minutes, followed by introduction of H<sub>2</sub> (g) by balloon. The reaction mixture is stirred overnight at room temperature. The next day the reaction mixture is filtered and the solvent is removed in vacuo leaving a foamy dark green solid. The solid dissolves in 10 ml of CH<sub>2</sub>CI<sub>2</sub> is applied to a column of 40 g of silica gel and eluted with a gradient of hexane / EtOAc; 90/10 to 30/70 over the course of 20 minutes. The title compound is isolated as a
620 white foamy solid as a mixture g, 48%.
jMmPJ
INSTITUTO MEXICANO DE LA rRDfXDAO INDUSTRIAL
<img file="MX339989B_D1025.tif" />
EXAMPLE 191G (2S) -1 - ((2S) -2- (5- (5- (4-bromophen¡l) -1- (4-tert-but¡lfen¡l) pyrrole¡d¡n-2i l ) -2- (2,4-dimethoxybenzyl no) phenylcarbamoil) methyl methyl-1-yl) -3-methyl-1-oxobutan-2-ylcarbamate
(S) -1 - ((S) -2- (methoxycarbonylamine) -3-methylbutanoyl) pyrrolidin-2-carboxylic acid (0.339 g, 1.245 mmol) and HOBt (0.191 g, 1.245 mmol) are dissolved in DMF ( 4 ml) is cooled in an ice bath and treated with EDAC (0.245 g, 1245 mmol) and N-Methylmorpholine (NMM) (0.55 ml, 4.98 mmol). The resulting solution is stirred for 5 minutes in the ice bath, treated by dripping with the product of Example 191F in DMF (4 ml) and the resulting dark mixture is stirred in the ice bath for 1 hour then at room temperature for 18 hours. The next day, the reaction mixture is diluted with EtOAc (50 ml) and the organic layer is washed with NaHCO<sub>3</sub> to the
10% and 10% NaCl, dried with Na<sub>2</sub>SW<sub>4</sub>(s) anhydrous, filtered and the solvent is removed in vacuo leaving an oily residue as the title compound as a mixture of isomers (0.65 g).
ESI + (m / z): 868.2.
621
EXAMPLE 191H
IMPI
INSTITUTO MEXICANO DE LA RFCTEEDAO INDUSTRIAL
<img file="MX339989B_D1026.tif" />
(2SI-1 - ((2S) -2- (2-amino-5- (5- (4-bromophenyl) -1 - (4-tert-butylphenyl) p¡rrol ¡di n-2-¡l) phenylcarbam ¡L) pyrrole ¡di n-1 -yl) -3-methyl-1 oxobutan-2-ylcarbamate of methyl
The product from Example 191G (0.65 g, 0.748 mmol) is dissolved in CH<sub>2</sub>CI<sub>2</sub> (10 ml) then concentrated trifluoroacetic acid (2 ml, 26 mmol)) is added and the reaction mixture is stirred for 10 minutes. The solvent is removed in vacuo and the residue is re-evaporated twice from CH<sub>2</sub>CI<sub>2</sub> and once from toluene. The residue is dissolved in EtOAc (100 ml), washed with NaHCO<sub>3</sub> 10%, dried with Na<sub>2</sub>SW<sub>4</sub>(s) anhydrous, filtered and the solvent is removed in vacuo leaving a foamy brown material as the title compound as a mixture of isomers (0.5 g).
EXAMPLE 1911 (2S) -1 - ((2S) -2- (6- (5- (4-bromophenyl) -1 - (4-tert-butyl) pyrrolidin-2-yl) -1 H-benzofd1¡ Methyl midazol-2-yl) p¡rrol¡din-1 -yl) -3-methyl-1-oxobutan-2ylcarbamate
The product from Example 191H (0.5 g, 0.696 mmol) is treated with acetic acid (5 ml, 87 mmol) and heated in an oil bath at 75 ° C for 70 minutes. The reaction mixture is cooled to room temperature and concentrated in vacuo which leaves an oily residue. The residue is dissolved in EtOAc (100 ml), washed with
622
NaHCO<sub>3</sub> at 10% (20 mi) and NaCI at 10% (20 mi)
<img file="MX339989B_D1027.tif" />
io 4iScC.Sb
INDUSTRIAL PROPERTY
<img file="MX339989B_D1028.tif" />
INSTl
Na<sub>2</sub>SW<sub>4</sub>(s) anhydrous, it is filtered and the solvent is removed in vacuo leaving a foamy brown solid. The residue is dissolved in 10 ml of CH<sub>2</sub>CI<sub>2</sub> and applied to a 12 g column of silica gel. The column is eluted with a gradient of CH<sub>2</sub>CI<sub>2</sub>/ MeOH, 99/1 to 95/5 over 15 minutes and the product is isolated as a tan solid as a mixture of Isomers (0.31 g).
ESI (m / z) +: 702.3.
EXAMPLE 191J (2S) -1 - ((2S) -2- (6- (1- (4-tert-butylphenyl) -5- (4- (4,4,5,5-tetramethyl) -1,3,2dloxaborolan-2-i Ufen ¡Dpi rrol ¡d¡n-2-¡l) -1H-benzordlim ¡dazol-2¡Dpyrrolidi n-1-¡l) -3-met¡ 1-1- Methyl oxobutan-2-Icarbamate
The product of Example 1911 (0.31g, 0.442mmol), b¡s (pinacholate) diboror (0.34g, 1.327mmol), and potassium acetate (0.17g, 1.77mmol) are combined and dissolved in toluene ( 5 ml), the complex 1,1'-b¡s (diphenylphosphine) ferrocened¡chloropallad¡o (ll) dichloromethane (32 mg, 0.044 mmol) is added and the reaction mixture is bubbled with N<sub>2</sub> for 5 minutes, seal and place in a 95 ° C oil bath for 2 hours. The mixture is cooled to room temperature and diluted with EtOAc (100 ml), washed with water (20 ml) and 10% NaCl (20 ml), dried with Na<sub>2</sub>SW<sub>4</sub>(s) anhydrous, filtered and the solvent is removed in vacuo, leaving a brown oil. The oil dissolves in CH<sub>2</sub>CI<sub>2</sub> (10 mi), I know
623
<img file="MX339989B_D1029.tif" />
Di UApply to a 12 g column of silica gel and the c
<img file="MX339989B_D1030.tif" />
with a gradient of hexane: EtOAc, 50:50 to 0: 100 over the course of 18 minutes. The title compound is isolated as a white solid as a mixture of isomers (0.23 g).
EXAMPLE 191K (2S) -2- (5- (4- (1- (4-tert-butylfenl) -5- (2 - ((S) -1 - ((S) -2 (methoxy carbon ¡Lam i no) -3-methyl butane i llpyrrole id ¡n-2-¡l) -1 HbenzordTimidazol-6-yl) pyrrolidin-2-yl) phenyl) -1 H-imidazol-2¡l) p¡rrolid Tert-butyl n-1-carboxylate
The product from Example 191J (0.23 g, 0.308 mmol) and the product from Example 26D (0.195g, 0.615 mmol) are combined in a 20 ml microwave tube and dissolved in toluene (1.5 ml) / ethanol (1.5 ml) . To this solution 1 M aqueous sodium carbonate 0.92 ml, 0.92 mmol) is added followed by 1,1'bis (diphenylphosphino) ferrocene-dichloropalladium (ll) dichloromethane complex (23 mg, 0.036 mmol) and the resulting mixture is bubbled with N<sub>2</sub> for 10 minutes, seal and heat at 100 ° C for 2 hours. The reaction mixture is cooled to room temperature and diluted with EtOAc (50 ml). The aqueous carbonate layer is separated and the organic layer is washed with water (20 ml) and 10% NaCl (20 ml), dried with Na<sub>2</sub>SW<sub>4</sub>(s) anhydrous, filtered and the solvent is removed in vacuo leaving a foamy solid. The solid dissolves in 10 ml of CH<sub>2</sub>CI<sub>2</sub> and applied to a 12 g column of silica gel. The column is<sup>r</sup>.'Z
624
<img file="MX339989B_D1031.tif" />
elutes with a gradient of CH<sub>2</sub>CI<sub>2</sub>/ MeOH, 99/1 to 95/5 Siaftscu
OF INDUSTRIAL PROPERTY
<img file="MX339989B_D1032.tif" />
20 minutes. The title compound is obtained as a tan solid as a mixture of isomers (0.11 g).
EXAMPLE 191L
(2S) -2- (5- (4- (1- (4-tert-but¡lfenll) -5- (2 - ((S) -1 - ((S) -2 (methoxy carbon ¡lam) chloride) ¡No) -3-methyl butanoi l) p¡ rrolidi η-2-yl) -1 Hbenzordlim ¡dazol-ei I) p8 rrolidi n-2-yl) phen¡ l) -1 H-imidazoi-2¡Dpyrrolidinium
The product from Example 191K (0.11 g, 0.28 mmol) is dissolved in dioxane (2 ml), then 4 N HCl / dioxane (1 ml) is added. The resulting solid mass is stirred for 30 minutes at room temperature. The solvent is removed in vacuo leaving a tan solid as the title compound as a mixture of isomers (0.092 g) which is stored in vacuo overnight.
EXAMPLE 191M f (2S) -1-r (2S) -2- (5- {4-r (2S, 5S) -1- (4-tert-butylphenyl) -5- (2-r (2S) -1 - {(2S) 2-Γ (methoxycarbonyl) amino 1-3-methylb uta noillpi rrolidi η-2-i H-1 Hbenzim¡dazol-6-yl> pyrrolidin-2-illfenii> -1 H-im¡dazole Methyl -2-yl) pyrrolodin1-¡ll-3-methyl-1-oxobutan-2-¡l) carbamate
Ϊ.
f (2S) -1-r (2S) -2- (5-f4-r (2R, 5R) -1 - (4-tert-butyl n¡l) -5- (2-H2S) -1- < (2S) 625
<img file="MX339989B_D1033.tif" />
2-Thymotoxycarbonyl) amnol-3-m tilbutanoylpyrrole-rewf-z-fil ·, benzim i dazol-6-yl) pyrrolid i n-2-¡Ufen ¡l) -1 H-imidazol-2-yl ) pírrond¡n
Methyl 1-¡Π-3-methyl-l-oxobutan-2-yl) carbamate
The product of Example 191L (0.092 g, 0.116 mmol), (S) -2- (methoxycarbonylamino) -3-methylbutanoic acid (0.020 g, 0.116 mmol) and HOBt (000.018 g, 0.116 mmol) are combined in a bottom flask 25 ml round and dissolves in DMF (1 ml). The reaction mixture is placed in an ice bath and treated with EDAC (0.022 g, 0.116 mmol) and N-methylmorpholine (0.12 ml, 1.091 mmol. The light yellow reaction mixture is stirred in the ice bath for 1 hour, then stirred at room temperature for 9 hours. The reaction mixture is diluted with EtOAc (100 ml), washed with water (20 ml) and 10% NaCl (20 ml), dried with Na<sub>2</sub>SW<sub>4</sub>(s) anhydrous, filtered and the solvent is removed in vacuo leaving an oily residue. The residue is dissolved in 5 ml of CH<sub>2</sub>CI<sub>2</sub> and applied to a 12 g column of silica gel. The column is eluted with a gradient of CH<sub>2</sub>CI<sub>2</sub>/ MeOH, 99/1 to 95/5 in 22 minutes. The title compound is isolated from the first fraction eluting from the column as a white solid consisting of a mixture of trans-pyrrolidine isomers, 21 mg, 19%.
<sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ ppm 0.71 - 0.95 (m, 12 H)
1.11 (s, 9H) 1.99 (m, 6H) 2.13 (m, 4H) 3.53 (s, 6H) 3.81 (m, 4H)
4.04 (m, 4H) 5.06 (m, 2H) 5.11 - 5.15 (m, 1H) 5.18 - 5.26 (m, 1H)
626
5.32 (m, 1 Η) 6.25 (m, 2 Η) 6.86 - 6.96 (m, 1 Η) 7.0
<img file="MX339989B_D1034.tif" />
(m, 6 Η) 7.61 (m, 2 Η) 11.53 (s, 1 Η) 11.68 (s, 1 Η) 12.00 (m, 2 Η).
ESI +: 914.5.
<img file="MX339989B_D1035.tif" />
EXAMPLE 192 f (2S) -1-r (2S) -2- (5- (4-H2R, 5S) -1- (4-tert-but¡lfen¡l) -5- {2-K2S) -1 - ((2S) 2 - [(methoxycarboninamino1-3-methylbutanoyl) pyrrolidin-2-¡n-1 Hbenc ¡m idazol-6-i Dpi rrol id ¡n-2-¡Ufen ¡I} -1 H- Methyl imidazol-2-¡l) p¡ rrol idi n1-¡Π-3-methyl-l-oxobutan-2-iDcarbamate
Y f (2S) -1-r (2S) -2- (5- (4-r (2S, 5R) -1- (4-tert-butylphenyl) -5-f2-r (2S) -1-U2S ) 2-r (methoxycarboniDaminol-3-methylbutanoyl pyrrol idi n-2-iD-1 Hbenzimidazol-6-¡Dp¡rrolidin-2-yl1pheniD-1 H-im idazol-2-¡Dpyrrolidin1-ill-3-methyl Methyl -1-oxobutan-2-iDcarbamate
The title compound is isolated from the last fraction eluting from the column described in Example 191 M as a white solid as a mixture of cis627 pyrrolidine isomers, 18 mg, 17%.
<img file="MX339989B_D1036.tif" />
<sup>1</sup>H NMR (free base) (400 MHz, DMSO-d<sub>6</sub>) δ ppm 0.71 0.95 (m, 12H) 1.11 (s, 9H) 1.99 (m, 6H) 2.13 (m, 4H) 3.53 (s, 6H)
3.81 (m, 4H) 4.04 (m, 4H) 4.72 (m, 1H), 4.83 (m, 1H) 5.11 - 5.15 (m, 1H) 5.18 - 5.26 (m, 1H) 5.32 (m, 1H) 6.25 (m, 2H) 6.86 - 6.96 (m, 1H) 7.05 (m, 2H) 7.33 (m, 6H) 7.61 (m, 2H) 11.53 (s, 1H) 11.68 (s , 1H) 12.00 (m, 2H).
ESI +: 914.5.
<img file="MX339989B_D1037.tif" />
EXAMPLE 193 (R2S, 5S) -1 - (4-re (morpholin-4-yl) pyridin-3-illphenylpyrrolidin-2,5-diylbisfbenzene-4,1-di-iiminor (2S) - Dimethyl 3-methy 1-1-oxobutan-1,2-diHUbiscarbamate
Ϊ.
(r (2R.5R) -1- (4-fe- (morphoi¡n-4-yl) pyridin-3-yl1phenyl) pyrrolidin-2.5-di¡II b¡s (benzene-4,1-di-limit dimethyl i nor (2S) -3-methyl-1-oxobutan-1,2-d¡¡HDbiscarbamate
Example 86A and 4- (5- (4,4,5,5-tetramethyl-1,3,2628
IMPI
MEXICAN rx ρεοηεγμο dioxaborolan-2-yl) pyridin-2-i!) Morpholine are processed useful'tZÉfrtdb
<img file="MX339989B_D1038.tif" />
sequentially the methods of Examples ~ ΟΟΑτ · »4Μ) Β, and 1Έ (substituting (S) -2- (methoxycarbonylamine) -3-methylbutanoic acid (38.2 mg, 0.218 mmol) for acid (S ) -1- (tert-butoxycarbonyl) pyrolidin2-carboxylic). Reverse phase HPLC (C<sub>18</sub>) provides the title compound, a white solid, as a 1: 1 mixture of trans diastereomers (40.4 mg, 50.6% yield).
1H NMR (free base) (400 MHz, DMSO-D6) δ ppm 0.89 (d, J = 6.72 Hz, 12 H) 1.67 (d, J = 5.64 Hz, 2 H) 1.92 - 2.04 (m, 2 H) 3.37 3.41 (m, 4H) 3.53 (d, J = 2.06Hz, 6H) 3.67 (d, J = 5.10Hz, 4H) 3.94 (t, J = 8.08Hz, 2H) 5.25 (s, 2H) 6.33 (d, J = 8.67 Hz, 2 H) 6.78 (d, J = 8.89 Hz, 1 H) 7.14 - 7.23 (m, 6 H) 7.32 (d, J = 8.67 Hz, 2 H) 7.54 (d, J = 7.92 Hz, 4H) 7.66 (dd, J = 8.84, 2.55 Hz, 1H) 8.26 (d, J = 2.49 Hz, 1
H) 10.01 (s, 2H).
MS ESI (+) m / z @ 806.5 (M + H) +.
<img file="MX339989B_D1039.tif" />
EXAMPLE 194 (f (2S, 5S) -1 -r4- (1-hydroxy-2-methylpropan-2-yl) phenylpyrrolidin-2,5-diyl) bis {benzene-4.1-di-ylcarbamoyl (2S) p¡rrolidin Dimethyl -2.1-di-iir (2S) -3-methyl-1-oxobutan-1,2-di-illDbiscarbamate)
629
EXAMPLE 194A
Ethyl 2-methyl-2- (4-nitrophenyl) propanoate
IMPI
ÜOTTUTO MEXICANO nc ia rer.rtrr'.An
<img file="MX339989B_D1040.tif" />
Ethyl 2- (4-nitrophenyl) acetate (10.0 g, 55.2 mmol), anhydrous dimethylformamide (200 ml) 18-crown-6 (2.189 g, 8.28) is added to a 500 ml Morton flask equipped for mechanical stirring at room temperature under nitrogen. mmol) and methyl iodide (23.13 ml, 370 mmol). The flask is cooled in an ice bath and sodium hydride is added portionwise as a 60% dispersion in mineral oil (7.73 g, 193 mmol) to maintain the internal temperature at or below + 10 ° C. the addition requires 53 minutes. Upon completion of the addition, the reaction mixture is allowed to warm slowly to room temperature and stir overnight. Subsequent cooling in an ice bath is followed by the dropwise addition of water (200 ml) with vigorous stirring. The mixture is partitioned between water (1200 ml) and ethyl ether (200 ml). The aqueous phase is extracted with ethyl ether (3 x 200 ml each) and the combined organics are washed with water (3 x 150 ml), dried over MgSO<sub>4</sub>, filter and concentrate to provide the title compound in nearly quantitative yield pure enough for use as isolated.
EXAMPLE 194B
2-methyl-2- (4-nitrophenyl) propan-1 -ol
630
IMPI
<img file="MX339989B_D1041.tif" />
To a solution of the product of ΕίβηΊρΐδ<sup>τ</sup>'ΤΗ ^ ΑίΑτί £ ίί2ώ22Μ
INDUSTRIAL _2
55.2 mmol) in anhydrous THF (300 ml) at room temperature under nitrogen is added dropwise through a BH cannula<sub>3</sub> 1 M in THF (200 ml) over the course of 10½ minutes. Upon completion of the addition the flask is fitted with a condenser and the mixture is heated under reflux under nitrogen in an oil bath for 10 hours before cooling to room temperature. The reaction is quenched by the careful dropwise addition of methanol (60 ml). The resulting mixture is concentrated to an oil which is then dissolved in ethyl acetate (150 ml) and treated with 1N HCl and allowed to stir at room temperature for one hour. The resulting organic phase is washed with brine (4 x 50 ml), dried over MgSO<sub>4</sub>, filter and concentrate. The residue is dissolved in toluene (25 ml) and reconcentrated. The oily solid is suspended in hexane (50 ml) and collected by vacuum filtration. The cake is washed with hexane (50 ml) then dried under vacuum to provide the title compound (9.55 g, 89% yield) as a light orange solid.
MS (DCI +) m / z @ 213.1 (M + NH<sub>4</sub>)+.
EXAMPLE 194C
2- (4-aminophenyl) -2-methylpropan-1-ol
The product from Example 194B (0.321g, 1.644mmol) is dissolved in a mixture of THF (10ml) and ethanol (2ml). To this I know
631
<img file="MX339989B_D1042.tif" />
adds platinum (IV) oxide (0.030 g, 0.131 mmeLfes * jfeí In
MEXICAN INSTITUTE
OE LA ΓΚΟΠΕΟΑΓ _ cover with a septum and the contents are degassed '<sup>N!</sup>a1 empty 'three times. Hydrogen is introduced by means of a gIobó'y<sup>1</sup>1st<sup>-</sup> m'ez'cía is stirred at room temperature. An additional 38.2 mg (0.167 mmol) of catalyst is added in two aliquots prior to chromatographic analysis indicating that the starting material was consumed. After stirring overnight under hydrogen the mixture is filtered through a plug of sand / celite followed by a rinse with ethyl acetate. The filtrate is concentrated to dryness and the residue is purified by chromatography on amine modified silica gel eluting with ethyl acetate-hexane starting at 8% and progressing to 66% ethyl acetate to provide the title compound (0.3645 g, 68% yield) as a clear oil.
MS (DCI +) m / z @ 183.1 (M + NH<sub>4</sub>)+.
EXAMPLE 194D
2- (4 - ((2S.5S) -2.5-bis (4-nitrophenyl) pyrolidin-1-Dphenyl) -2methylpropan-1 -ol
The product from Example 194C (0.595g, 3.60mmol) is combined in DMF (3ml) with (1R, 4R) -1,4-bis (4-nitrophenyl) butan-1,4-di-yl dimethanesulfonate (0.259 g , 0.530 mmol), prepared as described in Example 37C, then heated overnight under nitrogen in a 50 ° C oil bath. The mixture of ¡ΛλτΛ.
632 The reaction is partitioned between ethyl acetate (50 fhi • '· (ΝΓΜΚΤΒΙΑΙ.
IM
<img file="MX339989B_D1043.tif" />
The organic phase is washed with water (3 x 25 ml), dried with MgSO<sub>4</sub>, filtered and concentrated to an oil. Chromatography on silica gel eluting with ethyl acetate-hexane provides the title compound (0.0835 g, 34.1% yield) as an orange semisolid.
EXAMPLE 194E
2- (4 - ((2S, 5S) -2.5-bis (4-am inophenyl) pyrolidin-1 -¡ Dphenyl) -2methylpropan-1-ol
The product from Example 194D (83.5 mg, 0.181 mmol) is reacted as described in Example 99B to provide the title compound in quantitative yield as a light yellow solid.
MS (DCI +) m / z @ 402.3 (M + H) +.
EXAMPLE 194F (f (2S, 5S) -1 -r4- (1-hydroxy-2-methylpropan-2-¡l) phenylpyrrol¡d¡n-2,5-diyl) bis <benzene-4,1- dimethyl di-ylcarbamoyl (2S) pyrrolidin-2,1-di-iir (2Sj-3methyl-1-oxobutan-1,2-d¡-¡I1)) b¡scarbamate)
The product from Example 194E (73.0 mg, 0.181 mmol) is reacted with the product from Example 37B (104.0 mg, 0.380 mmol) as described in Example 37F. The title compound
633 isolated after HPL purification was I ·· $ (C18) as an off-white solid (97.4 mg, 59% yield).
INSTITUTE y. £ X¡CA.'in Dt LA f «ν ·> £ 3AO
<img file="MX339989B_D1044.tif" />
1H NMR (free base) (400MHz, DMSTTDb) P ppm O.? -0.96 (m, 12H) 1.03 (s, 6H) 1.61 (s, 2H) 1.76 - 2.04 (m, 8H) 2.04 2.17 (m, 2H) 3 20 (dd, J = 5.42, 1.84 Hz, 2H) 3.51 (s, 6H) 3.60 (dd, 2
H) 3.78 (s, 2H) 4.01 (t, J = 8.46 Hz, 2H) 4.35 - 4.49 (m, 3H) 5.14 (s, 2H) 6.16 (d, J = 8.78 Hz, 2H) 6.89 (d, J = 8.78 Hz, 2 H) 7.12 (d, J = 8.57 Hz, 4 H) 7.29 (d, J = 8.35 Hz, 2 H) 7.48 (d, J = 8.46 Hz, 4 H) 9.97 (s , two
H).
MS ESI (+), m / z @ 910.7 (M + H) +
<img file="MX339989B_D1045.tif" />
H1S.2R) -2-methox¡-1 - «(2S) -2-r4- (4-f5-r4- (2- (f2S) -1-rN (methoxycarbonyl) -0-methylL- treon¡l1p¡rrol¡d¡n-2-¡l) -1 Hi medazol-4ihfeni 11-1 - (β-pi period-1 -¡lpyrid¡n-3-¡l) -1 Hp¡ rrol- Methyl 2-i Ufen ¡l) -1 H¡midazol-2-illpyroidin-1-yl) carbonyl) propiHcarbamate
The title compound is prepared using the methods of Example 144E by substituting acid for (2S, 3S) -3-methoxy-2634 τ
ÁJdM Ρ 1
MEXICAN INSTITUTE OF PROPERTY p rovee r eí<sup>ND</sup>eS5Wfp
<img file="MX339989B_D1046.tif" />
12.12-11.70 (m, 2H), (methoxycarbonylamine) butanoic for (methoxycarbonylamine) -3-methylbutanoic for the title (280mg, 37% yield).
<sup>1</sup>H NMR (400 MHz, DMS0-D6) δ
7.85 - 7.76 (m, 1H), 7.63- 7.49 (m, 4H), 7.49 - 7.39 (m, 2H), 7.34 7.03 (m, 7H), 6.77 - 6.69 (m, 1H), 6.54 - 6.41 (m, 2H), 5.08 - 4.99 (m, 2H), 4.27 (t, J = 7.6, 2H), 3.86 - 3.75 (m, 4H), 3.54 (s, 6H), 3.50 3.43 (m, 4H), 3.17 (s , 6H), 2.19-1.88 (m, 10H), 1.61-1.44 (m, 6H),
1.12-0.99 (m, 6H).
MS (ESI, M + H) m / z = 997
<img file="MX339989B_D1047.tif" />
N- (methoxycarbonyl) -L-valyl-N-f4-r (2S, 5S) -5- (4-nN- (methoxycarbonyl) L-valillami nolfenih-l - (4-i6- (morphol) n-4-¡l) pyrodin-3inphenyl) pyrroiidin-2-illphenyl> -L-prolinam ida
AND.
N- (methoxycarbon¡l) -L-val¡lN-f4-y (2R, 5R) -5- (4- (ÍN- (methoxycarbon¡l) L-valyl-amino) phenyl) -1- ( 4-r6- (morpholin-4-yl) pyridin-3¡HfeniRpyroIidiη-2-illf ni DL-prol inamide
635
<img file="MX339989B_D1048.tif" />
IMPI
MEXICAN INSTITUTE OF PROFIEDAD
INDUSTRIAL
<img file="MX339989B_D1049.tif" />
EXAMPLE 196A (2S) -1- (4- (5- (4-am¡nophenyl) -1 - (4- (6-morphoiinopyrid¡n-3¡ Dfeni l) p¡ rrol ¡d ¡η-2-i Methyl Dfeni I am ino) -3-m ethi 1-1 -oxobutan-2ylcarbamate
Dissolve 4,4 '- (1- (4- (6-morpholnopyridin-3-yl) phenyl) pyrrolidin-2,5-di-yl) in a nitrogen purged oven-dried 5 ml round bottom flask dianiline (30 mg, 0.061 mmol; Prepared from Example 86A and 4- (5- (4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) pyridin-2-yl) morpholine using the methods of Examples 99A and 99B), and (S) -2- (methoxycarbonylamine) -3-methylbutanoic acid (11.22 mg, 0.064 mmol) in anhydrous DMSO (1 ml), add HATU (26.3 mg, 0.067 mmol) and di-isoprop Letylamine (0.021 ml, 0.122 mmol), and the yellow solution is stirred at 25 ° C for 30 minutes. The reaction is diluted with MeOH (1 mL) and purified by RPC HPLC<sub>18</sub> (Waters Prep LC, 40mm module with Nova Pak HR C cartridge<sub>18</sub> 6 pm 40 x 100 mm Prep Pak) eluting with a 30 minute gradient of 95: 5 0.1% TFA n H<sub>2</sub>O / AcCN up to 25:75 0.1% TFA
636 in H<sub>2</sub>O / AcCN, then 10 minutes until 100% AcCNjj ^^ r ^ PrJi
INSTITUTE V EXICANO
The pure fractions are concentrated by evaporation<sup>D</sup>¿Í'ím; igriratS «I KNOW ^ *<sup>z </sup>(go from water 35 °) to a small volume, it will split between 20% of ¡PrOH / CHCI<sub>3</sub> (50 mi) and NaHCO<sub>3</sub> saturated aqueous (15 ml), the layers are separated, the organic extract is dried over MgSO<sub>4</sub> anhydrous, filtered, and concentrated by rotary evaporation to obtain the title compound as an off-white solid (14.6 mg, 37%) as a mixture of stereoisomers.
MS (ESI +) m / z 649 (M + H)<sup>+</sup>, 707 (M + AcCN + NH<sub>4</sub>)<sup>+</sup>, 1297 (2M + H)<sup>+</sup>.
EXAMPLE 196B
N- (methoxycarbon¡l) -L-val¡lN- (4-R2S.5S) -5- (4- <TN- (methoxycarbon¡l) L-val¡Hamino | phenyl) -1-f4- re (morpholin-4-yl) pyridin-3illphenylpyrrol idin-2-illfeniD-L-prolinamide
AND
N- (methoxycarbonyl) -L-valyl-N-f4-r (2R, 5R) -5- (4-nN- (methoxycarbonyl) L-valyl-amino) phenyl) -1-f4-re (morpholin-4 -il) pyridin-3i Ufen i Dpi rrol idi n-2-illfenin-L-prol inamide
In a 5 ml round bottom flask purged with nitrogen, the product of Example 196A (14 mg, 0.022 mmol) is dissolved in anhydrous DMSO (1 ml), the product of Example 37B (6.46 mg, 0.024 mmol) is added, HATU (9.30 mg, 0.024 mmol), and diisopropylethylamine (7.54 µl, 0.043 mmol). Stir at 25 ° C for 1
637
<img file="MX339989B_D1050.tif" />
hour, the reaction is diluted with MeOH (1 ml) and piJi ^^ íeJ
INSTITUTE CS LA .1
HPLC RP-C<sub>18</sub> (Waters Prep LC, 40 mm module with cartridges, Mova Pak HR C,<sub>8</sub> 6 pm 40 x 100 mm Prep Pak) eluting-cuu a yiUllléHlé of 30 minutes of 95: 5 0.1% TFA in H<sub>2</sub>O / AcCN up to 25:75 0.1% TFA in H<sub>2</sub>O / AcCN, then 10 minutes to 100% AcCN at 20 ml / minute. The pure fractions are concentrated by rotary evaporation (water 35 ° C) almost to dryness, the residue is dissolved in CH<sub>2</sub>CI<sub>2</sub>/ hexanes 1: 5 v / v and evaporate (3 times), and the residue is dried in vacuo to obtain a yellow solid (11 mg). The TFA salt is dissolved in 20% PrOH / CHCI<sub>3</sub> (30 ml), washed thoroughly with NaHCO<sub>3</sub> aqueous saturated (5 ml), the aqueous phase is extracted with 20% PrOH / CHCl<sub>3</sub> (20 ml), the combined organic extracts are dried over MgSO<sub>4</sub> anhydrous, filtered, and concentrated by rotary evaporation to obtain the title compounds as a white solid (7 mg, 35%).
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ ppm 0.83 - 0.96 (m, 12
H), 1.60-1.71 (m, 2H), 1.81-2.21 (m, 7H), 3.36-3.43 (m, 4H),
3.49-3.56 (m, 6H), 3.58-365 (m, 1H), 3.65-3.70 (m, 4H), 3.75 3.85 (m, 1H), 3.94 (t, J = 8.08Hz, 1H ), 4.02 (t, J = 8.19 Hz, 1 H), 4.42 (dd, J = 7.86, 4.93 Hz, 1 H), 5.24 (d, J = 5.31 Hz, 2 H), 6.32 (d, J = 8.35 Hz, 2H), 6.78 (d, J = 9.00 Hz, 1H), 7.13 - 7.19 (m, 4H), 7.21 (d, J = 8.78 Hz, 2H), 7.26 - 7.35 (m, 2H ), 7.48 - 7.56 (m, 4 H), 7.66 (dd, J = 7.86, 1.14 Hz, 1 H), 8.25 (d, J = 2.17 Hz, 1 H), 10.00 (d, J = 3.47 Hz,
H).
MS (ESI +) m / z 903 (M + H) *.
638
<img file="MX339989B_D1051.tif" />
EXAMPLE 197 f (2S) -1-í (2S) -2- (4-f4-F (2S, 5S) -1- (4-tert-butylphenyl) -5- (4- {2-r ( 2S) -1 ((2S) -2-r (methoxycarbonyl) amnol-3,3-d¡methyl-Ibutanoylpyrrolidi n-2ill-1 H-m¡dazol-4-phenyl) p¡rrolid ¡N-2-¡l1phenyl> -1 H-imldazol-2-yl) pyrrolidin-1 -¡ll-3.3-dimethyl-1-oxobutan-2-yl> methyl carbamate
Y í (2S) -1-H2S) -2- (4-f4-f (2R, 5R) -1- (4-tert-but¡lfen¡l) -5- (4-f2-r (2S) -1 ((2S) -2-r (methoxycarboninam¡nol-3,3-d¡met¡lbutano¡l} p¡rrolid¡n-2¡Π-1 H-im¡dazol-4-yl) phe nyl ) pyrrole idin-2-infhenyl> -1 H-imidazol-2¡I) pyrrole id ¡n-1-yl-3,3-dimethyl-1-oxobutan-2-H> methyl carbamate
The product from Example 42F (0.228 g, 0.364 mmol) is processed as in Example 1H to obtain 0.035 g (10%) of the title compound as a solid as a mixture of trans isomers.
1H NMR (free base) (400 MHz, DMSO-D6) δ ppm 0.91 (d,
J = 7.59 Hz, 18H) 1.08 (s, 9H) 1.63 - 1.73 (m, 2H) 1.83 - 2.24 (m, 12
H) 3.54 (s, 6H) 3.70 - 3.80 (m, 2H) 4.21 (d, J = 7.92 Hz, 2H) 5.06
639
<img file="MX339989B_D1052.tif" />
(dd, J = 6.99, 3.52 Hz, 2 H) 5.15 - 5.25 (m, 2 H) 6.21 (cL „'' '' '' 'INSTITUTO MEXICANO
Q £ Lrt TROHEda »
H) 6.92 (dd, J = 8.73, 2.44 Hz, 2 H) 7.05 (d, J = 8.78 Hz, 2 H) 7 ^ ™ '
<img file="MX339989B_D1053.tif" />
J = 8.24, 3.47 Hz, 4H) 7.37 (s, 2H) 7.61 (d, J = 8.02 Hz 4H) ΓΙ .b and fST 2H).
MS ESI + m / z 968.8 (M + H) +.
<img file="MX339989B_D1054.tif" />
[(2S) -1 - {(2S) -2 - [(4 - {(2R, 5R) -5- (4-Hf 1 -í (2S) -2rímethoxycarbo ni l) am¡no1-4- (met ¡Lsulfanyl) butanoin pyrrole ¡din-2yl} carbon¡l) am¡nolfenyl) -1-r4- (trifluoromethyl) phenylp¡rrol¡d¡n-2¡ Ufen ¡Dcarbamo i II p¡rrolidin-1 -il Methyl) -4- (methiisuiphanyl) -1-oxobutan-2 yl carbamate
EXAMPLE 198A
Acid (S) -2- (methoxycarbonlamine) -4- (methyl) butane
To a solution of (S) -2-amino-4- (methylthio) butanoic acid (1.0 g, 6.7 mmol) in dioxane at 0 ° C is added NaOH (11.06 g,
22.12 mmol) followed by dropwise addition of chloroformate
640 of methyl (1.04 ml,
13.4 mmol) and the solution
<img file="MX339989B_D1055.tif" />
room temperature with stirring within 2 hours. The solution is diluted with EtOAc, washed with 1N HCl, brine, dried (Na<sub>2</sub>SW<sub>4</sub>), filtered and the solvent is removed in vacuo to obtain the title compound (1.3 g, 6.27 mmol, 94%).
<sup>1</sup>H NMR (400 MHz, CDCI<sub>3</sub>) δ ppm 1.95-2.07 (m, 1H) 2.072.13 (m, 3H) 2.14-2.28 (m, 1H) 2.59 (t, J = 7.4 Hz, 2H) 3.71 (s, 3H) 4.52 (br s, 1H) 5.33 (br s, 1H).
EXAMPLE 198B (2S, 2'S) -N<sub>l</sub>N<sup>,</sup>-(4.4<sup>,</sup>- (f2R.5R) -1- (4- (trifluoromethyl) phenyl) pyrrolid¡n-2.5di-yl) bis (4.1-phenylene) dipyrrol¡d¡n-2-carboxam ¡da
Example 38A and 4-trifluoromethylaniline are processed using the methods of Examples 34A, 34B, 34C, and 34D to provide the title compound.
EXAMPLE 198C
H2S) -1-ff2S) -2-r (4-R2R, 5R) -5- (4 - [({1 - [(25) -2r (methoxycarbonyl) aminol-4- (methylsulfanyl) butanoylpyrrolidin-2¡l ) carbon¡l) am¡no1phenyl) -1-il4- (tr¡fluorometh¡l) fen¡np¡rrol¡din-2¡l) phen¡l) carbamo¡np¡rrol¡din-1-¡l) Methyl -4- (methylsulfanyl) -1-oxobutan-2¡ll carbamate
Example 198B and Example 198A s process using
641
<img file="MX339989B_D1056.tif" />
The method of Example 1H to provide the compound is purified by Flash chromatography on silica gel eluting with 10-80% EtOAc / CH<sub>2</sub>CI<sub>2</sub> (2y mg).
<sup>1</sup>H NMR (400 MHz, CDCI<sub>3</sub>) δ ppm 1.78 (d, J = 6.1 Hz, 2H) 1.83-2.00 (m, 6H) 2.02 (s, 6H) 2.04-2.26 (m, 4H) 2.43-2.61 (m, 8H) 3.47-3.83 (m, 4H) 3.69 (s, 6H) 4.75 (dd, J = 8.0, 2.0 Hz, 4H) 5.15 (d, J = 6.7 Hz, 2H) 5.43 (d, 2H) 6.32 (d, J = 8.7 Hz, 2H) 7.09 (d, J = 8.5 Hz, 4H) 7.18 (d, J = 8.8 Hz, 2H) 7.42 (d, J = 8.6 Hz, 4H) 9.05 (s, 2H).
MS (ESI) m / z 971 (M + H)<sup>+</sup>.
<img file="MX339989B_D1057.tif" />
EXAMPLE 199
H2S.3S) -1-f (2S) -2-r (4-f (2R.5R) -5- (4-U (1 - ((2S, 3S) -2r (methoxycarbonyl) aminol-3-methylpentanoiDpyrrolidine -2yl) carbonylamino) phenyl) -1-r4- (trifluoromethii) phenylpyrrolidin-2ylKeni Dcarbamoillpyrrol idi n-1 -yl} -3-methyl-1-oxopentan-2H-carbamate
EXAMPLE 199A
(2S, 3S) -2- (m-toxiccarbonylamino) -3-methylpntanoic acid
642
<img file="MX339989B_D1058.tif" />
<img file="MX339989B_D1059.tif" />
acid 42SY2ÍS4-2
Pt THE PKOPItCAD,. ,.<sub>Λ</sub> tXDUSTRÍAt in dioxane (10 ml) at 0 ° C was followed by "
To a solution of methylpentanoic acid (1.0 g, 7.62 mmol) add NaOH (12.58 g, 25.2 mmol) dripping of methyl chloroformate (1.18 ml, 15.25 mmol). The solution is warmed to room temperature with stirring over the course of 2 hours, diluted with EtOAc, washed with 1N HCl, brine, dried (Na<sub>2</sub>SW<sub>4</sub>), filtered and the solvent is removed in vacuo to obtain the title compound (1.4 g, 7.4 mmol, 97%).
<sup>1</sup>H NMR (400 MHz, CDCI<sub>3</sub>) δ ppm 1.27-1.39 (m, 1H) 1.381.53 (m, 2H) 1.58-1.72 (m, 3H) 1.82-1.94 (m, 2H) 2.04 (d, J = 3.8 Hz, 2H) 3.70 (s, 3H) 4.94 (br s, 1H).
EXAMPLE 199B
I (2S, 3SM - {(2S) -2-r (4 - {{2R, 5R) -5- (4- {H1-f (2S.3S) -2r (methox¡carbon¡l) am¡no1 -3-methylpentano¡l) p¡rrol¡din-2¡Dcarbonillaminolfeni l) -1 -r4- (trifluoromethyl) phen¡llpyrrol¡din-2¡l) phen¡l) carbamoyl1pyrrol¡din-1- methyl iH-3-methyl-1-oxopentan-2¡ll carbamate
To a solution of Example 198B (60 mg, 0.101 mmol) in DMSO (0.5 ml) is added Example 199A (48 mg, 0.254 mmol), followed by HATU (96 mg, 0.254 mmol) and Ν, Ν-di-isopropylethylamine (0.089 ml, 0.507 mmol) and the solution is stirred at room temperature for 1 hour. Dilute with EtOAc, wash with H<sub>2</sub>O, brine, dries up (Na<sub>2</sub>SW<sub>4</sub>), filtered and the solvent is removed under vacuum
643 to obtain the crude product which is pu Jfij ^ J
INST'TUTS * '. £ XJCANO silica gel flash chromatography £ «layf
<img file="MX339989B_D1060.tif" />
with 10-80% EtOAc / CH<sub>2</sub>CI<sub>2</sub> to obtain the compound dal title ·. (11 mg, 0.012 mmol, 12%).
<sup>1</sup>H NMR (400 Hz, CDCI<sub>3</sub>) δ ppm 0.78-1.00 (m, 12H) 1.691.81 (m, 4H) 1.81-1.94 (m, 2H) 1.99-2.10 (m, 2H) 2.09-2.24 (m, 2H)
2.50 (br s, 2H) 2.53-2.61 (m, 2H) 3.63 (br s, 2H) 3.68 (s, 6H) 3.753.87 (m, 2H) 4.34 (t, J = 8.5 Hz, 2H) 4.79 (d , J = 6.3 Hz, 2H) 5.14 (d, J = 6.6 Hz, 2H) 5.28 (d, J = 9.3 Hz, 2H) 6.32 (d, J = 8.7 Hz, 2H) 7.08 (d, J = 8.4 Hz, 4H) 7.18 (d, J = 8.8 Hz, 2H) 7.41 (d, J = 8.5 Hz, 4H) 9.23 (s, 2H).
MS (ESI) m / z 935 (M + H)<sup>+</sup>.
<img file="MX339989B_D1061.tif" />
r (2S.3R) -3-methoxy-1-f (2S) -2 - [(4-f (2R, 5R) -5- (4- {r (1 - {(2S, 3R) -3methoxy- 2-r (methoxycarbonamino1butanoyl> p¡rrolidin-2-yl) carboniHamino) phenyl) -1-r4- (trifluoromethyl) phenylpyrrolidin-2-yl) phenyl) carbamoylpyrrolidin-1-yl) -1-oxobutan-2-ilcarbamate dm linden
644
EXAMPLE 200A
(2S.3R) -3-Methoxy-2- (methoxycarbonylamino) butanoic acid
IMPI
INSTITUTO .MEXICANO I? £ LA FLOTirPAD INDUSTRIAL
<img file="MX339989B_D1062.tif" />
A solution of O-methyl-L-threonine (1.01 g, 7.59 mmol) in saturated bicarbonate solution (93 ml) is drip-treated with methyl chloroformate (900 μΙ, 1.10 g, 11.61 mmol), followed by stirring at temperature environment for 24 hours. The mixture is extracted methyl-t-butyl ether and cooled to 0 ° C. The mixture is adjusted to pH 1-2 by adding concentrated hydrochloric acid solution. The mixture is extracted with ethyl acetate (3x) and the combined extracts are extracted with saturated sodium chloride solution and dried (Na<sub>2</sub>SW<sub>4</sub>). The solution is concentrated in vacuo to obtain the title compound (1.31 g, 90%) as a white solid.
<sup>1</sup>H NMR (400 MHz, CDCI<sub>3</sub>) δ 5.44 (d, J = 8.7 Hz, 1 H),
4.39 (dd, J = 8.7, 2.3 Hz, 1 H), 4.00 (dd, J = 6.2, 2.4 Hz, 1 H), 3.71 (s, 3 H), 3.36 (s, 3 H), 1.21 (t, J = 7.2 Hz, 3H).
MS (+ ESI) m / z (rel abundance) 192 (60, M + H), 209 (100, M + NH4).
EXAMPLE 200B n2S, 3R) -3-methoxy-1-H2S) -2-r (4-R2R, 5R) -5- (4- (í (1-R2S.3R) -3methoxy-2-f (methoxycarboniDaminolbutanoiDpyrrolidin- 2¡l) carbonylamino> phenyl) -1-r4- (tr¡fluorometh¡l) phenylpyrrol¡d¡n-2¡ Df eni Dea rbamoill pyrrolidi n-1-i D-1-oxobutan-2 -¡Hcarbamate d
645 methyl
Example 198B (60 mg, 0.101 mmol) and Example
Inst ID: tv
L> £
<img file="MX339989B_D1063.tif" />
200A (48.5 mg, 0.254 mmol) are processed in the same way as Example 199B to obtain the title compound (10.5 mg, 0.011 mmol, 11%).
<sup>1</sup>H NMR (400 MHz, CDCI<sub>3</sub>) δ ppm 1.19 (s, 3H) 1.21 (s, 3H)
1.78 (d, J = 6.1 Hz, 2H) 1.94-2.16 (m, 6H) 2.40-2.57 (m, 4H) 3.36 (s, 6H) 3.66-3.84 (m, 6H) 3.69 (s, 6H) 4.64-4.72 (m, 2H) 4.81 (d, J = 8.1 Hz, 2H) 5.14 (d, J = 6.7 Hz, 2H) 5.64 (d, J = 7.9 Hz, 2H) 6.31 (d, J = 8.8 Hz, 2H) 7.08 (d, J = 8.6 Hz, 4H) 7.18 (d, J = 8.8 Hz, 2H) 7.43 (d, J = 8.6 Hz, 4H) 8.85 (s, 2H).
MS (ESI) m / z 939 (M + H)<sup>+</sup>.
<img file="MX339989B_D1064.tif" />
/
EXAMPLE 201 r (2S, 3S) -3-methoxy-1-f (2S) -2-F (4-f (2R, 5R) -5- (4-fr (1 - ((2S.3S) -3methoxy -2-f (methoxycarbonyl) amino1butano¡l) pyrrolid¡n-2¡l) carbon¡llaminolfen¡l) -1 -r4- (tr¡fluorometh¡l) phenyl1p¡rrol¡din-2yl> phen¡l) carbam ¡Np¡rrol¡d¡n-1 -yl} -1-oxobutan-2-illcarbamate dm linden
646
EXAMPLE 201A
(2S.3S) -3-Methoxy-2- (methoxycarbonylamino) butanoic acid
IMPI
INSTITUTE v.-x <-. Mo DS THE PROPERTY
INDUSTRIAL
<img file="MX339989B_D1065.tif" />
A solution of allo-O-methyl-L-threonine (519 mg, 3.90 mmol) in saturated sodium bicarbonate solution (47.6 ml) is drip-treated with methyl chloroformate (453 μΙ, 553 mg,
5.85 mmol) followed by stirring at room temperature for 18 hours. The mixture is extracted with ether and the aqueous phase is cooled to 0 ° C and acidified to pH 2-3 by adding concentrated hydrochloric acid solution. The mixture is extracted with ethyl acetate (3x). The combined organic layers are extracted with saturated sodium chloride solution and dried (Na<sub>2</sub>SW<sub>4</sub>). Concentration in vacuo allows the title compound (640 mg, 86%) to be obtained as a colorless oil.
<sup>1</sup>H NMR (400 MHz, CDCI<sub>3</sub>) δ 5.48 (d, J = 7.8 Hz, 1 H), 4.52 (d, J = 4.7 Hz, 1 H), 3.71 (s, 3 H), 3.39 (s, 3 H), 1.25 (t, J = 7.6 Hz, 3H).
EXAMPLE 201B f (2S, 3S) -3-methoxy-1-f (2S) -2-r (4 - ((2R, 5R) -5- (4- (r (1-f (2S, 3S) - 3-methox8-2-r (methoxycarbonyl) aminolbutane¡Dpyrrolidin-2iDcafboniHaminoIpheny) -1-r4- (trtfluoromethyl) phenylpyrrolidin-2i l) fe ni i) carbamoi Ilpyrrol ¡di n-1 -yl) -1-oxobutan-2-¡llcarbamate d methyl
647
ΙΜΡΙ
Example 198B (40 mg, 0.068 mmoled ^^^^ gjgr "INDUSTRIAL
201A (32.3 mg, 0.169 mmol) are processed in the same way as
<img file="MX339989B_D1066.tif" />
that of Example 199B to obtain the title compound (22 mg, 0.023 mmol, 35%).
<sup>1</sup>H NMR (400 MHz, CDCI<sub>3</sub>) δ ppm 1.24 (s, 3H) 1.25 (s, 3H)
1.78 (d, J = 6.2 Hz, 2H) 1.87-1.99 (m, 2H) 1.99-2.16 (m, 4H) 2.45-2.58 (m, 4H) 3.20 (s, 6H) 3.46-3.56 (m, 2H) 3.65 -3.83 (m, 6H) 3.69 (s, 6H) 4.51-4.59 (m, 2H) 4.78 (d, J = 6.7 Hz, 2H) 5.14 (d, J = 6.7 Hz, 2H) 5.39 (d, J = 9.3 Hz, 2H) 6.30 (d, J = 8.7 Hz, 2H) 7.08 (d, J = 8.5 Hz, 4H) 7.16 (d, J = 8.8 Hz, 2H) 7.40 (d, J = 8.5 Hz, 4H) 8.94 ( s, 2H).
MS (ESI) m / z 939 (M + H)<sup>+</sup>.
<img file="MX339989B_D1067.tif" />
F (methoxycarbonyl) amino1-2-phenylacetyl> pyrrolidin-2ihcarbon¡Hamino> fenfü-1-r4- (ttiftuorometiDpheneHp¡rrol¡d¡n-2¡IIfen¡l) carbamoinplrrolid¡n-1-¡n-2-oxo- Methyl 1-phenylethincarbamate
648
EXAMPLE 202A
IMPI
MEXICAN INSTITUTE OF INDUSTRIAL PROPERTY
<img file="MX339989B_D1068.tif" />
(S) -2- (Methoxycarbonylamino) -2-phenylacetic acid
To a solution of (S) -2-amino-2-phenylacetic acid (0.5 g, 3.31 mmol) in dioxane at 0 ° C is added NaOH (5.46 g, 10.92 mmol) followed by dropwise addition of methyl chloroformate (0.51 ml, 6.62 mmol) and the solution is warmed to room temperature with stirring over the course of 1 hour. Dilute with EtOAc, wash with 1N HCl, brine, dry (Na<sub>2</sub>SW<sub>4</sub>), filtered and the solvent removed in vacuo to obtain the title compound (0.35 g, 1,673 mmol, 51%).
EXAMPLE 202B
R1S) -2-f (2S) -2-H4-f (2R, 5R) -5- (4 - {[(1 - ((2S) -2F (methoxycarbonyl) aminol-2-phenylacetylpyrrolidin-2¡ l) carbonamino) phenl) -1-f4- (trifluoromethyl) phenl1p¡rrolid¡n-2¡l) phen¡l) carbamo¡llp¡rrol¡d¡n-1-¡l Methyl) -2-oxo-1-phenylethylcarbamate
Example 198B (40 mg, 0.068 mmol) and Example 202A (35 mg, 0.169 mmol) are processed in the same manner as Example 199B to obtain the title compound (7.5 mg, 7.7 pmol, 11%).
<sup>1</sup>H NMR (400 MHz, CDCI<sub>3</sub>) δ ppm 1.76-2.05 (m, 8H) 2.432.58 (m, 4H) 3.18-3.29 (m, 2H) 3.57-3.65 (m, 2H) 3.67 (s, 6H) 4.824.86 (m, 2H) 5.18 (d, J = 6.9 Hz, 2H) 5.48 (d, J = 7.7 Hz, 2H) 5.99 (d,
649
IMPI
J = 7.7 Hz, 2H) 6.35 (d, J = 8.8 Hz, 2H) 7.11 (d, J = 8. ^ W ^ j ^ J = 8.7 Hz, 2H) 7.27-7.32 (m, 4H) 7.32-7.43 (m, 10H) 8.92 (s, 2HT MS (ESI) m / z 975 (M + H)<sup>+</sup>.
<img file="MX339989B_D1069.tif" />
<img file="MX339989B_D1070.tif" />
H2S) -3-methoxy-1 - ((2S) -2-R4-R2R, 5R) -5- (4- <r (1-R2S) -3-methoxy-2r (methoxycarbonyl) amino1-3-meth¡ lbutanoyl> pyrrolldin-2¡ Dcarbonillam ino) phenyl) -1 -í4- (trifluoromethyl) phenyl1pyrrolidin-2¡ Dfeni Dcarbamoi Dpi rrolidi n-1 -¡D-3-methyl 1-1-oxobutan-2¡ll methylcarbamate
EXAMPLE 203A
(S) - (tert-butoxycarbonylamino) -3-hydroxy-3-methylbutanoic acid
A solution of (S) -2-amino-3-hydroxy-3-methylbutanoic acid (252 mg, 1.89 mmol) in saturated sodium bicarbonate solution (6.3 ml) and tetrahydrofuran (6.3 ml) is treated with di-ter -butyl dicarbonate (764 mg, 3.50 mmol) followed by stirring at room temperature for 24 hours. The mixture is concentrated
650 ί · vacuum to remove tetrahydrofuran and hexanes. The aqueous phase is cooled to
IMPI the mix!
Dt INDUSTRIAL PROPERTY
0 ° C and acidifies to
<img file="MX339989B_D1071.tif" />
by adding 1 M citric acid solution. The mixture is extracted with ethyl acetate and the combined organic layers are dried (Na<sub>2</sub>SW<sub>4</sub>). Concentrating in vacuo makes it possible to obtain a gummy solid, which contains other impurities in addition to the desired product. This material is dissolved in ethyl acetate and the mixture is filtered through a millipore filter to remove undissolved material. The filtrate is concentrated in vacuo and after standing at room temperature for a week, it eventually solidifies to obtain the title compound as a white solid.
<sup>1</sup>H NMR (400 MHz, Methanol-d<sub>4</sub>) δ 4.08 (s, 1H), 1.45 (s, 9H), 1.29 (s, 3H), 1.25 (s, 3H).
MS (-ESI) m / z (rel abundance) 232 (100, MH).
EXAMPLE 203B
(S) -2- (tert-butoxycarbonylamino) -3-methoxy-3-methylbutanoic acid
To a solution of Example 203A (363 mg, 1.56 mmol) in THF (7 ml) at 0 ° C NaH (373 mg, 9.34 mmol) is added and stirring is continued for 15 minutes. Iodomethane (0.78 ml, 12.45 mmol) is added and the solution is allowed to warm to room temperature and is stirred for 18 hours. The solution is quenched with H<sub>2</sub>Or, dilute with EtOAc, wash with H<sub>2</sub>Or, brine, dries up
I (Na<sub>2</sub>SW<sub>4</sub>), it is filtered and the solvent is eliminated to obtain the compound
Μ-ia arrt „
651 of the title (165 mg, 0.67 mmol, 43%).
MS (ESI) m / z 248 (M + H)<sup>+</sup>.
IMPI
MEXICAN INSTITUTE OF INDUSTRIAL PROPERTY
<img file="MX339989B_D1072.tif" />
EXAMPLE 203C
(S) -3-Methoxy-2- (methoxycarbonylamino) -3-methylbutane acid
To a solution of Example 203B (163 mg, 0.66 mmol) in CH<sub>2</sub>CI<sub>2</sub> (2 ml) add trifluoroacetic acid (2 ml) and the solution is stirred at room temperature for 1 hour. The solvent is removed in vacuo and the residue is suspended in NaHCO<sub>3</sub> saturated, extracted with EtOAc, combined organic extracts, washed with brine, dried (Na<sub>2</sub>SW<sub>4</sub>), are filtered and the solvent is removed under vacuum. The residue is dissolved in dioxane (1 ml) and 1 M NaOH (1.1 ml, 2.175 mmol) is added followed by the dropwise addition of methyl chloroformate (0.102 ml, 1.3 mmol). The solution is stirred at room temperature for 16 hours, diluted with EtOAc, washed with 1N HCl, brine, dried (Na<sub>2</sub>SW<sub>4</sub>), filtered and the solvent is removed in vacuo to obtain the title compound (96 mg, 0.468 mmol, 71%).
EXAMPLE 203D f (2S) -3-methoxy-1-f (23) -2-f (4-ff2R.5R) -5- (4- <ni-ff2S) -3-methoxy-2r (methoxycarbon! l) am¡no1-3-met¡lbutano¡l) p¡rrol¡d¡n-2¡ Dcarboní II am ¡no) phenyl) -1-r4- (tr¡fluorometh¡l) fen¡H pyrrole ¡dín -2illphenyl Dcarbamoillpi rrolídin-1 -il) -3-methyl-1 -oxobutan-2652 methane ¿ge ¡Hcarbamate dm linden
IMPI
MEXICAN INSTITUTE OF INDUSTRIAL FROF'ÍDaD
<img file="MX339989B_D1073.tif" />
Example 198B (80.7 mg, 0.136 mmol) and Example 203C (70 mg, 0.341 mmol) are processed in the same manner as Example 199B to obtain the title compound (62 mg, 0.064 mmol, 47%).
<sup>1</sup>H NMR (400 MHz, CDCI<sub>3</sub>) δ ppm 1.25 (s, 3H) 1.33 (s, 3H)
1.39 (s, 2H) 1.74-1.82 (m, 2H) 1.89 (s, 2H) 1.93-2.16 (m, 5H) 2.382.59 (m, 4H) 3.16-3.27 (m, 2H) 3.24 (s, 3H) 3.43-3.56 (m, 2H) 3.69 (s, 3H) 3.71-3.78 (m, 2H) 3.80 (s, 3H) 3.84-3.94 (m, 1H) 4.61 (s, 1H) 4.70-4.81 (m, 2H) 5.15 (d, J = 6.3 Hz, 2H) 5.58 (s, 1H) 6.32 (d, J = 8.7 Hz, 2H) 7.05-7.13 (m, 4H) 7.19 (d, J = 8.7 Hz, 2H) 7.33-7.50 (m, 4H)
8.71 (s, 1H) 8.92 (s, 1H).
MS (ESI) m / z 967 (M + H) <sup>+</sup> .
<img file="MX339989B_D1074.tif" />
EXAMPLE 204 (R2S, 5S) -1 - (4-fluorophenyl ) pyrrolidin-2,5-di-llbisfbenzene-3,1-diylcarbamoyl (2S) pyrrolidin-2,1-di-ir (2S) -3-methyl-1-oxobutan-1,2-di653 dimethyl biscarbamate
AND
IMPI
INSTITUTO MEXLCa ^ O DÍ LA FRO-iEDAD INDUSTRlAL
<img file="MX339989B_D1075.tif" />
(R2R.5R) -1- (4-f luorofeni l) p¡ rrol¡d¡n-2,5-d ii ll bdrsíLmiiLeii'J.'l di »¡lcarbamo¡l (2S) p¡rrol¡d ¡N-2,1 -di-i lf (2S) -3-met¡ 1-1-oxobutan-1,2-d¡¡ Dimethyl HUbiscarbamate
EXAMPLE 204A (2S.2'S) -2.2 '- (3.3<sup>,</sup>- ((2S.5S) -1- (4-fluorophenyl) pyrrol¡d¡n-2,5-di¡l) b¡s (3,1-phenyl en)) bis tazan di-yl Ibis (oxom eti le n) d¡ pyrrolid i n-1 tert-butyl carboxylate
Y (2S, 2'S) -2.2 '- (3.3' - ((2R, 5R) -1- (4-fluorophenyl) pyrroled¡n-2,5-di Ubis (3.1 tert-butyl -phenylene-1) bis (azandi-yl) bis (oxomethylene) di-pyrrolidine-1 carboxylate
The ether fraction from the treatment of Example 55F is concentrated and purified by flash chromatography (silica gel, dichloromethane / EtOAc) to obtain the title compound as a mixture of trans diastereomers (0.20 g, 10%).
MS (ESI) m / z 742 (M + H)<sup>+</sup>.
EXAMPLE 204B (f (2S.5S) -1- (4-fluorophenyl) pyrrolidin-2,5-di-inbis (benzene-3,1-di¡ I carbam o¡ l (2S) pyrrolid ¡n-2,1 -di-i lf (2S) -3-m ethi 1-1-oxobutan-1,2-diillllbiscarbamate d dimethyl
654
IMPI
INSTITUTO MEXICANO DE LA I I. INDUSTRIAL PROPERTY
<img file="MX339989B_D1076.tif" />
(Í (2R, 5R) -1- (4-fluorophen ¡Dpi rroldin-2.5-di-ill bisIbenzene-3,1-diyl carbamoyl (2S) pyrrole ¡din-2,1-d¡-¡ir (2S Dimethyl) -3-meth¡ 1-1-oxobutan-1,2-diII D-biscarbamate
The product from Example 204A is processed using the method described in Examples 19D and 19E ((S) -2 (methoxycarbonylamino) -3-methylbutanoic acid is used) to obtain the title compounds (60.5 mg, 22%).
<sup>1</sup>H NMR (free base) (400 MHz, DMSO-D6) δ 0.99 - 0.81 (m, 12H), 1.67 (dd, J = 3.4, 5.0, 3H), 2.06 - 1.79 (m, 8H), 2.20 - 2.06 ( m, 5H), 3.52 (d, J = 2.3, 6H), 3.63 (q, J = 7.1, 1H), 3.88 - 3.75 (m, 1H), 4.08 - 3.96 (m, 2H), 4.41 (dt, J = 12.8, 25.2, 2H), 5.11 (d, J =
28.1, 2H), 6.24 (dd, J = 6.0, 10.9, 2H), 6.80 (td, J = 4.2, 8.9, 2H),
6.88 (dd, J = 5.5, 6.4, 2H), 7.22 (ddd, J = 5.3, 10.4, 20.8, 2H), 7.32 (d, J = 8.3, 2H), 7.43- 7.34 (m, 2H), 7.57 ( d, J = 7.8, 2H), 10.00 (d, J = 7.8, 2H).
MS (ESI) m / z 856 (M + H) +.
<img file="MX339989B_D1077.tif" />
*or
655
EXAMPLE 205 IMPI ——— INSTITUTE V.EXíCANO
DE LA ΓRO? ILDa0 (Í (2R, 5R) -1 -r4- (trifluorometh¡l) fen¡np¡ rrolidi n-2,5-d¡-¡llbísfbeñc
<img file="MX339989B_D1078.tif" />
Dimethyl 3,1 -d¡-¡lcarbamo¡l (2S) p¡rrol¡d¡n-2,1-d¡-¡ir (2S) -3-rñétll-1 -oXoputan1,2-di-illPbiscarbamate
EXAMPLE 205A (1S, 4S) -1,4-bis (3-n ¡troten ¡l) buta n-1,4-diol
The product from Example 55A is processed using the method described in Example 33 to obtain the title compound (1.74 g, 84%).
MS (DCI) m / z 350 (M + NH<sub>4</sub>)<sup>+</sup>.
EXAMPLE 205B (2R, 5R) -2,5-bis (3-nitrophenyl) -1 - (4- (trifluorometh, Dfen, Dpi rrolidine
The product from Example 205A and 4-amnobenzotrifluoride are processed using the method described in Examples 55C and 55D to obtain the title compound (0.27 g, 19%).
MS (ESI) m / z 858 (M + H)<sup>+</sup>.
EXAMPLE 205C
3,3 '- ((2R, 5R) -1- (4- (tr¡fluoromet¡Pfen¡ Dpi rrolidi n-2,5-d ¡-¡lidian ¡line
The product from Example 205B is processed using the method described in Example 55E. The title compound is isolated
656 by methanol / dichloromethane vaporization chromatography).
instant
<img file="MX339989B_D1079.tif" />
<img file="MX339989B_D1080.tif" />
MS (ESI) m / z 398 (M + H)<sup>+</sup>, 396 (MH)<sup>+</sup>.
EXAMPLE 205D (2S.2<sup>,</sup>S) -2.2 '- (3.3<sup>,</sup>- ((2R.5R) -1- (4-ftrifluorometh¡l) phenyl) p¡rrol¡din-2,5d i-¡l) b¡s (3,1-fen ilene)) bis (azand¡- ¡Ubis (oxomethi le n) d¡ tert-butyl pyrrole id i n-1 carboxylate
The product from Example 205C is processed using the method described in Example 19C replacing DMF with dichloromethane to obtain the title compound (0.36 g, 77%).
MS (ESI) m / z 792 (M + H +).
EXAMPLE 205E (f (2R, 5R) -1 -í4- (trifluoromethi Dfeni II pyrrole ¡di n-2,5-dl-yl) b¡sf benc n3,1 -d¡-¡Icar bamoll (2S) pyrrole Id ¡n-2,1 -di-llf (2S) -3-met¡ 1-1 -oxobutan1.2-di-illDimethiium biscarbamate
The product from Example 205D is processed using the method described in Examples 19D and 19E (using (S) -2 (methoxycarbonylamino) -3-methylbutanoic acid and replacing HATU with HOBt and EDC) to obtain the title compound (13.5 mg , 3%).
<sup>1</sup>H NMR (TFA salt) (400 MHz, METHANOL-D4) δ 1.08 0.89 (m, 12H), 1.88 - 1.73 (m, 2H), 2.32 - 1.93 (m, 10H), 2.62 (t, J =
6.9, 2H), 3.64 (s, 6H), 3.77-3.67 (m, 2H), 4.00-3.90 (m, 2H), 4.20
657 (d, J = 8.0, 2H), 4.56 - 4.45 (m, 2H), 5.26 (d, J = 6.5, = 8.8, 2H), 6.98 (d, J = 7.6, 2H), 7.17 (d, J = 7.4 7.8, 2H), 7.52-7.37 (m, 4H).
<img file="MX339989B_D1081.tif" />
2H), 7.27 (t, J =
MS (ESI) m / z 906 (M + H) <sup>+</sup> , 904 (MH)<sup>+</sup>.
F — ΗO
<img file="MX339989B_D1082.tif" />
EXAMPLE 206 (f (2R, 5S) -1-i4- (trifluorom ethyl phenyl pyrrolidi n-2,5-d ii Ubisfbenc n3,1-d¡-ylcarbamo¡l (2S) pyrrol¡d¡n-2.1 -di -iir (2S) -3-methyl-1-oxobutan-1,2-di-ill}) dimethyl b¡scarbamate
The product for Example 206 is isolated from the purification of Example 205E (12.5 mg, 3%).
<sup>1</sup>H NMR (TFA salt) (400 MHz, DMSO-D6) δ 0.90 (dt, J =
6.2, 10.3, 12H), 2.23 - 1.73 (m, 12H), 2.47 - 2.39 (m, 6H), 3.52 (d, J =
3.3, 4H), 3.89 - 3.73 (m, 2H), 4.03 (t, J = 8.4, 2H), 4.44 (dd, J = 4.9, 7.8, 2H), 4.83 (t, J = 5.5, 2H), 6.50 (d, J = 8.7, 2H), 7.36 - 7.15 (m,
6H), 7.39 (d, J = 8.7, 2H), 7.73-7.57 (m, 4H), 10.04 (d, J = 10.0, 2H).
658
MS (ESI) m / z 906 (M + H) <sup>+</sup> , 904 (MH)<sup>+</sup>
<img file="MX339989B_D1083.tif" />
MEXICAN INSTITUTE OF PROPERTY
INDUSTRIAL
<img file="MX339989B_D1084.tif" />
EXAMPLE 207 (Í (2S, 5S) -1 - (4-tert-but¡lfen¡l) p¡rrol¡din-2.5-di-yl1bisfpyr¡din-5,2-d¡ylcarbamo yl (2S) pyrrolidi dimethyl n-2,1-di-i lf (2S) -3-methy 1-1-oxobuta n-1,2-diylTPbiscarbamate
AND.
(i (2R, 5R) -1 - (4-tert-butylphenyl) pyrroled¡n-2,5-di-¡l1b¡s (pyridine-5,2-diylcarbam or ¡l (2S) p Dimethyl rrolidin-2,1-di-i ir (2S) -3-meth¡ 1-1-oxobuta n-1,2-di¡IIBbiscarbamate
EXAMPLE 207A
1,4-b¡s (6-chloropyridin-3-yl) butane-1,4-dione
Zinc chloride (3.04 g, 22.82 mmol), tert-butyl alcohol (1.576 ml, 16.71 mmol) and diethylamine (1.731 ml, 16.71 mmol) are combined in benzene (12 ml). The resulting suspension is stirred at room temperature for 2 hours until all the solid dissolves. To this suspension is added 1- (6-chloropyridine659
3-yl) ethanone (2.60 g, 16.71 mmol; reference: <sup>, N</sup>© Jt7p ^? Tn4c
I. NDUSTIUAI
IMPI
INDUSTJUM.
Medicine, Chemistry Leñera, 4998. 8, 3087-3092), followed by 2-
<img file="MX339989B_D1085.tif" />
Bromo-1- (6-chloropyridin-3-yl) ethanone (2.61 g, 11.14 mmol; reference: Bioorganic & Medicinal Chemistry Letters, 1998, 8, 30873092). The resulting light yellow solution is stirred at room temperature for 88 hours. The thick reaction mixture is treated with H<sub>2</sub>SW<sub>4</sub> 5% (10 ml), stir for 30 minutes, filter and dry to obtain the title compound (2.91 g, 85%) as a solid.
EXAMPLE 207B
1,4-bis (6-chloropyridin-3-ii) butan-1,4-diol
The product from Example 207A (2.90 g, 9.38 mmol) and sodium borohydride (0.745g, 19.70 mmol) are combined in ethanol (94 ml) at 0 ° C. The mixture is warmed to room temperature and stirred for 6 hours. The solvent is evaporated and the residue is partitioned between ethyl acetate and 1M HCl. The organic layer is washed with water, brine, dried over sodium sulfate, filtered and evaporated to obtain the title compound (2.62 g, 89%).
EXAMPLE 207C
1,4-bis (e-chloropyridin-3-yl) butan-1,4-di-yl dimethanesulfonate
The product of Example 207B (2.23 g, 7.12 mmol) and
660
<img file="MX339989B_D1086.tif" />
triethylamine (2.98 ml, 21.36 mmol) are combined e® JcMiigror
INSTITUTO MEXICANO TT DE LA I KOI IEDAD V (50 mi). The mixture is cooled to -20 ° C and '^ 0fSfttro methanesulfonyl (1,383 ml, 17.80 mmol) is added. The iiTezula was stirred at ·· room temperature for 1 hour. The solvent is evaporated to obtain the title product (approx. 3.34 g) which is used directly for the next reaction.
EXAMPLE 207D
5,5 '- (1 - (4-tert-butylphenyl) pyrrole idin-2,5-di-yl) bis (2-chloropyridine)
The product from Example 207C (3.34 g, 7.12 mmol) and 4-tert-butylaniline (6.38 g, 42.7 mmol) are combined in DMF (20 ml). The mixture is stirred at room temperature for 24 hours. The reaction mixture is partitioned between ethyl acetate and 1M HCl. The organic layer is washed with brine twice, dried over sodium sulfate, filtered, and evaporated. The residue is purified by chromatography on silica gel eluting with ethyl acetate / hexane (5% to 30%) to obtain the title compound (2.95 g, 97%) as a yellow solid as a mixture of stereoisomers.
EXAMPLE 207E ír (2S, 5S) -1- (4-tert-butyiphenyl) pyrrolidin-2,5-di-inbis (pyridin-5.2-diylcarbamoyl (2S) p¡rrolidin-2,1-di-¡ir ( Dimethyl 2S) -3-meth¡ 1-1 -oxobutan-1,2-di¡HDbiscarbamate
AND
661 (f (2R, 5R) -1 - (4-tert-butylphenyl) pyrrolidin-2,5-di-nb¡sEp ^^ p ^ z! -u «>.,.
. · Mexican institute w * - - ···
DE LA FROFIEDAD ¡lcarbamo¡H2S) p¡rrol¡d¡n-2J-d¡-iir (2S) -3-methyl-Í-oxobiOW-<sup>l</sup>f.2 Dimethyl biscarbamate ..........
<img file="MX339989B_D1087.tif" />
The product of Example 207D (0.171 g, 0.40 mmol), the product of Example 116C (0.326 g, 1,200 mmol), cesium carbonate (0.365 g, 1,120 mmol), tris (d¡benz¡l¡denacetone) d¡pallad ¡O (0) (0.022 g, 0.024 mmol) and (9,9-dimethyl-9H-xanthen-4,5-di¡l) bis (diphenylphosphine) (0.042 g, 0.072 mmol) are combined in dioxane (4 me). The mixture is purged with nitrogen for 15 minutes and stirred at 100 ° C for 3 hours. The reaction mixture is partitioned between ethyl acetate and saturated sodium bicarbonate. The organic layer is washed with brine, dried over sodium sulfate, filtered, and evaporated. The residue is purified by chromatography on silica gel eluting with methanol / dichloromethane (1% to 4%) to obtain the title compound (5 mg, 1%) as a mixture of trans diastereomers.
1H NMR (500 MHz, DMSO-D6) δ ppm 0.88 (t, J = 6.41 Hz, 6
H) 0.92 (t, J = 7.32 Hz, 6H) 1.12 (s, 9H) 1.68 - 1.75 (m, 2H) 1.81 20 1.99 (m, 8H) 2.07 - 2.18 (m, 2H) 2.50 - 2.53 (m, 2H) 3.52 (s, 6H)
3.57 - 3.64 (m, 2H) 3.78 - 3.86 (m, 2H) 3.98 - 4.03 (m, 2H) 4.55 4.63 (m, 2H) 5.27 (d, J = 6.26 Hz, 2H) 6.18 - 6.27 (m, 2H) 6.99 (dd,
J = 8.77, 1.60 Hz, 2 H) 7.28 - 7.37 (m, 2 H) 7.59 (dd, J = 8.62, 2.06 Hz,
H) 7.96 (d, J = 8.39 Hz, 2H) 8.12-8.20 (m, 2H) 10.53 (s, 2H).
MS (ESI +) m / z 896.6 (M + H) +.
662
<img file="MX339989B_D1088.tif" />
EXAMPLE 208 (R2S, 5S) -1-phenylpyrrolidin-2,5-di-811bisfbenzene-4,1-d¡¡lcarbamoyl (2S) pyrolidin-2,1-di-iir (2S) -3-methyl-1 dimethio-oxobutan-1,2-diyl biscarbamate
Ϊ.
(r (2R, 5R) -1-phenylpyrrolidin-2.5-di-inbisfbenzene-4.1-diylcarbam or l (2S) p¡rrolidin-2,1-di-yl (2S) -3-methi 1-1-oxobutan Dimethiium -1,2-diHHbiscarbamate
The title compound is isolated from Example 85C as an additional product.
1H NMR (TFA salt) (400 MHz, DMSO-D6) δ ppm 0.83 0.88 (m, 6H), 0.88 - 0.94 (m, 6H), 1.60 - 1.65 (m, 2H), 1.79 - 2.02 ( m, 8H), 2.06 - 2.18 (m, 2H), 3.51 (s, 6H), 3.55 - 3.64 (m, 2H), 3.75 - 3.83 (m, 2H), 4.01 (t, J = 8.3 Hz, 2 H), 4.38 - 4.43 (m, 2 H), 5.16 (d, J = 6.4 Hz, 2 H), 6.23 (d, J = 8.3 Hz, 2 H), 6.39 (t, J = 7.3 Hz, 1H), 6.90 (t, J = 7.9 Hz, 2H), 7.09 - 7.14 (m, 4H), 7.25 - 7.31 (m, 2H), 7.45 7.50 (m, 4H), 9.97 ( s, 2H).
MS m / z 838.4 (M + H)<sup>+</sup>.
663
<img file="MX339989B_D1089.tif" />
<img file="MX339989B_D1090.tif" />
ΙΜΡΙ
INSTITUTO MEXICANO DE LA l'RCHFDAD INDUSTRIAL
<img file="MX339989B_D1091.tif" />
EXAMPLE 209 ({(2S.5S1-1-M-trifluoro rom ethyl) fen¡ II pyrrolid ¡n-2,5-d ¡-¡Dbisfbencen4,1-di-ylcarbamoyl (2S) pyrrol¡din-2.1 -d Dimethyl ¡-¡ir (2S) -3,3-dimethyl-1-oxobutan-1,2-d¡-yl1)) biscarbamate
The product from Example 23C is separated by chiral chromatography on a Chiralpak AD-H semi-prep column eluting with 40% 2-PrOH: EtOH (1: 1) / 60% hexanes. The title compound is the first of the 2 components to elute.
1H NMR (400 MHz, DMSO-D6) δ ppm 0.97 (s, 18H), 1.61 - 1.73 (m, 2H), 1.75 - 1.93 (m, 4H), 1.94 - 2.06 (m, 2H), 2.08 - 2.21 (m, 2H), 3.54 (s, 6H), 3.57 - 3.70 (m, 2H), 3.70 - 3.83 (m, 2H), 4.21 (d, J = 8.89 Hz, 2H) , 4.38 - 4.48 (m, 2H), 5.27 (d, J = 6.51 Hz, 2H),
6.37 (d, J = 8.78 Hz, 2 H), 7.08 (d, J = 8.89 Hz, 2 H), 7.15 (d, J = 8.57 Hz, 4 H), 7.25 (d, J = 8.89 Hz, 2 H ), 7.52 (d, J = 8.57 Hz, 4H), 10.02 (s, 2H) ______
MS (ESI) m / z 951.6 (M + H)<sup>+</sup>.
664
<img file="MX339989B_D1092.tif" />
EXAMPLE 210 (f (2R, 5R) -1 -r4- (tr¡fluoromethinphen¡npyrrolid8n-2,5-di-yl) bisfbenzene4,1 -di-¡lcarbamoyl (2S) pyrrole idin-2,1-di- dimethyl yl f (2S) -3,3-di meth 1-oxobutan-1,2-di-ill)) biscarbamate
The product from Example 23C is separated by chiral chromatography on a Chiralpak AD-H semi-prep column eluting with 40% 2-PrOH: EtOH (1: 1) / 60% hexanes. The title compound is the second of the 2 components to elute.
1H NMR (400 MHz, DMSO-D6) δ ppm 0.96 (s, 18H), 1.64-1.75 (m, 2H), 1.76-1.93 (m, 4H), 1.94-2.06 (m, 2H), 2.07 - 2.21 (m, 2H), 3.54 (s, 6H), 3.58 - 3.70 (m, 2H), 3.70 - 3.86 (m, 2H), 4.20 (d, J = 8.89 Hz, 2H) , 4.38 - 4.47 (m, 2 H), 5.28 (d, J = 6.18 Hz, 2 H), 6.36 (d, J = 8.89 Hz, 2 H), 7.07 (d, J = 8.89 Hz, 2 H), 7.14 (d, J = 8.57 Hz, 4H), 7.25 (d, J = 8.78 Hz, 2H), 7.52 (d, J = 8.57 Hz, 4H), 10.03 (s, 2H).
MS (ESI) m / z 951.4 (M + H)<sup>+</sup>.
665
<img file="MX339989B_D1093.tif" />
EXAMPLE 211 (r (2R.5R) -1 - (4-f luorophenyl) p¡rrol ¡di n-2,5-d ii ilbis <benzene-4,1-diylcarbamoi l (2S) pyrrolidi n-2, Dimethyl 1-di-ir (2S, 3R) -3-methy 1-oxopentan-1,2di-ϊΠ D-biscarbamate
The product from Example 25 is separated by chiral chromatography on a semi-preparative AD-H Chiralpak column eluting with 50% 2-PrOH: EtOH (1: 1) / 50% hexanes. The title compound is the second of the 2 components to elute.
1H NMR (400 MHz, DMSO-D6) δ ppm 0.76 - 0.92 (m, 12H), 1.05 - 1.19 (m, 2H), 1.37 - 1.54 (m, 2H), 1.57 - 1.70 (m, 2H ), 1.69-1.96 (m, 6H), 1.94-2.07 (m, 2H), 2.07-2.22 (m, 2H), 3.53 (s, 6H), 3.55-3.64 (m, 2H), 3.69 - 3.83 (m, 2H), 4.17 - 4.28 (m, 2H), 4.42 (dd, J = 7.81, 5.20 Hz, 2H), 5.16 (d, J = 6.29 Hz, 2H), 6.20 ( dd, J = 9.22, 4.45 Hz, 2 H), 6.77 (t, J = 8.95 Hz, 2 H), 7.13 (d, J = 8.46 Hz, 4 H), 7.49 (d, J = 8.46 Hz, 2 H ), 9.97 (s, 2H).
MS (ESI) m / z 884.4 (M + H)<sup>+</sup>.
666
<img file="MX339989B_D1094.tif" />
EXAMPLE 212 (f (2R, 5R) -1- (4-fluorofert¡l) p¡rrolidi n-2.5-d¡-¡nb¡s (benzene-4,1-di¡ Ica rbamoyl (2S) pyrrole ¡ dimethyl di n-2,1-di-ili (2S.3S) -3-meth ¡1-1-oxopentan-1,2di-iylDbiscarbamate
The product from Example 24 is separated by chiral chromatography on a semi-preparative AD-H Chiralpak column eluting with 50% 2-PrOH: EtOH (1: 1) / 50% hexanes. The title compound is the second of the 2 components to elute.
1H NMR (400 MHz, DMSO-D6) δ ppm 0.80 (t, J = 7.37 Hz, 6 H), 0.88 (d, J = 6.72 Hz, 6 H), 1.02 - 1.18 (m, 2 H), 1.41 - 1.59 (m, 2H), 1.59 - 1.75 (m, 4H), 1.80 - 1.95 (m, 4H), 1.95 - 2.06 (m, 2H), 2.08 - 2.23 (m, 2H), 3.52 ( s, 6H), 3.56 - 3.67 (m, 2H), 3.74 - 3.89 (m, 2H), 4.07 (t, J = 8.95 Hz, 2H), 4.39 - 4.47 (m, 2H), 5.16 (d, J = 6.18 Hz, 2 H), 6.20 (dd, J = 9.22, 4.45 Hz, 2 H), 6.78 (t, J = 8.95 Hz, 2 H), 7.13 (d, J = 8.46 Hz, 4 H), 7.35 (d, J = 8.46 Hz, 2 H), 7.50 (d, J = 8.57 Hz, 4 H), 9.99 (s, two H).
MS (ESI) m / z 884.4 (M + H)<sup>+</sup>.
667
<img file="MX339989B_D1095.tif" />
<img file="MX339989B_D1096.tif" />
IMPI
INSTITUTO MEXICANO DE IA FROFIEDAD INDUSTRIAL
<img file="MX339989B_D1097.tif" />
EXAMPLE 213
N- (methoxycarbon¡l) -L-val¡lN- (4-r (2S.5S) -5- (4-aminophenyl) -1 - (4-t rbuti Ifen i llpyrrole ¡di n-2- illfenill-L-prol inamide
To a solution of the product of Example 37B (17.7 mg, 0.065 mmol) and the product of Example 37E (50 mg, 0.130 mmol) in anhydrous DMSO (1.3 ml), HATU (27.1 mg, 0.071 mmol) and Hunig's base ( 0.015 ml, 0.084 mmol). The resulting mixture is stirred at room temperature for 30 minutes, and then partitioned between H<sub>2</sub>O (5 ml) and EtOAc (3x5 ml). The combined organic layers are dried over Na<sub>2</sub>SW<sub>4</sub>. The drying agent is filtered off, and the solvent is removed under vacuum. The crude product is purified by silica gel column chromatography using a solvent gradient of 0-5% MeOH in CH<sub>2</sub>CI<sub>2</sub> to obtain the title compound (20 mg, 24%).
1H NMR (400 MHz, DMSO-D6) δ ppm 0.88 (d, J = 6.72 Hz,
H), 0.93 (d, J = 6.72 Hz, 3H), 1.11 (s, 9H), 1.52 - 1.66 (m, 2H),
1.79 - 2.06 (m, 4H), 2.06-2.20 (m, 1H), 2.34-2.47 (m, 2H), 3.52
668 (s, 3 Η), 3.56 - 3.67 (m, 1 Η), 3.74 - 3.87 (m, 1 Η), 4. (J p.J1
H), 4.42 (dd, J = 8.08, 4.83 Hz, 1 H), 4.83 - 4.94
INDUSTRIAL
<img file="MX339989B_D1098.tif" />
J = 7.16 Hz, 0.5 H), 5.08 (d, J = 7.59 Hz, 0.5 H), 6.18 (d, J = 8.78 Hz, 2 H), 6.48 (d, J = 8.35 Hz, 2 H), 6.84 ( d, J = 8.35 Hz, 2 H), 6.93 (d, J = 8.89 Hz, 2 H), 7.11 (d, J = 8.57 Hz, 2 H), 7.31 (d, J = 8.35 Hz, 1 H), 7.48 (d, J = 8.57 Hz, 2H), 9.97 (s, 1H).
MS (ESI) m / z 640.3 (M + H)<sup>+</sup>.
<img file="MX339989B_D1099.tif" />
EXAMPLE 214 (25.2<sup>.</sup>5) -1.1<sup>,</sup>- ((2S.2<sup>,</sup>S) -2.2 '- (4.4<sup>,</sup>- ((2R, 5R) -1- (4-tertbut¡Iphenyl) p¡rrol¡d¡ n-2.5-di-yl) b¡s (th¡azol-4,2-di-yl) bis (azand ¡¡L) b¡s (oxomethyl)) bis (p¡rrolidin-2,1-di-yl)) bis (3-methyl-1-oxobutan2.1- di-¡l) dimethyl d¡carbamate
Ϊ.
(25.2<sup>.</sup>5) -1,1<sup>,</sup>- ((2S, 2<sup>,</sup>S) -2.2<sup>,</sup>-(4.4<sup>,</sup>- ((2S<sub>1</sub>5S) -1- (4-tert-butylphenyl) p¡rrol¡din-2,5-di-yl) b¡s (thiazole-4,2-d¡-¡l) b¡s (azandiinbrs (oxymeton) ) dimethyl bis (prrrolidin-2,1-di-yin) bis (3-metn-T-oxobufan2.1-d¡-¡l) d¡carbamate
EXAMPLE 214A
669
- (4-tert-butylphenyl) pyrrolidine-2,5-dicarboxylate d_
SYLXICAN INSTITUTE OF FRCflEDAD
INDUSTRIAL
<img file="MX339989B_D1100.tif" />
<img file="MX339989B_D1101.tif" />
A solution of dletllü meso-2,5-dibromoadipatu (2.0 g, 5.55 mmol) and 4-tert-butylaniline (3.32 g, 22.22 mmol) in dimethoxyethane (12 ml) is stirred under reflux for 10 hours. The cold mixture is partitioned between EtOAc (100 mL) and 1N aqueous HCl (2 x 100 mL), and the organic layer is dried over Na<sub>2</sub>SW<sub>4</sub>. The drying agent is filtered off, and the solvent is removed under vacuum. The crude product is purified by silica gel column chromatography using a solvent gradient of 0-20% EtOAc in hexanes to obtain the title compound as an oil (1.95 g, quantitative).
1H NMR indicates a 3: 2 mixture of cis: trans pyrrolidine isomers.
EXAMPLE 214B
1 - (4-tert-butylpheni I) pyrolid i n-2,5-d icarboxylic acid i co
To a solution of the product of Example 214A (1.95 g,
5.61 mmol) in MeOH (50 ml) add a solution of NaOH (0.95 g, 23.8 mmol) in H<sub>2</sub>O (10 ml). The resulting mixture is stirred at room temperature overnight. The mixture is concentrated in vacuo to approximately 10 ml and poured into 1N HCl (50 ml). The mixture is extracted with CH<sub>2</sub>CI<sub>2</sub> (3 x 50 ml), and the combined organic layers are dried over Na<sub>2</sub>SW<sub>4</sub>. The drying agent is filtered, and the solvent is removed under vacuum to obtain the compound of the
670 »
title as a light orange solid (1.42 g, mixture of stereoisomers.
<img file="MX339989B_D1102.tif" />
EXAMPLE 214C
Trans-1 - (4-ter-b uti Ifeni Dpi rrolid i n-2.5-di carboxylic acid
The product of Example 214B is subjected to column chromatography on C18 silica gel using a solvent gradient of 10-60% acetonitrile in H<sub>2</sub>O (0.1% TFA). The title compound is the first of the 2 main components to elute.
EXAMPLE 214D
1,1 '- (trans-1 - (4-tert-butylpheni Dpi rrolid i n-2.5-di-Dbis (2-diazoethanone)
To a solution of the product of Example 214C (0.963 g, 3.31 mmol) in CH<sub>2</sub>CI<sub>2</sub> dry (20 ml) at 0 ° C, add oxalyl chloride (1.157 ml, 13.22 mmol), followed by 2-3 drops of DMF, and the resulting mixture is stirred at room temperature for 30 minutes until no bubbling is observed. The cold mixture is concentrated by evaporation with N<sub>2</sub> dry, and the residue is dissolved in CH<sub>2</sub>CI<sub>2</sub> dry (10 ml). To the solution at 0 ° C is added a solution of diazomethane in Et<sub>2</sub>O (~ 0.6 M, 20 ml) and the resulting mixture is stirred at 0 ° C for 1 hour. The mixture is concentrated in vacuo, and the crude product is purified by column chromatography with
671
I ^ Ví ΡI silica gel using a gradient of soIventertSsTí-déTMÍTrrWO'Sl ^ fe ^!
OF THE PROPERTY . INDUSTRIAL
EtOAc in hexanes to obtain the title compound (0.54 g,
48%).
EXAMPLE 214E
4,4 '- (trans-1- (4-tert-butyphenyl) pyrrolidin-2,5-di-yl) dithiazol-2-amine
A solution of the product of Example 214D (0.50 g, 1.47 mmol) in Et<sub>2</sub>O (10 ml) is drip-treated with 48% aqueous hydrogen bromide (0.500 ml, 4.42 mmol). The resulting mixture is stirred at room temperature for 30 minutes. Water (1 ml) is added, and the mixture is extracted with Et<sub>2</sub>O (3x10 ml). The combined organic layers are dried over Na<sub>2</sub>SW<sub>4</sub>, filtered, and concentrated in vacuo. The residue is dissolved in EtOH (15 ml). Thiourea (0.45 g, 5.89 mmol) is added to the resulting solution, and the resulting mixture is stirred at room temperature for 1 hour and then concentrated to about 1 ml. water (10 ml) is added, and the pH is neutralized using NaHCO<sub>3</sub> saturated aqueous. The resulting solid is collected by filtration and dried under vacuum to obtain the title compound (0.455 g, 77%).
EXAMPLE 214F (2S.2<sup>,</sup>S) -2.2<sup>,</sup>-f4.4<sup>,</sup>- (trans-1- (4-tert-but¡lfen¡l) p¡rrol¡d¡n-2,5-diyl) bis (thiazol-4.2-d¡-yl) bis (azandi-¡l) bis tert-butyl (oxomethyl)) dipyrrolidin-1 carboxylate
672
A mixture of the product of Example 2
<img file="MX339989B_D1103.tif" />
mmol), acid (S) -1- (tert-butoxycarbonyl) pyrrolidln-2 '-%<sup><</sup>áWOxiTf ^ (0.431 g, 2,002 mmol), and N1 - ((gt¡l¡m¡nü) inethylgn) hydrochloride N3, N3-dimethylpropan-1,3-diamine (1,151 g, 6.01 mmol) in DMF (4 ml) and pyridine (4 ml) are stirred at room temperature overnight. The mixture is partitioned between aqueous 1N HCl and EtOAc (3x), and the combined organic layers are dried over Na<sub>2</sub>SW<sub>4</sub>. The drying agent is filtered off, and the solvent is removed under vacuum. The crude product is purified by silica gel column chromatography using a solvent gradient of 0-100% EtOAc in hexanes to obtain the title compound (0.28 g, 71%) as a mixture of trans diastereomers.
EXAMPLE 214G (2S, 2'S) -1.1 '- ((2S, 2'S) -2.2<sup>,</sup>-(4,4<sup>,</sup>- ((2R, 5R) -1- (4-tert-butylphenyl) pyrrolidin-2.5-di-yl) bis (thiazol-4<sub>1</sub>Dimethyl 2-d¡-yl) bis (azandiyl) b¡s (oxomethylene)) bis (pyrrolidin-2.1-di-ii)) bis (3-methyl-1-oxobutan2,1-di-iDdicarbamate (2S , 2'S) -1,1 '- ((2S, 2'S) -2.2' - (4,4 '- ((2S.5S) -1- (4-terbuti Ifeni Dpirroi ¡di n-2,5-di- iDb isithiazole -4,2-di-i Ubis (azandi-
<img file="MX339989B_D1104.tif" />
Dimethyl 2,1-di-iPdicarbamate
A solution of the product from Example 214F is stirred in
673
2N HCl in dioxane (0.4 ml) for 1 hour then Js ^ Ji ^^ J
INSTITUTO MEXICANO empty. The residue is subjected to the procedure described 10 to obtain the title compound as a mixture of trans diastereomers.
<img file="MX339989B_D1105.tif" />
1H NMR (free base) (400 MHz, DMSO-D6) δ ppm 0.80 0.97 (m, 14 H), 1.12 - 1.16 (m, 9 H), 1.69 - 2.06 (m, 8 H), 2.08 - 2.22 (m , 2H), 3.51-3.57 (m, 6H), 3.57-368 (m, 2H), 3.77-3.91 (m, 2
H), 3.95 - 4.06 (m, 2H), 4.47 - 4.59 (m, J = 7.16 Hz, 1H), 5.08 - 5.17 (m, 2H), 6.31 (t, J = 8.24 Hz, 2H) , 6.70 (d, J = 21.04 Hz, 2H), 7.02 (dd, J = 8.67, 6.40 Hz, 2H), 7.35 (d, J = 8.35 Hz, 2H), 12.24 (s, 2H).
<img file="MX339989B_D1106.tif" />
EXAMPLE 215 (r3-bromo-1- (4-fluorophenyl) -1H-p¡rrole-2.5-di-¡nb¡sfbencen-4,1-d¡¡lcarbamoyl (2S) pyrolidi n-2,1 dimethiium -di-iir (2S) -3-meth¡ 1-1-oxobutan-1,2-di¡IIDbiscarbamate
To a suspension of the product of Example 51 (455 mg, 0.534 mmol) in CH<sub>2</sub>CI<sub>2</sub> (2.7 ml) add a mixture of 1bromopyrrole-2,5-dine (95 mg, 0.534 mmol) in CH<sub>2</sub>CI<sub>2</sub> (2.7 mi). The mixture is stirred overnight at room temperature then concentrated under reduced pressure and triturated with diethyl ether to
674 provide a mixture of compounds to be subjected
MEXICAN INSTITUTE
OF THE FlWiEDAO by means of reverse phase HPLC eluting with a 100% MeOH gradiefitlsPtite in 10 mM ammonium acetate "~ p<sup>,</sup>«=<sup>||,</sup>a ·· '· obtain οί title compound (84 mg, 17% yield).
<sup>1</sup>H NMR (free base) (400 MHz, DMSO-D6) δ 10.06 (s, 1H), 10.02 (s, 1H), 7.46 (d, J = 8.7, 2H), 7.41 (d, J = 8.7, 2H) , 7.30 (d, J = 7.7, 2H), 7.15 - 7.03 (m, 6H), 6.98 (d, J = 8.7, 2H), 6.53 (s, 1H), 4.45 - 4.33 (m, 2H), 4.01 ( t, J = 7.7, 2H), 3.85 - 3.73 (m, 2H), 3.66 - 3.54 (m, 2H), 3.51 (s, 6H), 2.20 - 2.05 (m, 2H), 2.03 - 1.77 (m, 8H ), 0.97 - 0.79 (m, 12H)
MS (ESI, M + H) m / z = 933
<img file="MX339989B_D1107.tif" />
EXAMPLE 216 (r3,4-dibromo-1- (4-fluorophenll) -1H-p¡rrole-2,5-d¡-¡Hbis {benzene-4.1di-ylcarbamoil (2S) pyrrolidin-2,1- di-ylf (2S) -3-methyl-1-oxobutan-1.2 -------------------------<sub>d</sub>_<sub>iin) b</sub> dimethyl iscarbamate
The title compound is formed as an additional product in Example 215. The product mixture is purified with reverse phase HPLC eluting with a gradient of
675 &
60-100% MeOH in 10 mM ammonium acetate title compound (125 mg, 23% yield)
<img file="MX339989B_D1108.tif" />
<sup>1</sup>H NMR (free base) (400 MHz, DMSO-D6) δ 10.08 (bs, 2H), 7.47 (d, J = 8.7, 4H), 7.33 - 7.27 (m, 2H), 7.13 - 7.01 (m, 8H) ,
4.43 - 4.35 (m, 2H), 4.01 (t, J = 8.4, 2H), 3.84 - 3.74 (m, 2H), 3.65 3.55 (m, 2H), 3.51 (s, 6H), 2.21 - 2.05 (m, 2H), 2.05 - 1.78 (m, 8H), 0.91 (d, J = 6.7, 6H), 0.86 (d, J = 6.6, 6H)
MS (ESI, M + H) m / z = 1011
<img file="MX339989B_D1109.tif" />
EXAMPLE 217
The title compound is formed as a by-product in Example 215. The product mixture is subjected to reverse phase HPLC purification eluting with a gradient of 60-100% MeOH in 10 mM ammonium acetate to obtain the thífulo compound. (61 mg, 12% yield) <sup>1</sup>H NMR (free base) (400 MHz, DMSO-D6) δ 10.00 (s,
2H), 7.41 (d, J = 8.7, 2H), 7.38 (d, J = 8.9, 2H), 7.29 (d, J = 6.6, 2H),
7.14 (d, J = 7.3, 1H), 7.11 - 7.05 (m, 3H), 7.01 - 6.93 (m, 2H), 6.89 (t,
J = 8.7, 2H), 4.37 (dd, J = 4.9, 7.4, 2H), 4.00 (t, J = 8.4, 2H), 3.84 676
3.74 (m, 2H), 3.64-3.55 (m, 2H), 3.51 (s, 6H), 2.19 IMW
INSTITUTO MEXICANO DELA i & Cf .'FOAD
<img file="MX339989B_D1110.tif" />
2.03 - 1.78 (m, 8H), 1.23 (s, 9H), 0.91 (dd, J = 2.1, 6.6, 6ΗΧ-Φ / 8-6
J = 6.4, 6H)
MS (ESI, M + H) m / z = 989
<img file="MX339989B_D1111.tif" />
or \
/
EXAMPLE 218 ((2S) -1-í (2S) -2-f4-f4-r4- (4-tert-butylphenyl) -5- (4- <2-r (2S) -1-f (2S ) -2f (methoxycarbonyl) amino1-3-methylbutanoyl} p¡rrol idi n-2-ill-1 H¡midazol-4-yl) phen¡ D-4H-1,2,4-tr¡azol-3 -¡L1phen¡l) -1 H-imidazol-2¡I) pyrrole idin-1 -i II-3-meth¡ 1-1-oxobutan-2-¡Rea rbam ato of methyl
EXAMPLE 218A
4-bromo-N '- (4-bromobenzol) benzoyl hydrazide
Equimolar amounts of 4-bromobenzohydrazide (1097 g, 5 mmol) and 4-bromobenzoyl chloride (1120 g, 5 mmol) are dissolved in anhydrous pyridine (25 ml) under nitrogen and heated under reflux (135 ° C oil bath) for 6 hours. Cool the reaction to room temperature, the mixture
677
<img file="MX339989B_D1112.tif" />
poured into absolute EtOH (100 ml), and cooled
OF THE CV PROPERTY overnight to obtain solid 'color-fela-nco' * crystals are collected by vacuum filtration, solid or washed with absolute EtOH (2x5 ml), and vacuum dried to obtain the compound of the titer as a white solid (953 mg, 48%).
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ ppm 7.75 (d, J = 8.57 Hz, 4H), 7.86 (d, J = 8.46 Hz, 4H), 10.63 (s, 2H).
MS (ESI-) m / z 395/397/399 (MH) - with two bromines.
EXAMPLE 218B
3,5-b¡s (4-bromophenyl) -4- (4-tert-butylphenyl) -4H-1,2,4-triazole
In an oven-dried 10 ml round bottom flask, equipped with a septum and purged with nitrogen, dissolve 4-terbutytaniline (450 mg, 3.01 mmol) in anhydrous 1,2-dichlorobenzene (1.5 ml) and the solution cools down to 0 ° C. A solution of phosphorus oxychloride (0.047 ml, 0.502 mmol) in anhydrous 1,2-dichlorobenzene (0.5 ml) is slowly added dropwise from a gas-tight syringe. After the addition is complete, remove the cooling bath and stir at room temperature for 1 hour to form the phosphoryltriamide in situ (the reaction becomes progressively cloudy). The product of Example 218A (200 mg, 0.502 mmol) is then added, the septum is replaced with a reflux condenser, and the reaction is heated in an oil bath at 200 ° C for 4 hours. The light brown solution is
678 cools to room temperature, then s
<img file="MX339989B_D1113.tif" />
freezer for 3 days and collect a white solid mg, by-product 4-bromo-N- (4-tert-butylphenyl) ben7'amide) and give it a vacuum filtration. The filtrate is treated with hexanes (-50 ml) and the cloudy solution is chilled in a freezer for 30 minutes. An off-white solid (73 mg) is collected by vacuum filtration and the filtrate is concentrated by rotary evaporation to a solution of product in 1,2-dichlorobenzene. The latter is purified by flash chromatography (silica gel, 3.8 cm x 15 cm bed, CH gradient<sub>2</sub>CI<sub>2</sub>, 20% EtOAc / CH<sub>2</sub>CI<sub>2</sub>, and 30% EtOAc / CH<sub>2</sub>CI<sub>2</sub>) to obtain the title compound as a fluffy white solid (154mg, 60%).
H NMR (400 MHz, CDCI<sub>3</sub>) δ ppm 1.36 (s, 9H), 7.06 (d,
J = 8.46 Hz, 2 H), 7.29 (d, J = 8.57 Hz, 4 H), 7.43 (d, J = 8.57 Hz, 4 H),
7.46 (d, J = 8.57 Hz, 2H).
MS (ESI +) m / z 510/512/514 (M + H)<sup>+</sup> with two bromines.
EXAMPLE 218C
4- (4-te r-butylphe ni l) -3,5-b¡s ((4 (4,4,5,5-tetramethyl 1-1,3,2-d ¡oxaborol n2-8l) fen8l) -4H-1,2,4-triazole
An oven-dried 25 ml round bottom flask, purged with nitrogen, is charged with the product of Example 218B (144.2 mg, 0.282 mmol), bis (pinacalate) diboron (215 mg, 0.846 mmol), potassium acetate (90 mg, 0.917 mmol), and dioxane
679 anhydrous (1.5 ml). The mixture is sprayed with
<img file="MX339989B_D1114.tif" />
minutes, add the complex 1,1'-bis (dfgO'q) ^^^^ palladium (ll) dichloromethane (23.03 mg, 0.028 mmol), sparge again with nitrogen for 5 minutes, the rubber septum is replaced with a glass stopper, and soaked in an oil bath (85 ° C) for 2 hours. The reaction is cooled to room temperature, filtered in vacuo through a small pad of Celite 545, the catalyst is washed thoroughly with CH2Cl2, and the filtrate is concentrated by rotary evaporation to a dark brown oil. Purify by flash chromatography (silica gel, Alltech Extract-Clean 10 g column, EtOAc / CH<sub>2</sub>CI<sub>2</sub> 1: 1) to obtain a dark beige solid (230 mg). Re-purify by flash chromatography (silica gel, Alltech Extract-Clean 10 g column, 3% MeOH / CH<sub>2</sub>CI<sub>2</sub>) eluting with to obtain the title compound as a beige solid (171 mg, 100%).
<sup>1</sup>H NMR (400 MHz, CDCI<sub>3</sub>) δ ppm 1.27 (s, 9H), 1.33 (s, 24H), 7.06 (d, J = 8.46 Hz, 2H), 7.38 - 7.47 (m, 6H), 7.71 (d, J = 7.92 Hz ,
H).
MS (ESI +) m / z 606 (M + H)<sup>+</sup>, 1211 (2M + H)<sup>+</sup>.
EXAMPLE 218D Í2S.2'S) -2.2 '- (4.4<sup>,</sup>- (4.4 '- (4- (4-tert-butylphenyl) -4H-1,2,4-triazole-3.5-diyl) bis (4,1-phenylene)) bis (1 H -im idazol-4,2-di-i l)) dipi rrolidi n-1 carboxylate dt r-butyl
680
F
A microwave tube purged with niti
<img file="MX339989B_D1115.tif" />
ml) is charged with the product of Example 218C mmol), the product of Example 26D (223 mg, Q_ZIlB_mmolesl. v a mixture of absolute EtOH (1.5 ml) and toluene (1.5 ml), then 1 M aqueous sodium carbonate is added (0.706 ml, 0.706 mmol) and the mixture was sparged with nitrogen for 20 minutes. Add the complex 1, r-bis (diphenylphosphino) ferrocene-palladium (ll) dichloride dichloromethane (23.07 mg, 0.028 mmol), sparge again with nitrogen for 5 minutes, the tube is sealed with an aluminum fold cap , and heated in a microwave reactor (Personal Chemistry Emrys Creator) with stirring at 100 ° C for 1 hour. The reaction is cooled to room temperature, the reaction is diluted in EtOAc (75 ml), washed with H<sub>2</sub>O (2 x 25 ml) and brine (25 ml), the organic phase is dried over MgSO<sub>4</sub> anhydrous, filtered, and concentrated by rotary evaporation to a yellow solid (330 mg). Purify by flash chromatography (silica gel, 3.8 cm x 15 cm, gradient of 4%, 6%, 8%, and 10% MeOH / CH<sub>2</sub>CI<sub>2</sub>) to obtain the title compound as a light yellow solid (135mg, 58%).
MS (ESI +) m / z 824 (M + H)<sup>+</sup>.
EXAMPLE 218E
4- (4-tert-butylphenyl) -3.5-b¡s (4- (2 - ((S) -pyrrol id¡n-2-yl) -1 H-imidazol-4yl) phenyl) - 4H-1,2,4-triazole
681
The product of Example- * 24-8® Λ1 $ -1 is dissolved <sup>one J r</sup> INSTITUTE MDW'O η ^ ** · * ^
From LA I-KO? JfcDAI> O «c * o« a
IN DUSTRIAL __
0.160 mmol) in CH<sub>2</sub>CI<sub>2</sub> anhydrous (2 ml) under nitrogen, add trifluoroacetic acid (1 ml, 12.85 mmol), and stir at -5 ° C for 30 minutes. The solvent is removed by rotary evaporation, the residue is dissolved in 20% PrOH / CHCI<sub>3</sub> (50 ml), wash with NaHCO<sub>3</sub> aqueous saturated (10 ml), the aqueous phase is extracted with 20% ¡PrOH / CHCb (2 x 25 ml), the combined organic extracts are dried over MgSO<sub>4</sub> anhydrous, filtered, and concentrated by rotary evaporation. The residue is dissolved in 1: 5 v / v CH2Cl2 / hexanes and concentrated in vacuo to obtain the title compound as a light tan solid (114 mg).
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ ppm 1.30 (s, 9H), 1.66 1.94 (m, 6H), 1.98 - 2.12 (m, 2H), 2.80 - 3.07 (m, 4H), 3.70 - 3.86 (m, 1H), 4.12 - 4.22 (m, 2H), 4.34 (d, J = 4.01 Hz, 1H), 7.34 (t, J = 8.08 Hz, 6H), 7.47 - 7.57 (m , 4H), 7.68 (d, J = 8.35Hz, 4H), 11.90 (s, 2H).
MS (ESI +) 624 (M + H)<sup>+</sup>; (ESI-) m / z 622 (MH) <->.
EXAMPLE 218F (((2S) -1-r (2S) -2- (4- (4-r4- (4-tert-butylphenih-5- (4- (2-í (2S) -1 - <(2S ) -2rtmethoxycarboni l) am¡no1-3-met¡lbutano¡l) p¡ rrol¡d¡n-2-¡Π-1Him¡dazol-4-¡l} phen¡l) -4H-1,2, 4-triazole-3-¡l1fenii) -1 H-imidazol-2¡l) p¡rrol¡d¡n-1-yn-3-methyl-1-oxobutan-2-¡l) methyl carbamate
In a 5 ml round bottom flask dried in the oven
682 • -Α. :
ΤΜΤΪ purged with nitrogen, the dWI product is dissolved
<img file="MX339989B_D1116.tif" />
mg, 0.080 mmol) in anhydrous DMF (1 ml), and (S) -2- (methoxycarbonylamino) -3-methylbutanoic acid (29.5 mg, 0.168 mmol), hydrated HOBt (27.6 mg, 0.180 mmol), EDAC are added sequentially (35.3 mg, 0.180 mmol), and N-methylmorpholine (0.035 ml, 0.321 mmol). The solution is stirred at 25 ° C for 15 hours. The reaction is diluted in EtOAc (50 ml), washed with NaHCO<sub>3 </sub>saturated aqueous (25 ml), H<sub>2</sub>O (3 x 25 ml), and brine (25 ml), the organic phase is dried over MgSO<sub>4</sub> anhydrous, filtered, and concentrated by rotary evaporation to an off-white solid (72 mg). Purify by flash chromatography (silica gel, Alltech Extract-Clean 10g column, 6% to 8% gradient MeOH / CH<sub>2</sub>Cl2) to obtain the title compound as an off-white solid (49mg, 65%).
<sup>1</sup>H NMR (400 MHz, DMSO-D6) δ ppm 0.82 (d, J = 6.72 Hz,
H), 0.86 (d, J = 6.72 Hz, 6H), 1.29 (s, 9H), 1.79 - 2.01 (m, 5H), 2.03 - 2.22 (m, 4H), 3.53 (s, 6H ), 3.70 - 3.86 (m, 4H), 4.04 (t, J = 8.35 Hz, 2H), 5.04 (dd, J = 6.67, 3.20 Hz, 2H), 7.23 - 7.43 (m, 8H),
7.48-7.60 (m, 4H), 7.61-7.73 (m, 4H), 11.77-12.21 (m, 2H).
MS (ESI +) m / z 939 (M + H)<sup>+</sup>.
683 tt £ EDtfiBfiS5 »í¿3a¿B
<img file="MX339989B_D1117.tif" />
EXAMPLE 219
IMPI
MEXICAN INSTITUTE OF INDUSTRIAL FRIDITY
<img file="MX339989B_D1118.tif" />
((2S) -1-f (2S) -2- (4- {4-f4- (4-cyclohexylphenyl-5- (4- (2-r (2S) -1-f (2S) -2r (methoxycarbonl) am¡nol-3-methylbutano¡l} pyrrol¡d¡n-2-¡H-1H¡mi dazol-4-¡Rphenyl) -4H-1,2,4-triazole- 3-illfeniD-1 H-imidazol-2¡l) p¡rrol¡d¡n-1-i Η-3-methyl-l-oxobutan-2-¡l) methyl carbamate
EXAMPLE 219A
3,5-b¡s (4-bromophenyl) -4- (4-cyclohex¡lfen¡l) -4H-1,2,4-triazole
In an oven-dried 10 ml round bottom flask, fitted with a septum and purged with nitrogen, 4-chlorhexylaniline (545 mg, 3.01 mmol) is dissolved in anhydrous 1,2-dichlorobenzene (1.5 ml) and the solution is cooled to 0 ° C. A solution of phosphorous oxychloride (78 mg, 0.502 mmol) in anhydrous 1,2-dichlorobenzene (0.5 ml) is slowly added dropwise from a gas-tight syringe. The reaction turns into a solid gel that cannot be shaken; the cooling bath is removed, additional 1,2-dichlorobenzene (0.5 ml) is added, the mixture is subjected to
684 sonic energy, and the thick suspension was adjusted for 1 hour to form phosphor # iafníd.a <Wo
Gave. THE INDUSTRIAL r.
ΪΜ / ϊ h & fcafl? Ttíi <a; cw} o,
Add the product of Example 218A (200 mg, 0.502 mmol), add
<img file="MX339989B_D1119.tif" />
replace the septum with a reflux condenser, and the reaction is heated in an oil bath at 200 ° C for 4 hours under nitrogen. The reaction rapidly turns to a homogeneous golden solution upon reflux. The solution is cooled to room temperature and purified by flash chromatography (silica gel, 3.8 cm x 15 cm, CH gradient<sub>2</sub>CI<sub>2</sub> to 20% EtOAc / CH<sub>2</sub>CI<sub>2</sub> up to 40% EtOAc / CH<sub>2</sub>CI<sub>2</sub>) to obtain the title compound as a fluffy white solid (201mg, 74%).
<sup>1</sup>H NMR (400 MHz, CDCI<sub>3</sub>) δ ppm 1.19 - 1.33 (m, 1H) 1.35 - 1.50 (m, 4H) 1.78 (d, J = 14.42 Hz, 1H) 1.84 - 1.98 (m, 4H) 2.51 2.65 (m, 1H) 7.04 (d, J = 8.35 Hz, 2H) 7.28 (d, J = 8.57 Hz, 6H) 7.43 (d, J = 8.57 Hz, 4H).
MS (ESI +) m / z 536/538540 (M + H) <sup>+</sup> , 1072/1074/1076 (2M + H)<sup>+</sup> with two bromines.
EXAMPLE 219B
4- (4-cyclohexylphenyl) -3,5-bis (4 (4,4,5.5-tetramethyl-1,3,2-dioxaboralan-2-¡l) phenyl) -4H- 1.2.4-triazole
One 10 ml round bottom flask dried in the oven,
685
<img file="MX339989B_D1120.tif" />
purged with nitrogen, charged with the product leJVÜW
WHITUTO MtXICA.fcU '* (100 mg, 0.186 mmol), bis (pinacalate) diboro mmol), potassium acetate (59.4 mg, 0.605 ro-moJes ^. And dipy.anQ ^. · Anhydrous (3 ml). The thick white mixture is sparged with nitrogen for 30 minutes, the complex 1,1'bis (diphenylphosphine) ferrocene-palladium (ll) dichloromethane (15.20 mg, 0.019 mmol) is added, it is returned to sparging with nitrogen for 5 minutes, the rubber septum is replaced with a glass stopper, and heated in an oil bath (85 ° C). The reaction becomes homogeneous on heating and darkens to a reddish brown over time. CCF (SiO<sub>2</sub>, 50% EtOAc / CH<sub>2</sub>CI<sub>2</sub>). After 2 hours, the reaction is cooled to room temperature, additional bis (pinacalate) diboron (71 mg, ~ 1.5 equiv) and potassium acetate (30 mg, -1.75 equiv) are added, and heated for 1 hour at 85 ° C. The brown reaction is cooled to room temperature, vacuum filtered through a small pad of Celite 545, the collected solids are washed thoroughly with CH<sub>2</sub>CI<sub>2</sub>, and the filtrate is concentrated by rotary evaporation to a brown foam. Purify by flash chromatography on silica gel (Alltech Extract-Clean column, 10 g bed) eluting with 30% EtOAc / CH<sub>2</sub>CI<sub>2</sub> to obtain the product as a light brown oil (190 mg). Re-purify by flash chromatography on silica gel (Alltech Extract-Clean column, 10 g bed) eluting with 3% MeOH / CH<sub>2</sub>CI<sub>2</sub> to get the compound
686 title as a light belge foam (122 rt | g £
MEXICAN INSTITUTE
MS (ESI +) m / z 632 (M + H)<sup>+</sup>, 1263 (2M + H)<sup>+</sup>.
<img file="MX339989B_D1121.tif" />
EXAMPLE 219C f (2S) -1-r (2S) -2- (4- <4-r4- (4-cyclohex¡lfenH) -5- (4- (2-r (2S) -1 - ((2S ) -2r (methoxycarbon¡l) amínol-3-meth¡lbutano¡l> p¡rrol¡d¡n-2-¡n-1Him¡dazol-4-yl) phen¡l) -4H-1, 2,4-tr¡azol-3-¡Hfen¡l) -1H-¡m¡dazol-2¡l) p¡rrol¡d¡n-1-¡l1-3-methyl-1-oxobutan- 2-¡l) methyl carbamate
A nitrogen purged microwave tube (size M, 5 ml) is charged with the product from Example 219B (118 mg, 0.187 mmol), the product from Example 126G (174 mg, 0.467 mmol), and a mixture of absolute EtOH ( 1 ml) and toluene (1 ml), then 1M aqueous sodium bicarbonate (0.467 ml, 0.467 mmol) is added and the mixture sparged with nitrogen for 20 minutes. Add the complex 1,1'-b¡s (d¡phenyphosphine) ferrocene-d¡palladium (ll) dichloromethane chloride (15.26 mg, 0.019 mmol), sparge again with nitrogen for 5 minutes, the tube is sealed with an aluminum fold-over cap, and heated in a microwave reactor (Personal Chemistry Emrys Creator) with stirring at 100 ° C for 1 hour. Cool the reaction to room temperature, dilute the reaction in EtOAc (50 mL), wash with H<sub>2</sub>O (2 x 25 ml) and brine (25 ml), the organic phase is dried over MgSO<sub>4</sub> anhydrous, filtered, and concentrated by rotary evaporation to a solid. Purify by flash chromatography (silica gel, gradient
687
<img file="MX339989B_D1122.tif" />
stepwise 5% to 8% to 10% MeOH / CH<sub>2</sub>CI<sub>2</sub>) pair.
as a tan solid (72 mg) which is major impurities). The impure product is diSDSn / S (1.5 ml of MeOH / DMSO 1: 1 v / v and purified by HPLC RP-C18 (Waters Prep LC, 40 mm module with Nova Pak HR C cartridge<sub>18</sub> 6 pm 40 x 100 mm Prep Pak) eluting with a 30 minute gradient of 95: 5 0.1% TFA in H2O / AcCN to 25:75 0.1% TFA in H<sub>2</sub>O / AcCN, then 10 minutes at 100% AcCN at 20 ml / minute. The pure fractions are concentrated by rotary evaporation (35 ° C water bath) to a small volume, partitioning between 20% of ¡PrOH / CHCb (50 ml) and NaHCO<sub>3</sub> saturated aqueous (15 ml), the layers are separated, the organic extract is dried over MgSO<sub>4</sub> anhydrous, filter, and concentrate by rotary evaporation to obtain the title compound as a white solid (34 mg, 19%)
H NMR (400 MHz, DMSO-D6) δ ppm 0.83 (d, J = 6.72 Hz,
H) 0.86 (d, J = 6.72 Hz, 6H) 1.29 - 1 47 (m, 5H) 1.65 - 2.01 (m, 12H) 2.04 - 2.21 (m, 4H) 3.53 (s, 6H) 3.72 - 3.84 (m, 4 H) 4.04 (t, J = 8.40 Hz, 2 H) 5.04 (dd, J = 6.89, 3 20 Hz, 2 H) 7.23 - 7.40 (m, 10 H)
7.51 - 7.72 (m, 6H) 11.84 (s, 2H),
MS (ESI +) m / z 965 (M + H)<sup>+</sup>
Examples 220-308 are prepared analogously in accordance with the methods and conditions illustrated in the following reaction schemes and examples.
688
<img file="MX339989B_D1123.tif" />
f (2S) -1-r (2S) -2- <5-r (2R, 5R) -1- (4-tert-butylphenyl) -5- (2-r (2S) -1-f ( 2S) -2Rmethoxycarbon¡l) am¡nol-3,3-dimethyl butano¡ l) pyrolidi n-2-¡11-1Hbenzimidazol-S-illpi rrolidi n-2-iyl-1H-benzimidazol-2-yl> pi rrolidi n-1 ¡ll-3,3-dimethyl-1-oxobutan-2-¡l) methyl carbamate <sup>1</sup>H NMR (400 MHz, DMSO-d6) δ ppm 0.88 (d, J = 13.55 Hz, 18H), 1.07 (s, 9H), 1.62 - 1.78 (m, 2H), 1.91 - 2.09 (m, 4 H), 2.10 2.26 (m, 4H), 2.54-262 (m, 2H), 3.55 (s, 6H), 3.74-3.90 (m, 4H),
4.23 (dd, J = 8.78, 4 55 Hz, 2 H), 5.09 - 5.23 (m, 2 H), 5.31 - 5.43 (m, 2 H), 6.26 (d, J = 8 89 Hz, 2 H), 6.84 - 6 97 (m, 2H), 7.06 (dd, J = 8.29,
2.55 Hz, 2 H), 7.12 (t, J = 9 43 Hz, 2 H), 7.20 (s, 1 H), 7.30 (s, 1 H),
7.38 (d, J = 8.24 Hz, 1 H) 7.45 (d, J = 8.24 Hz, 1 H), 12.02 (s, 2 H),
MS (ESI +) m / z 916 (M + H)<sup>+</sup>
689
<img file="MX339989B_D1124.tif" />
IMPI
INSTITUTO MEXiCA ^ O DE LA PRC'I icPaD INDUSTRIAL
<img file="MX339989B_D1125.tif" />
NH
<img file="MX339989B_D1126.tif" />
EXAMPLE 221 (R2R, 5R) -1 - (4-tert-butylphen8l) p¡rrolid¡n-2,5-d¡-¡Hb¡s {1Hbenc ¡m ¡dazol-5.2-d¡-¡l (2S ) pyrrolidi n-2,1-di-iir (2R) -1 -oxo-2-phenyl propan-1,2-di-l1)) dimethyl b¡scarbamate
1H NMR (400 MHz, DMSO-d6) δ ppm 1.03 - 1.10 (m, 9 H), 1 49 - 1.58 (m, 2 H), 1.67 (d, J = 16.70 Hz, 6 H), 1.70 - 1.95 ( m, 4H), 2.04 (s, 3H), 2.35-243 (m, 1H), 2 97-311 (m, 2H), 3 22-329 (m, 1H), 3.50 (s, 6H), 3 61 - 3.91 (m, 1H), 5.08 - 5.22 (m, 2H), 5.29 - 5.49 (m, 2H), 6.21 - 6.39 (m, 2H), 6.84 - 6.99 (m, 2H), 7.07-7.50 (m, 17H), 7.53 (d, J = 8.24 Hz, 1H), 7.61 (s, 2H), 12.10 (two s, 2H).
MS (ESI +) m / z 984 (M + H)<sup>+</sup>.
<img file="MX339989B_D1127.tif" />
690
IMPI idii
<img file="MX339989B_D1128.tif" />
EXAMPLE 222 (2R.2'R) -1.1 '- (í (2R, 5R) -1- (4-tert-butylphenyl) p¡ rroli d
ΙΚΟ'ΛΤΜΑΙ benzim ¡dazol-5.2-d¡-¡l (2S) p¡rrolid¡n-2,1 -di-ill) b¡s (2-am ¡no-2-phenylpropan-1 -one) <sup>1</sup>H NMR (400 MHz, DMSO-d6) δ ppm 1.10 (s, 9H), 1.55 1.66 (m, 3H), 1.68 - 1.82 (m, 4H), 1.83 - 2.02 (m, 5H), 1.93 (s, 6H),
2.12 - 2.31 (m, 3H), 2.57 (d, J = 3.90 Hz, 2H), 5.26 - 5.36 (m, 2H),
5.41 - 5.57 (m, 2 H), 6.30 (d, J = 8.78 Hz, 2 H), 6.93 (d, J = 8.78 Hz, 2
H), 7.17 - 7.31 (m, 2H), 7.38 (s, 2H), 7.47 - 7.66 (m, 13H), 8.43 (s,
H).
MS (ESI +) m / z 868 (M + H)<sup>+</sup>,
<img file="MX339989B_D1129.tif" />
EXAMPLE 223 {(2S.3R) -1-r (2S.4S) -2-f5-r (2R, 5R) -1- (4-tert-butylphenyl) -5- (2-f (2S.4S) 4-hydroxy-1-fN- (methoxycarbonyl) -0-methyl-L-threoniylpyrrolidin-2-¡l) 1 H-benzim idazol-5-yl) p¡ rrol idi n-2-¡11-1H-benzimidazole- 2-yl) -4-hydroxypyrrolidin-1-yl-3-m toxy-1-oxobutan-2-yl) carbamate d
691 methyl IMPI
INSTITUTE 'MEMORO »
DF INDUSTRIAL PROPERTY <sup>1</sup>H NMR (400 MHz, DMSO-d6) δ ppm 0.9gTO; -J ^ 5.9C-HZO'C H), 1.09 (s, 9 H), 1.74 (d, J = 5.64 Hz, 2 H), 2.06 - 2.15 (m, 3H), 2.96 3.03 (m, 1H), 3.10 (s, 6H), 3.55 (s, 6H), 3.72 (dd, J = 9.65, 2.39 Hz, 3H), 3.94 ( dd, J = 10.25, 4.72 Hz, 2 H), 4.23 - 4.33 (m, 2 H), 4.38 (t, J = 7.10 Hz, 1 H), 4.44 - 4.53 (m, 2 H), 5.26 (dd, J = 8.46, 4.23 Hz, 2 H),
5.49 (d, J = 5.53 Hz, 2 H), 6.25 (d, J = 8.78 Hz, 2 H), 6.94 (d, J = 8.78 Hz, 2 H), 7.22 (d, J = 8.46 Hz, 2 H ), 7.37 (d, J = 7.59 Hz, 2H), 7.46 (s, 2H), 7.69 (d, J = 7.92 Hz, 2H).
MS (ESI +) m / z 952 (M + H)<sup>+</sup>.
<img file="MX339989B_D1130.tif" />
<img file="MX339989B_D1131.tif" />
EXAMPLE 224 f (2S) -1-n2S) -2- (6-f (2R, 5R) -5-f2-I (2S) -1 - ((2S) -2r (methoxycarbonii) aminol-3-methylbutanoylpyrrolidine- 2-iH-1Hbenzimidazoi-5-ylI-1-r4- (1-methoxy-2-methylpropan-2ypheni Π pyrrol idi n-2-¡11-1 H-benzimidazoi-2-¡Dpi rrol id i n-1 -¡Ll-3-methi I1 -oxobutan-2-illcarbamate dm linden
692
1Η NMR (400 MHz, DMSO-D6) δ ppm 0 J
H) 1.04 (s, 6H) 1.69 (d, J = 4.34 Hz, 2H) 1.85 - 1.94'W, -
INDUSTRIAL
2.03 (m, 6H) 2.13 - 2.25 (m, 2H) 2.53 - 2.63 (m, 4H) 3.11 (s, 3H)
<img file="MX339989B_D1132.tif" />
3.53 (s, 6H) 3.81 (s, 4H) 4.05 - 4.15 (m, 2H) 5.09 - 5.19 (m, 2H)
5.32 - 5.41 (m, 2H) 6.25 (d, J = 8.78 Hz, 2H) 6.87 (ddd, J = 8.89, 4.77,
4.55 Hz, 2H) 7.07 (t, J = 7.37 Hz, 2H) 7.20 (s, 1H) 7.25 - 7.33 (m, 3H) 7.38 (d, J = 8.24 Hz, 1H) 7.46 (d, J = 8.46 Hz, 1H) 12.00-12.09 (m, 2H).
MS ESI + 918.
<img file="MX339989B_D1133.tif" />
EXAMPLE 225 {(2S) -1 -r (2S) -2- (6-r (2R, 5R) -1--4- (1-hydroxy-2-methylpropan-2-yl) phen n5- (2-í (2S) -1 - ((2S) -2-r (methoxycarbonl) am¡nob3methlbutanoyl) p¡rrolid¡n-2-ill-1 H-benzimidazole-5- methyl yl) pyrrolidin-2-iH1H-benzimidazol-2-¡Hp¡ rrolidin-1-yl-3-methyl-1-oxobutan-2¡Dcarbamate
1H NMR (400 MHz, DMSO-D6) d ppm 0.76 - 0.91 (m, 12
693
Η) 1.01 (d, J = 2.60 Hz, 6 H) 1.64 - 1.72 (m, 2 H) 1.9j $$ Ρΐ} ·
MEXICAN INSTITUTE
6.83 Hz, 2H) 1.95 - 2.05 (m, 4H) 2.14 - 2.23 (m, 4H) 2.g4<sup>TO</sup>, «W8 2 H) 3.53 (s, 6 H) 3.76 - 3.87 (m, 4 H) 4.11 (q,. · = <77 Ητ zu) / | (s, 1 Η) 5.09 - 5.17 (m, 2 Η) 5.31 - 5.40 (m, 2 Η) 6.25 (d, J = 8.78 Hz, 2 H) 6.83 - 6.92 (m, 2 H) 7.07 (t, J = 7.21 Hz, 2H) 7.20 (s, 1H) 7.26 7.32 (m, 3H) 7.38 (d, J = 8.13 Hz, 1H) 7.46 (d, J = 8.35 Hz, 1H) 11.99 - 12.06 ( m, 2H).
MS ESI + m / z 904.5 (M + H) +.
<img file="MX339989B_D1134.tif" />
<img file="MX339989B_D1135.tif" />
f (2S) -1-R2S) -2-f6-H2R.5R) -5- (2-H2S) -1 - ((2S) -2r (methoxycarbonyl) am¡nol-3-met¡lbutano¡l) pyrrolidi n-2-¡11-1Hbenzim¡dazol-5-iD-1 -f2-r4- (tr¡fluoromethyl) phenyl1-1,3-th¡azol-5¡ Dpi rrolidi η-2-i Π -1 H-benz¡m¡dazol-2-¡Dpi rrolidi n-1-i H-3-met¡ 1-1oxobutan-2-¡P-methyl carbamate
1H NMR (400 MHz, DMSO-D6) d ppm 0.73 - 0.91 (m, 12
694
Η) 1.79 - 1.95 (m, 4 Η) 1.96 - 2.06 (m, 4 Η) 2.15 - 2.27
<img file="MX339989B_D1136.tif" />
2.76 (m, 2 Η) 3.43 - 3.50 (m, 2 Η) 3.53 (s, 6 Η) 3.78 - 3 ^ 88¾ ^ H? 4.01 - 4.10 (m, 2 Η) 5.11 - 5.18 (m, 2 Η) 5.32 - 5.41 (ιττ, -2 Η) 0.4S * '(s ,, · 1 Η) 7.09 - 7.18 (m, 2 Η) 7.27 (dd, J = 8.24, 2.39 Hz, 2 Η) 7.35 (s, 1 Η)
7.41 - 7.46 (m, 2 Η) 7.51 (d, J = 8.35 Hz, 1H) 7.57 - 7.62 (m, 2H) 7.64 - 7.70 (m, 2H) 12.12 (s, 2H).
MS ESI + m / z 983.4 (M + H) +
EXAMPLE 227
R2S) -1-r (2S) -2-f6-r (2R, 5R) -1- (4-tert-butyl-2,6-d¡met¡lfen¡l) -5- {2R2S1-1 - f (2S 1-2-R-methoxycarbo ni Dam i nol-3-methyl butanoi Dpi rroii din2-i D-1 H-benzim idazoi-5-¡Dpi rrol ¡di n-2-¡11-1 H-benzim idazoi- Methyl 2yl) p¡rrolidin-1 -yl 1-3-methyl-1-oxobutan-2-iDcarbamate
1H NMR (400 MHz, DMSO-D6) d ppm 0.77 - 0.89 (m, 12
H) 1.02 (s, 9H) 1.84 - 2.05 (m, 10H) 2.13 - 2.19 (m, 4H) 2.24 - 2.30 (m, 6H) 3.53 (s, 6H) 3.80 (s, 4H) 4.04 (t, J = 8.O8 Hz, 2H) 5.07 5.14 (m, 2H) 5.25 (s, 2H) 6.61 (dd, J = 5.10, 2.71 Hz, 2H) 7.06 (dd,
695
J = 11.87, 8.51 Hz, 2H) 7.20 - 7.37 (m, 6H)
H).
<img file="MX339989B_D1137.tif" />
MS ESI + m / z 916.6 (M + H) +.
<img file="MX339989B_D1138.tif" />
EXAMPLE 228
H2S) -1-r (2S) -2-f6-r (2R.5R) -5-f2-r (2S) -1-phi2S) -2rimethoxy rbon i Dam i nol-3-methi Ibutanoi Dpi rrolid in 2-¡H-1 Hbenzimidazol-5-iD-1- (4-phenylcyclohexyDpyrrolidin-2-iH-1Hbe n cim i dazol-2-i Dpi rrolidin-1 -i II-3-methi 1-1-oxobutan -2¡P methyl carbamate
1H NMR (400 MHz, DMSO-D6) d ppm 0.78 - 0.93 (m, 12H) 1.15 - 1.44 (m, 4H) 1.46 - 1.59 (m, 2H) 1.67 - 1.78 (m, 2H) 1.84 1.96 (m, 4H) 1.98 - 2.10 (m, 4H) 2.14 - 2.27 (m, 4H) 2.67 - 2.75 (m, 2H) 3.07 - 3.21 (m, 1H) 3.45 - 3.52 (m, 1H ) 3.54 (s, 6H) 3.78 - 3.91 (m, 4H) 4.03 - 4.13 (m, 2H) 4.64 - 4.73 (m, 2H) 5.17 (d, J = 4.88 Hz, 2H) 7.00 - 7.06 (m, 2H) 7.09 (t, J = 7.32 Hz, 2H) 7.14 - 7.24 (m, 3H)
7.30 (d, J = 8.46 Hz, 2 H) 7.38 (d, J = 8.02 Hz, 1 H) 7.43 - 7.50 (m, 3 H)
696
<img file="MX339989B_D1139.tif" />
EXAMPLE 229 f (2SM-r (2S) -2- (6-f (2R, 5R) -5-f2-H2S) -1 - {(2S) -2Fimmethoxy carbon ¡l) am¡no1-3-methylbutane¡ l> p¡ rrol id in-2-ΙΠ-Ι Hbenzim¡dazol-5-yl) -1-Γ4- (tetrahydro-2H-pyran-4-yl) fen¡np¡rrol¡d¡n-2il Methyl) -1 H-benzimidazol-2-yl) pyrroiidin-1 -ϊΠ-3-methyl-l-oxobutan-2 yl carbamate
1H NMR (400 MHz, DMSO-D6) d ppm 0.73 - 0.94 (m, 12H) 1.41 - 1.60 (m, 6H) 1.65 - 1.75 (m, 2H) 1.86 - 1.94 (m, 2H) 1.95 2.05 (m, 4H) 2.14-2.24 (m, 4H) 2.37-2.46 (m, 2H) 3.53 (s, 6H)
3.77 - 3.86 (m, 7H) 4.02 - 4.10 (m, 2H) 5.09 - 5.17 (m, 2H) 5.32 5.39 (m, 2H) 6.26 (d, J = 8.67 Hz, 2H) 6.72 - 6.81 (m, 2H) 7.06 (t, J = 7.64 Hz, 2H) 7.20 (s, 1H) 7.26 - 7.31 (m, 3H) 7.37 (d, J = 8.13 Hz, 1H) 7.45 (d, J = 8.13 Hz, 1H) 12.00-12.05 (m, 2H).
MS ESLD + m / z 917 (M + H) +.
697
IMPI
<img file="MX339989B_D1140.tif" />
EXAMPLE 230
<img file="MX339989B_D1141.tif" />
<img file="MX339989B_D1142.tif" />
f (2S) -1 -F (2S, 4S) -2-f6-R2R, 5R) -1 - (4-tert-butHfenll) -5-í2-F (2S, 4S) -4h¡drox¡-1 -f (2S) -2-Rmethox¡carbon¡l) am¡noT-3met¡lbutane¡l1p¡rrolid¡n-2-iH-1H-benzim¡dazol-5-yl> p¡rrol¡din-2- methyl in1H-benzimidazol-2-iD-4-hydroxypyrrolidin-1-¡Π-3-methyl-l-oxobutan-yl) carbamate
1H NMR (500 MHz, DMSO-D6) d ppm 0.67 - 0.91 (m, 12H) 1.07 (s, 9H) 1.69 (d, J = 3.97 Hz, 2H) 1.78 - 1.89 (m, 2H) 2.01 (d, J = 13.12 Hz, 2H) 2.37 - 2.44 (m, 2H) 3.53 (s, 6H) 3.67 (d, J = 10.07 Hz, 2H) 3.95 - 4.07 (m, 4H) 4.38 ( s, 2H) 5.12 (s, 2H) 5.37 (s, 2H)
6.25 (d, J = 8.54 Hz, 2H) 6.34 (s, 2H) 6.86 - 6.94 (m, 2H) 7.09 (d, J = 7.93 Hz, 2H) 7.22 - 7.33 (m, 4H) 7.39 - 7.51 (m, 2H) 12.27 (d, J = 21.05 Hz, 2H).
MS ESLD + m / z 920.
698
<img file="MX339989B_D1143.tif" />
EXAMPLE 231 {(2S) -1-H2S) -2- <6-r (2R, 5R) -1- (1,3-benzod¡oxol-5-¡l) -5- {2-r (2S) -1f (2S) -2-r (methoxycarbonyl) ann¡no1-3-methylbutane¡Dp¡rrolidin-2-ill-1 Hbenzimidazol-5-¡Dpi rrol ¡di η-2-i 11-1 H-benzim idazole Methyl -2-¡l) p¡rrolid¡ n-1 ill-3-methyl-1-oxobutan-2-¡Dcarbamate
1H NMR (400 MHz, DMSO-D6) d ppm 0.78 - 0.91 (m, 12H) 1.64 - 1.72 (m, 2H) 1.86 - 2.04 (m, 6H) 2.14 - 2.24 (m, 4H) 3.29 ( s, 2H) 3.54 (s, 6H) 3.82 (s, 4H) 4.05 - 4.11 (m, 2H) 5.10 - 5.18 (m, 2H) 5.29 - 5.36 (m, 2H) 5.66 (d, J = 2.93 Hz, 1H) 5.70 - 5.75 (m, 2H)
5.99 (d, J = 2.28 Hz, 1H) 6.45 - 6.51 (m, 1H) 7.02 - 7.09 (m, 2H) 7.21 (s, 1H) 7.28 (s, 1H) 7.31 (d, J = 6.40 Hz, 2H) 7.37 (d, J = 8.13 Hz, 1H) 7.45 (d, J = 8.24 Hz, 1H) 12.03 (s, 2H).
MS TFA + m / z 876.8 (M + H) +.
699
<img file="MX339989B_D1144.tif" />
EXAMPLE 232 f (2S) -1-H2S) -2-f6-r (2R.5R) -542-r (2S) -1-í (2S) -2f (methoxycarbon¡l) amino1-3-methylbutane¡l ) p¡rrolid¡n-2-¡ll-1Hbenz¡midazol-5-¡l) -1- (4-fr (4S) -2-oxo-1,3-oxazolidin-4ill methi Ufen ¡Dpyrroli di n- Methyl 2-yl1-1 H-benzim i dazol-2-iR pyrrole idin-1 -¡Π-3-methyl-1-oxobutan-2-incarbamate
1H NMR (400 MHz, DMSO-D6) d ppm 0.77 - 0.92 (m, 12H) 1.63 - 1.74 (m, 2H) 1.86 - 2.04 (m, 6H) 2.13 - 2.26 (m, 4H) 2.55 2.65 (m, 2H) 3.25 - 3.33 (m, 2H) 3.54 (s, 6H) 3.75 - 3.87 (m, 6H) 4.05 - 4.17 (m, 3H) 5.09 - 5.19 (m, 2H) 5.36 (d, J = 5.10 Hz, 2H) 6.27 (d, J = 8.57 Hz, 2H) 6.71 - 6.79 (m, 2H) 7.05 (t, J = 9.60 Hz, 2H) 7.20 (s, 1H ) 7.27 - 7.33 (m, 3H) 7.37 (d, J = 8.24 Hz, 1H) 7.45 (d, J = 8.13 Hz, 1H) 7.63 (s, 1H) 12.03 (s, 2H).
MS ESI + m / z 931.5 (M + H) +.
700
<img file="MX339989B_D1145.tif" />
EXAMPLE 233 {(2S) -1-f (2S) -2- (6 - {(2R.5R) -542-n2SM-n2S) -2 yimethoxycarbon ¡Dam ¡nol-3-met¡lbutane ¡Dpi rrol ¡din- 2-ÍI1-1Hbenzim ¡dazol-5-¡R-1-r4- (propan-2-¡loxpfen¡H pyrrole id ¡n-2-yl) -1Hbenzim idazol-2-i Dpi rrol ¡di n-1 - methyl yl] -3-methy 1-1-oxobutan-2iDcarbamate
1H NMR (400 MHz, DMSO-D6) d ppm 0.76 - 0.89 (m, 12 H) 1.07 (t, J = 5.42 Hz, 6 H) 1.68 (d, J = 3.47 Hz, 2 H) 1.85 - 2.05 (m , 6H) 2.14 - 2.25 (m, 4H) 2.58 (d, J = 4.77 Hz, 2H) 3.53 (s, 6H) 3.81 (s, 4H) 4.05 (t, J = 8.40 Hz, 2H ) 4.13 - 4.25 (m, 1H) 5.08 - 5.20 (m, 2H)
5.32 (d, J = 5.31 Hz, 2 H) 6.23 (d, J = 9.00 Hz, 2 H) 6.45 - 6.55 (m, 2 H)
7.05 (t, J = 8.19 Hz, 2H) 7.20 (s, 1H) 7.26 - 7.33 (m, 3H) 7.37 (d, J = 8.24 Hz, 1H) 7.44 (d, J = 8.35 Hz, 1 H) 12.02 (d, J = 4.55 Hz, 2H).
MS ESI + m / z 890.4 (M + H) +.
701
<img file="MX339989B_D1146.tif" />
EXAMPLE 234 ((2S) -1-H2S) -2- (5-H2R, 5RM-r2- (4-fliophenin-1,3-thiazol-5-yl1-5- {2f (2S) -1- ((2S) -2-r (methoxycarbonyl) aminoT-3-methylbutanoyl1pyrrolidin2-ÍI1-1 H-benc¡m¡dazol-5-¡l) pyrrol¡d¡n-2-¡n-1 H-benzimidazol-2Π1βΐτΓθΙϊάίιν1ύ1ΐ £ 3 ^ τ »βυΐχ1 ^ 2ςοάυΐ3η222Η1θ3ΐ ^ 3 ^ η3ΐο_έΙβ_ΓηβΙΗο
1H NMR (400 MHz, DMSO-D6) d ppm 0.75 - 0.85 (m, 12H) 1.77 - 1.83 (m, 2H) 1.87 - 1.93 (m, 2H) 1.95 - 2.06 (m, 4H) 2.14 2.25 (m, 6H) 3.53 (s, 6H) 3.77 - 3.86 (m, 4H) 4.03 - 4.10 (m, 2H)
5.12 - 5.18 (m, 2H) 5.28 - 5.35 (m, 2H) 7.06 - 7.16 (m, 5H) 7.28 (dd, J = 8.29, 2.01 Hz, 2H) 7.33 (s, 1H) 7.40 - 7.45 (m, 2H) 7.47 7.55 (m, 3H) 12.10 (s, 2H).
MS ESI + m / z 933.4 (M + H) +.
MeWí'Ws!
702
<img file="MX339989B_D1147.tif" />
EXAMPLE 235 <(2S) -1-r (2S) -2- (5 - ((2R, 5R) -5- (2-r (2S) -1-f (2S) -2Rmethoxycarbonyl) amino1-3 -methylbutanoyl) pyrrolidin-2-¡n-1 Hbenz¡m¡dazol-5-yl) -1- [4- (tr¡fl uoromethoxypheni Π pyrrolidi n-2-¡l) -1 Hbenzimidazole Methyl -2-yl) pyrrol¡d¡n-1-ill-3-methyl-1-oxobutan-2¡Dcarbamate
1H NMR (400 MHz, DMSO-D6) d ppm 0.74 - 0.87 (m, 12
H) 1.67-1.76 (m, 2H) 1.86-1.92 (m, 2H) 1.96-2.06 (m, 4H) 2.15 2.23 (m, 6H) 3.53 (s, 6H) 3.77-3.88 (m, 4 H) 4.05 (t, J = 8.84 Hz, 2
H) 5.12 (t, J = 7.05 Hz, 2 H) 5.37 - 5.46 (m, 2 H) 6.34 (d, J = 9.11 Hz, 2
H) 6.89 (q, J = 7.30 Hz, 2 H) 7.02 - 7.11 (m, 2 H) 7.21 (s, 1 H) 7.26 7.33 (m, 3 H) 7.39 (d, J = 8.35 Hz, 1 H) 7.47 (d, J = 8.13 Hz, 1H) 12.06 (d, J = 17.02 Hz, 2H).
MS ESI + m / z 916.4 (M + H) +.
703
<img file="MX339989B_D1148.tif" />
IMPI
INSTITUTO MEXICANO Dt LA H'OHÍCaD INDUSTRIAL
<img file="MX339989B_D1149.tif" />
EXAMPLE 236 {(2S) -1-H2S, 4S) -2- (5-r (2R, 5R) -1- (4-tert-but¡lfen¡l) -5- (2-r (2S, 4S ) -4methoxy-1-f (2S) -2-r (methoxycarbonyl) am¡noT-3methyl butano¡l) pyrrol¡din-2-¡H-1 H-benzim idazol-5-yl> p¡rrol idin- Methyl 2-ill1 H-benzim idazoi-2-yl> -4-methoxy pyrrole idin-1-ill-3-methyl-1-oxobutan-iHcarbamate
1H NMR (400 MHz, DMSO-D6) d ppm 0.75 - 0.88 (m, 12
H) 1.07 (s, 9H) 1.67 - 1.76 (m, 2H) 1.88 - 2.00 (m, 4H) 2.06 - 2.16 (m, 2H) 3.12 - 3.21 (m, 2H) 3.25 (d, J = 4.23 Hz, 6H) 3.54 (s, 6H) 3.59 - 3.69 (m, 2H) 4.02 - 4.13 (m, 4H) 4.16 - 4.28 (m, 2H) 5.11 (td, J = 9.38, 6.51 Hz, 2H) 5.35 (t, J = 5.37 Hz, 2H) 6.23 - 6.28 (m, 2H)
6.90 (d, J = 8.89 Hz, 2 H) 7.06 (d, J = 10.19 Hz, 2 H) 7.22 (d, J = 3.25 Hz, 1 H) 7.25 - 7.32 (m, 3 H) 7.38 (d, J = 8.35 Hz, 1H) 7.45 (d, J = 8.24 Hz, 1H) 11.79 (d, J = 18.32 Hz, 2H).
MS ESI + m / z 948.5 (M + H) +.
704
IMPI
<img file="MX339989B_D1150.tif" />
INSTITUTO MEXICANO Dt LA? ROP'EDaD indüstiual
<img file="MX339989B_D1151.tif" />
EXAMPLE 237 ((2SI-1 -r (2S} -2- (5-H2R, 5R) -I -r2.5-difluoro-4- (trifluoromethyl) phenyl-5 (2-r (2S) -1- { (2S) -2-f (methoxycarbonyl) amino1-3-methylbutane¡np¡rrol¡d¡n-2-¡n-1 H-benzim ¡dazol-5-¡l) pyrrol¡d¡n-2-¡ H1 H-benzim idazol-2-i Dpi rrolidi n-1-yl-3-m ethyl-1-oxobutan-2 yl carbamate
1H NMR (400 MHz, DMSO-D6) d ppm 0.74 - 0.90 (m, 12
H) 1.74-1.83 (m, 2H) 1.86-193 (m, 2H) 1.94-2.05 (m, 4H) 2.13 2.25 (m, 4H) 3.44-3.48 (m, 2H) 3.53 (s, 6H) 3.77 - 3.88 (m, 4H) 4.06 (t, J = 4.23 Hz, 2H) 5.10 - 5.16 (m, 2H) 5.63 - 5.74 (m, 2H) 6.60 - 6.73 (m, 1H ) 7.04 - 7.20 (m, 4 H) 7.24 - 7.31 (m, 3 H) 7.38 (d, J = 8.46 Hz, 1 H) 7.46 (d, J = 8.13 Hz, 1 H) 12.08 (d, J = 27.11 Hz, 2H).
MS ESI + m / z 936.4 (M + H) +.
705
<img file="MX339989B_D1152.tif" />
EXAMPLE 238
H2S) -1-H2S) -2-f6-H2R, 5R) -1-r3-fluoro-4- (trifluoromethyl) phenin-5- {2r (2S) -1-R2S) -2-f (methoxycarbon8l) am¡no1-3-methylbutanoin pyrrolidi n2-ΙΙΊ-1 H-benz¡m¡dazol-5-yl) pyrrolidin-2-ill-1 H-benzimidazol-2¡l) p¡rrolidin-1-ill -3-methyl-1-oxobutan-2-yl> methyl carbamate
1H NMR (400 MHz, DMSO-D6) d ppm 0.75 - 0.90 (m, 12H) 1.71 - 1.79 (m, 2H) 1.87 - 1.95 (m, 2H) 1.97 - 2.04 (m, 4H) 2.13 2.25 (m, 6H) 3.53 (s, 6H) 3.77 - 3.86 (m, 4H) 4.04 - 4.11 (m, 2H)
5.11 - 5.18 (m, 2H) 5.46 - 5.56 (m, 2H) 6.24 (dd, J = 8.24, 2.39 Hz, 2H) 7.04 - 7.11 (m, 2H) 7.19 - 7.25 (m, 2H) 7.28 (dd, J = 8.46, 3.69 Hz, 2 H) 7.32 (s, 1 H) 7.41 (d, J = 8.13 Hz, 1 H) 7.49 (d, J = 8.24 Hz, 1 H) 12.09 (dd, J = 15.72, 2.17 Hz, 2H).
MS ESI + m / z 918.4 (M + H) +.
706
<img file="MX339989B_D1153.tif" />
EXAMPLE 239 f (2S) -1-F (2S) -2-f6-r (2R, 5R) -1- (4-cyanophenyl) -5-f2-r (2S) -1-n2S) -2r (methoxycarbonyl ) amino1-3-methylbutanoyl) pyrrol¡din-2-ill-1 Hbenzim¡dazol-5-¡l) p¡rrol¡din-2-in-1 H-benz¡m¡dazol-2-yl) pyrrolidin- Methyl 1ill-3-methy 1-1-oxobutan-2-ihcarbamate
1H NMR (400 MHz, DMSO-D6) d ppm 0.76 - 0.90 (m, 12H) 1.70 - 1.79 (m, 2H) 1.90 (dd, J = 12.25, 6.40 Hz, 2H) 1.95 - 2.02 (m, 4H) 2.15 - 2.24 (m, 6H) 3.54 (s, 6H) 3.78 - 3.85 (m, 4H) 4.06 (t, J = 8.29 Hz, 2H) 5.10 - 5.16 (m, 2H) 5.46 - 5.55 (m, 2H) 6.42 (d, J = 8.67 Hz, 2H) 7.05 (dd, J = 12.90, 8.57 Hz, 2H) 7.22 (s, 1H) 7.25 7.34 (m, 5H) 7.40 (d, J = 8.24 Hz, 1H) 7.47 (d, J = 8.24 Hz, 1H) 12.09 (s, 2H).
MS ESI + m / z 857.4 (M + H) +.
707
<img file="MX339989B_D1154.tif" />
Í (2S) -1 -H2S) -2- {6-r (2R, 5R) -1 -í4- (2-cyanopropan-2-¡l) fen¡ll-5- (2f (2S) -1- ((2S) -2-r (methoxycarbon¡l) am¡no1-3-met¡lbutano¡l) p¡rrol¡din2-ÍI1-1 H-benz¡m¡mdazol-5-yl} p¡ rrol¡d¡n-2-¡ll-1 H-benzimldazol-2¡l) p¡rrol¡din-1-iH-3-methyl-1-oxobutan-2-¡l} methyl carbamate
1H NMR (400 MHz, DMSO-D6) d ppm 0.75 - 0.91 (m, 12H) 1 47 (s, 6H) 1.67 - 1.76 (m, 2H) 1.85 - 1.95 (m, 2H) 1.96 - 2.03 (m, 4H) 2.15 - 2.24 (m, 6H) 3.53 (s, 6H) 3.77 - 3.85 (m, 4H) 4.05 (t, J = 8.46 Hz, 2H) 5.10 - 5.17 (m, 2 H) 5.37 - 5.45 (m, 2 H) 6.34 (d, J = 8 89 Hz, 2 H) 6 97 - 7.04 (m, 2 H) 7.07 (t, J = 8.35 Hz, 2 H) 7.21 (s, 1 HOUR)
7.28 (d, J = IO 52 Hz, 3 H) 7.39 (d, J = 8.13 Hz, 1 H) 7.47 (d, J = 8.24 Hz, 1 H) 12.05 (d, J = 13.01 Hz, 2 H),
MS ESI + m / z 899 4 (M + H) +.
708
<img file="MX339989B_D1155.tif" />
EXAMPLE 241 f (2S) -1-r (2S) -2-f6-r (2R.5R) -1- (4-cyano-3-fluorophenyl) -5-f2-r (2S) -1 {(2S ) -2-r (methoxycarbonyl) amino 1-3-methylbutanoyl) pyrrolidin-2-ill-1Hbenzimidazol-5-ii) pyrrolidi n-2-iH-1H-benzimidazol-2-yl> pyrrol idi methyl n-111-3-methyl-1-oxobutan-2-¡l) carbamate
1H NMR (400 MHz, DMSO-D6) d ppm 0.74 - 0.92 (m, 12H) 1.74 (t, J = 9.00 Hz, 2H) 1.87 - 1.94 (m, 2H) 1.96 - 2.06 (m, 4H )
2.15 - 2.25 (m, 4H) 2.55 - 2 63 (m, 2H) 3.54 (s, 6H) 3.82 (s, 4H)
4.06 (t, J = 8.40 Hz, 2 H) 5.14 (d, J = 2.28 Hz, 2 H) 5 55 (dd, J = 16.26,
6.07 Hz, 2H) 6.18 - 6.33 (m, 2H) 7.01 - 7.15 (m, 2H) 7.23 (s, 1H)
7.25 - 7.35 (m, 4 H) 7.42 (d, J = 7.70 Hz, 1 H) 7.49 (d, J = 8.46 Hz, 1 H)
12.10 (s, 2H),
MS ESI + m / z 875.4 (M + H) +.
709
<img file="MX339989B_D1156.tif" />
EXAMPLE 242 ((2S) -1-H2S) -2-f6-r <2R, 5R) -1- (2,2-d¡fluoro-1,3-benzodioxol-5-yl) -5 (2-F (2S) -1 -f (2S) -2-r (methoxycarbonyl) am¡nol-3-methylbutano¡l) p¡rrol¡din-2-ill-1 H-benzimidazol-5-yl) p¡ rrol¡d¡n-2-iH1 H-benz¡m¡dazol-2-¡l) p¡rrol¡d¡n-1-¡Π-3-methyl-l-oxobutan-2iDcarbamate of methyl
1H NMR (400 MHz, DMSO-D6) d ppm 0.75 - 0.91 (m, 12H) 1.69 - 1.77 (m, 2H) 1.91 (dd, J = 14.26, 6.67 Hz, 2H) 1.96 - 2.07 (m, 4 H) 2.14 - 2.24 (m, 4 H) 2.54 - 2 60 (m, 2 H) 3.53 (s, 6 H) 3.78 3.86 (m, 4 H) 4.06 (t, J = 8.40 Hz, 2 H) 5.10 - 5.17 (m, 2H) 5.36 - 5.44 (m, 2H) 6.05 (dd, J = 9 11, 2.17 Hz, 1 H) 6.29 (d, J = 2 60 Hz, 1 H) 6.89 - 6 95 ( m, 1 H) 7.06 (t, J = 8.51 Hz, 2 H) 7.22 (s, 1 H) 7.26 - 7.33 (m, 3 H) 7.39 (d, J = 8.35 Hz, 1 H) 7.47 (d, J = 7.59 Hz, 1H) 12.03 - 12.09 (m, 2H),
MS ESI + m / z 912 8 (M + H) +.
710
<img file="MX339989B_D1157.tif" />
EXAMPLE 243 f (2S) -1-r (2S) -2- (6-r (2R, 5R) -1 -r4- (1-amino-2-methiipropan-2-¡l) phenyl5- (2-r (2S) -1 - ((2S) -2-Rmethox¡carbon¡l) am¡nol-3methylbutane8npyrrolidin-2-8H-1H-benz¡midazol-5-yl) pyrrol¡d¡n-2-in1 H- benzimidazol-2-yl) p¡rrolidi n-1 -yl1-3-methii-1 -oxobutan-2yl methyl carbamate
1H NMR (400 MHz, DMSO-D6) d ppm 0.74 - 0.92 (m, 12H) 1.01 (d, J = 5.20 Hz, 6H) 1.65 - 1.76 (m, 2H) 1.86 - 1.93 (m, 2H )
1.98 (d, J = 4.01 Hz, 4H) 2.13 - 2.25 (m, 4H) 2.41 (s, 2H) 2.53 - 2.61 (m, 2H) 3.53 (s, 6H) 3.81 (s, 4H ) 4.05 (t, J = 8.35 Hz, 2 H) 5.08 20 5.17 (m, 2 H) 5.32 - 5.41 (m, 2 H) 6.27 (d, J = 8.89 Hz, 2 H) 6.81 - 6.92 (m, 2 H) 7.07 (t, J = 7.97 Hz, 2H) 7.20 (s, 1H) 7.25 - 7.32 (m, 3H)
7.38 (d, J = 8.13 Hz, 1H) 7.46 (d, J = 8.13 Hz, 1H) 12.02 (d, J = 19.63 Hz, 2H).
MS ESI + m / z 903 4 (M + H) + taa ^ ar,?. 711
<img file="MX339989B_D1158.tif" />
EXAMPLE 244 (2-f4-H2R, 5R) -2- {2-n2SM-n2S) -2-r (methoxycarbonl) amnol-3methyl butanoi Dpi rroli di η-2-i 11-1 H -benzimidazol-5-yl) -5- {2-r (2S) -1 ((2S) -2-F (methoxycarbonii) amino1-3-methylbutanoii) pyrrol¡d¡n-2-¡n-1Hbenzimidazol-6 -il) p¡rrolidin-1-amphenyl) -2-methylpropyl-carbamate
1H NMR (400 MHz, DMSO-D6) d ppm 0.75 - 0.91 (m, 12H) 1.00 (d, J = 6.07 Hz, 6H) 1.64 - 1.75 (m, 2H) 1.83 - 1.94 (m, 2H )
1.96 - 2.05 (m, 4H) 2.14 - 2.23 (m, 4H) 2.89 - 3.00 (m, 2H) 3.17 (d, J = 5.20 Hz, 2H) 3.42 (s, 3H) 3.53 (s, 6H) 3.77 - 3.87 (m, 4H) 3.99 4.07 (m, 2H) 5.08 - 5.20 (m, 2H) 5.32 - 5.42 (m, 2H) 6.27 (d, J = 8.46 Hz, 2H) 6.72 - 6.80 (m, 1H) 6.83 - 6.93 (m, 2H) 7.07 (t, J = 8.62 Hz, 2H) 7.20 (s, 1H) 7.26 - 7.33 (m, 3H) 7.38 (d, J = 8.13 Hz, 1H) 7.45 (d, J = 8.57 Hz, 1H) 12.03 (d, J = 12.36 Hz, 2H).
MS ESI + m / z 961.4 (M + H) +
712
-ΊΚΛΜΊΤΪί
<img file="MX339989B_D1159.tif" />
EXAMPLE 245 n2S) -1-r (2S) -2-f5-r (2R.5R) -1-r3-fluoro-4- (piper¡din-1-yl) phenyl1-5- <2T (2S) - 1 - {(2S) -2-f (methoxycarbon¡l) am¡nol-3-methylbutano¡l) p¡rrol¡d¡n2-II1-1 H-benz¡m¡dazoi-5-¡l } p¡rrol¡d¡n-2-¡H-1 H-benzimidazol-2¡l) p¡rrol¡d¡n-1-¡Π-3-methyl-l-oxobutan-2-¡Hcarbamate of methyl
MS (ESI) m / z 934 (M + H)<sup>+</sup>
<img file="MX339989B_D1160.tif" />
EXAMPLE 246 f (2S) -1-H2S) -2- (5-H2R, 5R) -1-r4- (1,1-dioxidothlomorpholin-4-¡l) -3713. •, 74 ^ 5 * 4 ' <sup>Χ</sup>Μ • '' Ίά
ΜΕΧICANO INSTITUTE fluorofenll1-5- {2-í (2S) -1 - ((2S) -2-Hrnetoxycarboni ν '
INSTITUTO MEXICANO met¡lbutano¡l) p¡rrolid¡n-2-¡n-1 H-benzim idazol-5-¡l) p¡ rPoU <íism¿-¡
H-benzimidazol-2-¡l) pyrrolldin-1 -¡H-3-methyl-1 ^ q / nhntan-2 ^ ¡Methyl ucarbamate
<img file="MX339989B_D1161.tif" />
EXAMPLE 247
Í (2S) -1 -r (2S) -2-f5-R2R.5R) -1 -r3-fluoro-4- (4-methylp¡perld¡n-1yl) phenyl-5-f2-r (2S) -1 -f (2S) -2-r (methox¡carbon¡l) am¡nol-3met¡lbutane¡npyrrolidin-2-¡n-1H-benz¡m¡mdazol-5-¡l> p¡rrolid¡ n-2-¡11H-benzimidazole-2-H> p¡rrolidi n-1-I Π-3-metll-l-oxobutan-2¡Ucarbamate methyl
MS (ESI) m / z 948 (M + H)
714 £ 31ü¡
<img file="MX339989B_D1162.tif" />
EXAMPLE 248 f (2S) -1-H2S) -2- (6-f (5R) -5- (2-n2S) -1-f (2S) -2r (methoxycarbonl) amno1-3 -methylbutane) p¡rrol¡d¡n-2-¡n-1 Hbenzim8dazol-5-yl> -1-r4- (tr¡cyclor3.3.1.1 ~ 3.7 ~ 1dec-1¡l) fen Hpyrrol¡d¡n-2-¡l) -1 H-benz¡m¡dazol-2-¡Upyrrol¡din-1-ill-3-methyl1-oxobutan-2-¡l) methyl carbamate + ESI m / z (relative abundance) 967 (100, M + H)
<img file="MX339989B_D1163.tif" />
715
EXAMPLE 249
IMPI
INSTITUTO MEXICANO Γ € LA
<img file="MX339989B_D1164.tif" />
f (2S) -1-R2S) -2- {6-H2R, 5R) -1-r4- (azepan-1-iP-3-fluorophenyl-5- {2Γί2β) -1 - ((2S) -2- f (methoxycarbonl) amno1-3-methilbuianoyl} pyrrolidin2-II1-1 H-benzimidazol-5-i Dpi rrolid in-2-yl1-1 H-benzim idazol-2¡Dpyrrolidin- Methyl 1-iD-3-methyl-1-oxobutan-2-iDcarbamate + ESI m / z (rel abundance) 948 (100, M + H)
EXAMPLE 250 {(2S, 3R) -1-r (2, S) -2- (6-n2R.5R) -1- (4-tert-but¡lfen¡l) -5- (2-R2S) - 1-rN (methoxycarboniD-O-methyl-L-threoniDpyrrolidin-2-iD-1Hbenz¡m¡dazol-6-¡Dpi rrolidi n-2-¡11-1 H-benzim ¡dazol-2-¡Dp¡ rrolidi n Methyl -1 yl 1-3-methoxy-1-oxobutan-2-D-carbamate
MS (ESI) m / z 920 (M + H) <sup>+</sup>.
716
<img file="MX339989B_D1165.tif" />
EXAMPLE 251 ((2S) -1-í (2S) -2-f 6-r (2R, 5R) -1- (4-cyclopropyl-2-f luorofen i 1) -5- (2f (2S) -1 -f (2S) -2-í (methox¡carbon¡l) am¡noT-3-met¡lbutanoinpyrrolid¡n2-ÍH-1 H-benzimidazol-6-i II pyrrole ¡di η-2-i Π- 1 H-benzim idazol-2-yl) p¡rrol¡din-1-¡H-3-methyl-1-oxobutan-2-¡l) methyl carbamate
MS (ESJ) m / z 890 (M + H) +
<img file="MX339989B_D1166.tif" />
EXAMPLE 252
R2S) -1 - {(2S) -2- [4- (3- (5- (3- {2-r (2S) -1 - <(2S) -2F (methoxycarbonyl) amino1-3-mt ¡Lbutanoyl) pyrrol¡d¡n-2-yl1-1 H717 ** · «·; í '. * ¡M¡dazol-4-¡l> f nil) -1-Γ6- (ρίρ r¡din-1 -¡L) p¡r¡din-3-¡tl-liÍ-A4rJ 'INSTITUTO MEXICANO DE LA Fí; C'! -; EDaO i Ufen ¡l) -1 H-¡m¡dazol-2-¡l1p¡ rrol¡d¡n-1-¡l) -3-methyl-1-oxobuf & n-2¡Ucarbamate methyl ——- MS (ESI; M + H) m / z = 964.5.
<img file="MX339989B_D1167.tif" />
<img file="MX339989B_D1168.tif" />
nmethoxycarbon¡l) amino1-3-met¡lbutano¡l} pyrroledin-2-¡H-1 Hbenz¡m¡dazol-6-¡l) -1- (4-r (2-methox¡et¡l ) (methyl) am¡ nolfeniRpyrrolidi n2-II1-1 H-benz¡m¡dazol-2-¡l} p¡rrol¡d¡n-1-¡Π-3-methyl-l-oxobutan-2¡Dcarbamate of methyl
MS (ESI; M + H) m / z = 919.4
718
<img file="MX339989B_D1169.tif" />
EXAMPLE 254 f (2S, 3R) -1 -r (2S) -2- (6-R2S, 5S) -1 - (4-tert-butylphenyl) -5- (2-R2S) -1 -ΓΝ (methox¡ carbon¡l) -O-methyllL-threon¡np¡rrolidi n-2-8l) -1 Hbenc¡mdazol-6-¡l) p¡rrol¡d¡ n-2-¡H-1 H -benzimidazol-2-¡l) p¡rrolidi n-1 ¡Π-3-methoxy-l-oxobutan-2-¡l) methyl carbamate
<img file="MX339989B_D1170.tif" />
R2S) -1- (2- (5-R2R, 5R) -5-r2- (14 (2S) -2-Rm toxycarbonl) amnol-3719
<img file="MX339989B_D1171.tif" />
mt¡lbutanoyl) p¡rrolid¡n-2-yl) -1 Hb ncimidazol- sI'MtPtT MEXICAN INSTITUTE OF PROPERTY (piperidin-1-¡l) ethox¡lfen¡l1pyrrol¡d¡n-2-¡ll-1 H-benzimtda ^ l ^ ZilÍpi rrol idi n-1 -il) -3-methyl-1 -oxobutan-2-¡llcarbam »tQ-do-me4Ho-
<img file="MX339989B_D1172.tif" />
EXAMPLE 256 ((2S) -1-r (2S) -2-5-H2R, 5R) -1-r3-chloro-4- (p8peridin-1-¡l) phenyl-5- <2R2S) -1 - ((2S) -2-í (methoxycarboni ham inol-3-methi Ibutanoi i) pyrolidin2-ΪΠ-1 H-benz¡m¡dazol-5-¡l) p¡rrolid¡n-2-¡H -1 H-benz¡m ¡dazol-2-yl) pyrroiidin-1 -¡Π-3-methyl-l-oxobutan-2-yl> methyl carbamate (ESI +) m / z 949.5 (M + H) +
720
<img file="MX339989B_D1173.tif" />
EXAMPLE 257 f (2S) -1-r (2S) -2- (5-f (2R.5R) -5- {2-r (2S) -1-f (2S) -2 [(methoxycarboniDam ¡nol- 3-methylbutano¡l) p¡rrol¡d¡n-2-¡ll-1 Hbenzimidazol-S-ill-l-F4- (piperidin-1-yl) -3 (trifiuoromethyl) phenylpyrrolidi n-2- methyl yl> -1 H-benzim i dazol-2-i Dpi rrolidi n1-¡Π-3-methyl-l-oxobutan-2-¡l) carbamate (ESI +) m / z 983.5 (M + H) +
<img file="MX339989B_D1174.tif" />
721 f (2S) -1-R2S) -2- (5-R2R.5R) -1-r3-cyano-4- (p¡per¡d¡n-1 -i Pfeni 11-5- (2EXAMPLE 258
WICKED
INSTITUTO MEXICANO '0 <<sup>rf</sup>'<sup>,</sup>'<sup>,</sup>'5 & te¡ ** ·· OF THE PROPERTY "
INDUSTRIAL
R2S) -1 -f (2S) -2-r (methoxycarbonyl) am¡nol-3-methylbutanoILTp¡rrol¡din2-II1-1 H-benz¡m¡dazol-5-yl) p¡rrol¡din-2 -¡Ll-1H-benzamidazol-2i Dpi rrolidi n-1 -¡Π-3-m ethi 1-1 -oxobutan-2-ylIcarbannate methyl
ESI +) m / z 940.4 (M + H) +
<img file="MX339989B_D1175.tif" />
EXAMPLE 259
R2S) -1-R2S) -2- (6-R2R, 5R) -1- (6-ethoxypyrid¡n-3-¡P-5- (2-R2S) -1-R2S) 2-Rmethox8carbon¡Damino] -3-MethylbutanoiDpyrrol¡din-2-¡n-1 Hbenzim¡dazol-6-¡Dpyrrol¡din-2-ill-1 H-benzim idazol-2-yl) pyrrol idi n-1¡ll-3-met ¡Methyl l-1-oxobutan-2-iPcarbamate
ESl + m / z 878 (M + H) +
722
<img file="MX339989B_D1176.tif" />
ΙΜΡΙ instituto mx; a ·· o DE LA FRDFitDAD INDUSTRIAL
<img file="MX339989B_D1177.tif" />
<img file="MX339989B_D1178.tif" />
EXAMPLE 260 f (2S) -1-f (2S) -246-r (2R.5R) -5- {2-r (2S) -1-f (2S) -2rfmethoxycarbonyl) amino1-3-methyl buta noil) p¡ rrolidi n-2-¡! 1-1 Hbenc¡m¡dazol-6-¡l) -1 -f6-fmethyl (methylsuifonyl) am¡nolpyr¡d¡n-3¡l) p¡rrol ¡D¡n-2-¡n-1 H-benzimidazol-2-ihpyrrolidin-1 -¡Π-3-methyl-l-oxobutan-2-yl) methyl carbamate
<img file="MX339989B_D1179.tif" />
723
EXAMPLE 261
<img file="MX339989B_D1180.tif" />
f5-r (2R, 5R) -2,5-b¡s (2-f (2S) -1-rN- (nrietox8carbon8l) -L-va lili pyrrole ¡di η2-i 1) -1 H-benc¡ 2-methylpropyl midazol-6-yl) p¡rrolidin-1 -¡llpyridin-2¡Dmethylcarbamate
ESl + m / z 963 (M + H) +
EXAMPLE 262 n2S) -1-h2S) -2- (er (2R.5R) -1-r4- (3.5-d¡met¡lp¡perídin-1-¡l) -3fluorophenyl-5-f2-rí2S) - 1 -f (2S) -2-f (methoxycarbonyl) amino1-3methyl butanoi Dpi rrolidin-2-i 11-1 H-benzim¡dazol-6-yl) pyrrole ¡di η-2-ϋΊ1H-benci m ¡ methyl dazol-2-yl) pyrroli di n-1-yl-3-methyl-1-oxobutan-2¡Dcarbamate
ESl + m / z 962 (M + H) +
724 wildebeest
<img file="MX339989B_D1181.tif" />
EXAMPLE 263 ((2SM-n2S) -2- {6-n2R, 5R) -1-r4- (dietlamno) -3-fluorophenin-5-f2r (2S) -1-f (2S) -2-f (methoxycarbon¡l) aminol-3-meth¡lbutane¡np¡rrolid¡n2-ill-1H-benzimidazol-6-yl) pyrrolidin-2-ill-1H-benzimidazol-2yl) p ¡Rrolldin-1-¡H-3-methyl-1-oxobutan-2-yl) methyl carbamate
<img file="MX339989B_D1182.tif" />
725
EXAMPLE 264 f (2S) -1-H2S) -2-í6-r (2R, 5R) -1- (6-cyclohexylp¡r¡d¡n-3-¡l) -5- (2-r (2S) -1
IMPI
MEXICAN INSTITUTE OF PROPERTY
INDUSTRIAL
<img file="MX339989B_D1183.tif" />
{(2S) -2-r (methoxycarbonihaminoI-3-methylbutane¡npyrrolid¡n-2-¡n-1 Hbenz¡m¡dazol-6-¡l} p¡rrol¡d¡n-2-¡n -1H-ben c¡midazol-2-¡l> p¡rro lid ¡n-1¡ll-3-methyl-1-oxobutan-2-HIcarbamate of methyl
LC / MS: m / z 916.4 TFA method
<img file="MX339989B_D1184.tif" />
EXAMPLE 265 {(2S) -1-r (2S} -2-f6-H2R.5R) -1-r3-fluoro-4- (pyrrolldin-1-¡l) phen¡II-5-f2H2S) -1- ((2S) -2f (methoxycarbon¡l) am¡no1-3-methylbutano¡l) p¡rrol¡d¡n-2-¡n-1 Hbenz¡midazol-6-¡l) p¡rrol¡ d¡n-2-¡H-1 H-benz¡m¡dazol-2-¡l) p¡rrol¡d¡n-1¡ll-3-methyl-1-oxobutan-2-¡D-methyl carbamate
ESI + (m / z): 919.4 (m + H) <sup>726</sup>
<img file="MX339989B_D1185.tif" />
IMPIAS
INSTITUTO MEXICANO r ^ '<sup>4</sup>*<sup>53 </sup>DE LA LROFIE PaD χ, **** ·
INDUSTRIAL
<img file="MX339989B_D1186.tif" />
<img file="MX339989B_D1187.tif" />
H
Vx or
EXAMPLE 266 ((2S) -1-r (2S) -2- {6-r (2R, 5RM- (4-tert-butylphenin-5-f2-r (2SM- «25) -2 rbo ni l ) am i nol-3-methyl butanoi Dpi rrol ¡din-2-¡H-1 H-indole10 6-¡Dpi rrol idi η-2-ill-l H-indole-2-I Dpi rrol id i n-1 -ill-3-m ethyl-1oxobutan-2-¡l) methyl carbamate f
<img file="MX339989B_D1188.tif" />
EXAMPLE 267 {(2S) -1-r (2S) -2- {6-r (2R.5R) -1- (4-tert-butoxy-3-fluorophenyl) -5-f2-I (2S) 1 - f (2S) -2-f (methoxycarbon¡l) am¡nol-3-meth¡ I butanoyl) p¡rrolidin-2-yl11 H-benzimldazol-6-Ι Dpi rrol idi η-2-i 11- 1 H-benzimidazol-2¡l) p¡rrolidin-1-yl1-3-methyl-1-oxobutan-2-¡Ilcarbamate of methyl
727
WHWTVl · »· (ESI; M + H) m / z = 922.4
IMPI institute y.FZíCANo DE LA PRCTIECaD INDOS t RlAL
<img file="MX339989B_D1189.tif" />
Handle
<img file="MX339989B_D1190.tif" />
EXAMPLE 268 ((2S) -1-r (2S) -2- (6-í (2R, 5R) -1-r3-fluoro-4- (propan-2-¡lox¡) phen¡ 11-5- ( 2H2S) -1 -f (2S) -2-r (methoxycarbonyl) am¡nol-3-methylbutanoiDpi rrolidi n2-II1-1 H-benzim¡dazol-6-¡l) p¡rrol¡d¡n-2- ¡Ll-1 H-benz¡m ¡dazol-2 ylpyrrolidin-1-yl 1-3-methyl-1-oxobutan-2-yl> methyl carbamate (ESI; M + H) m / z = 908.5
<img file="MX339989B_D1191.tif" />
f (2S) -1-r (2S) -2-f6-I (2R, 5R) -1- (3-fluoro-4-hydroxyphenyl) -5- (2-I (2S) -1f (2S) - 2-r (methoxycarbonyl) amino1-3-methylbutanoiDpyrrolidin-2-ill-1 Hb ncimidazol-6-i Dpi rrol ¡dín-2-ίΠ-Ι Hb ncimidazol-2-illpl rrol idi n-1 728 ¡ Η-3-m til-1-oxobutan-2-yl) carbamate
<img file="MX339989B_D1192.tif" />
INDUSTRIAL
<img file="MX339989B_D1193.tif" />
(ESI; M + H) m / z = 866.3
<img file="MX339989B_D1194.tif" />
EXAMPLE 270 {(2S) -14 (2S) -2- <er (2R, 5R) -1- (3-fluoro-4-methoxyphenyl) -5- <2-r (2S) -1 {(2S ) -2-F (methoxycarbonyl) am¡no1-3-methylbutane¡Dpyrrol¡d¡n-2-¡ll-1 Hb in clmidazol-6-yl) p¡rrol ¡din-2-¡11-1 H methyl -benzimidazole-2-¡l) pyrol id ln-1¡l1-3-methyl-1-oxobutan-2-iDcarbamate (ESI; M + H) m / z = 880
<img file="MX339989B_D1195.tif" />
or
729
IMPI
MEXICAN INSTITUTE DF. INDUSTRIAL PROPERTY
<img file="MX339989B_D1196.tif" />
EXAMPLE 271
H2S) -1 -R2S) -2- (5-R2R, 5R) -1 -r3,5-d¡fluoro-4- (p¡peridin-1 -yl) phenyll-5 (2-R2S) - 1 -R2S) -2-RmethoxycarboniPamino1-3methylbutanoylpyrrolidin-2-ιΠ-Ι H-benzimidazol-5-illp¡rrolid¡n-2-¡n1 H-benzim i dazol-2-¡Dpi rrolidi n-1 -i Methyl H-3-methyl-1-oxob utan-2 yl carbamate
1H NMR (400 MHz, DMSO-D6) δ ppm 0.73 - 0.90 (m, 12H) 1.32 - 2.28 (m, 20H) 2.76 (s, 4H) 3.54 (s, 6H) 3.82 (s, 4H ) 3.99 - 4.12 (m, 2H) 5.10 - 5.20 (m, 2H) 5.36 (d, J = 7.59 Hz, 2H) 5.83 5.95 (m, 2H) 7.01 - 7.14 (m, 2H) 7.20 ( s, 1H) 7.26 - 7.33 (m, 3H)
7.41 (d, J = 8.24 Hz, 1H) 7.49 (d, J = 8.24 Hz, 1H) 12.01-12.31 (m, 2H).
MS (ESI; M + H) m / z = 951.5.
<img file="MX339989B_D1197.tif" />
EXAMPLE 272 (rí2S, 5S) -1- (4-tert-but¡lfen¡Dp¡rrol¡din-2.5-di-illb¡s {1,3-thiazol-4,2-d¡ylcarbamoyl (2S) pyrrolidin-2.1 -di-ylR2S) -3-methyl-1-oxobutan-1,2-diillllb dimethyl scarbamate
730
<img file="MX339989B_D1198.tif" />
EXAMPLE 273 (H2R, 5R) -1- (4-tert-butyphenyl) pyrrolodin-2,5-di-iHbis {1,3-thiazole-4,2-diylcarbamoyl (2S) pyrrolidin-2, Dimethiium 1-di-iir (2S) -3-methi 1-1-oxobutan-1,2-di¡HDbiscarbamate
ESI m / z 908.4 (M + H)
<img file="MX339989B_D1199.tif" />
EXAMPLE 274 (r (2S.5S) -1 - (4-tert-butylphenyl) pyrrolidin-2,5-di-¡llbis (1,3-thiazole-4.2-d¡¡ IcarbamoiK 2S) p¡rrolidi n-2 Dimethyl, 1-di-iir (2S) -3,3-dimethyl 1-1-oxobutan-1,2di-illDbiscarbamate
ESI m / z 936.5 (M + H)
731
<img file="MX339989B_D1200.tif" />
EXAMPLE 275 (f (2S, 5S) -1 - (4-tert-butylphenyl) pyrrolidin-2.5-di-8llbis {1,3-thiazoi-4.2-di¡lcarbamoyl (2S) pyrrolid¡n-2,1 -di-¡ir (2S, 3R) -3-methoxy-1-oxobutan1,2-d¡-¡l1)) dimethyl b¡scarbamate
ESI m / z 940.5 (M + H)
<img file="MX339989B_D1201.tif" />
EXAMPLE 276 (R2R.5R) -1 -í4-tert-butylphenii) pyrrolidin-2.5-di-illbisf1,3-thiazoi-4.2-di20 ¡lcarbamo¡l (2S) p¡rrol¡d¡n-2,1- dimethyl d¡-¡ir (2S.3R) -3-methoxy-1-oxobutan 1,2-d ¡-¡HD-biscarbamate
ESI m / z 940.5 (M + H)
732
<img file="MX339989B_D1202.tif" />
EXAMPLE 277 (f (2S, 5S) -1- (4-tert-butylphenyl) pyrrolidin-2,5-di-Hbisf1.3-thiazole-4,2-di¡ Icarbam oil (2S) p ¡Rrol ¡din-2,1-d¡-¡lí (2S, 3S) -3-meth¡ 1-1 -oxopentan-1,2di-illDimethyl biscarbamate
ESI m / z 936.5 (M + H)
<img file="MX339989B_D1203.tif" />
EXAMPLE 278 (f (2R.5Rl-1- (4-tert-butylphenyl) pyrrolidin-2,5-di-ii1bis {1,3-thiazol-4,2-di le rbam oil (2S) pyrrole dimethyl idin-2,1 -di-8ir (2S.3S) -3-meth, 1-1 -oxopentan-1,2di-illD-biscarbamate
ESI m / z 936.5 (M + H)
733
<img file="MX339989B_D1204.tif" />
EXAMPLE 279 f (2S) -1-r (2S) -2-f6-M- (4-tert-but¡lfen¡n-5-f2-r (2S) -1-f (2S) -2Γ (methoxycarbonl l) am¡no1-3-metü buta noi Dpi rrol id ¡n-2-¡H-3Him¡dazor4,5-blpiridin-6-illpyrrol¡din-2-¡H-3H-im¡dazoI4.5-blp ¡R¡d¡n2-iDpyrrolidin-1-iH-3-methi 1-1-oxobutan-2-¡H methyl carbamate
LCMS m / z 890 (M + H)
<img file="MX339989B_D1205.tif" />
n2S) -1-H2S) -2-f6-n2R.5R) -1- (4-tert-butllphenyl) -5- (2-r (2S) -1-f (2S) -2r (methoxycarbon¡ l) am¡no1-3-met¡lbutano¡l) p¡rrol¡d¡n-2-¡H-1,3-benzoxazol-6-¡l) p¡rrol¡din-2-¡H-1,3-benzoxazole- 2-yl) plrrol¡d¡n-1 -Hl3-methyl-1-oxobutan-2-illcarbamate dm linden
734
<img file="MX339989B_D1206.tif" />
ESI +: (M + H): 890.5
<img file="MX339989B_D1207.tif" />
EXAMPLE 281
N- (methoxycarbon¡l) -L-valyl-N- (5-ri- (4-tert-but¡phenyl) -5- (2-f (2S) -1-rN (methoxycarbon¡l ) -L-val¡llp¡rrolid¡n-2-yl) -1H-benz¡m¡dazol-6¡l) pyrrol¡d¡n-2-iH-2-methoxyphen¡l) -L- lengthy
ESI +: (M + H): 921.5
<img file="MX339989B_D1208.tif" />
<(2S) -1-r (2S) -2- {6-r (2R.5R) -1- (4-tert-but¡l-2-fluorophen¡i) -5-f2-r (2S) -1 ((2S) -2-f (m -toxycarbonyl) amino1-3-m tilbutanoyl) pyrrolidin-2-ill-1 H735
IMPI h ^ nc¡<sub>m</sub>idazol-6-innirrolidin-2-lll-1H-benclmida7ol-'iif<sup>T</sup>-jH ^ M ^] ¡n.3-m «tll-1-o> ohutan-2-yl> methyl carhamate
ESI +: (M + H): 906.4
<img file="MX339989B_D1209.tif" />
(r (2R, 5R) -1 - (4-tert-but¡ Ifen ¡Upirrol id ¡n-2,5-d¡-¡llbisM liben cim idazol-6,2-d¡-¡l (2S) p ¡Rrol id ¡n-2,1 -di-ilDbisrd hydroxycyIoheptiUmethanonal
MS (ESI) positive ion 854 (M + H)<sup>+</sup>.
<img file="MX339989B_D1210.tif" />
EXAMPLE 284 (1S.4R.1 'S, 4'R) -1.1 <sup>,</sup>- <R2R) -1- (4-t r-butylf n¡Up¡rrol¡d¡n-2,5-d¡736 &. · 'RΙΜΡΙ illbisri H-benzimidazol-6.2-di-yl (2S) pyrrole ¡ATi ^^ g§ ^ iicarbonill) bis (7,7-dimethylbicycloF2.2.1 lheptan-2-one)
<img file="MX339989B_D1211.tif" />
MS (ESI) positive ion 902 (M + H) <sup>+</sup> .
<img file="MX339989B_D1212.tif" />
EXAMPLE 285
1,1 '- <r (2R, 5R) -1- (4-tert-buti Ifen ¡l) p¡ rrolidi n-2,5-di-¡llb¡sn Hbenz¡midazol-6.2-di-yl ( 2S) pyrrolidin-2,1-di-iinbis (2,2-diphenylpropan-1 -one)
<img file="MX339989B_D1213.tif" />
737
EXAMPLE 286 (2S, 2'S) -1,1 '- (f (2R.5R) -1 - (4-tert-but¡ Ifen i I) pyrrol ¡di n-2.5-d ii II bisf 1 HIMPI
INSTITUTO MEXICANO DE LA f?! OrÍFSAD issumjM
<img file="MX339989B_D1214.tif" />
benz¡m¡dazol-6<sub>1</sub>2-di-yl (2S) p¡rrolidin-2,1-di-ill) b¡s (3,3,3-trifluoro-2methoxy-2-phenylpropan-1-one)
MS (ESI) positive ion 1006 (M + H)<sup>+</sup>.
<img file="MX339989B_D1215.tif" />
EXAMPLE 287 <f (2R.5R) -1 - (4-tert-butylphenyl) p¡rrolidin-2,5-di-illbisf1Hbenzim¡dazol-6,2-di-yl (2S) pyrrolidin-2,1 -di-il'Pbisfdfen i le ¡clopentiDm ethane nal
MS (ESI) positive ion 918.6 (M + H)<sup>+</sup>.
<img file="MX339989B_D1216.tif" />
738
IMPI
MEXICAN INSTITUTE OF INDUSTRIAL FROI'IEDAD
EXAMPLE 288
I UI / VL
lr-ff (2R, 5R) -1 - (4-tert-butylphenyl) p¡rrol idi n-2,5-di-i llbisn H benzym idazol-6,2-di-yl (2S) pyrolidi n-2,1-di-yl1) bis (2-cyclopentyl-2-phenylethanone)
MS (ESI) positive ion 946 (M + H) <sup>+</sup> .
<img file="MX339989B_D1217.tif" />
I.1'-ff (2R, 5R) -1 - (4-tert-butylphen »l) pyrrole ¡din-2.5-di-i llbisf 1Hbenzim¡dazole-6,2-di-¡l (2S) pi rrolidi n-2,1 -di-i inbis (2-cyclohexyl-2-phenylethanone)
MS (ESI) positive ion 974 (M + H)<sup>+</sup>.
n
<img file="MX339989B_D1218.tif" />
<img file="MX339989B_D1219.tif" />
<img file="MX339989B_D1220.tif" />
<img file="MX339989B_D1221.tif" />
739
EXAMPLE 290
IMPI
MEXICAN INSTITUTE OF PROFITTY
<img file="MX339989B_D1222.tif" />
(2R, 2'R) -1.1'-fr (2R.5R) -1- (4-tert-but¡lfen¡l) p¡rrol¡d¡n-2,5-c¡i-WísíUr7 benc¡ m¡dazol-6,2-d¡-¡l (2S) p¡rrol¡d¡n-2,1-d¡-ylUb¡s (3.3,3-tritluoro-2methoxy-2-phenylpropan-1 -ona)
MS (ESI) positive ion 1006 (M + H) <sup>+</sup> .
EXAMPLE 291 (K2R, 5R) -1 - (4-tert-but¡lfen¡l) p¡rrolidin-2.5-di-iHb¡sriHbenzimidazol-6,2-di-yl (2S) pyrrolidin-2,1-d ¡-Iinb¡sr (2.2.3.3tetram ethylcyclopropiDmethan onal
MS (ESI) positive ion 822 (M + H) <sup>+</sup> .
<img file="MX339989B_D1223.tif" />
EXAMPLE 292
1,1 '- (r (2R, 5R) -1 - (4-tert-butyiphenyl) pyrrolidin-2.5-di-illb¡ Γ1H740 benzimidazol-6.2-di-¡l (2S) pyrrolid¡n-2,1- di-yl1> b¡ phenylbutan-1-one)
<img file="MX339989B_D1224.tif" />
MS (ESI) positive ion 893 (M + NH<sub>4</sub>-H<sub>2</sub>OR)<sup>+</sup>.
<img file="MX339989B_D1225.tif" />
EXAMPLE 293 (f (2R.5RM- (4-tert-but¡lfenihp¡rrol¡d¡n-2.5-di-¡Hb¡sMHbenzim¡dazol-6,2-d¡-yl (2S) pyrrolidin-2, 1-di-ill) bis <r (IR<sub>Í</sub>3R) -2<sub>l</sub>2-dimethyl-3- (2-methylprop-1-en-1-yl) propy cycium II meta no na)
MS (ESI) positive ion 874 (M + H)<sup>+</sup>.
<img file="MX339989B_D1226.tif" />
fr (2R, 5R) -1- (4-t r-butylphnyl) pyrrolidin-2,5-di-illbisf1 H741
IMPI benzimidazol-6.2-di-yl (2S) p¡rrol¡din-2,1-di-iinbisr (2PgqgTfctB¡r<sub>r</sub>a <g1- ^? »<sup>B</sup>ga
SSáO *
INOUSTMAL
<img file="MX339989B_D1227.tif" />
methylcyclopropyl Dmethanonal
MS (ESI) positive ion 874 (M + H)<sup>+</sup>.
<img file="MX339989B_D1228.tif" />
EXAMPLE 295 (2R, 2'RM .1 MH2R.5RM - (4-tert-but¡lfen¡l) pyrroledin-2,5-di-¡nb¡sMHbenzimidazol-6.2-d¡-yl (2S) p ¡Rrol¡din-2,1-d¡-¡H) bis (2-hydroxy¡-2-phenylbutan-1 -onal
MS (ESI) positive ion (M + H)<sup>+</sup>.
<img file="MX339989B_D1229.tif" />
(T (2R, 5R) -1- (4-t r-butylphenyl) pyrrolidin-2,5-d¡-illb¡ ΙΊΗ742
IMPI. INSTITUTE benzimidazol-6,2-d¡-¡l (2S) pyrrolid¡n-2,1-di-¡ll) b¡á<sup>?</sup>{n (trifluoromethylPcyclopropylmethanonaj mi / jcano
<img file="MX339989B_D1230.tif" />
MS (ESI) positive ion 846 (M + H)<sup>+</sup>.
<img file="MX339989B_D1231.tif" />
EXAMPLE 297
U (2R, 5R) -1- (4-tert-but¡lfeninpyrrol¡din-2.5-d¡-¡nb¡sMHbenz¡m¡dazol-6.2-d¡-¡l (2S) pyrrole¡d¡n- 2,1-di-ylUbisRIphenylcyclopropyl) methanonal
<img file="MX339989B_D1232.tif" />
taRSW3iaBafiaii ^ cs3CsaiC £ ¡2S ^ i ^ r¿v -i; „_.
743
EXAMPLE 298
R2S) -1-r (2S) -2- (5-r (2R, 5R) -1-I4- (d¡fluoromethox¡) phen¡n-5-f2-r (2S) -1IMPI
OF THE INDUSTRIAL FSCF'EDAD
<img file="MX339989B_D1233.tif" />
R2S) -2-Rmethox¡carbon¡l) am¡nol-3-methylbutane¡IIp¡rrolid ¡n-2-ill-1 Hbenci m ¡dazol-5-III pyrrole id i η-2-i Π-1 H -benclm ¡dazol-2-¡l) p¡rrol ¡di n-1 ¡Π-3-methyl-l-oxobutan-2-¡llcarbamate methyl (ESI +) m / z 898.4 (M + H) +
<img file="MX339989B_D1234.tif" />
R2S) -1-R2S) -2- <5-R2R.5R) -1- (3,5-d¡fluoro-4-methoxyphenyl) -5- (2-r (2S) 1 -f (2S ) -2-r (methoxycarbon¡l) am¡no1-3-metHbutanoll) p¡rrol¡d¡n-2-¡l11 H-benzimidazol-5-¡l) p¡rrol¡d¡n-2 -¡N-1 H-benclmidazol-220 ¡Dp¡rrol¡d¡n-1-¡H-3-methyl-1-oxobutan-2-yl> methyl carbamate (ESI +) m / z 898.4 (M + H ) +
744
<img file="MX339989B_D1235.tif" />
EXAMPLE 300 ((2S) -1-r (2S) -2- (5-r (2R, 5R) -1-f4- (4,4-di methyl piperidin-1-yl) -3-fluoropheniH-5- {2 -r (2S) -1-f (2S) -2-r (methoxycarbon¡l) am¡nol-3methyl butanoi Dpi rrolid¡n-2-¡ll-1 H-be ncim idazol-6-i Dpi rrol ¡din-2-i II1 H-benz¡m¡dazol-2-¡Dp¡rrol¡din-1 -ill-3-methyl-1-oxobutan-2¡ methyl Ucarbamate
MS + ESI m / z (rel abundance) 962 (100, M + H);
<sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 7.52 (d, J = 8.2, 1 H),
7.44 (d, J = 8.1, 1H), 7.35 (d, J = 8.1, 3H), 7.26 (s, 1H), 7.14 (m, 2H), 6.75 (s, 1H), 6.12 ( m, 2H), 5.40 (s, 2H), 5.19 (s, 2H), 4.12 (t, J = 8.4, 2H), 3.88 (s, 4H), 3.60 (s, 6H), 2.70 (m, 5H), 2.24 (s, 4H),
1.99 (m, 7H), 1.75 (s, 2H), 1.46 (s, 3H), 1.39 (s, 8H), 0.89 (m, 20H).
745
<img file="MX339989B_D1236.tif" />
EXAMPLE 301 ((2S) -1-n2S) -2- (6-ri- (4-tert-but¡lfen¡l) -5-f4-fluoro-2-n2S) -1-n2S) -2F (methoxycarbon ¡L) amino 1-3-methylbutano8l> p¡ rrol¡din-2-iH-1 Hbenzim idazol-6-¡l> p¡ rrolidi n-2-¡H-4-f luoro-1 H-benzim ¡dazoI- Methyl 2¡l) p¡rrolid¡n-1-ill-3-methyl-1-oxobutan-2-iRcarbamate
MS (ESI) m / z 924 (M + H) <sup>+</sup>
<img file="MX339989B_D1237.tif" />
EXAMPLE 302 (2S) -1-r (2S) -2- (5-r (2R, 5R) -1- (4-cyclopropyl-3-fluorof nl) -5- (2746
<img file="MX339989B_D1238.tif" />
F (2S) -1 - ((2S) -2-F (methoxycarboniDaminol-3-methiibutan "~ OF INDUSTRIAL PKCF
Methyl 2-iH-l H-benzimidazol-5-iRpyrrolidin-2-ill-1H-benzimidazol-2iDpi rrol id i n-1 -iH-3-methyl-1-oxobutaη-2-illcarbamate
MS (ESI) m / z 891 (M + H)<sup>+</sup>
<img file="MX339989B_D1239.tif" />
rfmethoxycarboni Dam ¡nol-3-methyl butanoi Dpi rrol ¡din-2-ΙΠ-1Hbenzimidazol-6-iD-1 -f4-r2- (2-methoxyethoxy) ethoxyphen¡Dpyrrolidin-2¡11-1 H-benzim¡ Methyl dazol-2-IDpyrrolidin-1-yl1-3-metll-1 -oxo buta n-2P-carbamate
MS (ESI) m / z 950 (M + H)<sup>+</sup>, 948 (MH)<sup>+</sup>.
747
<img file="MX339989B_D1240.tif" />
EXAMPLE 304 {(2S1-1 -r (2S) -2- (6-r (2R, 5R) -1-f3-fluoro-4- (3-methylpyrrolidin-1 ¡l) phenyl] - 5- {2 - [(2S) -1 - {(2S) -2-r (methox8carbon¡l) am¡no1-3met¡lbutane¡np¡rrolid¡n-2-¡11-1 H-benc¡m ¡Dazol-6-¡l) p¡rro8 ¡di n-2-¡Π1 H-benzimidazol-2-i Dpi rrolidin-1-i Π-3-methyl 1-1-oxo butane-215 ¡D methyl carbamate
1H NMR (400 MHz, DMSO-D6) δ ppm 0.76 - 0.89 (m, 12
H) 0.95 (d, J = 6.72 Hz, 3H) 1.62 - 1.72 (m, 2H) 1.83 - 2.06 (m, 9H)
2.09 - 2.24 (m, 6H) 2.52 - 2.61 (m, 2H) 2.91 - 3.15 (m, 4H) 3.52 (s,
6 H) 3.74 - 3.86 (m, 4H) 4.05 (t, J = 8.35 Hz, 2H) 5.08 - 5.17 (m, 2H)
5.26 - 5.38 (m, 2H) 5.97 - 6.10 (m, 2H) 6.35 - 6.45 (m, 1H) 7.01 7.08 (m, 2H) 7.19 (s, 1H) 7.25 - 7.32 (m, 3H ) 7.36 (d, J = 8.24 Hz, 1H) 7.44 (d, J = 7.92 Hz, 1H) 12.01 (s, 2H).
748
<img file="MX339989B_D1241.tif" />
EXAMPLE 305 f (2S) -1-r (2S) -2-f5-r (2R.5R) -1-r2.3-difiuoro-4- (piper¡din-1-yl) fenll-5 ( 2-R2S) -1 -f (2S) -2-r (methoxycarbonihaminol-3-methylbutanoylpyrrolidin-2-ill-1H-benzimidazol-5-yl> pyrrolidin-2-ill1 H-benzim idazo l-2-i Dpi rrol idi n Methyl -1 -¡Π-3-methyl-l-oxobutan-2 yl carbamate
ES1 + (m / z): 951.5;
1H NMR (400 MHz, DMSO-D6) δ ppm 0.74 - 0.90 (m, 12H) 1.35 - 1.41 (m, 2H) 1.44 - 1.51 (m, 4H) 1.73 - 1.83 (m, 2H) 1.86 2.02 (m, 6H) 2.14 - 2.23 (m, 4H) 2.59 - 2.72 (m, 6H) 3.53 (s, 6H)
3.77 - 3.84 (m, 4H) 3.97 - 4.10 (m, 2H) 5.06 - 5.18 (m, 2H) 5.46 5.56 (m, 2H) 6.36.6.47 (m, 2H) 7.03 - 7.11 (m, 2H) 7.23 - 7.45 (m, 6H) 11.95 - 12.10 (m, 2H)
749
<img file="MX339989B_D1242.tif" />
EXAMPLE 306 f (2S) -1-r (2S) -2- {e-n2R, 5R) -1- (4-ethoxy-3-fluorophenyl) -5-i2-R2S) -1 <(25 ) -2-r (methoxlcarbon¡l) am¡no1-3-methyl butanoiDpi rrolidi n-2-¡H-1Hbenz¡m¡dazol-6-yl) pyrrol¡d¡n-2-¡ll-1 Methyl H-benclmldazol-2-iPpyrrolldln-l¡Π-3-methyl-1-oxobutan-2-yl) carbamate
ESI + (m / z): 894.4
<img file="MX339989B_D1243.tif" />
EXAMPLE 307
H2S) -1-F (2S) -2-f6-r (2R, 5R) -1-r4- (t r-butlamine) -3-fluorophenyl-5-f2750
JnMiPrl
<img file="MX339989B_D1244.tif" />
R2S) -1 - {(2S) -2-r (methoxycarbonl) amnol-3-methlbut
MZXICAN INSTITUTE
OF THE RIVERY _
2-Ü1-1 H-benzimidazole-6-ii} pyrrolidin-2-in-1 H-benz¡mítfá2ot-2¡Rpyrrol¡din-1-¡Π-3-methi 1-1-oxobutan-2-¡l } douioMi carbamate
ESI + (m / z): 922;
1H NMR (400 MHz, DMSO-D6) δ ppm 0.75 - 0.90 (m, 12H) 0.97 (s, 9H) 1.61 - 1.71 (m, 2H) 1.83 - 2.04 (m, 6H) 2.12 - 2.23 ( m, 4H) 3.52 (s, 6H) 3.76 - 3.86 (m, 4H) 4.01 - 4.08 (m, 2H) 5.09 5.17 (m, 2H) 5.27 - 5.37 (m, 2H) 5.98 - 6.07 (m, 2H) 6.56 - 6.66 (m, 1H) 7.06 (t, J = 7.92 Hz, 2H) 7.19 (s, 1H) 7.27 (d, J = 9.00 Hz, 3H)
7.38 (d, J = 8.24 Hz, 1H) 7.46 (d, J = 8.13 Hz, 1H) 12.00 (s, 1H) 12.08 (s, 1H)
<img file="MX339989B_D1245.tif" />
(methoxycarbonin-L-valylpyrrolidin-2-yl) -1 H-benzimidazol-5illPyrrolidin-2-iD-2-f1-rN- (methoxycarbonyl) -L-valyllpyrrolidin-2-in1 H-benzimidazole-1- ethyl carboxylate and
751
5 - {(2R, 5R) -1- (4-tert-butylphenyl) -5-ri- (ethoxycarbon i 1) -2 ^ 1% ¾% ¾¾¾ ^
INDt ~ T * L: .AL
IMPI
<img file="MX339989B_D1246.tif" />
(methoxycarbonyl) -L-valH pyrrole idin-2-yl) -1 H-benzimidazoi-6ill pyrro! ethyl id¡n-2-yl) -2-I (2S) -1-rN- (methoxycarbon¡l) -L-val¡npyrrole ¡di n-2¡l) -1 H-benzimidazole-1-carboxylate
ESI + (m / z): 1032.5.
1H NMR (400 MHz, DMSO-D6) δ ppm 0.70 - 1.04 (m, 12H) 1.08 (s, 9H) 1.33 - 1.46 (m, 6H) 1.65 - 1.77 (m, 2H) 1.81 - 2.13 ( m, 8H) 2.20 - 2.28 (m, 2H) 2.55 - 2.62 (m, 2H) 3.53 (d, J = 4.23 Hz, 6H) 3.80 - 3.92 (m, 4H) 4.04 - 4.13 (m, 2H) 4.41 - 4.59 (m, 4H)
5.38 - 5.49 (m, 2H) 5.66 - 5.76 (m, 2H) 6.17 - 6.33 (m, 2H) 6.82 7.00 (m, 3H) 7.18 - 7.56 (m, 5H) 7.75 - 7.91 (m, 2H)
<td></td><td></td><td>The</td><td>com</td><td colspan="3">title positions</td><td>! the</td><td>Ahem</td><td>peeps</td><td> 52, 5:</td><td> 3, 54</td><td> , 58,</td>
<td> 59, 6</td><td>iO, 61</td><td> , 62,</td><td> 63,</td><td> 64, 65, 66</td><td> , 67,</td><td> 68, 6</td><td colspan="2">i9, 74, 75,</td><td> 76,</td><td> 77, 7'</td><td> 9, 80</td><td> , 81,</td>
<td colspan="3"> 82, 83, 84, 85,</td><td> , 86,</td><td> 87, 88, 8</td><td> 9, 90</td><td> 91,</td><td> 93,</td><td> 94, 9</td><td colspan="2"> '5, 96, 97,</td><td> 99,</td><td> 101,</td>
<td> 102,</td><td> 103,</td><td> 109,</td><td> 110,</td><td> 111, 112,</td><td> 113,</td><td> 117,</td><td> 121,</td><td> 122,</td><td> 123,</td><td> 125,</td><td> 126,</td><td> 127,</td>
<td> 128,</td><td> 129,</td><td> 130,</td><td> 131,</td><td> 132, 135,</td><td> 136,</td><td> 137,</td><td> 138,</td><td> 139,</td><td> 140,</td><td> 141,</td><td> 144,</td><td> 145,</td>
<td> 146,</td><td> 148,</td><td> 149,</td><td> 150,</td><td> 151, 152,</td><td> 153,</td><td> 154,</td><td> 155,</td><td> 156,</td><td> 157,</td><td> 159,</td><td> 160,</td><td> 161,</td>
<td> 162,</td><td> 163,</td><td> 166,</td><td> 167,</td><td> 168, 169,</td><td> 170,</td><td> 171,</td><td> 173,</td><td> 176,</td><td> 178,</td><td> 179,</td><td> 180,</td><td> 181,</td>
<td> 183,</td><td> 184,</td><td> 185,</td><td> 186,</td><td> 188, 189,</td><td> 191,</td><td> 192,</td><td> 194,</td><td> 195,</td><td> 197,</td><td> 198,</td><td> 199,</td><td> 200,</td>
<td> 201,</td><td> 202,</td><td> 203,</td><td> 205,</td><td> 207, 208,</td><td> 209,</td><td> 210,</td><td> 211,</td><td> 212,</td><td> 214,</td><td> 215,</td><td> 216,</td><td> 217,</td>
<td> 218,</td><td> 219,</td><td> 220,</td><td> 221,</td><td> 224, 226,</td><td> 227,</td><td> 228,</td><td> 229,</td><td> 230,</td><td> 231,</td><td> 233,</td><td> 234,</td><td> 235,</td>
<td> 236,</td><td> 237,</td><td> 238,</td><td> 240,</td><td> 241, 242,</td><td> 245,</td><td> 247,</td><td> 248,</td><td> 250,</td><td> 251,</td><td> 252,</td><td> 254,</td><td> 256,</td>
<td> 257,</td><td> 258,</td><td> 262,</td><td> 263,</td><td> 264, 266,</td><td> 267,</td><td> 268,</td><td> 270,</td><td> 271,</td><td> 272,</td><td> 273,</td><td> 274,</td><td> 275,</td>
752
276, 277, 278, 282, 294, 295, 296, 297, 298, 299, 300
<img file="MX339989B_D1247.tif" />
«Ί β WÍJWSiNO '£ LA Τί.ΟΓΙίί-'Λ
<img file="MX339989B_D1248.tif" />
and 306 show a value of CE<sub>5</sub>q less than approximately 0.1 nM in HCV 1b-Con1 replicon tests in the presence of 5% FBS. The title compounds of Examples 51, 55, 56, 57, 70, 71,
72, 73, 78, 98, 100, 108, 114, 115, 116, 119, 120, 133, 134, 142, 143, 147, 164, 172, 174, 182, 196, 204, 206, 222, 223, 225, 239, 244, 249, 253, 259, 261, 265, 281, 287, 288, 292, 303, 304, 307, and 308 show a value of CE<sub>50</sub> from about 0.1 to about 1 nM in the HCV 1b-Con1 replicon tests in the presence of 5% FBS. The title compounds of Examples 92, 105, 106, 107, 118, 124, 158, 165, 175, 177, 187, 190, 193, 213, 232, 243, 246, 255, 260, 269, 279, 280 , 283, 284, 285, 286, 289, 290, 291, and 293 show a value of CE<sub>50</sub> from about 1 to about 100 nM in the HCV 1b-Con1 replicon assays in the presence of 5% FBS.
The present invention also contemplates the pharmaceutically acceptable salts of each compound in Examples 1308, as well as the pharmaceutically acceptable salts of each compound described below in the present application.
The following compounds are prepared in a similar manner according to the procedures described above.
753
<img file="MX339989B_D1249.tif" />
F
<img file="MX339989B_D1250.tif" />
Cl
<img file="MX339989B_D1251.tif" />
754
<img file="MX339989B_D1252.tif" />
ζζ
<img file="MX339989B_D1253.tif" />
<img file="MX339989B_D1254.tif" />
<img file="MX339989B_D1255.tif" />
.0
<img file="MX339989B_D1256.tif" />
<img file="MX339989B_D1257.tif" />
0-0
Ν-Αθ
<img file="MX339989B_D1258.tif" />
θ '
755
BBSHHMHmBMtaeMUHMNM'TVFTZTT— Τζ
<img file="MX339989B_D1259.tif" />
756
<img file="MX339989B_D1260.tif" />
757
<img file="MX339989B_D1261.tif" />
<img file="MX339989B_D1262.tif" />
<img file="MX339989B_D1263.tif" />
<img file="MX339989B_D1264.tif" />
<img file="MX339989B_D1265.tif" />
<img file="MX339989B_D1266.tif" />
IMPI
I. AEXICANO INSTITUTE OF INDUSTRIAL PTOFIEDAD
<img file="MX339989B_D1267.tif" />
758
<img file="MX339989B_D1268.tif" />
<img file="MX339989B_D1269.tif" />
When analyzed using the HCV 1bCon1 replicon tests in the presence of 5% FBS, each of the above compounds shows an EC value.<sub>50</sub> less than 1 nM.
In addition, the following mixtures of stereoisomers are prepared according to procedures similar to those described above, wherein each compound in each mixture of stereoisomers can be readily isolated using chiral chromatography or other appropriate methods as appreciated by those skilled in the art and, therefore, the present invention also features each compound in these stereoisomer mixtures:
759
<img file="MX339989B_D1270.tif" />
<img file="MX339989B_D1271.tif" />
mix 2
F
<img file="MX339989B_D1272.tif" />
mix 3
MEXICAN INSTITUTE OF PROPERTY
INDUSTRIAL
I
760
<img file="MX339989B_D1273.tif" />
TO
<img file="MX339989B_D1274.tif" />
AND
IMPI
INSTITUTO MEXICANO f * E LA PROPERTY INDUSTRIAL
<img file="MX339989B_D1275.tif" />
<img file="MX339989B_D1276.tif" />
<img file="MX339989B_D1277.tif" />
<img file="MX339989B_D1278.tif" />
mix 6
761
ΙΜΡΪ
INSTITUTE MI WC ^ '.- OD £ La! 1'O'-1I;> 3
<img file="MX339989B_D1279.tif" />
<img file="MX339989B_D1280.tif" />
<img file="MX339989B_D1281.tif" />
mix 7
<img file="MX339989B_D1282.tif" />
<img file="MX339989B_D1283.tif" />
mix 9
762
<img file="MX339989B_D1284.tif" />
<img file="MX339989B_D1285.tif" />
mix 12
763
<img file="MX339989B_D1286.tif" />
<img file="MX339989B_D1287.tif" />
mix 1 3
F
<img file="MX339989B_D1288.tif" />
mix 14
<img file="MX339989B_D1289.tif" />
mix 15
764
<img file="MX339989B_D1290.tif" />
mix 16
F
<img file="MX339989B_D1291.tif" />
mix 17
765
<img file="MX339989B_D1292.tif" />
'”^ Ύ..Λ <ζν9
INSTITUTE MFX! CA NO DELA PKOr'IEDAO
INOUSTklAL <sup>to</sup> , Λ ^ Νγ<sup>0</sup>, n ^ / \ ι ΓΎ - ^ 'ν-Ό KZ<sup>N</sup>S ·· ^ J¡ « <sup>N</sup> mix 18
<img file="MX339989B_D1293.tif" />
<img file="MX339989B_D1294.tif" />
mix 19
766
<img file="MX339989B_D1295.tif" />
mix 20
<img file="MX339989B_D1296.tif" />
767
<img file="MX339989B_D1297.tif" />
ΙΜΡΙΓ
INSTITUTE ΜΕΧΙΟ.ΝΟ '£
OF FECPTITY
INDUSTRIAL <sup>Η</sup> > τ
ΓΠ. Η, Ο ° Λ0 mix 22
<img file="MX339989B_D1298.tif" />
<img file="MX339989B_D1299.tif" />
mix 23
768
<img file="MX339989B_D1300.tif" />
When tested using the HCV 1bCon1 replicon tests in the presence of 5% FBS, each of the above mixes (except mix 12) shows an EC value<sub>50</sub> less than 1 nM. Mix 12 showed an EC value<sub>50</sub> approximately 1 to 10 nM in the HCV 1b-Con1 replicon tests in the presence of
5% FBS.
Similarly, the following compounds of formula I or pharmaceutically acceptable salts thereof can be prepared in a similar manner in accordance with the reaction schemes and procedures described above,
D
I i-3, A — LX — L<sub>2</sub>—B.
AND Z
769 in which A is selected from Table la,
INSTITUTO MEXICANO íflj from Table Ib, D is selected from Taíj ^^^ Sy select each one independently from Table 3 i-3 and L — x — l<sub>2</sub> is selected from Table 4, and A, B, D, and X are each independently optionally substituted with one or more R<sub>TO</sub>, and in which Lt, L<sub>2</sub>, L<sub>3</sub> and R<sub>TO</sub> they are as described above. Preferably, L-ι, L<sub>2</sub> and L<sub>3</sub> they are link.
770
Table 1a. TO
IMPI
MEXICAN INSTITUTE OF THE JT-O-'EDAD INDUSTRIAL
<img file="MX339989B_D1301.tif" />
<img file="MX339989B_D1302.tif" />
<img file="MX339989B_D1303.tif" />
<img file="MX339989B_D1304.tif" />
wa
N- <sup>7</sup>
<img file="MX339989B_D1305.tif" />
<img file="MX339989B_D1306.tif" />
<img file="MX339989B_D1307.tif" />
<img file="MX339989B_D1308.tif" />
F
<img file="MX339989B_D1309.tif" />
N = \
G rP
F
<img file="MX339989B_D1310.tif" />
771
<img file="MX339989B_D1311.tif" />
772
<img file="MX339989B_D1312.tif" />
F
773
Table 3. Y and Ζ
IMPI
INSTITUTO MEXICANO DE LÁ? «; C« ItDAD í.N DUSTRtAL
<img file="MX339989B_D1313.tif" />
<img file="MX339989B_D1314.tif" />
774
<img file="MX339989B_D1315.tif" />
OR
775
<img file="MX339989B_D1316.tif" />
<img file="MX339989B_D1317.tif" />
<img file="MX339989B_D1318.tif" />
OR
<img file="MX339989B_D1319.tif" />
<img file="MX339989B_D1320.tif" />
<img file="MX339989B_D1321.tif" />
<img file="MX339989B_D1322.tif" />
777
IMP1
Other examples of the compounds of l »<sup>ST</sup>^^ fI
LSCU57KLM.
provided in Table 5.
Table 5
F
<img file="MX339989B_D1323.tif" />
778
<img file="MX339989B_D1324.tif" />
<img file="MX339989B_D1325.tif" />
<img file="MX339989B_D1326.tif" />
<img file="MX339989B_D1327.tif" />
<img file="MX339989B_D1328.tif" />
Ν.
779
<img file="MX339989B_D1329.tif" />
<img file="MX339989B_D1330.tif" />
<img file="MX339989B_D1331.tif" />
<img file="MX339989B_D1332.tif" />
<img file="MX339989B_D1333.tif" />
IMPI
MTXICANO INSTITUTE OF INDUSTRIAL CURRENCY
<img file="MX339989B_D1334.tif" />
780
WICKED
<img file="MX339989B_D1335.tif" />
<img file="MX339989B_D1336.tif" />
<img file="MX339989B_D1337.tif" />
MEXICAN INSTITUTE OF I ROBE DAD
INDUSTRIAL
781
<img file="MX339989B_D1338.tif" />
The anti-HCV activity of each compound can be determined by measuring the activity of the luciferase reporter gene in the replicon in the presence of 5% FBS. The luciferase reporter gene is placed under the translational control of the poliovirus IRES instead of the HCV IRES, and HuH-7 cells are used to support replication of the replicon.
The inhibitory activities of the compounds of the present invention can be evaluated using a variety of tests known in the art. For example, two stable subgenomic replicon cell lines can be used for characterization of the compound in cell culture: one obtained from genotype 1a-H77 and the other obtained from genotype 1b-Con1, obtained from the
782
<img file="MX339989B_D1339.tif" />
University of Texas Medical Division (Universit Branch), Galveston, TX or Apath, LLC, St. Louis, MO, respectively. The replicon constructs can be bicistronic subgenomic replicons. Genotype 1a of the replicon construct contains the NS3-NS5B coding region obtained from HCV strain H77 (1a-H77). The replicon also has a firefly luciferase reporter and a neomycin phosphotransferase (Neo) selectable marker. These two coding regions, separated by the FMDV 2a protease, comprise the first cistron of the bicistronic replicon construct, in which the second cistron contains the NS3-NS5B coding region with the addition of adaptive mutations E1202G, K1691R, K2040R and S2204I . The construction of replicon 1b-Con1 is identical to that of replicon 1a-H77, except that the or 5 'UTR, 3' UTR, and the coding region NS3-NS5B of HCV are obtained from the 1b-Con1 strain. and the adaptive mutations are K1609E, K1846T, and Y3005C. Furthermore, the 1b-Con1 replicon construct contains a poliovirus IRES between the HCV IRES and the luciferase gene. Replicon cell lines can be maintained in Dulbecco's Modified Eagles Medium (DMEM) containing 10% (v / v) Fetal Calf Serum (FBS), 100 20 IU / ml Penicillin, 100 mg / ml Streptomycin (Invitrogen), and 200 mg / ml G418 (Invitrogen).
The inhibitory effects of the compounds of the invention on HCV replication can be determined by measuring the activity of the luciferase reporter gene. For example, replicon-containing cells can be seeded in 96 well plates at a density
783
IMPI of 5000 cells per well in 100 μΙ of DMEM that
INDUSTRIAL
FBS. The following day the compounds can be diluted in sulfoxide of
<img file="MX339989B_D1340.tif" />
dimethyl (DMSO) to generate a 200x stock solution in a series of eight half-logarithmic dilutions. The dilution series can then be further diluted 100-fold in medium containing 5% FBS. The medium with the inhibitor is added to the overnight cell culture plates that already contain 100 µΙ of DMEM with 5% FBS. In the tests the Inhibitory activity is measured in the presence of human plasma, the medium from the night cell culture plates can be replaced with DMEM containing 40% human plasma and 5% FBS. Cells can be incubated for three days in tissue culture incubators after which time 30 μΙ of Passive Lysie Buffer (Promega) can be added to each well, and plates are then incubated for 15 minutes with rocking shaking to Use the cells. Luciferin solution (100 μΙ, Promega) can be added to each well, and luclferase activity can be measured with a Victor II luminometer (Perkln-Elmer). Percent Inhibition of HCV RNA Replication can be calculated for each compound concentration and EC value<sub>50</sub> can be calculated using nonlinear regression curve fitting for the 4-parameter logistic equation and GraphPad Prism 4 software. By using the tests described above or similar cell-based replicon tests, representative compounds of the present invention show Significantly Inhibitory activities against HCV replication.
784
IMPIg
The present invention also presented industrial pharmaceuticals comprising the compounds of the invention. A pharmaceutical composition of the present invention may comprise one or more compounds of the invention, each of which has the formula I (ol<sub>TO</sub>, Ib, le or I<sub>d</sub>).
Furthermore, the present invention features pharmaceutical compositions comprising pharmaceutically acceptable salts, solvates, or prodrugs of the compounds of the invention. Without limitation, the pharmaceutically acceptable salts may be zwitterions or may be obtained from pharmaceutically acceptable inorganic or organic acids or bases. Preferably, a pharmaceutically acceptable salt retains the biological effectiveness of the compound's free acid or base without undue toxicity, irritation, or allergic response, has a reasonable benefit / risk ratio, is effective for its intended use, and is not biologically or otherwise. otherwise undesirable.
The present invention also features pharmaceutical compositions comprising a compound of the invention (or a salt, solvate, or prodrugs thereof) and another therapeutic agent. By way of illustration and not limitation, these other therapeutic agents can be selected from antiviral agents (eg, anti-HIV agents, anti-HBV people, or other anti-HCV agents such as HCV protease inhibitors, HCV polymerase inhibitors, HCV helicase inhibitors, IRES inhibitors or NS5A inhibitors), antibacterial agents, antifungal agents, immuno-
<img file="MX339989B_D1341.tif" />
modulators, anti-cancer agents or anti-inflammation chemotherapeutic agents, anti-sense RNA, siRNA, antibodies, or agents for treating cirrhosis or inflammation of the liver. Specific examples of these other therapeutic agents include, but are not limited to, ribavirin, α-interferon, β-interferon, PEG-conjugated interferon-a, PEG-conjugated interferon-lambda, ribavirin, viramidine, R-5158, nitazoxanide, amantadine, Debio-025, NIM-811, R7128, R1626, R4048, T-1106, PSI-7851 (Pharmasset) (nucleoside polymerase inhibitor), PSI-938 (Pharmasset) (nucleoside polymerase inhibitor), PF00868554, ANA- 598, IDX184 (nucleoside polymerase inhibitor), IDX102, IDX375 (no nucleoside polymerase inhibitor), GS-9190 (no nucleoside polymerase inhibitor), VCH-759, VCH-916, MK-3281, BCX4678, MK-3281, VBY708, ANA598, GL59728, GL60667, BMS- 790052 (NS5A inhibitor), BMS-791325 (protease inhibitor), BMS-650032, BMS-824393, GS-9132, ACH-1095 (protease inhibitor), AP-H005, A831 (Arrow Therapeutics) (NS5A inhibitor) ), A-689 (Arrow Therapeutics) (NS5A inhibitor), INX08189 (Inhibitex) (polymerase inhibitor), AZD2836, telaprevir (protease inhibitor), boceprevir (protease inhibitor), ITMN-191 (Intermune / Roche), BI-201335 (protease inhibitor), VBY-376, VX-500 (Vertex) (protease inhibitor), PHX- B, ACH-1625, IDX136, IDX316, VX-813 (Vertex) (protease inhibitor), SCH900518 (Schering-Plow), TMC-435 (Tibotec) (protease inhibitor), ITMN-191 (Intermune, Roche) ( protease inhibitor), MK-7009 (Merck) (protease inhibitor), IDX-PI (Novartis), BI-201335 (Boehringer Ingelheim), R7128 (Roche) (inhibitor
786
<img file="MX339989B_D1342.tif" />
nucleoside polymerase), MK-3281 (Merck), MK-0608
INDUSTRIAL nucleoside polymerase), PF-868554 (Pfizer) (non nucleoside polymerase inhibitor), PF-4878691 (Pfizer), IDX-184 (Novartis), IDX375 (Pharmasset), PPI-461 (Presidio) (NS5A inhibitor) , BILB-1941 (Boehringer Ingelheim), GS-9190 (Gilead), BMS-790052 (BMS), Albuferon (Novartis), ABT-450 (Abbott / Enanta) (protease inhibitor), ABT-333 (Abbott) (no nucleoside polymerase inhibitor), ABT-072 (Abbott) (non-nucleoside polymerase inhibitor), ritonavir, another cytochrome P450 mono-oxygenase inhibitor, or any combination thereof.
In one embodiment, a pharmaceutical composition of the present invention comprises one or more compounds of the present invention (or salts, solvates or prodrugs thereof, and one or more other antiviral agents.
In another embodiment, a pharmaceutical composition of the present invention comprises one or more compounds of the present invention (or salts, solvates, or prodrugs thereof), and one or more other anti-HCV agents. For example, a pharmaceutical composition of the present invention may comprise compound or compounds of the present invention having the formula I, l<sub>TO</sub>, l<sub>B</sub>, le or Id (or a salt, solvate, or prodrug thereof), and an agent that is selected from HCV polymerase inhibitors (including nucleoside polymerase or non-nucleoside polymerase inhibitors), HCV protease inhibitors , HCV helicase inhibitors, CD81 inhibitors, cyclophilin inhibitors, IRES inhibitors, or inhibitors of
787
NS5A.
IMPIOS ι <Ά> ·
INSTITUTO ΜEXICA.NO fu · - * - DE LA r.kOPlECAD C »*«,
INDUSTRIAL
In yet another embodiment, a pharmaceutical composition of the present invention comprises one or more compounds of the present invention (or salts, solvates or prodrugs thereof), and one or more other antiviral agents, such as anti-HBV agents, agents anti-HIV, or anti-hepatitis A, anti-hepatitis D, anti-hepatitis E, or anti-hepatitis G agents. Non-limiting examples of anti-HBV agents include adefovir, lamivudine, and tenofovir. Non-limiting examples of anti-HIV drugs include rltonavir, lopinavir, ndinavir, nelfinavir, saquinavir, amprenavir, atazanavir, tipranavir, TMC-114, fosamprenavir, zidovudine, lamivudine, didanosine, stavudine, tenofovir, zalcitabine, evfavinabanzire , delavirdine, TMC-125, L-870812, S-1360, enfuvirtide, T-1249, or other HIV protease, reverse transcriptase, integrase or fusion inhibitors. Any other desirable antiviral agents may also be included in a pharmaceutical composition of the present invention, as appreciated by those skilled in the art.
In a preferred embodiment, a pharmaceutical composition of the invention comprises a compound of the invention (for example, a compound of formula I, l<sub>TO</sub>, Ib, le or I<sub>d</sub>, or preferably a compound selected from Examples 1-308, or a salt, solvate or prodrug thereof), and an HCV protease inhibitor. In another preferred embodiment, a pharmaceutical composition of the invention comprises a compound of the invention (for example, a compound of formula I, l<sub>TO</sub>, Ib, le, or I<sub>d</sub>, or preferably a compound
788
<img file="MX339989B_D1343.tif" />
which is selected from Examples 1-308, or a TiSiaC-tselvat
DE LA Fk0? F £ D / .O IN DL'STKiAb prodrug thereof), and an HCV polymerase inhibitor (eg, a non-nucleoside polymerase inhibitor, or preferably a nucleoside polymerase inhibitor). In yet another preferred embodiment, a pharmaceutical composition of the present invention comprises (1) a compound of the invention (for example, a compound of formula I, Ia, Ib, le, or I<sub>d</sub>, or preferably a compound selected from Examples 1-308, or a salt, solvate or prodrug thereof), (2) an HCV protease inhibitor, and (3) an HCV polymerase inhibitor (eg, a non-nucleoside polymerase inhibitor, or preferably a nucleoside polymerase inhibitor). Non-limiting examples of protease and polymerase inhibitors are described above.
A pharmaceutical composition of the present invention typically includes a pharmaceutically acceptable carrier or excipient. Non-limiting examples of suitable pharmaceutically acceptable carriers / excipients include sugars (for example, lactose, glucose or sucrose), starches (for example, corn starch or potato starch), cellulose or its derivatives (for example, sodium carboxymethyl cellulose, ethylcellulose or cellulose acetate), oils (for example, peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, or soybean oil), Glycol (for example, propylene glycol), buffering agents (for example, magnesium hydroxide or aluminum hydroxide), agar, alginic acid, powdered tragacanth, malt, gelatin,
<img file="MX339989B_D1344.tif" />
789
IMPI. . . . ...,. , INSTITUTO MEXICANO talc, cocoa butter, pyrogen-free water, sotonic sowi ^ jp ^ a, Ringer's solution, ethanol, or phosphate buffered solutions. Lubricants, colorants, release agents, coating agents, sweeteners, flavors or essences, preservatives or antioxidants may also be included in a pharmaceutical composition of the present invention.
The pharmaceutical compositions of the present invention can be formulated on the basis of their routes of administration using methods well known in the art. For example, a sterile injectable preparation can be prepared as a sterile injectable aqueous or oily suspension using appropriate dispersing or wetting agents and suspending agents. Suppositories for rectal administration can be prepared by mixing drugs with a suitable non-irritating excipient such as cocoa butter or polyethylene glycols which are solid at ordinary temperatures but liquid at rectal temperatures and therefore melt in the rectum and release. drugs. Solid dosage forms for oral administration can be capsules, tablets, pills, powders, or granules. In such solid dosage forms, the active compounds can be intimately mixed with at least one inert diluent such as sucrose lactose or starch. Solid dosage forms can also comprise other substances in addition to inert diluents, such as lubricating agents. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. The
790
<img file="MX339989B_D1345.tif" />
<img file="MX339989B_D1346.tif" />
<img file="MX339989B_D1347.tif" />
tablets and pills can be prepared add ^ r ^ ftf & mAnC
INDUSTRIAL enteric coatings. Liquid dosage forms for oral administration can include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, or elixirs containing inert diluents commonly used in the art. Liquid dosage forms can also comprise wetting agents, emulsifiers, suspending agents, sweeteners, flavors, or essences. The pharmaceutical compositions of the present invention can also be administered in the form of liposomes, as described in US Patent No. 6,703,403. The formulation of drugs that are applicable to the present invention is discussed in general terms in, for example, Hoover, John E., REMINGTON'S PHARMACEUTICAL SCIENCES (Mack Publishing Co., Easton, PA: 1975), and Lachman, L., eds. ., PHARMACEUTICAL DOSAGE FORMS (Marcel Decker, New York, NY, 1980).
Any compound described in the present application, or a pharmaceutically acceptable salt thereof, can be used for the prepared pharmaceutical compositions of the present invention.
In a preferred embodiment, a compound of the Invention (for example, a compound of formula I, l<sub>TO</sub>, Ib, le, ol<sub>D</sub>, or preferably a compound that is selected from Examples 1308, or a salt, solvate or prodrug thereof) is formulated in a solid dispersion, wherein the compound of the invention can be molecularly dispersed in an amorphous matrix that it comprises a pharmaceutically acceptable hydrophilic polymer. The matrix too
791
IMPI
INSTITUTO MEXICANO may contain a pharmaceutically active surfactant appropriate solid dispersion technology to formulate a compound of the invention includes, but is not limited to, melt extrusion, spray drying, co-precipitation, freeze drying, or other evaporative techniques solvent, with melt extrusion and spray drying being preferred. In one example, a compound of the invention is formulated in a solid dispersion comprising copovidone and vitamin E TPGS. In another example, a compound of the invention is formulated into a solid dispersion comprising copovidone and Span 20.
A solid dispersion described in the present application may contain at least 30% by weight of a pharmaceutically acceptable hydrophilic polymer or a combination of said hydrophilic polymers. Preferably, the solid dispersion contains at least 40% by weight of a pharmaceutically acceptable hydrophilic polymer or a combination of such hydrophilic polymers. More preferably, the solid dispersion contains at least 50% (including, for example, at least 60%, 70%, 80% or 90%) by weight of a pharmaceutically acceptable hydrophilic polymer or a combination of such polymers. A solid dispersion described in the present application may also contain at least 1% by weight of a pharmaceutically acceptable surface-active agent or a combination of said surface-active agents. Preferably, the solid dispersion contains at least 2% by weight of a pharmaceutically acceptable surfactant or a combination of such surfactants. By way of
<img file="MX339989B_D1348.tif" />
792
ΙΜΡΙβ! »: Ϊ́ more preferred, the solid dispersion contains from 4% Pfae ^ aet
INDUSTRIAL weight of surfactant (s), such as from 5% to 10% by weight of surfactant (s). Furthermore, a solid dispersion described in the present application may contain at least 1% by weight of a compound of the invention, preferably at least 5%, including, for example, at least 10%. In one example, the solid dispersion comprises 5% of a compound of the invention (for example, a compound of formula I, i<sub>TO</sub>, l<sub>B</sub>, him, ol<sub>D</sub>, or preferably a compound selected from Examples 1-308, or a salt, solvate or prodrug thereof), which is molecularly dispersed in an amorphous matrix comprising 7% Vitamin E-TPGS and 88 % copovidone; The solid dispersion can also be mixed with other excipients such as mannitol / aerosil (99: 1), and the weight ratio of the solid dispersion to the other excipients can vary from 5: 1 to 1: 5 with 1: 1 being preferred. . In another example, the solid dispersion comprises 5% of a compound of the invention (for example, a compound of formula I, l<sub>TO</sub>, l<sub>B</sub>, l<sub>c</sub>, ol<sub>D</sub>, or preferably a compound selected from Examples 1-308, or a salt, solvate or prodrug thereof), which is molecularly dispersed in an amorphous matrix comprising 5% Span 20 and 90% Span copovidone; the solid dispersion can also be mixed with other excipients such as mannitol / aerosil (99: 1), the solid dispersion can also be mixed with other excipients such as mannitol / aerosil (99: 1), and the weight ratio of the dispersion Solid with respect to the other excipients can vary from 5: 1 to 1: 5 with 1: 1 being preferred.
793
Various additives can also be included
OF THE PROPERTY
... ,, ... _, INDUSTRIAL solid dispersion. For example, at least one additive that is selected from flow regulators, binders, lubricants, fillers, disintegrants, plasticizers, colorants, or stabilizers can be used in compacting the solid dispersion as tablets. These additives can be mixed with the ground or crushed solid dispersion before compaction. The disintegrants promote rapid disintegration of the tablet in the stomach and keep the released granules separate from each other. Non-limiting examples of suitable disintegrants are crosslinked polymers such as crosslinked polyvinylpyrrolidone, crosslinked sodium carboxymethylcellulose or croscarmellose sodium. Non-limiting examples of suitable fillers (also referred to as bulking agents) are lactose monohydrate, calcium hydrogen phosphate, microcrystalline cellulose (eg Avicell), silicates, in particular silicon dioxide, magnesium oxide, talc, starch potato or corn, isomalt, or polymeric alcohol. Non-limiting examples of suitable flow regulators include highly dispersed silica (eg, colloidal silica such as Aerosll), and fats or waxes of animal or vegetable origin. Non-limiting examples of suitable lubricants include polyethylene glycol (eg, having a molecular weight of from 1000 to 6000), magnesium and calcium stearates, sodium stearyl fumarate, and the like. Non-limiting examples of stabilizers include antioxidants, light stabilizers, radical scavengers, or stabilizers against microbial attack.
794
The present invention also features
INDUSTRIAL S ^ Hr<sup>1</sup>"jj use the compounds of the present invention (or salts, solvates or prodrugs thereof) to inhibit HCV replication. The methods comprise contacting HCV virus-infected cells with an effective amount of a compound of the present invention (or a salt, solvate, or prodrug thereof), thereby inhibiting the replication of the hepatitis C virus in cells. . As used in the present application, Inhibit means to significantly reduce, or abolish, the activity that is being inhibited (eg, viral replication). In many cases, representative compounds of the present invention can reduce HCV virus replication (for example, in an HCV replicon test as described above) by at least 10%, 20%, 30%, 40%, fifty%,
60%, 70%, 80%, 90%, 95% or more.
The compounds of the present invention can inhibit one or more subtypes of HCV. Examples of HCV subtypes that are treatable for the present invention include, but should not be limited to, HCV genotypes 1, 2, 3, 4, 5, and 6, including genotypes la, Ib, 2a, 2b, 2c. , 3rd or 4th<sup>to</sup> of HCV. In one embodiment, a compound or compounds of the present invention (or salts, solvates or prodrugs thereof) are used to inhibit the replication of the HCV genotype. In another embodiment, a compound or compounds of the present invention (or salts, solvates, or prodrugs thereof) are used to inhibit the replication of the HCV genotype Ib. In yet another embodiment, a compound or compounds of the present Invention (or
795 irj> ijhi is used, <l presents methods for
<img file="MX339989B_D1349.tif" />
salts, solvates or prodrugs thereof) replication of both genotypes la and Ib of HCV
The present invention also uses the compounds of the present invention (or salts, solvates, or prodrugs thereof) to treat HCV infection. Methods typically comprise administering an effective therapeutic amount of a compound of the present invention (or a salt, solvate, or prodrug thereof), or a pharmaceutical composition comprising it, to a patient with HCV, thereby reducing the viral level. of HCV in the patient's blood or liver. As used in the present application, the term "treating" refers to reversing, ameliorating, inhibiting the advancement of, or preventing the disorder or condition, or one or more symptoms of said disorder or condition to which said term applies. The term treatment refers to the act of treating. In one embodiment, the methods comprise administering an effective therapeutic amount of two or more compounds of the present invention (or salts, solvates, or prodrugs thereof), or a pharmaceutical composition containing them, to a patient with HCV, thereby the viral level of HCV in the patient's blood or liver is reduced.
A compound of the present invention (or a salt, solvate, or prodrug thereof) can be administered as the sole active pharmaceutical agent, or in combination with another desired drug, such as other anti-HCV agents, anti-HIV agents, anti-HIV agents. -VHB, anti-hepatitis A agents, anti-hepatitis D agents, anti-hepatitis E agents, anti-hepatitis G agents, or other antiviral drugs. Any
796 compound described in the present application,
<img file="MX339989B_D1350.tif" />
acceptable thereof, can be used in the methods of the present invention. In one embodiment, the present invention features methods for treating HCV infection, wherein said methods comprise administering a compound of the invention (e.g., a compound of formula I, l<sub>TO</sub>, Ib, le, or Id, or preferably a compound selected from Examples 1-308, or a salt, solvate or prodrug thereof), interferon and ribavirin to a patient with HCV. The preferred interferon is α-interferon, and more preferably PEG-conjugated interferon-α such as PEGASYS (peginterferon alfa-2a).
A compound of the present invention (or a salt, solvent, or prodrug thereof) can be administered to a patient in single or divided doses. A typical daily dose can range, without limitation, from 0.1 to 200 mg / kg of body weight, such as from 0.25 to 100 mg / kg of body weight. Single dose compositions may contain these amounts or submultiples thereof to make up the daily dose. Preferably, each dose contains a sufficient amount of a compound of the present invention that is effective in reducing the HCV viral load in the blood or liver of the patient. The amount of the active ingredient, or of the active ingredients that are combined, to produce an individual dosage form can vary depending on the host treated and the particular mode of administration. It will be understood that the specific dose level for any particular patient will depend on a
797
Τ ΑΛ Ρ Τ variety of factors including the activity of the compiAslo-esfee & TteC '' ”'-: ¾ <sup>K</sup> MEJflCXSÜ INSTITUTE ..... ”
OF THE PROPERTY .-. Lll · .... , INDUSTRIAL used, age, body weight, general health, gender, diet, time of administration, route of administration, rate — ITS excretion, drug combination, and the severity of the particular disease undergoing therapy.
The present invention also presents methods for using the pharmaceutical compositions of the present invention to treat HCV infection. Methods typically comprise administering a pharmaceutical composition of the present invention to an HCV patient, thereby reducing the viral level of HCV in the patient's blood or liver. Any pharmaceutical composition described in the present application can be used in the methods of the present invention.
Furthermore, the present invention presents the use of the compounds or salts of the present invention for the manufacture of medicaments for the treatment of HCV infection. Any compound described in the present application, or a pharmaceutically acceptable salt thereof, can be used to make the medicaments of the present invention.
The compounds of the present invention can also be isotope substituted. The preferred isotopic substitution includes substitutions with stable or non-radioactive isotopes such as deuterium,<sup>13</sup>C, <sup>1S</sup>N u <sup>18</sup>O. The incorporation of a heavy atom, such as the substitution of hydrogen for deuterium, can give rise to an isotope effect that can alter the pharmacokinetics of the drug. In a
798
ΙΜΡ Π For example, at least 5 mol% (eg, at least ^ iJ ^^^ r ^ of the hydrogen in a compound of the present invention is substituted with deuterium. In another example, at least 25 mol% of the hydrogen in a compound of the present invention is substituted with deuterium. In a further example, at least 50, 60.70, 80 or 90 mole% of the hydrogen in a compound of the present invention is substituted with deuterium. The natural abundance of deuterium it is approximately 0.015%. Substitution or enrichment of deuterium can be achieved, without limitation, either by exchanging protons with deuterium or by synthesizing the molecule with enriched or substituted starting materials. Other methods known in the art for isotopic substitutions can also be used.
The foregoing description of the present invention provides illustration and description, but is not intended to be exhaustive or to limit the invention to that precisely described. Modifications and variations are possible in light of the above teachings or may be acquired from practice of the invention. Therefore, it should be noted that the scope of the invention is defined by the claims and their equivalents.
799
Contents890
1,350 sheets
Sheet 1 Sheet 2 Sheet 3 Sheet 4 Sheet 5 Sheet 6 Sheet 7 Sheet 8 Sheet 9 Sheet 10 Sheet 11 Sheet 12 Sheet 13 Sheet 14 Sheet 15 Sheet 16 Sheet 17 Sheet 18 Sheet 19 Sheet 20 Sheet 21 Sheet 22 Sheet 23 Sheet 24 Sheet 25 Sheet 26 Sheet 27 Sheet 28 Sheet 29 Sheet 30 Sheet 31 Sheet 32 Sheet 33 Sheet 34 Sheet 35 Sheet 36 Sheet 37 Sheet 38 Sheet 39 Sheet 40 Sheet 41 Sheet 42 Sheet 43 Sheet 44 Sheet 45 Sheet 46 Sheet 47 Sheet 48 Sheet 49 Sheet 50 Sheet 51 Sheet 52 Sheet 53 Sheet 54 Sheet 55 Sheet 56 Sheet 57 Sheet 58 Sheet 59 Sheet 60 Sheet 61 Sheet 62 Sheet 63 Sheet 64 Sheet 65 Sheet 66 Sheet 67 Sheet 68 Sheet 69 Sheet 70 Sheet 71 Sheet 72 Sheet 73 Sheet 74 Sheet 75 Sheet 76 Sheet 77 Sheet 78 Sheet 79 Sheet 80 Sheet 81 Sheet 82 Sheet 83 Sheet 84 Sheet 85 Sheet 86 Sheet 87 Sheet 88 Sheet 89 Sheet 90 Sheet 91 Sheet 92 Sheet 93 Sheet 94 Sheet 95 Sheet 96 Sheet 97 Sheet 98 Sheet 99 Sheet 100 Sheet 101 Sheet 102 Sheet 103 Sheet 104 Sheet 105 Sheet 106 Sheet 107 Sheet 108 Sheet 109 Sheet 110 Sheet 111 Sheet 112 Sheet 113 Sheet 114 Sheet 115 Sheet 116 Sheet 117 Sheet 118 Sheet 119 Sheet 120 Sheet 121 Sheet 122 Sheet 123 Sheet 124 Sheet 125 Sheet 126 Sheet 127 Sheet 128 Sheet 129 Sheet 130 Sheet 131 Sheet 132 Sheet 133 Sheet 134 Sheet 135 Sheet 136 Sheet 137 Sheet 138 Sheet 139 Sheet 140 Sheet 141 Sheet 142 Sheet 143 Sheet 144 Sheet 145 Sheet 146 Sheet 147 Sheet 148 Sheet 149 Sheet 150 Sheet 151 Sheet 152 Sheet 153 Sheet 154 Sheet 155 Sheet 156 Sheet 157 Sheet 158 Sheet 159 Sheet 160 Sheet 161 Sheet 162 Sheet 163 Sheet 164 Sheet 165 Sheet 166 Sheet 167 Sheet 168 Sheet 169 Sheet 170 Sheet 171 Sheet 172 Sheet 173 Sheet 174 Sheet 175 Sheet 176 Sheet 177 Sheet 178 Sheet 179 Sheet 180 Sheet 181 Sheet 182 Sheet 183 Sheet 184 Sheet 185 Sheet 186 Sheet 187 Sheet 188 Sheet 189 Sheet 190 Sheet 191 Sheet 192 Sheet 193 Sheet 194 Sheet 195 Sheet 196 Sheet 197 Sheet 198 Sheet 199 Sheet 200 Sheet 201 Sheet 202 Sheet 203 Sheet 204 Sheet 205 Sheet 206 Sheet 207 Sheet 208 Sheet 209 Sheet 210 Sheet 211 Sheet 212 Sheet 213 Sheet 214 Sheet 215 Sheet 216 Sheet 217 Sheet 218 Sheet 219 Sheet 220 Sheet 221 Sheet 222 Sheet 223 Sheet 224 Sheet 225 Sheet 226 Sheet 227 Sheet 228 Sheet 229 Sheet 230 Sheet 231 Sheet 232 Sheet 233 Sheet 234 Sheet 235 Sheet 236 Sheet 237 Sheet 238 Sheet 239 Sheet 240 Sheet 241 Sheet 242 Sheet 243 Sheet 244 Sheet 245 Sheet 246 Sheet 247 Sheet 248 Sheet 249 Sheet 250 Sheet 251 Sheet 252 Sheet 253 Sheet 254 Sheet 255 Sheet 256 Sheet 257 Sheet 258 Sheet 259 Sheet 260 Sheet 261 Sheet 262 Sheet 263 Sheet 264 Sheet 265 Sheet 266 Sheet 267 Sheet 268 Sheet 269 Sheet 270 Sheet 271 Sheet 272 Sheet 273 Sheet 274 Sheet 275 Sheet 276 Sheet 277 Sheet 278 Sheet 279 Sheet 280 Sheet 281 Sheet 282 Sheet 283 Sheet 284 Sheet 285 Sheet 286 Sheet 287 Sheet 288 Sheet 289 Sheet 290 Sheet 291 Sheet 292 Sheet 293 Sheet 294 Sheet 295 Sheet 296 Sheet 297 Sheet 298 Sheet 299 Sheet 300 Sheet 301 Sheet 302 Sheet 303 Sheet 304 Sheet 305 Sheet 306 Sheet 307 Sheet 308 Sheet 309 Sheet 310 Sheet 311 Sheet 312 Sheet 313 Sheet 314 Sheet 315 Sheet 316 Sheet 317 Sheet 318 Sheet 319 Sheet 320 Sheet 321 Sheet 322 Sheet 323 Sheet 324 Sheet 325 Sheet 326 Sheet 327 Sheet 328 Sheet 329 Sheet 330 Sheet 331 Sheet 332 Sheet 333 Sheet 334 Sheet 335 Sheet 336 Sheet 337 Sheet 338 Sheet 339 Sheet 340 Sheet 341 Sheet 342 Sheet 343 Sheet 344 Sheet 345 Sheet 346 Sheet 347 Sheet 348 Sheet 349 Sheet 350 Sheet 351 Sheet 352 Sheet 353 Sheet 354 Sheet 355 Sheet 356 Sheet 357 Sheet 358 Sheet 359 Sheet 360 Sheet 361 Sheet 362 Sheet 363 Sheet 364 Sheet 365 Sheet 366 Sheet 367 Sheet 368 Sheet 369 Sheet 370 Sheet 371 Sheet 372 Sheet 373 Sheet 374 Sheet 375 Sheet 376 Sheet 377 Sheet 378 Sheet 379 Sheet 380 Sheet 381 Sheet 382 Sheet 383 Sheet 384 Sheet 385 Sheet 386 Sheet 387 Sheet 388 Sheet 389 Sheet 390 Sheet 391 Sheet 392 Sheet 393 Sheet 394 Sheet 395 Sheet 396 Sheet 397 Sheet 398 Sheet 399 Sheet 400 Sheet 401 Sheet 402 Sheet 403 Sheet 404 Sheet 405 Sheet 406 Sheet 407 Sheet 408 Sheet 409 Sheet 410 Sheet 411 Sheet 412 Sheet 413 Sheet 414 Sheet 415 Sheet 416 Sheet 417 Sheet 418 Sheet 419 Sheet 420 Sheet 421 Sheet 422 Sheet 423 Sheet 424 Sheet 425 Sheet 426 Sheet 427 Sheet 428 Sheet 429 Sheet 430 Sheet 431 Sheet 432 Sheet 433 Sheet 434 Sheet 435 Sheet 436 Sheet 437 Sheet 438 Sheet 439 Sheet 440 Sheet 441 Sheet 442 Sheet 443 Sheet 444 Sheet 445 Sheet 446 Sheet 447 Sheet 448 Sheet 449 Sheet 450 Sheet 451 Sheet 452 Sheet 453 Sheet 454 Sheet 455 Sheet 456 Sheet 457 Sheet 458 Sheet 459 Sheet 460 Sheet 461 Sheet 462 Sheet 463 Sheet 464 Sheet 465 Sheet 466 Sheet 467 Sheet 468 Sheet 469 Sheet 470 Sheet 471 Sheet 472 Sheet 473 Sheet 474 Sheet 475 Sheet 476 Sheet 477 Sheet 478 Sheet 479 Sheet 480 Sheet 481 Sheet 482 Sheet 483 Sheet 484 Sheet 485 Sheet 486 Sheet 487 Sheet 488 Sheet 489 Sheet 490 Sheet 491 Sheet 492 Sheet 493 Sheet 494 Sheet 495 Sheet 496 Sheet 497 Sheet 498 Sheet 499 Sheet 500 Sheet 501 Sheet 502 Sheet 503 Sheet 504 Sheet 505 Sheet 506 Sheet 507 Sheet 508 Sheet 509 Sheet 510 Sheet 511 Sheet 512 Sheet 513 Sheet 514 Sheet 515 Sheet 516 Sheet 517 Sheet 518 Sheet 519 Sheet 520 Sheet 521 Sheet 522 Sheet 523 Sheet 524 Sheet 525 Sheet 526 Sheet 527 Sheet 528 Sheet 529 Sheet 530 Sheet 531 Sheet 532 Sheet 533 Sheet 534 Sheet 535 Sheet 536 Sheet 537 Sheet 538 Sheet 539 Sheet 540 Sheet 541 Sheet 542 Sheet 543 Sheet 544 Sheet 545 Sheet 546 Sheet 547 Sheet 548 Sheet 549 Sheet 550 Sheet 551 Sheet 552 Sheet 553 Sheet 554 Sheet 555 Sheet 556 Sheet 557 Sheet 558 Sheet 559 Sheet 560 Sheet 561 Sheet 562 Sheet 563 Sheet 564 Sheet 565 Sheet 566 Sheet 567 Sheet 568 Sheet 569 Sheet 570 Sheet 571 Sheet 572 Sheet 573 Sheet 574 Sheet 575 Sheet 576 Sheet 577 Sheet 578 Sheet 579 Sheet 580 Sheet 581 Sheet 582 Sheet 583 Sheet 584 Sheet 585 Sheet 586 Sheet 587 Sheet 588 Sheet 589 Sheet 590 Sheet 591 Sheet 592 Sheet 593 Sheet 594 Sheet 595 Sheet 596 Sheet 597 Sheet 598 Sheet 599 Sheet 600 Sheet 601 Sheet 602 Sheet 603 Sheet 604 Sheet 605 Sheet 606 Sheet 607 Sheet 608 Sheet 609 Sheet 610 Sheet 611 Sheet 612 Sheet 613 Sheet 614 Sheet 615 Sheet 616 Sheet 617 Sheet 618 Sheet 619 Sheet 620 Sheet 621 Sheet 622 Sheet 623 Sheet 624 Sheet 625 Sheet 626 Sheet 627 Sheet 628 Sheet 629 Sheet 630 Sheet 631 Sheet 632 Sheet 633 Sheet 634 Sheet 635 Sheet 636 Sheet 637 Sheet 638 Sheet 639 Sheet 640 Sheet 641 Sheet 642 Sheet 643 Sheet 644 Sheet 645 Sheet 646 Sheet 647 Sheet 648 Sheet 649 Sheet 650 Sheet 651 Sheet 652 Sheet 653 Sheet 654 Sheet 655 Sheet 656 Sheet 657 Sheet 658 Sheet 659 Sheet 660 Sheet 661 Sheet 662 Sheet 663 Sheet 664 Sheet 665 Sheet 666 Sheet 667 Sheet 668 Sheet 669 Sheet 670 Sheet 671 Sheet 672 Sheet 673 Sheet 674 Sheet 675 Sheet 676 Sheet 677 Sheet 678 Sheet 679 Sheet 680 Sheet 681 Sheet 682 Sheet 683 Sheet 684 Sheet 685 Sheet 686 Sheet 687 Sheet 688 Sheet 689 Sheet 690 Sheet 691 Sheet 692 Sheet 693 Sheet 694 Sheet 695 Sheet 696 Sheet 697 Sheet 698 Sheet 699 Sheet 700 Sheet 701 Sheet 702 Sheet 703 Sheet 704 Sheet 705 Sheet 706 Sheet 707 Sheet 708 Sheet 709 Sheet 710 Sheet 711 Sheet 712 Sheet 713 Sheet 714 Sheet 715 Sheet 716 Sheet 717 Sheet 718 Sheet 719 Sheet 720 Sheet 721 Sheet 722 Sheet 723 Sheet 724 Sheet 725 Sheet 726 Sheet 727 Sheet 728 Sheet 729 Sheet 730 Sheet 731 Sheet 732 Sheet 733 Sheet 734 Sheet 735 Sheet 736 Sheet 737 Sheet 738 Sheet 739 Sheet 740 Sheet 741 Sheet 742 Sheet 743 Sheet 744 Sheet 745 Sheet 746 Sheet 747 Sheet 748 Sheet 749 Sheet 750 Sheet 751 Sheet 752 Sheet 753 Sheet 754 Sheet 755 Sheet 756 Sheet 757 Sheet 758 Sheet 759 Sheet 760 Sheet 761 Sheet 762 Sheet 763 Sheet 764 Sheet 765 Sheet 766 Sheet 767 Sheet 768 Sheet 769 Sheet 770 Sheet 771 Sheet 772 Sheet 773 Sheet 774 Sheet 775 Sheet 776 Sheet 777 Sheet 778 Sheet 779 Sheet 780 Sheet 781 Sheet 782 Sheet 783 Sheet 784 Sheet 785 Sheet 786 Sheet 787 Sheet 788 Sheet 789 Sheet 790 Sheet 791 Sheet 792 Sheet 793 Sheet 794 Sheet 795 Sheet 796 Sheet 797 Sheet 798 Sheet 799 Sheet 800 Sheet 801 Sheet 802 Sheet 803 Sheet 804 Sheet 805 Sheet 806 Sheet 807 Sheet 808 Sheet 809 Sheet 810 Sheet 811 Sheet 812 Sheet 813 Sheet 814 Sheet 815 Sheet 816 Sheet 817 Sheet 818 Sheet 819 Sheet 820 Sheet 821 Sheet 822 Sheet 823 Sheet 824 Sheet 825 Sheet 826 Sheet 827 Sheet 828 Sheet 829 Sheet 830 Sheet 831 Sheet 832 Sheet 833 Sheet 834 Sheet 835 Sheet 836 Sheet 837 Sheet 838 Sheet 839 Sheet 840 Sheet 841 Sheet 842 Sheet 843 Sheet 844 Sheet 845 Sheet 846 Sheet 847 Sheet 848 Sheet 849 Sheet 850 Sheet 851 Sheet 852 Sheet 853 Sheet 854 Sheet 855 Sheet 856 Sheet 857 Sheet 858 Sheet 859 Sheet 860 Sheet 861 Sheet 862 Sheet 863 Sheet 864 Sheet 865 Sheet 866 Sheet 867 Sheet 868 Sheet 869 Sheet 870 Sheet 871 Sheet 872 Sheet 873 Sheet 874 Sheet 875 Sheet 876 Sheet 877 Sheet 878 Sheet 879 Sheet 880 Sheet 881 Sheet 882 Sheet 883 Sheet 884 Sheet 885 Sheet 886 Sheet 887 Sheet 888 Sheet 889 Sheet 890 Sheet 891 Sheet 892 Sheet 893 Sheet 894 Sheet 895 Sheet 896 Sheet 897 Sheet 898 Sheet 899 Sheet 900 Sheet 901 Sheet 902 Sheet 903 Sheet 904 Sheet 905 Sheet 906 Sheet 907 Sheet 908 Sheet 909 Sheet 910 Sheet 911 Sheet 912 Sheet 913 Sheet 914 Sheet 915 Sheet 916 Sheet 917 Sheet 918 Sheet 919 Sheet 920 Sheet 921 Sheet 922 Sheet 923 Sheet 924 Sheet 925 Sheet 926 Sheet 927 Sheet 928 Sheet 929 Sheet 930 Sheet 931 Sheet 932 Sheet 933 Sheet 934 Sheet 935 Sheet 936 Sheet 937 Sheet 938 Sheet 939 Sheet 940 Sheet 941 Sheet 942 Sheet 943 Sheet 944 Sheet 945 Sheet 946 Sheet 947 Sheet 948 Sheet 949 Sheet 950 Sheet 951 Sheet 952 Sheet 953 Sheet 954 Sheet 955 Sheet 956 Sheet 957 Sheet 958 Sheet 959 Sheet 960 Sheet 961 Sheet 962 Sheet 963 Sheet 964 Sheet 965 Sheet 966 Sheet 967 Sheet 968 Sheet 969 Sheet 970 Sheet 971 Sheet 972 Sheet 973 Sheet 974 Sheet 975 Sheet 976 Sheet 977 Sheet 978 Sheet 979 Sheet 980 Sheet 981 Sheet 982 Sheet 983 Sheet 984 Sheet 985 Sheet 986 Sheet 987 Sheet 988 Sheet 989 Sheet 990 Sheet 991 Sheet 992 Sheet 993 Sheet 994 Sheet 995 Sheet 996 Sheet 997 Sheet 998 Sheet 999 Sheet 1000 Sheet 1001 Sheet 1002 Sheet 1003 Sheet 1004 Sheet 1005 Sheet 1006 Sheet 1007 Sheet 1008 Sheet 1009 Sheet 1010 Sheet 1011 Sheet 1012 Sheet 1013 Sheet 1014 Sheet 1015 Sheet 1016 Sheet 1017 Sheet 1018 Sheet 1019 Sheet 1020 Sheet 1021 Sheet 1022 Sheet 1023 Sheet 1024 Sheet 1025 Sheet 1026 Sheet 1027 Sheet 1028 Sheet 1029 Sheet 1030 Sheet 1031 Sheet 1032 Sheet 1033 Sheet 1034 Sheet 1035 Sheet 1036 Sheet 1037 Sheet 1038 Sheet 1039 Sheet 1040 Sheet 1041 Sheet 1042 Sheet 1043 Sheet 1044 Sheet 1045 Sheet 1046 Sheet 1047 Sheet 1048 Sheet 1049 Sheet 1050 Sheet 1051 Sheet 1052 Sheet 1053 Sheet 1054 Sheet 1055 Sheet 1056 Sheet 1057 Sheet 1058 Sheet 1059 Sheet 1060 Sheet 1061 Sheet 1062 Sheet 1063 Sheet 1064 Sheet 1065 Sheet 1066 Sheet 1067 Sheet 1068 Sheet 1069 Sheet 1070 Sheet 1071 Sheet 1072 Sheet 1073 Sheet 1074 Sheet 1075 Sheet 1076 Sheet 1077 Sheet 1078 Sheet 1079 Sheet 1080 Sheet 1081 Sheet 1082 Sheet 1083 Sheet 1084 Sheet 1085 Sheet 1086 Sheet 1087 Sheet 1088 Sheet 1089 Sheet 1090 Sheet 1091 Sheet 1092 Sheet 1093 Sheet 1094 Sheet 1095 Sheet 1096 Sheet 1097 Sheet 1098 Sheet 1099 Sheet 1100 Sheet 1101 Sheet 1102 Sheet 1103 Sheet 1104 Sheet 1105 Sheet 1106 Sheet 1107 Sheet 1108 Sheet 1109 Sheet 1110 Sheet 1111 Sheet 1112 Sheet 1113 Sheet 1114 Sheet 1115 Sheet 1116 Sheet 1117 Sheet 1118 Sheet 1119 Sheet 1120 Sheet 1121 Sheet 1122 Sheet 1123 Sheet 1124 Sheet 1125 Sheet 1126 Sheet 1127 Sheet 1128 Sheet 1129 Sheet 1130 Sheet 1131 Sheet 1132 Sheet 1133 Sheet 1134 Sheet 1135 Sheet 1136 Sheet 1137 Sheet 1138 Sheet 1139 Sheet 1140 Sheet 1141 Sheet 1142 Sheet 1143 Sheet 1144 Sheet 1145 Sheet 1146 Sheet 1147 Sheet 1148 Sheet 1149 Sheet 1150 Sheet 1151 Sheet 1152 Sheet 1153 Sheet 1154 Sheet 1155 Sheet 1156 Sheet 1157 Sheet 1158 Sheet 1159 Sheet 1160 Sheet 1161 Sheet 1162 Sheet 1163 Sheet 1164 Sheet 1165 Sheet 1166 Sheet 1167 Sheet 1168 Sheet 1169 Sheet 1170 Sheet 1171 Sheet 1172 Sheet 1173 Sheet 1174 Sheet 1175 Sheet 1176 Sheet 1177 Sheet 1178 Sheet 1179 Sheet 1180 Sheet 1181 Sheet 1182 Sheet 1183 Sheet 1184 Sheet 1185 Sheet 1186 Sheet 1187 Sheet 1188 Sheet 1189 Sheet 1190 Sheet 1191 Sheet 1192 Sheet 1193 Sheet 1194 Sheet 1195 Sheet 1196 Sheet 1197 Sheet 1198 Sheet 1199 Sheet 1200 Sheet 1201 Sheet 1202 Sheet 1203 Sheet 1204 Sheet 1205 Sheet 1206 Sheet 1207 Sheet 1208 Sheet 1209 Sheet 1210 Sheet 1211 Sheet 1212 Sheet 1213 Sheet 1214 Sheet 1215 Sheet 1216 Sheet 1217 Sheet 1218 Sheet 1219 Sheet 1220 Sheet 1221 Sheet 1222 Sheet 1223 Sheet 1224 Sheet 1225 Sheet 1226 Sheet 1227 Sheet 1228 Sheet 1229 Sheet 1230 Sheet 1231 Sheet 1232 Sheet 1233 Sheet 1234 Sheet 1235 Sheet 1236 Sheet 1237 Sheet 1238 Sheet 1239 Sheet 1240 Sheet 1241 Sheet 1242 Sheet 1243 Sheet 1244 Sheet 1245 Sheet 1246 Sheet 1247 Sheet 1248 Sheet 1249 Sheet 1250 Sheet 1251 Sheet 1252 Sheet 1253 Sheet 1254 Sheet 1255 Sheet 1256 Sheet 1257 Sheet 1258 Sheet 1259 Sheet 1260 Sheet 1261 Sheet 1262 Sheet 1263 Sheet 1264 Sheet 1265 Sheet 1266 Sheet 1267 Sheet 1268 Sheet 1269 Sheet 1270 Sheet 1271 Sheet 1272 Sheet 1273 Sheet 1274 Sheet 1275 Sheet 1276 Sheet 1277 Sheet 1278 Sheet 1279 Sheet 1280 Sheet 1281 Sheet 1282 Sheet 1283 Sheet 1284 Sheet 1285 Sheet 1286 Sheet 1287 Sheet 1288 Sheet 1289 Sheet 1290 Sheet 1291 Sheet 1292 Sheet 1293 Sheet 1294 Sheet 1295 Sheet 1296 Sheet 1297 Sheet 1298 Sheet 1299 Sheet 1300 Sheet 1301 Sheet 1302 Sheet 1303 Sheet 1304 Sheet 1305 Sheet 1306 Sheet 1307 Sheet 1308 Sheet 1309 Sheet 1310 Sheet 1311 Sheet 1312 Sheet 1313 Sheet 1314 Sheet 1315 Sheet 1316 Sheet 1317 Sheet 1318 Sheet 1319 Sheet 1320 Sheet 1321 Sheet 1322 Sheet 1323 Sheet 1324 Sheet 1325 Sheet 1326 Sheet 1327 Sheet 1328 Sheet 1329 Sheet 1330 Sheet 1331 Sheet 1332 Sheet 1333 Sheet 1334 Sheet 1335 Sheet 1336 Sheet 1337 Sheet 1338 Sheet 1339 Sheet 1340 Sheet 1341 Sheet 1342 Sheet 1343 Sheet 1344 Sheet 1345 Sheet 1346 Sheet 1347 Sheet 1348 Sheet 1349 Sheet 1350
357 members in 46 offices
Priority claims15
| Document | Office | Kind | Date |
|---|---|---|---|
| 18629109 | United States of America | P | |
| 18629109 | United States of America | P | |
| 61186291 | United States of America | – | |
| 24283609 | United States of America | P | |
| 24283609 | United States of America | P | |
| 61242836 | United States of America | – | |
| 24359609 | United States of America | P | |
| 24359609 | United States of America | P | |
| 61243596 | United States of America | – | |
| 61186291 | – | – | – |
| 61242836 | – | – | – |
| 61243596 | – | – | – |
| US20090186291P | – | – | – |
| US20090242836P | – | – | – |
| US20090243596P | – | – | – |
Members357
| Document | Office | Kind | |
|---|---|---|---|
| AU2010258769A1 | Australia | A1 | |
| CA2737601A1 | Canada | A1 | |
| CA2847910A1 | Canada | A1 | |
| US2010317568A1 | United States of America | A1 | |
| WO2010144646A2 | World Intellectual Property Organization (WIPO) | A2 | |
| UY32699A | Uruguay | A | |
| TW201102063A | Taiwan Province of China | A | |
| WO2010144646A3 | World Intellectual Property Organization (WIPO) | A3 | |
| US2011092415A1 | United States of America | A1 | |
| ECSP11010937A | Ecuador | A | |
| MX2011005673A | Mexico | A | |
| EP2337781A2 | European Patent Office (EPO) | A2 | |
| IL211792D0 | Israel | D0 | |
| AR077060A1 | Argentina | A1 | |
| SG171708A1 | Singapore | A1 | |
| US2011207699A1 | United States of America | A1 | |
| EP2368890A1 | European Patent Office (EPO) | A1 | |
| PE20110679A1 | Peru | A1 | |
| EA201170401A1 | Eurasian Patent Organization (EAPO) | A1 | |
| CL2011000689A1 | Chile | A1 | |
| CA2802180A1 | Canada | A1 | |
| WO2011156578A1 | World Intellectual Property Organization (WIPO) | A1 | |
| US2012004196A1 | United States of America | A1 | |
| CN102333772A | China | A | |
| UY33446A | Uruguay | A | |
| TW201204713A | Taiwan Province of China | A | |
| HK1152620A1 | Hong Kong, China | A1 | |
| CA2807847A1 | Canada | A1 | |
| CA2938547A1 | Canada | A1 | |
| WO2012051361A1 | World Intellectual Property Organization (WIPO) | A1 | |
| UY33667A | Uruguay | A | |
| CO6440538A2 | Colombia | A2 | |
| EP2455376A1 | European Patent Office (EPO) | A1 | |
| CA2819894A1 | Canada | A1 | |
| WO2012083170A1 | World Intellectual Property Organization (WIPO) | A1 | |
| US2012172290A1 | United States of America | A1 | |
| AU2010258769B2 | Australia | B2 | |
| HK1161245A1 | Hong Kong, China | A1 | |
| CA2828495A1 | Canada | A1 | |
| US2012220562A1 | United States of America | A1 | |
| WO2012116257A1 | World Intellectual Property Organization (WIPO) | A1 | |
| ZA201102425B | South Africa | B | |
| TW201238948A | Taiwan Province of China | A | |
| US2012258909A1 | United States of America | A1 | |
| US2012264780A1 | United States of America | A1 | |
| KR20120117620A | Republic of Korea | A | |
| JP2012529534A | Japan | A | |
| TW201247648A | Taiwan Province of China | A | |
| AU2011264823A1 | Australia | A1 | |
| SG186251A1 | Singapore | A1 | |
| ZA201203502B | South Africa | B | |
| DOP2012000307A | Dominican Republic | A | |
| AR083240A1 | Argentina | A1 | |
| CL2012003470A1 | Chile | A1 | |
| AR083398A1 | Argentina | A1 | |
| AU2011316506A1 | Australia | A1 | |
| HK1170739A1 | Hong Kong, China | A1 | |
| ECSP13012382A | Ecuador | A | |
| NZ591973A | New Zealand | A | |
| EP2368890B1 | European Patent Office (EPO) | B1 | |
| EP2579854A1 | European Patent Office (EPO) | A1 | |
| CO6660490A2 | Colombia | A2 | |
| MX2012014384A | Mexico | A | |
| CR20120650A | Costa Rica | A | |
| KR20130053440A | Republic of Korea | A | |
| EA201291394A1 | Eurasian Patent Organization (EAPO) | A1 | |
| SG188951A1 | Singapore | A1 | |
| CN103153988A | China | A | |
| CN103172620A | China | A | |
| JP2013528225A | Japan | A | |
| CN103209686A | China | A | |
| PT2368890E | Portugal | E | |
| TWI402070B | Taiwan Province of China | B | |
| DK2368890T3 | Denmark | T3 | |
| ES2414934T3 | Spain | T3 | |
| ECSP13012622A | Ecuador | A | |
| CR20130170A | Costa Rica | A | |
| EP2627651A1 | European Patent Office (EPO) | A1 | |
| EP2628481A1 | European Patent Office (EPO) | A1 | |
| SI2368890T1 | Slovenia | T1 | |
| TW201334778A | Taiwan Province of China | A | |
| MX2013004150A | Mexico | A | |
| CL2013000970A1 | Chile | A1 | |
| UA103052C2 | Ukraine | C2 | |
| GT201100074A | Guatemala | A | |
| ZA201300112B | South Africa | B | |
| CO6761348A2 | Colombia | A2 | |
| DOP2013000185A | Dominican Republic | A | |
| EA201300495A1 | Eurasian Patent Organization (EAPO) | A1 | |
| MX2013006951A | Mexico | A | |
| HRP20130671T1 | Croatia | T1 | |
| CN103354808A | China | A | |
| PE20131036A1 | Peru | A1 | |
| EP2651885A1 | European Patent Office (EPO) | A1 | |
| JP2013539791A | Japan | A | |
| EP2368890B9 | European Patent Office (EPO) | B9 | |
| ECSP13010937A | Ecuador | A | |
| PL2368890T3 | Poland | T3 | |
| CL2013002299A1 | Chile | A1 | |
| ES2414934T9 | Spain | T9 |
Numbers
- Publication
- 339989
- Publication, DOCDB
- 339989
- Publication, EPODOC
- MX339989
- Application
- 2015002738
- Application, DOCDB
- 2015002738
- Application, EPODOC
- MX20150002738
Titles2
- English
- ANTI-VIRAL COMPOUNDS TO TREAT HCV INFECTION.
- Spanish
- COMPUESTOS ANTI-VIRALES.
Classification
- CPC, 29
- C07D403/14
- C07F9/65583
- A61P1/16
- C07D401/10
- C07D401/14
- C07D405/14
- C07D413/14
- C07D417/14
- C07D491/113
- C07D519/00
- C07K5/06034
- C07K5/06078
- C07K5/06139
- A61P31/00
- A61P31/12
- A61P31/14
- A61P31/18
- A61P43/00
- C07D453/00
- C07D207/08
- C07D207/09
- C07D207/16
- C07D471/04
- C07C33/26
- C07C201/06
- C07D403/12
- C07C205/19
- A61K31/4025
- C07K5/06
- IPC, 8
- C07D403 14
- A61K31 14
- A61K31 4178
- A61K31 4184
- A61K31 4196
- A61K31 425
- A61K31 4439
- C07D417 14